{"PMC7213029": [["Financial support and sponsorshipNil.Conflicts of interestThere are no conflicts of interest.", [["Financial support", "TREATMENT", 0, 17], ["sponsorshipNil", "TREATMENT", 22, 36], ["no", "UNCERTAINTY", 68, 70], ["conflicts", "OBSERVATION", 71, 80]]]], "PMC7089322": [["IntroductionIdiopathic pulmonary fibrosis (IPF), the most common form of interstitial pneumonia of unknown cause, is a chronic and progressive fibrotic process limited to the lung, occurring primarily in older adults, and associated with a histopathologic and radiologic pattern of a usual interstitial pneumonia (UIP).", [["pulmonary", "ANATOMY", 23, 32], ["interstitial", "ANATOMY", 73, 85], ["lung", "ANATOMY", 175, 179], ["interstitial", "ANATOMY", 290, 302], ["IntroductionIdiopathic pulmonary fibrosis", "DISEASE", 0, 41], ["IPF", "DISEASE", 43, 46], ["interstitial pneumonia", "DISEASE", 73, 95], ["interstitial pneumonia", "DISEASE", 290, 312], ["UIP", "DISEASE", 314, 317], ["pulmonary", "ORGAN", 23, 32], ["lung", "ORGAN", 175, 179], ["IntroductionIdiopathic pulmonary fibrosis (IPF)", "PROBLEM", 0, 47], ["interstitial pneumonia", "PROBLEM", 73, 95], ["a chronic and progressive fibrotic process", "PROBLEM", 117, 159], ["a usual interstitial pneumonia", "PROBLEM", 282, 312], ["pulmonary", "ANATOMY", 23, 32], ["fibrosis", "OBSERVATION", 33, 41], ["IPF", "OBSERVATION", 43, 46], ["most common", "OBSERVATION_MODIFIER", 53, 64], ["interstitial", "ANATOMY_MODIFIER", 73, 85], ["pneumonia", "OBSERVATION", 86, 95], ["chronic", "OBSERVATION_MODIFIER", 119, 126], ["progressive", "OBSERVATION_MODIFIER", 131, 142], ["fibrotic", "OBSERVATION", 143, 151], ["lung", "ANATOMY", 175, 179], ["interstitial", "ANATOMY_MODIFIER", 290, 302], ["pneumonia", "OBSERVATION", 303, 312]]], ["The diagnosis of IPF requires the exclusion of other forms of interstitial pneumonia, especially associated with occupational/environmental exposure, medication or systemic disease [1].IntroductionAlthough the median survival is about 2.5\u20133.5 years from the time of diagnosis, there is high variability in the evolution of IPF from one patient to another, and between different periods in time in a given individual.", [["interstitial", "ANATOMY", 62, 74], ["IPF", "DISEASE", 17, 20], ["interstitial pneumonia", "DISEASE", 62, 84], ["IPF", "DISEASE", 323, 326], ["patient", "ORGANISM", 336, 343], ["patient", "SPECIES", 336, 343], ["IPF", "PROBLEM", 17, 20], ["interstitial pneumonia", "PROBLEM", 62, 84], ["medication", "TREATMENT", 150, 160], ["systemic disease", "PROBLEM", 164, 180], ["high variability", "PROBLEM", 286, 302], ["IPF", "PROBLEM", 323, 326], ["IPF", "OBSERVATION", 17, 20], ["interstitial", "ANATOMY_MODIFIER", 62, 74], ["pneumonia", "OBSERVATION", 75, 84], ["high variability", "OBSERVATION", 286, 302], ["IPF", "OBSERVATION", 323, 326]]], ["Therefore, predicting the outcome in IPF is challenging.", [["IPF", "DISEASE", 37, 40], ["IPF", "PROBLEM", 37, 40], ["IPF", "OBSERVATION", 37, 40]]], ["Major progress has been made in recent years, with particular efforts to identify patients with the highest risk of disease progression who might benefit the most from treatment interventions.", [["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["disease progression", "PROBLEM", 116, 135], ["treatment interventions", "TREATMENT", 168, 191], ["disease", "OBSERVATION", 116, 123]]], ["Clinical phenotypes with different survival have been identified.", [["Clinical phenotypes", "PROBLEM", 0, 19], ["different survival", "PROBLEM", 25, 43]]], ["Overall, a poorer prognosis is associated with older age (>70 years), smoking history, low body mass index, severe physiological impairment, large radiological extent of disease and the presence of pulmonary hypertension [2].IntroductionPatients with IPF generally have a relatively slow, but progressive clinical course and are often referred to a pulmonary specialist months to years after the onset of symptoms [3].", [["body", "ANATOMY", 91, 95], ["pulmonary", "ANATOMY", 198, 207], ["pulmonary", "ANATOMY", 349, 358], ["physiological impairment", "DISEASE", 115, 139], ["pulmonary hypertension", "DISEASE", 198, 220], ["IPF", "DISEASE", 251, 254], ["body", "ORGANISM_SUBDIVISION", 91, 95], ["pulmonary", "ORGAN", 198, 207], ["pulmonary", "ORGAN", 349, 358], ["low body mass index", "PROBLEM", 87, 106], ["severe physiological impairment", "PROBLEM", 108, 139], ["disease", "PROBLEM", 170, 177], ["pulmonary hypertension", "PROBLEM", 198, 220], ["IPF", "PROBLEM", 251, 254], ["symptoms", "PROBLEM", 405, 413], ["low body", "OBSERVATION_MODIFIER", 87, 95], ["mass", "OBSERVATION", 96, 100], ["severe", "OBSERVATION_MODIFIER", 108, 114], ["physiological", "OBSERVATION_MODIFIER", 115, 128], ["impairment", "OBSERVATION", 129, 139], ["large", "OBSERVATION_MODIFIER", 141, 146], ["radiological extent", "OBSERVATION_MODIFIER", 147, 166], ["disease", "OBSERVATION", 170, 177], ["pulmonary", "ANATOMY", 198, 207], ["hypertension", "OBSERVATION", 208, 220], ["IPF", "OBSERVATION", 251, 254], ["pulmonary", "ANATOMY", 349, 358]]], ["At presentation, lung physiology displays a restrictive pattern, usually with a forced vital capacity (FVC) between 70 and 80 % of predicted values, with or without hypoxemia at rest, worsening during exercise.", [["lung", "ANATOMY", 17, 21], ["hypoxemia", "DISEASE", 165, 174], ["lung", "ORGAN", 17, 21], ["lung physiology", "TEST", 17, 32], ["a restrictive pattern", "PROBLEM", 42, 63], ["a forced vital capacity", "TEST", 78, 101], ["FVC", "TEST", 103, 106], ["hypoxemia", "PROBLEM", 165, 174], ["lung", "ANATOMY", 17, 21], ["restrictive pattern", "OBSERVATION", 44, 63], ["without", "UNCERTAINTY", 157, 164], ["hypoxemia", "OBSERVATION", 165, 174], ["worsening", "OBSERVATION_MODIFIER", 184, 193]]], ["During the course of the disease, progression is often unpredictable: the decrease in FVC is often not linear from ~75 % (when diagnosis is made) to ~25 % of predicted values (an FVC lower than 25\u201330 % of predicted is invariably associated with death within weeks or months.)", [["death", "DISEASE", 245, 250], ["FVC", "GENE_OR_GENE_PRODUCT", 86, 89], ["the disease", "PROBLEM", 21, 32], ["the decrease in FVC", "PROBLEM", 70, 89], ["an FVC", "TEST", 176, 182], ["disease", "OBSERVATION", 25, 32], ["decrease", "OBSERVATION_MODIFIER", 74, 82]]], ["Besides the typical pattern of chronic progressive disease, a subgroup of patients, mainly male cigarette smokers, have a rapidly progressive course associated with shorter survival, known as accelerated IPF, despite similar presentation at the time of diagnosis [4].IntroductionPatients with IPF may also experience acute respiratory deteriorations.", [["respiratory", "ANATOMY", 323, 334], ["chronic progressive disease", "DISEASE", 31, 58], ["IPF", "DISEASE", 204, 207], ["IPF", "DISEASE", 293, 296], ["respiratory deteriorations", "DISEASE", 323, 349], ["patients", "ORGANISM", 74, 82], ["cigarette", "ORGANISM", 96, 105], ["patients", "SPECIES", 74, 82], ["chronic progressive disease", "PROBLEM", 31, 58], ["accelerated IPF", "PROBLEM", 192, 207], ["IPF", "PROBLEM", 293, 296], ["acute respiratory deteriorations", "PROBLEM", 317, 349], ["chronic", "OBSERVATION_MODIFIER", 31, 38], ["progressive", "OBSERVATION_MODIFIER", 39, 50], ["disease", "OBSERVATION", 51, 58], ["IPF", "OBSERVATION", 204, 207], ["IPF", "OBSERVATION", 293, 296], ["acute", "OBSERVATION_MODIFIER", 317, 322], ["respiratory", "ANATOMY", 323, 334], ["deteriorations", "OBSERVATION", 335, 349]]], ["Many of these acute declines are idiopathic, i.e. without identifiable causes (infections, left heart failure, pulmonary embolism, etc.).", [["heart", "ANATOMY", 96, 101], ["pulmonary", "ANATOMY", 111, 120], ["infections", "DISEASE", 79, 89], ["left heart failure", "DISEASE", 91, 109], ["pulmonary embolism", "DISEASE", 111, 129], ["heart", "ORGAN", 96, 101], ["pulmonary", "ORGAN", 111, 120], ["these acute declines", "PROBLEM", 8, 28], ["idiopathic", "PROBLEM", 33, 43], ["identifiable causes (infections", "PROBLEM", 58, 89], ["left heart failure", "PROBLEM", 91, 109], ["pulmonary embolism", "PROBLEM", 111, 129], ["acute", "OBSERVATION_MODIFIER", 14, 19], ["declines", "OBSERVATION", 20, 28], ["idiopathic", "OBSERVATION", 33, 43], ["without", "UNCERTAINTY", 50, 57], ["infections", "OBSERVATION", 79, 89], ["left", "ANATOMY_MODIFIER", 91, 95], ["heart", "ANATOMY", 96, 101], ["failure", "OBSERVATION", 102, 109], ["pulmonary", "ANATOMY", 111, 120], ["embolism", "OBSERVATION", 121, 129]]], ["These episodes of idiopathic acute deterioration have been termed acute exacerbations (AE) of IPF [5].IntroductionBoth accelerated IPF and AE-IPF can occur successively in the same patient, suggesting that these different IPF phenotypes may represent an acceleration of the underlying fibroproliferative disorder.IntroductionIn contrast to AE of asthma or chronic obstructive pulmonary disease, AE-IPF designates idiopathic acute worsening with progression of fibrosis.", [["pulmonary", "ANATOMY", 376, 385], ["idiopathic acute deterioration", "DISEASE", 18, 48], ["IPF", "DISEASE", 94, 97], ["IPF", "DISEASE", 131, 134], ["IPF", "DISEASE", 142, 145], ["IPF", "DISEASE", 222, 225], ["fibroproliferative disorder", "DISEASE", 285, 312], ["asthma", "DISEASE", 346, 352], ["chronic obstructive pulmonary disease", "DISEASE", 356, 393], ["IPF", "DISEASE", 398, 401], ["fibrosis", "DISEASE", 460, 468], ["patient", "ORGANISM", 181, 188], ["pulmonary", "ORGAN", 376, 385], ["patient", "SPECIES", 181, 188], ["idiopathic acute deterioration", "PROBLEM", 18, 48], ["acute exacerbations", "PROBLEM", 66, 85], ["IPF", "PROBLEM", 94, 97], ["IntroductionBoth accelerated IPF", "PROBLEM", 102, 134], ["AE", "PROBLEM", 139, 141], ["IPF", "PROBLEM", 142, 145], ["these different IPF phenotypes", "PROBLEM", 206, 236], ["the underlying fibroproliferative disorder", "PROBLEM", 270, 312], ["IntroductionIn contrast", "TREATMENT", 313, 336], ["asthma", "PROBLEM", 346, 352], ["chronic obstructive pulmonary disease", "PROBLEM", 356, 393], ["IPF", "PROBLEM", 398, 401], ["idiopathic acute worsening", "PROBLEM", 413, 439], ["fibrosis", "PROBLEM", 460, 468], ["idiopathic", "OBSERVATION_MODIFIER", 18, 28], ["acute", "OBSERVATION_MODIFIER", 29, 34], ["deterioration", "OBSERVATION", 35, 48], ["acute", "OBSERVATION_MODIFIER", 66, 71], ["exacerbations", "OBSERVATION", 72, 85], ["IPF", "OBSERVATION", 94, 97], ["IPF", "OBSERVATION", 131, 134], ["IPF", "OBSERVATION", 142, 145], ["different", "OBSERVATION_MODIFIER", 212, 221], ["IPF", "OBSERVATION", 222, 225], ["may represent", "UNCERTAINTY", 237, 250], ["acceleration", "OBSERVATION_MODIFIER", 254, 266], ["underlying", "OBSERVATION_MODIFIER", 274, 284], ["fibroproliferative", "OBSERVATION_MODIFIER", 285, 303], ["disorder", "OBSERVATION", 304, 312], ["asthma", "OBSERVATION", 346, 352], ["chronic", "OBSERVATION_MODIFIER", 356, 363], ["obstructive", "OBSERVATION_MODIFIER", 364, 375], ["pulmonary", "ANATOMY", 376, 385], ["disease", "OBSERVATION", 386, 393], ["IPF", "OBSERVATION", 398, 401], ["idiopathic", "OBSERVATION_MODIFIER", 413, 423], ["acute", "OBSERVATION_MODIFIER", 424, 429], ["worsening", "OBSERVATION_MODIFIER", 430, 439], ["progression", "OBSERVATION_MODIFIER", 445, 456], ["fibrosis", "OBSERVATION", 460, 468]]], ["This article will review the definition, the pathophysiology and the clinical, diagnostic and therapeutic issues related to AE-IPF.DefinitionIn 1993, Kondoh et al. [6] described an acute clinical deterioration in three IPF patients in whom acute influenza-like symptoms, cough, fever, leukocytosis and progressive hypoxia developed in the absence of an identified infection.", [["IPF", "DISEASE", 127, 130], ["IPF", "DISEASE", 219, 222], ["influenza-like symptoms", "DISEASE", 246, 269], ["cough", "DISEASE", 271, 276], ["fever", "DISEASE", 278, 283], ["leukocytosis", "DISEASE", 285, 297], ["hypoxia", "DISEASE", 314, 321], ["infection", "DISEASE", 364, 373], ["patients", "ORGANISM", 223, 231], ["patients", "SPECIES", 223, 231], ["IPF", "PROBLEM", 127, 130], ["an acute clinical deterioration", "PROBLEM", 178, 209], ["acute influenza-like symptoms", "PROBLEM", 240, 269], ["cough", "PROBLEM", 271, 276], ["fever", "PROBLEM", 278, 283], ["leukocytosis", "PROBLEM", 285, 297], ["progressive hypoxia", "PROBLEM", 302, 321], ["an identified infection", "PROBLEM", 350, 373], ["IPF", "OBSERVATION", 127, 130], ["acute", "OBSERVATION_MODIFIER", 181, 186], ["acute", "OBSERVATION_MODIFIER", 240, 245], ["influenza", "OBSERVATION", 246, 255], ["leukocytosis", "OBSERVATION", 285, 297], ["progressive", "OBSERVATION_MODIFIER", 302, 313], ["hypoxia", "OBSERVATION", 314, 321], ["infection", "OBSERVATION", 364, 373]]], ["Histologic findings from open-lung biopsy showed both UIP and an organizing acute lung injury pattern.DefinitionMore recently, Collard et al. [5]\u2014in a consensus statement aimed at giving a standard definition of AE-IPF\u2014describe this event as an acute, clinically significant deterioration of unidentifiable cause in a patient with underlying IPF and distinct from acute respiratory worsening related to a known cause.", [["lung", "ANATOMY", 30, 34], ["lung", "ANATOMY", 82, 86], ["respiratory", "ANATOMY", 370, 381], ["UIP", "DISEASE", 54, 57], ["acute lung injury", "DISEASE", 76, 93], ["IPF", "DISEASE", 215, 218], ["IPF", "DISEASE", 342, 345], ["lung biopsy", "MULTI-TISSUE_STRUCTURE", 30, 41], ["lung", "ORGAN", 82, 86], ["patient", "ORGANISM", 318, 325], ["patient", "SPECIES", 318, 325], ["Histologic findings", "TEST", 0, 19], ["open-lung biopsy", "TEST", 25, 41], ["both UIP", "PROBLEM", 49, 57], ["an organizing acute lung injury pattern", "PROBLEM", 62, 101], ["IPF", "PROBLEM", 215, 218], ["underlying IPF", "PROBLEM", 331, 345], ["acute respiratory worsening", "PROBLEM", 364, 391], ["lung", "ANATOMY", 30, 34], ["biopsy", "OBSERVATION", 35, 41], ["both", "ANATOMY_MODIFIER", 49, 53], ["UIP", "OBSERVATION", 54, 57], ["organizing", "OBSERVATION_MODIFIER", 65, 75], ["acute", "OBSERVATION_MODIFIER", 76, 81], ["lung", "ANATOMY", 82, 86], ["injury", "OBSERVATION", 87, 93], ["acute", "OBSERVATION_MODIFIER", 245, 250], ["IPF", "OBSERVATION", 342, 345], ["acute", "OBSERVATION_MODIFIER", 364, 369], ["respiratory", "ANATOMY", 370, 381], ["worsening", "OBSERVATION", 382, 391]]], ["Criteria for the consensus definition of AE-IPF are listed in Table 1.", [["IPF", "DISEASE", 44, 47], ["IPF", "PROBLEM", 44, 47], ["IPF", "OBSERVATION", 44, 47]]], ["As criteria may be lacking [in patients with a clinical worsening for more than 30 days, or in patients in whom HRCT or bronchoalveolar lavage (BAL) has not been performed], IPF patients with clinical worsening of unknown cause but not fulfilling all criteria should be considered as \u201csuspected AE-IPF,\u201d an event that nevertheless is relevant in practice and possibly in clinical trials [5].", [["bronchoalveolar lavage", "ANATOMY", 120, 142], ["BAL", "ANATOMY", 144, 147], ["IPF", "DISEASE", 174, 177], ["IPF", "DISEASE", 298, 301], ["patients", "ORGANISM", 31, 39], ["patients", "ORGANISM", 95, 103], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 120, 142], ["BAL", "MULTI-TISSUE_STRUCTURE", 144, 147], ["patients", "ORGANISM", 178, 186], ["patients", "SPECIES", 31, 39], ["patients", "SPECIES", 95, 103], ["patients", "SPECIES", 178, 186], ["a clinical worsening", "PROBLEM", 45, 65], ["HRCT", "TEST", 112, 116], ["bronchoalveolar lavage (BAL", "TEST", 120, 147], ["IPF", "PROBLEM", 298, 301], ["bronchoalveolar lavage", "OBSERVATION", 120, 142], ["IPF", "OBSERVATION", 298, 301]]]], "d9b7e741f8d18d39308f908ac84b30b8434e8476": [["IntroductionVisceral leishmaniasis (VL) is a zoonosis caused by Leishmania (Leishmania) infantum that is found around the Mediterranean area as well throughout the neotropics.", [["IntroductionVisceral leishmaniasis", "DISEASE", 0, 34], ["VL", "DISEASE", 36, 38], ["zoonosis", "DISEASE", 45, 53], ["Leishmania (Leishmania) infantum", "DISEASE", 64, 96], ["Leishmania (Leishmania) infantum", "ORGANISM", 64, 96], ["Leishmania) infantum", "SPECIES", 76, 96], ["Leishmania) infantum", "SPECIES", 76, 96], ["IntroductionVisceral leishmaniasis", "PROBLEM", 0, 34], ["a zoonosis", "PROBLEM", 43, 53], ["Leishmania (Leishmania) infantum", "PROBLEM", 64, 96], ["leishmaniasis", "OBSERVATION", 21, 34], ["zoonosis", "OBSERVATION", 45, 53], ["Leishmania", "OBSERVATION", 64, 74], ["Leishmania", "OBSERVATION_MODIFIER", 76, 86], ["Mediterranean", "ANATOMY_MODIFIER", 122, 135]]], ["The human disease in these regions is associated with the presence of domestic dogs and the parasite is transmitted by phlebotomine sandflies (Diptera: Psychodidae), the main neotropical vector being Lutzomyia longipalpis (Lutz and Neiva, 1912) .IntroductionVL has an important role in public health in Brazil due to its high incidence, wide geographical distribution, marked increase in transmission associated with urbanisation, and following the emergence of the disease as an opportunistic infection in human immunodeficiency virus (HIV)-infected individuals.", [["human disease", "DISEASE", 4, 17], ["opportunistic infection", "DISEASE", 480, 503], ["human immunodeficiency virus (HIV)-infected", "DISEASE", 507, 550], ["human", "ORGANISM", 4, 9], ["dogs", "ORGANISM", 79, 83], ["phlebotomine sandflies", "ORGANISM", 119, 141], ["Diptera: Psychodidae", "ORGANISM", 143, 163], ["Lutzomyia longipalpis", "ORGANISM", 200, 221], ["human immunodeficiency virus", "ORGANISM", 507, 535], ["HIV", "ORGANISM", 537, 540], ["individuals", "ORGANISM", 551, 562], ["human", "SPECIES", 4, 9], ["dogs", "SPECIES", 79, 83], ["Lutzomyia longipalpis", "SPECIES", 200, 221], ["human immunodeficiency virus (HIV", "SPECIES", 507, 540], ["human", "SPECIES", 4, 9], ["Lutzomyia longipalpis", "SPECIES", 200, 221], ["human immunodeficiency virus", "SPECIES", 507, 535], ["HIV", "SPECIES", 537, 540], ["The human disease in these regions", "PROBLEM", 0, 34], ["domestic dogs", "PROBLEM", 70, 83], ["the parasite", "PROBLEM", 88, 100], ["the disease", "PROBLEM", 462, 473], ["an opportunistic infection", "PROBLEM", 477, 503], ["human immunodeficiency virus", "PROBLEM", 507, 535], ["infected individuals", "PROBLEM", 542, 562], ["human", "OBSERVATION_MODIFIER", 4, 9], ["disease", "OBSERVATION", 10, 17], ["domestic dogs", "OBSERVATION", 70, 83], ["parasite", "OBSERVATION_MODIFIER", 92, 100], ["marked", "OBSERVATION_MODIFIER", 369, 375], ["increase", "OBSERVATION_MODIFIER", 376, 384], ["opportunistic", "OBSERVATION_MODIFIER", 480, 493], ["infection", "OBSERVATION", 494, 503]]], ["Control measures are currently based on the treatment of human cases, spraying of houses and animal shelters with residual insecticides, and the culling of dogs identified as seropositive by the indirect immunofluorescent antibody test (IFAT) or enzyme-linked immunosorbent assays (ELISAs).", [["human", "ORGANISM", 57, 62], ["dogs", "ORGANISM", 156, 160], ["human", "SPECIES", 57, 62], ["dogs", "SPECIES", 156, 160], ["human", "SPECIES", 57, 62], ["residual insecticides", "PROBLEM", 114, 135], ["the indirect immunofluorescent antibody test", "TEST", 191, 235], ["IFAT", "TEST", 237, 241], ["enzyme", "TEST", 246, 252], ["immunosorbent assays", "TEST", 260, 280]]], ["These measures do not however represent a permanent solution and new VL foci continue to appear throughout the country.IntroductionIn urban areas, the domestic dog is the main reservoir of L. infantum and canine VL is associated with human cases of disease, acquired when sandflies infected by feeding on infected animals take a subsequent blood meal from humans (Moreno and Alvar, 2002) .", [["blood", "ANATOMY", 340, 345], ["VL", "DISEASE", 212, 214], ["sandflies infected", "DISEASE", 272, 290], ["dog", "ORGANISM", 160, 163], ["L. infantum", "ORGANISM", 189, 200], ["canine VL", "ORGANISM", 205, 214], ["human", "ORGANISM", 234, 239], ["blood", "ORGANISM_SUBSTANCE", 340, 345], ["humans", "ORGANISM", 356, 362], ["dog", "SPECIES", 160, 163], ["L. infantum", "SPECIES", 189, 200], ["canine", "SPECIES", 205, 211], ["human", "SPECIES", 234, 239], ["humans", "SPECIES", 356, 362], ["L. infantum", "SPECIES", 189, 200], ["canine", "SPECIES", 205, 211], ["human", "SPECIES", 234, 239], ["humans", "SPECIES", 356, 362], ["a permanent solution", "TREATMENT", 40, 60], ["new VL foci", "PROBLEM", 65, 76], ["IntroductionIn urban areas", "TREATMENT", 119, 145], ["disease", "PROBLEM", 249, 256], ["not however represent", "UNCERTAINTY", 18, 39], ["permanent", "OBSERVATION", 42, 51], ["new", "OBSERVATION_MODIFIER", 65, 68], ["VL", "OBSERVATION_MODIFIER", 69, 71], ["foci", "OBSERVATION", 72, 76], ["domestic dog", "OBSERVATION", 151, 163], ["main", "OBSERVATION_MODIFIER", 171, 175], ["reservoir", "OBSERVATION_MODIFIER", 176, 185], ["L. infantum", "OBSERVATION", 189, 200], ["disease", "OBSERVATION", 249, 256]]], ["Infected dogs may present with a wide range of clinical profiles, from apparently healthy to critically diseased (Ciaramella et al., 1997) , depending on the balance between cellular and humoral responses (Pinelli et al., 1994; Ferrer, 1999; Pinnelli et al., 1999) .", [["cellular", "ANATOMY", 174, 182], ["dogs", "ORGANISM", 9, 13], ["cellular", "CELL", 174, 182], ["dogs", "SPECIES", 9, 13], ["Infected dogs", "PROBLEM", 0, 13], ["dogs", "OBSERVATION", 9, 13]]], ["Mancianti et al. (1998) suggested that these animals could be classified as: asymptomatic, with no clinical signs of Leishmania infection; oligosymptomatic, presenting lymphadenopathy, slight weight loss and/or alopecia; or symptomatic, showing all or some of the severe signs of the disease, including cutaneous lesions, onychogryphosis, keratoconjunctivitis and rigidity of the hind limbs.IntroductionImmunoglobulin (Ig)G production by infected dogs may involve IgG 1 , IgG 2 , IgG 3 and IgG 4 subclasses of immunoglobulins (Deplazes et al., 1995; Quinnell et al., 2003) .", [["cutaneous lesions", "ANATOMY", 303, 320], ["hind limbs", "ANATOMY", 380, 390], ["Leishmania infection", "DISEASE", 117, 137], ["lymphadenopathy", "DISEASE", 168, 183], ["weight loss", "DISEASE", 192, 203], ["alopecia", "DISEASE", 211, 219], ["onychogryphosis", "DISEASE", 322, 337], ["keratoconjunctivitis", "DISEASE", 339, 359], ["rigidity", "DISEASE", 364, 372], ["animals", "ORGANISM", 45, 52], ["cutaneous lesions", "PATHOLOGICAL_FORMATION", 303, 320], ["hind limbs", "ORGANISM_SUBDIVISION", 380, 390], ["IntroductionImmunoglobulin (Ig)G", "GENE_OR_GENE_PRODUCT", 391, 423], ["dogs", "ORGANISM", 447, 451], ["IgG 1", "GENE_OR_GENE_PRODUCT", 464, 469], ["IgG 2", "GENE_OR_GENE_PRODUCT", 472, 477], ["IgG 3", "GENE_OR_GENE_PRODUCT", 480, 485], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 510, 525], ["IntroductionImmunoglobulin (Ig)G", "PROTEIN", 391, 423], ["IgG 1", "PROTEIN", 464, 469], ["IgG 2", "PROTEIN", 472, 477], ["IgG 3", "PROTEIN", 480, 485], ["IgG 4 subclasses", "PROTEIN", 490, 506], ["immunoglobulins", "PROTEIN", 510, 525], ["dogs", "SPECIES", 447, 451], ["Leishmania infection", "PROBLEM", 117, 137], ["oligosymptomatic", "PROBLEM", 139, 155], ["presenting lymphadenopathy", "PROBLEM", 157, 183], ["slight weight loss", "PROBLEM", 185, 203], ["alopecia", "PROBLEM", 211, 219], ["symptomatic", "PROBLEM", 224, 235], ["the disease", "PROBLEM", 280, 291], ["cutaneous lesions", "PROBLEM", 303, 320], ["onychogryphosis", "PROBLEM", 322, 337], ["keratoconjunctivitis", "PROBLEM", 339, 359], ["rigidity of the hind limbs", "PROBLEM", 364, 390], ["IntroductionImmunoglobulin (Ig)G production", "TREATMENT", 391, 434], ["infected dogs", "TEST", 438, 451], ["IgG", "TEST", 464, 467], ["IgG", "TEST", 472, 475], ["IgG", "TEST", 480, 483], ["IgG", "TEST", 490, 493], ["immunoglobulins", "TEST", 510, 525], ["Leishmania", "OBSERVATION_MODIFIER", 117, 127], ["infection", "OBSERVATION", 128, 137], ["lymphadenopathy", "OBSERVATION", 168, 183], ["slight", "OBSERVATION_MODIFIER", 185, 191], ["weight loss", "OBSERVATION", 192, 203], ["alopecia", "OBSERVATION", 211, 219], ["severe", "OBSERVATION_MODIFIER", 264, 270], ["disease", "OBSERVATION", 284, 291], ["cutaneous", "ANATOMY", 303, 312], ["lesions", "OBSERVATION", 313, 320], ["keratoconjunctivitis", "OBSERVATION", 339, 359], ["rigidity", "OBSERVATION_MODIFIER", 364, 372], ["hind limbs", "ANATOMY", 380, 390]]], ["Bourdoiseau et al. (1997a) detected IgG 1 and IgG 2 subclasses in serum samples from symptomatic and asymptomatic dogs.", [["serum samples", "ANATOMY", 66, 79], ["IgG 1", "GENE_OR_GENE_PRODUCT", 36, 41], ["IgG 2 subclasses", "GENE_OR_GENE_PRODUCT", 46, 62], ["serum samples", "ORGANISM_SUBSTANCE", 66, 79], ["dogs", "ORGANISM", 114, 118], ["IgG 1", "PROTEIN", 36, 41], ["IgG 2 subclasses", "PROTEIN", 46, 62], ["dogs", "SPECIES", 114, 118], ["IgG", "TEST", 36, 39], ["IgG", "TEST", 46, 49], ["serum samples", "TEST", 66, 79], ["symptomatic and asymptomatic dogs", "PROBLEM", 85, 118]]], ["The IgG 2 levels were always predominant but no differences were observed that could be correlated with categories of clinical signs.", [["IgG 2", "GENE_OR_GENE_PRODUCT", 4, 9], ["IgG 2", "PROTEIN", 4, 9], ["The IgG 2 levels", "TEST", 0, 16], ["clinical signs", "TEST", 118, 132], ["always predominant", "OBSERVATION_MODIFIER", 22, 40]]], ["Vercammen et al. (2002) found that dogs naturally infected with L. infantum presented great variations in IgG 1 and IgG 2 levels with IgG 2 always present at high levels but IgG 1 detected in only 6/ 11 animals examined.", [["dogs", "ORGANISM", 35, 39], ["L. infantum", "ORGANISM", 64, 75], ["IgG 1", "GENE_OR_GENE_PRODUCT", 106, 111], ["IgG 2", "GENE_OR_GENE_PRODUCT", 116, 121], ["IgG 2", "GENE_OR_GENE_PRODUCT", 134, 139], ["IgG 1", "GENE_OR_GENE_PRODUCT", 174, 179], ["IgG 1", "PROTEIN", 106, 111], ["IgG 2", "PROTEIN", 116, 121], ["IgG 2", "PROTEIN", 134, 139], ["IgG 1", "PROTEIN", 174, 179], ["dogs", "SPECIES", 35, 39], ["L. infantum", "SPECIES", 64, 75], ["L. infantum", "SPECIES", 64, 75], ["L. infantum", "PROBLEM", 64, 75], ["IgG", "TEST", 106, 109], ["IgG 2 levels", "TEST", 116, 128], ["IgG", "TEST", 134, 137], ["IgG", "TEST", 174, 177], ["great", "OBSERVATION_MODIFIER", 86, 91]]], ["In a study of Brazilian dogs naturally infected with L. infantum, Quinnell et al. (2003) obtained very different results from those of the previous study with animals in which the parasite could be detected showing higher levels of IgG 1 than IgG 2 .IntroductionHaematological and serum biochemical measurements in L. infantum-infected dogs have limited applications for disease diagnosis but can be very important in evaluating the clinical status of the animal, as well as in the understanding of VL pathogenesis (Ikeda et al., 2002; Reis et al., 2006a) .", [["serum", "ANATOMY", 281, 286], ["L. infantum", "DISEASE", 53, 64], ["VL", "DISEASE", 499, 501], ["dogs", "ORGANISM", 24, 28], ["L. infantum", "ORGANISM", 53, 64], ["IgG 1", "GENE_OR_GENE_PRODUCT", 232, 237], ["IgG 2", "GENE_OR_GENE_PRODUCT", 243, 248], ["serum", "ORGANISM_SUBSTANCE", 281, 286], ["L. infantum", "ORGANISM", 315, 326], ["dogs", "ORGANISM", 336, 340], ["IgG 1", "PROTEIN", 232, 237], ["IgG 2", "PROTEIN", 243, 248], ["dogs", "SPECIES", 24, 28], ["L. infantum", "SPECIES", 53, 64], ["L. infantum", "SPECIES", 315, 326], ["dogs", "SPECIES", 336, 340], ["L. infantum", "SPECIES", 53, 64], ["L. infantum", "SPECIES", 315, 326], ["a study", "TEST", 3, 10], ["the previous study", "TEST", 135, 153], ["IgG", "TEST", 232, 235], ["serum biochemical measurements", "TEST", 281, 311], ["infected dogs", "PROBLEM", 327, 340], ["disease diagnosis", "PROBLEM", 371, 388]]], ["Although not universally accepted (Moreno et al., 1998; Amusategui et al., 2003) , anaemia is a frequent clinical sign in canine VL, occurring in 50-70% of patients as normocytic, normochromic and non-regenerative (Abranches et al., 1991; Ciaramella et al., 1997; Koutinas et al., 1999; Ikeda et al., 2002; Reis et al., 2006a) .", [["anaemia", "DISEASE", 83, 90], ["canine VL", "DISEASE", 122, 131], ["canine", "ORGANISM", 122, 128], ["patients", "ORGANISM", 156, 164], ["patients", "SPECIES", 156, 164], ["canine", "SPECIES", 122, 128], ["anaemia", "PROBLEM", 83, 90], ["a frequent clinical sign in canine VL", "PROBLEM", 94, 131], ["normocytic", "PROBLEM", 168, 178], ["anaemia", "OBSERVATION", 83, 90], ["canine VL", "OBSERVATION", 122, 131], ["normocytic", "OBSERVATION", 168, 178]]], ["The possible causes of the anaemia are blood loss due to epistaxis and skin ulcerations, haemolysis, generalised inflammation, renal insufficiency and bone marrow hypoplasia or aplasia (Anosa and Idowu, 1983; Slappendel and Greene, 1990; Koutinas et al., 1999) .IntroductionDecreased lipid fluidity of erythrocytes was found in 17 dogs with anaemia caused by L. infantum infection by De Luna et al. (2000) .", [["blood", "ANATOMY", 39, 44], ["skin", "ANATOMY", 71, 75], ["renal", "ANATOMY", 127, 132], ["bone marrow", "ANATOMY", 151, 162], ["erythrocytes", "ANATOMY", 302, 314], ["anaemia", "DISEASE", 27, 34], ["blood loss", "DISEASE", 39, 49], ["epistaxis", "DISEASE", 57, 66], ["skin ulcerations", "DISEASE", 71, 87], ["haemolysis", "DISEASE", 89, 99], ["inflammation", "DISEASE", 113, 125], ["renal insufficiency", "DISEASE", 127, 146], ["bone marrow hypoplasia", "DISEASE", 151, 173], ["aplasia", "DISEASE", 177, 184], ["anaemia", "DISEASE", 341, 348], ["L. infantum infection", "DISEASE", 359, 380], ["blood", "ORGANISM_SUBSTANCE", 39, 44], ["skin", "ORGAN", 71, 75], ["renal", "ORGAN", 127, 132], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 151, 162], ["lipid", "SIMPLE_CHEMICAL", 284, 289], ["erythrocytes", "ORGANISM_SUBSTANCE", 302, 314], ["dogs", "ORGANISM", 331, 335], ["L. infantum", "ORGANISM", 359, 370], ["erythrocytes", "CELL_TYPE", 302, 314], ["dogs", "SPECIES", 331, 335], ["L. infantum", "SPECIES", 359, 370], ["L. infantum", "SPECIES", 359, 370], ["the anaemia", "PROBLEM", 23, 34], ["blood loss", "PROBLEM", 39, 49], ["epistaxis", "PROBLEM", 57, 66], ["skin ulcerations", "PROBLEM", 71, 87], ["haemolysis", "PROBLEM", 89, 99], ["generalised inflammation", "PROBLEM", 101, 125], ["renal insufficiency", "PROBLEM", 127, 146], ["bone marrow hypoplasia", "PROBLEM", 151, 173], ["aplasia", "PROBLEM", 177, 184], ["Decreased lipid fluidity of erythrocytes", "PROBLEM", 274, 314], ["anaemia", "PROBLEM", 341, 348], ["L. infantum infection", "PROBLEM", 359, 380], ["possible causes of", "UNCERTAINTY", 4, 22], ["anaemia", "OBSERVATION", 27, 34], ["blood loss", "OBSERVATION", 39, 49], ["epistaxis", "OBSERVATION", 57, 66], ["skin", "ANATOMY", 71, 75], ["ulcerations", "OBSERVATION", 76, 87], ["haemolysis", "OBSERVATION_MODIFIER", 89, 99], ["generalised", "OBSERVATION_MODIFIER", 101, 112], ["inflammation", "OBSERVATION", 113, 125], ["renal", "ANATOMY", 127, 132], ["insufficiency", "OBSERVATION", 133, 146], ["bone", "ANATOMY", 151, 155], ["marrow hypoplasia", "OBSERVATION", 156, 173], ["aplasia", "OBSERVATION", 177, 184], ["lipid fluidity", "OBSERVATION", 284, 298], ["erythrocytes", "ANATOMY", 302, 314], ["L.", "OBSERVATION_MODIFIER", 359, 361], ["infantum infection", "OBSERVATION", 362, 380]]], ["Sequestration of erythrocytes in the spleen due to cell rigidity, alterations in erythrocyte receptor ligands or both may result from decreased membrane fluidity and contribute to anaemia in these dogs.", [["erythrocytes", "ANATOMY", 17, 29], ["spleen", "ANATOMY", 37, 43], ["cell", "ANATOMY", 51, 55], ["erythrocyte", "ANATOMY", 81, 92], ["membrane", "ANATOMY", 144, 152], ["rigidity", "DISEASE", 56, 64], ["anaemia", "DISEASE", 180, 187], ["erythrocytes", "CELL", 17, 29], ["spleen", "ORGAN", 37, 43], ["cell", "CELL", 51, 55], ["erythrocyte receptor ligands", "GENE_OR_GENE_PRODUCT", 81, 109], ["membrane", "CELLULAR_COMPONENT", 144, 152], ["dogs", "ORGANISM", 197, 201], ["erythrocytes", "CELL_TYPE", 17, 29], ["erythrocyte receptor ligands", "PROTEIN", 81, 109], ["dogs", "SPECIES", 197, 201], ["Sequestration of erythrocytes in the spleen", "PROBLEM", 0, 43], ["cell rigidity", "PROBLEM", 51, 64], ["alterations in erythrocyte receptor ligands", "PROBLEM", 66, 109], ["decreased membrane fluidity", "PROBLEM", 134, 161], ["anaemia in these dogs", "PROBLEM", 180, 201], ["erythrocytes", "OBSERVATION", 17, 29], ["spleen", "ANATOMY", 37, 43], ["due to", "UNCERTAINTY", 44, 50], ["cell rigidity", "OBSERVATION", 51, 64], ["erythrocyte receptor ligands", "OBSERVATION", 81, 109], ["decreased membrane fluidity", "OBSERVATION", 134, 161], ["anaemia", "OBSERVATION", 180, 187]]], ["According to some authors (Amusategui et al., 2003; Reis et al., 2006a) anaemia in dogs with VL is related to the severity of clinical signs, with symptomatic dogs presenting with lower erythrocyte counts, haematocrit levels and haemoglobin concentrations.IntroductionXenodiagnosis cannot be recommended as a routine diagnostic technique, since it requires a ready supply of laboratory-colonised sandflies.", [["erythrocyte", "ANATOMY", 186, 197], ["anaemia", "DISEASE", 72, 79], ["VL", "DISEASE", 93, 95], ["dogs", "ORGANISM", 83, 87], ["dogs", "ORGANISM", 159, 163], ["erythrocyte", "CELL", 186, 197], ["haematocrit", "SIMPLE_CHEMICAL", 206, 217], ["haemoglobin", "SIMPLE_CHEMICAL", 229, 240], ["sandflies", "ORGANISM", 396, 405], ["dogs", "SPECIES", 83, 87], ["dogs", "SPECIES", 159, 163], ["anaemia in dogs", "PROBLEM", 72, 87], ["VL", "PROBLEM", 93, 95], ["clinical signs", "PROBLEM", 126, 140], ["symptomatic dogs", "PROBLEM", 147, 163], ["lower erythrocyte counts", "PROBLEM", 180, 204], ["haematocrit levels", "TEST", 206, 224], ["haemoglobin concentrations", "PROBLEM", 229, 255], ["a routine diagnostic technique", "TEST", 307, 337], ["anaemia", "OBSERVATION", 72, 79], ["VL", "ANATOMY", 93, 95], ["haemoglobin concentrations", "OBSERVATION", 229, 255]]], ["Using serial xenodiagnosis to assess the infectivity of dogs naturally infected with L. infantum, Travi et al. (2001) showed that asymptomatic individuals were unable to infect L. longipalpis females, while oligosymptomatic animals were infective at very low rates.", [["dogs", "ORGANISM", 56, 60], ["L. infantum", "ORGANISM", 85, 96], ["individuals", "ORGANISM", 143, 154], ["L. longipalpis", "ORGANISM", 177, 191], ["animals", "ORGANISM", 224, 231], ["dogs", "SPECIES", 56, 60], ["L. infantum", "SPECIES", 85, 96], ["L. longipalpis", "SPECIES", 177, 191], ["L. infantum", "SPECIES", 85, 96], ["L. longipalpis", "SPECIES", 177, 191], ["serial xenodiagnosis", "TEST", 6, 26], ["asymptomatic individuals", "PROBLEM", 130, 154], ["oligosymptomatic animals", "PROBLEM", 207, 231], ["infective", "PROBLEM", 237, 246], ["infective", "OBSERVATION", 237, 246]]], ["On the other hand, symptomatic animals were able to infect large numbers of females at a very high intensity.", [["symptomatic animals", "PROBLEM", 19, 38], ["a very high intensity", "PROBLEM", 87, 108], ["high intensity", "OBSERVATION_MODIFIER", 94, 108]]], ["These authors also showed the skin of the ear to be more heavily parasitised than that of the abdomen.", [["skin", "ANATOMY", 30, 34], ["ear", "ANATOMY", 42, 45], ["abdomen", "ANATOMY", 94, 101], ["skin", "ORGAN", 30, 34], ["ear", "ORGAN", 42, 45], ["abdomen", "ORGAN", 94, 101], ["skin", "ANATOMY", 30, 34], ["ear", "ANATOMY", 42, 45], ["more", "OBSERVATION_MODIFIER", 52, 56], ["heavily", "OBSERVATION_MODIFIER", 57, 64], ["parasitised", "OBSERVATION", 65, 76], ["abdomen", "ANATOMY", 94, 101]]], ["Courtenay et al. (2001) demonstrated that dogs became infective to L. longipalpis only after serum antibodies to the parasite could be detected and suggested that antibody titre could be used as a predictive factor.IntroductionIn the present study, xenodiagnosis was used as a tool to assess the reservoir competence of dogs with distinct clinical presentations and based on their serum levels of total IgG, IgG 1 and IgG 2 .", [["serum", "ANATOMY", 93, 98], ["serum", "ANATOMY", 381, 386], ["dogs", "ORGANISM", 42, 46], ["L. longipalpis", "ORGANISM", 67, 81], ["serum", "ORGANISM_SUBSTANCE", 93, 98], ["dogs", "ORGANISM", 320, 324], ["serum", "ORGANISM_SUBSTANCE", 381, 386], ["IgG", "GENE_OR_GENE_PRODUCT", 403, 406], ["IgG 1", "GENE_OR_GENE_PRODUCT", 408, 413], ["IgG 2", "GENE_OR_GENE_PRODUCT", 418, 423], ["serum antibodies", "PROTEIN", 93, 109], ["total IgG", "PROTEIN", 397, 406], ["IgG 1", "PROTEIN", 408, 413], ["IgG 2", "PROTEIN", 418, 423], ["dogs", "SPECIES", 42, 46], ["L. longipalpis", "SPECIES", 67, 81], ["dogs", "SPECIES", 320, 324], ["L. longipalpis", "SPECIES", 67, 81], ["infective to L. longipalpis", "PROBLEM", 54, 81], ["serum antibodies", "TEST", 93, 109], ["antibody titre", "TEST", 163, 177], ["the present study", "TEST", 230, 247], ["xenodiagnosis", "TEST", 249, 262], ["their serum levels", "TEST", 375, 393], ["total IgG", "TEST", 397, 406], ["IgG", "TEST", 408, 411], ["IgG", "TEST", 418, 421], ["infective", "OBSERVATION", 54, 63]]], ["Since dogs play a central role in the maintenance of VL foci, basic knowledge of infectivity to sandflies of dogs with different clinical presentations is important in order to generate epidemiological data from areas to which the disease has spread and where the prevalence of canine and human VL is increasing.AnimalsThe University Ethical Committee on Animal Experimentation sanctioned all experimental procedures.AnimalsForty-two male mongrel dogs obtained from the Belo Horizonte Municipal Zoonotic Diseases Control Department and weighing 5-35 kg were used in the experiments.", [["VL", "DISEASE", 295, 297], ["dogs", "ORGANISM", 6, 10], ["dogs", "ORGANISM", 109, 113], ["canine", "ORGANISM", 278, 284], ["human", "ORGANISM", 289, 294], ["mongrel", "ORGANISM", 439, 446], ["dogs", "ORGANISM", 447, 451], ["dogs", "SPECIES", 6, 10], ["dogs", "SPECIES", 109, 113], ["canine", "SPECIES", 278, 284], ["human", "SPECIES", 289, 294], ["dogs", "SPECIES", 447, 451], ["canine", "SPECIES", 278, 284], ["human", "SPECIES", 289, 294], ["VL foci", "PROBLEM", 53, 60], ["the disease", "PROBLEM", 227, 238], ["Animal Experimentation", "TREATMENT", 355, 377], ["all experimental procedures", "TREATMENT", 389, 416], ["central", "OBSERVATION_MODIFIER", 18, 25], ["VL", "ANATOMY", 53, 55], ["foci", "OBSERVATION", 56, 60], ["disease", "OBSERVATION", 231, 238], ["increasing", "OBSERVATION_MODIFIER", 301, 311]]], ["The animals had been diagnosed as Leishmania-seropositive and were destined for compulsory euthanasia, as required by Brazilian health regulations.", [["Leishmania-seropositive", "DISEASE", 34, 57], ["animals", "ORGANISM", 4, 11], ["Leishmania", "PROBLEM", 34, 44], ["seropositive", "PROBLEM", 45, 57], ["Leishmania", "OBSERVATION", 34, 44]]], ["The dogs received anti-parasitic medication during a 40 day settling-in period and were vaccinated against rabies, distemper, parvovirus, coronavirus, parainfluenza and two leptospirosis strains.", [["rabies, distemper, parvovirus, coronavirus, parainfluenza", "DISEASE", 107, 164], ["leptospirosis", "DISEASE", 173, 186], ["dogs", "ORGANISM", 4, 8], ["rabies", "ORGANISM", 107, 113], ["distemper", "ORGANISM", 115, 124], ["parvovirus", "ORGANISM", 126, 136], ["coronavirus", "ORGANISM", 138, 149], ["parainfluenza", "ORGANISM", 151, 164], ["dogs", "SPECIES", 4, 8], ["parvovirus, coronavirus", "SPECIES", 126, 149], ["parainfluenza", "SPECIES", 151, 164], ["rabies", "SPECIES", 107, 113], ["anti-parasitic medication", "TREATMENT", 18, 43], ["rabies", "PROBLEM", 107, 113], ["distemper", "PROBLEM", 115, 124], ["parvovirus", "PROBLEM", 126, 136], ["coronavirus", "PROBLEM", 138, 149], ["parainfluenza", "PROBLEM", 151, 164], ["two leptospirosis strains", "PROBLEM", 169, 194]]], ["During this period, as well as for the duration of the experiments, the animals were kept in communal kennels and received water and commercial dog food ad libitum.", [["animals", "ORGANISM", 72, 79], ["dog", "ORGANISM", 144, 147], ["dog", "SPECIES", 144, 147]]], ["They were then given a complete clinical examination and classified as asymptomatic, oligosymptomatic or symptomatic (Mancianti et al., 1998) .Collection of blood and serum samplesBlood for haematological analysis and serum for ELISA tests were obtained by jugular venepuncture from each dog, with 3 mL blood being collected into a vial containing ethylenediamine tetraacetic acid (EDTA).", [["blood", "ANATOMY", 157, 162], ["serum samples", "ANATOMY", 167, 180], ["Blood", "ANATOMY", 180, 185], ["haematological", "ANATOMY", 190, 204], ["serum", "ANATOMY", 218, 223], ["jugular", "ANATOMY", 257, 264], ["blood", "ANATOMY", 303, 308], ["ethylenediamine tetraacetic acid", "CHEMICAL", 348, 380], ["EDTA", "CHEMICAL", 382, 386], ["ethylenediamine tetraacetic acid", "CHEMICAL", 348, 380], ["EDTA", "CHEMICAL", 382, 386], ["blood", "ORGANISM_SUBSTANCE", 157, 162], ["serum samples", "ORGANISM_SUBSTANCE", 167, 180], ["Blood", "ORGANISM_SUBSTANCE", 180, 185], ["serum", "ORGANISM_SUBSTANCE", 218, 223], ["jugular venepuncture", "MULTI-TISSUE_STRUCTURE", 257, 277], ["dog", "ORGANISM", 288, 291], ["blood", "ORGANISM_SUBSTANCE", 303, 308], ["ethylenediamine tetraacetic acid", "SIMPLE_CHEMICAL", 348, 380], ["EDTA", "SIMPLE_CHEMICAL", 382, 386], ["a complete clinical examination", "TEST", 21, 52], ["asymptomatic", "PROBLEM", 71, 83], ["oligosymptomatic", "PROBLEM", 85, 101], ["symptomatic", "PROBLEM", 105, 116], ["Collection of blood", "TEST", 143, 162], ["serum samples", "TEST", 167, 180], ["haematological analysis", "TEST", 190, 213], ["serum for ELISA tests", "TEST", 218, 239], ["3 mL blood", "TREATMENT", 298, 308], ["a vial containing ethylenediamine tetraacetic acid (EDTA", "TREATMENT", 330, 386], ["blood", "ANATOMY", 157, 162], ["jugular", "ANATOMY", 257, 264]]], ["A further 7 mL aliquot was collected into tubes without anticoagulant (Sarstedt), centrifuged at 200 g and the serum divided into three 2 mL samples, which were stored at \u00c020\u00b0C until analysed.Haematological analysisThe blood samples collected into EDTA were submitted to automatic analysis (ABCVet, ABX) to obtain complete blood cell (CBC) and platelet counts.", [["tubes", "ANATOMY", 42, 47], ["serum", "ANATOMY", 111, 116], ["samples", "ANATOMY", 141, 148], ["blood samples", "ANATOMY", 219, 232], ["blood cell", "ANATOMY", 323, 333], ["CBC", "ANATOMY", 335, 338], ["platelet", "ANATOMY", 344, 352], ["EDTA", "CHEMICAL", 248, 252], ["serum", "ORGANISM_SUBSTANCE", 111, 116], ["blood samples", "ORGANISM_SUBSTANCE", 219, 232], ["EDTA", "SIMPLE_CHEMICAL", 248, 252], ["blood cell", "CELL", 323, 333], ["CBC", "CELL", 335, 338], ["platelet", "CELL", 344, 352], ["A further 7 mL aliquot", "TREATMENT", 0, 22], ["anticoagulant (Sarstedt)", "TREATMENT", 56, 80], ["the serum", "TEST", 107, 116], ["Haematological analysis", "TEST", 192, 215], ["The blood samples", "TEST", 215, 232], ["EDTA", "TEST", 248, 252], ["automatic analysis", "TEST", 271, 289], ["ABX", "TREATMENT", 299, 302], ["complete blood cell", "TEST", 314, 333], ["CBC", "TEST", 335, 338], ["platelet counts", "TEST", 344, 359]]], ["Morphological characteristics of the blood cells and differential leucocyte counts were obtained by blood smear analysis after prior staining by routine methods.", [["blood cells", "ANATOMY", 37, 48], ["leucocyte", "ANATOMY", 66, 75], ["blood", "ANATOMY", 100, 105], ["blood cells", "CELL", 37, 48], ["leucocyte", "CELL", 66, 75], ["blood", "ORGANISM_SUBSTANCE", 100, 105], ["blood cells", "CELL_TYPE", 37, 48], ["the blood cells", "TEST", 33, 48], ["differential leucocyte counts", "TEST", 53, 82], ["blood smear analysis", "TEST", 100, 120], ["prior staining", "TEST", 127, 141], ["routine methods", "TEST", 145, 160], ["blood cells", "OBSERVATION", 37, 48]]], ["Reference values from the Clinical Pathology Laboratory of the Veterinary School were used to analyse the CBC results.Antibody ELISATotal IgG T , IgG 1 and IgG 2 serum concentrations were detected using a technique modified from that of Voller et al. (1979) .", [["serum", "ANATOMY", 162, 167], ["IgG T", "GENE_OR_GENE_PRODUCT", 138, 143], ["IgG 1", "GENE_OR_GENE_PRODUCT", 146, 151], ["IgG 2", "GENE_OR_GENE_PRODUCT", 156, 161], ["serum", "ORGANISM_SUBSTANCE", 162, 167], ["Antibody ELISATotal IgG T", "PROTEIN", 118, 143], ["IgG 1", "PROTEIN", 146, 151], ["IgG 2", "PROTEIN", 156, 161], ["the CBC", "TEST", 102, 109], ["Antibody", "TEST", 118, 126], ["ELISATotal", "TEST", 127, 137], ["IgG", "TEST", 138, 141], ["T", "TEST", 142, 143], ["IgG", "TEST", 146, 149], ["IgG", "TEST", 156, 159], ["serum concentrations", "TEST", 162, 182], ["a technique", "TREATMENT", 203, 214]]], ["The antigen was produced from cultured promastigotes of L. infantum strain MHOM/BR/1967/ BH46, previously ruptured by ultrasound (40 x) and centrifuged at 150 g for 10 min.", [["BH46", "ANATOMY", 89, 93], ["L. infantum", "ORGANISM", 56, 67], ["strain", "ORGANISM", 68, 74], ["MHOM/BR", "ORGANISM", 75, 82], ["BH46", "CELL", 89, 93], ["L. infantum", "SPECIES", 56, 67], ["L. infantum strain MHOM/BR/1967/ BH46", "SPECIES", 56, 93], ["ultrasound", "TEST", 118, 128], ["ruptured", "OBSERVATION", 106, 114]]], ["Individual wells of a 96-well microplate were coated with soluble antigen at a final concentration of 2 lg/mL in 0.05 M carbonate buffer (pH 9.6).", [["carbonate", "CHEMICAL", 120, 129], ["carbonate", "SIMPLE_CHEMICAL", 120, 129], ["soluble antigen", "PROTEIN", 58, 73], ["soluble antigen", "TREATMENT", 58, 73], ["0.05 M carbonate buffer", "TREATMENT", 113, 136], ["pH", "TEST", 138, 140]]], ["A volume of 100 lL per well was left overnight at 4\u00b0C and then washed five times in phosphate buffered saline (PBS) containing 0.2% Tween-20.", [["phosphate", "CHEMICAL", 84, 93], ["phosphate", "CHEMICAL", 84, 93], ["Tween-20", "CHEMICAL", 132, 140], ["C", "SIMPLE_CHEMICAL", 52, 53], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 84, 109], ["Tween-20", "SIMPLE_CHEMICAL", 132, 140], ["phosphate buffered saline (PBS)", "TREATMENT", 84, 115]]], ["Antigenic sites were saturated for 30 min at 37\u00b0C with 150 lL PBS containing 0.2% Tween-20 and 2% casein (Sigma; C0376).Antibody ELISAThe wells were washed again three times with PBS containing 0.2% Tween-20 and 100 lL per well of dog sera diluted 1:400 for detection of IgG T and IgG subclasses.", [["sera", "ANATOMY", 235, 239], ["Tween-20", "CHEMICAL", 82, 90], ["Tween-20", "SIMPLE_CHEMICAL", 82, 90], ["casein", "SIMPLE_CHEMICAL", 98, 104], ["Sigma; C0376", "SIMPLE_CHEMICAL", 106, 118], ["dog", "ORGANISM", 231, 234], ["sera", "ORGANISM_SUBSTANCE", 235, 239], ["IgG T", "GENE_OR_GENE_PRODUCT", 271, 276], ["IgG", "GENE_OR_GENE_PRODUCT", 281, 284], ["IgG T", "PROTEIN", 271, 276], ["IgG subclasses", "PROTEIN", 281, 295], ["dog", "SPECIES", 231, 234], ["dog", "SPECIES", 231, 234], ["Antigenic sites", "PROBLEM", 0, 15], ["lL PBS", "TEST", 59, 65], ["Antibody ELISAThe wells", "TREATMENT", 120, 143], ["PBS", "TEST", 179, 182], ["dog sera", "TEST", 231, 239], ["IgG T and IgG subclasses", "PROBLEM", 271, 295], ["saturated", "OBSERVATION_MODIFIER", 21, 30]]], ["After incubation for 45 min at 37\u00b0C, the plates were washed five times, followed by the addition of 100 lL per well of rabbit anti-dog IgG labelled with peroxidase (Sigma; P6782) diluted 1:2000.", [["rabbit", "ORGANISM", 119, 125], ["IgG", "GENE_OR_GENE_PRODUCT", 135, 138], ["peroxidase", "GENE_OR_GENE_PRODUCT", 153, 163], ["rabbit anti-dog IgG", "PROTEIN", 119, 138], ["peroxidase", "PROTEIN", 153, 163], ["rabbit", "SPECIES", 119, 125], ["rabbit", "SPECIES", 119, 125], ["the plates", "TREATMENT", 37, 47], ["rabbit anti-dog IgG", "TREATMENT", 119, 138]]], ["Peroxidase-labelled goat anti dog-specific chain immunoglobulins (Bethyl Laboratories; A120p, A121p) were used for IgG 1 and IgG 2 fraction detection.Antibody ELISAEnzyme-labelled antibody was diluted to 1:2000 and 1:1200 for IgG 1 and IgG 2 assays, respectively.", [["ELISAEnzyme", "CHEMICAL", 159, 170], ["Peroxidase", "GENE_OR_GENE_PRODUCT", 0, 10], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 49, 64], ["Bethyl", "GENE_OR_GENE_PRODUCT", 66, 72], ["A120p", "GENE_OR_GENE_PRODUCT", 87, 92], ["A121p", "GENE_OR_GENE_PRODUCT", 94, 99], ["IgG 1", "GENE_OR_GENE_PRODUCT", 115, 120], ["ELISAEnzyme", "SIMPLE_CHEMICAL", 159, 170], ["IgG 1", "GENE_OR_GENE_PRODUCT", 226, 231], ["Peroxidase-labelled goat anti dog-specific chain immunoglobulins", "PROTEIN", 0, 64], ["Bethyl Laboratories", "PROTEIN", 66, 85], ["A120p", "PROTEIN", 87, 92], ["A121p", "PROTEIN", 94, 99], ["IgG 1", "PROTEIN", 115, 120], ["Antibody ELISAEnzyme-labelled antibody", "PROTEIN", 150, 188], ["IgG 1", "PROTEIN", 226, 231], ["IgG 2", "PROTEIN", 236, 241], ["goat", "SPECIES", 20, 24], ["dog", "SPECIES", 30, 33], ["goat", "SPECIES", 20, 24], ["Peroxidase", "TEST", 0, 10], ["specific chain immunoglobulins", "TEST", 34, 64], ["Bethyl Laboratories", "TEST", 66, 85], ["IgG", "TEST", 115, 118], ["IgG 2 fraction detection", "TREATMENT", 125, 149], ["Antibody ELISAEnzyme", "TEST", 150, 170], ["labelled antibody", "TEST", 171, 188], ["IgG", "TEST", 226, 229], ["IgG", "TEST", 236, 239]]], ["These conjugates were incubated for 45 min at 37\u00b0C and the plates washed five times before 100 lL of a mixture of a 40% solution (w/v) of ortho-phenylenediamine (OPD) in phosphate/ citrate buffer (pH 5) and 30 volumes of H 2 O 2 was added to each well.", [["ortho-phenylenediamine", "CHEMICAL", 138, 160], ["phosphate/ citrate", "CHEMICAL", 170, 188], ["H 2 O", "CHEMICAL", 221, 226], ["ortho-phenylenediamine", "CHEMICAL", 138, 160], ["OPD", "CHEMICAL", 162, 165], ["phosphate", "CHEMICAL", 170, 179], ["citrate", "CHEMICAL", 181, 188], ["H 2 O 2", "CHEMICAL", 221, 228], ["C", "SIMPLE_CHEMICAL", 49, 50], ["ortho-phenylenediamine", "SIMPLE_CHEMICAL", 138, 160], ["OPD", "SIMPLE_CHEMICAL", 162, 165], ["phosphate/ citrate buffer", "SIMPLE_CHEMICAL", 170, 195], ["H 2 O 2", "SIMPLE_CHEMICAL", 221, 228], ["the plates", "TREATMENT", 55, 65], ["a 40% solution (w/v", "TREATMENT", 114, 133], ["ortho-phenylenediamine (OPD", "TREATMENT", 138, 165], ["phosphate/ citrate buffer", "TREATMENT", 170, 195]]], ["After incubation for 10 min in darkness, the reaction was stopped by the addition of 25 lL of 4N H 2 SO 4 to each well.", [["4N H", "CHEMICAL", 94, 98], ["4N H 2 SO 4", "CHEMICAL", 94, 105], ["the reaction", "PROBLEM", 41, 53]]], ["Absorbance values were read at 492 nm in an automatic ELISA reader (BioRad Model 550).", [["Absorbance values", "TEST", 0, 17]]], ["The cut-off point for each plate was determined as being the average absorbance reading plus twice the standard deviation of values for Brazilian dog samples obtained from areas not endemic for L. infantum.Source of sandfliesFive-day-old male and female L. longipalpis from a closed laboratory colony were used in the experiments.", [["samples", "ANATOMY", 150, 157], ["colony", "ANATOMY", 294, 300], ["dog", "ORGANISM", 146, 149], ["L. infantum", "ORGANISM", 194, 205], ["L. longipalpis", "ORGANISM", 254, 268], ["L. infantum", "SPECIES", 194, 205], ["L. longipalpis", "SPECIES", 254, 268], ["L. infantum", "SPECIES", 194, 205], ["L. longipalpis", "SPECIES", 254, 268], ["Brazilian dog samples", "TEST", 136, 157], ["L. infantum", "PROBLEM", 194, 205], ["a closed laboratory colony", "TREATMENT", 274, 300]]], ["This colony was initiated from sandflies collected in Teresina, in the North-Eastern Brazilian State of Piau\u00ed.", [["colony", "ANATOMY", 5, 11], ["This colony", "TREATMENT", 0, 11], ["colony", "OBSERVATION", 5, 11]]], ["The insects used in this study belonged to generations 46-51.", [["this study", "TEST", 20, 30]]], ["The colony was maintained according to the protocol of Modi and Tesh (1983) .Exposure of sandflies to L. infantum infectionSandflies were fed on dogs by putting the insects in a specially designed receptacle (FleboContainer), consisting of a semi-transparent PVC container 10 cm high and with a diameter of 8.7 cm.", [["colony", "ANATOMY", 4, 10], ["L. infantum infection", "DISEASE", 102, 123], ["sandflies", "ORGANISM", 89, 98], ["L. infantum", "ORGANISM", 102, 113], ["Sandflies", "ORGANISM", 123, 132], ["dogs", "ORGANISM", 145, 149], ["L. infantum", "SPECIES", 102, 113], ["dogs", "SPECIES", 145, 149], ["L. infantum", "SPECIES", 102, 113], ["L. infantum infection", "PROBLEM", 102, 123], ["a semi-transparent PVC container", "TREATMENT", 240, 272], ["colony", "OBSERVATION", 4, 10], ["diameter", "OBSERVATION_MODIFIER", 295, 303], ["8.7 cm", "OBSERVATION_MODIFIER", 307, 313]]], ["The screw lid had a 6 cm diameter nylon mesh window (80 apertures) cut in the centre, secured with silicon cement (Fig. 1) .", [["silicon", "CHEMICAL", 99, 106], ["The screw lid", "TREATMENT", 0, 13], ["a 6 cm diameter nylon mesh window", "TREATMENT", 18, 51], ["silicon cement", "TREATMENT", 99, 113], ["screw lid", "OBSERVATION", 4, 13], ["6 cm", "OBSERVATION_MODIFIER", 20, 24], ["diameter", "OBSERVATION_MODIFIER", 25, 33], ["nylon", "OBSERVATION_MODIFIER", 34, 39], ["mesh window", "OBSERVATION", 40, 51], ["silicon cement", "OBSERVATION", 99, 113]]], ["A 15 mm hole was made in the wall of the container about 10 cm from the bottom and sealed with a cork.", [["wall", "ANATOMY", 29, 33], ["wall", "TISSUE", 29, 33], ["A 15 mm hole", "TREATMENT", 0, 12], ["15 mm", "OBSERVATION_MODIFIER", 2, 7], ["hole", "OBSERVATION_MODIFIER", 8, 12], ["wall", "ANATOMY_MODIFIER", 29, 33], ["10 cm", "OBSERVATION_MODIFIER", 57, 62], ["bottom", "ANATOMY_MODIFIER", 72, 78], ["cork", "OBSERVATION_MODIFIER", 97, 101]]], ["Between 40-45 females and about the same number of males were used in each experimental replicate.Exposure of sandflies to L. infantum infectionThe FleboContainer netting was placed in direct contact with the medial skin of the dog's right ear (Travi et al., 2001) .", [["medial skin", "ANATOMY", 209, 220], ["right ear", "ANATOMY", 234, 243], ["L. infantum infection", "DISEASE", 123, 144], ["sandflies", "ORGANISM", 110, 119], ["L. infantum", "ORGANISM", 123, 134], ["medial skin", "ORGAN", 209, 220], ["dog", "ORGANISM", 228, 231], ["ear", "ORGAN", 240, 243], ["L. infantum", "SPECIES", 123, 134], ["dog", "SPECIES", 228, 231], ["L. infantum", "SPECIES", 123, 134], ["L. infantum infection", "PROBLEM", 123, 144], ["The FleboContainer netting", "TREATMENT", 144, 170], ["L.", "OBSERVATION_MODIFIER", 123, 125], ["infantum", "OBSERVATION_MODIFIER", 126, 134], ["infection", "OBSERVATION", 135, 144], ["medial", "ANATOMY_MODIFIER", 209, 215], ["skin", "ANATOMY", 216, 220], ["right ear", "ANATOMY", 234, 243]]], ["In order to prevent excessive movement, dogs were previously sedated with 0.8 or 1.2 mL/kg of acepromazine (Univet).", [["acepromazine", "CHEMICAL", 94, 106], ["acepromazine", "CHEMICAL", 94, 106], ["dogs", "ORGANISM", 40, 44], ["acepromazine", "SIMPLE_CHEMICAL", 94, 106], ["dogs", "SPECIES", 40, 44], ["excessive movement", "PROBLEM", 20, 38], ["acepromazine", "TREATMENT", 94, 106], ["excessive", "OBSERVATION_MODIFIER", 20, 29], ["movement", "OBSERVATION", 30, 38]]], ["Sandflies were allowed to feed directly on the ears of infected dogs for 40 min in a darkened room.", [["Sandflies", "ANATOMY", 0, 9], ["ears", "ANATOMY", 47, 51], ["ears", "ORGAN", 47, 51], ["dogs", "ORGANISM", 64, 68], ["dogs", "SPECIES", 64, 68]]], ["After feeding, the insects were returned to the insectary for five days.", [["insects", "ORGANISM", 19, 26]]], ["Twenty-four hours after the meal, fed flies were provided with a solution of fructose in distilled water (50:50 v/v) and kept at 28\u00b0C. Survival of the flies was monitored at least twice daily until they could be dissected and examined.Sandfly dissectionFive days after feeding, live male and female sandflies were counted and the engorged females dissected in a drop of PBS.", [["fructose", "CHEMICAL", 77, 85], ["fructose", "CHEMICAL", 77, 85], ["fructose", "SIMPLE_CHEMICAL", 77, 85], ["flies", "ORGANISM", 151, 156], ["sandflies", "ORGANISM", 299, 308], ["a solution of fructose in distilled water", "TREATMENT", 63, 104]]], ["The head of each engorged female fly was severed with a mounted needle and the gut removed.", [["head", "ANATOMY", 4, 8], ["gut", "ANATOMY", 79, 82], ["head", "ORGAN", 4, 8], ["gut", "ORGANISM_SUBDIVISION", 79, 82], ["a mounted needle", "TREATMENT", 54, 70], ["head", "ANATOMY", 4, 8], ["gut", "ANATOMY", 79, 82], ["removed", "OBSERVATION", 83, 90]]], ["The guts were examined under interference microscopy (Johnson et al., 1963) and the proportions of infected females and appearance of flagellates within the digestive tract of each sandfly recorded.", [["guts", "ANATOMY", 4, 8], ["digestive tract", "ANATOMY", 157, 172], ["guts", "ORGAN", 4, 8], ["digestive tract", "ORGANISM_SUBDIVISION", 157, 172], ["infected females", "PROBLEM", 99, 115], ["infected females", "OBSERVATION", 99, 115], ["flagellates", "OBSERVATION", 134, 145], ["digestive tract", "ANATOMY", 157, 172]]], ["The approximate numbers of promastigotes and their distribution in different parts of the gut were estimated based on observations using the 40\u00b7 objective of a microscope.Sandfly dissectionThe intensity of the sandfly infections showed great variability with regard to motility and localisation of promastigotes in the gut.", [["gut", "ANATOMY", 90, 93], ["gut", "ANATOMY", 319, 322], ["infections", "DISEASE", 218, 228], ["promastigotes", "CELL", 27, 40], ["gut", "ORGAN", 90, 93], ["gut", "ORGANISM_SUBDIVISION", 319, 322], ["promastigotes", "PROBLEM", 27, 40], ["a microscope", "TEST", 158, 170], ["Sandfly dissection", "PROBLEM", 171, 189], ["the sandfly infections", "PROBLEM", 206, 228], ["great variability", "PROBLEM", 236, 253], ["promastigotes in the gut", "PROBLEM", 298, 322], ["numbers", "OBSERVATION_MODIFIER", 16, 23], ["promastigotes", "OBSERVATION_MODIFIER", 27, 40], ["distribution", "OBSERVATION_MODIFIER", 51, 63], ["gut", "ANATOMY", 90, 93], ["dissection", "OBSERVATION", 179, 189], ["intensity", "OBSERVATION_MODIFIER", 193, 202], ["sandfly infections", "OBSERVATION", 210, 228], ["great variability", "OBSERVATION", 236, 253], ["gut", "ANATOMY", 319, 322]]], ["Intensity of infections was classified as ''low'' when few promastigotes were seen in the sandfly midgut with little or no motility.", [["midgut", "ANATOMY", 98, 104], ["infections", "DISEASE", 13, 23], ["sandfly", "ORGANISM", 90, 97], ["midgut", "ORGAN", 98, 104], ["Intensity of infections", "PROBLEM", 0, 23], ["few promastigotes", "PROBLEM", 55, 72], ["infections", "OBSERVATION", 13, 23]]], ["Intensity was classified as ''medium'' when many motile promastigotes where seen in the fore-and midgut.", [["midgut", "ANATOMY", 97, 103], ["promastigotes", "CELL", 56, 69], ["midgut", "ORGAN", 97, 103], ["many motile promastigotes", "PROBLEM", 44, 69], ["midgut", "ANATOMY", 97, 103]]], ["In ''high'' intensity infections, large numbers of promastigotes were seen throughout the gut and rosettes of parasites were visible.Sandfly dissectionThe unruptured guts of sandflies containing promastigotes were transferred to a drop of inactivated bovine fetal serum and dissected to liberate parasites, which were photographed immediately or after staining with Giemsa.Statistical analysisThe data were submitted to statistical analysis using the Instat program (GraphPad).", [["gut", "ANATOMY", 90, 93], ["rosettes", "ANATOMY", 98, 106], ["guts", "ANATOMY", 166, 170], ["fetal serum", "ANATOMY", 258, 269], ["infections", "DISEASE", 22, 32], ["promastigotes", "CELL", 51, 64], ["gut", "ORGANISM_SUBDIVISION", 90, 93], ["guts", "ORGAN", 166, 170], ["sandflies", "ORGANISM", 174, 183], ["promastigotes", "CELL", 195, 208], ["bovine", "ORGANISM", 251, 257], ["fetal serum", "ORGANISM_SUBSTANCE", 258, 269], ["Giemsa", "SIMPLE_CHEMICAL", 366, 372], ["bovine", "SPECIES", 251, 257], ["bovine", "SPECIES", 251, 257], ["high'' intensity infections", "PROBLEM", 5, 32], ["large numbers of promastigotes", "PROBLEM", 34, 64], ["parasites", "PROBLEM", 110, 119], ["Sandfly dissection", "PROBLEM", 133, 151], ["The unruptured guts of sandflies containing promastigotes", "PROBLEM", 151, 208], ["inactivated bovine fetal serum", "PROBLEM", 239, 269], ["Giemsa", "TEST", 366, 372], ["Statistical analysis", "TEST", 373, 393], ["statistical analysis", "TEST", 420, 440], ["high'' intensity", "OBSERVATION_MODIFIER", 5, 21], ["infections", "OBSERVATION", 22, 32], ["large", "OBSERVATION_MODIFIER", 34, 39], ["numbers", "OBSERVATION_MODIFIER", 40, 47], ["gut", "ANATOMY", 90, 93], ["parasites", "OBSERVATION", 110, 119], ["dissection", "OBSERVATION", 141, 151], ["unruptured", "OBSERVATION", 155, 165]]], ["Statistical methods were chosen according to the data features.", [["Statistical methods", "TEST", 0, 19]]], ["A v 2 test was performed when data were parametric and a contingency table could be prepared, as in the following comparisons: anaemia vs. category of clinical signs; anaemia vs. sandfly infection rate; IgG T , IgG 1 and IgG 2 concentrations vs. category of clinical signs; sandfly infection rate vs. category of clinical signs; and IgG T , IgG 1 and IgG 2 levels vs. sandfly infection rate.", [["anaemia", "DISEASE", 127, 134], ["anaemia", "DISEASE", 167, 174], ["infection", "DISEASE", 187, 196], ["sandfly infection", "DISEASE", 274, 291], ["sandfly infection", "DISEASE", 368, 385], ["sandfly", "ORGANISM", 179, 186], ["IgG T", "GENE_OR_GENE_PRODUCT", 203, 208], ["IgG 1", "GENE_OR_GENE_PRODUCT", 211, 216], ["IgG 2", "GENE_OR_GENE_PRODUCT", 221, 226], ["IgG T", "GENE_OR_GENE_PRODUCT", 333, 338], ["IgG 1", "GENE_OR_GENE_PRODUCT", 341, 346], ["IgG 2", "GENE_OR_GENE_PRODUCT", 351, 356], ["sandfly", "ORGANISM", 368, 375], ["IgG T", "PROTEIN", 203, 208], ["IgG 1", "PROTEIN", 211, 216], ["IgG 2", "PROTEIN", 221, 226], ["IgG T", "PROTEIN", 333, 338], ["IgG 1", "PROTEIN", 341, 346], ["IgG 2", "PROTEIN", 351, 356], ["A v 2 test", "TEST", 0, 10], ["anaemia vs", "PROBLEM", 127, 137], ["clinical signs", "TEST", 151, 165], ["anaemia", "PROBLEM", 167, 174], ["sandfly infection rate", "PROBLEM", 179, 201], ["IgG T", "TEST", 203, 208], ["IgG", "TEST", 211, 214], ["IgG", "TREATMENT", 221, 224], ["clinical signs", "TEST", 258, 272], ["sandfly infection rate vs", "PROBLEM", 274, 299], ["clinical signs", "TEST", 313, 327], ["IgG T", "TEST", 333, 338], ["IgG", "TEST", 341, 344], ["IgG", "TEST", 351, 354], ["sandfly infection rate", "PROBLEM", 368, 390], ["anaemia", "OBSERVATION", 127, 134], ["anaemia", "OBSERVATION", 167, 174], ["infection", "OBSERVATION", 187, 196], ["infection", "OBSERVATION", 376, 385]]], ["Parametric data on neutrophils or lymphocyte numbers vs. category of clinical signs were analysed by ANOVA When data were non-parametric or did not show normality after transformation, the Kruskal-Wallis test was used, as in comparisons between eosinophil and monocyte numbers and category of clinical signs.", [["neutrophils", "ANATOMY", 19, 30], ["lymphocyte", "ANATOMY", 34, 44], ["eosinophil", "ANATOMY", 245, 255], ["monocyte", "ANATOMY", 260, 268], ["neutrophils", "CELL", 19, 30], ["lymphocyte", "CELL", 34, 44], ["eosinophil", "CELL", 245, 255], ["monocyte", "CELL", 260, 268], ["neutrophils", "CELL_TYPE", 19, 30], ["eosinophil", "CELL_TYPE", 245, 255], ["Parametric data", "TEST", 0, 15], ["neutrophils", "TEST", 19, 30], ["lymphocyte numbers", "TEST", 34, 52], ["clinical signs", "TEST", 69, 83], ["the Kruskal-Wallis test", "TEST", 185, 208], ["eosinophil", "TEST", 245, 255], ["monocyte numbers", "TEST", 260, 276], ["clinical signs", "TEST", 293, 307]]], ["Correlation between IgG 1 and IgG 2 levels was analysed by paired-sample t test.Correlation of clinical categories with haematology resultsWhen the 42 dogs were classified according to their clinical signs, as described by Mancianti et al. (1998) , 13 (31%) were symptomatic, 22 (52%) oligosymptomatic and 7 (17%) asymptomatic.", [["oligosymptomatic", "DISEASE", 285, 301], ["IgG 1", "GENE_OR_GENE_PRODUCT", 20, 25], ["IgG 2", "GENE_OR_GENE_PRODUCT", 30, 35], ["dogs", "ORGANISM", 151, 155], ["IgG 1", "PROTEIN", 20, 25], ["IgG 2", "PROTEIN", 30, 35], ["dogs", "SPECIES", 151, 155], ["Correlation between", "TEST", 0, 19], ["IgG", "TEST", 20, 23], ["IgG 2 levels", "TEST", 30, 42], ["symptomatic", "TEST", 263, 274], ["oligosymptomatic", "TEST", 285, 301], ["asymptomatic", "PROBLEM", 314, 326]]], ["The most common clinical sign presented by the dogs was lymphadenopathy, mainly of the superficial cervical lymph nodes.", [["superficial cervical lymph nodes", "ANATOMY", 87, 119], ["lymphadenopathy", "DISEASE", 56, 71], ["dogs", "ORGANISM", 47, 51], ["cervical lymph nodes", "MULTI-TISSUE_STRUCTURE", 99, 119], ["dogs", "SPECIES", 47, 51], ["lymphadenopathy", "PROBLEM", 56, 71], ["the superficial cervical lymph nodes", "PROBLEM", 83, 119], ["lymphadenopathy", "OBSERVATION", 56, 71], ["superficial", "ANATOMY_MODIFIER", 87, 98], ["cervical", "ANATOMY", 99, 107], ["lymph nodes", "OBSERVATION", 108, 119]]], ["Red blood cell counts revealed a high frequency of anaemia: 20/42 dogs (47%) presented with erythrocyte counts (mean value 5.09 \u00b7 10 6 /lL; standard error 1.09 \u00b7 10 6 /lL; reference range 5.5-8.5 \u00b7 10 6 / lL), haemoglobin concentrations (mean value 11.07 g/dL; standard error 2.59 g/dL; reference range 12-18 g/dL) and haematocrit (mean value 34-43%; standard error: 6.21%; reference range 37-55%) all below reference values.Correlation of clinical categories with haematology resultsWhen these parameters were analysed on the basis of reticulocyte counts, the anaemia was shown to be normocytic, normochromic and non-regenerative.", [["Red blood cell", "ANATOMY", 0, 14], ["erythrocyte", "ANATOMY", 92, 103], ["reticulocyte", "ANATOMY", 536, 548], ["anaemia", "DISEASE", 51, 58], ["anaemia", "DISEASE", 561, 568], ["Red blood cell", "CELL", 0, 14], ["erythrocyte", "CELL", 92, 103], ["haemoglobin", "GENE_OR_GENE_PRODUCT", 210, 221], ["reticulocyte", "CELL", 536, 548], ["dogs", "SPECIES", 66, 70], ["Red blood cell counts", "TEST", 0, 21], ["anaemia", "PROBLEM", 51, 58], ["dogs", "TEST", 66, 70], ["erythrocyte counts", "TEST", 92, 110], ["mean value", "TEST", 112, 122], ["lL", "TEST", 136, 138], ["error", "TEST", 149, 154], ["lL", "TEST", 168, 170], ["haemoglobin concentrations", "TEST", 210, 236], ["mean value", "TEST", 238, 248], ["dL", "TEST", 257, 259], ["error", "TEST", 270, 275], ["dL", "TEST", 283, 285], ["range", "TEST", 297, 302], ["haematocrit", "TEST", 319, 330], ["mean value", "TEST", 332, 342], ["standard error", "TEST", 351, 365], ["reticulocyte counts", "TEST", 536, 555], ["the anaemia", "PROBLEM", 557, 568], ["normocytic", "PROBLEM", 585, 595], ["normochromic", "PROBLEM", 597, 609], ["high frequency", "OBSERVATION_MODIFIER", 33, 47], ["anaemia", "OBSERVATION", 51, 58], ["anaemia", "OBSERVATION", 561, 568], ["shown to be", "UNCERTAINTY", 573, 584], ["normocytic", "OBSERVATION", 585, 595], ["normochromic", "OBSERVATION_MODIFIER", 597, 609]]], ["As it was considered to be a more reliable red blood cell index than total erythrocyte count or haemoglobin concentration (Willard et al., 1994) , only the haematocrit value was used to obtain correlations between anaemia and the clinical signs of each dog, as well as between anaemia and sandfly infection rates.", [["red blood cell", "ANATOMY", 43, 57], ["erythrocyte", "ANATOMY", 75, 86], ["anaemia", "DISEASE", 214, 221], ["anaemia", "DISEASE", 277, 284], ["sandfly infection", "DISEASE", 289, 306], ["red blood cell", "CELL", 43, 57], ["erythrocyte", "CELL", 75, 86], ["haemoglobin", "SIMPLE_CHEMICAL", 96, 107], ["dog", "ORGANISM", 253, 256], ["red blood cell index", "TEST", 43, 63], ["total erythrocyte count", "TEST", 69, 92], ["haemoglobin concentration", "TEST", 96, 121], ["the haematocrit value", "TEST", 152, 173], ["anaemia", "PROBLEM", 214, 221], ["each dog", "PROBLEM", 248, 256], ["anaemia", "PROBLEM", 277, 284], ["sandfly infection rates", "PROBLEM", 289, 312], ["sandfly infection", "OBSERVATION", 289, 306]]], ["Dogs with low haematocrit values infected more female sandflies than those presenting with normal values.", [["Dogs", "ORGANISM", 0, 4], ["low haematocrit values", "PROBLEM", 10, 32], ["low haematocrit", "OBSERVATION_MODIFIER", 10, 25]]], ["On the other hand, no correlation was observed between haematocrit values and clinical signs presented by dogs.Correlation of clinical categories with haematology resultsTwenty-nine dogs presented with normal leucocyte counts, while nine had leucocytosis (always with degenerative left shift) and four had leucopenia.", [["leucocyte", "ANATOMY", 209, 218], ["leucocytosis", "DISEASE", 242, 254], ["degenerative left shift", "DISEASE", 268, 291], ["leucopenia", "DISEASE", 306, 316], ["dogs", "ORGANISM", 106, 110], ["dogs", "ORGANISM", 182, 186], ["leucocyte", "CELL", 209, 218], ["dogs", "SPECIES", 106, 110], ["dogs", "SPECIES", 182, 186], ["haematocrit values", "TEST", 55, 73], ["clinical signs", "TEST", 78, 92], ["leucocytosis", "PROBLEM", 242, 254], ["degenerative left shift", "PROBLEM", 268, 291], ["leucopenia", "PROBLEM", 306, 316], ["normal leucocyte counts", "OBSERVATION", 202, 225], ["leucocytosis", "OBSERVATION", 242, 254], ["left", "ANATOMY_MODIFIER", 281, 285], ["leucopenia", "OBSERVATION", 306, 316]]], ["No correlation was found between leucocyte count and clinical signs in these animals.", [["leucocyte", "ANATOMY", 33, 42], ["leucocyte", "CELL", 33, 42], ["leucocyte count", "TEST", 33, 48], ["clinical signs", "TEST", 53, 67]]], ["This observation was also true for each leucocyte category, except for lymphocytes; asymptomatic dogs presented with the highest lymphocyte counts, followed by oligosymptomatic and symptomatic animals (P < 0.05).Correlation of clinical categories with haematology resultsSignificant correlations were found when the categories were compared (P < 0.05).", [["leucocyte", "ANATOMY", 40, 49], ["lymphocytes", "ANATOMY", 71, 82], ["lymphocyte", "ANATOMY", 129, 139], ["leucocyte", "CELL", 40, 49], ["lymphocytes", "CELL", 71, 82], ["dogs", "ORGANISM", 97, 101], ["lymphocyte", "CELL", 129, 139], ["lymphocytes", "CELL_TYPE", 71, 82], ["dogs", "SPECIES", 97, 101], ["This observation", "TEST", 0, 16], ["each leucocyte category", "TEST", 35, 58], ["lymphocytes", "PROBLEM", 71, 82], ["asymptomatic dogs", "PROBLEM", 84, 101], ["the highest lymphocyte counts", "PROBLEM", 117, 146], ["oligosymptomatic and symptomatic animals", "PROBLEM", 160, 200], ["lymphocyte counts", "OBSERVATION", 129, 146], ["symptomatic", "OBSERVATION_MODIFIER", 181, 192]]], ["Although no positive correlation could be elicited between clinical category and eosinophil counts, 5/9 dogs with exfoliative dermatitis had eosinophilia.", [["eosinophil", "ANATOMY", 81, 91], ["exfoliative dermatitis", "DISEASE", 114, 136], ["eosinophilia", "DISEASE", 141, 153], ["eosinophil", "CELL", 81, 91], ["dogs", "ORGANISM", 104, 108], ["dogs", "SPECIES", 104, 108], ["clinical category", "TEST", 59, 76], ["eosinophil counts", "TEST", 81, 98], ["exfoliative dermatitis", "PROBLEM", 114, 136], ["eosinophilia", "PROBLEM", 141, 153], ["eosinophil counts", "OBSERVATION", 81, 98], ["dermatitis", "OBSERVATION", 126, 136], ["eosinophilia", "OBSERVATION", 141, 153]]], ["Only 7/42 dogs had thrombocytopenia, but none of these presented with haemorrhage.", [["thrombocytopenia", "DISEASE", 19, 35], ["haemorrhage", "DISEASE", 70, 81], ["dogs", "ORGANISM", 10, 14], ["dogs", "SPECIES", 10, 14], ["thrombocytopenia", "PROBLEM", 19, 35], ["haemorrhage", "PROBLEM", 70, 81], ["thrombocytopenia", "OBSERVATION", 19, 35], ["haemorrhage", "OBSERVATION", 70, 81]]], ["One dog had epistaxis but a normal platelet count.", [["platelet", "ANATOMY", 35, 43], ["epistaxis", "DISEASE", 12, 21], ["dog", "ORGANISM", 4, 7], ["platelet", "CELL", 35, 43], ["dog", "SPECIES", 4, 7], ["epistaxis", "PROBLEM", 12, 21], ["epistaxis", "OBSERVATION", 12, 21], ["normal platelet count", "OBSERVATION", 28, 49]]], ["No correlation was found between clinical category and platelet counts.Correlation of clinical categories with serology resultsThe cut off point for total IgG ELISA was 0.05 and the absorbance values ranged from 0.069 to 0.559.", [["platelet", "ANATOMY", 55, 63], ["platelet", "CELL", 55, 63], ["clinical category", "TEST", 33, 50], ["platelet counts", "TEST", 55, 70], ["serology results", "TEST", 111, 127], ["total IgG ELISA", "TEST", 149, 164], ["the absorbance values", "TEST", 178, 199], ["platelet counts", "OBSERVATION", 55, 70]]], ["To permit statistical analysis, absorbance values were approximately divided into three parts of the range values and then categorised as ''low'' (0.096-0.190), ''medium'' (0.191-0.380) and ''high'' (0.381-0.559).", [["statistical analysis", "TEST", 10, 30], ["absorbance values", "TEST", 32, 49]]], ["When the clinical category was compared with total IgG ELISA absorbance, no significant difference was found between absorbance values for symptomatic and oligosymptomatic dogs (P > 0.05), although asymptomatic dogs showed significantly lower absorbance values than the other two clinical categories (P < 0.05), as can be seen in Fig. 2 .", [["IgG", "GENE_OR_GENE_PRODUCT", 51, 54], ["dogs", "ORGANISM", 211, 215], ["IgG", "PROTEIN", 51, 54], ["dogs", "SPECIES", 211, 215], ["total IgG ELISA absorbance", "TEST", 45, 71], ["absorbance values", "TEST", 117, 134], ["symptomatic and oligosymptomatic dogs", "PROBLEM", 139, 176], ["P", "TEST", 178, 179], ["asymptomatic dogs", "PROBLEM", 198, 215], ["significantly lower absorbance values", "PROBLEM", 223, 260]]], ["All dogs presented positive results to IgG 1 and IgG 2 ELISA tests.", [["dogs", "ORGANISM", 4, 8], ["IgG 1", "GENE_OR_GENE_PRODUCT", 39, 44], ["IgG 2", "GENE_OR_GENE_PRODUCT", 49, 54], ["IgG 1", "PROTEIN", 39, 44], ["dogs", "SPECIES", 4, 8], ["IgG", "TEST", 39, 42], ["IgG", "TEST", 49, 52], ["ELISA tests", "TEST", 55, 66]]], ["The values for the second immunoglobulin subclass were significantly higher than those of the first (P < 0.0001).Correlation of clinical categories with serology resultsAbsorbance values of the IgG subclasses were categorised as IgG T to permit further statistical analysis.", [["immunoglobulin", "GENE_OR_GENE_PRODUCT", 26, 40], ["IgG", "GENE_OR_GENE_PRODUCT", 194, 197], ["IgG T", "GENE_OR_GENE_PRODUCT", 229, 234], ["immunoglobulin subclass", "PROTEIN", 26, 49], ["IgG subclasses", "PROTEIN", 194, 208], ["IgG T", "PROTEIN", 229, 234], ["The values", "TEST", 0, 10], ["the second immunoglobulin subclass", "TEST", 15, 49], ["serology results", "TEST", 153, 169], ["Absorbance values", "TEST", 169, 186], ["the IgG subclasses", "TEST", 190, 208], ["IgG T", "TEST", 229, 234], ["further statistical analysis", "TEST", 245, 273], ["higher", "OBSERVATION_MODIFIER", 69, 75]]], ["Thus for IgG 1 , in which the cut-off point was 0.05, the optical density (OD) values were categorised as ''low'' (0.055-0.3), ''medium'' (0.301-0.6) or ''high'' (0.601-0.96) based on antibody levels.", [["IgG 1", "GENE_OR_GENE_PRODUCT", 9, 14], ["IgG 1", "PROTEIN", 9, 14], ["IgG", "TEST", 9, 12], ["the optical density (OD) values", "TEST", 54, 85], ["antibody levels", "TEST", 184, 199], ["density", "OBSERVATION", 66, 73]]], ["The cut-off point for IgG 2 was 0.084 and values for low, medium and high antibody levels were set at 0.092-0.320, 0.321-0.640 and 0.641-0.961, respectively.Correlation of clinical categories with serology resultsNo statistically significant differences were observed when the clinical categories were compared with IgG 1 absorbance values.", [["IgG 2", "GENE_OR_GENE_PRODUCT", 22, 27], ["IgG 1", "GENE_OR_GENE_PRODUCT", 316, 321], ["IgG 2", "PROTEIN", 22, 27], ["IgG 1", "PROTEIN", 316, 321], ["The cut-", "TEST", 0, 8], ["IgG", "TEST", 22, 25], ["values", "TEST", 42, 48], ["low, medium and high antibody levels", "PROBLEM", 53, 89], ["serology results", "TEST", 197, 213], ["the clinical categories", "TEST", 273, 296], ["IgG 1 absorbance values", "TEST", 316, 339], ["statistically", "OBSERVATION_MODIFIER", 216, 229], ["significant", "OBSERVATION_MODIFIER", 230, 241]]], ["On the other hand, when this comparison was made for OD values of IgG 2 , significant differences were seen between dogs of different categories.", [["IgG 2", "GENE_OR_GENE_PRODUCT", 66, 71], ["dogs", "ORGANISM", 116, 120], ["IgG 2", "PROTEIN", 66, 71], ["dogs", "SPECIES", 116, 120], ["OD values", "TEST", 53, 62], ["IgG", "TEST", 66, 69], ["significant differences", "PROBLEM", 74, 97]]], ["The difference was more pronounced when asymptomatic and oligosymptomatic animals (P < 0.001) were compared than when the former were compared with symptomatic ones (P < 0.05).", [["asymptomatic", "PROBLEM", 40, 52], ["oligosymptomatic animals", "PROBLEM", 57, 81], ["more pronounced", "OBSERVATION_MODIFIER", 19, 34]]], ["The variations for each category are shown in Fig. 3.Correlation of clinical categories with infectivity for sandfliesXenodiagnosis was positive in 37/42 (88%) dogs.", [["dogs", "ORGANISM", 160, 164], ["dogs", "SPECIES", 160, 164], ["sandfliesXenodiagnosis", "TEST", 109, 131]]], ["Interestingly, no female sandflies could be infected from some dogs, while other dogs infected all insects that bit them.", [["female sandflies", "ORGANISM", 18, 34], ["dogs", "ORGANISM", 63, 67], ["dogs", "ORGANISM", 81, 85], ["dogs", "SPECIES", 63, 67], ["dogs", "SPECIES", 81, 85], ["female sandflies", "PROBLEM", 18, 34], ["some dogs", "PROBLEM", 58, 67], ["no", "UNCERTAINTY", 15, 17], ["infected", "OBSERVATION", 44, 52]]], ["When the number of infected sandflies was correlated with the intensity of infection for each dog, a statistically significant association (P < 0.001) was detected; dogs that infected a large number of sandflies did so with high intensity.", [["infection", "DISEASE", 75, 84], ["sandflies", "ORGANISM", 28, 37], ["dog", "ORGANISM", 94, 97], ["dogs", "ORGANISM", 165, 169], ["dogs", "SPECIES", 165, 169], ["dog", "SPECIES", 94, 97], ["infected sandflies", "PROBLEM", 19, 37], ["infection", "PROBLEM", 75, 84], ["infected", "OBSERVATION_MODIFIER", 19, 27], ["sandflies", "OBSERVATION", 28, 37], ["infection", "OBSERVATION", 75, 84], ["large", "OBSERVATION_MODIFIER", 186, 191], ["number", "OBSERVATION_MODIFIER", 192, 198], ["high intensity", "OBSERVATION_MODIFIER", 224, 238]]], ["Low intensity infections were observed in a few dogs.Correlation of clinical categories with infectivity for sandfliesA positive correlation between the number of positive sandflies and clinical category showed an interesting progression; symptomatic dogs showed higher infection rates (51.9%) than oligosymptomatic (41.9%) and asymptomatic (18.3%) animals.", [["infections", "DISEASE", 14, 24], ["infection", "DISEASE", 270, 279], ["dogs", "ORGANISM", 48, 52], ["dogs", "ORGANISM", 251, 255], ["dogs", "SPECIES", 48, 52], ["dogs", "SPECIES", 251, 255], ["Low intensity infections", "PROBLEM", 0, 24], ["clinical category", "TEST", 186, 203], ["an interesting progression", "PROBLEM", 211, 237], ["symptomatic dogs", "PROBLEM", 239, 255], ["higher infection rates", "PROBLEM", 263, 285], ["oligosymptomatic", "TEST", 299, 315], ["asymptomatic", "PROBLEM", 328, 340], ["intensity", "OBSERVATION_MODIFIER", 4, 13], ["infections", "OBSERVATION", 14, 24], ["higher", "OBSERVATION_MODIFIER", 263, 269], ["infection", "OBSERVATION", 270, 279]]], ["Data were however qualitative and insufficient to permit statistical correlations between the intensity of infection and clinical signs.", [["infection", "DISEASE", 107, 116], ["infection", "PROBLEM", 107, 116], ["clinical signs", "TEST", 121, 135], ["infection", "OBSERVATION", 107, 116]]], ["Only one symptomatic dog infected no sandflies at all; six oligosymptomatic and five asymptomatic dogs infected no sandflies or did so at very low intensities of infection.Correlation of clinical categories with infectivity for sandfliesPromastigotes in the sandfly gut can be observed in Fig. 4 .", [["gut", "ANATOMY", 266, 269], ["infection", "DISEASE", 162, 171], ["Promastigotes", "CHEMICAL", 237, 250], ["dog", "ORGANISM", 21, 24], ["dogs", "ORGANISM", 98, 102], ["sandfly", "ORGANISM", 258, 265], ["gut", "ORGANISM_SUBDIVISION", 266, 269], ["dog", "SPECIES", 21, 24], ["dogs", "SPECIES", 98, 102], ["sandflies", "PROBLEM", 37, 46], ["six oligosymptomatic", "PROBLEM", 55, 75], ["five asymptomatic dogs infected", "PROBLEM", 80, 111], ["sandflies", "PROBLEM", 115, 124], ["infection", "PROBLEM", 162, 171], ["infectivity", "PROBLEM", 212, 223], ["sandfliesPromastigotes", "PROBLEM", 228, 250], ["symptomatic", "OBSERVATION_MODIFIER", 9, 20], ["dog", "OBSERVATION_MODIFIER", 21, 24], ["infected", "OBSERVATION", 25, 33], ["low intensities", "OBSERVATION_MODIFIER", 143, 158], ["infection", "OBSERVATION", 162, 171]]], ["A significant positive association was observed between sandfly infection rates and IgG T ELISA absorbance values; the dogs whose sera showed highest absorbance values were those that infected more L. longipalpis females.", [["sera", "ANATOMY", 130, 134], ["sandfly infection", "DISEASE", 56, 73], ["IgG T ELISA", "GENE_OR_GENE_PRODUCT", 84, 95], ["dogs", "ORGANISM", 119, 123], ["sera", "ORGANISM_SUBSTANCE", 130, 134], ["L. longipalpis", "ORGANISM", 198, 212], ["IgG", "PROTEIN", 84, 87], ["dogs", "SPECIES", 119, 123], ["L. longipalpis", "SPECIES", 198, 212], ["L. longipalpis", "SPECIES", 198, 212], ["A significant positive association", "PROBLEM", 0, 34], ["sandfly infection rates", "PROBLEM", 56, 79], ["IgG T ELISA absorbance values", "TEST", 84, 113], ["the dogs whose sera", "TEST", 115, 134], ["highest absorbance values", "PROBLEM", 142, 167], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["positive", "OBSERVATION", 14, 22], ["longipalpis females", "OBSERVATION", 201, 220]]], ["Once again, data insufficiency after categorization, as well as its qualitative nature, meant that no statistical correlations could be established between the intensity of infection and the IgG T ELISA.Correlation of clinical categories with infectivity for sandfliesWhen the absorbance values obtained from the ELISA IgG 1 and IgG 2 subclasses were compared to the sandfly infection rates, it was found that dogs with lower IgG 1 values infected more L. longipalpis females while those with higher IgG 2 values infected greater numbers of sandflies (P < 0.0001).DiscussionThe group of dogs studied was not representative of the general canine VL population in Belo Horizonte.", [["infection", "DISEASE", 173, 182], ["infection", "DISEASE", 375, 384], ["IgG T ELISA", "GENE_OR_GENE_PRODUCT", 191, 202], ["IgG 1", "GENE_OR_GENE_PRODUCT", 319, 324], ["IgG 2", "GENE_OR_GENE_PRODUCT", 329, 334], ["dogs", "ORGANISM", 410, 414], ["L. longipalpis", "ORGANISM", 453, 467], ["dogs", "ORGANISM", 587, 591], ["canine", "ORGANISM", 638, 644], ["ELISA IgG 1", "PROTEIN", 313, 324], ["IgG 2 subclasses", "PROTEIN", 329, 345], ["IgG 1", "PROTEIN", 426, 431], ["IgG 2", "PROTEIN", 500, 505], ["dogs", "SPECIES", 410, 414], ["L. longipalpis", "SPECIES", 453, 467], ["dogs", "SPECIES", 587, 591], ["L. longipalpis", "SPECIES", 453, 467], ["data insufficiency", "PROBLEM", 12, 30], ["categorization", "TEST", 37, 51], ["infection", "PROBLEM", 173, 182], ["the IgG T ELISA", "TEST", 187, 202], ["sandflies", "PROBLEM", 259, 268], ["the absorbance values", "TEST", 273, 294], ["the ELISA IgG", "TEST", 309, 322], ["IgG", "TEST", 329, 332], ["the sandfly infection rates", "PROBLEM", 363, 390], ["lower IgG 1 values", "PROBLEM", 420, 438], ["higher IgG", "TEST", 493, 503], ["insufficiency", "OBSERVATION", 17, 30], ["infection", "OBSERVATION", 173, 182], ["greater", "OBSERVATION_MODIFIER", 522, 529], ["numbers", "OBSERVATION_MODIFIER", 530, 537]]], ["The most common clinical sign in the infected dogs studied was lymphadenopathy.", [["lymphadenopathy", "DISEASE", 63, 78], ["dogs", "ORGANISM", 46, 50], ["dogs", "SPECIES", 46, 50], ["lymphadenopathy", "PROBLEM", 63, 78], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["infected", "OBSERVATION_MODIFIER", 37, 45], ["lymphadenopathy", "OBSERVATION", 63, 78]]], ["Dogs already known to be seropositive were chosen based on their gross clinical findings and those with severe dermatological signs were rejected.", [["Dogs", "ORGANISM", 0, 4], ["seropositive", "PROBLEM", 25, 37], ["severe dermatological signs", "PROBLEM", 104, 131], ["severe", "OBSERVATION_MODIFIER", 104, 110]]], ["These data thus differ from earlier reports in the literature, where skin lesions were reported to be the most common clinical sign in canine VL (Ciaramella et al., 1997; Ferrer, 2002; Strauss-Ayali and Baneth, 2001; Amusategui et al., 2003; Solano-Gallego et al., 2004) .DiscussionThe results obtained when categories of clinical signs were compared with ELISA absorbance values agree with other work (Cabral et al., 1992; Pinelli et al., 1994; Quinnell et al., 2001; Solano-Gallego et al., 2001; Fernendez-Perez et al., 2003; Mendes et al., 2003; Reis et al., 2006b ) and corroborate the view that hypergammaglobulinaemia due to excessive antibody production in canine VL may be responsible for some of the clinical signs presented by dogs through complement activation and immune complex formation.", [["skin lesions", "ANATOMY", 69, 81], ["skin lesions", "DISEASE", 69, 81], ["hypergammaglobulinaemia", "DISEASE", 600, 623], ["skin lesions", "CANCER", 69, 81], ["canine", "ORGANISM", 135, 141], ["canine VL", "ORGANISM", 664, 673], ["dogs", "ORGANISM", 737, 741], ["immune complex", "GENE_OR_GENE_PRODUCT", 776, 790], ["canine", "SPECIES", 135, 141], ["dogs", "SPECIES", 737, 741], ["canine", "SPECIES", 135, 141], ["canine", "SPECIES", 664, 670], ["skin lesions", "PROBLEM", 69, 81], ["clinical signs", "TEST", 322, 336], ["ELISA absorbance values", "TEST", 356, 379], ["Fernendez", "TEST", 498, 507], ["the view", "TEST", 586, 594], ["hypergammaglobulinaemia", "PROBLEM", 600, 623], ["excessive antibody production in canine VL", "PROBLEM", 631, 673], ["the clinical signs", "PROBLEM", 705, 723], ["immune complex formation", "PROBLEM", 776, 800], ["skin", "ANATOMY", 69, 73], ["lesions", "OBSERVATION", 74, 81], ["excessive", "OBSERVATION_MODIFIER", 631, 640], ["antibody", "OBSERVATION", 641, 649]]], ["A common feature reported in various studies (Gradoni et al., 1987; Alvar et al., 1994; Molina et al., 1994) is a strong positive correlation between infectivity to sandflies and serological response, although none of these authors used ELISA to determine this correlation.DiscussionThe finding of IgG subclasses 1 and 2 in dogs with VL is consistent with other reports (Deplazes et al., 1995; Bourdoiseau et al., 1997a; Vercammen et al., 2002; Quinnell et al., 2003) .", [["VL", "DISEASE", 334, 336], ["IgG subclasses 1", "GENE_OR_GENE_PRODUCT", 298, 314], ["2", "GENE_OR_GENE_PRODUCT", 319, 320], ["dogs", "ORGANISM", 324, 328], ["IgG subclasses 1 and 2", "PROTEIN", 298, 320], ["dogs", "SPECIES", 324, 328], ["serological response", "TEST", 179, 199], ["IgG subclasses", "TEST", 298, 312], ["VL", "ANATOMY", 334, 336], ["consistent with", "UNCERTAINTY", 340, 355]]], ["In fact, given that polyclonal B lymphocyte activation occurs in L. infantum infection, the presence of both immunoglobulin subclasses is to be expected.", [["B lymphocyte", "ANATOMY", 31, 43], ["L. infantum infection", "DISEASE", 65, 86], ["B lymphocyte", "CELL", 31, 43], ["L. infantum", "ORGANISM", 65, 76], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 109, 123], ["immunoglobulin subclasses", "PROTEIN", 109, 134], ["L. infantum", "SPECIES", 65, 76], ["L. infantum", "SPECIES", 65, 76], ["polyclonal B lymphocyte activation", "PROBLEM", 20, 54], ["L. infantum infection", "PROBLEM", 65, 86], ["both immunoglobulin subclasses", "PROBLEM", 104, 134], ["lymphocyte activation", "OBSERVATION", 33, 54], ["L.", "OBSERVATION_MODIFIER", 65, 67], ["infantum infection", "OBSERVATION", 68, 86], ["immunoglobulin subclasses", "OBSERVATION", 109, 134]]], ["Other authors have also described IgG 2 predominance (Deplazes et al., 1995; Vercammen et al., 2002) .", [["IgG 2", "PROTEIN", 34, 39]]], ["The lack of association between clinical signs in affected dogs and IgG 1 levels has been observed by others, as has a positive correlation with IgG 2 levels (Vercammen et al., 2002) .", [["dogs", "ORGANISM", 59, 63], ["IgG 1", "GENE_OR_GENE_PRODUCT", 68, 73], ["IgG 2", "GENE_OR_GENE_PRODUCT", 145, 150], ["IgG 1", "PROTEIN", 68, 73], ["IgG 2", "PROTEIN", 145, 150], ["dogs", "SPECIES", 59, 63], ["clinical signs in affected dogs", "PROBLEM", 32, 63], ["IgG 1 levels", "TEST", 68, 80]]], ["When considered together with the observation that parasites could be demonstrated in all dogs (data not shown), it appears that these IgG subclasses may not play a role in the development of clinical signs or control of the disease as in the murine model.DiscussionThe results obtained from xenodiagnosis disagree with the findings of previous workers Guarga et al., 2000) who could not demonstrate significant associations between clinical signs in dogs and sandfly infection rates.", [["sandfly infection", "DISEASE", 460, 477], ["dogs", "ORGANISM", 90, 94], ["IgG", "GENE_OR_GENE_PRODUCT", 135, 138], ["murine", "ORGANISM", 243, 249], ["dogs", "ORGANISM", 451, 455], ["IgG subclasses", "PROTEIN", 135, 149], ["dogs", "SPECIES", 90, 94], ["murine", "SPECIES", 243, 249], ["dogs", "SPECIES", 451, 455], ["the observation", "TEST", 30, 45], ["parasites", "PROBLEM", 51, 60], ["these IgG subclasses", "PROBLEM", 129, 149], ["clinical signs", "PROBLEM", 192, 206], ["the disease", "PROBLEM", 221, 232], ["clinical signs in dogs", "PROBLEM", 433, 455], ["sandfly infection rates", "PROBLEM", 460, 483], ["disease", "OBSERVATION", 225, 232]]], ["These differences may be attributed to the fact that these authors used Phlebotomus perniciosus females in their studies.", [["Phlebotomus perniciosus", "ORGANISM", 72, 95], ["Phlebotomus perniciosus", "SPECIES", 72, 95], ["may be attributed to", "UNCERTAINTY", 18, 38]]], ["On the other hand, differences in infection rates when sandflies were fed on oligosymptomatic and symptomatic dogs have been found by others (Travi et al., 2001 (Travi et al., , 2002 , although asymptomatic dogs from these experiments were not able to infect the insects.", [["infection", "DISEASE", 34, 43], ["dogs", "ORGANISM", 110, 114], ["dogs", "ORGANISM", 207, 211], ["dogs", "SPECIES", 110, 114], ["dogs", "SPECIES", 207, 211], ["infection rates", "PROBLEM", 34, 49], ["oligosymptomatic and symptomatic dogs", "PROBLEM", 77, 114], ["asymptomatic dogs", "PROBLEM", 194, 211], ["infection", "OBSERVATION", 34, 43]]], ["Although Travi et al. (2001 Travi et al. ( , 2002 employed L. longipalpis in their experiments, the absence of infection in this clinical category can be explained by the fact that a different feeding method was used with sandflies being fed directly on the blood of asymptomatic dogs.", [["blood", "ANATOMY", 258, 263], ["infection", "DISEASE", 111, 120], ["L. longipalpis", "ORGANISM", 59, 73], ["blood", "ORGANISM_SUBSTANCE", 258, 263], ["dogs", "ORGANISM", 280, 284], ["L. longipalpis", "SPECIES", 59, 73], ["dogs", "SPECIES", 280, 284], ["L. longipalpis", "SPECIES", 59, 73], ["infection", "PROBLEM", 111, 120], ["a different feeding method", "TREATMENT", 181, 207], ["asymptomatic dogs", "PROBLEM", 267, 284], ["infection", "OBSERVATION", 111, 120]]], ["This method proved to be less efficient, since the same authors obtained positive results by xenodiagnosis in 2/7 oligosymptomatic and 4/8 symptomatic dogs.", [["dogs", "ORGANISM", 151, 155], ["dogs", "SPECIES", 151, 155], ["xenodiagnosis", "TEST", 93, 106], ["4/8 symptomatic dogs", "PROBLEM", 135, 155]]], ["The small number of dogs used in those experiments, compared to the study reported here, may also have contributed to the discrepancy between the two sets of results.DiscussionIf one considers that dogs showing more clinical signs are less able to control the disease so that there is greater parasite dissemination in the skin, the number of amastigotes in the skin could be equivalent to the quantity of promastigotes within the insect gut, although in the gut promastigotes are able to divide.", [["skin", "ANATOMY", 323, 327], ["skin", "ANATOMY", 362, 366], ["gut", "ANATOMY", 438, 441], ["gut promastigotes", "ANATOMY", 459, 476], ["dogs", "ORGANISM", 20, 24], ["dogs", "ORGANISM", 198, 202], ["skin", "ORGAN", 323, 327], ["skin", "ORGAN", 362, 366], ["gut", "ORGANISM_SUBDIVISION", 438, 441], ["gut promastigotes", "ORGANISM", 459, 476], ["dogs", "SPECIES", 20, 24], ["dogs", "SPECIES", 198, 202], ["the study", "TEST", 64, 73], ["the discrepancy", "PROBLEM", 118, 133], ["the disease", "PROBLEM", 256, 267], ["greater parasite dissemination in the skin", "PROBLEM", 285, 327], ["small", "OBSERVATION_MODIFIER", 4, 9], ["number", "OBSERVATION_MODIFIER", 10, 16], ["dogs", "OBSERVATION", 20, 24], ["disease", "OBSERVATION", 260, 267], ["greater", "OBSERVATION_MODIFIER", 285, 292], ["parasite", "OBSERVATION_MODIFIER", 293, 301], ["dissemination", "OBSERVATION", 302, 315], ["skin", "ANATOMY", 323, 327], ["amastigotes", "OBSERVATION", 343, 354], ["skin", "ANATOMY", 362, 366]]], ["A significant positive correlation between the numbers of infected L. longipalpis females and the intensity of infection has been observed previously (Travi et al., 2001) , although the criteria chosen by these authors differed from those we used in the present study.DiscussionNo published studies linking total IgG antibody levels and sandfly infection rates have been found.", [["infection", "DISEASE", 111, 120], ["sandfly infection", "DISEASE", 337, 354], ["L. longipalpis", "ORGANISM", 67, 81], ["IgG antibody", "PROTEIN", 313, 325], ["L. longipalpis", "SPECIES", 67, 81], ["L. longipalpis", "SPECIES", 67, 81], ["infected L. longipalpis females", "PROBLEM", 58, 89], ["infection", "PROBLEM", 111, 120], ["the present study", "TEST", 250, 267], ["published studies", "TEST", 281, 298], ["total IgG antibody levels", "TEST", 307, 332], ["sandfly infection rates", "PROBLEM", 337, 360], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["positive", "OBSERVATION", 14, 22], ["infected", "OBSERVATION_MODIFIER", 58, 66], ["L.", "OBSERVATION_MODIFIER", 67, 69], ["longipalpis females", "OBSERVATION", 70, 89], ["intensity", "OBSERVATION_MODIFIER", 98, 107], ["infection", "OBSERVATION", 111, 120]]], ["It has been demonstrated here that dogs with more clinical signs presented higher levels of total IgG and IgG 2 and were able to infect large numbers of female sandflies.", [["dogs", "ORGANISM", 35, 39], ["IgG", "GENE_OR_GENE_PRODUCT", 98, 101], ["IgG 2", "GENE_OR_GENE_PRODUCT", 106, 111], ["IgG", "PROTEIN", 98, 101], ["IgG 2", "PROTEIN", 106, 111], ["dogs", "SPECIES", 35, 39], ["total IgG", "TEST", 92, 101], ["IgG", "TEST", 106, 109]]], ["From these observations it can be surmised that dogs with higher antibody levels are able to infect more sandflies.", [["dogs", "ORGANISM", 48, 52], ["dogs", "SPECIES", 48, 52], ["higher antibody levels", "PROBLEM", 58, 80]]], ["This conclusion addresses a crucial epidemiological question, linking these two parameters and supporting the findings of Courtenay et al. (2001) who observed that female sandflies can be infected by dogs only after they show antibodies in their sera; they considered antibody titres to be the best predictor of infectivity.DiscussionForty-five percent of the dogs we studied presented normocytic and normochromic anaemia, as has been observed by other authors (Abranches et al., 1991; Ciaramella et al., 1997; Koutinas et al., 1999; Ikeda et Reis et al., 2006a) .", [["sera", "ANATOMY", 246, 250], ["normocytic", "DISEASE", 386, 396], ["anaemia", "DISEASE", 414, 421], ["female sandflies", "ORGANISM", 164, 180], ["dogs", "ORGANISM", 200, 204], ["sera", "ORGANISM_SUBSTANCE", 246, 250], ["dogs", "ORGANISM", 360, 364], ["antibodies", "PROTEIN", 226, 236], ["dogs", "SPECIES", 200, 204], ["dogs", "SPECIES", 360, 364], ["antibodies in their sera", "PROBLEM", 226, 250], ["antibody titres", "PROBLEM", 268, 283], ["infectivity", "PROBLEM", 312, 323], ["normocytic", "PROBLEM", 386, 396], ["normochromic anaemia", "PROBLEM", 401, 421], ["infectivity", "OBSERVATION", 312, 323], ["normochromic anaemia", "OBSERVATION", 401, 421]]], ["The non-regenerative feature of the anaemia can be attributed to infection of the bone marrow by L. infantum, inducing infiltration by lymphocytes, plasma cells and macrophages that could contribute to a decrease in erythrocyte production.", [["bone marrow", "ANATOMY", 82, 93], ["lymphocytes", "ANATOMY", 135, 146], ["plasma cells", "ANATOMY", 148, 160], ["macrophages", "ANATOMY", 165, 176], ["erythrocyte", "ANATOMY", 216, 227], ["anaemia", "DISEASE", 36, 43], ["infection", "DISEASE", 65, 74], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 82, 93], ["L. infantum", "ORGANISM", 97, 108], ["lymphocytes", "CELL", 135, 146], ["plasma cells", "CELL", 148, 160], ["macrophages", "CELL", 165, 176], ["erythrocyte", "CELL", 216, 227], ["lymphocytes", "CELL_TYPE", 135, 146], ["plasma cells", "CELL_TYPE", 148, 160], ["macrophages", "CELL_TYPE", 165, 176], ["L. infantum", "SPECIES", 97, 108], ["L. infantum", "SPECIES", 97, 108], ["the anaemia", "PROBLEM", 32, 43], ["infection of the bone marrow", "PROBLEM", 65, 93], ["L. infantum", "PROBLEM", 97, 108], ["infiltration", "PROBLEM", 119, 131], ["lymphocytes", "PROBLEM", 135, 146], ["plasma cells", "PROBLEM", 148, 160], ["macrophages", "PROBLEM", 165, 176], ["a decrease in erythrocyte production", "PROBLEM", 202, 238], ["anaemia", "OBSERVATION", 36, 43], ["can be attributed to", "UNCERTAINTY", 44, 64], ["infection", "OBSERVATION", 65, 74], ["bone marrow", "ANATOMY", 82, 93], ["infiltration", "OBSERVATION", 119, 131], ["lymphocytes", "ANATOMY", 135, 146], ["plasma cells", "OBSERVATION", 148, 160], ["macrophages", "OBSERVATION", 165, 176], ["decrease", "OBSERVATION_MODIFIER", 204, 212], ["erythrocyte production", "OBSERVATION", 216, 238]]], ["The elevated blood urea nitrogen (BUN) levels encountered in most of the animals (data not shown) could also contribute to the anaemia, as this would alter erythropoietin function and reduce erythrocyte life span by its toxic action.", [["blood", "ANATOMY", 13, 18], ["erythrocyte", "ANATOMY", 191, 202], ["blood urea nitrogen", "CHEMICAL", 13, 32], ["BUN", "CHEMICAL", 34, 37], ["anaemia", "DISEASE", 127, 134], ["urea", "CHEMICAL", 19, 23], ["nitrogen", "CHEMICAL", 24, 32], ["blood", "ORGANISM_SUBSTANCE", 13, 18], ["urea nitrogen", "SIMPLE_CHEMICAL", 19, 32], ["BUN", "SIMPLE_CHEMICAL", 34, 37], ["erythropoietin", "GENE_OR_GENE_PRODUCT", 156, 170], ["erythrocyte", "CELL", 191, 202], ["erythropoietin", "PROTEIN", 156, 170], ["The elevated blood urea nitrogen", "PROBLEM", 0, 32], ["BUN) levels", "TEST", 34, 45], ["the anaemia", "PROBLEM", 123, 134], ["erythropoietin function", "TREATMENT", 156, 179], ["erythrocyte life span", "PROBLEM", 191, 212], ["elevated", "OBSERVATION_MODIFIER", 4, 12], ["anaemia", "OBSERVATION", 127, 134]]], ["More studies are needed to examine further the pathology of anaemia in canine VL.DiscussionOther workers have observed that symptomatic dogs showed more severe anaemia (Amusategui et al., 2003; Reis et al., 2006a) , although the results of the present study did not confirm these findings.", [["anaemia", "DISEASE", 60, 67], ["VL", "DISEASE", 78, 80], ["anaemia", "DISEASE", 160, 167], ["canine", "ORGANISM", 71, 77], ["dogs", "ORGANISM", 136, 140], ["dogs", "SPECIES", 136, 140], ["canine", "SPECIES", 71, 77], ["More studies", "TEST", 0, 12], ["the pathology", "TEST", 43, 56], ["anaemia in canine VL", "PROBLEM", 60, 80], ["symptomatic dogs", "PROBLEM", 124, 140], ["more severe anaemia", "PROBLEM", 148, 167], ["the present study", "TEST", 240, 257], ["anaemia", "OBSERVATION", 60, 67], ["severe", "OBSERVATION_MODIFIER", 153, 159], ["anaemia", "OBSERVATION", 160, 167]]], ["Anaemia would be responsible for some of the classic clinical signs of canine VL, such as apathy, weakness and emaciation, although the clinical presentation is also the sum of disturbances caused by presence of the parasite and inflammatory reactions produced by the immune response.", [["Anaemia", "DISEASE", 0, 7], ["canine VL", "DISEASE", 71, 80], ["apathy", "DISEASE", 90, 96], ["weakness", "DISEASE", 98, 106], ["emaciation", "DISEASE", 111, 121], ["canine", "ORGANISM", 71, 77], ["canine", "SPECIES", 71, 77], ["Anaemia", "PROBLEM", 0, 7], ["canine VL", "PROBLEM", 71, 80], ["apathy", "PROBLEM", 90, 96], ["weakness", "PROBLEM", 98, 106], ["emaciation", "PROBLEM", 111, 121], ["the parasite", "PROBLEM", 212, 224], ["inflammatory reactions", "PROBLEM", 229, 251], ["canine VL", "OBSERVATION", 71, 80], ["weakness", "OBSERVATION", 98, 106], ["emaciation", "OBSERVATION", 111, 121], ["parasite", "OBSERVATION", 216, 224], ["inflammatory", "OBSERVATION_MODIFIER", 229, 241]]], ["The differences observed can be attributed to the larger number of dogs used in our study.DiscussionNo published work has been found that examines the relationship between the haematological status of dogs with VL and sandfly infection rates.", [["VL", "DISEASE", 211, 213], ["sandfly infection", "DISEASE", 218, 235], ["dogs", "ORGANISM", 67, 71], ["dogs", "ORGANISM", 201, 205], ["dogs", "SPECIES", 201, 205], ["our study", "TEST", 80, 89], ["VL", "PROBLEM", 211, 213], ["sandfly infection rates", "PROBLEM", 218, 241], ["larger", "OBSERVATION_MODIFIER", 50, 56], ["number", "OBSERVATION_MODIFIER", 57, 63], ["dogs", "OBSERVATION", 67, 71]]], ["In order to complete its blood meal on an anaemic animal, a sandfly might have to feed for a longer period or ingest more blood, both being factors that could contribute to higher infection rates.DiscussionThe great variability in the leucocyte count of dogs with VL was confirmed in this study (Anosa and Idowu, 1983; Moreno et al., 1998; Koutinas et al., 1999; J\u00fc ttner et al., 2001; Ikeda et al., 2002; Amusategui et al., 2003) .", [["blood", "ANATOMY", 25, 30], ["blood", "ANATOMY", 122, 127], ["leucocyte", "ANATOMY", 235, 244], ["infection", "DISEASE", 180, 189], ["VL", "DISEASE", 264, 266], ["blood", "ORGANISM_SUBSTANCE", 25, 30], ["blood", "ORGANISM_SUBSTANCE", 122, 127], ["leucocyte", "CELL", 235, 244], ["dogs", "ORGANISM", 254, 258], ["dogs", "SPECIES", 254, 258], ["its blood meal", "TEST", 21, 35], ["higher infection rates", "PROBLEM", 173, 195], ["the leucocyte count", "TEST", 231, 250], ["VL", "TEST", 264, 266], ["higher", "OBSERVATION_MODIFIER", 173, 179], ["infection", "OBSERVATION", 180, 189], ["great", "OBSERVATION_MODIFIER", 210, 215], ["variability", "OBSERVATION_MODIFIER", 216, 227]]], ["The high number of dogs presenting with normal leucocyte counts, as well as the absence of relationships between clinical category and the counts of total leucocytes (or subcategories of leucocytes) showed that the disease has little influence on this parameter.", [["leucocyte", "ANATOMY", 47, 56], ["leucocytes", "ANATOMY", 155, 165], ["leucocytes", "ANATOMY", 187, 197], ["dogs", "ORGANISM", 19, 23], ["leucocyte", "CELL", 47, 56], ["leucocytes", "CELL", 155, 165], ["leucocytes", "CELL", 187, 197], ["total leucocytes", "CELL_TYPE", 149, 165], ["leucocytes", "CELL_TYPE", 187, 197], ["dogs", "SPECIES", 19, 23], ["normal leucocyte counts", "PROBLEM", 40, 63], ["clinical category", "TEST", 113, 130], ["total leucocytes", "PROBLEM", 149, 165], ["leucocytes", "TEST", 187, 197], ["the disease", "PROBLEM", 211, 222], ["high", "OBSERVATION_MODIFIER", 4, 8], ["number", "OBSERVATION_MODIFIER", 9, 15], ["dogs", "OBSERVATION", 19, 23], ["leucocyte counts", "OBSERVATION", 47, 63], ["disease", "OBSERVATION", 215, 222]]], ["On the other hand, lymphocyte counts do appear to be influenced by the disease, as lymphocytopenia increased in severity with manifestation of clinical disease.", [["lymphocyte", "ANATOMY", 19, 29], ["lymphocytopenia", "DISEASE", 83, 98], ["lymphocyte", "CELL", 19, 29], ["lymphocyte counts", "TEST", 19, 36], ["the disease", "PROBLEM", 67, 78], ["lymphocytopenia", "PROBLEM", 83, 98], ["clinical disease", "PROBLEM", 143, 159], ["disease", "OBSERVATION", 71, 78], ["lymphocytopenia", "OBSERVATION", 83, 98], ["clinical disease", "OBSERVATION", 143, 159]]], ["This may be attributed to the immunosuppressive nature of VL (Bourdoiseau et al., 1997b; Reis et al., 2006b) .DiscussionEven though the number of animals presenting with eosinophilia and dermatological signs was low and statistical analyses could not be performed, a trend towards an association between these two factors was observed, as has been noted previously by others (Amusategui et al., 2003) .", [["eosinophilia", "DISEASE", 170, 182], ["eosinophilia", "PROBLEM", 170, 182], ["dermatological signs", "TEST", 187, 207], ["statistical analyses", "TEST", 220, 240], ["may be attributed to", "UNCERTAINTY", 5, 25], ["immunosuppressive", "OBSERVATION_MODIFIER", 30, 47], ["eosinophilia", "OBSERVATION", 170, 182]]], ["Moreover, thrombocytopenia was rarely observed among animals used in the present study, as others have also found (Slappendel and Greene, 1990; Alvar et al., 1994; Ciaramella et al., 1997) .ConclusionFrom the data presented here, it can be concluded that dogs naturally infected with L. infantum may present with a wide range of clinical signs, the severity of which is related to high levels of total IgG and IgG 2 antibodies.", [["thrombocytopenia", "DISEASE", 10, 26], ["L. infantum", "DISEASE", 284, 295], ["dogs", "ORGANISM", 255, 259], ["L. infantum", "ORGANISM", 284, 295], ["IgG", "GENE_OR_GENE_PRODUCT", 402, 405], ["IgG 2 antibodies", "GENE_OR_GENE_PRODUCT", 410, 426], ["IgG", "PROTEIN", 402, 405], ["IgG 2 antibodies", "PROTEIN", 410, 426], ["dogs", "SPECIES", 255, 259], ["L. infantum", "SPECIES", 284, 295], ["L. infantum", "SPECIES", 284, 295], ["thrombocytopenia", "PROBLEM", 10, 26], ["the present study", "TEST", 69, 86], ["L. infantum", "PROBLEM", 284, 295], ["clinical signs", "PROBLEM", 329, 343], ["total IgG", "TEST", 396, 405], ["IgG 2 antibodies", "TEST", 410, 426], ["thrombocytopenia", "OBSERVATION", 10, 26]]], ["It was also found that anaemic dogs have a higher infectivity for L. longipalpis sandflies, although anaemia was not related to the severity of clinical signs.", [["anaemia", "DISEASE", 101, 108], ["dogs", "ORGANISM", 31, 35], ["L. longipalpis", "ORGANISM", 66, 80], ["sandflies", "ORGANISM", 81, 90], ["dogs", "SPECIES", 31, 35], ["L. longipalpis", "SPECIES", 66, 80], ["L. longipalpis", "SPECIES", 66, 80], ["anaemic dogs", "PROBLEM", 23, 35], ["a higher infectivity", "PROBLEM", 41, 61], ["L. longipalpis sandflies", "PROBLEM", 66, 90], ["anaemia", "PROBLEM", 101, 108], ["clinical signs", "PROBLEM", 144, 158], ["higher infectivity", "OBSERVATION_MODIFIER", 43, 61]]], ["Lymphocytes seemed to be the only leucocyte category influenced by the disease.", [["Lymphocytes", "ANATOMY", 0, 11], ["leucocyte", "ANATOMY", 34, 43], ["Lymphocytes", "CELL", 0, 11], ["leucocyte", "CELL", 34, 43], ["Lymphocytes", "CELL_TYPE", 0, 11], ["Lymphocytes", "PROBLEM", 0, 11], ["the disease", "PROBLEM", 67, 78], ["disease", "OBSERVATION", 71, 78]]]], "87dfc1515971608965169339701f291eec28dccb": [["ExpectorationExpectoration is the coughing up of material from the lungs or major airways.", [["lungs", "ANATOMY", 67, 72], ["airways", "ANATOMY", 82, 89], ["lungs", "ORGAN", 67, 72], ["airways", "MULTI-TISSUE_STRUCTURE", 82, 89], ["the coughing", "PROBLEM", 30, 42], ["lungs", "ANATOMY", 67, 72], ["major airways", "ANATOMY", 76, 89]]], ["The material typically is frothy mucus or red blood; bile and food are absent.", [["frothy mucus", "ANATOMY", 26, 38], ["red blood", "ANATOMY", 42, 51], ["bile", "ANATOMY", 53, 57], ["mucus", "ORGANISM_SUBSTANCE", 33, 38], ["blood", "ORGANISM_SUBSTANCE", 46, 51], ["bile", "MULTI-TISSUE_STRUCTURE", 53, 57], ["frothy mucus or red blood", "PROBLEM", 26, 51], ["frothy", "OBSERVATION_MODIFIER", 26, 32], ["mucus", "OBSERVATION", 33, 38], ["red blood", "OBSERVATION", 42, 51], ["bile", "ANATOMY", 53, 57]]], ["The characteristic sequence of coughing followed by oral expulsion must be determined from the history or observation.", [["oral", "ANATOMY", 52, 56], ["coughing", "DISEASE", 31, 39], ["oral", "ORGANISM_SUBDIVISION", 52, 56], ["coughing", "PROBLEM", 31, 39], ["oral expulsion", "PROBLEM", 52, 66], ["coughing", "OBSERVATION", 31, 39]]], ["Regurgitation and vomiting typically occur without simultaneous coughing, although regurgitation is often accompanied by tracheitis and aspiration pneumonia.", [["Regurgitation", "DISEASE", 0, 13], ["vomiting", "DISEASE", 18, 26], ["coughing", "DISEASE", 64, 72], ["tracheitis", "DISEASE", 121, 131], ["pneumonia", "DISEASE", 147, 156], ["Regurgitation", "PROBLEM", 0, 13], ["vomiting", "PROBLEM", 18, 26], ["simultaneous coughing", "PROBLEM", 51, 72], ["regurgitation", "PROBLEM", 83, 96], ["tracheitis", "PROBLEM", 121, 131], ["aspiration pneumonia", "PROBLEM", 136, 156], ["coughing", "OBSERVATION", 64, 72], ["regurgitation", "OBSERVATION", 83, 96], ["tracheitis", "OBSERVATION", 121, 131], ["aspiration", "OBSERVATION_MODIFIER", 136, 146], ["pneumonia", "OBSERVATION", 147, 156]]], ["However, a patient that is expectorating may \"gag\" so hard because of pharyngeal/laryngeal irritation that it eventually vomits.RegurgitationRegurgitation is due to oral, pharyngeal, or esophageal dysfunction and is typically characterized as a relatively passive expulsion of esophageal contents.", [["pharyngeal", "ANATOMY", 70, 80], ["laryngeal", "ANATOMY", 81, 90], ["oral", "ANATOMY", 165, 169], ["pharyngeal", "ANATOMY", 171, 181], ["esophageal", "ANATOMY", 186, 196], ["esophageal", "ANATOMY", 277, 287], ["RegurgitationRegurgitation", "DISEASE", 128, 154], ["esophageal dysfunction", "DISEASE", 186, 208], ["patient", "ORGANISM", 11, 18], ["pharyngeal", "ORGANISM_SUBDIVISION", 70, 80], ["laryngeal", "ORGAN", 81, 90], ["oral", "ORGANISM_SUBDIVISION", 165, 169], ["pharyngeal", "ORGAN", 171, 181], ["esophageal", "ORGAN", 186, 196], ["esophageal", "ORGAN", 277, 287], ["patient", "SPECIES", 11, 18], ["\"gag", "PROBLEM", 45, 49], ["pharyngeal/laryngeal irritation", "PROBLEM", 70, 101], ["RegurgitationRegurgitation", "PROBLEM", 128, 154], ["oral, pharyngeal, or esophageal dysfunction", "PROBLEM", 165, 208], ["a relatively passive expulsion of esophageal contents", "PROBLEM", 243, 296], ["pharyngeal", "ANATOMY", 70, 80], ["laryngeal", "ANATOMY", 81, 90], ["irritation", "OBSERVATION", 91, 101], ["pharyngeal", "ANATOMY", 171, 181], ["esophageal", "ANATOMY", 186, 196], ["dysfunction", "OBSERVATION", 197, 208], ["relatively", "OBSERVATION_MODIFIER", 245, 255], ["passive", "OBSERVATION_MODIFIER", 256, 263], ["expulsion", "OBSERVATION", 264, 273], ["esophageal", "ANATOMY", 277, 287], ["contents", "OBSERVATION", 288, 296]]], ["Gagging is the expulsion of oral or pharyngeal material and may be associated with disorders causing dysphagia (i.e., difficult swallowing) or regurgitation.", [["oral", "ANATOMY", 28, 32], ["pharyngeal material", "ANATOMY", 36, 55], ["dysphagia", "DISEASE", 101, 110], ["oral", "ORGANISM_SUBDIVISION", 28, 32], ["pharyngeal material", "MULTI-TISSUE_STRUCTURE", 36, 55], ["Gagging", "PROBLEM", 0, 7], ["the expulsion of oral or pharyngeal material", "PROBLEM", 11, 55], ["disorders", "PROBLEM", 83, 92], ["dysphagia", "PROBLEM", 101, 110], ["regurgitation", "PROBLEM", 143, 156], ["pharyngeal", "ANATOMY", 36, 46], ["may be associated with", "UNCERTAINTY", 60, 82], ["dysphagia", "OBSERVATION", 101, 110], ["regurgitation", "OBSERVATION", 143, 156]]], ["The relatively minor abdominal contractions associated with gagging are typically different than the vigorous abdominal contractions that classically occur with vomiting.", [["abdominal", "ANATOMY", 21, 30], ["abdominal", "ANATOMY", 110, 119], ["vomiting", "DISEASE", 161, 169], ["abdominal", "ORGAN", 21, 30], ["abdominal", "ORGANISM_SUBDIVISION", 110, 119], ["The relatively minor abdominal contractions", "PROBLEM", 0, 43], ["gagging", "PROBLEM", 60, 67], ["the vigorous abdominal contractions", "PROBLEM", 97, 132], ["vomiting", "PROBLEM", 161, 169], ["relatively", "OBSERVATION_MODIFIER", 4, 14], ["minor", "OBSERVATION_MODIFIER", 15, 20], ["abdominal contractions", "ANATOMY", 21, 43], ["gagging", "OBSERVATION", 60, 67], ["vigorous", "OBSERVATION_MODIFIER", 101, 109], ["abdominal contractions", "ANATOMY", 110, 132]]], ["Regurgitation may follow seconds to hours after eating or drinking.", [["Regurgitation", "DISEASE", 0, 13], ["Regurgitation", "PROBLEM", 0, 13]]], ["Patients may regurgitate white foam (i.e., salivary secretions that have been swallowed) and/or food.", [["salivary secretions", "ANATOMY", 43, 62], ["Patients", "ORGANISM", 0, 8], ["salivary secretions", "ORGAN", 43, 62], ["Patients", "SPECIES", 0, 8], ["white foam", "TREATMENT", 25, 35], ["salivary secretions", "PROBLEM", 43, 62]]], ["Regurgitated food material is undigested and sometimes has a tubular form conforming to the shape of the esophageal lumen.", [["tubular", "ANATOMY", 61, 68], ["esophageal lumen", "ANATOMY", 105, 121], ["tubular", "TISSUE", 61, 68], ["esophageal lumen", "MULTI-TISSUE_STRUCTURE", 105, 121], ["food material", "OBSERVATION", 13, 26], ["tubular", "OBSERVATION", 61, 68], ["esophageal", "ANATOMY", 105, 115], ["lumen", "ANATOMY_MODIFIER", 116, 121]]], ["Regurgitated material that has remained in the esophagus for long time periods can appear \"partially digested\" because it is macerated, odoriferous, and mixed with saliva.", [["esophagus", "ANATOMY", 47, 56], ["esophagus", "ORGAN", 47, 56], ["saliva", "ORGANISM_SUBSTANCE", 164, 170], ["Regurgitated material", "PROBLEM", 0, 21], ["esophagus", "ANATOMY", 47, 56], ["macerated", "OBSERVATION", 125, 134]]], ["If blood is present, it is usually undigested (i.e., bright red), whereas blood originating from the stomach is usually partially digested by gastric acid and has a \"coffee grounds\" appearance readily distinguishing it from the undigested form (unless the patient vomits before the blood can be partially digested).RegurgitationIt is sometimes difficult to differentiate vomiting from regurgitation via history, and in some patients the processes are concurrent.", [["blood", "ANATOMY", 3, 8], ["blood", "ANATOMY", 74, 79], ["stomach", "ANATOMY", 101, 108], ["gastric", "ANATOMY", 142, 149], ["blood", "ANATOMY", 282, 287], ["Regurgitation", "DISEASE", 315, 328], ["vomiting", "DISEASE", 371, 379], ["blood", "ORGANISM_SUBSTANCE", 3, 8], ["blood", "ORGANISM_SUBSTANCE", 74, 79], ["stomach", "ORGAN", 101, 108], ["gastric acid", "SIMPLE_CHEMICAL", 142, 154], ["patient", "ORGANISM", 256, 263], ["blood", "ORGANISM_SUBSTANCE", 282, 287], ["patients", "ORGANISM", 424, 432], ["patient", "SPECIES", 256, 263], ["patients", "SPECIES", 424, 432], ["blood", "PROBLEM", 3, 8], ["Regurgitation", "PROBLEM", 315, 328], ["vomiting", "PROBLEM", 371, 379], ["regurgitation", "PROBLEM", 385, 398], ["stomach", "ANATOMY", 101, 108], ["gastric", "ANATOMY", 142, 149], ["acid", "OBSERVATION", 150, 154], ["regurgitation", "OBSERVATION", 385, 398]]], ["Vomiting may cause secondary esophagitis and subsequent regurgitation, or a patient with long-standing esophageal disease may develop another concurrent disorder causing vomiting.", [["esophageal", "ANATOMY", 103, 113], ["Vomiting", "DISEASE", 0, 8], ["esophagitis", "DISEASE", 29, 40], ["esophageal disease", "DISEASE", 103, 121], ["vomiting", "DISEASE", 170, 178], ["patient", "ORGANISM", 76, 83], ["esophageal", "ORGAN", 103, 113], ["patient", "SPECIES", 76, 83], ["Vomiting", "PROBLEM", 0, 8], ["secondary esophagitis", "PROBLEM", 19, 40], ["subsequent regurgitation", "PROBLEM", 45, 69], ["long-standing esophageal disease", "PROBLEM", 89, 121], ["another concurrent disorder", "PROBLEM", 134, 161], ["vomiting", "PROBLEM", 170, 178], ["may cause", "UNCERTAINTY", 9, 18], ["secondary esophagitis", "OBSERVATION", 19, 40], ["regurgitation", "OBSERVATION", 56, 69], ["esophageal", "ANATOMY", 103, 113], ["disease", "OBSERVATION", 114, 121]]], ["It is therefore important to clarify the chronologic order of specific signs.", [["specific signs", "TEST", 62, 76]]], ["Finally, some patients with signs \"classic\" for regurgitation are vomiting instead.", [["vomiting", "DISEASE", 66, 74], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["regurgitation", "PROBLEM", 48, 61], ["vomiting", "PROBLEM", 66, 74], ["regurgitation", "OBSERVATION", 48, 61]]], ["To aid in differentiation, one may attempt to observe the act of expulsion by feeding the patient, although this is very unreliable (\"watched\" regurgitating patients often do not regurgitate).", [["patient", "ORGANISM", 90, 97], ["patients", "ORGANISM", 157, 165], ["patient", "SPECIES", 90, 97], ["patients", "SPECIES", 157, 165]]], ["Watching the patient eat occasionally helps if there is obvious pharyngeal dysphagia that suggests oropharyngeal disease.", [["pharyngeal", "ANATOMY", 64, 74], ["oropharyngeal", "ANATOMY", 99, 112], ["dysphagia", "DISEASE", 75, 84], ["oropharyngeal disease", "DISEASE", 99, 120], ["patient", "ORGANISM", 13, 20], ["pharyngeal", "ORGANISM_SUBDIVISION", 64, 74], ["oropharyngeal", "ORGANISM_SUBDIVISION", 99, 112], ["patient", "SPECIES", 13, 20], ["obvious pharyngeal dysphagia", "PROBLEM", 56, 84], ["oropharyngeal disease", "PROBLEM", 99, 120], ["pharyngeal", "ANATOMY", 64, 74], ["dysphagia", "OBSERVATION", 75, 84], ["oropharyngeal", "ANATOMY", 99, 112], ["disease", "OBSERVATION", 113, 120]]], ["Some patients with pharyngeal dysphagia also have concurrent esophageal dysfunction.", [["pharyngeal", "ANATOMY", 19, 29], ["esophageal", "ANATOMY", 61, 71], ["pharyngeal dysphagia", "DISEASE", 19, 39], ["esophageal dysfunction", "DISEASE", 61, 83], ["patients", "ORGANISM", 5, 13], ["pharyngeal", "ORGANISM_SUBDIVISION", 19, 29], ["esophageal", "ORGAN", 61, 71], ["patients", "SPECIES", 5, 13], ["pharyngeal dysphagia", "PROBLEM", 19, 39], ["concurrent esophageal dysfunction", "PROBLEM", 50, 83], ["pharyngeal", "ANATOMY", 19, 29], ["dysphagia", "OBSERVATION", 30, 39], ["esophageal", "ANATOMY", 61, 71], ["dysfunction", "OBSERVATION", 72, 83]]], ["Contrast radiographs and/or fluoroscopy of the pharynx and esophagus can usually differentiate vomiting from regurgitation.RegurgitationRegurgitation is usually best evaluated by history, physical examination, plain and contrast radiographs, and/or esophagoscopy (Figure 9 -1).", [["pharynx", "ANATOMY", 47, 54], ["esophagus", "ANATOMY", 59, 68], ["vomiting", "DISEASE", 95, 103], ["RegurgitationRegurgitation", "DISEASE", 123, 149], ["pharynx", "ORGAN", 47, 54], ["esophagus", "ORGAN", 59, 68], ["Contrast radiographs", "TEST", 0, 20], ["fluoroscopy of the pharynx and esophagus", "TEST", 28, 68], ["vomiting", "PROBLEM", 95, 103], ["regurgitation", "PROBLEM", 109, 122], ["RegurgitationRegurgitation", "PROBLEM", 123, 149], ["physical examination", "TEST", 188, 208], ["plain and contrast radiographs", "TEST", 210, 240], ["esophagoscopy", "TEST", 249, 262], ["pharynx", "ANATOMY", 47, 54], ["esophagus", "ANATOMY", 59, 68], ["regurgitation", "OBSERVATION", 109, 122]]], ["Contrast radiographs should use barium instead of iodide contrast agents unless esophageal rupture is suspected (e.g., finding air or fluid in the mediastinum on plain radiographs).", [["esophageal", "ANATOMY", 80, 90], ["fluid", "ANATOMY", 134, 139], ["mediastinum", "ANATOMY", 147, 158], ["esophageal rupture", "DISEASE", 80, 98], ["iodide", "CHEMICAL", 50, 56], ["iodide", "SIMPLE_CHEMICAL", 50, 56], ["esophageal", "ORGAN", 80, 90], ["mediastinum", "ORGAN", 147, 158], ["Contrast radiographs", "TEST", 0, 20], ["barium", "TREATMENT", 32, 38], ["iodide contrast agents", "TREATMENT", 50, 72], ["esophageal rupture", "PROBLEM", 80, 98], ["fluid in the mediastinum", "PROBLEM", 134, 158], ["plain radiographs", "TEST", 162, 179], ["esophageal", "ANATOMY", 80, 90], ["rupture", "OBSERVATION", 91, 98], ["air", "OBSERVATION", 127, 130], ["fluid", "OBSERVATION", 134, 139], ["mediastinum", "ANATOMY", 147, 158]]], ["TheDiet and ParasitesDiet and parasites commonly cause acute and chronic vomiting; hence, dietary change (to a bland or hypoallergenic diet), fecal examination, and broad-spectrum anthelmintic therapy (e.g., fenbendazole, pyrantel) are reasonable initial choices in patients not suspected of having a clinically important disease.", [["fecal", "ANATOMY", 142, 147], ["vomiting", "DISEASE", 73, 81], ["fenbendazole", "CHEMICAL", 208, 220], ["pyrantel", "CHEMICAL", 222, 230], ["fenbendazole", "CHEMICAL", 208, 220], ["pyrantel", "CHEMICAL", 222, 230], ["fecal", "ORGANISM_SUBDIVISION", 142, 147], ["fenbendazole", "SIMPLE_CHEMICAL", 208, 220], ["pyrantel", "SIMPLE_CHEMICAL", 222, 230], ["patients", "ORGANISM", 266, 274], ["patients", "SPECIES", 266, 274], ["TheDiet", "TREATMENT", 0, 7], ["parasites", "TREATMENT", 30, 39], ["acute and chronic vomiting", "PROBLEM", 55, 81], ["a bland or hypoallergenic diet", "TREATMENT", 109, 139], ["fecal examination", "TEST", 142, 159], ["broad-spectrum anthelmintic therapy", "TREATMENT", 165, 200], ["fenbendazole", "TREATMENT", 208, 220], ["pyrantel", "TREATMENT", 222, 230], ["a clinically important disease", "PROBLEM", 299, 329], ["acute", "OBSERVATION_MODIFIER", 55, 60], ["chronic", "OBSERVATION_MODIFIER", 65, 72], ["vomiting", "OBSERVATION", 73, 81], ["fecal", "ANATOMY", 142, 147], ["anthelmintic therapy", "OBSERVATION", 180, 200]]], ["Continued vomiting is an indication for laboratory tests or imaging.ObstructionGastric or intestinal obstruction does not usually require clinicopathologic testing for diagnosis.", [["ObstructionGastric", "ANATOMY", 68, 86], ["intestinal", "ANATOMY", 90, 100], ["vomiting", "DISEASE", 10, 18], ["ObstructionGastric", "DISEASE", 68, 86], ["intestinal obstruction", "DISEASE", 90, 112], ["intestinal", "ORGAN", 90, 100], ["vomiting", "PROBLEM", 10, 18], ["laboratory tests", "TEST", 40, 56], ["imaging", "TEST", 60, 67], ["ObstructionGastric or intestinal obstruction", "PROBLEM", 68, 112], ["clinicopathologic testing", "TEST", 138, 163], ["vomiting", "OBSERVATION", 10, 18], ["intestinal", "ANATOMY", 90, 100], ["obstruction", "OBSERVATION", 101, 112]]], ["A complete blood count (CBC) may suggest sepsis, disseminated intravascular coagulation (DIC), or severe blood loss.", [["blood", "ANATOMY", 11, 16], ["intravascular", "ANATOMY", 62, 75], ["blood", "ANATOMY", 105, 110], ["sepsis", "DISEASE", 41, 47], ["disseminated intravascular coagulation", "DISEASE", 49, 87], ["DIC", "DISEASE", 89, 92], ["blood loss", "DISEASE", 105, 115], ["blood", "ORGANISM_SUBSTANCE", 11, 16], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 62, 75], ["blood", "ORGANISM_SUBSTANCE", 105, 110], ["A complete blood count", "TEST", 0, 22], ["CBC", "TEST", 24, 27], ["sepsis", "PROBLEM", 41, 47], ["disseminated intravascular coagulation", "PROBLEM", 49, 87], ["severe blood loss", "PROBLEM", 98, 115], ["may suggest", "UNCERTAINTY", 29, 40], ["sepsis", "OBSERVATION", 41, 47], ["disseminated", "OBSERVATION_MODIFIER", 49, 61], ["intravascular coagulation", "OBSERVATION", 62, 87], ["severe", "OBSERVATION_MODIFIER", 98, 104], ["blood loss", "OBSERVATION", 105, 115]]], ["Renal function, electrolyte, and acid-base evaluations are recommended before anesthesia.", [["Renal", "ANATOMY", 0, 5], ["Renal", "ORGAN", 0, 5], ["Renal function", "TEST", 0, 14], ["electrolyte", "TEST", 16, 27], ["acid-base evaluations", "TEST", 33, 54], ["anesthesia", "TREATMENT", 78, 88]]], ["One cannot reliably predict changes in these parameters even when the site of obstruction is known.", [["obstruction", "DISEASE", 78, 89], ["obstruction", "PROBLEM", 78, 89], ["obstruction", "OBSERVATION", 78, 89]]], ["Persistent and profuse loss of gastric contents from any cause may produce main purpose of a contrast esophagram is to distinguish esophageal motility abnormalities from anatomic lesions (e.g., obstruction, mass, inflammation, fistula).", [["gastric", "ANATOMY", 31, 38], ["esophageal", "ANATOMY", 131, 141], ["lesions", "ANATOMY", 179, 186], ["fistula", "ANATOMY", 227, 234], ["loss of gastric contents", "DISEASE", 23, 47], ["esophageal motility abnormalities", "DISEASE", 131, 164], ["obstruction", "DISEASE", 194, 205], ["inflammation", "DISEASE", 213, 225], ["fistula", "DISEASE", 227, 234], ["gastric", "ORGAN", 31, 38], ["esophageal", "ORGANISM_SUBDIVISION", 131, 141], ["anatomic lesions", "PATHOLOGICAL_FORMATION", 170, 186], ["fistula", "PATHOLOGICAL_FORMATION", 227, 234], ["Persistent and profuse loss of gastric contents", "PROBLEM", 0, 47], ["a contrast esophagram", "TEST", 91, 112], ["esophageal motility abnormalities", "PROBLEM", 131, 164], ["anatomic lesions", "PROBLEM", 170, 186], ["obstruction", "PROBLEM", 194, 205], ["mass", "PROBLEM", 207, 211], ["inflammation", "PROBLEM", 213, 225], ["fistula", "PROBLEM", 227, 234], ["profuse", "OBSERVATION_MODIFIER", 15, 22], ["loss", "OBSERVATION_MODIFIER", 23, 27], ["gastric", "ANATOMY", 31, 38], ["contents", "OBSERVATION", 39, 47], ["esophageal", "ANATOMY", 131, 141], ["anatomic", "OBSERVATION_MODIFIER", 170, 178], ["lesions", "OBSERVATION", 179, 186], ["obstruction", "OBSERVATION", 194, 205], ["mass", "OBSERVATION", 207, 211], ["inflammation", "OBSERVATION", 213, 225], ["fistula", "OBSERVATION", 227, 234]]], ["Some drugs (e.g., xylazine, ketamine) can cause esophageal hypomotility, making the radiographs potentially misleading.", [["esophageal", "ANATOMY", 48, 58], ["xylazine", "CHEMICAL", 18, 26], ["ketamine", "CHEMICAL", 28, 36], ["esophageal hypomotility", "DISEASE", 48, 71], ["xylazine", "CHEMICAL", 18, 26], ["ketamine", "CHEMICAL", 28, 36], ["xylazine", "SIMPLE_CHEMICAL", 18, 26], ["ketamine", "SIMPLE_CHEMICAL", 28, 36], ["esophageal", "ORGAN", 48, 58], ["Some drugs", "TREATMENT", 0, 10], ["xylazine", "TREATMENT", 18, 26], ["ketamine", "TREATMENT", 28, 36], ["esophageal hypomotility", "PROBLEM", 48, 71], ["the radiographs", "TEST", 80, 95], ["esophageal", "ANATOMY", 48, 58], ["hypomotility", "OBSERVATION", 59, 71]]], ["Esophagoscopy is insensitive for diagnosing esophageal muscular weakness but sensitive for finding anatomic lesions, differentiating intramural from extramural obstruction, identifying esophagitis, and removing foreign objects.", [["esophageal muscular", "ANATOMY", 44, 63], ["lesions", "ANATOMY", 108, 115], ["esophageal muscular weakness", "DISEASE", 44, 72], ["obstruction", "DISEASE", 160, 171], ["esophagitis", "DISEASE", 185, 196], ["esophageal muscular", "ORGANISM_SUBDIVISION", 44, 63], ["lesions", "PATHOLOGICAL_FORMATION", 108, 115], ["Esophagoscopy", "TEST", 0, 13], ["esophageal muscular weakness", "PROBLEM", 44, 72], ["anatomic lesions", "PROBLEM", 99, 115], ["intramural from extramural obstruction", "PROBLEM", 133, 171], ["esophagitis", "PROBLEM", 185, 196], ["insensitive for", "UNCERTAINTY", 17, 32], ["esophageal muscular", "ANATOMY", 44, 63], ["weakness", "OBSERVATION", 64, 72], ["lesions", "OBSERVATION", 108, 115], ["intramural", "OBSERVATION_MODIFIER", 133, 143], ["extramural", "OBSERVATION_MODIFIER", 149, 159], ["obstruction", "OBSERVATION", 160, 171], ["esophagitis", "OBSERVATION", 185, 196], ["foreign objects", "OBSERVATION", 211, 226]]], ["Patients with acquired esophageal weakness should be evaluated for myopathies, neuropathies, and myasthenia gravis (generalized or localized to the esophagus).", [["esophageal", "ANATOMY", 23, 33], ["esophagus", "ANATOMY", 148, 157], ["esophageal weakness", "DISEASE", 23, 42], ["myopathies", "DISEASE", 67, 77], ["neuropathies", "DISEASE", 79, 91], ["myasthenia gravis", "DISEASE", 97, 114], ["Patients", "ORGANISM", 0, 8], ["esophageal", "ORGAN", 23, 33], ["esophagus", "ORGAN", 148, 157], ["Patients", "SPECIES", 0, 8], ["acquired esophageal weakness", "PROBLEM", 14, 42], ["myopathies", "PROBLEM", 67, 77], ["neuropathies", "PROBLEM", 79, 91], ["myasthenia gravis", "PROBLEM", 97, 114], ["esophageal", "ANATOMY", 23, 33], ["weakness", "OBSERVATION", 34, 42], ["neuropathies", "OBSERVATION", 79, 91], ["myasthenia", "OBSERVATION", 97, 107], ["esophagus", "ANATOMY", 148, 157]]], ["Occasionally, hypoadrenocorticism, hyperkalemia, lead poisoning, Spirocerca lupi, and selected central nervous system (CNS) disorders (e.g., distemper, hydrocephalus) may be responsible.", [["central nervous system", "ANATOMY", 95, 117], ["CNS", "ANATOMY", 119, 122], ["hypoadrenocorticism", "DISEASE", 14, 33], ["hyperkalemia", "DISEASE", 35, 47], ["poisoning", "DISEASE", 54, 63], ["Spirocerca lupi", "DISEASE", 65, 80], ["central nervous system (CNS) disorders", "DISEASE", 95, 133], ["distemper", "DISEASE", 141, 150], ["hydrocephalus", "DISEASE", 152, 165], ["central nervous system", "ANATOMICAL_SYSTEM", 95, 117], ["CNS", "ANATOMICAL_SYSTEM", 119, 122], ["Spirocerca lupi", "SPECIES", 65, 80], ["hypoadrenocorticism", "PROBLEM", 14, 33], ["hyperkalemia", "PROBLEM", 35, 47], ["lead poisoning", "PROBLEM", 49, 63], ["Spirocerca lupi", "PROBLEM", 65, 80], ["selected central nervous system (CNS) disorders", "PROBLEM", 86, 133], ["distemper", "PROBLEM", 141, 150], ["hydrocephalus", "PROBLEM", 152, 165], ["hyperkalemia", "OBSERVATION", 35, 47], ["central", "ANATOMY_MODIFIER", 95, 102], ["nervous system", "ANATOMY", 103, 117], ["hydrocephalus", "OBSERVATION", 152, 165], ["may be responsible", "UNCERTAINTY", 167, 185]]], ["Generalized or localized myopathies and neuropathies have several causes (e.g., trauma, dermatomyositis, thymoma, botulism, tick paralysis, systemic lupus erythematosus, nutritional factors, toxoplasmosis, trypanosomiasis).", [["thymoma", "ANATOMY", 105, 112], ["myopathies", "DISEASE", 25, 35], ["neuropathies", "DISEASE", 40, 52], ["trauma", "DISEASE", 80, 86], ["dermatomyositis", "DISEASE", 88, 103], ["thymoma", "DISEASE", 105, 112], ["botulism", "DISEASE", 114, 122], ["tick paralysis", "DISEASE", 124, 138], ["systemic lupus erythematosus", "DISEASE", 140, 168], ["toxoplasmosis", "DISEASE", 191, 204], ["trypanosomiasis", "DISEASE", 206, 221], ["thymoma", "CANCER", 105, 112], ["Generalized or localized myopathies", "PROBLEM", 0, 35], ["neuropathies", "PROBLEM", 40, 52], ["trauma", "PROBLEM", 80, 86], ["dermatomyositis", "PROBLEM", 88, 103], ["thymoma", "PROBLEM", 105, 112], ["botulism", "PROBLEM", 114, 122], ["tick paralysis", "PROBLEM", 124, 138], ["systemic lupus erythematosus", "PROBLEM", 140, 168], ["nutritional factors", "PROBLEM", 170, 189], ["toxoplasmosis", "PROBLEM", 191, 204], ["trypanosomiasis", "PROBLEM", 206, 221], ["localized", "OBSERVATION_MODIFIER", 15, 24], ["myopathies", "OBSERVATION", 25, 35], ["neuropathies", "OBSERVATION", 40, 52], ["dermatomyositis", "OBSERVATION", 88, 103], ["thymoma", "OBSERVATION", 105, 112], ["lupus erythematosus", "OBSERVATION", 149, 168]]], ["Dysautonomia occurs in dogs and cats, causing generalized dysfunction of the autonomic nervous system producing esophageal hypomotility.", [["autonomic nervous system", "ANATOMY", 77, 101], ["esophageal", "ANATOMY", 112, 122], ["Dysautonomia", "DISEASE", 0, 12], ["dysfunction of the autonomic nervous system", "DISEASE", 58, 101], ["esophageal hypomotility", "DISEASE", 112, 135], ["dogs", "ORGANISM", 23, 27], ["cats", "ORGANISM", 32, 36], ["autonomic nervous system", "ANATOMICAL_SYSTEM", 77, 101], ["esophageal hypomotility", "PATHOLOGICAL_FORMATION", 112, 135], ["dogs", "SPECIES", 23, 27], ["cats", "SPECIES", 32, 36], ["Dysautonomia", "PROBLEM", 0, 12], ["generalized dysfunction of the autonomic nervous system", "PROBLEM", 46, 101], ["esophageal hypomotility", "PROBLEM", 112, 135], ["generalized", "OBSERVATION_MODIFIER", 46, 57], ["dysfunction", "OBSERVATION", 58, 69], ["autonomic nervous", "ANATOMY", 77, 94], ["esophageal", "ANATOMY", 112, 122], ["hypomotility", "OBSERVATION", 123, 135]]], ["It is important to detect underlying disorders so that one may treat the cause rather than just the symptoms.", [["underlying disorders", "PROBLEM", 26, 46], ["the symptoms", "PROBLEM", 96, 108]]], ["It is also wise to evaluate patients with unexpected esophageal foreign objects (e.g., a relatively small bolus of food) for partial obstructions (e.g., subclinical vascular ring anomaly, stricture).VomitingVomiting is a reflex act originating in the CNS that can be stimulated by various conditions.", [["esophageal", "ANATOMY", 53, 63], ["vascular", "ANATOMY", 165, 173], ["stricture", "ANATOMY", 188, 197], ["CNS", "ANATOMY", 251, 254], ["partial obstructions", "DISEASE", 125, 145], ["vascular ring anomaly", "DISEASE", 165, 186], ["stricture", "DISEASE", 188, 197], ["patients", "ORGANISM", 28, 36], ["esophageal", "ORGAN", 53, 63], ["vascular ring", "PATHOLOGICAL_FORMATION", 165, 178], ["stricture", "PATHOLOGICAL_FORMATION", 188, 197], ["CNS", "ANATOMICAL_SYSTEM", 251, 254], ["patients", "SPECIES", 28, 36], ["unexpected esophageal foreign objects", "PROBLEM", 42, 79], ["a relatively small bolus of food", "TREATMENT", 87, 119], ["partial obstructions (e.g., subclinical vascular ring anomaly", "PROBLEM", 125, 186], ["stricture", "PROBLEM", 188, 197], ["VomitingVomiting", "PROBLEM", 199, 215], ["esophageal", "ANATOMY", 53, 63], ["foreign objects", "OBSERVATION", 64, 79], ["obstructions", "OBSERVATION", 133, 145], ["vascular ring", "ANATOMY", 165, 178], ["anomaly", "OBSERVATION", 179, 186], ["stricture", "OBSERVATION", 188, 197], ["CNS", "ANATOMY", 251, 254]]], ["One must consider primary GI disease and non-GI disorders (e.g., metabolic, inflammatory, and toxic conditions) as causes of vomiting.", [["primary GI", "ANATOMY", 18, 28], ["primary GI disease", "DISEASE", 18, 36], ["non-GI disorders", "DISEASE", 41, 57], ["metabolic, inflammatory, and toxic conditions", "DISEASE", 65, 110], ["vomiting", "DISEASE", 125, 133], ["primary GI disease", "PROBLEM", 18, 36], ["non-GI disorders", "PROBLEM", 41, 57], ["inflammatory", "PROBLEM", 76, 88], ["toxic conditions", "PROBLEM", 94, 110], ["vomiting", "PROBLEM", 125, 133], ["GI", "ANATOMY", 26, 28], ["disease", "OBSERVATION", 29, 36], ["inflammatory", "OBSERVATION_MODIFIER", 76, 88]]], ["Many vomiting patients have non-GI problems.", [["vomiting", "DISEASE", 5, 13], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["Many vomiting", "PROBLEM", 0, 13], ["non-GI problems", "PROBLEM", 28, 43]]], ["Vomiting is classically characterized by prodromal nausea (i.e., salivation, licking of lips) followed by retching or forceful abdominal contractions.", [["lips", "ANATOMY", 88, 92], ["abdominal", "ANATOMY", 127, 136], ["Vomiting", "DISEASE", 0, 8], ["nausea", "DISEASE", 51, 57], ["retching", "DISEASE", 106, 114], ["lips", "ORGANISM_SUBDIVISION", 88, 92], ["abdominal", "ORGANISM_SUBDIVISION", 127, 136], ["Vomiting", "PROBLEM", 0, 8], ["prodromal nausea (i.e., salivation, licking of lips", "PROBLEM", 41, 92], ["retching", "PROBLEM", 106, 114], ["forceful abdominal contractions", "PROBLEM", 118, 149], ["prodromal", "OBSERVATION_MODIFIER", 41, 50], ["nausea", "OBSERVATION", 51, 57], ["lips", "ANATOMY", 88, 92], ["abdominal contractions", "ANATOMY", 127, 149]]], ["Vomiting may occur any time after eating or drinking (seconds to hours).", [["Vomiting", "DISEASE", 0, 8], ["Vomiting", "PROBLEM", 0, 8]]], ["A patient may vomit food, water, fresh blood, or mucus that is indistinguishable from regurgitated material.", [["blood", "ANATOMY", 39, 44], ["mucus", "ANATOMY", 49, 54], ["patient", "ORGANISM", 2, 9], ["blood", "ORGANISM_SUBSTANCE", 39, 44], ["mucus", "ORGANISM_SUBSTANCE", 49, 54], ["patient", "SPECIES", 2, 9], ["vomit food", "PROBLEM", 14, 24], ["fresh blood", "PROBLEM", 33, 44], ["mucus", "PROBLEM", 49, 54], ["regurgitated material", "PROBLEM", 86, 107], ["mucus", "ANATOMY", 49, 54]]], ["Bile, partially digested blood (i.e., \"coffee grounds\"), or expelled material with a pH of 5 or less strongly suggests vomiting as opposed to regurgitation.", [["Bile", "ANATOMY", 0, 4], ["blood", "ANATOMY", 25, 30], ["vomiting", "DISEASE", 119, 127], ["Bile", "MULTI-TISSUE_STRUCTURE", 0, 4], ["blood", "ORGANISM_SUBSTANCE", 25, 30], ["partially digested blood", "PROBLEM", 6, 30], ["a pH", "TEST", 83, 87], ["vomiting", "PROBLEM", 119, 127], ["regurgitation", "PROBLEM", 142, 155], ["vomiting", "OBSERVATION", 119, 127], ["regurgitation", "OBSERVATION", 142, 155]]], ["Vomited duodenal contents may have a pH greater than or equal to 7 and are usually positive for bile.", [["duodenal", "ANATOMY", 8, 16], ["bile", "ANATOMY", 96, 100], ["duodenal", "MULTI-TISSUE_STRUCTURE", 8, 16], ["bile", "MULTI-TISSUE_STRUCTURE", 96, 100], ["Vomited duodenal contents", "PROBLEM", 0, 25], ["a pH", "TEST", 35, 39], ["duodenal", "ANATOMY", 8, 16], ["contents", "OBSERVATION", 17, 25], ["pH greater", "OBSERVATION_MODIFIER", 37, 47], ["positive", "OBSERVATION", 83, 91], ["bile", "ANATOMY", 96, 100]]], ["A urine dipstick with a pH indicator is useful in making pH determinations.", [["urine", "ANATOMY", 2, 7], ["urine", "ORGANISM_SUBSTANCE", 2, 7], ["A urine dipstick", "TEST", 0, 16], ["a pH indicator", "TEST", 22, 36], ["pH determinations", "TEST", 57, 74]]], ["A patient that has \"dry heaves\" is typically vomiting as opposed to regurgitating.VomitingVomiting patients are best divided into those with acute (<2 weeks) versus those with chronic (>2 weeks) vomiting.", [["dry heaves", "DISEASE", 20, 30], ["vomiting", "DISEASE", 45, 53], ["vomiting", "DISEASE", 195, 203], ["patient", "ORGANISM", 2, 9], ["patients", "ORGANISM", 99, 107], ["patient", "SPECIES", 2, 9], ["patients", "SPECIES", 99, 107], ["\"dry heaves", "PROBLEM", 19, 30], ["vomiting", "PROBLEM", 45, 53], ["regurgitating", "PROBLEM", 68, 81], ["vomiting", "PROBLEM", 195, 203], ["acute", "OBSERVATION_MODIFIER", 141, 146], ["chronic", "OBSERVATION_MODIFIER", 176, 183]]], ["The most common categories of causes for each are listed in Boxes 9-1 and 9-2.", [["Boxes 9-1 and 9-2", "DNA", 60, 77], ["most common", "OBSERVATION_MODIFIER", 4, 15]]], ["Patients with acute vomiting often spontaneously resolve if they are supported by fluid therapy.", [["fluid", "ANATOMY", 82, 87], ["vomiting", "DISEASE", 20, 28], ["Patients", "ORGANISM", 0, 8], ["fluid", "ORGANISM_SUBSTANCE", 82, 87], ["Patients", "SPECIES", 0, 8], ["acute vomiting", "PROBLEM", 14, 28], ["fluid therapy", "TREATMENT", 82, 95], ["acute", "OBSERVATION_MODIFIER", 14, 19], ["vomiting", "OBSERVATION", 20, 28], ["fluid therapy", "OBSERVATION", 82, 95]]], ["A thorough history and physical examination are indicated first.", [["A thorough history", "TEST", 0, 18], ["physical examination", "TEST", 23, 43]]], ["Laboratory evaluation and/or imaging should be considered if the disease is severe or a serious disease (e.g., obstruction) is suspected.", [["obstruction", "DISEASE", 111, 122], ["Laboratory evaluation", "TEST", 0, 21], ["imaging", "TEST", 29, 36], ["the disease", "PROBLEM", 61, 72], ["a serious disease", "PROBLEM", 86, 103], ["obstruction", "PROBLEM", 111, 122], ["severe", "OBSERVATION_MODIFIER", 76, 82], ["serious", "OBSERVATION_MODIFIER", 88, 95], ["disease", "OBSERVATION", 96, 103], ["obstruction", "OBSERVATION", 111, 122]]], ["If vomiting persists, is progressive, or is attended by other clinical signs (e.g., polyuria-polydipsia [pu-pd] , weight loss, icterus, painful abdomen, ascites, weakness, hematemesis), additional testing is indicated (Figure 9 -2).Gastrointestinal ObstructionForeign objects (common) Intussusception Neoplasia (gastric or intestinal) Pyloric stenosis (infrequent) Gastric antral mucosal hyperplasia Inflammatory infiltrates of the stomach or intestines (e.g., pythiosis, eosinophilic masses) Chronic partial gastric volvulus (uncommon) Hypomotility of stomach/intestines (physiologic obstruction) (uncommon) Congenital structural abnormalities (rare)Gastrointestinal ObstructionAbdominal Inflammation Pancreatitis (common) Chronic enteritis (dietary-responsive or antibioticresponsive) (common) Gastrointestinal ulceration/erosion Peritonitis (sterile or septic) Inflammatory bowel disease Chronic gastritis (infrequent) Pharyngitis (caused by upper respiratory virus in cats) (rare) Parasites (e.g., Physaloptera) (regionally important) Systemic (extra-alimentary tract diseases) (common) Hepatic disease/insufficiency (common) Hypoadrenocorticism (uncommon but important) Diabetic ketoacidosis (common) Uremia (common) Hypercalcemia (important) Cholecystitis Pyometra (common) Feline hyperthyroidism (common) Central nervous system (CNS) disease (e.g., \"limbic epilepsy\", tumor, encephalitis, or increased intracranial pressure) (rare) Psychotic or behavioral changes (rare) hypokalemic, hypochloremic metabolic alkalosis with aciduria.", [["abdomen", "ANATOMY", 144, 151], ["ascites", "ANATOMY", 153, 160], ["gastric", "ANATOMY", 312, 319], ["intestinal", "ANATOMY", 323, 333], ["Gastric antral mucosal", "ANATOMY", 365, 387], ["stomach", "ANATOMY", 432, 439], ["intestines", "ANATOMY", 443, 453], ["pythiosis", "ANATOMY", 461, 470], ["eosinophilic masses", "ANATOMY", 472, 491], ["gastric", "ANATOMY", 509, 516], ["stomach", "ANATOMY", 553, 560], ["intestines", "ANATOMY", 561, 571], ["Gastrointestinal", "ANATOMY", 796, 812], ["bowel", "ANATOMY", 877, 882], ["alimentary tract", "ANATOMY", 1055, 1071], ["Hepatic", "ANATOMY", 1091, 1098], ["Central nervous system", "ANATOMY", 1312, 1334], ["CNS", "ANATOMY", 1336, 1339], ["limbic", "ANATOMY", 1357, 1363], ["tumor", "ANATOMY", 1375, 1380], ["intracranial", "ANATOMY", 1409, 1421], ["vomiting", "DISEASE", 3, 11], ["polyuria", "DISEASE", 84, 92], ["polydipsia", "DISEASE", 93, 103], ["weight loss", "DISEASE", 114, 125], ["icterus", "DISEASE", 127, 134], ["ascites", "DISEASE", 153, 160], ["weakness", "DISEASE", 162, 170], ["hematemesis", "DISEASE", 172, 183], ["Intussusception Neoplasia", "DISEASE", 285, 310], ["gastric or intestinal) Pyloric stenosis", "DISEASE", 312, 351], ["infiltrates of the stomach or intestines", "DISEASE", 413, 453], ["pythiosis", "DISEASE", 461, 470], ["partial gastric volvulus", "DISEASE", 501, 525], ["Hypomotility of stomach/intestines", "DISEASE", 537, 571], ["physiologic obstruction", "DISEASE", 573, 596], ["Congenital structural abnormalities", "DISEASE", 609, 644], ["Pancreatitis", "DISEASE", 702, 714], ["enteritis", "DISEASE", 732, 741], ["Gastrointestinal ulceration", "DISEASE", 796, 823], ["Peritonitis", "DISEASE", 832, 843], ["Inflammatory bowel disease", "DISEASE", 864, 890], ["gastritis", "DISEASE", 899, 908], ["Pharyngitis", "DISEASE", 922, 933], ["alimentary tract diseases", "DISEASE", 1055, 1080], ["Hepatic disease/insufficiency", "DISEASE", 1091, 1120], ["Hypoadrenocorticism", "DISEASE", 1130, 1149], ["Diabetic ketoacidosis", "DISEASE", 1175, 1196], ["Uremia", "DISEASE", 1206, 1212], ["Hypercalcemia", "DISEASE", 1222, 1235], ["Cholecystitis Pyometra", "DISEASE", 1248, 1270], ["Feline hyperthyroidism", "DISEASE", 1280, 1302], ["Central nervous system (CNS) disease", "DISEASE", 1312, 1348], ["limbic epilepsy", "DISEASE", 1357, 1372], ["tumor", "DISEASE", 1375, 1380], ["encephalitis", "DISEASE", 1382, 1394], ["Psychotic", "DISEASE", 1439, 1448], ["hypokalemic", "DISEASE", 1478, 1489], ["metabolic alkalosis", "DISEASE", 1505, 1524], ["aciduria", "DISEASE", 1530, 1538], ["abdomen", "ORGANISM_SUBDIVISION", 144, 151], ["gastric", "ORGAN", 312, 319], ["intestinal", "ORGAN", 323, 333], ["Gastric antral mucosal", "PATHOLOGICAL_FORMATION", 365, 387], ["stomach", "ORGAN", 432, 439], ["intestines", "ORGAN", 443, 453], ["eosinophilic masses", "CANCER", 472, 491], ["gastric volvulus", "PATHOLOGICAL_FORMATION", 509, 525], ["stomach", "ORGAN", 553, 560], ["intestines", "ORGAN", 561, 571], ["bowel", "ORGAN", 877, 882], ["upper respiratory virus", "ORGANISM", 945, 968], ["cats", "ORGANISM", 972, 976], ["alimentary tract", "ORGANISM_SUBDIVISION", 1055, 1071], ["Hepatic", "ORGAN", 1091, 1098], ["Feline", "ORGANISM", 1280, 1286], ["nervous system", "ANATOMICAL_SYSTEM", 1320, 1334], ["CNS", "ANATOMICAL_SYSTEM", 1336, 1339], ["tumor", "CANCER", 1375, 1380], ["cats", "SPECIES", 972, 976], ["vomiting", "PROBLEM", 3, 11], ["clinical signs", "TEST", 62, 76], ["polyuria", "PROBLEM", 84, 92], ["polydipsia", "PROBLEM", 93, 103], ["pu", "PROBLEM", 105, 107], ["pd", "PROBLEM", 108, 110], ["weight loss", "PROBLEM", 114, 125], ["icterus", "PROBLEM", 127, 134], ["painful abdomen", "PROBLEM", 136, 151], ["ascites", "PROBLEM", 153, 160], ["weakness", "PROBLEM", 162, 170], ["hematemesis", "PROBLEM", 172, 183], ["additional testing", "TEST", 186, 204], ["Gastrointestinal ObstructionForeign objects", "PROBLEM", 232, 275], ["Intussusception Neoplasia (gastric or intestinal) Pyloric stenosis (infrequent)", "PROBLEM", 285, 364], ["Gastric antral mucosal hyperplasia", "PROBLEM", 365, 399], ["Inflammatory infiltrates of the stomach or intestines", "PROBLEM", 400, 453], ["pythiosis", "PROBLEM", 461, 470], ["eosinophilic masses", "PROBLEM", 472, 491], ["Chronic partial gastric volvulus", "PROBLEM", 493, 525], ["Hypomotility of stomach/intestines (physiologic obstruction)", "PROBLEM", 537, 597], ["Congenital structural abnormalities (rare)", "PROBLEM", 609, 651], ["Gastrointestinal ObstructionAbdominal Inflammation Pancreatitis", "PROBLEM", 651, 714], ["Chronic enteritis", "PROBLEM", 724, 741], ["antibioticresponsive)", "PROBLEM", 765, 786], ["Gastrointestinal ulceration", "PROBLEM", 796, 823], ["erosion Peritonitis (sterile or septic) Inflammatory bowel disease", "PROBLEM", 824, 890], ["Chronic gastritis (infrequent) Pharyngitis", "PROBLEM", 891, 933], ["upper respiratory virus in cats", "PROBLEM", 945, 976], ["Parasites (e.g., Physaloptera)", "PROBLEM", 985, 1015], ["Systemic (extra-alimentary tract diseases)", "PROBLEM", 1039, 1081], ["Hepatic disease/insufficiency (common) Hypoadrenocorticism (uncommon", "PROBLEM", 1091, 1159], ["Diabetic ketoacidosis", "PROBLEM", 1175, 1196], ["Uremia (common) Hypercalcemia", "PROBLEM", 1206, 1235], ["Cholecystitis Pyometra (common) Feline hyperthyroidism", "PROBLEM", 1248, 1302], ["Central nervous system (CNS) disease (e.g., \"limbic epilepsy\"", "PROBLEM", 1312, 1373], ["tumor", "PROBLEM", 1375, 1380], ["encephalitis", "PROBLEM", 1382, 1394], ["increased intracranial pressure)", "PROBLEM", 1399, 1431], ["Psychotic or behavioral changes (rare)", "PROBLEM", 1439, 1477], ["hypokalemic", "PROBLEM", 1478, 1489], ["hypochloremic metabolic alkalosis", "PROBLEM", 1491, 1524], ["aciduria", "PROBLEM", 1530, 1538], ["progressive", "OBSERVATION_MODIFIER", 25, 36], ["icterus", "OBSERVATION", 127, 134], ["abdomen", "ANATOMY", 144, 151], ["ascites", "OBSERVATION", 153, 160], ["weakness", "OBSERVATION", 162, 170], ["hematemesis", "OBSERVATION", 172, 183], ["ObstructionForeign objects", "OBSERVATION", 249, 275], ["Intussusception", "OBSERVATION_MODIFIER", 285, 300], ["Neoplasia", "OBSERVATION", 301, 310], ["gastric", "ANATOMY", 312, 319], ["intestinal", "ANATOMY", 323, 333], ["Pyloric", "ANATOMY", 335, 342], ["stenosis", "OBSERVATION", 343, 351], ["Gastric", "ANATOMY", 365, 372], ["antral", "ANATOMY_MODIFIER", 373, 379], ["mucosal", "ANATOMY", 380, 387], ["hyperplasia", "OBSERVATION", 388, 399], ["Inflammatory", "OBSERVATION_MODIFIER", 400, 412], ["infiltrates", "OBSERVATION", 413, 424], ["stomach", "ANATOMY", 432, 439], ["intestines", "ANATOMY", 443, 453], ["eosinophilic", "OBSERVATION_MODIFIER", 472, 484], ["masses", "OBSERVATION", 485, 491], ["partial", "OBSERVATION_MODIFIER", 501, 508], ["gastric", "ANATOMY", 509, 516], ["volvulus", "OBSERVATION", 517, 525], ["Hypomotility", "OBSERVATION", 537, 549], ["stomach", "ANATOMY", 553, 560], ["intestines", "ANATOMY", 561, 571], ["obstruction", "OBSERVATION", 585, 596], ["Gastrointestinal", "ANATOMY", 651, 667], ["ObstructionAbdominal", "ANATOMY_MODIFIER", 668, 688], ["Inflammation", "OBSERVATION_MODIFIER", 689, 701], ["Pancreatitis", "OBSERVATION", 702, 714], ["Chronic", "OBSERVATION_MODIFIER", 724, 731], ["enteritis", "OBSERVATION", 732, 741], ["Gastrointestinal", "ANATOMY", 796, 812], ["ulceration", "OBSERVATION", 813, 823], ["erosion", "OBSERVATION_MODIFIER", 824, 831], ["Peritonitis", "OBSERVATION", 832, 843], ["septic", "OBSERVATION_MODIFIER", 856, 862], ["Inflammatory", "OBSERVATION_MODIFIER", 864, 876], ["bowel", "ANATOMY", 877, 882], ["disease", "OBSERVATION", 883, 890], ["Chronic", "OBSERVATION_MODIFIER", 891, 898], ["gastritis", "OBSERVATION", 899, 908], ["Pharyngitis", "OBSERVATION", 922, 933], ["upper", "ANATOMY_MODIFIER", 945, 950], ["respiratory virus", "ANATOMY", 951, 968], ["alimentary tract", "ANATOMY", 1055, 1071], ["Hepatic", "ANATOMY", 1091, 1098], ["disease", "OBSERVATION", 1099, 1106], ["insufficiency", "OBSERVATION", 1107, 1120], ["Uremia", "OBSERVATION", 1206, 1212], ["Hypercalcemia", "OBSERVATION", 1222, 1235], ["Cholecystitis", "OBSERVATION", 1248, 1261], ["hyperthyroidism", "OBSERVATION", 1287, 1302], ["Central", "ANATOMY_MODIFIER", 1312, 1319], ["nervous system", "ANATOMY", 1320, 1334], ["CNS", "ANATOMY", 1336, 1339], ["disease", "OBSERVATION", 1341, 1348], ["limbic epilepsy", "OBSERVATION", 1357, 1372], ["tumor", "OBSERVATION", 1375, 1380], ["encephalitis", "OBSERVATION", 1382, 1394], ["increased", "OBSERVATION_MODIFIER", 1399, 1408], ["intracranial pressure", "OBSERVATION", 1409, 1430], ["metabolic alkalosis", "OBSERVATION", 1505, 1524], ["aciduria", "OBSERVATION", 1530, 1538]]], ["However, most patients with gastric vomiting are not alkalotic.", [["gastric", "ANATOMY", 28, 35], ["gastric vomiting", "DISEASE", 28, 44], ["patients", "ORGANISM", 14, 22], ["gastric", "ORGAN", 28, 35], ["patients", "SPECIES", 14, 22], ["gastric vomiting", "PROBLEM", 28, 44], ["alkalotic", "PROBLEM", 53, 62], ["gastric", "ANATOMY", 28, 35], ["vomiting", "OBSERVATION", 36, 44], ["alkalotic", "OBSERVATION", 53, 62]]], ["Insignificant acid-base changes or metabolic acidosis due to dehydration are probably more common.", [["metabolic acidosis", "DISEASE", 35, 53], ["dehydration", "DISEASE", 61, 72], ["Insignificant acid-base changes", "PROBLEM", 0, 31], ["metabolic acidosis", "PROBLEM", 35, 53], ["dehydration", "PROBLEM", 61, 72], ["acid", "OBSERVATION_MODIFIER", 14, 18], ["base", "ANATOMY_MODIFIER", 19, 23], ["metabolic acidosis", "OBSERVATION", 35, 53], ["dehydration", "OBSERVATION", 61, 72], ["more common", "OBSERVATION_MODIFIER", 86, 97]]], ["Intestinal obstruction may cause acidosis due to loss of pancreatic bicarbonate, although some patients have a normal blood pH or a metabolic alkalosis if the obstruction is high in the duodenum.Gastrointestinal ObstructionAbdominal radiographs and ultrasound are the best initial tests.", [["Intestinal", "ANATOMY", 0, 10], ["pancreatic", "ANATOMY", 57, 67], ["blood", "ANATOMY", 118, 123], ["duodenum", "ANATOMY", 186, 194], ["Gastrointestinal", "ANATOMY", 195, 211], ["Intestinal obstruction", "DISEASE", 0, 22], ["acidosis", "DISEASE", 33, 41], ["bicarbonate", "CHEMICAL", 68, 79], ["metabolic alkalosis", "DISEASE", 132, 151], ["obstruction", "DISEASE", 159, 170], ["bicarbonate", "CHEMICAL", 68, 79], ["Intestinal", "ORGAN", 0, 10], ["pancreatic", "ORGAN", 57, 67], ["bicarbonate", "SIMPLE_CHEMICAL", 68, 79], ["patients", "ORGANISM", 95, 103], ["blood", "ORGANISM_SUBSTANCE", 118, 123], ["duodenum", "ORGAN", 186, 194], ["patients", "SPECIES", 95, 103], ["Intestinal obstruction", "PROBLEM", 0, 22], ["acidosis", "PROBLEM", 33, 41], ["loss of pancreatic bicarbonate", "PROBLEM", 49, 79], ["a metabolic alkalosis", "PROBLEM", 130, 151], ["the obstruction", "PROBLEM", 155, 170], ["Gastrointestinal ObstructionAbdominal radiographs", "TEST", 195, 244], ["ultrasound", "TEST", 249, 259], ["obstruction", "OBSERVATION", 11, 22], ["acidosis", "OBSERVATION", 33, 41], ["pancreatic", "ANATOMY", 57, 67], ["normal", "OBSERVATION", 111, 117], ["blood pH", "OBSERVATION_MODIFIER", 118, 126], ["metabolic alkalosis", "OBSERVATION", 132, 151], ["obstruction", "OBSERVATION", 159, 170], ["high", "OBSERVATION_MODIFIER", 174, 178], ["duodenum", "ANATOMY", 186, 194]]], ["In otherwise occult cases, contrast radiographs may be necessary, in which case barium is preferred over iodide compounds unless intestinal rupture is suspected.", [["intestinal", "ANATOMY", 129, 139], ["intestinal rupture", "DISEASE", 129, 147], ["iodide", "CHEMICAL", 105, 111], ["iodide compounds", "SIMPLE_CHEMICAL", 105, 121], ["intestinal", "ORGAN", 129, 139], ["contrast radiographs", "TEST", 27, 47], ["barium", "TREATMENT", 80, 86], ["intestinal rupture", "PROBLEM", 129, 147], ["intestinal", "ANATOMY", 129, 139], ["rupture", "OBSERVATION", 140, 147]]], ["Barium leakage into the abdomen causes peritonitis and requires vigorous abdominal lavage at the time of surgery (see Chapter 10).Extra-alimentary Tract DiseaseA serum chemistry profile should be obtained to help rule out hepatic disease (alanine aminotransferase [ALT] , serum alkaline phosphatase [SAP] , blood urea nitrogen [BUN] , and albumin), hypoadrenocorticism (sodium and potassium), hypercalcemia (calcium and albumin), uremia (creatinine, BUN, and urinalysis), and diabetic ketoacidosis (glucose and urinalysis).", [["abdomen", "ANATOMY", 24, 31], ["abdominal lavage", "ANATOMY", 73, 89], ["serum", "ANATOMY", 162, 167], ["hepatic", "ANATOMY", 222, 229], ["serum", "ANATOMY", 272, 277], ["blood", "ANATOMY", 307, 312], ["Barium", "CHEMICAL", 0, 6], ["peritonitis", "DISEASE", 39, 50], ["hepatic disease", "DISEASE", 222, 237], ["alanine", "CHEMICAL", 239, 246], ["blood urea nitrogen", "CHEMICAL", 307, 326], ["sodium", "CHEMICAL", 370, 376], ["potassium", "CHEMICAL", 381, 390], ["hypercalcemia", "DISEASE", 393, 406], ["calcium", "CHEMICAL", 408, 415], ["uremia", "DISEASE", 430, 436], ["creatinine", "CHEMICAL", 438, 448], ["diabetic ketoacidosis", "DISEASE", 476, 497], ["glucose", "CHEMICAL", 499, 506], ["Barium", "CHEMICAL", 0, 6], ["alanine", "CHEMICAL", 239, 246], ["urea", "CHEMICAL", 313, 317], ["nitrogen", "CHEMICAL", 318, 326], ["sodium", "CHEMICAL", 370, 376], ["potassium", "CHEMICAL", 381, 390], ["calcium", "CHEMICAL", 408, 415], ["creatinine", "CHEMICAL", 438, 448], ["glucose", "CHEMICAL", 499, 506], ["Barium", "SIMPLE_CHEMICAL", 0, 6], ["abdomen", "ORGAN", 24, 31], ["serum", "ORGANISM_SUBSTANCE", 162, 167], ["hepatic", "ORGAN", 222, 229], ["alanine aminotransferase", "GENE_OR_GENE_PRODUCT", 239, 263], ["ALT", "SIMPLE_CHEMICAL", 265, 268], ["serum", "ORGANISM_SUBSTANCE", 272, 277], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 278, 298], ["SAP", "GENE_OR_GENE_PRODUCT", 300, 303], ["blood", "ORGANISM_SUBSTANCE", 307, 312], ["urea nitrogen", "SIMPLE_CHEMICAL", 313, 326], ["BUN", "SIMPLE_CHEMICAL", 328, 331], ["albumin", "GENE_OR_GENE_PRODUCT", 339, 346], ["hypoadrenocorticism", "SIMPLE_CHEMICAL", 349, 368], ["sodium", "SIMPLE_CHEMICAL", 370, 376], ["potassium", "SIMPLE_CHEMICAL", 381, 390], ["calcium", "SIMPLE_CHEMICAL", 408, 415], ["albumin", "SIMPLE_CHEMICAL", 420, 427], ["creatinine", "SIMPLE_CHEMICAL", 438, 448], ["BUN", "SIMPLE_CHEMICAL", 450, 453], ["glucose", "SIMPLE_CHEMICAL", 499, 506], ["alanine aminotransferase", "PROTEIN", 239, 263], ["ALT", "PROTEIN", 265, 268], ["serum alkaline phosphatase", "PROTEIN", 272, 298], ["SAP", "PROTEIN", 300, 303], ["Barium leakage into the abdomen", "PROBLEM", 0, 31], ["peritonitis", "PROBLEM", 39, 50], ["vigorous abdominal lavage", "TREATMENT", 64, 89], ["surgery", "TREATMENT", 105, 112], ["Extra-alimentary Tract DiseaseA", "PROBLEM", 130, 161], ["serum chemistry profile", "TEST", 162, 185], ["hepatic disease", "PROBLEM", 222, 237], ["alanine aminotransferase", "TEST", 239, 263], ["ALT", "TEST", 265, 268], ["serum alkaline phosphatase", "TEST", 272, 298], ["SAP", "TEST", 300, 303], ["blood urea nitrogen", "TEST", 307, 326], ["BUN", "TEST", 328, 331], ["albumin", "TEST", 339, 346], ["hypoadrenocorticism", "TEST", 349, 368], ["sodium", "TEST", 370, 376], ["potassium", "TEST", 381, 390], ["hypercalcemia", "PROBLEM", 393, 406], ["calcium", "TEST", 408, 415], ["albumin", "TEST", 420, 427], ["uremia", "PROBLEM", 430, 436], ["creatinine", "TEST", 438, 448], ["BUN", "TEST", 450, 453], ["urinalysis", "TEST", 459, 469], ["diabetic ketoacidosis", "PROBLEM", 476, 497], ["glucose", "TEST", 499, 506], ["urinalysis", "TEST", 511, 521], ["leakage", "OBSERVATION", 7, 14], ["abdomen", "ANATOMY", 24, 31], ["peritonitis", "OBSERVATION", 39, 50], ["vigorous", "OBSERVATION_MODIFIER", 64, 72], ["abdominal", "ANATOMY", 73, 82], ["lavage", "OBSERVATION", 83, 89], ["hepatic", "ANATOMY", 222, 229], ["disease", "OBSERVATION", 230, 237], ["hypercalcemia", "OBSERVATION", 393, 406], ["uremia", "OBSERVATION", 430, 436], ["diabetic", "OBSERVATION_MODIFIER", 476, 484], ["ketoacidosis", "OBSERVATION", 485, 497]]], ["Very young (i.e., <12 to 14 weeks of age) and very small (i.e., <3 kg) patients should undergo blood glucose monitoring to detect secondary hypoglycemia.", [["blood", "ANATOMY", 95, 100], ["glucose", "CHEMICAL", 101, 108], ["hypoglycemia", "DISEASE", 140, 152], ["glucose", "CHEMICAL", 101, 108], ["patients", "ORGANISM", 71, 79], ["blood", "ORGANISM_SUBSTANCE", 95, 100], ["glucose", "SIMPLE_CHEMICAL", 101, 108], ["patients", "SPECIES", 71, 79], ["blood glucose monitoring", "TEST", 95, 119], ["secondary hypoglycemia", "PROBLEM", 130, 152], ["small", "OBSERVATION_MODIFIER", 51, 56]]], ["More precise testing is occasionally required to diagnose these disorders (e.g., serum bile acids for hepatic insufficiency, adrenocorticotropic hormone [ACTH] stimulation test for hypoadrenocorticism).", [["serum", "ANATOMY", 81, 86], ["hepatic", "ANATOMY", 102, 109], ["bile acids", "CHEMICAL", 87, 97], ["hepatic insufficiency", "DISEASE", 102, 123], ["hypoadrenocorticism", "DISEASE", 181, 200], ["bile acids", "CHEMICAL", 87, 97], ["serum", "ORGANISM_SUBSTANCE", 81, 86], ["bile acids", "SIMPLE_CHEMICAL", 87, 97], ["hepatic", "ORGAN", 102, 109], ["adrenocorticotropic hormone", "GENE_OR_GENE_PRODUCT", 125, 152], ["ACTH", "GENE_OR_GENE_PRODUCT", 154, 158], ["these disorders", "PROBLEM", 58, 73], ["serum bile acids", "TEST", 81, 97], ["hepatic insufficiency", "PROBLEM", 102, 123], ["adrenocorticotropic hormone", "TREATMENT", 125, 152], ["ACTH] stimulation test", "TEST", 154, 176], ["hypoadrenocorticism", "PROBLEM", 181, 200], ["hepatic", "ANATOMY", 102, 109], ["insufficiency", "OBSERVATION", 110, 123]]], ["Other tests to consider are serum gastrin for gastrinoma, and serum thyroxine for feline hyperthyroidism.PancreatitisAcute pancreatitis occurs commonly.", [["serum", "ANATOMY", 28, 33], ["gastrinoma", "ANATOMY", 46, 56], ["serum", "ANATOMY", 62, 67], ["gastrinoma", "DISEASE", 46, 56], ["thyroxine", "CHEMICAL", 68, 77], ["feline hyperthyroidism", "DISEASE", 82, 104], ["pancreatitis", "DISEASE", 123, 135], ["thyroxine", "CHEMICAL", 68, 77], ["serum", "ORGANISM_SUBSTANCE", 28, 33], ["gastrin", "GENE_OR_GENE_PRODUCT", 34, 41], ["gastrinoma", "CANCER", 46, 56], ["serum", "ORGANISM_SUBSTANCE", 62, 67], ["thyroxine", "SIMPLE_CHEMICAL", 68, 77], ["feline", "ORGANISM", 82, 88], ["Other tests", "TEST", 0, 11], ["serum gastrin", "TEST", 28, 41], ["gastrinoma", "PROBLEM", 46, 56], ["serum thyroxine", "TEST", 62, 77], ["feline hyperthyroidism", "PROBLEM", 82, 104], ["PancreatitisAcute pancreatitis", "PROBLEM", 105, 135], ["hyperthyroidism", "OBSERVATION", 89, 104], ["pancreatitis", "OBSERVATION", 123, 135]]], ["Predisposing causes in dogs include hyperlipidemia, fatty meals, or obesity.", [["hyperlipidemia", "DISEASE", 36, 50], ["fatty meals", "DISEASE", 52, 63], ["obesity", "DISEASE", 68, 75], ["dogs", "ORGANISM", 23, 27], ["dogs", "SPECIES", 23, 27], ["Predisposing causes in dogs", "PROBLEM", 0, 27], ["hyperlipidemia", "PROBLEM", 36, 50], ["fatty meals", "PROBLEM", 52, 63], ["obesity", "PROBLEM", 68, 75], ["hyperlipidemia", "OBSERVATION", 36, 50], ["fatty meals", "OBSERVATION", 52, 63], ["obesity", "OBSERVATION", 68, 75]]], ["Pancreatitis can occur in any dog, but middle-aged obese female dogs, schnauzers, and Yorkshire terriers seem to be predisposed.", [["Pancreatitis", "DISEASE", 0, 12], ["dog", "ORGANISM", 30, 33], ["dogs", "ORGANISM", 64, 68], ["dog", "SPECIES", 30, 33], ["dogs", "SPECIES", 64, 68], ["Pancreatitis", "PROBLEM", 0, 12]]], ["Vomiting may or may not be associated with eating, abdominal pain, fasting hyperlipidemia, bloody diarrhea, and, rarely, diffuse subcutaneous fat necrosis.", [["abdominal", "ANATOMY", 51, 60], ["subcutaneous fat", "ANATOMY", 129, 145], ["Vomiting", "DISEASE", 0, 8], ["abdominal pain", "DISEASE", 51, 65], ["fasting hyperlipidemia", "DISEASE", 67, 89], ["bloody diarrhea", "DISEASE", 91, 106], ["fat necrosis", "DISEASE", 142, 154], ["abdominal", "ORGANISM_SUBDIVISION", 51, 60], ["fat", "TISSUE", 142, 145], ["Vomiting", "PROBLEM", 0, 8], ["abdominal pain", "PROBLEM", 51, 65], ["fasting hyperlipidemia", "PROBLEM", 67, 89], ["bloody diarrhea", "PROBLEM", 91, 106], ["diffuse subcutaneous fat necrosis", "PROBLEM", 121, 154], ["may not be", "UNCERTAINTY", 16, 26], ["abdominal", "ANATOMY", 51, 60], ["pain", "OBSERVATION", 61, 65], ["hyperlipidemia", "OBSERVATION", 75, 89], ["bloody diarrhea", "OBSERVATION", 91, 106], ["diffuse", "OBSERVATION_MODIFIER", 121, 128], ["subcutaneous fat", "ANATOMY", 129, 145], ["necrosis", "OBSERVATION", 146, 154]]], ["On radiographic examination, a mass or indistinctness due to localized peritonitis may be visible in the cranial right abdominal quadrant.", [["cranial right abdominal quadrant", "ANATOMY", 105, 137], ["indistinctness", "DISEASE", 39, 53], ["peritonitis", "DISEASE", 71, 82], ["abdominal", "ORGANISM_SUBDIVISION", 119, 128], ["radiographic examination", "TEST", 3, 27], ["a mass", "PROBLEM", 29, 35], ["indistinctness", "PROBLEM", 39, 53], ["localized peritonitis", "PROBLEM", 61, 82], ["mass", "OBSERVATION", 31, 35], ["indistinctness", "OBSERVATION", 39, 53], ["localized", "OBSERVATION_MODIFIER", 61, 70], ["peritonitis", "OBSERVATION", 71, 82], ["cranial", "ANATOMY_MODIFIER", 105, 112], ["right", "ANATOMY_MODIFIER", 113, 118], ["abdominal", "ANATOMY", 119, 128], ["quadrant", "ANATOMY_MODIFIER", 129, 137]]], ["CBC, serum amylase, and serum lipase activities are insensitive and nonspecific; patients with pancreatitis can have almost any result on these tests.", [["serum", "ANATOMY", 5, 10], ["serum", "ANATOMY", 24, 29], ["pancreatitis", "DISEASE", 95, 107], ["CBC", "ORGANISM_SUBSTANCE", 0, 3], ["serum", "ORGANISM_SUBSTANCE", 5, 10], ["amylase", "GENE_OR_GENE_PRODUCT", 11, 18], ["serum", "ORGANISM_SUBSTANCE", 24, 29], ["lipase", "GENE_OR_GENE_PRODUCT", 30, 36], ["patients", "ORGANISM", 81, 89], ["CBC", "PROTEIN", 0, 3], ["serum amylase", "PROTEIN", 5, 18], ["serum lipase", "PROTEIN", 24, 36], ["patients", "SPECIES", 81, 89], ["CBC", "TEST", 0, 3], ["serum amylase", "TEST", 5, 18], ["serum lipase activities", "TEST", 24, 47], ["pancreatitis", "PROBLEM", 95, 107], ["these tests", "TEST", 138, 149], ["nonspecific", "OBSERVATION_MODIFIER", 68, 79], ["pancreatitis", "OBSERVATION", 95, 107]]], ["Increased ALT and SAP concentrations (as the result of the proximity of the pancreas to the liver and obstruction of the biliary duct) are common but insensitive and nonspecific.", [["pancreas", "ANATOMY", 76, 84], ["liver", "ANATOMY", 92, 97], ["biliary duct", "ANATOMY", 121, 133], ["ALT", "GENE_OR_GENE_PRODUCT", 10, 13], ["SAP", "GENE_OR_GENE_PRODUCT", 18, 21], ["pancreas", "ORGAN", 76, 84], ["liver", "ORGAN", 92, 97], ["biliary duct", "MULTI-TISSUE_STRUCTURE", 121, 133], ["ALT", "PROTEIN", 10, 13], ["SAP", "PROTEIN", 18, 21], ["Increased ALT and SAP concentrations", "PROBLEM", 0, 36], ["obstruction of the biliary duct", "PROBLEM", 102, 133], ["ALT", "OBSERVATION_MODIFIER", 10, 13], ["SAP concentrations", "OBSERVATION_MODIFIER", 18, 36], ["pancreas", "ANATOMY", 76, 84], ["liver", "ANATOMY", 92, 97], ["obstruction", "OBSERVATION", 102, 113], ["biliary duct", "ANATOMY", 121, 133], ["nonspecific", "OBSERVATION_MODIFIER", 166, 177]]], ["Mild to moderate hypocalcemia sometimes occurs.", [["hypocalcemia", "DISEASE", 17, 29], ["Mild to moderate hypocalcemia", "PROBLEM", 0, 29], ["moderate", "OBSERVATION_MODIFIER", 8, 16], ["hypocalcemia", "OBSERVATION", 17, 29]]], ["Abdominal ultrasonography can be very specific for canine pancreatitis, but its sensitivity depends upon operator skill and timing (i.e., ultrasound findings can change dramatically in a matter of hours).", [["Abdominal", "ANATOMY", 0, 9], ["pancreatitis", "DISEASE", 58, 70], ["canine", "ORGANISM", 51, 57], ["canine", "SPECIES", 51, 57], ["Abdominal ultrasonography", "TEST", 0, 25], ["canine pancreatitis", "PROBLEM", 51, 70], ["ultrasound findings", "TEST", 138, 157], ["pancreatitis", "OBSERVATION", 58, 70]]], ["If a pancreatic mass is discovered during surgery, it must be biopsied; chronic pancreatitis can be grossly indistinguishable from pancreatic neoplasia.", [["pancreatic mass", "ANATOMY", 5, 20], ["pancreatic neoplasia", "ANATOMY", 131, 151], ["pancreatic mass", "DISEASE", 5, 20], ["pancreatitis", "DISEASE", 80, 92], ["pancreatic neoplasia", "DISEASE", 131, 151], ["pancreatic", "ORGAN", 5, 15], ["pancreatic neoplasia", "CANCER", 131, 151], ["a pancreatic mass", "PROBLEM", 3, 20], ["surgery", "TREATMENT", 42, 49], ["chronic pancreatitis", "PROBLEM", 72, 92], ["pancreatic neoplasia", "PROBLEM", 131, 151], ["pancreatic", "ANATOMY", 5, 15], ["mass", "OBSERVATION", 16, 20], ["chronic", "OBSERVATION_MODIFIER", 72, 79], ["pancreatitis", "OBSERVATION", 80, 92], ["pancreatic", "ANATOMY", 131, 141], ["neoplasia", "OBSERVATION", 142, 151]]], ["The canine immunoreactive pancreatic lipase (spec cPL) (IDEXX, Westbrook, ME) test is the most sensitive test for pancreatitis, but its specificity for clinically important disease is still being determined.", [["pancreatic", "ANATOMY", 26, 36], ["pancreatitis", "DISEASE", 114, 126], ["canine", "ORGANISM", 4, 10], ["pancreatic", "ORGAN", 26, 36], ["lipase", "GENE_OR_GENE_PRODUCT", 37, 43], ["spec cPL", "GENE_OR_GENE_PRODUCT", 45, 53], ["canine immunoreactive pancreatic lipase", "PROTEIN", 4, 43], ["cPL", "PROTEIN", 50, 53], ["canine", "SPECIES", 4, 10], ["The canine immunoreactive pancreatic lipase", "TEST", 0, 43], ["pancreatitis", "PROBLEM", 114, 126], ["clinically important disease", "PROBLEM", 152, 180], ["immunoreactive", "OBSERVATION_MODIFIER", 11, 25], ["pancreatic", "ANATOMY", 26, 36], ["lipase", "ANATOMY", 37, 43], ["pancreatitis", "OBSERVATION", 114, 126]]], ["Chronic pancreatitis may be presumptively diagnosed if one finds exocrine pancreatic insufficiency in a breed that is not affected by pancreatic acinar cell atrophy.PancreatitisPancreatitis is an important but difficult-to-diagnose disease in cats.", [["exocrine pancreatic", "ANATOMY", 65, 84], ["pancreatic acinar cell", "ANATOMY", 134, 156], ["pancreatitis", "DISEASE", 8, 20], ["exocrine pancreatic insufficiency", "DISEASE", 65, 98], ["pancreatic acinar cell atrophy", "DISEASE", 134, 164], ["Pancreatitis", "DISEASE", 165, 177], ["Pancreatitis", "DISEASE", 177, 189], ["exocrine pancreatic", "MULTI-TISSUE_STRUCTURE", 65, 84], ["pancreatic acinar cell", "CELL", 134, 156], ["cats", "ORGANISM", 243, 247], ["cats", "SPECIES", 243, 247], ["Chronic pancreatitis", "PROBLEM", 0, 20], ["exocrine pancreatic insufficiency", "PROBLEM", 65, 98], ["pancreatic acinar cell atrophy", "PROBLEM", 134, 164], ["PancreatitisPancreatitis", "PROBLEM", 165, 189], ["diagnose disease in cats", "PROBLEM", 223, 247], ["pancreatitis", "OBSERVATION", 8, 20], ["pancreatic", "ANATOMY", 74, 84], ["insufficiency", "OBSERVATION", 85, 98], ["not affected", "UNCERTAINTY", 118, 130], ["pancreatic", "ANATOMY", 134, 144], ["acinar cell atrophy", "OBSERVATION", 145, 164], ["Pancreatitis", "OBSERVATION", 177, 189]]], ["Chronic pancreatitis in older cats sometimes occurs in conjunction with cholangiohepatitis and/ or inflammatory bowel disease (IBD) (often referred to as a triaditis syndrome involving all three organs).", [["bowel", "ANATOMY", 112, 117], ["organs", "ANATOMY", 195, 201], ["pancreatitis", "DISEASE", 8, 20], ["cholangiohepatitis", "DISEASE", 72, 90], ["inflammatory bowel disease", "DISEASE", 99, 125], ["IBD", "DISEASE", 127, 130], ["triaditis syndrome", "DISEASE", 156, 174], ["cats", "ORGANISM", 30, 34], ["bowel", "ORGAN", 112, 117], ["organs", "ORGAN", 195, 201], ["cats", "SPECIES", 30, 34], ["Chronic pancreatitis", "PROBLEM", 0, 20], ["older cats", "PROBLEM", 24, 34], ["cholangiohepatitis", "PROBLEM", 72, 90], ["inflammatory bowel disease", "PROBLEM", 99, 125], ["IBD)", "PROBLEM", 127, 131], ["a triaditis syndrome", "PROBLEM", 154, 174], ["pancreatitis", "OBSERVATION", 8, 20], ["inflammatory", "OBSERVATION_MODIFIER", 99, 111], ["bowel", "ANATOMY", 112, 117], ["disease", "OBSERVATION", 118, 125]]], ["Vomiting is not as prominent in feline pancreatitis as it is in canine pancreatitis.", [["Vomiting", "DISEASE", 0, 8], ["pancreatitis", "DISEASE", 39, 51], ["pancreatitis", "DISEASE", 71, 83], ["feline", "ORGANISM", 32, 38], ["canine", "ORGANISM", 64, 70], ["canine", "SPECIES", 64, 70], ["canine", "SPECIES", 64, 70], ["Vomiting", "PROBLEM", 0, 8], ["feline pancreatitis", "PROBLEM", 32, 51], ["canine pancreatitis", "PROBLEM", 64, 83], ["not as", "UNCERTAINTY", 12, 18], ["prominent", "OBSERVATION_MODIFIER", 19, 28], ["feline", "OBSERVATION_MODIFIER", 32, 38], ["pancreatitis", "OBSERVATION", 39, 51], ["canine", "OBSERVATION_MODIFIER", 64, 70], ["pancreatitis", "OBSERVATION", 71, 83]]], ["Feline trypsin-like immunoreactivity (fTLI) concentrations are increased in some patients.", [["Feline", "ORGANISM", 0, 6], ["trypsin-like immunoreactivity", "GENE_OR_GENE_PRODUCT", 7, 36], ["fTLI", "SIMPLE_CHEMICAL", 38, 42], ["patients", "ORGANISM", 81, 89], ["trypsin", "PROTEIN", 7, 14], ["patients", "SPECIES", 81, 89], ["Feline trypsin", "TEST", 0, 14], ["increased", "OBSERVATION_MODIFIER", 63, 72]]], ["Abdominal ultrasonography is specific, but the sensitivity is uncertain.", [["Abdominal", "ANATOMY", 0, 9], ["Abdominal ultrasonography", "TEST", 0, 25], ["the sensitivity", "TEST", 43, 58]]], ["A pancreatic biopsy may be required for a definitive diagnosis.", [["pancreatic biopsy", "ANATOMY", 2, 19], ["pancreatic biopsy", "CANCER", 2, 19], ["A pancreatic biopsy", "TEST", 0, 19], ["a definitive diagnosis", "TEST", 40, 62], ["pancreatic", "ANATOMY", 2, 12], ["biopsy", "OBSERVATION", 13, 19]]], ["The feline immunoreactive pancreatic lipase (spec fPL) test appears to be useful in diagnosing pancreatitis.", [["pancreatic", "ANATOMY", 26, 36], ["pancreatitis", "DISEASE", 95, 107], ["feline", "ORGANISM", 4, 10], ["pancreatic lipase", "GENE_OR_GENE_PRODUCT", 26, 43], ["spec fPL", "GENE_OR_GENE_PRODUCT", 45, 53], ["feline immunoreactive pancreatic lipase", "PROTEIN", 4, 43], ["fPL", "PROTEIN", 50, 53], ["feline", "SPECIES", 4, 10], ["The feline immunoreactive pancreatic lipase (spec fPL) test", "TEST", 0, 59], ["pancreatitis", "PROBLEM", 95, 107], ["feline", "OBSERVATION_MODIFIER", 4, 10], ["immunoreactive", "OBSERVATION_MODIFIER", 11, 25], ["pancreatic", "ANATOMY", 26, 36], ["lipase", "ANATOMY", 37, 43], ["pancreatitis", "OBSERVATION", 95, 107]]], ["Feline pancreatitis occasionally is due to FIGURE 9-2 Diagnostic approach to chronic vomiting in a dog or cat that has been unresponsive to dietary change and anthelmintic therapy.", [["Feline pancreatitis", "DISEASE", 0, 19], ["chronic vomiting", "DISEASE", 77, 93], ["Feline", "ORGANISM", 0, 6], ["dog", "ORGANISM", 99, 102], ["cat", "ORGANISM", 106, 109], ["dog", "SPECIES", 99, 102], ["cat", "SPECIES", 106, 109], ["dog", "SPECIES", 99, 102], ["Feline pancreatitis", "PROBLEM", 0, 19], ["chronic vomiting", "PROBLEM", 77, 93], ["a dog or cat", "PROBLEM", 97, 109], ["dietary change", "TREATMENT", 140, 154], ["anthelmintic therapy", "TREATMENT", 159, 179], ["pancreatitis", "OBSERVATION", 7, 19], ["chronic", "OBSERVATION_MODIFIER", 77, 84], ["vomiting", "OBSERVATION", 85, 93]]], ["ACTH, Adrenocorticotropic hormone; CBC, complete blood count.Gastritis, Enteritis, and ColitisChronic enteritis, colitis, or gastritis can cause various degrees of vomiting and may require mucosal biopsy for diagnosis.", [["blood", "ANATOMY", 49, 54], ["mucosal", "ANATOMY", 189, 196], ["Gastritis", "DISEASE", 61, 70], ["Enteritis", "DISEASE", 72, 81], ["ColitisChronic enteritis", "DISEASE", 87, 111], ["colitis", "DISEASE", 113, 120], ["gastritis", "DISEASE", 125, 134], ["vomiting", "DISEASE", 164, 172], ["ACTH", "GENE_OR_GENE_PRODUCT", 0, 4], ["Adrenocorticotropic hormone", "GENE_OR_GENE_PRODUCT", 6, 33], ["CBC", "CELL", 35, 38], ["blood", "ORGANISM_SUBSTANCE", 49, 54], ["colitis", "PATHOLOGICAL_FORMATION", 113, 120], ["mucosal biopsy", "MULTI-TISSUE_STRUCTURE", 189, 203], ["ACTH", "TEST", 0, 4], ["Adrenocorticotropic hormone", "TEST", 6, 33], ["CBC", "TEST", 35, 38], ["complete blood count", "TEST", 40, 60], ["Gastritis", "PROBLEM", 61, 70], ["Enteritis", "PROBLEM", 72, 81], ["ColitisChronic enteritis", "PROBLEM", 87, 111], ["colitis", "PROBLEM", 113, 120], ["gastritis", "PROBLEM", 125, 134], ["vomiting", "PROBLEM", 164, 172], ["mucosal biopsy", "TEST", 189, 203], ["Enteritis", "OBSERVATION", 72, 81], ["ColitisChronic", "OBSERVATION_MODIFIER", 87, 101], ["enteritis", "OBSERVATION", 102, 111], ["colitis", "OBSERVATION", 113, 120], ["gastritis", "OBSERVATION", 125, 134], ["various degrees", "OBSERVATION_MODIFIER", 145, 160], ["mucosal", "ANATOMY", 189, 196], ["biopsy", "OBSERVATION", 197, 203]]], ["Abdominal ultrasound is potentially specific and may delineate infiltrative or inflammatory intestinal patterns, but it is insensitive.", [["Abdominal", "ANATOMY", 0, 9], ["intestinal", "ANATOMY", 92, 102], ["intestinal", "ORGAN", 92, 102], ["Abdominal ultrasound", "TEST", 0, 20], ["infiltrative or inflammatory intestinal patterns", "PROBLEM", 63, 111], ["infiltrative", "OBSERVATION", 63, 75], ["inflammatory", "OBSERVATION", 79, 91]]], ["If gastritis or enteritis is suspected or if the other major causes of chronic vomiting have been ruled out, gastric and intestinal mucosal biopsies via endoscopy or laparotomy may be helpful.", [["gastric", "ANATOMY", 109, 116], ["intestinal mucosal", "ANATOMY", 121, 139], ["gastritis", "DISEASE", 3, 12], ["enteritis", "DISEASE", 16, 25], ["chronic vomiting", "DISEASE", 71, 87], ["gastritis", "PATHOLOGICAL_FORMATION", 3, 12], ["gastric", "MULTI-TISSUE_STRUCTURE", 109, 116], ["intestinal mucosal biopsies", "MULTI-TISSUE_STRUCTURE", 121, 148], ["gastritis", "PROBLEM", 3, 12], ["enteritis", "PROBLEM", 16, 25], ["chronic vomiting", "PROBLEM", 71, 87], ["gastric and intestinal mucosal biopsies", "TEST", 109, 148], ["endoscopy", "TEST", 153, 162], ["laparotomy", "TREATMENT", 166, 176], ["gastritis", "OBSERVATION", 3, 12], ["enteritis", "OBSERVATION", 16, 25], ["chronic", "OBSERVATION_MODIFIER", 71, 78], ["vomiting", "OBSERVATION", 79, 87], ["gastric", "ANATOMY", 109, 116], ["intestinal mucosal", "ANATOMY", 121, 139], ["laparotomy", "OBSERVATION", 166, 176]]], ["Inflammatory bowel disease is an important cause of feline chronic vomiting.", [["bowel", "ANATOMY", 13, 18], ["Inflammatory bowel disease", "DISEASE", 0, 26], ["feline chronic vomiting", "DISEASE", 52, 75], ["bowel", "ORGAN", 13, 18], ["feline", "ORGANISM", 52, 58], ["Inflammatory bowel disease", "PROBLEM", 0, 26], ["feline chronic vomiting", "PROBLEM", 52, 75], ["bowel", "ANATOMY", 13, 18], ["disease", "OBSERVATION", 19, 26], ["important cause of", "UNCERTAINTY", 33, 51], ["feline", "OBSERVATION_MODIFIER", 52, 58], ["chronic", "OBSERVATION_MODIFIER", 59, 66], ["vomiting", "OBSERVATION", 67, 75]]], ["Duodenitis is also a significant cause of vomiting without diarrhea in dogs; therefore both gastric and intestinal biopsies should be performed.", [["gastric", "ANATOMY", 92, 99], ["intestinal biopsies", "ANATOMY", 104, 123], ["Duodenitis", "DISEASE", 0, 10], ["vomiting", "DISEASE", 42, 50], ["diarrhea", "DISEASE", 59, 67], ["dogs", "ORGANISM", 71, 75], ["gastric", "MULTI-TISSUE_STRUCTURE", 92, 99], ["intestinal biopsies", "MULTI-TISSUE_STRUCTURE", 104, 123], ["dogs", "SPECIES", 71, 75], ["Duodenitis", "PROBLEM", 0, 10], ["vomiting", "PROBLEM", 42, 50], ["diarrhea in dogs", "PROBLEM", 59, 75], ["both gastric and intestinal biopsies", "TEST", 87, 123], ["significant", "OBSERVATION_MODIFIER", 21, 32], ["vomiting", "OBSERVATION", 42, 50], ["gastric", "ANATOMY", 92, 99], ["intestinal", "ANATOMY", 104, 114], ["biopsies", "OBSERVATION", 115, 123]]], ["Finally, because 10% to 20% of patients with colitis vomit, it is sometimes helpful to perform endoscopy on the upper and lower intestinal tracts in patients (especially cats) with chronic vomiting.", [["upper", "ANATOMY", 112, 117], ["lower intestinal tracts", "ANATOMY", 122, 145], ["colitis", "DISEASE", 45, 52], ["chronic vomiting", "DISEASE", 181, 197], ["patients", "ORGANISM", 31, 39], ["upper", "ORGANISM_SUBDIVISION", 112, 117], ["lower intestinal", "ORGANISM_SUBDIVISION", 122, 138], ["tracts", "ORGANISM_SUBDIVISION", 139, 145], ["patients", "ORGANISM", 149, 157], ["cats", "ORGANISM", 170, 174], ["patients", "SPECIES", 31, 39], ["patients", "SPECIES", 149, 157], ["cats", "SPECIES", 170, 174], ["colitis vomit", "PROBLEM", 45, 58], ["endoscopy", "TEST", 95, 104], ["chronic vomiting", "PROBLEM", 181, 197], ["colitis", "OBSERVATION", 45, 52], ["upper", "ANATOMY_MODIFIER", 112, 117], ["lower", "ANATOMY_MODIFIER", 122, 127], ["intestinal tracts", "ANATOMY", 128, 145], ["chronic", "OBSERVATION_MODIFIER", 181, 188], ["vomiting", "OBSERVATION", 189, 197]]], ["It is critical that goodquality mucosal tissue samples be taken and handled properly to avoid artifacts, which can render them nondiagnostic.HematemesisHematemesis is the vomiting of blood; it suggests GI ulceration/erosion, coagulopathy, or ingestion of blood.", [["mucosal tissue samples", "ANATOMY", 32, 54], ["blood", "ANATOMY", 183, 188], ["GI", "ANATOMY", 202, 204], ["blood", "ANATOMY", 255, 260], ["Hematemesis", "DISEASE", 141, 152], ["Hematemesis", "DISEASE", 152, 163], ["vomiting", "DISEASE", 171, 179], ["erosion", "DISEASE", 216, 223], ["coagulopathy", "DISEASE", 225, 237], ["mucosal tissue samples", "TISSUE", 32, 54], ["blood", "ORGANISM_SUBSTANCE", 183, 188], ["GI", "ORGANISM_SUBDIVISION", 202, 204], ["blood", "ORGANISM_SUBSTANCE", 255, 260], ["goodquality mucosal tissue samples", "TREATMENT", 20, 54], ["artifacts", "PROBLEM", 94, 103], ["Hematemesis", "PROBLEM", 141, 152], ["Hematemesis", "PROBLEM", 152, 163], ["the vomiting of blood", "PROBLEM", 167, 188], ["GI ulceration", "PROBLEM", 202, 215], ["erosion", "PROBLEM", 216, 223], ["coagulopathy", "PROBLEM", 225, 237], ["ingestion of blood", "PROBLEM", 242, 260], ["Hematemesis", "OBSERVATION", 152, 163], ["GI", "ANATOMY", 202, 204], ["ulceration", "OBSERVATION", 205, 215], ["erosion", "OBSERVATION", 216, 223], ["coagulopathy", "OBSERVATION", 225, 237]]], ["The vomitus may contain bright-red blood or digested blood that resembles coffee grounds.", [["vomitus", "ANATOMY", 4, 11], ["blood", "ANATOMY", 35, 40], ["blood", "ANATOMY", 53, 58], ["blood", "ORGANISM_SUBSTANCE", 35, 40], ["blood", "ORGANISM_SUBSTANCE", 53, 58], ["The vomitus", "PROBLEM", 0, 11], ["bright-red blood or digested blood", "PROBLEM", 24, 58], ["vomitus", "OBSERVATION", 4, 11], ["bright", "OBSERVATION_MODIFIER", 24, 30], ["red blood", "OBSERVATION", 31, 40], ["coffee grounds", "OBSERVATION", 74, 88]]], ["Administration of nonsteroidal anti-inflammatory drugs (especially concurrently with corticosteroids) is a major reason for canine ulceration.", [["nonsteroidal", "ANATOMY", 18, 30], ["corticosteroids", "CHEMICAL", 85, 100], ["nonsteroidal anti-inflammatory drugs", "SIMPLE_CHEMICAL", 18, 54], ["canine", "ORGANISM", 124, 130], ["canine", "SPECIES", 124, 130], ["nonsteroidal anti-inflammatory drugs", "TREATMENT", 18, 54], ["corticosteroids", "TREATMENT", 85, 100], ["canine ulceration", "PROBLEM", 124, 141], ["nonsteroidal anti-inflammatory drugs", "OBSERVATION", 18, 54], ["ulceration", "OBSERVATION", 131, 141]]], ["Hepatic failure, mast cell tumor, shock, submaximal exertion, and dexamethasone administration must also be considered.", [["Hepatic", "ANATOMY", 0, 7], ["mast cell tumor", "ANATOMY", 17, 32], ["Hepatic failure", "DISEASE", 0, 15], ["mast cell tumor", "DISEASE", 17, 32], ["shock", "DISEASE", 34, 39], ["dexamethasone", "CHEMICAL", 66, 79], ["dexamethasone", "CHEMICAL", 66, 79], ["Hepatic", "ORGAN", 0, 7], ["mast cell tumor", "CANCER", 17, 32], ["dexamethasone", "SIMPLE_CHEMICAL", 66, 79], ["Hepatic failure", "PROBLEM", 0, 15], ["mast cell tumor", "PROBLEM", 17, 32], ["shock", "PROBLEM", 34, 39], ["submaximal exertion", "PROBLEM", 41, 60], ["dexamethasone administration", "TREATMENT", 66, 94], ["failure", "OBSERVATION", 8, 15], ["mast cell tumor", "OBSERVATION", 17, 32], ["shock", "OBSERVATION_MODIFIER", 34, 39], ["submaximal exertion", "OBSERVATION", 41, 60]]], ["After these have been ruled out, endoscopy is indicated and allows diagnosis of ulceration (especially because of a foreign object, inflammatory disease, or neoplasia).", [["neoplasia", "ANATOMY", 157, 166], ["ulceration", "DISEASE", 80, 90], ["neoplasia", "DISEASE", 157, 166], ["ulceration", "PATHOLOGICAL_FORMATION", 80, 90], ["neoplasia", "CANCER", 157, 166], ["endoscopy", "TEST", 33, 42], ["ulceration", "PROBLEM", 80, 90], ["a foreign object", "PROBLEM", 114, 130], ["inflammatory disease", "PROBLEM", 132, 152], ["neoplasia", "PROBLEM", 157, 166], ["ulceration", "OBSERVATION", 80, 90], ["foreign object", "OBSERVATION", 116, 130], ["inflammatory", "OBSERVATION_MODIFIER", 132, 144], ["neoplasia", "OBSERVATION", 157, 166]]], ["Depending upon the particulars of the case, one may perform endoscopy or treat symptomatically.", [["endoscopy", "TEST", 60, 69]]], ["Analysis \u2022 Gastrin is measured in serum by radioimmunoassay (RIA).Abdominal InflammationNormal Values \u2022 Depends on laboratory (the assay must be validated for the species).", [["serum", "ANATOMY", 34, 39], ["Abdominal", "ANATOMY", 66, 75], ["Gastrin", "GENE_OR_GENE_PRODUCT", 11, 18], ["serum", "ORGANISM_SUBSTANCE", 34, 39], ["Gastrin", "PROTEIN", 11, 18], ["Analysis", "TEST", 0, 8], ["Gastrin", "TEST", 11, 18], ["Abdominal InflammationNormal Values", "PROBLEM", 66, 101], ["the assay", "TEST", 127, 136]]], ["To convert pg/ml to ng/L, multiply pg/ml \u00d7 1.0 = ng/L.Abdominal InflammationArtifacts \u2022 Gastrin may be falsely decreased by hormone degradation as the result of sample storage for several days at temperatures above freezing.Abdominal InflammationDrug Therapy That May Increase Gastrin \u2022 Antacids, including histamine 2 (H 2 ) receptor antagonist drugs and proton pump inhibitors, may increase gastrin concentration.Abdominal InflammationCauses of Hypogastrinemia \u2022 Not significant.Abdominal InflammationCauses of Hypergastrinemia \u2022 Atrophic gastritis (uncommon), antral G-cell hyperplasia (rare), short bowel syndrome, hyperparathyroidism, gastric ulcers, gastric outlet obstruction, renal failure, and gastrinoma may cause hypergastrinemia; the last four are probably the most common.", [["sample", "ANATOMY", 161, 167], ["Abdominal", "ANATOMY", 224, 233], ["Abdominal", "ANATOMY", 415, 424], ["Abdominal", "ANATOMY", 481, 490], ["antral G-cell", "ANATOMY", 563, 576], ["bowel", "ANATOMY", 603, 608], ["gastric ulcers", "ANATOMY", 640, 654], ["gastric outlet", "ANATOMY", 656, 670], ["renal", "ANATOMY", 684, 689], ["gastrinoma", "ANATOMY", 703, 713], ["Antacids", "CHEMICAL", 287, 295], ["histamine", "CHEMICAL", 307, 316], ["gastrin", "CHEMICAL", 393, 400], ["Hypogastrinemia", "DISEASE", 447, 462], ["Hypergastrinemia", "DISEASE", 513, 529], ["Atrophic gastritis", "DISEASE", 532, 550], ["antral G-cell hyperplasia", "DISEASE", 563, 588], ["short bowel syndrome", "DISEASE", 597, 617], ["hyperparathyroidism", "DISEASE", 619, 638], ["gastric ulcers", "DISEASE", 640, 654], ["gastric outlet obstruction", "DISEASE", 656, 682], ["renal failure", "DISEASE", 684, 697], ["gastrinoma", "DISEASE", 703, 713], ["hypergastrinemia", "DISEASE", 724, 740], ["histamine", "CHEMICAL", 307, 316], ["Gastrin", "GENE_OR_GENE_PRODUCT", 88, 95], ["histamine 2 (H 2 ) receptor antagonist drugs", "SIMPLE_CHEMICAL", 307, 351], ["proton pump inhibitors", "SIMPLE_CHEMICAL", 356, 378], ["gastrin", "GENE_OR_GENE_PRODUCT", 393, 400], ["bowel", "ORGAN", 603, 608], ["gastric ulcers", "PATHOLOGICAL_FORMATION", 640, 654], ["gastric outlet", "MULTI-TISSUE_STRUCTURE", 656, 670], ["renal", "ORGAN", 684, 689], ["gastrinoma", "CANCER", 703, 713], ["gastrin", "PROTEIN", 393, 400], ["Gastrin", "PROBLEM", 88, 95], ["hormone degradation", "PROBLEM", 124, 143], ["sample storage", "TEST", 161, 175], ["Abdominal InflammationDrug Therapy", "TREATMENT", 224, 258], ["Gastrin \u2022 Antacids", "TREATMENT", 277, 295], ["histamine", "TREATMENT", 307, 316], ["receptor antagonist drugs", "TREATMENT", 326, 351], ["proton pump inhibitors", "TREATMENT", 356, 378], ["gastrin concentration", "TREATMENT", 393, 414], ["Abdominal InflammationCauses of Hypogastrinemia", "PROBLEM", 415, 462], ["Abdominal InflammationCauses", "PROBLEM", 481, 509], ["Hypergastrinemia", "PROBLEM", 513, 529], ["Atrophic gastritis", "PROBLEM", 532, 550], ["antral G-cell hyperplasia", "PROBLEM", 563, 588], ["short bowel syndrome", "PROBLEM", 597, 617], ["hyperparathyroidism", "PROBLEM", 619, 638], ["gastric ulcers", "PROBLEM", 640, 654], ["gastric outlet obstruction", "PROBLEM", 656, 682], ["renal failure", "PROBLEM", 684, 697], ["gastrinoma", "PROBLEM", 703, 713], ["hypergastrinemia", "PROBLEM", 724, 740], ["Inflammation", "OBSERVATION", 234, 246], ["InflammationCauses", "OBSERVATION", 425, 443], ["Hypogastrinemia", "OBSERVATION", 447, 462], ["Not", "UNCERTAINTY", 465, 468], ["significant", "OBSERVATION_MODIFIER", 469, 480], ["Hypergastrinemia", "OBSERVATION", 513, 529], ["Atrophic", "OBSERVATION_MODIFIER", 532, 540], ["gastritis", "OBSERVATION", 541, 550], ["antral G-cell hyperplasia", "OBSERVATION", 563, 588], ["short", "OBSERVATION_MODIFIER", 597, 602], ["bowel", "ANATOMY", 603, 608], ["syndrome", "OBSERVATION", 609, 617], ["hyperparathyroidism", "OBSERVATION", 619, 638], ["gastric", "ANATOMY", 640, 647], ["ulcers", "OBSERVATION", 648, 654], ["gastric", "ANATOMY", 656, 663], ["outlet", "ANATOMY_MODIFIER", 664, 670], ["obstruction", "OBSERVATION", 671, 682], ["renal", "ANATOMY", 684, 689], ["failure", "OBSERVATION", 690, 697], ["gastrinoma", "OBSERVATION", 703, 713], ["hypergastrinemia", "OBSERVATION", 724, 740], ["most common", "OBSERVATION_MODIFIER", 773, 784]]], ["If gastrinoma is suspected in a patient that has a normal or equivocal serum gastrin concentration, secretin or calcium stimulation tests may be performed.", [["gastrinoma", "ANATOMY", 3, 13], ["serum", "ANATOMY", 71, 76], ["gastrinoma", "DISEASE", 3, 13], ["calcium", "CHEMICAL", 112, 119], ["calcium", "CHEMICAL", 112, 119], ["gastrinoma", "CANCER", 3, 13], ["patient", "ORGANISM", 32, 39], ["serum", "ORGANISM_SUBSTANCE", 71, 76], ["gastrin", "GENE_OR_GENE_PRODUCT", 77, 84], ["secretin", "GENE_OR_GENE_PRODUCT", 100, 108], ["calcium", "SIMPLE_CHEMICAL", 112, 119], ["patient", "SPECIES", 32, 39], ["gastrinoma", "PROBLEM", 3, 13], ["serum gastrin concentration", "TEST", 71, 98], ["secretin or calcium stimulation tests", "TEST", 100, 137], ["gastrinoma", "OBSERVATION", 3, 13]]], ["A rise in the serum gastrin concentration after giving either of these drugs suggests a gastrinoma.ACUTE DIARRHEAPatients with diarrhea are best classified into those with acute (<2 to 3 weeks) versus those with chronic (>2 to 3 weeks) diarrhea.", [["serum", "ANATOMY", 14, 19], ["gastrinoma", "ANATOMY", 88, 98], ["gastrin", "CHEMICAL", 20, 27], ["gastrinoma", "DISEASE", 88, 98], ["diarrhea", "DISEASE", 127, 135], ["diarrhea", "DISEASE", 236, 244], ["serum", "ORGANISM_SUBSTANCE", 14, 19], ["gastrin", "GENE_OR_GENE_PRODUCT", 20, 27], ["gastrinoma", "CANCER", 88, 98], ["A rise in the serum gastrin concentration", "PROBLEM", 0, 41], ["these drugs", "TREATMENT", 65, 76], ["a gastrinoma", "PROBLEM", 86, 98], ["ACUTE DIARRHEAPatients", "PROBLEM", 99, 121], ["diarrhea", "PROBLEM", 127, 135], ["diarrhea", "PROBLEM", 236, 244], ["rise", "OBSERVATION_MODIFIER", 2, 6], ["gastrinoma", "OBSERVATION", 88, 98], ["DIARRHEAPatients", "OBSERVATION", 105, 121], ["diarrhea", "OBSERVATION", 127, 135], ["acute", "OBSERVATION_MODIFIER", 172, 177], ["chronic", "OBSERVATION_MODIFIER", 212, 219]]], ["Acute diarrhea (Box 9-4) is usually self-limiting, although some conditions may be severe and cause mortality (e.g., acute hemorrhagicFELINE IMMUNOREACTIVE PANCREATIC LIPASE (SPEC FPL)Common Indications \u2022 Indications for measurement of spec fPL are cats suspected of having pancreatitis and those with vague clinical signs (e.g., unexplained anorexia, abdominal discomfort, unexplained weight loss) that remain undiagnosed despite testing.FELINE IMMUNOREACTIVE PANCREATIC LIPASE (SPEC FPL)Advantages \u2022 The spec fPL is the most sensitive test for feline pancreatitis.FELINE IMMUNOREACTIVE PANCREATIC LIPASE (SPEC FPL)Disadvantages \u2022 The spec fPL has uncertain specificity for clinically important pancreatic disease.Analysis \u2022The spec fPL is measured in serum by ELISA.Analysis \u2022Normal Values \u2022 Less than 3.5 \u00b5g/L.Analysis \u2022Artifacts \u2022 None known.Analysis \u2022performed, but establishing a cause-and-effect relationship between the organism and disease can be difficult.", [["abdominal", "ANATOMY", 352, 361], ["pancreatic", "ANATOMY", 696, 706], ["serum", "ANATOMY", 753, 758], ["diarrhea", "DISEASE", 6, 14], ["FPL", "CHEMICAL", 180, 183], ["pancreatitis", "DISEASE", 274, 286], ["anorexia", "DISEASE", 342, 350], ["abdominal discomfort", "DISEASE", 352, 372], ["weight loss", "DISEASE", 386, 397], ["feline pancreatitis", "DISEASE", 546, 565], ["FPL", "CHEMICAL", 612, 615], ["pancreatic disease", "DISEASE", 696, 714], ["abdominal", "ORGANISM_SUBDIVISION", 352, 361], ["feline", "ORGANISM", 546, 552], ["pancreatic", "ORGAN", 696, 706], ["fPL", "GENE_OR_GENE_PRODUCT", 734, 737], ["serum", "ORGANISM_SUBSTANCE", 753, 758], ["spec fPL", "DNA", 729, 737], ["Acute diarrhea", "PROBLEM", 0, 14], ["some conditions", "PROBLEM", 60, 75], ["acute hemorrhagicFELINE IMMUNOREACTIVE PANCREATIC LIPASE", "PROBLEM", 117, 173], ["measurement of spec fPL", "TEST", 221, 244], ["pancreatitis", "PROBLEM", 274, 286], ["vague clinical signs", "PROBLEM", 302, 322], ["unexplained anorexia", "PROBLEM", 330, 350], ["abdominal discomfort", "PROBLEM", 352, 372], ["unexplained weight loss)", "PROBLEM", 374, 398], ["testing", "TEST", 431, 438], ["FELINE IMMUNOREACTIVE PANCREATIC LIPASE", "TEST", 439, 478], ["The spec fPL", "TEST", 502, 514], ["feline pancreatitis", "PROBLEM", 546, 565], ["FELINE IMMUNOREACTIVE PANCREATIC LIPASE", "TEST", 566, 605], ["The spec fPL", "TEST", 632, 644], ["clinically important pancreatic disease", "PROBLEM", 675, 714], ["Analysis", "TEST", 715, 723], ["The spec fPL", "TEST", 725, 737], ["Analysis", "TEST", 768, 776], ["Analysis", "TEST", 846, 854], ["the organism", "PROBLEM", 924, 936], ["disease", "PROBLEM", 941, 948], ["diarrhea", "OBSERVATION", 6, 14], ["self-limiting", "OBSERVATION_MODIFIER", 36, 49], ["acute", "OBSERVATION_MODIFIER", 117, 122], ["PANCREATIC", "ANATOMY", 156, 166], ["pancreatitis", "OBSERVATION", 274, 286], ["abdominal", "ANATOMY", 352, 361], ["PANCREATIC", "ANATOMY", 461, 471], ["pancreatitis", "OBSERVATION", 553, 565], ["PANCREATIC", "ANATOMY", 588, 598], ["pancreatic", "ANATOMY", 696, 706], ["disease", "OBSERVATION", 707, 714], ["Normal", "OBSERVATION", 778, 784]]], ["Not all patients with canine parvoviral diarrhea are severely ill, diarrheic, febrile, or have identifiable leukopenia.", [["parvoviral diarrhea", "DISEASE", 29, 48], ["diarrheic", "DISEASE", 67, 76], ["febrile", "DISEASE", 78, 85], ["leukopenia", "DISEASE", 108, 118], ["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["canine", "SPECIES", 22, 28], ["canine", "SPECIES", 22, 28], ["canine parvoviral diarrhea", "PROBLEM", 22, 48], ["severely ill", "PROBLEM", 53, 65], ["diarrheic", "PROBLEM", 67, 76], ["febrile", "PROBLEM", 78, 85], ["identifiable leukopenia", "PROBLEM", 95, 118], ["leukopenia", "OBSERVATION", 108, 118]]], ["Leukopenia may only persist 24 to 36 hours and be missed if a CBC is not performed during that period.", [["Leukopenia", "DISEASE", 0, 10], ["Leukopenia", "PROBLEM", 0, 10], ["a CBC", "TEST", 60, 65]]], ["Other diseases causing severe sepsis (i.e., perforating linear foreign body with peritonitis or overwhelming salmonellosis) can cause leukopenia indistinguishable from that of canine parvoviral enteritis.", [["body", "ANATOMY", 71, 75], ["sepsis", "DISEASE", 30, 36], ["peritonitis", "DISEASE", 81, 92], ["salmonellosis", "DISEASE", 109, 122], ["leukopenia", "DISEASE", 134, 144], ["parvoviral enteritis", "DISEASE", 183, 203], ["canine parvoviral enteritis", "ORGANISM", 176, 203], ["canine", "SPECIES", 176, 182], ["canine parvoviral enteritis", "SPECIES", 176, 203], ["Other diseases", "PROBLEM", 0, 14], ["severe sepsis", "PROBLEM", 23, 36], ["perforating linear foreign body", "PROBLEM", 44, 75], ["peritonitis", "PROBLEM", 81, 92], ["overwhelming salmonellosis", "PROBLEM", 96, 122], ["leukopenia", "PROBLEM", 134, 144], ["canine parvoviral enteritis", "PROBLEM", 176, 203], ["diseases", "OBSERVATION", 6, 14], ["severe", "OBSERVATION_MODIFIER", 23, 29], ["sepsis", "OBSERVATION", 30, 36], ["perforating", "OBSERVATION_MODIFIER", 44, 55], ["linear", "OBSERVATION_MODIFIER", 56, 62], ["foreign body", "OBSERVATION", 63, 75], ["peritonitis", "OBSERVATION", 81, 92], ["overwhelming", "OBSERVATION_MODIFIER", 96, 108], ["salmonellosis", "OBSERVATION", 109, 122], ["canine", "OBSERVATION_MODIFIER", 176, 182], ["parvoviral enteritis", "OBSERVATION", 183, 203]]], ["Routinely used vaccination schedules do not necessarily guarantee protection against canine parvovirus.", [["canine parvovirus", "DISEASE", 85, 102], ["canine parvovirus", "ORGANISM", 85, 102], ["canine parvovirus", "SPECIES", 85, 102], ["canine parvovirus", "SPECIES", 85, 102], ["vaccination schedules", "TREATMENT", 15, 36], ["canine parvovirus", "PROBLEM", 85, 102]]], ["In-house ELISA tests for parvovirus performed on feces appear to be specific for parvoviral antigen, but testing may be negative if done too early or too late.", [["feces", "ANATOMY", 49, 54], ["parvovirus", "ORGANISM", 25, 35], ["feces", "ORGANISM_SUBSTANCE", 49, 54], ["parvoviral antigen", "GENE_OR_GENE_PRODUCT", 81, 99], ["parvoviral antigen", "PROTEIN", 81, 99], ["parvovirus", "SPECIES", 25, 35], ["parvoviral", "SPECIES", 81, 91], ["ELISA tests", "TEST", 9, 20], ["parvovirus", "PROBLEM", 25, 35], ["parvoviral antigen", "PROBLEM", 81, 99], ["testing", "TEST", 105, 112]]], ["Fecal shedding of viral particles may not occur for 1 to 3 days after signs begin and decreases rapidly with time.", [["Fecal", "ANATOMY", 0, 5], ["Fecal", "ORGANISM_SUBSTANCE", 0, 5], ["Fecal shedding of viral particles", "PROBLEM", 0, 33], ["viral particles", "OBSERVATION", 18, 33], ["decreases", "OBSERVATION_MODIFIER", 86, 95]]], ["The test result should be strongly positive within 3 days of the onset of clinical signs and remain positive for several days.", [["The test", "TEST", 0, 8], ["clinical signs", "TEST", 74, 88], ["positive", "OBSERVATION", 100, 108]]], ["A recent vaccination may result in a weakly positive fecal ELISA.CHRONIC DIARRHEAChronic diarrhea should first be defined as either small intestinal or large intestinal in origin (Table 9 -1).", [["intestinal", "ANATOMY", 138, 148], ["intestinal", "ANATOMY", 158, 168], ["diarrhea", "DISEASE", 89, 97], ["fecal", "ORGANISM_SUBSTANCE", 53, 58], ["intestinal", "ORGAN", 138, 148], ["intestinal", "ORGAN", 158, 168], ["A recent vaccination", "TREATMENT", 0, 20], ["a weakly positive fecal ELISA", "PROBLEM", 35, 64], ["CHRONIC DIARRHEAChronic diarrhea", "PROBLEM", 65, 97], ["small intestinal or large intestinal in origin", "PROBLEM", 132, 178], ["fecal ELISA", "OBSERVATION", 53, 64], ["DIARRHEAChronic", "OBSERVATION_MODIFIER", 73, 88], ["diarrhea", "OBSERVATION", 89, 97], ["small", "OBSERVATION_MODIFIER", 132, 137], ["intestinal", "ANATOMY", 138, 148], ["large", "OBSERVATION_MODIFIER", 152, 157], ["intestinal", "ANATOMY", 158, 168]]], ["Occasionally, large and small intestines are concurrently gastroenteritis, parvoviral disease, hookworms, intoxication).", [["intestines", "ANATOMY", 30, 40], ["parvoviral", "ANATOMY", 75, 85], ["gastroenteritis", "DISEASE", 58, 73], ["parvoviral disease", "DISEASE", 75, 93], ["hookworms", "DISEASE", 95, 104], ["intestines", "ORGAN", 30, 40], ["large and small intestines", "PROBLEM", 14, 40], ["gastroenteritis", "PROBLEM", 58, 73], ["parvoviral disease", "PROBLEM", 75, 93], ["hookworms", "PROBLEM", 95, 104], ["intoxication", "PROBLEM", 106, 118], ["large", "OBSERVATION_MODIFIER", 14, 19], ["small", "OBSERVATION_MODIFIER", 24, 29], ["intestines", "ANATOMY", 30, 40], ["gastroenteritis", "OBSERVATION", 58, 73]]], ["History should explore the possibility of recent dietary change and exposure to infectious agents.", [["recent dietary change", "PROBLEM", 42, 63], ["infectious agents", "TREATMENT", 80, 97]]], ["Diet, bacteria, viruses, and parasites are the major identifiable causes of acute diarrhea in dogs and cats.", [["diarrhea", "DISEASE", 82, 90], ["dogs", "ORGANISM", 94, 98], ["cats", "ORGANISM", 103, 107], ["dogs", "SPECIES", 94, 98], ["cats", "SPECIES", 103, 107], ["bacteria", "PROBLEM", 6, 14], ["viruses", "PROBLEM", 16, 23], ["parasites", "PROBLEM", 29, 38], ["acute diarrhea in dogs and cats", "PROBLEM", 76, 107], ["bacteria", "OBSERVATION", 6, 14], ["viruses", "OBSERVATION", 16, 23], ["acute", "OBSERVATION_MODIFIER", 76, 81], ["diarrhea", "OBSERVATION", 82, 90]]], ["Because intestinal parasites may contribute to any diarrheic state, fecal examinations (direct and flotation) are typically warranted in diarrheic patients.", [["intestinal", "ANATOMY", 8, 18], ["fecal", "ANATOMY", 68, 73], ["intestinal parasites", "DISEASE", 8, 28], ["diarrheic", "DISEASE", 137, 146], ["intestinal parasites", "CELL", 8, 28], ["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 147, 155], ["intestinal parasites", "PROBLEM", 8, 28], ["any diarrheic state", "PROBLEM", 47, 66], ["fecal examinations", "TEST", 68, 86], ["intestinal", "ANATOMY", 8, 18], ["parasites", "OBSERVATION", 19, 28]]], ["Giardiasis may require special diagnostic techniques (see Fecal Giardia Detection later in this chapter).", [["Giardiasis", "DISEASE", 0, 10], ["Giardiasis", "PROBLEM", 0, 10], ["special diagnostic techniques", "TEST", 23, 52], ["Fecal Giardia Detection", "TEST", 58, 81]]], ["The need for diagnostics depends upon (1) the severity of the problem (i.e., more severely ill patients require more diagnostics), and (2) the likelihood that the patient has an infectious agent that has potential to be nosocomial or zoonotic.CHRONIC DIARRHEAFeeding bland or elimination diets may be diagnostic and therapeutic.", [["patients", "ORGANISM", 95, 103], ["patient", "ORGANISM", 163, 170], ["patients", "SPECIES", 95, 103], ["patient", "SPECIES", 163, 170], ["an infectious agent", "PROBLEM", 175, 194], ["nosocomial", "PROBLEM", 220, 230], ["zoonotic", "PROBLEM", 234, 242], ["CHRONIC DIARRHEAFeeding bland", "PROBLEM", 243, 272], ["infectious", "OBSERVATION", 178, 188]]], ["Depressed, weak, and dehydrated patients should undergo electrolyte and acid-base evaluations to aid in selecting fluid replacement therapy.", [["fluid", "ANATOMY", 114, 119], ["Depressed", "DISEASE", 0, 9], ["patients", "ORGANISM", 32, 40], ["electrolyte", "SIMPLE_CHEMICAL", 56, 67], ["patients", "SPECIES", 32, 40], ["Depressed, weak", "PROBLEM", 0, 15], ["electrolyte", "TREATMENT", 56, 67], ["acid-base evaluations", "TEST", 72, 93], ["selecting fluid replacement therapy", "TREATMENT", 104, 139], ["weak", "OBSERVATION_MODIFIER", 11, 15], ["fluid replacement", "OBSERVATION", 114, 131]]], ["All patients less than 12 to 14 weeks of age and those that are emaciated or weighing less than 3 kg should undergo blood glucose monitoring to detect secondary hypoglycemia.", [["blood", "ANATOMY", 116, 121], ["glucose", "CHEMICAL", 122, 129], ["hypoglycemia", "DISEASE", 161, 173], ["glucose", "CHEMICAL", 122, 129], ["patients", "ORGANISM", 4, 12], ["blood", "ORGANISM_SUBSTANCE", 116, 121], ["glucose", "SIMPLE_CHEMICAL", 122, 129], ["patients", "SPECIES", 4, 12], ["blood glucose monitoring", "TEST", 116, 140], ["secondary hypoglycemia", "PROBLEM", 151, 173], ["secondary hypoglycemia", "OBSERVATION", 151, 173]]], ["CBC is indicated in most febrile or severely depressed patients so that sepsis or transmural inflammation can be detected.", [["transmural", "ANATOMY", 82, 92], ["febrile", "DISEASE", 25, 32], ["depressed", "DISEASE", 45, 54], ["sepsis", "DISEASE", 72, 78], ["inflammation", "DISEASE", 93, 105], ["CBC", "CELL", 0, 3], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["CBC", "TEST", 0, 3], ["most febrile", "PROBLEM", 20, 32], ["severely depressed patients", "PROBLEM", 36, 63], ["sepsis", "PROBLEM", 72, 78], ["transmural inflammation", "PROBLEM", 82, 105], ["most febrile", "OBSERVATION_MODIFIER", 20, 32], ["severely", "OBSERVATION_MODIFIER", 36, 44], ["depressed", "OBSERVATION_MODIFIER", 45, 54], ["sepsis", "OBSERVATION", 72, 78], ["transmural", "OBSERVATION_MODIFIER", 82, 92], ["inflammation", "OBSERVATION", 93, 105]]], ["Fecal cultures, ELISA, and/or polymerase chain reaction (PCR) for Salmonella spp., Campylobacter jejuni, Yersinia enterocolitica, verotoxin-positive Escherichia coli, Clostridium perfringens, or Clostridium difficile may beSmall Intestinal DiseaseSmall intestinal disease has different parasites (e.g., Giardia), dietary problems (e.g., lymphangiectasia), and bacterial problems (i.e., so-called antibiotic-responsive enteropathy [ARE] or dysbiosis that may respond to a variety of antibacterials) than large bowel disease.", [["Fecal cultures", "ANATOMY", 0, 14], ["intestinal", "ANATOMY", 253, 263], ["bowel", "ANATOMY", 509, 514], ["Campylobacter jejuni", "DISEASE", 83, 103], ["Yersinia enterocolitica", "DISEASE", 105, 128], ["Clostridium perfringens", "DISEASE", 167, 190], ["Clostridium difficile", "DISEASE", 195, 216], ["intestinal disease", "DISEASE", 253, 271], ["dietary problems", "DISEASE", 313, 329], ["lymphangiectasia", "DISEASE", 337, 353], ["bacterial problems", "DISEASE", 360, 378], ["enteropathy", "DISEASE", 418, 429], ["dysbiosis", "DISEASE", 439, 448], ["bowel disease", "DISEASE", 509, 522], ["Salmonella spp.", "ORGANISM", 66, 81], ["Campylobacter jejuni", "ORGANISM", 83, 103], ["Yersinia enterocolitica", "ORGANISM", 105, 128], ["verotoxin-positive Escherichia coli", "ORGANISM", 130, 165], ["Clostridium perfringens", "ORGANISM", 167, 190], ["Clostridium difficile", "ORGANISM", 195, 216], ["intestinal", "ORGAN", 253, 263], ["lymphangiectasia", "PATHOLOGICAL_FORMATION", 337, 353], ["bowel", "ORGAN", 509, 514], ["Salmonella spp.", "SPECIES", 66, 81], ["Campylobacter jejuni", "SPECIES", 83, 103], ["Yersinia enterocolitica", "SPECIES", 105, 128], ["Escherichia coli", "SPECIES", 149, 165], ["Clostridium perfringens", "SPECIES", 167, 190], ["Clostridium difficile", "SPECIES", 195, 216], ["Salmonella spp.", "SPECIES", 66, 81], ["Campylobacter jejuni", "SPECIES", 83, 103], ["Yersinia enterocolitica", "SPECIES", 105, 128], ["Escherichia coli", "SPECIES", 149, 165], ["Clostridium perfringens", "SPECIES", 167, 190], ["Clostridium difficile", "SPECIES", 195, 216], ["Fecal cultures", "TEST", 0, 14], ["ELISA", "TEST", 16, 21], ["polymerase chain reaction", "PROBLEM", 30, 55], ["PCR", "TEST", 57, 60], ["Salmonella spp.", "PROBLEM", 66, 81], ["Campylobacter jejuni", "PROBLEM", 83, 103], ["Yersinia enterocolitica", "PROBLEM", 105, 128], ["verotoxin", "PROBLEM", 130, 139], ["Escherichia coli", "PROBLEM", 149, 165], ["Clostridium perfringens", "PROBLEM", 167, 190], ["Clostridium difficile", "PROBLEM", 195, 216], ["Intestinal DiseaseSmall intestinal disease", "PROBLEM", 229, 271], ["different parasites", "PROBLEM", 276, 295], ["Giardia", "PROBLEM", 303, 310], ["dietary problems", "PROBLEM", 313, 329], ["lymphangiectasia", "PROBLEM", 337, 353], ["bacterial problems", "PROBLEM", 360, 378], ["so-called antibiotic", "TREATMENT", 386, 406], ["responsive enteropathy", "PROBLEM", 407, 429], ["dysbiosis", "PROBLEM", 439, 448], ["a variety of antibacterials", "TREATMENT", 469, 496], ["large bowel disease", "PROBLEM", 503, 522], ["Campylobacter jejuni", "ANATOMY", 83, 103], ["Yersinia enterocolitica", "OBSERVATION", 105, 128], ["Escherichia coli", "OBSERVATION", 149, 165], ["Clostridium perfringens", "OBSERVATION_MODIFIER", 167, 190], ["Clostridium difficile", "OBSERVATION", 195, 216], ["Intestinal", "ANATOMY", 229, 239], ["DiseaseSmall", "ANATOMY_MODIFIER", 240, 252], ["intestinal", "ANATOMY", 253, 263], ["disease", "OBSERVATION", 264, 271], ["different", "OBSERVATION_MODIFIER", 276, 285], ["parasites", "OBSERVATION", 286, 295], ["lymphangiectasia", "OBSERVATION", 337, 353], ["bacterial problems", "OBSERVATION", 360, 378], ["responsive enteropathy", "OBSERVATION", 407, 429], ["bowel", "ANATOMY", 509, 514], ["disease", "OBSERVATION", 515, 522]]], ["Chronic and severe small intestinal diarrhea necessitates differentiation of maldigestion, protein-losing enteropathy (PLE), and malabsorptive disease without protein loss ( Figure 9 -4).", [["intestinal", "ANATOMY", 25, 35], ["diarrhea", "DISEASE", 36, 44], ["maldigestion", "DISEASE", 77, 89], ["enteropathy", "DISEASE", 106, 117], ["PLE", "DISEASE", 119, 122], ["malabsorptive disease", "DISEASE", 129, 150], ["protein loss", "DISEASE", 159, 171], ["intestinal", "ORGAN", 25, 35], ["Chronic and severe small intestinal diarrhea", "PROBLEM", 0, 44], ["maldigestion", "PROBLEM", 77, 89], ["protein-losing enteropathy", "PROBLEM", 91, 117], ["malabsorptive disease", "PROBLEM", 129, 150], ["protein loss", "PROBLEM", 159, 171], ["Figure", "TEST", 174, 180], ["severe", "OBSERVATION_MODIFIER", 12, 18], ["small", "OBSERVATION_MODIFIER", 19, 24], ["intestinal", "ANATOMY", 25, 35], ["diarrhea", "OBSERVATION", 36, 44], ["malabsorptive disease", "OBSERVATION", 129, 150], ["without", "UNCERTAINTY", 151, 158], ["protein loss", "OBSERVATION", 159, 171]]], ["Weight loss and diarrhea are usually present, but some patients only have weight loss.MaldigestionMaldigestion due to bile acid insufficiency caused by biliary obstruction is rare.", [["bile", "ANATOMY", 118, 122], ["biliary", "ANATOMY", 152, 159], ["Weight loss", "DISEASE", 0, 11], ["diarrhea", "DISEASE", 16, 24], ["weight loss", "DISEASE", 74, 85], ["Maldigestion", "DISEASE", 98, 110], ["bile acid", "CHEMICAL", 118, 127], ["insufficiency", "DISEASE", 128, 141], ["biliary obstruction", "DISEASE", 152, 171], ["bile acid", "CHEMICAL", 118, 127], ["patients", "ORGANISM", 55, 63], ["bile acid", "SIMPLE_CHEMICAL", 118, 127], ["biliary obstruction", "PATHOLOGICAL_FORMATION", 152, 171], ["patients", "SPECIES", 55, 63], ["Weight loss", "PROBLEM", 0, 11], ["diarrhea", "PROBLEM", 16, 24], ["weight loss", "PROBLEM", 74, 85], ["MaldigestionMaldigestion", "PROBLEM", 86, 110], ["bile acid insufficiency", "PROBLEM", 118, 141], ["biliary obstruction", "PROBLEM", 152, 171], ["loss", "OBSERVATION", 7, 11], ["diarrhea", "OBSERVATION", 16, 24], ["weight loss", "OBSERVATION", 74, 85], ["bile", "ANATOMY", 118, 122], ["acid insufficiency", "OBSERVATION", 123, 141], ["biliary", "ANATOMY", 152, 159], ["obstruction", "OBSERVATION", 160, 171]]], ["Intestinal lactase deficiency is uncommon, but a lactose-free diet may be tried in selected patients (especially cats).", [["Intestinal", "ANATOMY", 0, 10], ["lactase deficiency", "DISEASE", 11, 29], ["lactose", "CHEMICAL", 49, 56], ["lactose", "CHEMICAL", 49, 56], ["Intestinal", "ORGAN", 0, 10], ["lactase", "GENE_OR_GENE_PRODUCT", 11, 18], ["lactose", "SIMPLE_CHEMICAL", 49, 56], ["patients", "ORGANISM", 92, 100], ["cats", "ORGANISM", 113, 117], ["patients", "SPECIES", 92, 100], ["cats", "SPECIES", 113, 117], ["Intestinal lactase deficiency", "PROBLEM", 0, 29], ["a lactose-free diet", "TREATMENT", 47, 66], ["lactase deficiency", "OBSERVATION", 11, 29]]], ["EPI is the principal cause of maldigestion but is rare in cats.", [["maldigestion", "DISEASE", 30, 42], ["cats", "ORGANISM", 58, 62], ["cats", "SPECIES", 58, 62], ["EPI", "TREATMENT", 0, 3], ["maldigestion", "PROBLEM", 30, 42], ["maldigestion", "OBSERVATION", 30, 42]]], ["Differentiation of EPI from malabsorptive intestinal disease is important.", [["intestinal", "ANATOMY", 42, 52], ["EPI", "CHEMICAL", 19, 22], ["intestinal disease", "DISEASE", 42, 60], ["EPI", "CANCER", 19, 22], ["intestinal", "ORGAN", 42, 52], ["EPI", "TREATMENT", 19, 22], ["malabsorptive intestinal disease", "PROBLEM", 28, 60], ["malabsorptive intestinal disease", "OBSERVATION", 28, 60]]], ["EPI is often overlooked in afflicted dogs or may erroneously be diagnosed in patients without the malady.", [["dogs", "ORGANISM", 37, 41], ["patients", "ORGANISM", 77, 85], ["dogs", "SPECIES", 37, 41], ["patients", "SPECIES", 77, 85], ["EPI", "TREATMENT", 0, 3], ["malady", "OBSERVATION", 98, 104]]], ["Clinical trials using pancreatic enzyme preparations are very insensitive and nonspecific.", [["pancreatic", "ANATOMY", 22, 32], ["pancreatic", "ORGAN", 22, 32], ["Clinical trials", "TEST", 0, 15], ["pancreatic enzyme preparations", "TEST", 22, 52], ["pancreatic", "ANATOMY", 22, 32], ["nonspecific", "OBSERVATION_MODIFIER", 78, 89]]], ["Powdered enzyme is often superior to tablet formulations, and some enzyme preparations are clearly superior to others.", [["Powdered enzyme", "TEST", 0, 15], ["some enzyme preparations", "TREATMENT", 62, 86]]], ["Some dogs with EPI also require a low-fat diet, antacid therapy (rare), or treatment for concurrent ARE (common) before the enzyme replacement therapy becomes effective, even when appropriate enzymes are administered.", [["antacid", "CHEMICAL", 48, 55], ["dogs", "ORGANISM", 5, 9], ["fat", "TISSUE", 38, 41], ["antacid", "SIMPLE_CHEMICAL", 48, 55], ["enzymes", "PROTEIN", 192, 199], ["dogs", "SPECIES", 5, 9], ["EPI", "TREATMENT", 15, 18], ["a low-fat diet", "TREATMENT", 32, 46], ["antacid therapy", "TREATMENT", 48, 63], ["treatment", "TREATMENT", 75, 84], ["the enzyme replacement therapy", "TREATMENT", 120, 150], ["appropriate enzymes", "TEST", 180, 199]]], ["Up to 15% of dogs with EPI never respond to therapy.", [["dogs", "ORGANISM", 13, 17], ["dogs", "SPECIES", 13, 17], ["dogs", "TREATMENT", 13, 17], ["EPI", "TREATMENT", 23, 26], ["therapy", "TREATMENT", 44, 51]]], ["Too often, failure of empirical enzyme replacement therapy leads to unnecessary tests (i.e., biopsy) because EPI was incorrectly eliminated.", [["empirical enzyme replacement therapy", "TREATMENT", 22, 58], ["unnecessary tests", "TEST", 68, 85], ["biopsy", "TEST", 93, 99], ["EPI", "TREATMENT", 109, 112]]], ["No consistent hematologic or serum chemistry profile changes are seen.", [["serum", "ANATOMY", 29, 34], ["hematologic", "CANCER", 14, 25], ["serum", "ORGANISM_SUBSTANCE", 29, 34], ["consistent hematologic or serum chemistry profile changes", "PROBLEM", 3, 60], ["consistent", "UNCERTAINTY", 3, 13], ["hematologic", "OBSERVATION", 14, 25], ["serum chemistry profile", "OBSERVATION_MODIFIER", 29, 52]]], ["Undigested fats can often be found in the feces; however, this is inconsistent.", [["Undigested fats", "ANATOMY", 0, 15], ["feces", "ANATOMY", 42, 47], ["fats", "SIMPLE_CHEMICAL", 11, 15], ["feces", "ORGANISM_SUBDIVISION", 42, 47], ["Undigested fats", "PROBLEM", 0, 15], ["fats", "OBSERVATION", 11, 15], ["feces", "OBSERVATION", 42, 47]]], ["The fat absorption test yields many false results.", [["fat", "ANATOMY", 4, 7], ["fat", "TISSUE", 4, 7], ["The fat absorption test", "TEST", 0, 23]]], ["The TLI assay is the standard test for EPI.", [["The TLI assay", "TEST", 0, 13], ["EPI", "TREATMENT", 39, 42]]], ["It is important to note that the TLI tests are species specific.", [["the TLI tests", "TEST", 29, 42]]], ["Measurement of fecal proteolytic activity involved.", [["fecal", "ORGANISM_SUBSTANCE", 15, 20], ["fecal", "ANATOMY", 15, 20], ["proteolytic activity", "OBSERVATION", 21, 41]]], ["Patients with chronic diarrhea in which clinical disease is not severe are often treated with therapeutic trials before aggressive diagnostics are instituted.", [["diarrhea", "DISEASE", 22, 30], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["chronic diarrhea", "PROBLEM", 14, 30], ["clinical disease", "PROBLEM", 40, 56], ["therapeutic trials", "TREATMENT", 94, 112], ["aggressive diagnostics", "TREATMENT", 120, 142], ["chronic", "OBSERVATION_MODIFIER", 14, 21], ["diarrhea", "OBSERVATION", 22, 30], ["not", "UNCERTAINTY", 60, 63], ["severe", "OBSERVATION_MODIFIER", 64, 70]]], ["The specifics of the therapeutic trials are influenced by whether the patient has large or small bowel disease.", [["bowel", "ANATOMY", 97, 102], ["patient", "ORGANISM", 70, 77], ["bowel", "ORGAN", 97, 102], ["patient", "SPECIES", 70, 77], ["the therapeutic trials", "TREATMENT", 17, 39], ["large or small bowel disease", "PROBLEM", 82, 110], ["large", "OBSERVATION_MODIFIER", 82, 87], ["small", "OBSERVATION_MODIFIER", 91, 96], ["bowel", "ANATOMY", 97, 102], ["disease", "OBSERVATION", 103, 110]]], ["Patients should usually have at least three fecal examinations at 48-hour intervals.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["fecal examinations", "TEST", 44, 62], ["fecal", "ANATOMY", 44, 49]]], ["If these tests are negative, it is still acceptable (depending upon the risk of parasites in the geographic location) to treat empirically for Giardia infection and whipworms before aggressive diagnostics are begun.", [["Giardia infection", "DISEASE", 143, 160], ["Giardia", "ORGANISM", 143, 150], ["these tests", "TEST", 3, 14], ["parasites", "PROBLEM", 80, 89], ["Giardia infection", "PROBLEM", 143, 160], ["aggressive diagnostics", "TEST", 182, 204]]], ["Giardiasis may be particularly difficult to diagnose (see Fecal Giardia Detection later in this chapter).", [["Giardiasis", "DISEASE", 0, 10], ["Giardiasis", "PROBLEM", 0, 10], ["Fecal Giardia Detection", "TEST", 58, 81]]], ["Adverse food reactions (i.e., allergy, intolerance, fiber deficiency) commonly cause chronic diarrhea.", [["allergy", "DISEASE", 30, 37], ["intolerance, fiber deficiency", "DISEASE", 39, 68], ["diarrhea", "DISEASE", 93, 101], ["Adverse food reactions", "PROBLEM", 0, 22], ["allergy", "PROBLEM", 30, 37], ["intolerance", "PROBLEM", 39, 50], ["fiber deficiency)", "PROBLEM", 52, 69], ["chronic diarrhea", "PROBLEM", 85, 101], ["food reactions", "OBSERVATION", 8, 22], ["chronic", "OBSERVATION_MODIFIER", 85, 92], ["diarrhea", "OBSERVATION", 93, 101]]], ["Dietary intolerances are a reaction to a particular substance in the diet, whereas true food allergies are immunologic reactions to specific antigens.", [["food allergies", "DISEASE", 88, 102], ["Dietary intolerances", "PROBLEM", 0, 20], ["a reaction", "PROBLEM", 25, 35], ["true food allergies", "PROBLEM", 83, 102], ["immunologic reactions", "PROBLEM", 107, 128]]], ["Dietary food trials are indicated in suspected cases.", [["Dietary food trials", "TREATMENT", 0, 19]]], ["There are antibiotic-responsive intestinal diseases that are also treated empirically; however, the specific therapy varies with whether the patient has large or small bowel disease (see next section).", [["intestinal", "ANATOMY", 32, 42], ["bowel", "ANATOMY", 168, 173], ["intestinal diseases", "DISEASE", 32, 51], ["intestinal", "ORGAN", 32, 42], ["patient", "ORGANISM", 141, 148], ["bowel", "ORGAN", 168, 173], ["patient", "SPECIES", 141, 148], ["antibiotic-responsive intestinal diseases", "PROBLEM", 10, 51], ["large or small bowel disease", "PROBLEM", 153, 181], ["antibiotic", "OBSERVATION_MODIFIER", 10, 20], ["responsive intestinal diseases", "OBSERVATION", 21, 51], ["large", "OBSERVATION_MODIFIER", 153, 158], ["small", "OBSERVATION_MODIFIER", 162, 167], ["bowel", "ANATOMY", 168, 173], ["disease", "OBSERVATION", 174, 181]]], ["Failing to respond to empirical anthelmintic, dietary, and antibacterial therapy indicates the need for further diagnostics.Large Intestinal DiseaseLarge intestinal disease has different parasites (i.e., Trichuris vulpis, Tritrichomonas fetus), dietary problems (i.e., fiberresponsive diarrhea), and bacterial problems (i.e., so-called clostridial colitis that responds best to tylosin or amoxicillin) than small bowel disease.", [["intestinal", "ANATOMY", 154, 164], ["bowel", "ANATOMY", 413, 418], ["DiseaseLarge intestinal disease", "DISEASE", 141, 172], ["Trichuris vulpis", "DISEASE", 204, 220], ["dietary problems", "DISEASE", 245, 261], ["diarrhea", "DISEASE", 285, 293], ["bacterial problems", "DISEASE", 300, 318], ["clostridial colitis", "DISEASE", 336, 355], ["tylosin", "CHEMICAL", 378, 385], ["amoxicillin", "CHEMICAL", 389, 400], ["small bowel disease", "DISEASE", 407, 426], ["tylosin", "CHEMICAL", 378, 385], ["amoxicillin", "CHEMICAL", 389, 400], ["intestinal", "ORGAN", 154, 164], ["Trichuris vulpis", "ORGANISM", 204, 220], ["Tritrichomonas fetus", "ORGANISM", 222, 242], ["colitis", "PATHOLOGICAL_FORMATION", 348, 355], ["tylosin", "SIMPLE_CHEMICAL", 378, 385], ["amoxicillin", "SIMPLE_CHEMICAL", 389, 400], ["bowel", "ORGAN", 413, 418], ["Trichuris vulpis", "SPECIES", 204, 220], ["Tritrichomonas fetus", "SPECIES", 222, 242], ["Trichuris vulpis", "SPECIES", 204, 220], ["empirical anthelmintic", "TREATMENT", 22, 44], ["dietary", "TREATMENT", 46, 53], ["antibacterial therapy", "TREATMENT", 59, 80], ["further diagnostics", "TEST", 104, 123], ["Large Intestinal DiseaseLarge intestinal disease", "PROBLEM", 124, 172], ["different parasites", "PROBLEM", 177, 196], ["Trichuris vulpis", "PROBLEM", 204, 220], ["Tritrichomonas fetus)", "PROBLEM", 222, 243], ["dietary problems", "PROBLEM", 245, 261], ["fiberresponsive diarrhea", "PROBLEM", 269, 293], ["bacterial problems", "PROBLEM", 300, 318], ["so-called clostridial colitis", "PROBLEM", 326, 355], ["tylosin", "TREATMENT", 378, 385], ["amoxicillin", "TREATMENT", 389, 400], ["small bowel disease", "PROBLEM", 407, 426], ["Intestinal", "ANATOMY", 130, 140], ["DiseaseLarge", "ANATOMY_MODIFIER", 141, 153], ["intestinal", "ANATOMY", 154, 164], ["disease", "OBSERVATION", 165, 172], ["different", "OBSERVATION_MODIFIER", 177, 186], ["parasites", "OBSERVATION", 187, 196], ["bacterial problems", "OBSERVATION", 300, 318], ["clostridial colitis", "OBSERVATION", 336, 355], ["bowel", "ANATOMY", 413, 418], ["disease", "OBSERVATION", 419, 426]]], ["Once parasitic, dietary, and \"clostridial colitis\" are eliminated by diagnostics and therapeutic trials, additional diagnostic steps, such as rectal mucosal scrapings (not swabs) with cytologic examination (Figure 9 -3) might be appropriate.", [["rectal mucosal scrapings", "ANATOMY", 142, 166], ["swabs", "ANATOMY", 172, 177], ["colitis", "DISEASE", 42, 49], ["colitis", "PATHOLOGICAL_FORMATION", 42, 49], ["rectal mucosal scrapings", "MULTI-TISSUE_STRUCTURE", 142, 166], ["parasitic", "PROBLEM", 5, 14], ["\"clostridial colitis", "PROBLEM", 29, 49], ["therapeutic trials", "TREATMENT", 85, 103], ["rectal mucosal scrapings", "TEST", 142, 166], ["swabs", "TEST", 172, 177], ["cytologic examination", "TEST", 184, 205], ["clostridial colitis", "OBSERVATION", 30, 49], ["rectal mucosal", "ANATOMY", 142, 156]]], ["Persistent large intestinal disease that fails to respond to these therapeutic trials or that is associated with hypoalbuminemia or obvious weight loss is usually an indication for abdominal ultrasound followed by fine-needle aspiration and/or colonoscopy-ileoscopy plus biopsy.", [["intestinal", "ANATOMY", 17, 27], ["abdominal", "ANATOMY", 181, 190], ["intestinal disease", "DISEASE", 17, 35], ["hypoalbuminemia", "DISEASE", 113, 128], ["weight loss", "DISEASE", 140, 151], ["intestinal", "ORGAN", 17, 27], ["abdominal", "ORGANISM_SUBDIVISION", 181, 190], ["Persistent large intestinal disease", "PROBLEM", 0, 35], ["these therapeutic trials", "TREATMENT", 61, 85], ["hypoalbuminemia", "PROBLEM", 113, 128], ["weight loss", "PROBLEM", 140, 151], ["abdominal ultrasound", "TEST", 181, 201], ["fine-needle aspiration", "TEST", 214, 236], ["colonoscopy", "TEST", 244, 255], ["ileoscopy", "TREATMENT", 256, 265], ["biopsy", "TEST", 271, 277], ["large", "OBSERVATION_MODIFIER", 11, 16], ["intestinal", "ANATOMY", 17, 27], ["disease", "OBSERVATION", 28, 35], ["hypoalbuminemia", "OBSERVATION", 113, 128]]], ["Rigid colonoscopy of the descending colon is adequate for diagnosis in most cases.", [["descending colon", "ANATOMY", 25, 41], ["colon", "ORGAN", 36, 41], ["Rigid colonoscopy", "TEST", 0, 17], ["descending", "ANATOMY_MODIFIER", 25, 35], ["colon", "ANATOMY", 36, 41], ["adequate", "OBSERVATION", 45, 53]]], ["Flexible endoscopy allows access to the descending, transverse, and ascending colon;A BFIGURE 9-4 Diagnostic approach to chronic diarrhea in dogs and cats in which multiple fecal examination results are negative and empirical anthelmintic, antiprotozoal, and dietary therapy do not resolve the diarrhea.", [["ascending colon", "ANATOMY", 68, 83], ["fecal", "ANATOMY", 173, 178], ["chronic diarrhea", "DISEASE", 121, 137], ["diarrhea", "DISEASE", 294, 302], ["colon", "ORGAN", 78, 83], ["dogs", "ORGANISM", 141, 145], ["cats", "ORGANISM", 150, 154], ["dogs", "SPECIES", 141, 145], ["cats", "SPECIES", 150, 154], ["Flexible endoscopy", "TEST", 0, 18], ["chronic diarrhea in dogs", "PROBLEM", 121, 145], ["cats", "TREATMENT", 150, 154], ["multiple fecal examination", "TEST", 164, 190], ["empirical anthelmintic", "TREATMENT", 216, 238], ["antiprotozoal", "TREATMENT", 240, 253], ["dietary therapy", "TREATMENT", 259, 274], ["the diarrhea", "PROBLEM", 290, 302], ["descending", "ANATOMY_MODIFIER", 40, 50], ["transverse", "ANATOMY_MODIFIER", 52, 62], ["ascending colon", "ANATOMY", 68, 83], ["chronic", "OBSERVATION_MODIFIER", 121, 128], ["diarrhea", "OBSERVATION", 129, 137], ["fecal", "ANATOMY", 173, 178], ["diarrhea", "OBSERVATION", 294, 302]]], ["CBC, Complete blood count; ELISA, enzyme-linked immunosorbent assay; EPI, exocrine pancreatic insufficiency; PCR, polymerase chain reaction; TLI, trypsin-like immunoreactivity.A BHistory and physical examination (see Table 9Protein-Losing EnteropathyPLE is uncommon in cats but seen with some regularity in dogs.", [["blood", "ANATOMY", 14, 19], ["exocrine pancreatic", "ANATOMY", 74, 93], ["exocrine pancreatic insufficiency", "DISEASE", 74, 107], ["CBC", "CELL", 0, 3], ["blood", "ORGANISM_SUBSTANCE", 14, 19], ["exocrine pancreatic", "MULTI-TISSUE_STRUCTURE", 74, 93], ["trypsin", "GENE_OR_GENE_PRODUCT", 146, 153], ["cats", "ORGANISM", 269, 273], ["dogs", "ORGANISM", 307, 311], ["trypsin", "PROTEIN", 146, 153], ["cats", "SPECIES", 269, 273], ["dogs", "SPECIES", 307, 311], ["CBC", "TEST", 0, 3], ["Complete blood count", "TEST", 5, 25], ["ELISA", "TEST", 27, 32], ["enzyme", "TEST", 34, 40], ["immunosorbent assay", "TEST", 48, 67], ["EPI", "TEST", 69, 72], ["exocrine pancreatic insufficiency", "PROBLEM", 74, 107], ["PCR", "TEST", 109, 112], ["polymerase chain reaction", "PROBLEM", 114, 139], ["TLI", "TEST", 141, 144], ["trypsin", "TEST", 146, 153], ["A BHistory and physical examination", "TEST", 176, 211], ["pancreatic", "ANATOMY", 83, 93], ["insufficiency", "OBSERVATION", 94, 107], ["TLI", "ANATOMY", 141, 144]]], ["PLEs are classically described as causing panhypoproteinemia.", [["panhypoproteinemia", "DISEASE", 42, 60], ["PLEs", "GENE_OR_GENE_PRODUCT", 0, 4], ["panhypoproteinemia", "PROBLEM", 42, 60], ["panhypoproteinemia", "OBSERVATION", 42, 60]]], ["However dogs with diseases causing hyperglobulinemia (e.g., chronic skin disease, rickettsial disease, heartworm disease) and some breeds (e.g., basenji dogs) may have only hypoalbuminemia because the serum globulin concentration is initially increased, and even though much of this fraction is lost into the intestines, the amount remaining in the blood keeps concentrations in the normal range.", [["skin", "ANATOMY", 68, 72], ["serum", "ANATOMY", 201, 206], ["intestines", "ANATOMY", 309, 319], ["blood", "ANATOMY", 349, 354], ["hyperglobulinemia", "DISEASE", 35, 52], ["chronic skin disease", "DISEASE", 60, 80], ["rickettsial disease", "DISEASE", 82, 101], ["heartworm disease", "DISEASE", 103, 120], ["hypoalbuminemia", "DISEASE", 173, 188], ["dogs", "ORGANISM", 8, 12], ["skin", "ORGAN", 68, 72], ["basenji dogs", "ORGANISM", 145, 157], ["serum", "ORGANISM_SUBSTANCE", 201, 206], ["globulin", "GENE_OR_GENE_PRODUCT", 207, 215], ["intestines", "ORGAN", 309, 319], ["blood", "ORGANISM_SUBSTANCE", 349, 354], ["dogs", "SPECIES", 8, 12], ["dogs", "SPECIES", 153, 157], ["diseases", "PROBLEM", 18, 26], ["hyperglobulinemia", "PROBLEM", 35, 52], ["chronic skin disease", "PROBLEM", 60, 80], ["rickettsial disease", "PROBLEM", 82, 101], ["heartworm disease)", "PROBLEM", 103, 121], ["some breeds", "PROBLEM", 126, 137], ["basenji dogs", "TREATMENT", 145, 157], ["hypoalbuminemia", "PROBLEM", 173, 188], ["the serum globulin concentration", "TEST", 197, 229], ["the blood", "TEST", 345, 354], ["diseases", "OBSERVATION", 18, 26], ["chronic", "OBSERVATION_MODIFIER", 60, 67], ["skin", "ANATOMY", 68, 72], ["disease", "OBSERVATION", 73, 80], ["rickettsial disease", "OBSERVATION", 82, 101], ["heartworm", "ANATOMY", 103, 112], ["hypoalbuminemia", "OBSERVATION", 173, 188], ["increased", "OBSERVATION_MODIFIER", 243, 252], ["intestines", "ANATOMY", 309, 319], ["amount", "OBSERVATION_MODIFIER", 325, 331], ["remaining", "OBSERVATION_MODIFIER", 332, 341], ["normal range", "OBSERVATION", 383, 395]]], ["If red blood cells (RBCs) are also being lost, iron deficiency anemia may occur (see Chapter 3).", [["red blood cells", "ANATOMY", 3, 18], ["RBCs", "ANATOMY", 20, 24], ["iron", "CHEMICAL", 47, 51], ["anemia", "DISEASE", 63, 69], ["iron", "CHEMICAL", 47, 51], ["red blood cells", "CELL", 3, 18], ["RBCs", "CELL", 20, 24], ["iron", "SIMPLE_CHEMICAL", 47, 51], ["red blood cells", "CELL_TYPE", 3, 18], ["RBCs", "CELL_TYPE", 20, 24], ["red blood cells", "TEST", 3, 18], ["RBCs", "TEST", 20, 24], ["iron deficiency anemia", "PROBLEM", 47, 69], ["blood cells", "ANATOMY", 7, 18]]], ["PLE may be the result of various GI diseases (e.g., hookworms, chronic intussusception, fungal infections, ulcers and erosions), but lymphangiectasia, alimentary lymphosarcoma, ARE, and IBD seemingly are the most common causes in adult dogs.", [["GI", "ANATOMY", 33, 35], ["ulcers", "ANATOMY", 107, 113], ["lymphangiectasia", "ANATOMY", 133, 149], ["alimentary lymphosarcoma", "ANATOMY", 151, 175], ["PLE", "DISEASE", 0, 3], ["GI diseases", "DISEASE", 33, 44], ["hookworms", "DISEASE", 52, 61], ["intussusception", "DISEASE", 71, 86], ["fungal infections", "DISEASE", 88, 105], ["ulcers", "DISEASE", 107, 113], ["erosions", "DISEASE", 118, 126], ["lymphangiectasia", "DISEASE", 133, 149], ["alimentary lymphosarcoma", "DISEASE", 151, 175], ["IBD", "DISEASE", 186, 189], ["ulcers", "PATHOLOGICAL_FORMATION", 107, 113], ["erosions", "PATHOLOGICAL_FORMATION", 118, 126], ["lymphangiectasia", "PATHOLOGICAL_FORMATION", 133, 149], ["alimentary lymphosarcoma", "CANCER", 151, 175], ["dogs", "ORGANISM", 236, 240], ["dogs", "SPECIES", 236, 240], ["various GI diseases", "PROBLEM", 25, 44], ["hookworms", "PROBLEM", 52, 61], ["chronic intussusception", "PROBLEM", 63, 86], ["fungal infections", "PROBLEM", 88, 105], ["ulcers", "PROBLEM", 107, 113], ["erosions", "PROBLEM", 118, 126], ["lymphangiectasia", "PROBLEM", 133, 149], ["alimentary lymphosarcoma", "PROBLEM", 151, 175], ["IBD", "PROBLEM", 186, 189], ["GI", "ANATOMY", 33, 35], ["diseases", "OBSERVATION", 36, 44], ["chronic", "OBSERVATION_MODIFIER", 63, 70], ["intussusception", "OBSERVATION", 71, 86], ["fungal", "OBSERVATION_MODIFIER", 88, 94], ["infections", "OBSERVATION", 95, 105], ["ulcers", "OBSERVATION", 107, 113], ["erosions", "OBSERVATION", 118, 126], ["lymphangiectasia", "OBSERVATION", 133, 149], ["alimentary lymphosarcoma", "OBSERVATION", 151, 175], ["most common", "OBSERVATION_MODIFIER", 208, 219]]], ["Intestinal lymphangiectasia produces some of the lowest serum albumin concentrations that occur in alimentary disease (e.g., <1.0 g/dl).", [["Intestinal lymphangiectasia", "ANATOMY", 0, 27], ["serum", "ANATOMY", 56, 61], ["alimentary", "ANATOMY", 99, 109], ["Intestinal lymphangiectasia", "DISEASE", 0, 27], ["alimentary disease", "DISEASE", 99, 117], ["Intestinal lymphangiectasia", "PATHOLOGICAL_FORMATION", 0, 27], ["serum", "ORGANISM_SUBSTANCE", 56, 61], ["albumin", "GENE_OR_GENE_PRODUCT", 62, 69], ["alimentary", "ORGAN", 99, 109], ["Intestinal lymphangiectasia", "PROBLEM", 0, 27], ["the lowest serum albumin concentrations", "PROBLEM", 45, 84], ["alimentary disease", "PROBLEM", 99, 117], ["lymphangiectasia", "OBSERVATION", 11, 27], ["alimentary disease", "OBSERVATION", 99, 117]]], ["Hypocholesterolemia is common, and peripheral lymphocyte counts occasionally are decreased.", [["peripheral lymphocyte", "ANATOMY", 35, 56], ["Hypocholesterolemia", "DISEASE", 0, 19], ["peripheral lymphocyte", "CELL", 35, 56], ["peripheral lymphocyte", "CELL_TYPE", 35, 56], ["Hypocholesterolemia", "PROBLEM", 0, 19], ["peripheral lymphocyte counts", "TEST", 35, 63], ["common", "OBSERVATION_MODIFIER", 23, 29], ["peripheral", "ANATOMY_MODIFIER", 35, 45], ["lymphocyte counts", "OBSERVATION", 46, 63], ["decreased", "OBSERVATION_MODIFIER", 81, 90]]], ["If hepatic insufficiency and loss from the kidneys and skin have been eliminated in a severely hypoalbuminemic patient, PLE becomes the major differential diagnosis by process of elimination.", [["hepatic", "ANATOMY", 3, 10], ["kidneys", "ANATOMY", 43, 50], ["skin", "ANATOMY", 55, 59], ["hepatic insufficiency", "DISEASE", 3, 24], ["PLE", "DISEASE", 120, 123], ["hepatic", "ORGAN", 3, 10], ["kidneys", "ORGAN", 43, 50], ["skin", "ORGAN", 55, 59], ["patient", "ORGANISM", 111, 118], ["patient", "SPECIES", 111, 118], ["hepatic insufficiency", "PROBLEM", 3, 24], ["loss from the kidneys and skin", "PROBLEM", 29, 59], ["a severely hypoalbuminemic patient", "PROBLEM", 84, 118], ["hepatic", "ANATOMY", 3, 10], ["insufficiency", "OBSERVATION", 11, 24], ["loss", "OBSERVATION", 29, 33], ["kidneys", "ANATOMY", 43, 50], ["skin", "ANATOMY", 55, 59], ["severely", "OBSERVATION_MODIFIER", 86, 94], ["hypoalbuminemic", "OBSERVATION", 95, 110]]], ["If PLE is suspected in a patient that has another potential explanation for its hypoalbuminemia (e.g., renal protein loss, hepatic insufficiency, severe exudative skin disease), then measuring fecal alpha 1 -protease inhibitor concentrations may clarify whether or not excessive GI protein loss is occurring.", [["renal", "ANATOMY", 103, 108], ["hepatic", "ANATOMY", 123, 130], ["skin", "ANATOMY", 163, 167], ["PLE", "DISEASE", 3, 6], ["hypoalbuminemia", "DISEASE", 80, 95], ["renal protein loss", "DISEASE", 103, 121], ["hepatic insufficiency", "DISEASE", 123, 144], ["exudative skin disease", "DISEASE", 153, 175], ["patient", "ORGANISM", 25, 32], ["renal", "ORGAN", 103, 108], ["hepatic", "ORGAN", 123, 130], ["skin", "ORGAN", 163, 167], ["fecal alpha 1 -protease", "GENE_OR_GENE_PRODUCT", 193, 216], ["patient", "SPECIES", 25, 32], ["its hypoalbuminemia", "PROBLEM", 76, 95], ["renal protein loss", "PROBLEM", 103, 121], ["hepatic insufficiency", "PROBLEM", 123, 144], ["severe exudative skin disease", "PROBLEM", 146, 175], ["fecal alpha 1 -protease inhibitor concentrations", "TREATMENT", 193, 241], ["excessive GI protein loss", "PROBLEM", 269, 294], ["hypoalbuminemia", "OBSERVATION", 80, 95], ["renal", "ANATOMY", 103, 108], ["protein loss", "OBSERVATION", 109, 121], ["hepatic", "ANATOMY", 123, 130], ["insufficiency", "OBSERVATION", 131, 144], ["severe", "OBSERVATION_MODIFIER", 146, 152], ["exudative", "OBSERVATION_MODIFIER", 153, 162], ["skin", "ANATOMY", 163, 167], ["disease", "OBSERVATION", 168, 175], ["protein loss", "OBSERVATION", 282, 294]]], ["Alpha 1 -protease is relatively stable and resistant to GI degradation; consequently, it can be measured in the feces.", [["feces", "ANATOMY", 112, 117], ["Alpha 1 -protease", "GENE_OR_GENE_PRODUCT", 0, 17], ["GI", "ORGANISM_SUBDIVISION", 56, 58], ["feces", "ORGANISM_SUBDIVISION", 112, 117], ["Alpha 1 -protease", "PROTEIN", 0, 17], ["Alpha", "TEST", 0, 5], ["GI degradation", "PROBLEM", 56, 70], ["stable", "OBSERVATION_MODIFIER", 32, 38], ["GI degradation", "OBSERVATION_MODIFIER", 56, 70]]], ["Intestinal biopsy is usually the definitive test for determining the cause of PLE.", [["Intestinal", "ANATOMY", 0, 10], ["PLE", "DISEASE", 78, 81], ["Intestinal biopsy", "MULTI-TISSUE_STRUCTURE", 0, 17], ["Intestinal biopsy", "TEST", 0, 17], ["the definitive test", "TEST", 29, 48], ["PLE", "PROBLEM", 78, 81], ["biopsy", "OBSERVATION", 11, 17]]], ["Fullthickness biopsy may risk dehiscence if the serum albumin level is less than 1.5 g/dl; serosal patch graft techniques decrease the risk of dehiscence.", [["serum", "ANATOMY", 48, 53], ["serosal", "ANATOMY", 91, 98], ["serum", "ORGANISM_SUBSTANCE", 48, 53], ["albumin", "GENE_OR_GENE_PRODUCT", 54, 61], ["serosal", "MULTI-TISSUE_STRUCTURE", 91, 98], ["dehiscence", "PATHOLOGICAL_FORMATION", 143, 153], ["Fullthickness biopsy", "TEST", 0, 20], ["risk dehiscence", "PROBLEM", 25, 40], ["the serum albumin level", "TEST", 44, 67], ["serosal patch graft techniques", "TREATMENT", 91, 121], ["dehiscence", "PROBLEM", 143, 153], ["dehiscence", "OBSERVATION", 30, 40], ["serosal", "ANATOMY", 91, 98], ["patch graft", "OBSERVATION", 99, 110], ["dehiscence", "OBSERVATION", 143, 153]]], ["Gastroduodenoscopyileoscopy plus biopsy is relatively safe and often diagnostic.", [["Gastroduodenoscopyileoscopy", "TEST", 0, 27], ["biopsy", "TEST", 33, 39]]], ["Occasionally the intestinal lesion is inaccessible via endoscopy.", [["intestinal lesion", "ANATOMY", 17, 34], ["intestinal lesion", "PATHOLOGICAL_FORMATION", 17, 34], ["the intestinal lesion", "PROBLEM", 13, 34], ["endoscopy", "TEST", 55, 64], ["intestinal", "ANATOMY", 17, 27], ["lesion", "OBSERVATION", 28, 34]]], ["Although not recommended, dietary trial with an ultra-low-fat diet may be substituted for biopsy in patients suspected of having lymphangiectasia.", [["lymphangiectasia", "DISEASE", 129, 145], ["patients", "ORGANISM", 100, 108], ["lymphangiectasia", "PATHOLOGICAL_FORMATION", 129, 145], ["patients", "SPECIES", 100, 108], ["an ultra-low-fat diet", "TREATMENT", 45, 66], ["biopsy", "TEST", 90, 96], ["lymphangiectasia", "PROBLEM", 129, 145], ["lymphangiectasia", "OBSERVATION", 129, 145]]], ["Therapeutic trials with steroids without a definitive diagnosis can be potentially dangerous (especially in dogs) and are not recommended.FECAL CHARACTERMucoid feces should be approached as a large intestinal or a distal small intestinal problem.", [["intestinal", "ANATOMY", 198, 208], ["intestinal", "ANATOMY", 227, 237], ["steroids", "CHEMICAL", 24, 32], ["steroids", "CHEMICAL", 24, 32], ["dogs", "ORGANISM", 108, 112], ["feces", "ORGANISM_SUBSTANCE", 160, 165], ["intestinal", "ORGAN", 198, 208], ["intestinal", "ORGAN", 227, 237], ["dogs", "SPECIES", 108, 112], ["Therapeutic trials", "TREATMENT", 0, 18], ["steroids", "TREATMENT", 24, 32], ["FECAL CHARACTERMucoid feces", "PROBLEM", 138, 165], ["a large intestinal", "PROBLEM", 190, 208], ["a distal small intestinal problem", "PROBLEM", 212, 245], ["CHARACTERMucoid feces", "OBSERVATION", 144, 165], ["large", "OBSERVATION_MODIFIER", 192, 197], ["intestinal", "ANATOMY", 198, 208], ["distal", "ANATOMY_MODIFIER", 214, 220], ["small intestinal problem", "OBSERVATION", 221, 245]]], ["In dogs and cats with large bowel disease but no weight loss or hypoalbuminemia, multiple fecal examinations, digital rectal examination, and therapeutic trials (i.e., dietary, antibacterial and/or anthelmintic) are often the best initial steps.", [["bowel", "ANATOMY", 28, 33], ["fecal", "ANATOMY", 90, 95], ["rectal", "ANATOMY", 118, 124], ["bowel disease", "DISEASE", 28, 41], ["weight loss", "DISEASE", 49, 60], ["hypoalbuminemia", "DISEASE", 64, 79], ["dogs", "ORGANISM", 3, 7], ["cats", "ORGANISM", 12, 16], ["bowel", "ORGAN", 28, 33], ["dogs", "SPECIES", 3, 7], ["cats", "SPECIES", 12, 16], ["large bowel disease", "PROBLEM", 22, 41], ["weight loss", "PROBLEM", 49, 60], ["hypoalbuminemia", "PROBLEM", 64, 79], ["multiple fecal examinations", "TEST", 81, 108], ["digital rectal examination", "TEST", 110, 136], ["therapeutic trials", "TREATMENT", 142, 160], ["antibacterial", "TREATMENT", 177, 190], ["large", "OBSERVATION_MODIFIER", 22, 27], ["bowel", "ANATOMY", 28, 33], ["disease", "OBSERVATION", 34, 41], ["no", "UNCERTAINTY", 46, 48], ["weight loss", "OBSERVATION", 49, 60], ["hypoalbuminemia", "OBSERVATION", 64, 79], ["multiple", "OBSERVATION_MODIFIER", 81, 89], ["fecal", "ANATOMY", 90, 95], ["rectal", "ANATOMY", 118, 124]]], ["If these are unsuccessful, then colonoscopyileoscopy plus biopsy generally becomes the most useful is often accurate for diagnosing EPI; however, it is more cumbersome and has limited availability.Malabsorptive Disease Without Protein LossOnce maldigestion has been eliminated, malabsorption becomes the most likely diagnosis in diarrheic animals with weight loss.", [["malabsorption", "DISEASE", 278, 291], ["diarrheic", "DISEASE", 329, 338], ["weight loss", "DISEASE", 352, 363], ["colonoscopyileoscopy", "TEST", 32, 52], ["biopsy", "TEST", 58, 64], ["EPI", "TEST", 132, 135], ["Malabsorptive Disease", "PROBLEM", 197, 218], ["Protein LossOnce maldigestion", "PROBLEM", 227, 256], ["malabsorption", "PROBLEM", 278, 291], ["diarrheic animals", "PROBLEM", 329, 346], ["weight loss", "PROBLEM", 352, 363], ["most likely", "UNCERTAINTY", 304, 315], ["weight loss", "OBSERVATION", 352, 363]]], ["One must then decide whether to perform diagnostic therapeutic trials or diagnostic tests.", [["diagnostic therapeutic trials", "TEST", 40, 69], ["diagnostic tests", "TEST", 73, 89]]], ["Patients that are emaciated, have serum albumin less than 2.1 g/dl, or are progressing rapidly should usually next undergo abdominal ultrasonography and intestinal biopsies (preferably via endoscopy unless ultrasonography shows lesions that cannot be diagnosed endoscopically or that can be aspirated with ultrasound guidance).", [["serum", "ANATOMY", 34, 39], ["abdominal", "ANATOMY", 123, 132], ["intestinal biopsies", "ANATOMY", 153, 172], ["lesions", "ANATOMY", 228, 235], ["Patients", "ORGANISM", 0, 8], ["serum", "ORGANISM_SUBSTANCE", 34, 39], ["albumin", "GENE_OR_GENE_PRODUCT", 40, 47], ["abdominal", "ORGANISM_SUBDIVISION", 123, 132], ["intestinal biopsies", "MULTI-TISSUE_STRUCTURE", 153, 172], ["lesions", "PATHOLOGICAL_FORMATION", 228, 235], ["Patients", "SPECIES", 0, 8], ["serum albumin", "TEST", 34, 47], ["abdominal ultrasonography", "TEST", 123, 148], ["intestinal biopsies", "TEST", 153, 172], ["endoscopy", "TEST", 189, 198], ["ultrasonography", "TEST", 206, 221], ["lesions", "PROBLEM", 228, 235], ["ultrasound guidance", "TEST", 306, 325], ["emaciated", "OBSERVATION_MODIFIER", 18, 27], ["abdominal", "ANATOMY", 123, 132], ["intestinal", "ANATOMY", 153, 163], ["lesions", "OBSERVATION", 228, 235]]], ["Patients that are not critically ill may first receive carefully designed therapeutic trials.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["critically ill", "PROBLEM", 22, 36], ["therapeutic trials", "TREATMENT", 74, 92]]], ["Therapeutic trials may be chosen more rationally with the aid of minimal laboratory data (e.g., biochemical profile, fecal examinations).", [["Therapeutic trials", "TREATMENT", 0, 18], ["minimal laboratory data", "TEST", 65, 88], ["biochemical profile", "TEST", 96, 115], ["fecal examinations", "TEST", 117, 135]]], ["The two major therapeutic trials are (1) food trials for dietary-responsive diease (i.e., elimination diets) and (2) antibacterial trials for ARE or dysbiosis.", [["dietary-responsive diease", "TREATMENT", 57, 82], ["antibacterial trials", "TREATMENT", 117, 137], ["dysbiosis", "PROBLEM", 149, 158], ["dysbiosis", "OBSERVATION", 149, 158]]], ["ARE (previously called \"small intestinal bacterial overgrowth\" or SIBO; now sometimes called dysbiosis) may exist by itself or coexist with another GI malady.", [["intestinal", "ANATOMY", 30, 40], ["bacterial overgrowth", "DISEASE", 41, 61], ["SIBO", "DISEASE", 66, 70], ["dysbiosis", "DISEASE", 93, 102], ["intestinal", "ORGAN", 30, 40], ["GI malady", "CANCER", 148, 157], ["ARE", "DNA", 0, 3], ["small intestinal bacterial overgrowth\"", "PROBLEM", 24, 62], ["SIBO", "PROBLEM", 66, 70], ["small", "OBSERVATION_MODIFIER", 24, 29], ["intestinal", "ANATOMY", 30, 40], ["bacterial", "OBSERVATION_MODIFIER", 41, 50], ["overgrowth", "OBSERVATION", 51, 61]]], ["No consistent CBC or serum chemistry profile changes are seen in this syndrome.", [["serum", "ANATOMY", 21, 26], ["CBC", "CELL", 14, 17], ["serum", "ORGANISM_SUBSTANCE", 21, 26], ["consistent CBC", "PROBLEM", 3, 17], ["serum chemistry profile changes", "PROBLEM", 21, 52], ["this syndrome", "PROBLEM", 65, 78], ["consistent", "UNCERTAINTY", 3, 13], ["CBC", "OBSERVATION", 14, 17], ["serum chemistry profile", "OBSERVATION_MODIFIER", 21, 44]]], ["Fecal culture is not informative, and ultrasound and intestinal biopsy are seldom diagnostic.", [["Fecal culture", "ANATOMY", 0, 13], ["intestinal biopsy", "ANATOMY", 53, 70], ["Fecal", "ORGANISM_SUBSTANCE", 0, 5], ["intestinal biopsy", "MULTI-TISSUE_STRUCTURE", 53, 70], ["Fecal culture", "TEST", 0, 13], ["ultrasound", "TEST", 38, 48], ["intestinal biopsy", "TEST", 53, 70], ["intestinal", "ANATOMY", 53, 63]]], ["A barium contrast study very rarely identifies a segmental lesion or partial obstruction responsible for secondary ARE.", [["segmental lesion", "ANATOMY", 49, 65], ["obstruction", "DISEASE", 77, 88], ["ARE", "DNA", 115, 118], ["A barium contrast study", "TEST", 0, 23], ["a segmental lesion", "PROBLEM", 47, 65], ["partial obstruction", "PROBLEM", 69, 88], ["secondary ARE", "PROBLEM", 105, 118], ["segmental", "OBSERVATION_MODIFIER", 49, 58], ["lesion", "OBSERVATION", 59, 65], ["partial", "OBSERVATION_MODIFIER", 69, 76], ["obstruction", "OBSERVATION", 77, 88], ["responsible for", "UNCERTAINTY", 89, 104], ["secondary", "OBSERVATION_MODIFIER", 105, 114]]], ["Quantitated culture of duodenal or proximal jejunal fluid for aerobes and anaerobes is difficult to interpret, because clinically normal dogs may have as many as or more bacteria than clinically affected dogs.", [["duodenal", "ANATOMY", 23, 31], ["jejunal fluid", "ANATOMY", 44, 57], ["duodenal", "MULTI-TISSUE_STRUCTURE", 23, 31], ["jejunal", "MULTI-TISSUE_STRUCTURE", 44, 51], ["dogs", "ORGANISM", 137, 141], ["dogs", "ORGANISM", 204, 208], ["dogs", "SPECIES", 137, 141], ["dogs", "SPECIES", 204, 208], ["Quantitated culture", "TEST", 0, 19], ["duodenal or proximal jejunal fluid", "PROBLEM", 23, 57], ["aerobes", "PROBLEM", 62, 69], ["anaerobes", "PROBLEM", 74, 83], ["clinically affected dogs", "PROBLEM", 184, 208], ["duodenal", "ANATOMY", 23, 31], ["proximal", "ANATOMY_MODIFIER", 35, 43], ["jejunal", "ANATOMY", 44, 51], ["fluid", "OBSERVATION", 52, 57]]], ["Serum cobalamin and folate concentrations are insensitive and nonspecific for ARE.", [["Serum", "ANATOMY", 0, 5], ["cobalamin", "CHEMICAL", 6, 15], ["folate", "CHEMICAL", 20, 26], ["cobalamin", "CHEMICAL", 6, 15], ["folate", "CHEMICAL", 20, 26], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["cobalamin", "SIMPLE_CHEMICAL", 6, 15], ["folate", "SIMPLE_CHEMICAL", 20, 26], ["ARE", "DNA", 78, 81], ["Serum cobalamin and folate concentrations", "TEST", 0, 41]]], ["Dogs with ARE usually respond within 3 to 4 weeks to appropriate antibacterial therapy (e.g., tetracycline, tylosin, metronidazole \u00b1 enrofloxacin), usually combined with a high-quality elimination diet unless irreversible mucosal changes or primary underlying intestinal disease are present.Malabsorptive Disease Without Protein LossDietary intolerance is relatively common, and elimination diets (e.g., fish and potato, turkey and potato, tofu and beans, hydrolyzed) are reasonable trials.", [["mucosal", "ANATOMY", 222, 229], ["intestinal", "ANATOMY", 260, 270], ["beans", "ANATOMY", 449, 454], ["tetracycline", "CHEMICAL", 94, 106], ["tylosin", "CHEMICAL", 108, 115], ["metronidazole", "CHEMICAL", 117, 130], ["enrofloxacin", "CHEMICAL", 133, 145], ["intestinal disease", "DISEASE", 260, 278], ["tetracycline", "CHEMICAL", 94, 106], ["tylosin", "CHEMICAL", 108, 115], ["metronidazole", "CHEMICAL", 117, 130], ["enrofloxacin", "CHEMICAL", 133, 145], ["Dogs", "ORGANISM", 0, 4], ["tetracycline", "SIMPLE_CHEMICAL", 94, 106], ["tylosin", "SIMPLE_CHEMICAL", 108, 115], ["metronidazole", "SIMPLE_CHEMICAL", 117, 130], ["enrofloxacin", "SIMPLE_CHEMICAL", 133, 145], ["mucosal", "MULTI-TISSUE_STRUCTURE", 222, 229], ["intestinal", "ORGAN", 260, 270], ["fish", "ORGANISM_SUBDIVISION", 404, 408], ["potato", "ORGANISM_SUBDIVISION", 413, 419], ["turkey", "ORGANISM_SUBDIVISION", 421, 427], ["potato", "ORGANISM_SUBDIVISION", 432, 438], ["tofu", "ORGANISM_SUBDIVISION", 440, 444], ["beans", "ORGANISM_SUBDIVISION", 449, 454], ["ARE", "DNA", 10, 13], ["potato", "SPECIES", 413, 419], ["turkey", "SPECIES", 421, 427], ["potato", "SPECIES", 432, 438], ["tofu", "SPECIES", 440, 444], ["beans", "SPECIES", 449, 454], ["potato", "SPECIES", 413, 419], ["turkey", "SPECIES", 421, 427], ["potato", "SPECIES", 432, 438], ["appropriate antibacterial therapy", "TREATMENT", 53, 86], ["tetracycline", "TREATMENT", 94, 106], ["tylosin", "TREATMENT", 108, 115], ["metronidazole", "TREATMENT", 117, 130], ["enrofloxacin", "TREATMENT", 133, 145], ["a high-quality elimination diet", "TREATMENT", 170, 201], ["irreversible mucosal changes", "PROBLEM", 209, 237], ["primary underlying intestinal disease", "PROBLEM", 241, 278], ["Malabsorptive Disease", "PROBLEM", 291, 312], ["Protein LossDietary intolerance", "PROBLEM", 321, 352], ["irreversible", "OBSERVATION_MODIFIER", 209, 221], ["mucosal", "ANATOMY", 222, 229], ["primary", "OBSERVATION_MODIFIER", 241, 248], ["intestinal", "ANATOMY", 260, 270], ["disease", "OBSERVATION", 271, 278], ["Without", "UNCERTAINTY", 313, 320], ["Protein LossDietary intolerance", "OBSERVATION", 321, 352]]], ["At least 3 and preferably 4 weeks should be allotted for such a dietary trial, during which time absolutely nothing else should be fed (including flavored treats or medications).Malabsorptive Disease Without Protein LossIf dietary, antibiotic, and repeated anthelmintic and antiprotozoal therapies are ineffective, ultrasonography followed by small intestinal biopsy is probably necessary.", [["intestinal", "ANATOMY", 349, 359], ["intestinal biopsy", "MULTI-TISSUE_STRUCTURE", 349, 366], ["a dietary trial", "TREATMENT", 62, 77], ["medications", "TREATMENT", 165, 176], ["Malabsorptive Disease", "PROBLEM", 178, 199], ["Protein LossIf dietary", "TREATMENT", 208, 230], ["antibiotic", "TREATMENT", 232, 242], ["repeated anthelmintic", "TREATMENT", 248, 269], ["antiprotozoal therapies", "TREATMENT", 274, 297], ["ultrasonography", "TEST", 315, 330], ["small intestinal biopsy", "TEST", 343, 366], ["small", "OBSERVATION_MODIFIER", 343, 348], ["intestinal", "ANATOMY", 349, 359], ["biopsy", "OBSERVATION", 360, 366], ["probably necessary", "UNCERTAINTY", 370, 388]]], ["Ultrasonography is done to look for lesions that can be aspirated (thus avoiding the need for anesthesia and biopsy) and to ensure that endoscopy can reach the lesion.", [["lesions", "ANATOMY", 36, 43], ["lesion", "ANATOMY", 160, 166], ["lesions", "PATHOLOGICAL_FORMATION", 36, 43], ["lesion", "CANCER", 160, 166], ["Ultrasonography", "TEST", 0, 15], ["lesions", "PROBLEM", 36, 43], ["anesthesia", "TREATMENT", 94, 104], ["biopsy", "TEST", 109, 115], ["endoscopy", "TEST", 136, 145], ["the lesion", "PROBLEM", 156, 166], ["lesions", "OBSERVATION", 36, 43], ["lesion", "OBSERVATION", 160, 166]]], ["In most patients, the stomach, duodenum, ileum, and colon may be endoscopically sampled.", [["stomach", "ANATOMY", 22, 29], ["duodenum", "ANATOMY", 31, 39], ["ileum", "ANATOMY", 41, 46], ["colon", "ANATOMY", 52, 57], ["patients", "ORGANISM", 8, 16], ["stomach", "ORGAN", 22, 29], ["duodenum", "MULTI-TISSUE_STRUCTURE", 31, 39], ["ileum", "MULTI-TISSUE_STRUCTURE", 41, 46], ["colon", "ORGAN", 52, 57], ["patients", "SPECIES", 8, 16], ["stomach", "ANATOMY", 22, 29], ["duodenum", "ANATOMY", 31, 39], ["ileum", "ANATOMY", 41, 46], ["colon", "ANATOMY", 52, 57]]], ["Duodenal cytology is helpful in some disorders (e.g., eosinophilic enteritis, purulent enteritis, giardiasis, lymphoma).", [["Duodenal", "ANATOMY", 0, 8], ["lymphoma", "ANATOMY", 110, 118], ["eosinophilic enteritis", "DISEASE", 54, 76], ["purulent enteritis", "DISEASE", 78, 96], ["giardiasis", "DISEASE", 98, 108], ["lymphoma", "DISEASE", 110, 118], ["Duodenal", "MULTI-TISSUE_STRUCTURE", 0, 8], ["lymphoma", "CANCER", 110, 118], ["Duodenal cytology", "TEST", 0, 17], ["some disorders", "PROBLEM", 32, 46], ["eosinophilic enteritis", "PROBLEM", 54, 76], ["purulent enteritis", "PROBLEM", 78, 96], ["giardiasis", "PROBLEM", 98, 108], ["lymphoma", "PROBLEM", 110, 118], ["cytology", "OBSERVATION", 9, 17], ["eosinophilic enteritis", "OBSERVATION", 54, 76], ["purulent", "OBSERVATION_MODIFIER", 78, 86], ["enteritis", "OBSERVATION", 87, 96], ["giardiasis", "OBSERVATION", 98, 108], ["lymphoma", "OBSERVATION", 110, 118]]], ["If laparotomy is performed, multiple representative fullthickness specimens (e.g., stomach, duodenum, jejunum, ileum, mesenteric lymph node) are indicated, because lesions can be spotty, even in severely affected patients.", [["fullthickness specimens", "ANATOMY", 52, 75], ["stomach", "ANATOMY", 83, 90], ["duodenum", "ANATOMY", 92, 100], ["jejunum", "ANATOMY", 102, 109], ["ileum", "ANATOMY", 111, 116], ["mesenteric lymph node", "ANATOMY", 118, 139], ["lesions", "ANATOMY", 164, 171], ["fullthickness specimens", "CANCER", 52, 75], ["stomach", "ORGAN", 83, 90], ["duodenum", "MULTI-TISSUE_STRUCTURE", 92, 100], ["jejunum", "MULTI-TISSUE_STRUCTURE", 102, 109], ["ileum", "MULTI-TISSUE_STRUCTURE", 111, 116], ["mesenteric lymph node", "MULTI-TISSUE_STRUCTURE", 118, 139], ["lesions", "PATHOLOGICAL_FORMATION", 164, 171], ["patients", "ORGANISM", 213, 221], ["patients", "SPECIES", 213, 221], ["laparotomy", "TREATMENT", 3, 13], ["multiple representative fullthickness specimens (e.g., stomach, duodenum, jejunum, ileum, mesenteric lymph node", "PROBLEM", 28, 139], ["lesions", "PROBLEM", 164, 171], ["laparotomy", "OBSERVATION", 3, 13], ["stomach", "ANATOMY", 83, 90], ["duodenum", "ANATOMY", 92, 100], ["jejunum", "ANATOMY", 102, 109], ["ileum", "ANATOMY", 111, 116], ["mesenteric", "ANATOMY", 118, 128], ["lymph node", "OBSERVATION", 129, 139]]], ["If endoscopy is performed, multiple high-quality tissue Disadvantages \u2022 The test has uncertain sensitivity and specificity for C. perfringens-associated disease.", [["tissue", "ANATOMY", 49, 55], ["C. perfringens-associated disease", "DISEASE", 127, 160], ["tissue", "TISSUE", 49, 55], ["C. perfringens", "ORGANISM", 127, 141], ["C. perfringens", "SPECIES", 127, 141], ["C. perfringens", "SPECIES", 127, 141], ["endoscopy", "TEST", 3, 12], ["multiple high-quality tissue Disadvantages", "PROBLEM", 27, 69], ["The test", "TEST", 72, 80], ["C. perfringens", "PROBLEM", 127, 141], ["associated disease", "PROBLEM", 142, 160], ["quality tissue", "OBSERVATION_MODIFIER", 41, 55], ["perfringens", "OBSERVATION", 130, 141], ["disease", "OBSERVATION", 153, 160]]], ["Presence of toxin does not mean the patient has disease due to that toxin.", [["patient", "ORGANISM", 36, 43], ["patient", "SPECIES", 36, 43], ["toxin", "PROBLEM", 12, 17], ["disease", "PROBLEM", 48, 55], ["that toxin", "PROBLEM", 63, 73]]], ["Conversely, absence of toxin does not guarantee the patient is not diseased because of the bacteria producing the toxin.", [["patient", "ORGANISM", 52, 59], ["patient", "SPECIES", 52, 59], ["toxin", "PROBLEM", 23, 28], ["diseased", "PROBLEM", 67, 75], ["the bacteria", "PROBLEM", 87, 99], ["the toxin", "PROBLEM", 110, 119]]], ["Animals may be toxin-positive and not have diarrhea, and dogs with toxin-negative diarrhea may respond to antibiotics.", [["diarrhea", "DISEASE", 43, 51], ["diarrhea", "DISEASE", 82, 90], ["Animals", "ORGANISM", 0, 7], ["dogs", "ORGANISM", 57, 61], ["dogs", "SPECIES", 57, 61], ["toxin", "TEST", 15, 20], ["diarrhea", "PROBLEM", 43, 51], ["toxin", "TEST", 67, 72], ["negative diarrhea", "PROBLEM", 73, 90], ["antibiotics", "TREATMENT", 106, 117]]], ["Old fecal samples might yield false-positive results.Malabsorptive Disease Without Protein LossAnalysis \u2022 Fresh or frozen feces are used according to the instructions on the test kit.", [["fecal samples", "ANATOMY", 4, 17], ["feces", "ANATOMY", 122, 127], ["fecal samples", "CANCER", 4, 17], ["feces", "ORGANISM_SUBSTANCE", 122, 127], ["Old fecal samples", "TEST", 0, 17], ["Malabsorptive Disease", "PROBLEM", 53, 74], ["Protein LossAnalysis", "TEST", 83, 103], ["Fresh or frozen feces", "PROBLEM", 106, 127], ["the test kit", "TEST", 170, 182], ["fecal", "ANATOMY", 4, 9], ["Without", "UNCERTAINTY", 75, 82], ["Protein LossAnalysis", "OBSERVATION", 83, 103], ["frozen feces", "OBSERVATION", 115, 127]]], ["Reverse passive latex agglutination (RPLA) (i.e., PET-RPLA Toxin detection kit; OxoidLimited, Cambridge, UK) and ELISA (i.e., C. perfringens Enterotoxin Test; TechLab, Blacksburg, VA) methods are available for C. perfringens enterotoxin.Malabsorptive Disease Without Protein LossInterpretation \u2022 Results from ELISA methodology appear to correlate better with disease than do results from RPLA methodology.", [["C. perfringens enterotoxin", "ORGANISM", 210, 236], ["C. perfringens enterotoxin", "PROTEIN", 210, 236], ["C. perfringens", "SPECIES", 126, 140], ["C. perfringens", "SPECIES", 210, 224], ["C. perfringens", "SPECIES", 126, 140], ["C. perfringens", "SPECIES", 210, 224], ["Reverse passive latex agglutination", "PROBLEM", 0, 35], ["PET-", "TEST", 50, 54], ["ELISA", "TEST", 113, 118], ["C. perfringens Enterotoxin Test", "TEST", 126, 157], ["C. perfringens enterotoxin", "PROBLEM", 210, 236], ["Malabsorptive Disease", "PROBLEM", 237, 258], ["Protein LossInterpretation", "TEST", 267, 293], ["ELISA methodology", "TEST", 309, 326], ["disease", "PROBLEM", 359, 366], ["passive", "OBSERVATION_MODIFIER", 8, 15], ["latex agglutination", "OBSERVATION", 16, 35]]], ["Finding C. perfringens enterotoxin in feces plus clinical signs consistent with clostridial diarrhea has been considered diagnostic.", [["feces", "ANATOMY", 38, 43], ["clostridial diarrhea", "DISEASE", 80, 100], ["C. perfringens enterotoxin", "ORGANISM", 8, 34], ["feces", "ORGANISM_SUBSTANCE", 38, 43], ["C. perfringens enterotoxin", "SPECIES", 8, 34], ["C. perfringens", "SPECIES", 8, 22], ["C. perfringens enterotoxin in feces", "PROBLEM", 8, 43], ["clinical signs", "TEST", 49, 63], ["clostridial diarrhea", "PROBLEM", 80, 100], ["perfringens", "OBSERVATION_MODIFIER", 11, 22], ["consistent with", "UNCERTAINTY", 64, 79], ["clostridial diarrhea", "OBSERVATION", 80, 100]]], ["However, enterotoxin cannot be found in all patients responding to tylosin or amoxicillin therapy.", [["tylosin", "CHEMICAL", 67, 74], ["amoxicillin", "CHEMICAL", 78, 89], ["tylosin", "CHEMICAL", 67, 74], ["amoxicillin", "CHEMICAL", 78, 89], ["enterotoxin", "GENE_OR_GENE_PRODUCT", 9, 20], ["patients", "ORGANISM", 44, 52], ["tylosin", "SIMPLE_CHEMICAL", 67, 74], ["amoxicillin", "SIMPLE_CHEMICAL", 78, 89], ["enterotoxin", "PROTEIN", 9, 20], ["patients", "SPECIES", 44, 52], ["enterotoxin", "PROBLEM", 9, 20], ["tylosin", "TREATMENT", 67, 74], ["amoxicillin therapy", "TREATMENT", 78, 97]]], ["In suspected cases with a negative toxin assay, one may repeat the test again at the onset of recurrence of clinical signs or perform a therapeutic trial with amoxicillin or tylosin.Malabsorptive Disease Without Protein LossFecal spore counts do not correlate well with C. perfringens enterotoxin production or with the presence of diarrhea.", [["amoxicillin", "CHEMICAL", 159, 170], ["tylosin", "CHEMICAL", 174, 181], ["diarrhea", "DISEASE", 332, 340], ["amoxicillin", "CHEMICAL", 159, 170], ["tylosin", "CHEMICAL", 174, 181], ["amoxicillin", "SIMPLE_CHEMICAL", 159, 170], ["tylosin", "SIMPLE_CHEMICAL", 174, 181], ["C. perfringens", "ORGANISM", 270, 284], ["enterotoxin", "GENE_OR_GENE_PRODUCT", 285, 296], ["C. perfringens", "SPECIES", 270, 284], ["C. perfringens", "SPECIES", 270, 284], ["a negative toxin assay", "TEST", 24, 46], ["the test", "TEST", 63, 71], ["clinical signs", "PROBLEM", 108, 122], ["amoxicillin", "TREATMENT", 159, 170], ["tylosin", "TREATMENT", 174, 181], ["Malabsorptive Disease", "PROBLEM", 182, 203], ["Protein LossFecal spore counts", "TEST", 212, 242], ["C. perfringens enterotoxin production", "PROBLEM", 270, 307], ["diarrhea", "PROBLEM", 332, 340], ["diarrhea", "OBSERVATION", 332, 340]]], ["Examining fecal smears (see Fecal Microscopic Cytology later in this chapter) to look for the presence of spores is not an acceptable screening procedure.FECAL ANALYSIS FOR CLOSTRIDIUM DIFFICILEOccasional Indications \u2022 The importance of C. difficile in small animal medicine is unknown.", [["fecal smears", "ANATOMY", 10, 22], ["C. difficile", "DISEASE", 237, 249], ["fecal smears", "MULTI-TISSUE_STRUCTURE", 10, 22], ["C. difficile", "ORGANISM", 237, 249], ["C. difficile", "SPECIES", 237, 249], ["C. difficile", "SPECIES", 237, 249], ["fecal smears", "TEST", 10, 22], ["Fecal Microscopic Cytology", "TEST", 28, 54], ["spores", "PROBLEM", 106, 112], ["an acceptable screening procedure", "TREATMENT", 120, 153], ["FECAL ANALYSIS", "TEST", 154, 168], ["CLOSTRIDIUM DIFFICILEOccasional Indications", "TREATMENT", 173, 216], ["C. difficile", "PROBLEM", 237, 249], ["fecal", "ANATOMY", 10, 15], ["C. difficile", "OBSERVATION", 237, 249]]], ["The test seems most appropriate for suspected nosocomial or antibioticassociated diarrheas.FECAL ANALYSIS FOR CLOSTRIDIUM DIFFICILEAdvantages \u2022 The ELISA for C. difficile antigen is very sensitive and has excellent negative predictive value.", [["diarrheas", "DISEASE", 81, 90], ["C. difficile antigen", "GENE_OR_GENE_PRODUCT", 158, 178], ["C. difficile", "SPECIES", 158, 170], ["C. difficile", "SPECIES", 158, 170], ["The test", "TEST", 0, 8], ["nosocomial", "PROBLEM", 46, 56], ["antibioticassociated diarrheas", "PROBLEM", 60, 90], ["FECAL ANALYSIS", "TEST", 91, 105], ["CLOSTRIDIUM DIFFICILEAdvantages", "TEST", 110, 141], ["The ELISA", "TEST", 144, 153], ["C. difficile antigen", "TEST", 158, 178]]], ["The ELISA for C. difficile toxin is thought to be specific, but of uncertain sensitivity.FECAL ANALYSIS FOR CLOSTRIDIUM DIFFICILEDisadvantages \u2022 Interpretation is not simply based upon positive/negative test results.", [["C. difficile toxin", "ORGANISM", 14, 32], ["C. difficile", "SPECIES", 14, 26], ["C. difficile", "SPECIES", 14, 26], ["The ELISA", "TEST", 0, 9], ["C. difficile toxin", "PROBLEM", 14, 32], ["FECAL ANALYSIS", "TEST", 89, 103], ["thought to be", "UNCERTAINTY", 36, 49]]], ["Presence of toxin does not mean the patient has disease due to that toxin.", [["patient", "ORGANISM", 36, 43], ["patient", "SPECIES", 36, 43], ["toxin", "PROBLEM", 12, 17], ["disease", "PROBLEM", 48, 55], ["that toxin", "PROBLEM", 63, 73]]], ["Conversely, absence of toxin does not guarantee the patient is not diseased because of C. difficile.", [["C. difficile", "DISEASE", 87, 99], ["patient", "ORGANISM", 52, 59], ["C. difficile", "ORGANISM", 87, 99], ["patient", "SPECIES", 52, 59], ["C. difficile", "SPECIES", 87, 99], ["C. difficile", "SPECIES", 87, 99], ["toxin", "PROBLEM", 23, 28], ["C. difficile", "PROBLEM", 87, 99], ["difficile", "OBSERVATION", 90, 99]]], ["Animals may be toxin-positive and not have diarrhea, and dogs with toxin-negative diarrhea may respond to appropriate antibacterials.FECAL ANALYSIS FOR CLOSTRIDIUM DIFFICILEAnalysis \u2022 ELISA methodology is available to look for C. difficile toxin A (ImmunoCard Toxin A; Meridan Diagnostics, Cincinnati, OH).FECAL ANALYSIS FOR CLOSTRIDIUM DIFFICILEDrug Therapy That May Alter Analysis \u2022 Unknown. diagnostic tool.", [["diarrhea", "DISEASE", 43, 51], ["diarrhea", "DISEASE", 82, 90], ["OH", "CHEMICAL", 302, 304], ["Animals", "ORGANISM", 0, 7], ["dogs", "ORGANISM", 57, 61], ["C. difficile", "ORGANISM", 227, 239], ["toxin A", "SIMPLE_CHEMICAL", 240, 247], ["dogs", "SPECIES", 57, 61], ["C. difficile", "SPECIES", 227, 239], ["C. difficile", "SPECIES", 227, 239], ["toxin", "TEST", 15, 20], ["diarrhea", "PROBLEM", 43, 51], ["toxin", "TEST", 67, 72], ["negative diarrhea", "PROBLEM", 73, 90], ["appropriate antibacterials", "TREATMENT", 106, 132], ["FECAL ANALYSIS", "TEST", 133, 147], ["CLOSTRIDIUM DIFFICILEAnalysis", "TEST", 152, 181], ["ELISA methodology", "TEST", 184, 201], ["C. difficile toxin", "PROBLEM", 227, 245], ["FECAL ANALYSIS", "TEST", 306, 320], ["CLOSTRIDIUM DIFFICILEDrug Therapy", "TREATMENT", 325, 358], ["diagnostic tool", "TEST", 394, 409]]], ["Hematochezia should also be considered as a large bowel problem.", [["bowel", "ANATOMY", 50, 55], ["Hematochezia", "DISEASE", 0, 12], ["bowel", "ORGAN", 50, 55], ["Hematochezia", "PROBLEM", 0, 12], ["a large bowel problem", "PROBLEM", 42, 63], ["large", "OBSERVATION_MODIFIER", 44, 49], ["bowel", "ANATOMY", 50, 55], ["problem", "OBSERVATION", 56, 63]]], ["Melena signifies swallowed blood from any source, coagulopathy, or gastric and upper intestinal bleeding.", [["blood", "ANATOMY", 27, 32], ["gastric", "ANATOMY", 67, 74], ["upper intestinal", "ANATOMY", 79, 95], ["coagulopathy", "DISEASE", 50, 62], ["gastric and upper intestinal bleeding", "DISEASE", 67, 104], ["Melena", "SIMPLE_CHEMICAL", 0, 6], ["blood", "ORGANISM_SUBSTANCE", 27, 32], ["gastric", "ORGAN", 67, 74], ["upper intestinal", "ORGANISM_SUBDIVISION", 79, 95], ["Melena", "PROBLEM", 0, 6], ["swallowed blood", "PROBLEM", 17, 32], ["coagulopathy", "PROBLEM", 50, 62], ["gastric and upper intestinal bleeding", "PROBLEM", 67, 104], ["coagulopathy", "OBSERVATION", 50, 62], ["gastric", "ANATOMY", 67, 74], ["upper", "ANATOMY_MODIFIER", 79, 84], ["intestinal", "ANATOMY", 85, 95], ["bleeding", "OBSERVATION", 96, 104]]], ["Therefore before performing an exploratory laparotomy, one should consider all the possible causes of ingesting blood (e.g., coughing up blood from the respiratory tract, posterior nasal bleeding).", [["blood", "ANATOMY", 112, 117], ["blood", "ANATOMY", 137, 142], ["respiratory tract", "ANATOMY", 152, 169], ["nasal", "ANATOMY", 181, 186], ["nasal bleeding", "DISEASE", 181, 195], ["blood", "ORGANISM_SUBSTANCE", 112, 117], ["blood", "ORGANISM_SUBSTANCE", 137, 142], ["respiratory tract", "ORGANISM_SUBDIVISION", 152, 169], ["nasal", "ORGANISM_SUBDIVISION", 181, 186], ["an exploratory laparotomy", "TEST", 28, 53], ["ingesting blood", "PROBLEM", 102, 117], ["coughing up blood from the respiratory tract", "PROBLEM", 125, 169], ["posterior nasal bleeding", "PROBLEM", 171, 195], ["laparotomy", "OBSERVATION", 43, 53], ["respiratory tract", "ANATOMY", 152, 169], ["posterior", "ANATOMY_MODIFIER", 171, 180], ["nasal", "ANATOMY", 181, 186], ["bleeding", "OBSERVATION", 187, 195]]], ["Ingestion of bismuth subsalicylate or liver can cause feces to appear melenic.", [["liver", "ANATOMY", 38, 43], ["feces", "ANATOMY", 54, 59], ["bismuth subsalicylate", "CHEMICAL", 13, 34], ["bismuth subsalicylate", "CHEMICAL", 13, 34], ["bismuth subsalicylate", "SIMPLE_CHEMICAL", 13, 34], ["liver", "ORGAN", 38, 43], ["feces", "ORGANISM_SUBSTANCE", 54, 59], ["bismuth subsalicylate", "TREATMENT", 13, 34], ["feces", "PROBLEM", 54, 59], ["melenic", "PROBLEM", 70, 77], ["liver", "ANATOMY", 38, 43], ["feces", "OBSERVATION", 54, 59], ["melenic", "OBSERVATION", 70, 77]]], ["Diet and changes in intestinal bacterial flora influence fecal color but do not generally signify disease.FECAL ENZYME-LINKED IMMUNOSORBENT ASSAY FOR PARVOVIRUSOccasional Indications \u2022 A fecal ELISA for parvovirus is indicated in dogs suspected of having parvoviral enteritis (especially those not displaying classic signs), or in acute neutropenia of unknown cause.", [["intestinal", "ANATOMY", 20, 30], ["fecal color", "ANATOMY", 57, 68], ["parvovirus", "DISEASE", 203, 213], ["parvoviral enteritis", "DISEASE", 255, 275], ["neutropenia", "DISEASE", 337, 348], ["intestinal", "ORGAN", 20, 30], ["fecal", "ORGANISM_SUBSTANCE", 57, 62], ["fecal", "ORGANISM_SUBSTANCE", 187, 192], ["parvovirus", "ORGANISM", 203, 213], ["dogs", "ORGANISM", 230, 234], ["dogs", "SPECIES", 230, 234], ["parvovirus", "SPECIES", 203, 213], ["intestinal bacterial flora influence fecal color", "PROBLEM", 20, 68], ["disease", "PROBLEM", 98, 105], ["FECAL ENZYME", "TEST", 106, 118], ["IMMUNOSORBENT ASSAY", "TEST", 126, 145], ["PARVOVIRUSOccasional Indications", "TREATMENT", 150, 182], ["A fecal ELISA", "TEST", 185, 198], ["parvovirus", "PROBLEM", 203, 213], ["parvoviral enteritis", "PROBLEM", 255, 275], ["acute neutropenia", "PROBLEM", 331, 348], ["intestinal", "ANATOMY", 20, 30], ["bacterial flora", "OBSERVATION", 31, 46], ["disease", "OBSERVATION", 98, 105], ["fecal", "ANATOMY", 187, 192], ["enteritis", "OBSERVATION", 266, 275], ["acute", "OBSERVATION_MODIFIER", 331, 336], ["neutropenia", "OBSERVATION", 337, 348]]], ["The test can be used in cats to diagnose panleukopenia caused by canine parvovirus 2a and 2b.FECAL ENZYME-LINKED IMMUNOSORBENT ASSAY FOR PARVOVIRUSAdvantages \u2022 The test is quick and available, and has good sensitivity and specificity if done at the appropriate time (e.g., approximately 1 to 3 days after onset of clinical signs).FECAL ANALYSIS FOR CLOSTRIDIUM PERFRINGENSOccasional Indications \u2022 Fecal analysis for C. perfringens is occasionally indicated in dogs with acute, nosocomial diarrhea or chronic large bowel diarrhea of unknown cause.FECAL ANALYSIS FOR CLOSTRIDIUM PERFRINGENSDisadvantages (Semiqualitative Analysis) \u2022 The test occasionally produces misleading results.FECAL ANALYSIS FOR CLOSTRIDIUM PERFRINGENSAnalysis \u2022 The clinician performs a semiqualitative analysis for undigested fats by mixing a drop of fresh feces with a drop of Sudan III, heating the slide to a boil, and examining the smear microscopically.", [["bowel", "ANATOMY", 514, 519], ["fats", "ANATOMY", 799, 803], ["feces", "ANATOMY", 830, 835], ["panleukopenia", "DISEASE", 41, 54], ["C. perfringens", "DISEASE", 416, 430], ["diarrhea", "DISEASE", 488, 496], ["diarrhea", "DISEASE", 520, 528], ["cats", "ORGANISM", 24, 28], ["canine parvovirus 2a", "ORGANISM", 65, 85], ["Fecal", "ORGANISM_SUBSTANCE", 397, 402], ["C. perfringens", "ORGANISM", 416, 430], ["dogs", "ORGANISM", 460, 464], ["bowel", "ORGAN", 514, 519], ["fats", "ORGANISM_SUBDIVISION", 799, 803], ["feces", "ORGANISM_SUBDIVISION", 830, 835], ["canine parvovirus", "SPECIES", 65, 82], ["C. perfringens", "SPECIES", 416, 430], ["dogs", "SPECIES", 460, 464], ["canine parvovirus 2a", "SPECIES", 65, 85], ["C. perfringens", "SPECIES", 416, 430], ["FECAL ENZYME", "TEST", 93, 105], ["The test", "TEST", 160, 168], ["clinical signs", "TEST", 314, 328], ["FECAL ANALYSIS", "TEST", 330, 344], ["CLOSTRIDIUM PERFRINGENSOccasional Indications", "TREATMENT", 349, 394], ["Fecal analysis", "TEST", 397, 411], ["C. perfringens", "PROBLEM", 416, 430], ["acute, nosocomial diarrhea", "PROBLEM", 470, 496], ["chronic large bowel diarrhea", "PROBLEM", 500, 528], ["FECAL ANALYSIS", "TEST", 546, 560], ["The test", "TEST", 631, 639], ["FECAL ANALYSIS", "TEST", 681, 695], ["a semiqualitative analysis", "TEST", 757, 783], ["undigested fats", "PROBLEM", 788, 803], ["a drop of fresh feces", "PROBLEM", 814, 835], ["the smear", "TEST", 905, 914], ["Fecal", "ANATOMY", 397, 402], ["acute", "OBSERVATION_MODIFIER", 470, 475], ["chronic", "OBSERVATION_MODIFIER", 500, 507], ["large", "OBSERVATION_MODIFIER", 508, 513], ["bowel", "ANATOMY", 514, 519], ["diarrhea", "OBSERVATION", 520, 528]]], ["The clinician performs analysis for digested fats by mixing one drop of fresh feces, one drop of 36% acetic acid, and one drop of Sudan III.", [["fats", "ANATOMY", 45, 49], ["feces", "ANATOMY", 78, 83], ["acetic acid", "CHEMICAL", 101, 112], ["acetic acid", "CHEMICAL", 101, 112], ["Sudan III", "CHEMICAL", 130, 139], ["fats", "ORGANISM_SUBDIVISION", 45, 49], ["feces", "ORGANISM_SUBDIVISION", 78, 83], ["acetic acid", "SIMPLE_CHEMICAL", 101, 112], ["acetic acid", "TEST", 101, 112]]], ["This is put on a microscope slide, heated to boiling, and examined while still warm.", [["a microscope slide", "TREATMENT", 15, 33], ["warm", "OBSERVATION", 79, 83]]], ["In both cases, identifying orange droplets is a positive finding.", [["orange droplets", "ANATOMY", 27, 42], ["orange droplets", "OBSERVATION", 27, 42]]], ["It is important that the patient has been eating a moderate-to high-fat diet.", [["patient", "ORGANISM", 25, 32], ["fat", "TISSUE", 68, 71], ["patient", "SPECIES", 25, 32], ["a moderate-to high-fat diet", "TREATMENT", 49, 76]]], ["Feeding low-fat diets to malabsorptive dogs may cause the test result to be negative.FECAL ANALYSIS FOR CLOSTRIDIUM PERFRINGENSNormal Values \u2022 Semiqualitative: few or no undigested and digested fat globules per high-power field (hpf).FECAL ANALYSIS FOR CLOSTRIDIUM PERFRINGENSArtifacts \u2022 The semiqualitative analysis may have unexplained false-negative and false-positive reactions.", [["fat globules", "ANATOMY", 194, 206], ["dogs", "ORGANISM", 39, 43], ["fat globules", "TISSUE", 194, 206], ["dogs", "SPECIES", 39, 43], ["Feeding low-fat diets", "TREATMENT", 0, 21], ["malabsorptive dogs", "TREATMENT", 25, 43], ["the test", "TEST", 54, 62], ["FECAL ANALYSIS", "TEST", 85, 99], ["CLOSTRIDIUM PERFRINGENSNormal Values", "TEST", 104, 140], ["undigested and digested fat globules", "PROBLEM", 170, 206], ["FECAL ANALYSIS", "TEST", 234, 248], ["The semiqualitative analysis", "TEST", 288, 316], ["unexplained false-negative and false-positive reactions", "PROBLEM", 326, 381], ["CLOSTRIDIUM PERFRINGENSArtifacts", "OBSERVATION", 253, 285], ["positive reactions", "OBSERVATION", 363, 381]]], ["Administration of barium sulfate, bismuth, psyllium fiber, mineral oil, or castor oil or feeding a low-fat diet may also confuse semiqualitative analysis.FECAL ANALYSIS FOR CLOSTRIDIUM PERFRINGENSCauses of Increased Fecal Fat \u2022 Finding several orange globules/hpf, if repeatable on several examinations, is principally caused by malabsorption or maldigestion.", [["mineral oil", "ANATOMY", 59, 70], ["oil", "ANATOMY", 82, 85], ["barium sulfate", "CHEMICAL", 18, 32], ["bismuth", "CHEMICAL", 34, 41], ["psyllium fiber, mineral oil", "CHEMICAL", 43, 70], ["malabsorption", "DISEASE", 329, 342], ["maldigestion", "DISEASE", 346, 358], ["barium sulfate", "CHEMICAL", 18, 32], ["bismuth", "CHEMICAL", 34, 41], ["barium sulfate", "SIMPLE_CHEMICAL", 18, 32], ["bismuth", "SIMPLE_CHEMICAL", 34, 41], ["psyllium fiber", "SIMPLE_CHEMICAL", 43, 57], ["mineral oil", "SIMPLE_CHEMICAL", 59, 70], ["barium sulfate", "TREATMENT", 18, 32], ["bismuth", "TREATMENT", 34, 41], ["psyllium fiber", "TREATMENT", 43, 57], ["mineral oil", "TREATMENT", 59, 70], ["castor oil", "TREATMENT", 75, 85], ["a low-fat diet", "TREATMENT", 97, 111], ["FECAL ANALYSIS", "TEST", 154, 168], ["several examinations", "TEST", 282, 302], ["malabsorption", "PROBLEM", 329, 342], ["maldigestion", "PROBLEM", 346, 358], ["Increased", "OBSERVATION_MODIFIER", 206, 215], ["Fecal Fat", "OBSERVATION", 216, 225]]], ["It is a reasonable screening test and helps distinguish EPI (positive for undigested fats) from malabsorption (positive for digested fats).", [["fats", "ANATOMY", 85, 89], ["fats", "ANATOMY", 133, 137], ["malabsorption", "DISEASE", 96, 109], ["EPI", "SIMPLE_CHEMICAL", 56, 59], ["fats", "ORGANISM_SUBDIVISION", 85, 89], ["a reasonable screening test", "TEST", 6, 33], ["EPI", "TEST", 56, 59], ["undigested fats", "PROBLEM", 74, 89], ["malabsorption (positive for digested fats", "PROBLEM", 96, 137]]], ["Despite occasional false-positive reactions, strongly positive results for undigested fecal fat in a dog with signs consistent with maldigestion are an indication for TLI.", [["fecal fat", "ANATOMY", 86, 95], ["maldigestion", "DISEASE", 132, 144], ["fecal fat", "MULTI-TISSUE_STRUCTURE", 86, 95], ["dog", "ORGANISM", 101, 104], ["dog", "SPECIES", 101, 104], ["occasional false-positive reactions", "PROBLEM", 8, 43], ["undigested fecal fat", "PROBLEM", 75, 95], ["maldigestion", "PROBLEM", 132, 144], ["positive reactions", "OBSERVATION", 25, 43], ["fecal fat", "OBSERVATION", 86, 95]]], ["Fecal fat may not be detectable in some dogs with EPI.FECAL PROTEOLYTIC ACTIVITYThis test was used to detect maldigestion in animals with chronic diarrhea or weight loss of unknown cause.", [["Fecal fat", "ANATOMY", 0, 9], ["diarrhea", "DISEASE", 146, 154], ["weight loss", "DISEASE", 158, 169], ["Fecal fat", "ORGANISM_SUBSTANCE", 0, 9], ["dogs", "ORGANISM", 40, 44], ["dogs", "SPECIES", 40, 44], ["Fecal fat", "PROBLEM", 0, 9], ["EPI", "TREATMENT", 50, 53], ["FECAL PROTEOLYTIC ACTIVITYThis test", "TEST", 54, 89], ["maldigestion", "PROBLEM", 109, 121], ["chronic diarrhea", "PROBLEM", 138, 154], ["weight loss", "PROBLEM", 158, 169], ["fat", "OBSERVATION", 6, 9], ["may not be", "UNCERTAINTY", 10, 20], ["chronic", "OBSERVATION_MODIFIER", 138, 145], ["diarrhea", "OBSERVATION", 146, 154]]], ["Theoretically it may diagnose EPI in rare patients that have EPI secondary to obstruction of the pancreatic duct or ducts.", [["pancreatic duct", "ANATOMY", 97, 112], ["ducts", "ANATOMY", 116, 121], ["obstruction of the pancreatic duct", "DISEASE", 78, 112], ["patients", "ORGANISM", 42, 50], ["pancreatic duct", "MULTI-TISSUE_STRUCTURE", 97, 112], ["ducts", "MULTI-TISSUE_STRUCTURE", 116, 121], ["patients", "SPECIES", 42, 50], ["EPI", "TREATMENT", 61, 64], ["obstruction of the pancreatic duct or ducts", "PROBLEM", 78, 121], ["obstruction", "OBSERVATION", 78, 89], ["pancreatic duct", "ANATOMY", 97, 112], ["ducts", "ANATOMY", 116, 121]]], ["However, the radiograph film digestion test is useless and should never be used.", [["the radiograph film digestion test", "TEST", 9, 43]]], ["The most reliable procedure for measuring fecal proteolytic activity is difficult to perform and requires special handling of the feces; it is described in prior editions.", [["fecal", "ANATOMY", 42, 47], ["feces", "ANATOMY", 130, 135], ["fecal", "ORGANISM_SUBSTANCE", 42, 47], ["feces", "ORGANISM_SUBSTANCE", 130, 135], ["The most reliable procedure", "TREATMENT", 0, 27], ["measuring fecal proteolytic activity", "PROBLEM", 32, 68]]], ["The TLI test is the test of choice for EPI.FECAL ALPHA-1 PROTEASE INHIBITOR ACTIVITYInfrequent Indications \u2022 Hypoalbuminemia of uncertain cause or suspected PLE in a patient with concurrent hepatic insufficiency or protein loss from the kidneys or skin are indications for testing fecal alpha-1 protease inhibitor activity.FECAL ALPHA-1 PROTEASE INHIBITOR ACTIVITYAdvantages \u2022 The test can define the GI tract as the source of protein loss.", [["hepatic", "ANATOMY", 190, 197], ["kidneys", "ANATOMY", 237, 244], ["skin", "ANATOMY", 248, 252], ["GI tract", "ANATOMY", 401, 409], ["Hypoalbuminemia", "DISEASE", 109, 124], ["PLE", "DISEASE", 157, 160], ["hepatic insufficiency", "DISEASE", 190, 211], ["patient", "ORGANISM", 166, 173], ["hepatic", "ORGAN", 190, 197], ["kidneys", "ORGAN", 237, 244], ["skin", "ORGAN", 248, 252], ["alpha-1 protease", "GENE_OR_GENE_PRODUCT", 287, 303], ["GI tract", "ORGANISM_SUBDIVISION", 401, 409], ["fecal alpha", "PROTEIN", 281, 292], ["patient", "SPECIES", 166, 173], ["The TLI test", "TEST", 0, 12], ["EPI", "TREATMENT", 39, 42], ["FECAL ALPHA", "TREATMENT", 43, 54], ["PROTEASE INHIBITOR ACTIVITYInfrequent Indications", "TREATMENT", 57, 106], ["Hypoalbuminemia", "PROBLEM", 109, 124], ["suspected PLE", "PROBLEM", 147, 160], ["concurrent hepatic insufficiency", "PROBLEM", 179, 211], ["protein loss from the kidneys", "PROBLEM", 215, 244], ["testing", "TEST", 273, 280], ["fecal alpha", "TREATMENT", 281, 292], ["protease inhibitor activity", "TREATMENT", 295, 322], ["PROTEASE INHIBITOR ACTIVITYAdvantages", "TREATMENT", 337, 374], ["The test", "TEST", 377, 385], ["the GI tract", "PROBLEM", 397, 409], ["protein loss", "PROBLEM", 427, 439], ["Hypoalbuminemia", "OBSERVATION", 109, 124], ["hepatic", "ANATOMY", 190, 197], ["insufficiency", "OBSERVATION", 198, 211], ["protein loss", "OBSERVATION", 215, 227], ["kidneys", "ANATOMY", 237, 244], ["skin", "ANATOMY", 248, 252], ["GI tract", "ANATOMY", 401, 409], ["protein loss", "OBSERVATION", 427, 439]]], ["Alpha-1 protease inhibitor is a plasma protein.", [["plasma", "ANATOMY", 32, 38], ["Alpha-1 protease", "GENE_OR_GENE_PRODUCT", 0, 16], ["plasma", "ORGANISM_SUBSTANCE", 32, 38], ["Alpha-1 protease", "PROTEIN", 0, 16], ["plasma protein", "PROTEIN", 32, 46], ["Alpha-1 protease inhibitor", "TREATMENT", 0, 26], ["a plasma protein", "TREATMENT", 30, 46]]], ["If it leaks into the intestinal lumen, it Interpretation \u2022 The best approach is to first check for the presence of bacteria using the ELISA for the bacterial antigen.", [["intestinal lumen", "ANATOMY", 21, 37], ["intestinal lumen", "MULTI-TISSUE_STRUCTURE", 21, 37], ["bacterial antigen", "GENE_OR_GENE_PRODUCT", 148, 165], ["bacterial antigen", "PROTEIN", 148, 165], ["it leaks into the intestinal lumen", "PROBLEM", 3, 37], ["bacteria", "PROBLEM", 115, 123], ["the ELISA", "TEST", 130, 139], ["the bacterial antigen", "PROBLEM", 144, 165], ["leaks", "OBSERVATION", 6, 11], ["intestinal lumen", "ANATOMY", 21, 37], ["bacteria", "OBSERVATION", 115, 123]]], ["If the test is negative, then it is very unlikely that C. difficile is present.", [["C. difficile", "DISEASE", 55, 67], ["C. difficile", "ORGANISM", 55, 67], ["C. difficile", "SPECIES", 55, 67], ["C. difficile", "SPECIES", 55, 67], ["the test", "TEST", 3, 11], ["C. difficile", "PROBLEM", 55, 67], ["very unlikely", "UNCERTAINTY", 36, 49], ["C.", "OBSERVATION_MODIFIER", 55, 57], ["difficile", "OBSERVATION", 58, 67]]], ["If the ELISA for the bacterial antigen is positive, then one should test for the toxin using an ELISA that detects both A and B toxin.", [["B toxin", "GENE_OR_GENE_PRODUCT", 126, 133], ["bacterial antigen", "PROTEIN", 21, 38], ["toxin", "PROTEIN", 81, 86], ["A and B toxin", "PROTEIN", 120, 133], ["the ELISA", "TEST", 3, 12], ["the bacterial antigen", "TEST", 17, 38], ["the toxin", "TEST", 77, 86], ["an ELISA", "TEST", 93, 101]]], ["Finding C. difficile toxin A in feces of diarrheic patients seems suggestive of a cause-and-effect relationship.", [["feces", "ANATOMY", 32, 37], ["diarrheic", "DISEASE", 41, 50], ["C. difficile toxin A", "GENE_OR_GENE_PRODUCT", 8, 28], ["feces", "ORGANISM_SUBSTANCE", 32, 37], ["patients", "ORGANISM", 51, 59], ["C. difficile toxin", "SPECIES", 8, 26], ["patients", "SPECIES", 51, 59], ["C. difficile", "SPECIES", 8, 20], ["C. difficile toxin", "PROBLEM", 8, 26], ["diarrheic", "PROBLEM", 41, 50], ["difficile", "OBSERVATION_MODIFIER", 11, 20], ["suggestive of", "UNCERTAINTY", 66, 79]]], ["However, the importance of C. difficile in canine and feline medicine and any risk it may have for people is currently not understood.FECAL CULTURERare Indications \u2022 Fecal culture is rarely indicated for dogs and cats with diarrhea (especially large bowel) that appears to be nosocomial, is potentially infectious (e.g., fever, leukocytosis, neutrophilic fecal cytology), or is suspected of being due to a specific infectious agent (i.e., Salmonella spp., C. jejuni, verotoxin-positive E. coli, and Y. enterocolitica).", [["Fecal culture", "ANATOMY", 166, 179], ["bowel", "ANATOMY", 250, 255], ["C. difficile", "DISEASE", 27, 39], ["diarrhea", "DISEASE", 223, 231], ["nosocomial", "DISEASE", 276, 286], ["fever", "DISEASE", 321, 326], ["leukocytosis", "DISEASE", 328, 340], ["Y. enterocolitica", "DISEASE", 499, 516], ["C. difficile", "ORGANISM", 27, 39], ["canine", "ORGANISM", 43, 49], ["feline", "ORGANISM", 54, 60], ["people", "ORGANISM", 99, 105], ["dogs", "ORGANISM", 204, 208], ["cats", "ORGANISM", 213, 217], ["bowel", "ORGAN", 250, 255], ["Salmonella spp.", "ORGANISM", 439, 454], ["C. jejuni", "ORGANISM", 456, 465], ["verotoxin", "GENE_OR_GENE_PRODUCT", 467, 476], ["E. coli", "ORGANISM", 486, 493], ["Y. enterocolitica", "ORGANISM", 499, 516], ["C. difficile", "SPECIES", 27, 39], ["canine", "SPECIES", 43, 49], ["feline", "SPECIES", 54, 60], ["people", "SPECIES", 99, 105], ["dogs", "SPECIES", 204, 208], ["cats", "SPECIES", 213, 217], ["Salmonella spp.", "SPECIES", 439, 454], ["C. jejuni", "SPECIES", 456, 465], ["E. coli", "SPECIES", 486, 493], ["Y. enterocolitica", "SPECIES", 499, 516], ["C. difficile", "SPECIES", 27, 39], ["canine", "SPECIES", 43, 49], ["Salmonella spp.", "SPECIES", 439, 454], ["C. jejuni", "SPECIES", 456, 465], ["E. coli", "SPECIES", 486, 493], ["Y. enterocolitica", "SPECIES", 499, 516], ["C. difficile in canine and feline medicine", "PROBLEM", 27, 69], ["Fecal culture", "TEST", 166, 179], ["dogs", "PROBLEM", 204, 208], ["diarrhea", "PROBLEM", 223, 231], ["nosocomial", "PROBLEM", 276, 286], ["infectious", "PROBLEM", 303, 313], ["fever", "PROBLEM", 321, 326], ["leukocytosis", "PROBLEM", 328, 340], ["neutrophilic fecal cytology", "TEST", 342, 369], ["a specific infectious agent", "PROBLEM", 404, 431], ["Salmonella spp.", "PROBLEM", 439, 454], ["C. jejuni", "PROBLEM", 456, 465], ["verotoxin", "PROBLEM", 467, 476], ["positive E. coli", "PROBLEM", 477, 493], ["difficile", "OBSERVATION", 30, 39], ["Fecal", "ANATOMY", 166, 171], ["bowel", "ANATOMY", 250, 255], ["appears to be", "UNCERTAINTY", 262, 275], ["nosocomial", "OBSERVATION", 276, 286], ["potentially", "UNCERTAINTY", 291, 302], ["infectious", "OBSERVATION_MODIFIER", 303, 313], ["neutrophilic", "OBSERVATION_MODIFIER", 342, 354], ["E. coli", "OBSERVATION_MODIFIER", 486, 493]]], ["Nonculture techniques looking at DNA are probably more useful but are generally limited to research laboratories.FECAL CULTUREDisadvantages \u2022 The clinician must specify which pathogen(s) to culture for and must provide the laboratory with fresh feces or feces submitted in appropriate transport media.", [["feces", "ANATOMY", 245, 250], ["DNA", "CELLULAR_COMPONENT", 33, 36], ["feces", "ORGANISM_SUBSTANCE", 245, 250], ["feces", "ORGANISM_SUBSTANCE", 254, 259], ["Nonculture techniques", "TEST", 0, 21], ["culture", "TEST", 190, 197]]], ["Testing requires a microbiology laboratory familiar with the specific enrichment and isolation techniques for each pathogen.", [["a microbiology laboratory", "TEST", 17, 42], ["isolation techniques", "TREATMENT", 85, 105], ["each pathogen", "PROBLEM", 110, 123]]], ["Using culture swabs is not adequate for isolation of most enteric pathogens.", [["culture swabs", "ANATOMY", 6, 19], ["culture swabs", "TEST", 6, 19], ["most enteric pathogens", "PROBLEM", 53, 75], ["most enteric", "OBSERVATION_MODIFIER", 53, 65], ["pathogens", "OBSERVATION", 66, 75]]], ["Finally, growing a \"pathogen\" does not mean that it is responsible for clinical signs.FECAL CULTUREAnalysis \u2022 Fresh feces must be promptly submitted to the laboratory, and the laboratory must know the specific pathogen(s) sought.", [["feces", "ANATOMY", 116, 121], ["feces", "ORGANISM_SUBSTANCE", 116, 121], ["clinical signs", "TEST", 71, 85], ["FECAL CULTUREAnalysis", "TEST", 86, 107], ["Fresh feces", "PROBLEM", 110, 121]]], ["To submit old feces or feces that have not been collected or handled properly or to request a \"general culture for pathogens\" is generally a waste of time and money.", [["feces", "ANATOMY", 14, 19], ["feces", "ANATOMY", 23, 28], ["feces", "ORGANISM_SUBSTANCE", 14, 19], ["feces", "ORGANISM_SUBSTANCE", 23, 28], ["old feces or feces", "PROBLEM", 10, 28], ["a \"general culture", "TEST", 92, 110], ["pathogens", "PROBLEM", 115, 124], ["feces", "OBSERVATION", 14, 19], ["feces", "OBSERVATION", 23, 28]]], ["It requires laboratories that are properly equipped to culture for enteric pathogens.", [["laboratories", "TEST", 12, 24], ["culture", "TEST", 55, 62], ["enteric pathogens", "PROBLEM", 67, 84]]], ["Culture for C. perfringens is not helpful diagnostically.FECAL CULTUREInterpretation \u2022 Any clinically normal animal may have any of the pathogens listed earlier cultured from its feces, although Y. enterocolitica is particularly uncommon in the United States.", [["feces", "ANATOMY", 179, 184], ["C. perfringens", "DISEASE", 12, 26], ["Y. enterocolitica", "DISEASE", 195, 212], ["C. perfringens", "ORGANISM", 12, 26], ["feces", "ORGANISM_SUBDIVISION", 179, 184], ["Y. enterocolitica", "ORGANISM", 195, 212], ["C. perfringens", "SPECIES", 12, 26], ["Y. enterocolitica", "SPECIES", 195, 212], ["C. perfringens", "SPECIES", 12, 26], ["Y. enterocolitica", "SPECIES", 195, 212], ["Culture", "TEST", 0, 7], ["C. perfringens", "PROBLEM", 12, 26], ["FECAL CULTUREInterpretation", "TEST", 57, 84], ["the pathogens", "PROBLEM", 132, 145], ["enterocolitica", "OBSERVATION", 198, 212]]], ["Interpretation of the fecal culture must consider the history, physical examination, laboratory data, and sometimes numbers of organisms (i.e., number of bacterial colony-forming units per gram of feces) found.FECAL FATRare Indications \u2022 Fecal fat testing may be used to detect malabsorption or maldigestion in animals with diarrhea or unexplained weight loss.FECAL FATAdvantages (Semiqualitative Analysis) \u2022 Fecal fat has minimal expense, availability, and reasonable accuracy as a screening test.FECAL FATInterpretation \u2022 Fecal WBCs (specifically neutrophils) can be observed with bacterial (e.g., salmonellosis, campylobacteriosis) and inflammatory mucosal disease.", [["colony", "ANATOMY", 164, 170], ["Fecal fat", "ANATOMY", 238, 247], ["Fecal fat", "ANATOMY", 409, 418], ["Fecal WBCs", "ANATOMY", 524, 534], ["neutrophils", "ANATOMY", 549, 560], ["mucosal", "ANATOMY", 652, 659], ["malabsorption", "DISEASE", 278, 291], ["maldigestion", "DISEASE", 295, 307], ["diarrhea", "DISEASE", 324, 332], ["weight loss", "DISEASE", 348, 359], ["salmonellosis", "DISEASE", 600, 613], ["campylobacteriosis", "DISEASE", 615, 633], ["mucosal disease", "DISEASE", 652, 667], ["feces", "ORGANISM_SUBDIVISION", 197, 202], ["Fecal WBCs", "CELL", 524, 534], ["neutrophils", "CELL", 549, 560], ["mucosal", "ORGAN", 652, 659], ["Fecal WBCs", "CELL_TYPE", 524, 534], ["neutrophils", "CELL_TYPE", 549, 560], ["the fecal culture", "TEST", 18, 35], ["physical examination", "TEST", 63, 83], ["laboratory data", "TEST", 85, 100], ["organisms", "PROBLEM", 127, 136], ["bacterial colony", "TEST", 154, 170], ["Fecal fat testing", "TEST", 238, 255], ["malabsorption", "PROBLEM", 278, 291], ["maldigestion in animals", "PROBLEM", 295, 318], ["diarrhea", "PROBLEM", 324, 332], ["unexplained weight loss", "PROBLEM", 336, 359], ["FECAL FATAdvantages (Semiqualitative Analysis", "TEST", 360, 405], ["a screening test", "TEST", 481, 497], ["FECAL FATInterpretation", "TEST", 498, 521], ["Fecal WBCs", "TEST", 524, 534], ["neutrophils", "TEST", 549, 560], ["bacterial (e.g.", "PROBLEM", 583, 598], ["salmonellosis", "PROBLEM", 600, 613], ["campylobacteriosis", "PROBLEM", 615, 633], ["inflammatory mucosal disease", "PROBLEM", 639, 667], ["fecal", "ANATOMY", 22, 27], ["Fecal fat", "ANATOMY", 409, 418], ["Fecal WBCs", "OBSERVATION", 524, 534], ["salmonellosis", "OBSERVATION", 600, 613], ["campylobacteriosis", "OBSERVATION", 615, 633], ["inflammatory", "OBSERVATION_MODIFIER", 639, 651], ["mucosal disease", "OBSERVATION", 652, 667]]], ["Transmural colitides occasionally have increased fecal WBCs.", [["fecal WBCs", "ANATOMY", 49, 59], ["WBCs", "CELL", 55, 59], ["fecal WBCs", "CELL_TYPE", 49, 59], ["Transmural colitides", "PROBLEM", 0, 20], ["increased fecal WBCs", "PROBLEM", 39, 59], ["increased", "OBSERVATION_MODIFIER", 39, 48], ["fecal WBCs", "OBSERVATION", 49, 59]]], ["Fecal WBCs can be an indication to biopsy colonic mucosa in patients with chronic colitis.", [["Fecal WBCs", "ANATOMY", 0, 10], ["biopsy colonic mucosa", "ANATOMY", 35, 56], ["chronic colitis", "DISEASE", 74, 89], ["Fecal WBCs", "ORGANISM_SUBSTANCE", 0, 10], ["biopsy colonic mucosa", "MULTI-TISSUE_STRUCTURE", 35, 56], ["patients", "ORGANISM", 60, 68], ["Fecal WBCs", "CELL_TYPE", 0, 10], ["patients", "SPECIES", 60, 68], ["Fecal WBCs", "TEST", 0, 10], ["biopsy colonic mucosa", "PROBLEM", 35, 56], ["chronic colitis", "PROBLEM", 74, 89], ["WBCs", "OBSERVATION", 6, 10], ["colonic mucosa", "ANATOMY", 42, 56], ["chronic", "OBSERVATION_MODIFIER", 74, 81], ["colitis", "OBSERVATION", 82, 89]]], ["Eosinophils may sometimes be seen with allergic or parasitic colitis.", [["Eosinophils", "ANATOMY", 0, 11], ["allergic or parasitic colitis", "DISEASE", 39, 68], ["Eosinophils", "CELL", 0, 11], ["colitis", "PATHOLOGICAL_FORMATION", 61, 68], ["Eosinophils", "CELL_TYPE", 0, 11], ["Eosinophils", "TEST", 0, 11], ["allergic", "PROBLEM", 39, 47], ["parasitic colitis", "PROBLEM", 51, 68], ["sometimes be seen with", "UNCERTAINTY", 16, 38], ["allergic", "OBSERVATION", 39, 47], ["parasitic colitis", "OBSERVATION", 51, 68]]], ["Increased numbers of yeast or a uniform population of bacteria may help identify the cause of diarrhea in a patient, but the mere presence of an organism (e.g., Cyniclomyces guttulatus [ Figure 9 -5]) does not ensure that it is causing disease.FECAL OCCULT BLOODRare Indications \u2022 A fecal occult blood test may be used to detect GI bleeding that is not grossly apparent.Disadvantages \u2022 See Artifacts.Analysis \u2022 Fresh feces are smeared on a test pad.", [["fecal", "ANATOMY", 283, 288], ["blood", "ANATOMY", 296, 301], ["GI", "ANATOMY", 329, 331], ["feces", "ANATOMY", 417, 422], ["diarrhea", "DISEASE", 94, 102], ["GI bleeding", "DISEASE", 329, 340], ["patient", "ORGANISM", 108, 115], ["Cyniclomyces guttulatus", "ORGANISM", 161, 184], ["fecal", "ORGANISM_SUBSTANCE", 283, 288], ["blood", "ORGANISM_SUBSTANCE", 296, 301], ["GI", "ORGANISM_SUBDIVISION", 329, 331], ["feces", "ORGANISM_SUBSTANCE", 417, 422], ["yeast", "SPECIES", 21, 26], ["patient", "SPECIES", 108, 115], ["Cyniclomyces guttulatus", "SPECIES", 161, 184], ["yeast", "SPECIES", 21, 26], ["Cyniclomyces guttulatus", "SPECIES", 161, 184], ["Increased numbers of yeast", "PROBLEM", 0, 26], ["a uniform population of bacteria", "PROBLEM", 30, 62], ["diarrhea", "PROBLEM", 94, 102], ["an organism", "PROBLEM", 142, 153], ["Cyniclomyces", "TEST", 161, 173], ["disease", "PROBLEM", 236, 243], ["FECAL OCCULT BLOODRare Indications", "PROBLEM", 244, 278], ["A fecal occult blood test", "TEST", 281, 306], ["GI bleeding", "PROBLEM", 329, 340], ["Analysis", "TEST", 400, 408], ["Fresh feces", "PROBLEM", 411, 422], ["a test pad", "TEST", 438, 448], ["numbers", "OBSERVATION_MODIFIER", 10, 17], ["yeast", "OBSERVATION", 21, 26], ["uniform", "OBSERVATION_MODIFIER", 32, 39], ["population", "OBSERVATION_MODIFIER", 40, 50], ["bacteria", "OBSERVATION", 54, 62], ["diarrhea", "OBSERVATION", 94, 102], ["organism", "OBSERVATION", 145, 153], ["OCCULT BLOODRare", "OBSERVATION", 250, 266], ["bleeding", "OBSERVATION", 332, 340], ["Fresh feces", "OBSERVATION", 411, 422]]], ["The patient must have been on a meat-free diet for at least 3 days before the feces are obtained.", [["feces", "ANATOMY", 78, 83], ["patient", "ORGANISM", 4, 11], ["meat", "ORGANISM_SUBDIVISION", 32, 36], ["feces", "ORGANISM_SUBSTANCE", 78, 83], ["patient", "SPECIES", 4, 11], ["a meat-free diet", "TREATMENT", 30, 46]]], ["Sensitivity varies markedly between different assays.Normal Values \u2022 See Artifacts.Artifacts \u2022 Fecal occult blood results may be falsely decreased by sampling unmixed feces (blood may not be distributed homogeneously throughout the feces) and vitamin C supplementation.", [["Fecal", "ANATOMY", 95, 100], ["blood", "ANATOMY", 108, 113], ["feces", "ANATOMY", 167, 172], ["blood", "ANATOMY", 174, 179], ["feces", "ANATOMY", 232, 237], ["vitamin C", "CHEMICAL", 243, 252], ["vitamin C", "CHEMICAL", 243, 252], ["Fecal", "ORGANISM_SUBSTANCE", 95, 100], ["blood", "ORGANISM_SUBSTANCE", 108, 113], ["feces", "ORGANISM_SUBSTANCE", 167, 172], ["blood", "ORGANISM_SUBSTANCE", 174, 179], ["feces", "ORGANISM_SUBDIVISION", 232, 237], ["vitamin C", "SIMPLE_CHEMICAL", 243, 252], ["Sensitivity", "TEST", 0, 11], ["Artifacts", "TEST", 83, 92], ["Fecal occult blood", "TEST", 95, 113], ["sampling unmixed feces", "PROBLEM", 150, 172], ["vitamin C supplementation", "TREATMENT", 243, 268], ["may be", "UNCERTAINTY", 122, 128], ["falsely", "OBSERVATION_MODIFIER", 129, 136], ["decreased", "OBSERVATION_MODIFIER", 137, 146]]], ["Results may be falsely increased by diets containing fresh meats (i.e., hemoglobin) or fresh uncooked vegetables (i.e., peroxidases), which cause a positive reaction.Normal Values \u2022 See Artifacts.Causes of Fecal Occult Blood \u2022 Bleeding into the GI tract at any level and as the result of any cause may result in fecal occult blood.", [["meats", "ANATOMY", 59, 64], ["vegetables", "ANATOMY", 102, 112], ["Blood", "ANATOMY", 219, 224], ["GI tract", "ANATOMY", 245, 253], ["fecal occult blood", "ANATOMY", 312, 330], ["Bleeding", "DISEASE", 227, 235], ["fecal occult blood", "DISEASE", 312, 330], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 72, 82], ["vegetables", "ORGANISM_SUBDIVISION", 102, 112], ["peroxidases", "GENE_OR_GENE_PRODUCT", 120, 131], ["Fecal", "ORGANISM_SUBSTANCE", 206, 211], ["Blood", "ORGANISM_SUBSTANCE", 219, 224], ["GI tract", "ORGANISM_SUBDIVISION", 245, 253], ["fecal", "ORGANISM_SUBSTANCE", 312, 317], ["blood", "ORGANISM_SUBSTANCE", 325, 330], ["hemoglobin", "PROTEIN", 72, 82], ["hemoglobin", "TEST", 72, 82], ["fresh uncooked vegetables", "PROBLEM", 87, 112], ["a positive reaction", "PROBLEM", 146, 165], ["Fecal Occult Blood", "PROBLEM", 206, 224], ["Bleeding into the GI tract", "PROBLEM", 227, 253], ["fecal occult blood", "PROBLEM", 312, 330], ["increased", "OBSERVATION_MODIFIER", 23, 32], ["positive reaction", "OBSERVATION", 148, 165], ["Fecal", "ANATOMY", 206, 211], ["Bleeding", "OBSERVATION", 227, 235], ["GI tract", "ANATOMY", 245, 253]]], ["GI blood loss of resists GI degradation and hence can be measured in the feces.Normal Values \u2022 See Artifacts.Disadvantages \u2022 The test has limited availability.", [["blood", "ANATOMY", 3, 8], ["feces", "ANATOMY", 73, 78], ["blood loss", "DISEASE", 3, 13], ["blood", "ORGANISM_SUBSTANCE", 3, 8], ["GI", "ORGANISM_SUBDIVISION", 25, 27], ["feces", "ORGANISM_SUBDIVISION", 73, 78], ["GI blood loss", "PROBLEM", 0, 13], ["resists GI degradation", "PROBLEM", 17, 39], ["blood loss", "OBSERVATION", 3, 13], ["GI degradation", "OBSERVATION", 25, 39]]], ["The magnitude of alpha-1 protease inhibitor in the feces is variable and may not reflect the severity of the disease.Normal Values \u2022 See Artifacts.Analysis \u2022 Three 1-g fecal samples from three different bowel movements are submitted in tubes provided by the laboratory.", [["feces", "ANATOMY", 51, 56], ["fecal samples", "ANATOMY", 168, 181], ["bowel", "ANATOMY", 203, 208], ["alpha-1 protease", "GENE_OR_GENE_PRODUCT", 17, 33], ["feces", "ORGANISM_SUBSTANCE", 51, 56], ["bowel", "ORGAN", 203, 208], ["alpha-1 protease", "PROTEIN", 17, 33], ["alpha-1 protease inhibitor", "TREATMENT", 17, 43], ["the disease", "PROBLEM", 105, 116], ["Analysis", "TEST", 147, 155], ["magnitude", "OBSERVATION_MODIFIER", 4, 13], ["feces", "ANATOMY", 51, 56], ["may not reflect", "UNCERTAINTY", 73, 88], ["disease", "OBSERVATION", 109, 116], ["bowel", "ANATOMY", 203, 208], ["movements", "OBSERVATION", 209, 218]]], ["It is critically important that three samples (preferably from different days or at least different bowel movements) be submitted, that the feces be collected promptly after defecation, and that the feces not be collected by digitally removing them from the rectum.", [["samples", "ANATOMY", 38, 45], ["bowel", "ANATOMY", 100, 105], ["feces", "ANATOMY", 140, 145], ["feces", "ANATOMY", 199, 204], ["rectum", "ANATOMY", 258, 264], ["bowel", "ORGAN", 100, 105], ["feces", "ORGANISM", 140, 145], ["feces", "ORGANISM", 199, 204], ["rectum", "ORGAN", 258, 264], ["defecation", "PROBLEM", 174, 184], ["the feces", "PROBLEM", 195, 204], ["rectum", "ANATOMY", 258, 264]]], ["Samples must be frozen while one awaits shipping and must be shipped on a cold pack.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["a cold pack", "TREATMENT", 72, 83]]], ["Currently the only laboratory offering this test is GI Laboratory, College of Veterinary Medicine, Texas A&M University, College Station, TX 77843-4474.Normal Values \u2022 See Artifacts.Normal Values \u2022 0.23 to 5.67 \u00b5g/g feces.", [["TX 77843-4474", "CHEMICAL", 138, 151], ["feces", "ORGANISM_SUBSTANCE", 216, 221], ["TX", "TEST", 138, 140]]], ["The clinician must look at individual values and the mean of all three values.Normal Values \u2022 See Artifacts.Causes of Abnormalities \u2022 Abnormally high values in the feces indicate loss of serum proteins into the alimentary tract and might indicate that PLE is the cause of hypoalbuminemia.", [["feces", "ANATOMY", 164, 169], ["serum", "ANATOMY", 187, 192], ["alimentary tract", "ANATOMY", 211, 227], ["PLE", "DISEASE", 252, 255], ["hypoalbuminemia", "DISEASE", 272, 287], ["feces", "ORGANISM_SUBSTANCE", 164, 169], ["serum", "ORGANISM_SUBSTANCE", 187, 192], ["alimentary tract", "ORGAN", 211, 227], ["serum proteins", "PROTEIN", 187, 201], ["Abnormalities", "PROBLEM", 118, 131], ["Abnormally high values in the feces", "PROBLEM", 134, 169], ["loss of serum proteins into the alimentary tract", "PROBLEM", 179, 227], ["hypoalbuminemia", "PROBLEM", 272, 287], ["Abnormalities", "OBSERVATION", 118, 131], ["Abnormally", "OBSERVATION_MODIFIER", 134, 144], ["high values", "OBSERVATION_MODIFIER", 145, 156], ["loss", "OBSERVATION", 179, 183], ["alimentary tract", "ANATOMY", 211, 227], ["PLE", "OBSERVATION", 252, 255], ["hypoalbuminemia", "OBSERVATION", 272, 287]]], ["Interpretation of the magnitude of the loss is as per the laboratory.FECAL MICROSCOPIC CYTOLOGYRare Indications \u2022 Fecal microscopic cytology is rarely indicated in cases of large or small intestinal diarrhea.FECAL MICROSCOPIC CYTOLOGYAdvantages \u2022 The test is widely available and easy to perform.FECAL MICROSCOPIC CYTOLOGYDisadvantages \u2022 The test has poor sensitivity and variable specificity for different agents.FECAL MICROSCOPIC CYTOLOGYAnalysis \u2022 Thin, air-dried, fresh fecal smears are stained with new methylene blue (NMB) or Wright stain and examined using high-power and oil immersion microscopy.", [["intestinal", "ANATOMY", 188, 198], ["fecal smears", "ANATOMY", 474, 486], ["intestinal diarrhea", "DISEASE", 188, 207], ["methylene blue", "CHEMICAL", 508, 522], ["methylene blue", "CHEMICAL", 508, 522], ["NMB", "CHEMICAL", 524, 527], ["intestinal", "ORGAN", 188, 198], ["fecal smears", "ORGANISM_SUBSTANCE", 474, 486], ["methylene blue", "SIMPLE_CHEMICAL", 508, 522], ["NMB", "SIMPLE_CHEMICAL", 524, 527], ["the loss", "PROBLEM", 35, 43], ["Fecal microscopic cytology", "TEST", 114, 140], ["large or small intestinal diarrhea", "PROBLEM", 173, 207], ["FECAL MICROSCOPIC CYTOLOGYAdvantages", "TEST", 208, 244], ["The test", "TEST", 338, 346], ["poor sensitivity", "PROBLEM", 351, 367], ["different agents", "TREATMENT", 397, 413], ["FECAL MICROSCOPIC CYTOLOGYAnalysis", "TEST", 414, 448], ["fresh fecal smears", "TEST", 468, 486], ["new methylene blue", "PROBLEM", 504, 522], ["Wright stain", "TEST", 532, 544], ["oil immersion microscopy", "TEST", 579, 603], ["magnitude", "OBSERVATION_MODIFIER", 22, 31], ["loss", "OBSERVATION", 39, 43], ["large", "OBSERVATION_MODIFIER", 173, 178], ["small", "OBSERVATION_MODIFIER", 182, 187], ["intestinal", "ANATOMY", 188, 198], ["diarrhea", "OBSERVATION", 199, 207], ["MICROSCOPIC CYTOLOGYDisadvantages", "OBSERVATION", 302, 335], ["fecal", "ANATOMY", 474, 479], ["smears", "OBSERVATION", 480, 486]]], ["Rectal and colonic mucosal scrapings obtained with a curette are also a means of examining mucosal cells.SERUM COBALAMIN AND SERUM FOLATEOccasional Indications \u2022 Chronic small bowel diarrhea, unexplained weight loss, or uncertain but suspected small intestinal disease are occasional indications for serum cobalamin and folate testing.", [["Rectal", "ANATOMY", 0, 6], ["colonic mucosal", "ANATOMY", 11, 26], ["mucosal cells", "ANATOMY", 91, 104], ["bowel", "ANATOMY", 176, 181], ["intestinal", "ANATOMY", 250, 260], ["serum", "ANATOMY", 300, 305], ["small bowel diarrhea", "DISEASE", 170, 190], ["weight loss", "DISEASE", 204, 215], ["intestinal disease", "DISEASE", 250, 268], ["cobalamin", "CHEMICAL", 306, 315], ["folate", "CHEMICAL", 320, 326], ["cobalamin", "CHEMICAL", 306, 315], ["folate", "CHEMICAL", 320, 326], ["Rectal", "MULTI-TISSUE_STRUCTURE", 0, 6], ["colonic mucosal scrapings", "TISSUE", 11, 36], ["mucosal cells", "CELL", 91, 104], ["bowel", "ORGAN", 176, 181], ["intestinal", "ORGAN", 250, 260], ["serum", "ORGANISM_SUBSTANCE", 300, 305], ["cobalamin", "SIMPLE_CHEMICAL", 306, 315], ["folate", "SIMPLE_CHEMICAL", 320, 326], ["mucosal cells", "CELL_TYPE", 91, 104], ["Rectal and colonic mucosal scrapings", "TEST", 0, 36], ["a curette", "TREATMENT", 51, 60], ["SERUM COBALAMIN", "TEST", 105, 120], ["SERUM FOLATEOccasional Indications", "TREATMENT", 125, 159], ["Chronic small bowel diarrhea", "PROBLEM", 162, 190], ["unexplained weight loss", "PROBLEM", 192, 215], ["small intestinal disease", "PROBLEM", 244, 268], ["serum cobalamin", "TEST", 300, 315], ["folate testing", "TEST", 320, 334], ["colonic mucosal", "ANATOMY", 11, 26], ["scrapings", "OBSERVATION", 27, 36], ["mucosal cells", "OBSERVATION", 91, 104], ["Chronic", "OBSERVATION_MODIFIER", 162, 169], ["small", "OBSERVATION_MODIFIER", 170, 175], ["bowel", "ANATOMY", 176, 181], ["diarrhea", "OBSERVATION", 182, 190], ["weight loss", "OBSERVATION", 204, 215], ["small", "OBSERVATION_MODIFIER", 244, 249], ["intestinal", "ANATOMY", 250, 260], ["disease", "OBSERVATION", 261, 268]]], ["These tests are more important in the cat than in the dog.", [["cat", "ORGANISM", 38, 41], ["dog", "ORGANISM", 54, 57], ["dog", "SPECIES", 54, 57], ["These tests", "TEST", 0, 11]]], ["Causes of Decreased Serum Cobalamin Concentrations \u2022 The major reasons for decreased serum cobalamin concentrations in dogs and cats are ileal disease or resection (rare), EPI, intestinal mucosal disease, and ARE (\"dysbiosis\").", [["Serum", "ANATOMY", 20, 25], ["serum", "ANATOMY", 85, 90], ["ileal", "ANATOMY", 137, 142], ["intestinal mucosal", "ANATOMY", 177, 195], ["Cobalamin", "CHEMICAL", 26, 35], ["cobalamin", "CHEMICAL", 91, 100], ["ileal disease", "DISEASE", 137, 150], ["intestinal mucosal disease", "DISEASE", 177, 203], ["Cobalamin", "CHEMICAL", 26, 35], ["cobalamin", "CHEMICAL", 91, 100], ["Serum", "ORGANISM_SUBSTANCE", 20, 25], ["Cobalamin", "SIMPLE_CHEMICAL", 26, 35], ["serum", "ORGANISM_SUBSTANCE", 85, 90], ["cobalamin", "SIMPLE_CHEMICAL", 91, 100], ["dogs", "ORGANISM", 119, 123], ["cats", "ORGANISM", 128, 132], ["ileal", "MULTI-TISSUE_STRUCTURE", 137, 142], ["intestinal mucosal", "MULTI-TISSUE_STRUCTURE", 177, 195], ["dogs", "SPECIES", 119, 123], ["cats", "SPECIES", 128, 132], ["Decreased Serum Cobalamin Concentrations", "PROBLEM", 10, 50], ["decreased serum cobalamin concentrations in dogs", "PROBLEM", 75, 123], ["ileal disease", "PROBLEM", 137, 150], ["resection", "TREATMENT", 154, 163], ["EPI", "TREATMENT", 172, 175], ["intestinal mucosal disease", "PROBLEM", 177, 203], ["Decreased", "OBSERVATION_MODIFIER", 10, 19], ["Serum Cobalamin", "OBSERVATION", 20, 35], ["ileal", "ANATOMY", 137, 142], ["disease", "OBSERVATION", 143, 150], ["resection", "OBSERVATION", 154, 163], ["intestinal mucosal", "ANATOMY", 177, 195], ["disease", "OBSERVATION", 196, 203]]], ["In cats, hepatic disease and hyperthyroidism might cause hypocobalaminemia.", [["hepatic", "ANATOMY", 9, 16], ["hepatic disease", "DISEASE", 9, 24], ["hyperthyroidism", "DISEASE", 29, 44], ["hypocobalaminemia", "DISEASE", 57, 74], ["cats", "ORGANISM", 3, 7], ["hepatic", "ORGAN", 9, 16], ["cats", "SPECIES", 3, 7], ["hepatic disease", "PROBLEM", 9, 24], ["hyperthyroidism", "PROBLEM", 29, 44], ["hypocobalaminemia", "PROBLEM", 57, 74], ["hepatic", "ANATOMY", 9, 16], ["disease", "OBSERVATION", 17, 24], ["hyperthyroidism", "OBSERVATION", 29, 44], ["might cause", "UNCERTAINTY", 45, 56], ["hypocobalaminemia", "OBSERVATION", 57, 74]]], ["The major differentiation to be made is among EPI and intestinal disease; therefore decreased serum cobalamin is an indication to measure serum TLI.", [["intestinal", "ANATOMY", 54, 64], ["serum", "ANATOMY", 94, 99], ["serum", "ANATOMY", 138, 143], ["intestinal disease", "DISEASE", 54, 72], ["cobalamin", "CHEMICAL", 100, 109], ["cobalamin", "CHEMICAL", 100, 109], ["EPI", "SIMPLE_CHEMICAL", 46, 49], ["intestinal", "ORGAN", 54, 64], ["serum", "ORGANISM_SUBSTANCE", 94, 99], ["cobalamin", "SIMPLE_CHEMICAL", 100, 109], ["serum", "ORGANISM_SUBSTANCE", 138, 143], ["EPI", "TREATMENT", 46, 49], ["intestinal disease", "PROBLEM", 54, 72], ["decreased serum cobalamin", "PROBLEM", 84, 109], ["serum TLI", "TEST", 138, 147], ["intestinal", "ANATOMY", 54, 64], ["disease", "OBSERVATION", 65, 72]]], ["Not all dogs with EPI, mucosal disease, or ARE have decreased serum cobalamin.", [["mucosal", "ANATOMY", 23, 30], ["serum", "ANATOMY", 62, 67], ["mucosal disease", "DISEASE", 23, 38], ["cobalamin", "CHEMICAL", 68, 77], ["cobalamin", "CHEMICAL", 68, 77], ["dogs", "ORGANISM", 8, 12], ["mucosal", "MULTI-TISSUE_STRUCTURE", 23, 30], ["serum", "ORGANISM_SUBSTANCE", 62, 67], ["cobalamin", "SIMPLE_CHEMICAL", 68, 77], ["serum cobalamin", "PROTEIN", 62, 77], ["dogs", "SPECIES", 8, 12], ["EPI", "TREATMENT", 18, 21], ["mucosal disease", "PROBLEM", 23, 38], ["decreased serum cobalamin", "PROBLEM", 52, 77], ["mucosal", "ANATOMY", 23, 30], ["disease", "OBSERVATION", 31, 38]]], ["Cats with EPI, severe small intestinal disease (e.g., lymphoma, IBD), and some hepatic diseases (e.g., idiopathic hepatic lipidosis) can have very low cobalamin concentrations.", [["intestinal", "ANATOMY", 28, 38], ["lymphoma", "ANATOMY", 54, 62], ["hepatic", "ANATOMY", 79, 86], ["hepatic", "ANATOMY", 114, 121], ["intestinal disease", "DISEASE", 28, 46], ["lymphoma", "DISEASE", 54, 62], ["IBD", "DISEASE", 64, 67], ["hepatic diseases", "DISEASE", 79, 95], ["idiopathic hepatic lipidosis", "DISEASE", 103, 131], ["cobalamin", "CHEMICAL", 151, 160], ["cobalamin", "CHEMICAL", 151, 160], ["intestinal", "ORGAN", 28, 38], ["lymphoma", "CANCER", 54, 62], ["hepatic", "ORGAN", 79, 86], ["hepatic", "ORGAN", 114, 121], ["cobalamin", "SIMPLE_CHEMICAL", 151, 160], ["EPI", "TREATMENT", 10, 13], ["severe small intestinal disease", "PROBLEM", 15, 46], ["lymphoma", "PROBLEM", 54, 62], ["IBD", "PROBLEM", 64, 67], ["some hepatic diseases", "PROBLEM", 74, 95], ["idiopathic hepatic lipidosis", "PROBLEM", 103, 131], ["very low cobalamin concentrations", "PROBLEM", 142, 175], ["severe", "OBSERVATION_MODIFIER", 15, 21], ["small", "OBSERVATION_MODIFIER", 22, 27], ["intestinal", "ANATOMY", 28, 38], ["disease", "OBSERVATION", 39, 46], ["lymphoma", "OBSERVATION", 54, 62], ["hepatic", "ANATOMY", 79, 86], ["diseases", "OBSERVATION", 87, 95], ["idiopathic", "OBSERVATION_MODIFIER", 103, 113], ["hepatic", "ANATOMY", 114, 121], ["lipidosis", "OBSERVATION", 122, 131], ["low", "OBSERVATION_MODIFIER", 147, 150], ["cobalamin concentrations", "OBSERVATION", 151, 175]]], ["Finding a significantly decreased serum cobalamin concentration can be an indication of small intestinal disease in animals that were previously not suspected to have such disease.Advantages \u2022Causes of Increased Serum Cobalamin Concentrations \u2022 Cobalamin concentration may be increased by cobalamin supplementation.Advantages \u2022volumes of 2 ml blood/30 kg body weight will give positive results.FAT ABSORPTION TESTRare Indications \u2022 A fat absorption test may be used to detect and distinguish maldigestion from malabsorption in chronic small intestinal diarrhea or unexplained weight loss.", [["serum", "ANATOMY", 34, 39], ["intestinal", "ANATOMY", 94, 104], ["Serum", "ANATOMY", 212, 217], ["blood", "ANATOMY", 343, 348], ["body", "ANATOMY", 355, 359], ["fat", "ANATOMY", 434, 437], ["intestinal", "ANATOMY", 541, 551], ["cobalamin", "CHEMICAL", 40, 49], ["intestinal disease", "DISEASE", 94, 112], ["Cobalamin", "CHEMICAL", 218, 227], ["Cobalamin", "CHEMICAL", 245, 254], ["cobalamin", "CHEMICAL", 289, 298], ["maldigestion", "DISEASE", 492, 504], ["malabsorption", "DISEASE", 510, 523], ["diarrhea", "DISEASE", 552, 560], ["weight loss", "DISEASE", 576, 587], ["cobalamin", "CHEMICAL", 40, 49], ["Cobalamin", "CHEMICAL", 218, 227], ["Cobalamin", "CHEMICAL", 245, 254], ["cobalamin", "CHEMICAL", 289, 298], ["serum", "ORGANISM_SUBSTANCE", 34, 39], ["cobalamin", "SIMPLE_CHEMICAL", 40, 49], ["intestinal", "ORGAN", 94, 104], ["Serum", "ORGANISM_SUBSTANCE", 212, 217], ["Cobalamin", "SIMPLE_CHEMICAL", 218, 227], ["Cobalamin", "SIMPLE_CHEMICAL", 245, 254], ["cobalamin", "SIMPLE_CHEMICAL", 289, 298], ["blood", "ORGANISM_SUBSTANCE", 343, 348], ["body", "ORGANISM_SUBDIVISION", 355, 359], ["fat", "TISSUE", 434, 437], ["intestinal", "ORGAN", 541, 551], ["a significantly decreased serum cobalamin concentration", "PROBLEM", 8, 63], ["small intestinal disease", "PROBLEM", 88, 112], ["such disease", "PROBLEM", 167, 179], ["Increased Serum Cobalamin Concentrations", "TREATMENT", 202, 242], ["Cobalamin concentration", "TREATMENT", 245, 268], ["cobalamin supplementation", "TREATMENT", 289, 314], ["body weight", "TEST", 355, 366], ["A fat absorption test", "TEST", 432, 453], ["maldigestion", "PROBLEM", 492, 504], ["malabsorption", "PROBLEM", 510, 523], ["chronic small intestinal diarrhea", "PROBLEM", 527, 560], ["unexplained weight loss", "PROBLEM", 564, 587], ["significantly", "OBSERVATION_MODIFIER", 10, 23], ["decreased", "OBSERVATION_MODIFIER", 24, 33], ["indication of", "UNCERTAINTY", 74, 87], ["small", "OBSERVATION_MODIFIER", 88, 93], ["intestinal", "ANATOMY", 94, 104], ["disease", "OBSERVATION", 105, 112], ["Increased", "OBSERVATION_MODIFIER", 202, 211], ["chronic", "OBSERVATION_MODIFIER", 527, 534], ["small", "OBSERVATION_MODIFIER", 535, 540], ["intestinal", "ANATOMY", 541, 551], ["diarrhea", "OBSERVATION", 552, 560], ["weight loss", "OBSERVATION", 576, 587]]], ["The test has many false-negative and false-positive results and is not recommended.FAT ABSORPTION TESTAnalysis \u2022 The test is described in prior editions.", [["The test", "TEST", 0, 8]]], ["Artifacts \u2022 Theoretically, EPI caused by an obstructed pancreatic duct instead of acinar cell atrophy would yield a normal or even increased serum TLI value.TRYPSIN-LIKE IMMUNOREACTIVITYDrug Therapy That May Alter TLI \u2022 Drugs causing acute pancreatitis (see Box 9-3) might increase serum TLI.", [["pancreatic duct", "ANATOMY", 55, 70], ["acinar cell", "ANATOMY", 82, 93], ["serum", "ANATOMY", 141, 146], ["serum", "ANATOMY", 282, 287], ["pancreatitis", "DISEASE", 240, 252], ["pancreatic duct", "MULTI-TISSUE_STRUCTURE", 55, 70], ["acinar cell", "CELL", 82, 93], ["serum", "ORGANISM_SUBSTANCE", 141, 146], ["serum", "ORGANISM_SUBSTANCE", 282, 287], ["Artifacts", "PROBLEM", 0, 9], ["EPI", "TREATMENT", 27, 30], ["an obstructed pancreatic duct", "PROBLEM", 41, 70], ["acinar cell atrophy", "PROBLEM", 82, 101], ["increased serum TLI value", "PROBLEM", 131, 156], ["TRYPSIN-LIKE IMMUNOREACTIVITYDrug Therapy", "TREATMENT", 157, 198], ["acute pancreatitis", "PROBLEM", 234, 252], ["increase serum TLI", "PROBLEM", 273, 291], ["obstructed", "OBSERVATION", 44, 54], ["pancreatic duct", "ANATOMY", 55, 70], ["acinar cell atrophy", "OBSERVATION", 82, 101], ["normal", "OBSERVATION", 116, 122], ["increased", "OBSERVATION_MODIFIER", 131, 140], ["serum TLI", "OBSERVATION_MODIFIER", 141, 150], ["acute", "OBSERVATION_MODIFIER", 234, 239], ["pancreatitis", "OBSERVATION", 240, 252], ["increase", "OBSERVATION_MODIFIER", 273, 281], ["serum TLI", "OBSERVATION_MODIFIER", 282, 291]]], ["Oral pancreatic enzyme supplementation does not affect serum TLI concentrations.TRYPSIN-LIKE IMMUNOREACTIVITYCauses of Decreased TLI \u2022 TLI is the test of choice for EPI.", [["pancreatic", "ANATOMY", 5, 15], ["serum", "ANATOMY", 55, 60], ["pancreatic", "ORGAN", 5, 15], ["serum", "ORGANISM_SUBSTANCE", 55, 60], ["TLI", "SIMPLE_CHEMICAL", 61, 64], ["Oral pancreatic enzyme supplementation", "TREATMENT", 0, 38], ["serum TLI concentrations", "PROBLEM", 55, 79], ["EPI", "TREATMENT", 165, 168], ["pancreatic", "ANATOMY", 5, 15], ["Decreased", "OBSERVATION_MODIFIER", 119, 128], ["TLI", "OBSERVATION", 129, 132]]], ["A serum TLI concentration less than 2.5 \u00b5g/L (dog) or 8 \u00b5g/L (cat) is generally considered diagnostic for EPI.", [["serum", "ANATOMY", 2, 7], ["serum", "ORGANISM_SUBSTANCE", 2, 7], ["dog", "ORGANISM", 46, 49], ["cat", "ORGANISM", 62, 65], ["A serum TLI concentration", "TEST", 0, 25], ["EPI", "TREATMENT", 106, 109]]], ["Subclinical canine EPI may be suspected by finding intermediate values (>2.5 \u00b5g/L and <5.0 \u00b5g/L).", [["canine", "ORGANISM", 12, 18], ["canine", "SPECIES", 12, 18], ["Subclinical canine EPI", "TREATMENT", 0, 22]]], ["In such cases repeated testing should be performed.", [["repeated testing", "TEST", 14, 30]]], ["Some dogs will later develop EPI, whereas others will not.TRYPSIN-LIKE IMMUNOREACTIVITYCauses of Increased TLI \u2022 Values greater than 50 \u00b5g/L in dogs and greater than 100 \u00b5g/L in cats may occur with pancreatitis (the spec PL is better than TLI for this purpose in dogs and cats), renal failure, prerenal azotemia (may increase two times), and malnutrition.", [["renal", "ANATOMY", 279, 284], ["pancreatitis", "DISEASE", 198, 210], ["renal failure", "DISEASE", 279, 292], ["azotemia", "DISEASE", 303, 311], ["malnutrition", "DISEASE", 342, 354], ["dogs", "ORGANISM", 5, 9], ["dogs", "ORGANISM", 144, 148], ["cats", "ORGANISM", 178, 182], ["dogs", "ORGANISM", 263, 267], ["cats", "ORGANISM", 272, 276], ["renal", "ORGAN", 279, 284], ["dogs", "SPECIES", 5, 9], ["dogs", "SPECIES", 144, 148], ["cats", "SPECIES", 178, 182], ["dogs", "SPECIES", 263, 267], ["cats", "SPECIES", 272, 276], ["Some dogs", "PROBLEM", 0, 9], ["EPI", "TREATMENT", 29, 32], ["Increased TLI", "PROBLEM", 97, 110], ["Values", "TEST", 113, 119], ["pancreatitis", "PROBLEM", 198, 210], ["the spec PL", "TEST", 212, 223], ["renal failure", "PROBLEM", 279, 292], ["prerenal azotemia", "PROBLEM", 294, 311], ["malnutrition", "PROBLEM", 342, 354], ["Increased", "OBSERVATION_MODIFIER", 97, 106], ["TLI", "OBSERVATION", 107, 110], ["pancreatitis", "OBSERVATION", 198, 210], ["renal", "ANATOMY", 279, 284], ["failure", "OBSERVATION", 285, 292], ["prerenal azotemia", "OBSERVATION", 294, 311], ["malnutrition", "OBSERVATION", 342, 354]]], ["An increased fTLI test is potentially consistent with pancreatitis.", [["pancreatitis", "DISEASE", 54, 66], ["fTLI", "DNA", 13, 17], ["An increased fTLI test", "TEST", 0, 22], ["pancreatitis", "PROBLEM", 54, 66], ["increased", "OBSERVATION_MODIFIER", 3, 12], ["fTLI", "OBSERVATION", 13, 17], ["potentially consistent with", "UNCERTAINTY", 26, 53], ["pancreatitis", "OBSERVATION", 54, 66]]], ["In dogs, TLI seems to increase early in pancreatitis but then quickly returns to reference ranges.FECAL SMEAR (WET MOUNT) FOR PARASITESCommon Indications \u2022 A fecal smear is used to screen for parasites and parasitic ova; it is indicated in any patient with diarrhea, melena, hematochezia, fecal mucus, weight loss, or vomiting.FECAL SMEAR (WET MOUNT) FOR PARASITESAdvantages \u2022 The test is widely available, easy to perform, and inexpensive.FECAL SMEAR (WET MOUNT) FOR PARASITESDisadvantages \u2022 A fecal smear requires fresh feces, and is insensitive compared with concentration and molecular techniques.FECAL SMEAR (WET MOUNT) FOR PARASITESAnalysis \u2022 A thin smear is made of very fresh (<5 minutes old) feces, mixed with a drop of saline solution or water and coverslipped to prevent dehydration.", [["fecal smear", "ANATOMY", 158, 169], ["ova", "ANATOMY", 216, 219], ["fecal mucus", "ANATOMY", 289, 300], ["fecal smear", "ANATOMY", 495, 506], ["feces", "ANATOMY", 522, 527], ["pancreatitis", "DISEASE", 40, 52], ["parasitic ova", "DISEASE", 206, 219], ["diarrhea", "DISEASE", 257, 265], ["melena", "DISEASE", 267, 273], ["hematochezia", "DISEASE", 275, 287], ["fecal mucus", "DISEASE", 289, 300], ["weight loss", "DISEASE", 302, 313], ["vomiting", "DISEASE", 318, 326], ["dehydration", "DISEASE", 782, 793], ["dogs", "ORGANISM", 3, 7], ["ova", "ORGAN", 216, 219], ["patient", "ORGANISM", 244, 251], ["melena", "PATHOLOGICAL_FORMATION", 267, 273], ["feces", "ORGANISM_SUBSTANCE", 522, 527], ["feces", "ORGANISM", 701, 706], ["saline", "SIMPLE_CHEMICAL", 729, 735], ["dogs", "SPECIES", 3, 7], ["patient", "SPECIES", 244, 251], ["pancreatitis", "PROBLEM", 40, 52], ["FECAL SMEAR", "TEST", 98, 109], ["A fecal smear", "TEST", 156, 169], ["parasites", "PROBLEM", 192, 201], ["parasitic ova", "PROBLEM", 206, 219], ["diarrhea", "PROBLEM", 257, 265], ["melena", "PROBLEM", 267, 273], ["hematochezia", "PROBLEM", 275, 287], ["fecal mucus", "PROBLEM", 289, 300], ["weight loss", "PROBLEM", 302, 313], ["vomiting", "PROBLEM", 318, 326], ["FECAL SMEAR", "TEST", 327, 338], ["FECAL SMEAR", "TEST", 440, 451], ["PARASITESDisadvantages", "TEST", 468, 490], ["A fecal smear", "TEST", 493, 506], ["FECAL SMEAR", "TEST", 601, 612], ["PARASITESAnalysis", "TEST", 629, 646], ["A thin smear", "TEST", 649, 661], ["a drop of saline solution", "TREATMENT", 719, 744], ["dehydration", "PROBLEM", 782, 793], ["TLI", "ANATOMY", 9, 12], ["increase", "OBSERVATION_MODIFIER", 22, 30], ["early", "OBSERVATION_MODIFIER", 31, 36], ["pancreatitis", "OBSERVATION", 40, 52], ["fecal", "ANATOMY", 158, 163], ["hematochezia", "OBSERVATION", 275, 287], ["fecal", "ANATOMY", 289, 294], ["SMEAR", "OBSERVATION", 446, 451], ["fecal", "ANATOMY", 495, 500], ["fresh feces", "OBSERVATION", 516, 527], ["dehydration", "OBSERVATION", 782, 793]]], ["If protozoa are visible and better cytologic detail is desired, a drop of Lugol's iodine or Dobell and O'Connor's iodine may be placed at the corner of the coverslip.FECAL SMEAR (WET MOUNT) FOR PARASITESCauses of Decreased Serum Folate \u2022 Severe mucosal disease of the proximal small intestine decreases serum folate.", [["Serum", "ANATOMY", 223, 228], ["mucosal", "ANATOMY", 245, 252], ["proximal small intestine", "ANATOMY", 268, 292], ["serum", "ANATOMY", 303, 308], ["Lugol's iodine", "CHEMICAL", 74, 88], ["iodine", "CHEMICAL", 114, 120], ["Folate", "CHEMICAL", 229, 235], ["folate", "CHEMICAL", 309, 315], ["Lugol", "CHEMICAL", 74, 79], ["iodine", "CHEMICAL", 82, 88], ["Dobell", "CHEMICAL", 92, 98], ["O", "CHEMICAL", 103, 104], ["iodine", "CHEMICAL", 114, 120], ["Folate", "CHEMICAL", 229, 235], ["folate", "CHEMICAL", 309, 315], ["Lugol", "SIMPLE_CHEMICAL", 74, 79], ["iodine", "SIMPLE_CHEMICAL", 82, 88], ["Dobell", "SIMPLE_CHEMICAL", 92, 98], ["iodine", "SIMPLE_CHEMICAL", 114, 120], ["Serum", "ORGANISM_SUBSTANCE", 223, 228], ["Folate", "SIMPLE_CHEMICAL", 229, 235], ["mucosal", "MULTI-TISSUE_STRUCTURE", 245, 252], ["small intestine", "ORGAN", 277, 292], ["serum", "ORGANISM_SUBSTANCE", 303, 308], ["folate", "SIMPLE_CHEMICAL", 309, 315], ["protozoa", "PROBLEM", 3, 11], ["Lugol's iodine", "TREATMENT", 74, 88], ["Dobell", "TREATMENT", 92, 98], ["Connor's iodine", "TREATMENT", 105, 120], ["FECAL SMEAR", "TEST", 166, 177], ["PARASITESCauses", "TEST", 194, 209], ["Decreased Serum Folate", "PROBLEM", 213, 235], ["Severe mucosal disease of the proximal small intestine", "PROBLEM", 238, 292], ["serum folate", "TEST", 303, 315], ["corner", "ANATOMY_MODIFIER", 142, 148], ["mucosal", "ANATOMY", 245, 252], ["disease", "OBSERVATION", 253, 260], ["proximal", "ANATOMY_MODIFIER", 268, 276], ["small intestine", "ANATOMY", 277, 292], ["decreases", "OBSERVATION_MODIFIER", 293, 302], ["serum folate", "OBSERVATION", 303, 315]]], ["Not all patients with such disease have decreased folate levels.FECAL SMEAR (WET MOUNT) FOR PARASITESCauses of Increased Serum Folate \u2022 ARE, EPI, and dietary supplementation are probably the major causes.", [["Serum", "ANATOMY", 121, 126], ["folate", "CHEMICAL", 50, 56], ["Folate", "CHEMICAL", 127, 133], ["folate", "CHEMICAL", 50, 56], ["Folate", "CHEMICAL", 127, 133], ["patients", "ORGANISM", 8, 16], ["folate", "SIMPLE_CHEMICAL", 50, 56], ["Serum", "ORGANISM_SUBSTANCE", 121, 126], ["Folate", "SIMPLE_CHEMICAL", 127, 133], ["EPI", "SIMPLE_CHEMICAL", 141, 144], ["patients", "SPECIES", 8, 16], ["such disease", "PROBLEM", 22, 34], ["decreased folate levels", "PROBLEM", 40, 63], ["FECAL SMEAR", "TEST", 64, 75], ["PARASITESCauses", "TEST", 92, 107], ["Increased Serum Folate \u2022 ARE", "TREATMENT", 111, 139], ["EPI", "TREATMENT", 141, 144], ["dietary supplementation", "TREATMENT", 150, 173], ["Increased", "OBSERVATION_MODIFIER", 111, 120], ["Serum Folate", "OBSERVATION", 121, 133]]], ["Many patients with these diseases do not have increased folate levels.", [["folate", "CHEMICAL", 56, 62], ["folate", "CHEMICAL", 56, 62], ["patients", "ORGANISM", 5, 13], ["folate", "SIMPLE_CHEMICAL", 56, 62], ["patients", "SPECIES", 5, 13], ["these diseases", "PROBLEM", 19, 33], ["increased folate levels", "PROBLEM", 46, 69]]], ["The combination of low cobalamin plus increased folate is consistent with ARE, but is insensitive and nonspecific.C-REACTIVE PROTEIN (CRP)Occasional Indications \u2022 CRP has been used in one formula for determining a Canine IBD Activity Index (CIBDAI).Advantages \u2022 The test is very sensitive for detecting inflammation.Disadvantages \u2022 The test will detect inflammation almost anywhere in the body; it is nonspecific as far as type or location or cause.Advantages \u2022 The test is very sensitive for detecting inflammation.Analysis \u2022 CRP is measured on a sample of refrigerated or frozen fasting serum.Advantages \u2022 The test is very sensitive for detecting inflammation.Normal Values \u2022 Less than 7.6 mg/L.Artifacts \u2022 None known.Drug Therapy That May Alter C-Reactive Protein \u2022 Unknown.Artifacts \u2022 None known.Interpretation \u2022 Any inflammation almost anywhere in the body can increase the CRP.", [["body", "ANATOMY", 389, 393], ["serum", "ANATOMY", 589, 594], ["body", "ANATOMY", 857, 861], ["cobalamin", "CHEMICAL", 23, 32], ["folate", "CHEMICAL", 48, 54], ["inflammation", "DISEASE", 303, 315], ["inflammation", "DISEASE", 353, 365], ["inflammation", "DISEASE", 503, 515], ["inflammation", "DISEASE", 649, 661], ["inflammation", "DISEASE", 821, 833], ["cobalamin", "CHEMICAL", 23, 32], ["folate", "CHEMICAL", 48, 54], ["cobalamin", "SIMPLE_CHEMICAL", 23, 32], ["folate", "SIMPLE_CHEMICAL", 48, 54], ["CRP", "GENE_OR_GENE_PRODUCT", 163, 166], ["body", "ORGANISM_SUBDIVISION", 389, 393], ["CRP", "GENE_OR_GENE_PRODUCT", 527, 530], ["serum", "ORGANISM_SUBSTANCE", 589, 594], ["body", "ORGANISM_SUBDIVISION", 857, 861], ["CRP", "GENE_OR_GENE_PRODUCT", 879, 882], ["ARE", "DNA", 74, 77], ["CRP", "PROTEIN", 134, 137], ["CRP", "PROTEIN", 163, 166], ["CRP", "PROTEIN", 527, 530], ["May Alter C-Reactive Protein", "PROTEIN", 738, 766], ["CRP", "PROTEIN", 879, 882], ["Canine", "SPECIES", 214, 220], ["low cobalamin plus increased folate", "PROBLEM", 19, 54], ["CRP", "TEST", 134, 137], ["CRP", "TEST", 163, 166], ["The test", "TEST", 262, 270], ["inflammation", "PROBLEM", 303, 315], ["The test", "TEST", 332, 340], ["inflammation", "PROBLEM", 353, 365], ["The test", "TEST", 462, 470], ["inflammation", "PROBLEM", 503, 515], ["Analysis", "TEST", 516, 524], ["CRP", "TEST", 527, 530], ["a sample", "TEST", 546, 554], ["frozen fasting serum", "TEST", 574, 594], ["The test", "TEST", 608, 616], ["inflammation", "PROBLEM", 649, 661], ["Drug Therapy", "TREATMENT", 720, 732], ["Reactive Protein", "TEST", 750, 766], ["Any inflammation", "PROBLEM", 817, 833], ["the CRP", "TEST", 875, 882], ["low cobalamin", "OBSERVATION", 19, 32], ["increased folate", "OBSERVATION", 38, 54], ["consistent with", "UNCERTAINTY", 58, 73], ["nonspecific", "OBSERVATION_MODIFIER", 102, 113], ["REACTIVE PROTEIN", "OBSERVATION", 116, 132], ["inflammation", "OBSERVATION", 303, 315], ["inflammation", "OBSERVATION", 353, 365], ["body", "ANATOMY", 389, 393], ["nonspecific", "OBSERVATION_MODIFIER", 401, 412], ["inflammation", "OBSERVATION", 503, 515], ["inflammation", "OBSERVATION", 649, 661], ["Reactive Protein", "OBSERVATION", 750, 766], ["inflammation", "OBSERVATION", 821, 833], ["body", "ANATOMY", 857, 861], ["CRP", "OBSERVATION_MODIFIER", 879, 882]]], ["The greatest utility in measuring CRP is to see what change occurs in a given patient after therapy (i.e., whether therapy is associated with an increase or decrease in CRP).", [["CRP", "GENE_OR_GENE_PRODUCT", 34, 37], ["patient", "ORGANISM", 78, 85], ["CRP", "GENE_OR_GENE_PRODUCT", 169, 172], ["CRP", "PROTEIN", 34, 37], ["CRP", "PROTEIN", 169, 172], ["patient", "SPECIES", 78, 85], ["measuring CRP", "TEST", 24, 37], ["therapy", "TREATMENT", 92, 99], ["therapy", "TREATMENT", 115, 122], ["CRP", "TEST", 169, 172], ["greatest", "OBSERVATION_MODIFIER", 4, 12], ["increase", "OBSERVATION_MODIFIER", 145, 153], ["decrease", "OBSERVATION_MODIFIER", 157, 165]]], ["Changes in the CRP can reveal resolving or worsening inflammation, even if all values are normal.HYDROGEN BREATH TESTRare Indications \u2022 The hydrogen breath test is rarely indicated in cases of chronic small bowel diarrhea or unexplained weight loss.", [["bowel", "ANATOMY", 207, 212], ["inflammation", "DISEASE", 53, 65], ["hydrogen", "CHEMICAL", 140, 148], ["diarrhea", "DISEASE", 213, 221], ["weight loss", "DISEASE", 237, 248], ["hydrogen", "CHEMICAL", 140, 148], ["CRP", "GENE_OR_GENE_PRODUCT", 15, 18], ["hydrogen", "SIMPLE_CHEMICAL", 140, 148], ["bowel", "ORGAN", 207, 212], ["CRP", "PROTEIN", 15, 18], ["the CRP", "TEST", 11, 18], ["worsening inflammation", "PROBLEM", 43, 65], ["The hydrogen breath test", "TEST", 136, 160], ["chronic small bowel diarrhea", "PROBLEM", 193, 221], ["unexplained weight loss", "PROBLEM", 225, 248], ["resolving", "OBSERVATION_MODIFIER", 30, 39], ["worsening", "OBSERVATION_MODIFIER", 43, 52], ["inflammation", "OBSERVATION", 53, 65], ["normal", "OBSERVATION", 90, 96], ["chronic", "OBSERVATION_MODIFIER", 193, 200], ["small", "OBSERVATION_MODIFIER", 201, 206], ["bowel", "ANATOMY", 207, 212], ["diarrhea", "OBSERVATION", 213, 221], ["weight loss", "OBSERVATION", 237, 248]]], ["The test detects hydrogen production as a by-product of bacterial fermentation of carbohydrates.", [["hydrogen", "CHEMICAL", 17, 25], ["hydrogen", "CHEMICAL", 17, 25], ["carbohydrates", "CHEMICAL", 82, 95], ["hydrogen", "SIMPLE_CHEMICAL", 17, 25], ["carbohydrates", "SIMPLE_CHEMICAL", 82, 95], ["The test", "TEST", 0, 8], ["bacterial fermentation of carbohydrates", "TREATMENT", 56, 95], ["hydrogen production", "OBSERVATION", 17, 36], ["bacterial fermentation", "OBSERVATION", 56, 78]]], ["Increase in hydrogen production indicates ARE or carbohydrate malabsorption.", [["hydrogen", "CHEMICAL", 12, 20], ["carbohydrate malabsorption", "DISEASE", 49, 75], ["hydrogen", "CHEMICAL", 12, 20], ["carbohydrate", "CHEMICAL", 49, 61], ["hydrogen", "SIMPLE_CHEMICAL", 12, 20], ["carbohydrate", "SIMPLE_CHEMICAL", 49, 61], ["Increase in hydrogen production", "PROBLEM", 0, 31], ["carbohydrate malabsorption", "PROBLEM", 49, 75], ["hydrogen production", "OBSERVATION", 12, 31]]], ["The clinician should contact the laboratory for specifics.HYDROGEN BREATH TESTInterpretation \u2022 Carbohydrate malabsorption and ARE may increase expired hydrogen.", [["Carbohydrate malabsorption", "DISEASE", 95, 121], ["hydrogen", "CHEMICAL", 151, 159], ["hydrogen", "CHEMICAL", 151, 159], ["hydrogen", "SIMPLE_CHEMICAL", 151, 159], ["ARE", "DNA", 126, 129], ["HYDROGEN BREATH TESTInterpretation", "TREATMENT", 58, 92], ["Carbohydrate malabsorption", "PROBLEM", 95, 121]]], ["The only source of hydrogen is bacterial fermentation of carbohydrates.", [["hydrogen", "CHEMICAL", 19, 27], ["hydrogen", "CHEMICAL", 19, 27], ["carbohydrates", "CHEMICAL", 57, 70], ["hydrogen", "SIMPLE_CHEMICAL", 19, 27], ["carbohydrates", "SIMPLE_CHEMICAL", 57, 70], ["bacterial fermentation", "OBSERVATION", 31, 53]]], ["The sensitivity and specificity of this test for ARE in dogs are unknown.HYDROGEN BREATH TESTNOTE: Iodine kills protozoa, thus stopping motility.Normal Values \u2022 No parasites or ova.Artifacts \u2022 Cooling of the slide or dehydration inhibits the motility of protozoa.Normal Values \u2022 No parasites or ova.Drug Therapy That May Alter Results \u2022 Orally administered compounds containing kaolin, pectin, barium sulfate, bismuth, and other intestinally active compounds (e.g., cathartics, enemas) may make it difficult to find and identify parasites, ova, and cysts.Normal Values \u2022 No parasites or ova.Parasites, Bacteria, and Ova That May Be Identified \u2022 Giardia spp.", [["ova", "ANATOMY", 177, 180], ["ova", "ANATOMY", 295, 298], ["ova", "ANATOMY", 540, 543], ["cysts", "ANATOMY", 549, 554], ["ova", "ANATOMY", 587, 590], ["Iodine", "CHEMICAL", 99, 105], ["dehydration", "DISEASE", 217, 228], ["kaolin, pectin, barium sulfate", "CHEMICAL", 378, 408], ["bismuth", "CHEMICAL", 410, 417], ["Iodine", "CHEMICAL", 99, 105], ["kaolin", "CHEMICAL", 378, 384], ["barium sulfate", "CHEMICAL", 394, 408], ["bismuth", "CHEMICAL", 410, 417], ["dogs", "ORGANISM", 56, 60], ["Iodine", "SIMPLE_CHEMICAL", 99, 105], ["ova", "ORGANISM_SUBSTANCE", 177, 180], ["ova", "ORGANISM_SUBSTANCE", 295, 298], ["kaolin", "SIMPLE_CHEMICAL", 378, 384], ["pectin", "SIMPLE_CHEMICAL", 386, 392], ["barium sulfate", "SIMPLE_CHEMICAL", 394, 408], ["bismuth", "SIMPLE_CHEMICAL", 410, 417], ["cysts", "PATHOLOGICAL_FORMATION", 549, 554], ["ova", "ORGANISM_SUBSTANCE", 587, 590], ["Parasites", "CELL", 591, 600], ["Giardia spp", "ORGANISM", 645, 656], ["ARE", "DNA", 49, 52], ["dogs", "SPECIES", 56, 60], ["The sensitivity", "TEST", 0, 15], ["this test", "TEST", 35, 44], ["Iodine kills protozoa", "TREATMENT", 99, 120], ["parasites", "PROBLEM", 164, 173], ["ova", "PROBLEM", 177, 180], ["Artifacts", "PROBLEM", 181, 190], ["the slide", "TREATMENT", 204, 213], ["dehydration", "PROBLEM", 217, 228], ["protozoa", "PROBLEM", 254, 262], ["parasites", "PROBLEM", 282, 291], ["ova", "PROBLEM", 295, 298], ["Drug Therapy", "TREATMENT", 299, 311], ["Orally administered compounds", "TREATMENT", 337, 366], ["kaolin", "TREATMENT", 378, 384], ["pectin", "TREATMENT", 386, 392], ["barium sulfate", "TREATMENT", 394, 408], ["bismuth", "TREATMENT", 410, 417], ["other intestinally active compounds", "TREATMENT", 423, 458], ["cathartics", "TREATMENT", 466, 476], ["enemas", "TREATMENT", 478, 484], ["parasites", "PROBLEM", 529, 538], ["ova", "PROBLEM", 540, 543], ["cysts", "PROBLEM", 549, 554], ["parasites", "PROBLEM", 574, 583], ["ova", "PROBLEM", 587, 590], ["Parasites", "PROBLEM", 591, 600], ["Bacteria", "PROBLEM", 602, 610], ["Ova", "PROBLEM", 616, 619], ["Giardia spp", "PROBLEM", 645, 656], ["No", "UNCERTAINTY", 161, 163], ["parasites", "OBSERVATION", 164, 173], ["ova", "OBSERVATION", 177, 180], ["No", "UNCERTAINTY", 279, 281], ["parasites", "OBSERVATION", 282, 291], ["ova", "OBSERVATION", 295, 298], ["parasites", "OBSERVATION", 529, 538], ["cysts", "OBSERVATION", 549, 554], ["No", "UNCERTAINTY", 571, 573], ["parasites", "OBSERVATION", 574, 583], ["ova", "OBSERVATION", 587, 590], ["Bacteria", "OBSERVATION", 602, 610], ["Giardia spp", "OBSERVATION", 645, 656]]], ["(Figure 9 -6A), Tritrichomonas spp. (see Figure 9 -6A), Entamoeba histolytica, Balantidium coli, Strongyloides stercoralis (Figure 9 -6B), and Aelurostrongylus abstrusus may be detected.", [["Entamoeba histolytica", "DISEASE", 56, 77], ["Strongyloides stercoralis", "DISEASE", 97, 122], ["Tritrichomonas spp.", "ORGANISM", 16, 35], ["Entamoeba histolytica", "ORGANISM", 56, 77], ["Balantidium coli", "ORGANISM", 79, 95], ["Strongyloides stercoralis", "ORGANISM", 97, 122], ["Figure 9 -6B", "ORGANISM", 124, 136], ["Aelurostrongylus abstrusus", "ORGANISM", 143, 169], ["Tritrichomonas spp.", "SPECIES", 16, 35], ["Entamoeba histolytica", "SPECIES", 56, 77], ["Balantidium coli", "SPECIES", 79, 95], ["Strongyloides stercoralis", "SPECIES", 97, 122], ["Aelurostrongylus abstrusus", "SPECIES", 143, 169], ["Tritrichomonas spp.", "SPECIES", 16, 35], ["Entamoeba histolytica", "SPECIES", 56, 77], ["Balantidium coli", "SPECIES", 79, 95], ["Strongyloides stercoralis (Figure 9 -6B", "SPECIES", 97, 136], ["Aelurostrongylus abstrusus", "SPECIES", 143, 169], ["Tritrichomonas spp.", "PROBLEM", 16, 35], ["Entamoeba histolytica", "PROBLEM", 56, 77], ["Balantidium coli", "PROBLEM", 79, 95], ["Strongyloides stercoralis", "PROBLEM", 97, 122], ["Aelurostrongylus abstrusus", "PROBLEM", 143, 169], ["Strongyloides stercoralis", "OBSERVATION", 97, 122]]], ["Any ova may be found, but this test may be useful for detecting Spirocerca lupi and Trichuris vulpis ova.", [["ova", "ANATOMY", 4, 7], ["ova", "ORGANISM_SUBSTANCE", 4, 7], ["Spirocerca lupi", "ORGANISM", 64, 79], ["Trichuris vulpis ova", "ORGANISM", 84, 104], ["Spirocerca lupi", "SPECIES", 64, 79], ["Trichuris vulpis", "SPECIES", 84, 100], ["Spirocerca lupi", "SPECIES", 64, 79], ["Trichuris vulpis", "SPECIES", 84, 100], ["Any ova", "PROBLEM", 0, 7], ["this test", "TEST", 26, 35], ["Spirocerca lupi", "TREATMENT", 64, 79], ["Trichuris vulpis", "OBSERVATION", 84, 100]]], ["With oil immersion, small motile bacterial spirochetes in conjunction with fecal WBCs suggest Campylobacter spp. as a possible cause.FECAL FLOTATIONCommon Indications \u2022 Indications for a fecal flotation test are as for a fecal smear.FECAL FLOTATIONAdvantages \u2022 The test has reasonable sensitivity, high specificity, availability, and low cost.FECAL FLOTATIONAnalysis \u2022 Feces are well mixed with either a saturated sugar solution or a zinc sulfate solution (prepared by mixing 331 g ZnSO 4 \u2022 7 H 2 O in 1 L water to attain a specific gravity of 1.18 to 1.20 [as determined with a hydrometer]).", [["oil", "ANATOMY", 5, 8], ["spirochetes", "ANATOMY", 43, 54], ["fecal WBCs", "ANATOMY", 75, 85], ["fecal", "ANATOMY", 187, 192], ["fecal smear", "ANATOMY", 221, 232], ["Campylobacter spp.", "DISEASE", 94, 112], ["zinc sulfate", "CHEMICAL", 434, 446], ["sugar", "CHEMICAL", 414, 419], ["zinc sulfate", "CHEMICAL", 434, 446], ["ZnSO", "CHEMICAL", 482, 486], ["H 2 O", "CHEMICAL", 493, 498], ["oil", "ORGANISM_SUBSTANCE", 5, 8], ["WBCs", "CELL", 81, 85], ["Campylobacter spp.", "ORGANISM", 94, 112], ["fecal", "ORGANISM_SUBSTANCE", 187, 192], ["sugar", "SIMPLE_CHEMICAL", 414, 419], ["zinc sulfate", "SIMPLE_CHEMICAL", 434, 446], ["fecal WBCs", "CELL_TYPE", 75, 85], ["Campylobacter spp.", "SPECIES", 94, 112], ["Campylobacter spp.", "SPECIES", 94, 112], ["oil immersion", "TREATMENT", 5, 18], ["small motile bacterial spirochetes", "PROBLEM", 20, 54], ["fecal WBCs", "TEST", 75, 85], ["Campylobacter spp.", "PROBLEM", 94, 112], ["a fecal flotation test", "TEST", 185, 207], ["a fecal smear", "TEST", 219, 232], ["The test", "TEST", 261, 269], ["FECAL FLOTATIONAnalysis", "TEST", 343, 366], ["a saturated sugar solution", "TREATMENT", 402, 428], ["a zinc sulfate solution", "TREATMENT", 432, 455], ["ZnSO", "TREATMENT", 482, 486], ["a specific gravity", "TEST", 522, 540], ["small", "OBSERVATION_MODIFIER", 20, 25], ["motile", "OBSERVATION_MODIFIER", 26, 32], ["bacterial spirochetes", "OBSERVATION", 33, 54], ["fecal", "ANATOMY", 75, 80], ["Campylobacter spp.", "OBSERVATION", 94, 112], ["possible", "UNCERTAINTY", 118, 126]]], ["This is the best fecal flotation technique for to 2 hours.", [["fecal", "ANATOMY", 17, 22], ["fecal", "ORGANISM_SUBSTANCE", 17, 22]]], ["The sediment is then examined microscopically.", [["sediment", "OBSERVATION", 4, 12]]], ["When formalin and ethyl acetate are used, the strained feces are centrifuged, the pellet is resuspended in 9 ml of 5% formalin solution, 3 ml ethyl acetate is added, and the mixture is shaken vigorously.", [["feces", "ANATOMY", 55, 60], ["formalin and ethyl acetate", "CHEMICAL", 5, 31], ["formalin", "CHEMICAL", 118, 126], ["ethyl acetate", "CHEMICAL", 142, 155], ["formalin", "CHEMICAL", 5, 13], ["ethyl acetate", "CHEMICAL", 18, 31], ["formalin", "CHEMICAL", 118, 126], ["ethyl acetate", "CHEMICAL", 142, 155], ["formalin", "SIMPLE_CHEMICAL", 5, 13], ["ethyl acetate", "SIMPLE_CHEMICAL", 18, 31], ["feces", "ORGANISM", 55, 60], ["formalin", "SIMPLE_CHEMICAL", 118, 126], ["ethyl acetate", "SIMPLE_CHEMICAL", 142, 155], ["formalin and ethyl acetate", "TREATMENT", 5, 31], ["the strained feces", "TREATMENT", 42, 60], ["5% formalin solution", "TREATMENT", 115, 135], ["3 ml ethyl acetate", "TREATMENT", 137, 155]]], ["This is recentrifuged, the debris at the formalin and ethyl acetate interface is discarded, and the sediment is then examined.Normal Values \u2022 No ova.Artifacts \u2022 Same as discussed in the previous section on Fecal Flotation.Normal Values \u2022 No ova.Parasite Ova That May Be Identified \u2022 Fecal sedimentation may detect all the ova that may be found by fecal flotation, plus Alaria canis, Nanophyetus salmincola, and Heterobilharzia americana (Figure 9-7) .Normal Values \u2022 No ova.Giardia spp. because it does not distort the cysts.", [["Fecal", "ANATOMY", 283, 288], ["ova", "ANATOMY", 322, 325], ["fecal", "ANATOMY", 347, 352], ["cysts", "ANATOMY", 519, 524], ["formalin and ethyl acetate", "CHEMICAL", 41, 67], ["formalin", "CHEMICAL", 41, 49], ["ethyl acetate", "CHEMICAL", 54, 67], ["formalin", "SIMPLE_CHEMICAL", 41, 49], ["ethyl acetate", "SIMPLE_CHEMICAL", 54, 67], ["Fecal", "ORGANISM_SUBSTANCE", 283, 288], ["fecal", "ORGANISM_SUBSTANCE", 347, 352], ["Alaria canis", "ORGANISM", 369, 381], ["Nanophyetus salmincola", "ORGANISM", 383, 405], ["Heterobilharzia americana", "ORGANISM", 411, 436], ["Giardia spp.", "ORGANISM", 474, 486], ["cysts", "PATHOLOGICAL_FORMATION", 519, 524], ["Alaria canis", "SPECIES", 369, 381], ["Nanophyetus salmincola", "SPECIES", 383, 405], ["Heterobilharzia americana", "SPECIES", 411, 436], ["Giardia spp.", "SPECIES", 474, 486], ["Alaria canis", "SPECIES", 369, 381], ["Nanophyetus salmincola", "SPECIES", 383, 405], ["Heterobilharzia americana", "SPECIES", 411, 436], ["Giardia spp.", "SPECIES", 474, 486], ["the debris", "PROBLEM", 23, 33], ["ethyl acetate interface", "TREATMENT", 54, 77], ["ova", "PROBLEM", 145, 148], ["Artifacts", "PROBLEM", 149, 158], ["Fecal Flotation", "TREATMENT", 206, 221], ["ova", "PROBLEM", 241, 244], ["Parasite Ova", "TREATMENT", 245, 257], ["Fecal sedimentation", "PROBLEM", 283, 302], ["all the ova", "PROBLEM", 314, 325], ["fecal flotation", "TEST", 347, 362], ["Alaria canis", "PROBLEM", 369, 381], ["Nanophyetus salmincola", "TREATMENT", 383, 405], ["ova", "PROBLEM", 470, 473], ["Giardia spp.", "PROBLEM", 474, 486], ["the cysts", "PROBLEM", 515, 524], ["debris", "OBSERVATION", 27, 33], ["sediment", "OBSERVATION", 100, 108], ["No", "UNCERTAINTY", 142, 144], ["ova", "OBSERVATION", 145, 148], ["Fecal", "ANATOMY", 206, 211], ["No", "UNCERTAINTY", 238, 240], ["ova", "OBSERVATION", 241, 244], ["May Be", "UNCERTAINTY", 263, 269], ["Fecal sedimentation", "OBSERVATION", 283, 302], ["ova", "OBSERVATION", 322, 325], ["fecal", "ANATOMY", 347, 352], ["flotation", "OBSERVATION", 353, 362], ["No", "UNCERTAINTY", 467, 469], ["ova", "OBSERVATION", 470, 473], ["cysts", "OBSERVATION", 519, 524]]], ["Ova and cysts are allowed to rise to the surface and are retrieved with a coverslip.", [["cysts", "ANATOMY", 8, 13], ["surface", "ANATOMY", 41, 48], ["Ova", "ORGANISM_SUBSTANCE", 0, 3], ["cysts", "CANCER", 8, 13], ["surface", "CELLULAR_COMPONENT", 41, 48], ["Ova", "PROBLEM", 0, 3], ["cysts", "PROBLEM", 8, 13], ["a coverslip", "TREATMENT", 72, 83], ["cysts", "OBSERVATION", 8, 13], ["surface", "OBSERVATION_MODIFIER", 41, 48]]], ["Samples for Giardia detection should be examined within 15 minutes to avoid distortion and lysis of cysts.", [["Samples", "ANATOMY", 0, 7], ["cysts", "ANATOMY", 100, 105], ["cysts", "DISEASE", 100, 105], ["cysts", "PATHOLOGICAL_FORMATION", 100, 105], ["Samples", "TEST", 0, 7], ["Giardia detection", "TEST", 12, 29], ["distortion", "PROBLEM", 76, 86], ["lysis of cysts", "PROBLEM", 91, 105], ["lysis", "OBSERVATION_MODIFIER", 91, 96], ["cysts", "OBSERVATION", 100, 105]]], ["Centrifugation of the sample increases the sensitivity of the procedure.", [["sample", "ANATOMY", 22, 28], ["the procedure", "TREATMENT", 58, 71]]], ["Samples that will be sent to an outside laboratory for analysis may be refrigerated (not frozen) for 1 to 2 days or preserved by mixing 1 part feces with 3 parts sodium acetate-acetic acid-formalin (prepared by mixing 1.5 g sodium acetate + 2 ml glacial acetic acid + 4 ml 40% formaldehyde solution + 92.5 ml water).Normal Values \u2022 No ova or oocysts present.Artifacts \u2022 Diarrhea may decrease ova concentration within a sample.Normal Values \u2022 No ova or oocysts present.Parasite Ova and Cysts That May Be Identified \u2022 Ancylostoma spp., Toxocara spp., Toxascaris leonina, Trichuris vulpis, Spirocerca lupi, Physaloptera rara (using dichromate solution), Capillaria aerophilia, Capillaria plica, Onciolo canis, Dioctophyme renale, Isospora spp., Giardia spp., Toxoplasma gondii, Cryptosporidium spp., Paragonimus kellicotti, and some tapeworms may be detected.FECAL SEDIMENTATIONRare Indications \u2022 Indications for fecal sedimentation testing are the same as for fecal smear and flotation, especially if flukes are being considered.", [["ova", "ANATOMY", 335, 338], ["ova", "ANATOMY", 392, 395], ["ova", "ANATOMY", 445, 448], ["fecal", "ANATOMY", 910, 915], ["fecal smear", "ANATOMY", 958, 969], ["flukes", "ANATOMY", 999, 1005], ["sodium acetate-acetic acid-formalin", "CHEMICAL", 162, 197], ["sodium acetate", "CHEMICAL", 224, 238], ["glacial acetic acid", "CHEMICAL", 246, 265], ["formaldehyde", "CHEMICAL", 277, 289], ["Diarrhea", "DISEASE", 370, 378], ["Ancylostoma spp.", "DISEASE", 516, 532], ["Toxocara spp.", "DISEASE", 534, 547], ["Trichuris vulpis", "DISEASE", 569, 585], ["dichromate", "CHEMICAL", 629, 639], ["Toxoplasma gondii", "DISEASE", 756, 773], ["sodium acetate", "CHEMICAL", 162, 176], ["acetic acid-formalin", "CHEMICAL", 177, 197], ["sodium acetate", "CHEMICAL", 224, 238], ["acetic acid", "CHEMICAL", 254, 265], ["formaldehyde", "CHEMICAL", 277, 289], ["dichromate", "CHEMICAL", 629, 639], ["sodium acetate-acetic acid-formalin", "SIMPLE_CHEMICAL", 162, 197], ["sodium acetate", "SIMPLE_CHEMICAL", 224, 238], ["acetic acid", "SIMPLE_CHEMICAL", 254, 265], ["formaldehyde", "SIMPLE_CHEMICAL", 277, 289], ["ova", "ORGANISM_SUBSTANCE", 392, 395], ["Parasite Ova", "ORGANISM", 468, 480], ["Ancylostoma spp.", "ORGANISM", 516, 532], ["Toxocara spp.", "ORGANISM", 534, 547], ["Toxascaris leonina", "ORGANISM", 549, 567], ["Trichuris vulpis", "ORGANISM", 569, 585], ["Spirocerca lupi", "ORGANISM", 587, 602], ["Physaloptera rara", "ORGANISM", 604, 621], ["dichromate", "SIMPLE_CHEMICAL", 629, 639], ["Capillaria aerophilia", "ORGANISM", 651, 672], ["Capillaria plica", "ORGANISM", 674, 690], ["Onciolo canis", "ORGANISM", 692, 705], ["Dioctophyme renale", "ORGANISM", 707, 725], ["Isospora spp.", "ORGANISM", 727, 740], ["Giardia spp.", "ORGANISM", 742, 754], ["Toxoplasma gondii", "ORGANISM", 756, 773], ["Cryptosporidium spp.", "ORGANISM", 775, 795], ["Paragonimus kellicotti", "ORGANISM", 797, 819], ["fecal", "ORGANISM_SUBSTANCE", 910, 915], ["fecal", "ORGANISM_SUBSTANCE", 958, 963], ["Ancylostoma spp.", "SPECIES", 516, 532], ["Toxocara spp.", "SPECIES", 534, 547], ["Toxascaris leonina", "SPECIES", 549, 567], ["Trichuris vulpis", "SPECIES", 569, 585], ["Spirocerca lupi", "SPECIES", 587, 602], ["Physaloptera rara", "SPECIES", 604, 621], ["Capillaria aerophilia", "SPECIES", 651, 672], ["Capillaria plica", "SPECIES", 674, 690], ["Onciolo canis", "SPECIES", 692, 705], ["Dioctophyme renale", "SPECIES", 707, 725], ["Isospora spp.", "SPECIES", 727, 740], ["Giardia spp.", "SPECIES", 742, 754], ["Toxoplasma gondii", "SPECIES", 756, 773], ["Cryptosporidium spp.", "SPECIES", 775, 795], ["Paragonimus kellicotti", "SPECIES", 797, 819], ["Ancylostoma spp.", "SPECIES", 516, 532], ["Toxocara spp.", "SPECIES", 534, 547], ["Toxascaris leonina", "SPECIES", 549, 567], ["Trichuris vulpis", "SPECIES", 569, 585], ["Spirocerca lupi", "SPECIES", 587, 602], ["Physaloptera rara", "SPECIES", 604, 621], ["Capillaria aerophilia", "SPECIES", 651, 672], ["Capillaria plica", "SPECIES", 674, 690], ["Onciolo canis", "SPECIES", 692, 705], ["Dioctophyme renale", "SPECIES", 707, 725], ["Isospora spp.", "SPECIES", 727, 740], ["Giardia spp.", "SPECIES", 742, 754], ["Toxoplasma gondii", "SPECIES", 756, 773], ["Cryptosporidium spp.", "SPECIES", 775, 795], ["Paragonimus kellicotti", "SPECIES", 797, 819], ["Samples", "TEST", 0, 7], ["3 parts sodium acetate", "TREATMENT", 154, 176], ["acetic acid-formalin", "TREATMENT", 177, 197], ["sodium acetate", "TREATMENT", 224, 238], ["glacial acetic acid", "TREATMENT", 246, 265], ["ova", "PROBLEM", 335, 338], ["oocysts", "PROBLEM", 342, 349], ["Artifacts", "PROBLEM", 358, 367], ["Diarrhea", "PROBLEM", 370, 378], ["ova concentration", "PROBLEM", 392, 409], ["ova", "PROBLEM", 445, 448], ["oocysts", "PROBLEM", 452, 459], ["Parasite Ova", "PROBLEM", 468, 480], ["Cysts", "PROBLEM", 485, 490], ["Ancylostoma spp.", "PROBLEM", 516, 532], ["dichromate solution", "TREATMENT", 629, 648], ["Capillaria aerophilia", "TEST", 651, 672], ["Capillaria plica", "TEST", 674, 690], ["Onciolo canis", "TEST", 692, 705], ["Isospora spp.", "TEST", 727, 740], ["Giardia spp.", "TEST", 742, 754], ["Toxoplasma gondii", "PROBLEM", 756, 773], ["Cryptosporidium spp.", "PROBLEM", 775, 795], ["Paragonimus kellicotti", "PROBLEM", 797, 819], ["some tapeworms", "PROBLEM", 825, 839], ["FECAL SEDIMENTATIONRare Indications", "TREATMENT", 856, 891], ["fecal sedimentation testing", "TEST", 910, 937], ["fecal smear", "TEST", 958, 969], ["flotation", "TREATMENT", 974, 983], ["flukes", "PROBLEM", 999, 1005], ["No", "UNCERTAINTY", 332, 334], ["ova", "OBSERVATION", 335, 338], ["oocysts", "OBSERVATION", 342, 349], ["No", "UNCERTAINTY", 442, 444], ["ova", "OBSERVATION", 445, 448], ["oocysts", "OBSERVATION", 452, 459], ["Ova", "OBSERVATION", 477, 480], ["Cysts", "OBSERVATION", 485, 490], ["May Be", "UNCERTAINTY", 496, 502], ["Ancylostoma spp.", "OBSERVATION", 516, 532], ["Trichuris vulpis", "OBSERVATION", 569, 585], ["Capillaria plica", "ANATOMY", 674, 690], ["Paragonimus kellicotti", "OBSERVATION", 797, 819], ["tapeworms", "OBSERVATION", 830, 839]]], ["If feces contain excessive fat, then formalin and ethyl acetate is probably better than water for sedimentation.FECAL SEDIMENTATIONDisadvantages \u2022 The test requires more time than a direct fecal smear or fecal flotation.FECAL SEDIMENTATIONAnalysis \u2022 Feces are mixed with the sedimentation solution (e.g., water or saline), strained once or twice to remove large debris, and allowed to settle for 30 minutesFECAL HETEROBILHARZIA DETECTIONOccasional Indications \u2022 Fecal PCR testing for Heterobilharzia is primarily used in dogs with intestinal or hepatic disease or unexplained hypercalcemia from areas where Heterobilharzia is endemic.FECAL HETEROBILHARZIA DETECTIONAdvantages \u2022 The test is more sensitive than fecal sedimentation; it can detect 1 to 2 ova/g of feces.FECAL HETEROBILHARZIA DETECTIONDisadvantages \u2022 There is limited availability of testing.", [["feces", "ANATOMY", 3, 8], ["fat", "ANATOMY", 27, 30], ["fecal smear", "ANATOMY", 189, 200], ["fecal", "ANATOMY", 204, 209], ["intestinal", "ANATOMY", 531, 541], ["hepatic", "ANATOMY", 545, 552], ["feces", "ANATOMY", 761, 766], ["formalin and ethyl acetate", "CHEMICAL", 37, 63], ["Heterobilharzia", "CHEMICAL", 484, 499], ["intestinal or hepatic disease", "DISEASE", 531, 560], ["hypercalcemia", "DISEASE", 576, 589], ["formalin", "CHEMICAL", 37, 45], ["ethyl acetate", "CHEMICAL", 50, 63], ["feces", "ORGANISM_SUBSTANCE", 3, 8], ["fat", "TISSUE", 27, 30], ["formalin", "SIMPLE_CHEMICAL", 37, 45], ["ethyl acetate", "SIMPLE_CHEMICAL", 50, 63], ["water", "SIMPLE_CHEMICAL", 88, 93], ["fecal", "ORGANISM_SUBSTANCE", 189, 194], ["fecal", "ORGANISM_SUBSTANCE", 204, 209], ["saline", "SIMPLE_CHEMICAL", 314, 320], ["dogs", "ORGANISM", 521, 525], ["intestinal", "ORGAN", 531, 541], ["hepatic", "ORGAN", 545, 552], ["fecal", "ORGANISM_SUBSTANCE", 710, 715], ["feces", "ORGANISM_SUBSTANCE", 761, 766], ["dogs", "SPECIES", 521, 525], ["excessive fat", "PROBLEM", 17, 30], ["formalin and ethyl acetate", "TREATMENT", 37, 63], ["sedimentation", "PROBLEM", 98, 111], ["a direct fecal smear", "TEST", 180, 200], ["fecal flotation", "TEST", 204, 219], ["FECAL SEDIMENTATIONAnalysis", "TEST", 220, 247], ["the sedimentation solution", "TREATMENT", 271, 297], ["water or saline", "TREATMENT", 305, 320], ["large debris", "PROBLEM", 356, 368], ["Fecal PCR testing", "TEST", 462, 479], ["Heterobilharzia", "PROBLEM", 484, 499], ["intestinal or hepatic disease", "PROBLEM", 531, 560], ["unexplained hypercalcemia", "PROBLEM", 564, 589], ["Heterobilharzia", "PROBLEM", 607, 622], ["endemic", "PROBLEM", 626, 633], ["FECAL HETEROBILHARZIA DETECTIONAdvantages", "PROBLEM", 634, 675], ["The test", "TEST", 678, 686], ["fecal sedimentation", "PROBLEM", 710, 729], ["testing", "TEST", 847, 854], ["excessive fat", "OBSERVATION", 17, 30], ["SEDIMENTATIONDisadvantages", "OBSERVATION", 118, 144], ["fecal", "ANATOMY", 204, 209], ["Feces", "OBSERVATION", 250, 255], ["large", "OBSERVATION_MODIFIER", 356, 361], ["debris", "OBSERVATION", 362, 368], ["intestinal", "ANATOMY", 531, 541], ["hepatic", "ANATOMY", 545, 552], ["disease", "OBSERVATION", 553, 560], ["unexplained", "OBSERVATION_MODIFIER", 564, 575], ["hypercalcemia", "OBSERVATION", 576, 589], ["endemic", "OBSERVATION_MODIFIER", 626, 633], ["HETEROBILHARZIA", "OBSERVATION", 640, 655], ["feces", "OBSERVATION", 761, 766], ["HETEROBILHARZIA", "OBSERVATION", 773, 788]]], ["The test is currently available at GI Laboratory, College of Veterinary Medicine, Texas A&M University, College Station, TX 77843-4474.Analysis \u2022 PCR is performed on feces.Artifacts \u2022 None known.Analysis \u2022 PCR is performed on feces.Drug Therapy That May Alter Test Results \u2022 None known.Analysis \u2022 PCR is performed on feces.Interpretation \u2022 A positive result in an animal with clinical signs consistent with heterobiliharziasis is an indication to treat.HEPATIC ABNORMALITIESPerhaps the most difficult aspect of dealing with hepatic disease is distinguishing primary hepatic disease (i.e., the liver is or will be the cause of the patient's illness) fromFECAL TRITRICHOMONAS DETECTIONOccasional Indications \u2022 Fecal testing for Tritrichomonas is indicated for chronic large bowel diarrhea in cats, especially exotic breeds such as Somalis, ocicats, and Bengals.FECAL TRITRICHOMONAS DETECTIONAdvantages \u2022 Culture is more sensitive (approximately 1000 organisms/50 mg of feces) than direct fecal examination, while PCR is the most sensitive test (approximately 10 organisms per 200 mg feces).Disadvantages \u2022 Different techniques have differentsensitivities that the clinician must be aware of.", [["hepatic", "ANATOMY", 524, 531], ["hepatic", "ANATOMY", 566, 573], ["liver", "ANATOMY", 593, 598], ["bowel", "ANATOMY", 772, 777], ["fecal", "ANATOMY", 986, 991], ["TX 77843-4474", "CHEMICAL", 121, 134], ["heterobiliharziasis", "DISEASE", 407, 426], ["hepatic disease", "DISEASE", 524, 539], ["primary hepatic disease", "DISEASE", 558, 581], ["Tritrichomonas", "CHEMICAL", 726, 740], ["bowel diarrhea", "DISEASE", 772, 786], ["feces", "ORGANISM_SUBSTANCE", 166, 171], ["feces", "ORGANISM_SUBSTANCE", 226, 231], ["feces", "ORGANISM_SUBSTANCE", 317, 322], ["hepatic", "ORGAN", 524, 531], ["hepatic", "ORGAN", 566, 573], ["liver", "ORGAN", 593, 598], ["patient", "ORGANISM", 630, 637], ["Fecal", "ORGANISM_SUBSTANCE", 708, 713], ["Tritrichomonas", "ORGANISM", 726, 740], ["bowel", "ORGAN", 772, 777], ["cats", "ORGANISM", 790, 794], ["feces", "ORGANISM_SUBDIVISION", 967, 972], ["fecal", "ORGANISM_SUBDIVISION", 986, 991], ["feces", "ORGANISM_SUBDIVISION", 1081, 1086], ["patient", "SPECIES", 630, 637], ["cats", "SPECIES", 790, 794], ["TX", "TEST", 121, 123], ["Analysis", "TEST", 135, 143], ["PCR", "TEST", 146, 149], ["Analysis", "TEST", 195, 203], ["PCR", "TEST", 206, 209], ["Drug Therapy", "TREATMENT", 232, 244], ["Analysis", "TEST", 286, 294], ["PCR", "TEST", 297, 300], ["clinical signs", "TEST", 376, 390], ["heterobiliharziasis", "PROBLEM", 407, 426], ["HEPATIC ABNORMALITIESPerhaps", "PROBLEM", 453, 481], ["hepatic disease", "PROBLEM", 524, 539], ["primary hepatic disease", "PROBLEM", 558, 581], ["the patient's illness", "PROBLEM", 626, 647], ["Fecal testing", "TEST", 708, 721], ["Tritrichomonas", "PROBLEM", 726, 740], ["chronic large bowel diarrhea in cats", "PROBLEM", 758, 794], ["exotic breeds", "PROBLEM", 807, 820], ["FECAL TRITRICHOMONAS DETECTIONAdvantages", "TEST", 859, 899], ["Culture", "TEST", 902, 909], ["direct fecal examination", "TEST", 979, 1003], ["PCR", "TEST", 1011, 1014], ["consistent with", "UNCERTAINTY", 391, 406], ["heterobiliharziasis", "OBSERVATION", 407, 426], ["ABNORMALITIESPerhaps", "OBSERVATION", 461, 481], ["most difficult", "OBSERVATION_MODIFIER", 486, 500], ["hepatic", "ANATOMY", 524, 531], ["disease", "OBSERVATION", 532, 539], ["primary", "OBSERVATION_MODIFIER", 558, 565], ["hepatic", "ANATOMY", 566, 573], ["disease", "OBSERVATION", 574, 581], ["liver", "ANATOMY", 593, 598], ["chronic", "OBSERVATION_MODIFIER", 758, 765], ["large", "OBSERVATION_MODIFIER", 766, 771], ["bowel", "ANATOMY", 772, 777], ["diarrhea", "OBSERVATION", 778, 786], ["TRITRICHOMONAS", "OBSERVATION", 865, 879]]], ["Feces should be fresh, not refrigerated.", [["Feces", "TREATMENT", 0, 5]]], ["Old feces can give falsenegative results for direct examination and culture.", [["feces", "ANATOMY", 4, 9], ["feces", "ORGANISM", 4, 9], ["Old feces", "PROBLEM", 0, 9], ["direct examination", "TEST", 45, 63], ["culture", "TEST", 68, 75], ["feces", "OBSERVATION", 4, 9]]], ["Direct fecal examination is relatively insensitive (<15%).Disadvantages \u2022 Different techniques have differentAnalysis \u2022 Fresh fecal samples can be examined microscopically (see Fecal Smear earlier in this chapter) (see Figure 9 -6A).", [["fecal", "ANATOMY", 7, 12], ["fecal samples", "ANATOMY", 126, 139], ["fecal", "ORGANISM_SUBSTANCE", 7, 12], ["Direct fecal examination", "TEST", 0, 24], ["differentAnalysis", "TEST", 100, 117], ["Fresh fecal samples", "TEST", 120, 139], ["Fecal Smear", "TEST", 177, 188], ["fecal", "ANATOMY", 7, 12]]], ["Feces (very fresh, approximately 0.05 g) can be cultured using commercially available pouches designed for culturing Trichomonas foetus from cattle (i.e., In Pouch TF; Biomed Diagnostics, White City, Oregon).", [["Feces", "ANATOMY", 0, 5], ["pouches", "ANATOMY", 86, 93], ["pouches", "ORGANISM_SUBDIVISION", 86, 93], ["Trichomonas foetus", "ORGANISM", 117, 135], ["cattle", "ORGANISM", 141, 147], ["Trichomonas foetus", "SPECIES", 117, 135], ["cattle", "SPECIES", 141, 147], ["Trichomonas foetus", "SPECIES", 117, 135], ["cattle", "SPECIES", 141, 147], ["Feces (very fresh", "PROBLEM", 0, 17], ["commercially available pouches", "TREATMENT", 63, 93], ["culturing Trichomonas foetus", "PROBLEM", 107, 135], ["Pouch", "ANATOMY", 158, 163]]], ["This test is best done in the clinic without sending off the feces or the pouch.", [["feces", "ANATOMY", 61, 66], ["pouch", "ANATOMY", 74, 79], ["feces", "ORGANISM_SUBDIVISION", 61, 66], ["pouch", "ORGANISM_SUBDIVISION", 74, 79], ["This test", "TEST", 0, 9], ["pouch", "ANATOMY", 74, 79]]], ["The inoculated pouch is incubated upright in the dark at either 37\u00b0 C or room temperature for 2 or 12 days, respectively.", [["pouch", "ANATOMY", 15, 20], ["pouch", "ORGAN", 15, 20], ["room temperature", "TEST", 73, 89], ["inoculated pouch", "OBSERVATION", 4, 20]]], ["Finally, feces may be preserved (approximately 200 mg in 3 to 5 ml of 70% isopropyl alcohol; be sure to strongly suspected and the serum bile acid concentrations are not as high as anticipated, one should not hesitate to perform other tests to characterize the liver.", [["feces", "ANATOMY", 9, 14], ["serum", "ANATOMY", 131, 136], ["liver", "ANATOMY", 261, 266], ["isopropyl alcohol", "CHEMICAL", 74, 91], ["bile acid", "CHEMICAL", 137, 146], ["isopropyl alcohol", "CHEMICAL", 74, 91], ["bile acid", "CHEMICAL", 137, 146], ["feces", "ORGANISM_SUBSTANCE", 9, 14], ["isopropyl alcohol", "SIMPLE_CHEMICAL", 74, 91], ["serum", "ORGANISM_SUBSTANCE", 131, 136], ["bile acid", "SIMPLE_CHEMICAL", 137, 146], ["liver", "ORGAN", 261, 266], ["70% isopropyl alcohol", "TREATMENT", 70, 91], ["the serum bile acid concentrations", "TEST", 127, 161], ["other tests", "TEST", 229, 240], ["liver", "ANATOMY", 261, 266]]], ["If hepatic atrophy is likely, abdominal ultrasonography, advanced imaging (e.g., contrast portography, computed tomography, magnetic resonance imaging), hepatic biopsy, or a combination of these might be considered.Disadvantages \u2022 Different techniques have differentSmall livers with clearly rounded or blunt hepatic margins are often fibrotic/cirrhotic.", [["hepatic", "ANATOMY", 3, 10], ["abdominal", "ANATOMY", 30, 39], ["hepatic", "ANATOMY", 153, 160], ["livers", "ANATOMY", 272, 278], ["hepatic margins", "ANATOMY", 309, 324], ["hepatic atrophy", "DISEASE", 3, 18], ["cirrhotic", "DISEASE", 344, 353], ["hepatic", "ORGAN", 3, 10], ["abdominal", "ORGANISM_SUBDIVISION", 30, 39], ["hepatic biopsy", "MULTI-TISSUE_STRUCTURE", 153, 167], ["livers", "ORGAN", 272, 278], ["hepatic margins", "PATHOLOGICAL_FORMATION", 309, 324], ["hepatic atrophy", "PROBLEM", 3, 18], ["abdominal ultrasonography", "TEST", 30, 55], ["advanced imaging", "TEST", 57, 73], ["contrast portography", "TEST", 81, 101], ["computed tomography", "TEST", 103, 122], ["magnetic resonance imaging", "TEST", 124, 150], ["hepatic biopsy", "TEST", 153, 167], ["clearly rounded or blunt hepatic margins", "PROBLEM", 284, 324], ["cirrhotic", "PROBLEM", 344, 353], ["hepatic", "ANATOMY", 3, 10], ["atrophy", "OBSERVATION", 11, 18], ["is likely", "UNCERTAINTY", 19, 28], ["abdominal", "ANATOMY", 30, 39], ["hepatic", "ANATOMY", 153, 160], ["biopsy", "OBSERVATION", 161, 167], ["Small", "OBSERVATION_MODIFIER", 266, 271], ["livers", "ANATOMY", 272, 278], ["rounded", "OBSERVATION_MODIFIER", 292, 299], ["blunt", "OBSERVATION_MODIFIER", 303, 308], ["hepatic", "ANATOMY", 309, 316], ["margins", "OBSERVATION_MODIFIER", 317, 324], ["often", "OBSERVATION_MODIFIER", 329, 334], ["fibrotic", "OBSERVATION", 335, 343], ["cirrhotic", "OBSERVATION", 344, 353]]], ["Significant increases in serum ALT and SAP are often present, but some dogs with marked hepatic cirrhosis have normal hepatic enzymes.", [["serum", "ANATOMY", 25, 30], ["hepatic cirrhosis", "ANATOMY", 88, 105], ["hepatic", "ANATOMY", 118, 125], ["hepatic cirrhosis", "DISEASE", 88, 105], ["serum", "ORGANISM_SUBSTANCE", 25, 30], ["ALT", "SIMPLE_CHEMICAL", 31, 34], ["SAP", "GENE_OR_GENE_PRODUCT", 39, 42], ["dogs", "ORGANISM", 71, 75], ["hepatic cirrhosis", "CANCER", 88, 105], ["hepatic", "ORGAN", 118, 125], ["serum ALT", "PROTEIN", 25, 34], ["SAP", "PROTEIN", 39, 42], ["hepatic enzymes", "PROTEIN", 118, 133], ["Significant increases", "PROBLEM", 0, 21], ["serum ALT", "TEST", 25, 34], ["SAP", "PROBLEM", 39, 42], ["some dogs", "PROBLEM", 66, 75], ["marked hepatic cirrhosis", "PROBLEM", 81, 105], ["increases", "OBSERVATION_MODIFIER", 12, 21], ["serum ALT", "OBSERVATION_MODIFIER", 25, 34], ["SAP", "OBSERVATION_MODIFIER", 39, 42], ["marked", "OBSERVATION_MODIFIER", 81, 87], ["hepatic", "ANATOMY", 88, 95], ["cirrhosis", "OBSERVATION", 96, 105], ["normal", "OBSERVATION", 111, 117], ["hepatic", "ANATOMY", 118, 125]]], ["Serum albumin and BUN are more variable.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["albumin", "GENE_OR_GENE_PRODUCT", 6, 13], ["BUN", "GENE_OR_GENE_PRODUCT", 18, 21], ["BUN", "PROTEIN", 18, 21], ["Serum albumin", "TEST", 0, 13], ["BUN", "TEST", 18, 21], ["more variable", "OBSERVATION_MODIFIER", 26, 39]]], ["If cirrhosis appears likely, a biopsy is often indicated.", [["cirrhosis", "DISEASE", 3, 12], ["cirrhosis", "PROBLEM", 3, 12], ["a biopsy", "TEST", 29, 37], ["cirrhosis", "OBSERVATION", 3, 12], ["appears likely", "UNCERTAINTY", 13, 27]]], ["An obviously nodular or \"cobblestone\" appearance is very suggestive of cirrhosis; however, significant fibrosis can be present without major gross changes, and some noncirrhotic diseases (e.g., hepatic collapse with nodular regeneration, nodular hyperplasia) may grossly resemble cirrhosis.", [["nodular", "ANATOMY", 13, 20], ["hepatic", "ANATOMY", 194, 201], ["nodular", "ANATOMY", 216, 223], ["nodular hyperplasia", "ANATOMY", 238, 257], ["cirrhosis", "DISEASE", 71, 80], ["fibrosis", "DISEASE", 103, 111], ["noncirrhotic diseases", "DISEASE", 165, 186], ["hepatic collapse", "DISEASE", 194, 210], ["hyperplasia", "DISEASE", 246, 257], ["cirrhosis", "DISEASE", 280, 289], ["hepatic", "ORGAN", 194, 201], ["nodular hyperplasia", "PATHOLOGICAL_FORMATION", 238, 257], ["An obviously nodular or \"cobblestone\" appearance", "PROBLEM", 0, 48], ["cirrhosis", "PROBLEM", 71, 80], ["significant fibrosis", "PROBLEM", 91, 111], ["major gross changes", "PROBLEM", 135, 154], ["some noncirrhotic diseases", "PROBLEM", 160, 186], ["hepatic collapse", "PROBLEM", 194, 210], ["nodular regeneration", "PROBLEM", 216, 236], ["nodular hyperplasia", "PROBLEM", 238, 257], ["grossly resemble cirrhosis", "PROBLEM", 263, 289], ["obviously", "OBSERVATION_MODIFIER", 3, 12], ["nodular", "OBSERVATION_MODIFIER", 13, 20], ["cobblestone\"", "OBSERVATION", 25, 37], ["very suggestive of", "UNCERTAINTY", 52, 70], ["cirrhosis", "OBSERVATION", 71, 80], ["significant", "OBSERVATION_MODIFIER", 91, 102], ["fibrosis", "OBSERVATION", 103, 111], ["some", "OBSERVATION_MODIFIER", 160, 164], ["noncirrhotic", "OBSERVATION_MODIFIER", 165, 177], ["diseases", "OBSERVATION", 178, 186], ["hepatic", "ANATOMY", 194, 201], ["collapse", "OBSERVATION", 202, 210], ["nodular", "OBSERVATION_MODIFIER", 216, 223], ["regeneration", "OBSERVATION_MODIFIER", 224, 236], ["nodular", "OBSERVATION_MODIFIER", 238, 245], ["hyperplasia", "OBSERVATION", 246, 257], ["grossly", "OBSERVATION_MODIFIER", 263, 270], ["cirrhosis", "OBSERVATION", 280, 289]]], ["Acquired multiple shunts visible at laparoscopy or laparotomy are usually due to cirrhosis but can be secondary to congenital hepatic AV fistula, veno-occlusive disease, portal vein obstruction, or infiltrative disease.Hepatomegaly: Enlarged LiverFocal or asymmetric hepatic enlargement generally necessitates further laboratory investigation, imaging, and possibly biopsy.", [["hepatic AV fistula", "ANATOMY", 126, 144], ["veno-occlusive", "ANATOMY", 146, 160], ["portal vein", "ANATOMY", 170, 181], ["LiverFocal", "ANATOMY", 242, 252], ["hepatic", "ANATOMY", 267, 274], ["cirrhosis", "DISEASE", 81, 90], ["congenital hepatic AV fistula", "DISEASE", 115, 144], ["veno-occlusive disease", "DISEASE", 146, 168], ["portal vein obstruction", "DISEASE", 170, 193], ["Hepatomegaly", "DISEASE", 219, 231], ["hepatic enlargement", "DISEASE", 267, 286], ["portal vein", "MULTI-TISSUE_STRUCTURE", 170, 181], ["hepatic", "ORGAN", 267, 274], ["Acquired multiple shunts", "PROBLEM", 0, 24], ["laparoscopy", "TREATMENT", 36, 47], ["laparotomy", "TREATMENT", 51, 61], ["cirrhosis", "PROBLEM", 81, 90], ["congenital hepatic AV fistula", "PROBLEM", 115, 144], ["veno-occlusive disease", "PROBLEM", 146, 168], ["portal vein obstruction", "PROBLEM", 170, 193], ["infiltrative disease", "PROBLEM", 198, 218], ["Hepatomegaly", "PROBLEM", 219, 231], ["Enlarged LiverFocal", "PROBLEM", 233, 252], ["asymmetric hepatic enlargement", "PROBLEM", 256, 286], ["further laboratory investigation", "TEST", 310, 342], ["imaging", "TEST", 344, 351], ["biopsy", "TEST", 366, 372], ["multiple", "OBSERVATION_MODIFIER", 9, 17], ["shunts", "OBSERVATION", 18, 24], ["laparoscopy", "OBSERVATION", 36, 47], ["laparotomy", "OBSERVATION", 51, 61], ["cirrhosis", "OBSERVATION", 81, 90], ["congenital", "OBSERVATION_MODIFIER", 115, 125], ["hepatic", "ANATOMY", 126, 133], ["AV", "ANATOMY", 134, 136], ["fistula", "OBSERVATION", 137, 144], ["veno-occlusive", "OBSERVATION_MODIFIER", 146, 160], ["disease", "OBSERVATION", 161, 168], ["portal vein", "ANATOMY", 170, 181], ["obstruction", "OBSERVATION", 182, 193], ["infiltrative", "OBSERVATION_MODIFIER", 198, 210], ["Enlarged", "OBSERVATION_MODIFIER", 233, 241], ["LiverFocal", "OBSERVATION", 242, 252], ["asymmetric", "OBSERVATION_MODIFIER", 256, 266], ["hepatic", "ANATOMY", 267, 274], ["enlargement", "OBSERVATION", 275, 286]]], ["Neoplasia is a prominent but not invariable cause of focal hepatomegaly.", [["Neoplasia", "DISEASE", 0, 9], ["hepatomegaly", "DISEASE", 59, 71], ["Neoplasia", "CANCER", 0, 9], ["focal hepatomegaly", "PATHOLOGICAL_FORMATION", 53, 71], ["Neoplasia", "PROBLEM", 0, 9], ["focal hepatomegaly", "PROBLEM", 53, 71], ["prominent", "OBSERVATION_MODIFIER", 15, 24], ["focal", "OBSERVATION_MODIFIER", 53, 58], ["hepatomegaly", "OBSERVATION", 59, 71]]], ["The magnitude of the enlargement is not prognostic.Hepatomegaly: Enlarged LiverGeneralized hepatomegaly necessitates careful clinicopathologic evaluation.", [["Hepatomegaly", "DISEASE", 51, 63], ["hepatomegaly", "DISEASE", 91, 103], ["the enlargement", "PROBLEM", 17, 32], ["Hepatomegaly", "PROBLEM", 51, 63], ["Enlarged LiverGeneralized hepatomegaly", "PROBLEM", 65, 103], ["careful clinicopathologic evaluation", "TEST", 117, 153], ["magnitude", "OBSERVATION_MODIFIER", 4, 13], ["enlargement", "OBSERVATION", 21, 32], ["not", "UNCERTAINTY", 36, 39], ["prognostic", "OBSERVATION_MODIFIER", 40, 50], ["Enlarged", "OBSERVATION_MODIFIER", 65, 73], ["LiverGeneralized", "OBSERVATION_MODIFIER", 74, 90], ["hepatomegaly", "OBSERVATION", 91, 103]]], ["Hepatomegaly may be caused by primary or secondary hepatic disease.", [["hepatic", "ANATOMY", 51, 58], ["Hepatomegaly", "DISEASE", 0, 12], ["primary or secondary hepatic disease", "DISEASE", 30, 66], ["hepatic", "ORGAN", 51, 58], ["Hepatomegaly", "PROBLEM", 0, 12], ["secondary hepatic disease", "PROBLEM", 41, 66], ["may be caused", "UNCERTAINTY", 13, 26], ["secondary", "OBSERVATION_MODIFIER", 41, 50], ["hepatic", "ANATOMY", 51, 58], ["disease", "OBSERVATION", 59, 66]]], ["Diagnosis may be confirmed with a history of exposure to certain toxins (Boxes 9-5 and 9-6) or diagnosis of a systemic disease (e.g., hyperadrenocorticism) known to affect the liver.", [["liver", "ANATOMY", 176, 181], ["Boxes 9-5 and 9-6", "CHEMICAL", 73, 90], ["systemic disease", "DISEASE", 110, 126], ["hyperadrenocorticism", "DISEASE", 134, 154], ["liver", "ORGAN", 176, 181], ["certain toxins", "PROBLEM", 57, 71], ["Boxes", "TEST", 73, 78], ["a systemic disease", "PROBLEM", 108, 126], ["hyperadrenocorticism)", "PROBLEM", 134, 155], ["systemic", "OBSERVATION_MODIFIER", 110, 118], ["disease", "OBSERVATION", 119, 126], ["hyperadrenocorticism", "OBSERVATION", 134, 154], ["liver", "ANATOMY", 176, 181]]], ["Changes in ALT, SAP, hepatic function tests, and hepatic size, although suggestive of hepatic disease, are not diagnostic of specific entities.", [["hepatic", "ANATOMY", 21, 28], ["hepatic", "ANATOMY", 49, 56], ["hepatic", "ANATOMY", 86, 93], ["hepatic disease", "DISEASE", 86, 101], ["ALT", "SIMPLE_CHEMICAL", 11, 14], ["SAP", "GENE_OR_GENE_PRODUCT", 16, 19], ["hepatic", "MULTI-TISSUE_STRUCTURE", 21, 28], ["hepatic", "ORGAN", 49, 56], ["hepatic", "ORGAN", 86, 93], ["ALT", "PROTEIN", 11, 14], ["SAP", "PROTEIN", 16, 19], ["Changes in ALT, SAP", "TEST", 0, 19], ["hepatic function tests", "TEST", 21, 43], ["hepatic disease", "PROBLEM", 86, 101], ["ALT", "ANATOMY", 11, 14], ["hepatic", "ANATOMY", 21, 28], ["hepatic", "ANATOMY", 49, 56], ["size", "OBSERVATION_MODIFIER", 57, 61], ["suggestive of", "UNCERTAINTY", 72, 85], ["hepatic", "ANATOMY", 86, 93], ["disease", "OBSERVATION", 94, 101], ["not diagnostic of", "UNCERTAINTY", 107, 124], ["specific", "OBSERVATION_MODIFIER", 125, 133], ["entities", "OBSERVATION", 134, 142]]], ["This is true even in breeds with predispositions to specific hepatic diseases (e.g., Doberman pinschers, Bedlington terriers).", [["hepatic", "ANATOMY", 61, 68], ["hepatic diseases", "DISEASE", 61, 77], ["hepatic", "ORGAN", 61, 68], ["specific hepatic diseases", "PROBLEM", 52, 77], ["Doberman pinschers", "TREATMENT", 85, 103], ["hepatic", "ANATOMY", 61, 68], ["diseases", "OBSERVATION", 69, 77]]], ["Changes in the SAP or ALT may also be caused by primary nonhepatic disease (e.g., hyperadrenocorticism, IBD, diabetes mellitus, heart failure).", [["nonhepatic", "ANATOMY", 56, 66], ["heart", "ANATOMY", 128, 133], ["primary nonhepatic disease", "DISEASE", 48, 74], ["hyperadrenocorticism", "DISEASE", 82, 102], ["IBD", "DISEASE", 104, 107], ["diabetes mellitus", "DISEASE", 109, 126], ["heart failure", "DISEASE", 128, 141], ["SAP", "GENE_OR_GENE_PRODUCT", 15, 18], ["ALT", "SIMPLE_CHEMICAL", 22, 25], ["heart", "ORGAN", 128, 133], ["SAP", "PROTEIN", 15, 18], ["ALT", "PROTEIN", 22, 25], ["Changes in the SAP", "PROBLEM", 0, 18], ["ALT", "PROBLEM", 22, 25], ["primary nonhepatic disease", "PROBLEM", 48, 74], ["hyperadrenocorticism", "PROBLEM", 82, 102], ["IBD", "PROBLEM", 104, 107], ["diabetes mellitus", "PROBLEM", 109, 126], ["heart failure", "PROBLEM", 128, 141], ["SAP", "OBSERVATION_MODIFIER", 15, 18], ["may also be caused", "UNCERTAINTY", 26, 44], ["nonhepatic", "ANATOMY", 56, 66], ["disease", "OBSERVATION", 67, 74], ["hyperadrenocorticism", "OBSERVATION", 82, 102], ["heart", "ANATOMY", 128, 133], ["failure", "OBSERVATION", 134, 141]]], ["A definitive diagnosis usually requires hepatic biopsy.", [["hepatic biopsy", "ANATOMY", 40, 54], ["hepatic biopsy", "MULTI-TISSUE_STRUCTURE", 40, 54], ["hepatic biopsy", "TEST", 40, 54], ["hepatic", "ANATOMY", 40, 47], ["biopsy", "OBSERVATION", 48, 54]]], ["The clinician should first seek to rule out nonhepatic causes of secondary hepatic dysfunction.", [["hepatic", "ANATOMY", 75, 82], ["hepatic dysfunction", "DISEASE", 75, 94], ["hepatic", "ORGAN", 75, 82], ["secondary hepatic dysfunction", "PROBLEM", 65, 94], ["nonhepatic", "ANATOMY", 44, 54], ["secondary", "OBSERVATION_MODIFIER", 65, 74], ["hepatic", "ANATOMY", 75, 82], ["dysfunction", "OBSERVATION", 83, 94]]], ["Hepatic biopsy should be considered in patients with obviously significant hepatic disease, those that do not have obvious nonhepatic causes (e.g., hyperadrenocorticism, right heart failure), and those that have persistent (>1 month) changes in serum ALT consistent with chronic or progressive hepatic disease or abnormal hepatic function tests (see Figure 9 -8).", [["Hepatic biopsy", "ANATOMY", 0, 14], ["hepatic", "ANATOMY", 75, 82], ["nonhepatic", "ANATOMY", 123, 133], ["right heart", "ANATOMY", 170, 181], ["serum", "ANATOMY", 245, 250], ["hepatic", "ANATOMY", 294, 301], ["hepatic", "ANATOMY", 322, 329], ["hepatic disease", "DISEASE", 75, 90], ["hyperadrenocorticism", "DISEASE", 148, 168], ["right heart failure", "DISEASE", 170, 189], ["hepatic disease", "DISEASE", 294, 309], ["abnormal hepatic function", "DISEASE", 313, 338], ["Hepatic biopsy", "MULTI-TISSUE_STRUCTURE", 0, 14], ["patients", "ORGANISM", 39, 47], ["hepatic", "ORGAN", 75, 82], ["heart", "ORGAN", 176, 181], ["serum", "ORGANISM_SUBSTANCE", 245, 250], ["ALT", "SIMPLE_CHEMICAL", 251, 254], ["hepatic", "ORGAN", 294, 301], ["hepatic", "ORGAN", 322, 329], ["patients", "SPECIES", 39, 47], ["Hepatic biopsy", "TEST", 0, 14], ["significant hepatic disease", "PROBLEM", 63, 90], ["obvious nonhepatic causes", "PROBLEM", 115, 140], ["hyperadrenocorticism", "PROBLEM", 148, 168], ["right heart failure", "PROBLEM", 170, 189], ["serum ALT", "TEST", 245, 254], ["chronic or progressive hepatic disease", "PROBLEM", 271, 309], ["abnormal hepatic function tests", "PROBLEM", 313, 344], ["biopsy", "OBSERVATION", 8, 14], ["significant", "OBSERVATION_MODIFIER", 63, 74], ["hepatic", "ANATOMY", 75, 82], ["disease", "OBSERVATION", 83, 90], ["nonhepatic", "ANATOMY", 123, 133], ["right", "ANATOMY_MODIFIER", 170, 175], ["heart", "ANATOMY", 176, 181], ["failure", "OBSERVATION", 182, 189], ["persistent", "OBSERVATION_MODIFIER", 212, 222], ["consistent with", "UNCERTAINTY", 255, 270], ["chronic", "OBSERVATION_MODIFIER", 271, 278], ["progressive", "OBSERVATION_MODIFIER", 282, 293], ["hepatic", "ANATOMY", 294, 301], ["disease", "OBSERVATION", 302, 309], ["abnormal", "OBSERVATION_MODIFIER", 313, 321], ["hepatic", "ANATOMY", 322, 329]]], ["It is not always possible to accurately distinguish primary hepatic from secondary hepatic disease before biopsy; therefore whenever hepatic biopsy is performed via laparotomy or laparoscopy, the rest of the abdomen should be explored and other organs sampled if they might be involved.", [["hepatic", "ANATOMY", 60, 67], ["hepatic", "ANATOMY", 83, 90], ["hepatic biopsy", "ANATOMY", 133, 147], ["abdomen", "ANATOMY", 208, 215], ["organs", "ANATOMY", 245, 251], ["primary hepatic from secondary hepatic disease", "DISEASE", 52, 98], ["hepatic", "ORGAN", 60, 67], ["hepatic", "ORGAN", 83, 90], ["hepatic biopsy", "MULTI-TISSUE_STRUCTURE", 133, 147], ["abdomen", "ORGAN", 208, 215], ["organs", "ORGAN", 245, 251], ["secondary hepatic disease", "PROBLEM", 73, 98], ["biopsy", "TEST", 106, 112], ["hepatic biopsy", "TEST", 133, 147], ["laparotomy", "TEST", 165, 175], ["laparoscopy", "TREATMENT", 179, 190], ["not always possible", "UNCERTAINTY", 6, 25], ["hepatic", "ANATOMY", 60, 67], ["secondary", "OBSERVATION_MODIFIER", 73, 82], ["hepatic", "ANATOMY", 83, 90], ["disease", "OBSERVATION", 91, 98], ["hepatic", "ANATOMY", 133, 140], ["biopsy", "OBSERVATION", 141, 147], ["laparotomy", "OBSERVATION", 165, 175], ["laparoscopy", "OBSERVATION", 179, 190], ["abdomen", "ANATOMY", 208, 215]]], ["Fine-needle aspirates with cytology are sometimes useful in detecting diffuse hepatic infiltrative disease and hepatic lipidosis ( Figure 9-9) ; however, fine-needle aspirates (even when guided by ultrasound) often miss infiltrative processes.", [["diffuse hepatic infiltrative", "ANATOMY", 70, 98], ["hepatic", "ANATOMY", 111, 118], ["hepatic infiltrative disease", "DISEASE", 78, 106], ["hepatic lipidosis", "DISEASE", 111, 128], ["Figure 9-9", "CHEMICAL", 131, 141], ["hepatic infiltrative disease", "CANCER", 78, 106], ["hepatic lipidosis", "CANCER", 111, 128], ["needle aspirates", "MULTI-TISSUE_STRUCTURE", 159, 175], ["Fine-needle aspirates", "TEST", 0, 21], ["cytology", "TEST", 27, 35], ["diffuse hepatic infiltrative disease", "PROBLEM", 70, 106], ["hepatic lipidosis", "PROBLEM", 111, 128], ["Figure", "TEST", 131, 137], ["fine-needle aspirates", "TEST", 154, 175], ["ultrasound", "TEST", 197, 207], ["infiltrative processes", "PROBLEM", 220, 242], ["diffuse", "OBSERVATION_MODIFIER", 70, 77], ["hepatic", "ANATOMY", 78, 85], ["infiltrative", "OBSERVATION", 86, 98], ["hepatic", "ANATOMY", 111, 118], ["lipidosis", "OBSERVATION", 119, 128], ["infiltrative", "OBSERVATION", 220, 232]]], ["A negative cytologic finding from a fine-needle aspirate never secondary hepatic disease (i.e., the liver disease is caused by the patient's nonhepatic illness).", [["hepatic", "ANATOMY", 73, 80], ["liver", "ANATOMY", 100, 105], ["secondary hepatic disease", "DISEASE", 63, 88], ["liver disease", "DISEASE", 100, 113], ["nonhepatic illness", "DISEASE", 141, 159], ["hepatic", "ORGAN", 73, 80], ["liver", "ORGAN", 100, 105], ["patient", "ORGANISM", 131, 138], ["patient", "SPECIES", 131, 138], ["a fine-needle aspirate", "TEST", 34, 56], ["secondary hepatic disease", "PROBLEM", 63, 88], ["the liver disease", "PROBLEM", 96, 113], ["the patient's nonhepatic illness", "PROBLEM", 127, 159], ["negative", "OBSERVATION_MODIFIER", 2, 10], ["cytologic", "OBSERVATION", 11, 20], ["hepatic", "ANATOMY", 73, 80], ["disease", "OBSERVATION", 81, 88], ["liver", "ANATOMY", 100, 105], ["disease", "OBSERVATION", 106, 113], ["nonhepatic", "ANATOMY", 141, 151]]], ["Primary hepatic disease may be heralded by relatively suggestive signs (e.g., hepatomegaly, microhepatia, icterus, ascites, hepatic encephalopathy) or associated with nonspecific signs (e.g., depression, weight loss, anorexia, vomiting).", [["hepatic", "ANATOMY", 8, 15], ["microhepatia", "ANATOMY", 92, 104], ["ascites", "ANATOMY", 115, 122], ["hepatic", "ANATOMY", 124, 131], ["Primary hepatic disease", "DISEASE", 0, 23], ["hepatomegaly", "DISEASE", 78, 90], ["microhepatia", "DISEASE", 92, 104], ["icterus", "DISEASE", 106, 113], ["ascites", "DISEASE", 115, 122], ["hepatic encephalopathy", "DISEASE", 124, 146], ["depression", "DISEASE", 192, 202], ["weight loss", "DISEASE", 204, 215], ["anorexia", "DISEASE", 217, 225], ["vomiting", "DISEASE", 227, 235], ["hepatic", "ORGAN", 8, 15], ["hepatic", "ORGAN", 124, 131], ["Primary hepatic disease", "PROBLEM", 0, 23], ["signs (e.g., hepatomegaly", "PROBLEM", 65, 90], ["microhepatia", "PROBLEM", 92, 104], ["icterus", "PROBLEM", 106, 113], ["ascites", "PROBLEM", 115, 122], ["hepatic encephalopathy", "PROBLEM", 124, 146], ["nonspecific signs (e.g.", "PROBLEM", 167, 190], ["depression", "PROBLEM", 192, 202], ["weight loss", "PROBLEM", 204, 215], ["anorexia", "PROBLEM", 217, 225], ["vomiting", "PROBLEM", 227, 235], ["hepatic", "ANATOMY", 8, 15], ["disease", "OBSERVATION", 16, 23], ["hepatomegaly", "OBSERVATION", 78, 90], ["icterus", "OBSERVATION", 106, 113], ["ascites", "OBSERVATION", 115, 122], ["hepatic", "ANATOMY", 124, 131], ["encephalopathy", "OBSERVATION", 132, 146], ["nonspecific", "OBSERVATION_MODIFIER", 167, 178]]], ["The latter are common presenting complaints of many diseases, which is why serum biochemistry profiling is indicated in patients with chronic signs or evidence of systemic disease.", [["serum", "ANATOMY", 75, 80], ["systemic disease", "DISEASE", 163, 179], ["serum", "ORGANISM_SUBSTANCE", 75, 80], ["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128], ["many diseases", "PROBLEM", 47, 60], ["serum biochemistry profiling", "TEST", 75, 103], ["chronic signs", "PROBLEM", 134, 147], ["systemic disease", "PROBLEM", 163, 179], ["many", "OBSERVATION_MODIFIER", 47, 51], ["diseases", "OBSERVATION", 52, 60], ["systemic", "OBSERVATION_MODIFIER", 163, 171], ["disease", "OBSERVATION", 172, 179]]], ["There are no signs or laboratory abnormalities consistently found in patients with primary hepatic disease.", [["hepatic", "ANATOMY", 91, 98], ["primary hepatic disease", "DISEASE", 83, 106], ["patients", "ORGANISM", 69, 77], ["hepatic", "ORGAN", 91, 98], ["patients", "SPECIES", 69, 77], ["signs or laboratory abnormalities", "PROBLEM", 13, 46], ["primary hepatic disease", "PROBLEM", 83, 106], ["no signs", "UNCERTAINTY", 10, 18], ["hepatic", "ANATOMY", 91, 98], ["disease", "OBSERVATION", 99, 106]]], ["When screening for hepatic disease, one should request at least a CBC, serum ALT, SAP, total bilirubin, albumin, cholesterol, BUN, glucose, urinalysis, and abdominal imaging.", [["hepatic", "ANATOMY", 19, 26], ["serum", "ANATOMY", 71, 76], ["abdominal", "ANATOMY", 156, 165], ["hepatic disease", "DISEASE", 19, 34], ["bilirubin", "CHEMICAL", 93, 102], ["cholesterol", "CHEMICAL", 113, 124], ["glucose", "CHEMICAL", 131, 138], ["bilirubin", "CHEMICAL", 93, 102], ["cholesterol", "CHEMICAL", 113, 124], ["glucose", "CHEMICAL", 131, 138], ["hepatic", "ORGAN", 19, 26], ["serum", "ORGANISM_SUBSTANCE", 71, 76], ["ALT", "SIMPLE_CHEMICAL", 77, 80], ["SAP", "SIMPLE_CHEMICAL", 82, 85], ["bilirubin", "SIMPLE_CHEMICAL", 93, 102], ["albumin", "SIMPLE_CHEMICAL", 104, 111], ["cholesterol", "SIMPLE_CHEMICAL", 113, 124], ["BUN", "SIMPLE_CHEMICAL", 126, 129], ["glucose", "SIMPLE_CHEMICAL", 131, 138], ["abdominal", "ORGANISM_SUBDIVISION", 156, 165], ["serum ALT", "PROTEIN", 71, 80], ["SAP", "PROTEIN", 82, 85], ["albumin", "PROTEIN", 104, 111], ["hepatic disease", "PROBLEM", 19, 34], ["a CBC", "TEST", 64, 69], ["serum ALT", "TEST", 71, 80], ["SAP", "TEST", 82, 85], ["total bilirubin", "TEST", 87, 102], ["albumin", "TEST", 104, 111], ["cholesterol", "TEST", 113, 124], ["BUN", "TEST", 126, 129], ["glucose", "TEST", 131, 138], ["urinalysis", "TEST", 140, 150], ["abdominal imaging", "TEST", 156, 173], ["hepatic", "ANATOMY", 19, 26], ["disease", "OBSERVATION", 27, 34], ["abdominal", "ANATOMY", 156, 165]]], ["Hepatic function tests (i.e., serum bile acids and/or blood ammonia) and ultrasound are often very helpful.", [["Hepatic", "ANATOMY", 0, 7], ["serum", "ANATOMY", 30, 35], ["blood", "ANATOMY", 54, 59], ["ammonia", "CHEMICAL", 60, 67], ["bile acids", "CHEMICAL", 36, 46], ["ammonia", "CHEMICAL", 60, 67], ["Hepatic", "MULTI-TISSUE_STRUCTURE", 0, 7], ["serum", "ORGANISM_SUBSTANCE", 30, 35], ["bile acids", "SIMPLE_CHEMICAL", 36, 46], ["blood", "ORGANISM_SUBSTANCE", 54, 59], ["ammonia", "SIMPLE_CHEMICAL", 60, 67], ["Hepatic function tests", "TEST", 0, 22], ["serum bile acids", "TEST", 30, 46], ["blood ammonia", "TEST", 54, 67], ["ultrasound", "TEST", 73, 83]]], ["Hepatic cytology/biopsy is usually necessary for definitive diagnosis except in patients with portovascular anomalies.", [["Hepatic cytology", "ANATOMY", 0, 16], ["portovascular", "ANATOMY", 94, 107], ["portovascular anomalies", "DISEASE", 94, 117], ["Hepatic", "MULTI-TISSUE_STRUCTURE", 0, 7], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["Hepatic cytology/biopsy", "TEST", 0, 23], ["portovascular anomalies", "PROBLEM", 94, 117], ["cytology", "OBSERVATION", 8, 16], ["biopsy", "OBSERVATION", 17, 23], ["anomalies", "OBSERVATION", 108, 117]]], ["Abnormalities in hepatic-specific enzymes may result from primary hepatic disease or hepatic involvement secondary to nonhepatic disease (e.g., glucocorticoid hepatopathy, septicemia, IBD, pancreatitis).", [["hepatic", "ANATOMY", 17, 24], ["hepatic", "ANATOMY", 66, 73], ["hepatic", "ANATOMY", 85, 92], ["nonhepatic", "ANATOMY", 118, 128], ["primary hepatic disease", "DISEASE", 58, 81], ["nonhepatic disease", "DISEASE", 118, 136], ["hepatopathy", "DISEASE", 159, 170], ["septicemia", "DISEASE", 172, 182], ["IBD", "DISEASE", 184, 187], ["pancreatitis", "DISEASE", 189, 201], ["hepatic", "MULTI-TISSUE_STRUCTURE", 17, 24], ["hepatic", "ORGAN", 66, 73], ["hepatic", "ORGAN", 85, 92], ["hepatic-specific enzymes", "PROTEIN", 17, 41], ["Abnormalities in hepatic-specific enzymes", "PROBLEM", 0, 41], ["primary hepatic disease", "PROBLEM", 58, 81], ["hepatic involvement", "PROBLEM", 85, 104], ["nonhepatic disease", "PROBLEM", 118, 136], ["glucocorticoid hepatopathy", "PROBLEM", 144, 170], ["septicemia", "PROBLEM", 172, 182], ["IBD", "PROBLEM", 184, 187], ["pancreatitis", "PROBLEM", 189, 201], ["hepatic", "ANATOMY", 17, 24], ["hepatic", "ANATOMY", 66, 73], ["disease", "OBSERVATION", 74, 81], ["hepatic", "ANATOMY", 85, 92], ["nonhepatic", "ANATOMY", 118, 128], ["disease", "OBSERVATION", 129, 136], ["glucocorticoid hepatopathy", "OBSERVATION", 144, 170], ["septicemia", "OBSERVATION", 172, 182], ["IBD", "OBSERVATION", 184, 187], ["pancreatitis", "OBSERVATION", 189, 201]]], ["After identifying abnormalities in ALT, aspartate aminotransferase (AST), SAP, or gamma-glutamyl transpeptidase (GGT), one should investigate first for a secondary hepatic disease because these are the most common causes of increased values.", [["hepatic", "ANATOMY", 164, 171], ["aspartate", "CHEMICAL", 40, 49], ["hepatic disease", "DISEASE", 164, 179], ["aspartate", "CHEMICAL", 40, 49], ["ALT", "SIMPLE_CHEMICAL", 35, 38], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 40, 66], ["AST", "SIMPLE_CHEMICAL", 68, 71], ["SAP", "GENE_OR_GENE_PRODUCT", 74, 77], ["gamma-glutamyl transpeptidase", "GENE_OR_GENE_PRODUCT", 82, 111], ["GGT", "SIMPLE_CHEMICAL", 113, 116], ["hepatic", "ORGAN", 164, 171], ["ALT", "PROTEIN", 35, 38], ["aspartate aminotransferase", "PROTEIN", 40, 66], ["AST", "PROTEIN", 68, 71], ["SAP", "PROTEIN", 74, 77], ["gamma", "PROTEIN", 82, 87], ["glutamyl transpeptidase", "PROTEIN", 88, 111], ["GGT", "PROTEIN", 113, 116], ["abnormalities", "PROBLEM", 18, 31], ["ALT", "TEST", 35, 38], ["aspartate aminotransferase", "TEST", 40, 66], ["AST", "TEST", 68, 71], ["SAP", "TEST", 74, 77], ["gamma", "TEST", 82, 87], ["glutamyl transpeptidase (GGT", "TEST", 88, 116], ["a secondary hepatic disease", "PROBLEM", 152, 179], ["increased values", "PROBLEM", 224, 240], ["ALT", "ANATOMY", 35, 38], ["hepatic", "ANATOMY", 164, 171], ["disease", "OBSERVATION", 172, 179], ["increased", "OBSERVATION", 224, 233]]], ["In such cases the liver usually has reactive but reversible degenerative changes.", [["liver", "ANATOMY", 18, 23], ["liver", "ORGAN", 18, 23], ["reversible degenerative changes", "PROBLEM", 49, 80], ["liver", "ANATOMY", 18, 23], ["reactive", "OBSERVATION_MODIFIER", 36, 44], ["reversible", "OBSERVATION_MODIFIER", 49, 59], ["degenerative", "OBSERVATION", 60, 72]]], ["Laboratory tests and ultrasound should be used for two main purposes: (1) to identify the presence of hepatic disease and (2) to help determine if hepatic biopsy is indicated.Microhepatia: Small LiverA small liver suggests atrophy (i.e., congenital portosystemic shunt [PSS], hepatic arteriovenous [AV] fistula), fibrosis and cirrhosis, or diffuse massive hepatic necrosis (Figure 9-8) .", [["hepatic", "ANATOMY", 102, 109], ["hepatic biopsy", "ANATOMY", 147, 161], ["liver", "ANATOMY", 208, 213], ["hepatic arteriovenous [AV] fistula", "ANATOMY", 276, 310], ["hepatic", "ANATOMY", 356, 363], ["hepatic disease", "DISEASE", 102, 117], ["Microhepatia", "DISEASE", 175, 187], ["atrophy", "DISEASE", 223, 230], ["congenital portosystemic shunt", "DISEASE", 238, 268], ["PSS", "DISEASE", 270, 273], ["hepatic arteriovenous [AV] fistula", "DISEASE", 276, 310], ["fibrosis", "DISEASE", 313, 321], ["cirrhosis", "DISEASE", 326, 335], ["massive hepatic necrosis", "DISEASE", 348, 372], ["hepatic", "ORGAN", 102, 109], ["hepatic biopsy", "MULTI-TISSUE_STRUCTURE", 147, 161], ["liver", "ORGAN", 208, 213], ["hepatic arteriovenous", "MULTI-TISSUE_STRUCTURE", 276, 297], ["Laboratory tests", "TEST", 0, 16], ["ultrasound", "TEST", 21, 31], ["hepatic disease", "PROBLEM", 102, 117], ["hepatic biopsy", "TEST", 147, 161], ["Small LiverA small liver", "PROBLEM", 189, 213], ["atrophy", "PROBLEM", 223, 230], ["congenital portosystemic shunt", "PROBLEM", 238, 268], ["hepatic arteriovenous [AV] fistula", "PROBLEM", 276, 310], ["fibrosis", "PROBLEM", 313, 321], ["cirrhosis", "PROBLEM", 326, 335], ["diffuse massive hepatic necrosis", "PROBLEM", 340, 372], ["Figure", "TEST", 374, 380], ["hepatic", "ANATOMY", 102, 109], ["disease", "OBSERVATION", 110, 117], ["hepatic", "ANATOMY", 147, 154], ["biopsy", "OBSERVATION", 155, 161], ["Small", "OBSERVATION_MODIFIER", 189, 194], ["LiverA", "ANATOMY_MODIFIER", 195, 201], ["small", "ANATOMY_MODIFIER", 202, 207], ["liver", "ANATOMY", 208, 213], ["suggests", "UNCERTAINTY", 214, 222], ["atrophy", "OBSERVATION", 223, 230], ["congenital", "OBSERVATION_MODIFIER", 238, 248], ["portosystemic shunt", "OBSERVATION", 249, 268], ["hepatic", "ANATOMY", 276, 283], ["arteriovenous", "ANATOMY_MODIFIER", 284, 297], ["AV", "ANATOMY", 299, 301], ["fistula", "OBSERVATION", 303, 310], ["fibrosis", "OBSERVATION", 313, 321], ["cirrhosis", "OBSERVATION", 326, 335], ["diffuse", "OBSERVATION_MODIFIER", 340, 347], ["massive", "OBSERVATION_MODIFIER", 348, 355], ["hepatic", "ANATOMY", 356, 363], ["necrosis", "OBSERVATION", 364, 372]]], ["Hepatic atrophy tends to be characterized by sharp borders as opposed to the rounded or blunted hepatic margins typically associated with fibrosis and cirrhosis.", [["Hepatic", "ANATOMY", 0, 7], ["hepatic margins", "ANATOMY", 96, 111], ["Hepatic atrophy", "DISEASE", 0, 15], ["fibrosis", "DISEASE", 138, 146], ["cirrhosis", "DISEASE", 151, 160], ["Hepatic", "ORGAN", 0, 7], ["hepatic margins", "MULTI-TISSUE_STRUCTURE", 96, 111], ["Hepatic atrophy", "PROBLEM", 0, 15], ["the rounded or blunted hepatic margins", "PROBLEM", 73, 111], ["fibrosis", "PROBLEM", 138, 146], ["cirrhosis", "PROBLEM", 151, 160], ["atrophy", "OBSERVATION", 8, 15], ["sharp", "OBSERVATION_MODIFIER", 45, 50], ["rounded", "OBSERVATION_MODIFIER", 77, 84], ["blunted", "OBSERVATION_MODIFIER", 88, 95], ["hepatic", "ANATOMY", 96, 103], ["margins", "OBSERVATION", 104, 111], ["fibrosis", "OBSERVATION", 138, 146], ["cirrhosis", "OBSERVATION", 151, 160]]], ["Some patients with primary hepatic fibrosis severe enough to cause portal hypertension also have sharp hepatic margins, however.", [["hepatic", "ANATOMY", 27, 34], ["portal", "ANATOMY", 67, 73], ["hepatic margins", "ANATOMY", 103, 118], ["primary hepatic fibrosis", "DISEASE", 19, 43], ["hypertension", "DISEASE", 74, 86], ["patients", "ORGANISM", 5, 13], ["hepatic", "ORGAN", 27, 34], ["portal", "MULTI-TISSUE_STRUCTURE", 67, 73], ["hepatic margins", "PATHOLOGICAL_FORMATION", 103, 118], ["patients", "SPECIES", 5, 13], ["primary hepatic fibrosis", "PROBLEM", 19, 43], ["portal hypertension", "PROBLEM", 67, 86], ["sharp hepatic margins", "PROBLEM", 97, 118], ["primary", "OBSERVATION_MODIFIER", 19, 26], ["hepatic", "ANATOMY", 27, 34], ["fibrosis", "OBSERVATION", 35, 43], ["portal", "ANATOMY", 67, 73], ["hypertension", "OBSERVATION", 74, 86], ["sharp", "OBSERVATION_MODIFIER", 97, 102], ["hepatic", "ANATOMY", 103, 110], ["margins", "OBSERVATION_MODIFIER", 111, 118]]], ["Many patients with marked hepatic atrophy due to congenital PSS are relatively young (<3 to 4 years) and have had signs of hepatic disease since (or before) weaning, whereas most patients with cirrhosis are middle-aged or older and clearly have late onset of clinical signs.", [["hepatic", "ANATOMY", 26, 33], ["hepatic", "ANATOMY", 123, 130], ["hepatic atrophy", "DISEASE", 26, 41], ["congenital PSS", "DISEASE", 49, 63], ["hepatic disease", "DISEASE", 123, 138], ["cirrhosis", "DISEASE", 193, 202], ["patients", "ORGANISM", 5, 13], ["hepatic", "ORGAN", 26, 33], ["hepatic", "ORGAN", 123, 130], ["patients", "ORGANISM", 179, 187], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 179, 187], ["marked hepatic atrophy", "PROBLEM", 19, 41], ["congenital PSS", "PROBLEM", 49, 63], ["hepatic disease", "PROBLEM", 123, 138], ["cirrhosis", "PROBLEM", 193, 202], ["clinical signs", "PROBLEM", 259, 273], ["marked", "OBSERVATION_MODIFIER", 19, 25], ["hepatic", "ANATOMY", 26, 33], ["atrophy", "OBSERVATION", 34, 41], ["congenital", "OBSERVATION_MODIFIER", 49, 59], ["PSS", "OBSERVATION", 60, 63], ["hepatic", "ANATOMY", 123, 130], ["disease", "OBSERVATION", 131, 138], ["cirrhosis", "OBSERVATION", 193, 202]]], ["Hepatic AV fistula is an uncommon cause of microhepatia, but it is usually diagnosed in dogs less than 2 years of age.", [["Hepatic AV fistula", "ANATOMY", 0, 18], ["microhepatia", "ANATOMY", 43, 55], ["Hepatic AV fistula", "DISEASE", 0, 18], ["microhepatia", "DISEASE", 43, 55], ["Hepatic AV", "MULTI-TISSUE_STRUCTURE", 0, 10], ["microhepatia", "CANCER", 43, 55], ["dogs", "ORGANISM", 88, 92], ["dogs", "SPECIES", 88, 92], ["Hepatic AV fistula", "PROBLEM", 0, 18], ["microhepatia", "PROBLEM", 43, 55], ["AV", "ANATOMY", 8, 10], ["fistula", "OBSERVATION", 11, 18], ["microhepatia", "OBSERVATION", 43, 55]]], ["However, some dogs with congenital PSS are first diagnosed when they are more than 10 years old.", [["congenital PSS", "DISEASE", 24, 38], ["dogs", "ORGANISM", 14, 18], ["dogs", "SPECIES", 14, 18], ["congenital PSS", "PROBLEM", 24, 38]]], ["Likewise, some dogs with acquired PSS due to cirrhosis are diagnosed when less than 6 months old.Microhepatia: Small LiverHepatic atrophy typically causes abnormalities in hepatic function tests (e.g., serum bile acids, blood ammonia) but may yield normal or abnormal ALT, SAP, BUN, and serum albumin.", [["hepatic", "ANATOMY", 172, 179], ["serum", "ANATOMY", 202, 207], ["blood", "ANATOMY", 220, 225], ["serum", "ANATOMY", 287, 292], ["PSS", "DISEASE", 34, 37], ["cirrhosis", "DISEASE", 45, 54], ["Microhepatia", "DISEASE", 97, 109], ["LiverHepatic atrophy", "DISEASE", 117, 137], ["abnormalities in hepatic function", "DISEASE", 155, 188], ["ammonia", "CHEMICAL", 226, 233], ["bile acids", "CHEMICAL", 208, 218], ["ammonia", "CHEMICAL", 226, 233], ["dogs", "ORGANISM", 15, 19], ["cirrhosis", "CANCER", 45, 54], ["hepatic", "ORGAN", 172, 179], ["serum", "ORGANISM_SUBSTANCE", 202, 207], ["bile acids", "SIMPLE_CHEMICAL", 208, 218], ["blood", "ORGANISM_SUBSTANCE", 220, 225], ["ammonia", "SIMPLE_CHEMICAL", 226, 233], ["ALT", "SIMPLE_CHEMICAL", 268, 271], ["SAP", "GENE_OR_GENE_PRODUCT", 273, 276], ["BUN", "SIMPLE_CHEMICAL", 278, 281], ["serum", "ORGANISM_SUBSTANCE", 287, 292], ["albumin", "GENE_OR_GENE_PRODUCT", 293, 300], ["ALT", "PROTEIN", 268, 271], ["SAP", "PROTEIN", 273, 276], ["BUN", "PROTEIN", 278, 281], ["serum albumin", "PROTEIN", 287, 300], ["dogs", "SPECIES", 15, 19], ["some dogs", "PROBLEM", 10, 19], ["acquired PSS", "PROBLEM", 25, 37], ["cirrhosis", "PROBLEM", 45, 54], ["Microhepatia", "PROBLEM", 97, 109], ["Small LiverHepatic atrophy", "PROBLEM", 111, 137], ["abnormalities in hepatic function tests", "PROBLEM", 155, 194], ["serum bile acids", "TEST", 202, 218], ["blood ammonia", "TEST", 220, 233], ["abnormal ALT", "PROBLEM", 259, 271], ["SAP", "TEST", 273, 276], ["BUN", "TEST", 278, 281], ["serum albumin", "TEST", 287, 300], ["cirrhosis", "OBSERVATION", 45, 54], ["Small", "OBSERVATION_MODIFIER", 111, 116], ["LiverHepatic", "OBSERVATION_MODIFIER", 117, 129], ["atrophy", "OBSERVATION", 130, 137], ["hepatic", "ANATOMY", 172, 179]]], ["A single normal or abnormal hepatic function test result does not mean that other hepatic function tests will have similar results.", [["hepatic", "ANATOMY", 28, 35], ["hepatic", "ANATOMY", 82, 89], ["hepatic", "ORGAN", 28, 35], ["hepatic", "ORGAN", 82, 89], ["abnormal hepatic function test", "PROBLEM", 19, 49], ["other hepatic function tests", "TEST", 76, 104], ["normal", "OBSERVATION", 9, 15], ["hepatic", "ANATOMY", 28, 35], ["hepatic", "ANATOMY", 82, 89]]], ["Pre-and postprandial serum bile acid concentrations are generally sensitive function tests.", [["serum", "ANATOMY", 21, 26], ["bile acid", "CHEMICAL", 27, 36], ["bile acid", "CHEMICAL", 27, 36], ["serum", "ORGANISM_SUBSTANCE", 21, 26], ["bile acid", "SIMPLE_CHEMICAL", 27, 36], ["Pre-and postprandial serum bile acid concentrations", "TEST", 0, 51], ["generally sensitive function tests", "PROBLEM", 56, 90]]], ["(NOTE: Cholestatic diseases also increase bile acids; therefore, bile acids are not a \"pure\" test of hepatic function.)", [["bile", "ANATOMY", 65, 69], ["hepatic", "ANATOMY", 101, 108], ["Cholestatic diseases", "DISEASE", 7, 27], ["bile acids", "CHEMICAL", 42, 52], ["bile acids", "CHEMICAL", 42, 52], ["bile acids", "CHEMICAL", 65, 75], ["bile acids", "SIMPLE_CHEMICAL", 42, 52], ["bile acids", "SIMPLE_CHEMICAL", 65, 75], ["hepatic", "ORGAN", 101, 108], ["Cholestatic diseases", "PROBLEM", 7, 27], ["bile acids", "TREATMENT", 42, 52], ["bile acids", "TEST", 65, 75], ["Cholestatic", "OBSERVATION", 7, 18], ["increase", "OBSERVATION_MODIFIER", 33, 41], ["bile acids", "OBSERVATION", 42, 52], ["bile", "ANATOMY", 65, 69], ["hepatic", "ANATOMY", 101, 108]]], ["However, if hepatic disease is Danger Values \u2022 Dogs, uncertain, but values greater than 20 mg/dl cause concern (i.e., kernicterus); cats, unknown.Microhepatia: Small LiverArtifacts \u2022 Exposure to bright sunlight or fluorescent lighting can decrease bilirubin by 50% per hour (see Chapter 1).Microhepatia: Small LiverDrug Therapy That May Alter Serum Bilirubin \u2022 Decreased bilirubin may be caused by drugs that cause hepatic enzyme induction (e.g., phenobarbital).", [["hepatic", "ANATOMY", 12, 19], ["hepatic", "ANATOMY", 415, 422], ["hepatic disease", "DISEASE", 12, 27], ["Microhepatia", "DISEASE", 146, 158], ["bilirubin", "CHEMICAL", 248, 257], ["Microhepatia", "DISEASE", 290, 302], ["bilirubin", "CHEMICAL", 371, 380], ["phenobarbital", "CHEMICAL", 447, 460], ["bilirubin", "CHEMICAL", 248, 257], ["Bilirubin", "CHEMICAL", 349, 358], ["bilirubin", "CHEMICAL", 371, 380], ["phenobarbital", "CHEMICAL", 447, 460], ["hepatic", "ORGAN", 12, 19], ["cats", "ORGANISM", 132, 136], ["bilirubin", "SIMPLE_CHEMICAL", 248, 257], ["Serum", "ORGANISM_SUBSTANCE", 343, 348], ["Bilirubin", "SIMPLE_CHEMICAL", 349, 358], ["bilirubin", "SIMPLE_CHEMICAL", 371, 380], ["hepatic", "ORGAN", 415, 422], ["phenobarbital", "SIMPLE_CHEMICAL", 447, 460], ["hepatic enzyme", "PROTEIN", 415, 429], ["cats", "SPECIES", 132, 136], ["hepatic disease", "PROBLEM", 12, 27], ["kernicterus", "PROBLEM", 118, 129], ["Small LiverArtifacts", "PROBLEM", 160, 180], ["bright sunlight", "TREATMENT", 195, 210], ["fluorescent lighting", "TREATMENT", 214, 234], ["bilirubin", "TEST", 248, 257], ["Small LiverDrug Therapy", "TREATMENT", 304, 327], ["Serum Bilirubin", "TEST", 343, 358], ["Decreased bilirubin", "PROBLEM", 361, 380], ["drugs", "TREATMENT", 398, 403], ["hepatic enzyme induction", "TREATMENT", 415, 439], ["phenobarbital", "TREATMENT", 447, 460], ["hepatic", "ANATOMY", 12, 19], ["disease", "OBSERVATION", 20, 27], ["kernicterus", "OBSERVATION", 118, 129], ["Small", "OBSERVATION_MODIFIER", 160, 165], ["LiverArtifacts", "OBSERVATION", 166, 180], ["Small", "OBSERVATION_MODIFIER", 304, 309], ["LiverDrug Therapy", "OBSERVATION", 310, 327], ["hepatic", "ANATOMY", 415, 422]]], ["Increased bilirubin may be the result of drugs causing hemolytic anemia or acute hepatic necrosis or dysfunction (see Box 9-5).Microhepatia: Small LiverCauses of Hyperbilirubinemia \u2022 Hemolytic disease and hepatobiliary disease are the two main causes (see Figure 9 -10).", [["hepatic", "ANATOMY", 81, 88], ["hepatobiliary", "ANATOMY", 205, 218], ["bilirubin", "CHEMICAL", 10, 19], ["hemolytic anemia", "DISEASE", 55, 71], ["acute hepatic necrosis", "DISEASE", 75, 97], ["Microhepatia", "DISEASE", 127, 139], ["Hyperbilirubinemia", "DISEASE", 162, 180], ["Hemolytic disease", "DISEASE", 183, 200], ["hepatobiliary disease", "DISEASE", 205, 226], ["bilirubin", "CHEMICAL", 10, 19], ["bilirubin", "GENE_OR_GENE_PRODUCT", 10, 19], ["hepatic", "ORGAN", 81, 88], ["hepatobiliary", "ORGAN", 205, 218], ["Increased bilirubin", "PROBLEM", 0, 19], ["drugs", "TREATMENT", 41, 46], ["hemolytic anemia", "PROBLEM", 55, 71], ["acute hepatic necrosis", "PROBLEM", 75, 97], ["dysfunction", "PROBLEM", 101, 112], ["Small LiverCauses of Hyperbilirubinemia", "PROBLEM", 141, 180], ["Hemolytic disease", "PROBLEM", 183, 200], ["hepatobiliary disease", "PROBLEM", 205, 226], ["bilirubin", "OBSERVATION", 10, 19], ["may be the result of", "UNCERTAINTY", 20, 40], ["hemolytic", "OBSERVATION_MODIFIER", 55, 64], ["acute", "OBSERVATION_MODIFIER", 75, 80], ["hepatic", "ANATOMY", 81, 88], ["necrosis", "OBSERVATION", 89, 97], ["Small", "OBSERVATION_MODIFIER", 141, 146], ["LiverCauses", "OBSERVATION", 147, 158], ["Hyperbilirubinemia", "OBSERVATION", 162, 180], ["Hemolytic", "OBSERVATION_MODIFIER", 183, 192], ["hepatobiliary", "ANATOMY", 205, 218], ["disease", "OBSERVATION", 219, 226], ["main", "OBSERVATION_MODIFIER", 239, 243]]], ["A CBC should be determined in every icteric patient to help rule out hemolytic disease.", [["hemolytic disease", "DISEASE", 69, 86], ["CBC", "CELL", 2, 5], ["patient", "ORGANISM", 44, 51], ["patient", "SPECIES", 44, 51], ["A CBC", "TEST", 0, 5], ["hemolytic disease", "PROBLEM", 69, 86], ["hemolytic", "OBSERVATION", 69, 78]]], ["RBC numbers must decrease rapidly and significantly (i.e., packed cell volume [PCV] usually <20%) to cause clinical icterus.", [["RBC", "ANATOMY", 0, 3], ["cell", "ANATOMY", 66, 70], ["icterus", "DISEASE", 116, 123], ["RBC", "CELL", 0, 3], ["cell", "CELL", 66, 70], ["RBC", "CELL_TYPE", 0, 3], ["RBC numbers", "TEST", 0, 11], ["packed cell volume", "TEST", 59, 77], ["PCV", "TEST", 79, 82], ["clinical icterus", "PROBLEM", 107, 123], ["decrease", "OBSERVATION_MODIFIER", 17, 25], ["rapidly", "OBSERVATION_MODIFIER", 26, 33], ["icterus", "OBSERVATION", 116, 123]]], ["Very regenerative anemias may suggest that icterus is due to immune-mediated hemolytic anemia (IMHA).", [["anemias", "DISEASE", 18, 25], ["icterus", "DISEASE", 43, 50], ["hemolytic anemia", "DISEASE", 77, 93], ["IMHA", "DISEASE", 95, 99], ["Very regenerative anemias", "PROBLEM", 0, 25], ["icterus", "PROBLEM", 43, 50], ["immune-mediated hemolytic anemia", "PROBLEM", 61, 93], ["regenerative", "OBSERVATION_MODIFIER", 5, 17], ["anemias", "OBSERVATION", 18, 25], ["icterus", "OBSERVATION", 43, 50], ["hemolytic", "OBSERVATION_MODIFIER", 77, 86], ["anemia", "OBSERVATION", 87, 93]]], ["Reticulocytosis, hemoglobinemia, hemoglobinuria, erythrocytic autoagglutination, spherocytosis, positive Coombs test results, splenomegaly, or hepatomegaly are often present.", [["Reticulocytosis", "DISEASE", 0, 15], ["hemoglobinemia", "DISEASE", 17, 31], ["hemoglobinuria", "DISEASE", 33, 47], ["erythrocytic autoagglutination", "DISEASE", 49, 79], ["spherocytosis", "DISEASE", 81, 94], ["splenomegaly", "DISEASE", 126, 138], ["hepatomegaly", "DISEASE", 143, 155], ["Reticulocytosis", "PROBLEM", 0, 15], ["hemoglobinemia", "PROBLEM", 17, 31], ["hemoglobinuria", "PROBLEM", 33, 47], ["erythrocytic autoagglutination", "PROBLEM", 49, 79], ["spherocytosis", "PROBLEM", 81, 94], ["positive Coombs test results", "PROBLEM", 96, 124], ["splenomegaly", "PROBLEM", 126, 138], ["hepatomegaly", "PROBLEM", 143, 155], ["hemoglobinuria", "OBSERVATION", 33, 47], ["erythrocytic autoagglutination", "OBSERVATION", 49, 79], ["spherocytosis", "OBSERVATION", 81, 94], ["splenomegaly", "OBSERVATION", 126, 138], ["hepatomegaly", "OBSERVATION", 143, 155]]], ["Chapter 3 includes further discussion of IMHA and other regenerative anemias (e.g., Heinz body, zinc intoxication, Babesia, Cytauxzoonosis, hemotrophic Mycoplasma).", [["body", "ANATOMY", 90, 94], ["IMHA", "DISEASE", 41, 45], ["anemias", "DISEASE", 69, 76], ["zinc", "CHEMICAL", 96, 100], ["Babesia", "DISEASE", 115, 122], ["zinc", "CHEMICAL", 96, 100], ["IMHA", "CANCER", 41, 45], ["zinc", "SIMPLE_CHEMICAL", 96, 100], ["IMHA", "PROBLEM", 41, 45], ["other regenerative anemias", "PROBLEM", 50, 76], ["Heinz body", "PROBLEM", 84, 94], ["zinc intoxication", "PROBLEM", 96, 113], ["Babesia", "PROBLEM", 115, 122], ["Cytauxzoonosis", "PROBLEM", 124, 138], ["hemotrophic Mycoplasma)", "PROBLEM", 140, 163], ["regenerative", "OBSERVATION_MODIFIER", 56, 68], ["anemias", "OBSERVATION", 69, 76]]], ["Bilirubinuria theoretically should be absent in hemolytic disease but is typically present in IMHA because canine kidneys conjugate bilirubin.", [["kidneys", "ANATOMY", 114, 121], ["Bilirubinuria", "DISEASE", 0, 13], ["hemolytic disease", "DISEASE", 48, 65], ["bilirubin", "CHEMICAL", 132, 141], ["bilirubin", "CHEMICAL", 132, 141], ["IMHA", "CANCER", 94, 98], ["canine", "ORGANISM", 107, 113], ["kidneys", "ORGAN", 114, 121], ["bilirubin", "GENE_OR_GENE_PRODUCT", 132, 141], ["canine", "SPECIES", 107, 113], ["canine", "SPECIES", 107, 113], ["hemolytic disease", "PROBLEM", 48, 65], ["canine kidneys conjugate bilirubin", "TEST", 107, 141], ["hemolytic disease", "OBSERVATION", 48, 65], ["kidneys", "ANATOMY", 114, 121], ["conjugate bilirubin", "OBSERVATION", 122, 141]]], ["The clinician must not be misled by increases in ALT, because severe, acute hemolytic anemia may cause increased ALT (ostensibly caused by acute hepatic hypoxia).", [["hepatic", "ANATOMY", 145, 152], ["hemolytic anemia", "DISEASE", 76, 92], ["acute hepatic hypoxia", "DISEASE", 139, 160], ["ALT", "SIMPLE_CHEMICAL", 49, 52], ["ALT", "SIMPLE_CHEMICAL", 113, 116], ["hepatic", "ORGAN", 145, 152], ["ALT", "TEST", 49, 52], ["acute hemolytic anemia", "PROBLEM", 70, 92], ["increased ALT", "PROBLEM", 103, 116], ["acute hepatic hypoxia", "PROBLEM", 139, 160], ["acute", "OBSERVATION_MODIFIER", 70, 75], ["hemolytic", "OBSERVATION", 76, 85], ["acute", "OBSERVATION_MODIFIER", 139, 144], ["hepatic", "ANATOMY", 145, 152], ["hypoxia", "OBSERVATION", 153, 160]]], ["Severe hepatic disease (especially acute necrosis) is sometimes accompanied by DIC and subsequent hemolytic anemia.", [["hepatic", "ANATOMY", 7, 14], ["hepatic disease", "DISEASE", 7, 22], ["necrosis", "DISEASE", 41, 49], ["DIC", "DISEASE", 79, 82], ["hemolytic anemia", "DISEASE", 98, 114], ["hepatic", "ORGAN", 7, 14], ["Severe hepatic disease", "PROBLEM", 0, 22], ["acute necrosis)", "PROBLEM", 35, 50], ["DIC", "PROBLEM", 79, 82], ["subsequent hemolytic anemia", "PROBLEM", 87, 114], ["hepatic", "ANATOMY", 7, 14], ["disease", "OBSERVATION", 15, 22], ["acute", "OBSERVATION_MODIFIER", 35, 40], ["necrosis", "OBSERVATION", 41, 49], ["DIC", "OBSERVATION", 79, 82], ["hemolytic", "OBSERVATION_MODIFIER", 98, 107], ["anemia", "OBSERVATION", 108, 114]]], ["These cases may be difficult to distinguish from IMHA.", [["IMHA", "DISEASE", 49, 53], ["IMHA", "CANCER", 49, 53]]], ["However, anemia caused by DIC is usually not as regenerative as in IMHA; in addition, the presence of RBC fragments, thrombocytopenia, increased fibrin degradation products (FDP), decreased antithrombin III, prolonged clotting time, and abnormal hepatic function tests usually allow differentiation, as do vomiting, abdominal pain, and encephalopathy when present.Microhepatia: Small LiverDogs and cats often have relatively severe hepatic disease before icterus is observed; however, the magnitude of the total serum bilirubin is not prognostic or diagnostic.", [["RBC fragments", "ANATOMY", 102, 115], ["hepatic", "ANATOMY", 246, 253], ["abdominal", "ANATOMY", 316, 325], ["hepatic", "ANATOMY", 432, 439], ["serum", "ANATOMY", 512, 517], ["anemia", "DISEASE", 9, 15], ["DIC", "DISEASE", 26, 29], ["thrombocytopenia", "DISEASE", 117, 133], ["abnormal hepatic function", "DISEASE", 237, 262], ["vomiting", "DISEASE", 306, 314], ["abdominal pain", "DISEASE", 316, 330], ["encephalopathy", "DISEASE", 336, 350], ["Microhepatia", "DISEASE", 364, 376], ["hepatic disease", "DISEASE", 432, 447], ["icterus", "DISEASE", 455, 462], ["bilirubin", "CHEMICAL", 518, 527], ["bilirubin", "CHEMICAL", 518, 527], ["RBC", "CELL", 102, 105], ["fibrin", "GENE_OR_GENE_PRODUCT", 145, 151], ["FDP", "SIMPLE_CHEMICAL", 174, 177], ["antithrombin III", "GENE_OR_GENE_PRODUCT", 190, 206], ["hepatic", "MULTI-TISSUE_STRUCTURE", 246, 253], ["abdominal", "ORGANISM_SUBDIVISION", 316, 325], ["cats", "ORGANISM", 398, 402], ["hepatic", "ORGAN", 432, 439], ["serum", "ORGANISM_SUBSTANCE", 512, 517], ["bilirubin", "GENE_OR_GENE_PRODUCT", 518, 527], ["fibrin degradation products", "PROTEIN", 145, 172], ["FDP", "PROTEIN", 174, 177], ["antithrombin III", "PROTEIN", 190, 206], ["cats", "SPECIES", 398, 402], ["anemia", "PROBLEM", 9, 15], ["DIC", "PROBLEM", 26, 29], ["RBC fragments", "PROBLEM", 102, 115], ["thrombocytopenia", "PROBLEM", 117, 133], ["increased fibrin degradation products", "PROBLEM", 135, 172], ["FDP", "TEST", 174, 177], ["decreased antithrombin III", "PROBLEM", 180, 206], ["prolonged clotting time", "PROBLEM", 208, 231], ["abnormal hepatic function tests", "PROBLEM", 237, 268], ["vomiting", "PROBLEM", 306, 314], ["abdominal pain", "PROBLEM", 316, 330], ["encephalopathy", "PROBLEM", 336, 350], ["Small LiverDogs and cats", "PROBLEM", 378, 402], ["relatively severe hepatic disease", "PROBLEM", 414, 447], ["icterus", "PROBLEM", 455, 462], ["the total serum bilirubin", "TEST", 502, 527], ["anemia", "OBSERVATION", 9, 15], ["RBC fragments", "OBSERVATION", 102, 115], ["thrombocytopenia", "OBSERVATION", 117, 133], ["increased", "OBSERVATION_MODIFIER", 135, 144], ["fibrin degradation", "OBSERVATION", 145, 163], ["decreased", "OBSERVATION_MODIFIER", 180, 189], ["antithrombin III", "OBSERVATION_MODIFIER", 190, 206], ["prolonged", "OBSERVATION_MODIFIER", 208, 217], ["clotting", "OBSERVATION", 218, 226], ["hepatic", "ANATOMY", 246, 253], ["abdominal", "ANATOMY", 316, 325], ["pain", "OBSERVATION", 326, 330], ["encephalopathy", "OBSERVATION", 336, 350], ["Small", "OBSERVATION_MODIFIER", 378, 383], ["LiverDogs", "OBSERVATION", 384, 393], ["relatively", "OBSERVATION_MODIFIER", 414, 424], ["severe", "OBSERVATION_MODIFIER", 425, 431], ["hepatic", "ANATOMY", 432, 439], ["disease", "OBSERVATION", 440, 447], ["icterus", "OBSERVATION", 455, 462]]], ["Secondary hepatic disease (reactive disease or so-called bystander phenomenon as the result of septicemia, toxemia, or inflammation) may cause icterus.", [["hepatic", "ANATOMY", 10, 17], ["Secondary hepatic disease", "DISEASE", 0, 25], ["septicemia", "DISEASE", 95, 105], ["toxemia", "DISEASE", 107, 114], ["inflammation", "DISEASE", 119, 131], ["icterus", "DISEASE", 143, 150], ["hepatic", "ORGAN", 10, 17], ["Secondary hepatic disease", "PROBLEM", 0, 25], ["reactive disease", "PROBLEM", 27, 43], ["so-called bystander phenomenon", "PROBLEM", 47, 77], ["septicemia", "PROBLEM", 95, 105], ["toxemia", "PROBLEM", 107, 114], ["inflammation", "PROBLEM", 119, 131], ["icterus", "PROBLEM", 143, 150], ["hepatic", "ANATOMY", 10, 17], ["disease", "OBSERVATION", 18, 25], ["reactive disease", "OBSERVATION", 27, 43], ["septicemia", "OBSERVATION", 95, 105], ["toxemia", "OBSERVATION", 107, 114], ["icterus", "OBSERVATION", 143, 150]]], ["Certain bacterial endotoxins and acute phase inflammatory mediators are thought to alter normal bilirubin metabolism and cause increases in total bilirubin concentrations.Microhepatia: Small LiverMost feline hepatic diseases eventually cause icterus; the most common conditions include hepatic lipidosis, cholangitis and cholangiohepatitis, hepatic lymphoma, and FIP.", [["Liver", "ANATOMY", 191, 196], ["hepatic", "ANATOMY", 208, 215], ["hepatic", "ANATOMY", 286, 293], ["hepatic lymphoma", "ANATOMY", 341, 357], ["bilirubin", "CHEMICAL", 96, 105], ["bilirubin", "CHEMICAL", 146, 155], ["Microhepatia", "DISEASE", 171, 183], ["feline hepatic diseases", "DISEASE", 201, 224], ["icterus", "DISEASE", 242, 249], ["hepatic lipidosis", "DISEASE", 286, 303], ["cholangitis", "DISEASE", 305, 316], ["cholangiohepatitis", "DISEASE", 321, 339], ["hepatic lymphoma", "DISEASE", 341, 357], ["FIP", "DISEASE", 363, 366], ["bilirubin", "CHEMICAL", 96, 105], ["bilirubin", "CHEMICAL", 146, 155], ["bilirubin", "SIMPLE_CHEMICAL", 96, 105], ["bilirubin", "SIMPLE_CHEMICAL", 146, 155], ["Liver", "ORGAN", 191, 196], ["feline", "ORGANISM", 201, 207], ["hepatic", "ORGAN", 208, 215], ["hepatic", "ORGAN", 286, 293], ["hepatic lymphoma", "CANCER", 341, 357], ["acute phase inflammatory mediators", "PROTEIN", 33, 67], ["feline", "SPECIES", 201, 207], ["Certain bacterial endotoxins", "PROBLEM", 0, 28], ["acute phase inflammatory mediators", "PROBLEM", 33, 67], ["total bilirubin concentrations", "TEST", 140, 170], ["Small LiverMost feline hepatic diseases", "PROBLEM", 185, 224], ["icterus", "PROBLEM", 242, 249], ["hepatic lipidosis", "PROBLEM", 286, 303], ["cholangitis", "PROBLEM", 305, 316], ["cholangiohepatitis", "PROBLEM", 321, 339], ["hepatic lymphoma", "PROBLEM", 341, 357], ["FIP", "PROBLEM", 363, 366], ["bacterial", "OBSERVATION_MODIFIER", 8, 17], ["endotoxins", "OBSERVATION", 18, 28], ["acute", "OBSERVATION_MODIFIER", 33, 38], ["phase", "OBSERVATION_MODIFIER", 39, 44], ["inflammatory", "OBSERVATION", 45, 57], ["bilirubin metabolism", "OBSERVATION", 96, 116], ["increases", "OBSERVATION_MODIFIER", 127, 136], ["total", "OBSERVATION_MODIFIER", 140, 145], ["bilirubin concentrations", "OBSERVATION", 146, 170], ["Small", "OBSERVATION_MODIFIER", 185, 190], ["Liver", "ANATOMY", 191, 196], ["Most feline", "OBSERVATION_MODIFIER", 196, 207], ["hepatic", "ANATOMY", 208, 215], ["diseases", "OBSERVATION", 216, 224], ["icterus", "OBSERVATION", 242, 249], ["most common", "OBSERVATION_MODIFIER", 255, 266], ["hepatic", "ANATOMY", 286, 293], ["lipidosis", "OBSERVATION", 294, 303], ["cholangitis", "OBSERVATION", 305, 316], ["hepatic", "ANATOMY", 341, 348], ["lymphoma", "OBSERVATION", 349, 357], ["FIP", "OBSERVATION", 363, 366]]], ["Icterus in cats is an indication for a CBC and serum biochemistry panel.", [["serum", "ANATOMY", 47, 52], ["cats", "ORGANISM", 11, 15], ["serum", "ORGANISM_SUBSTANCE", 47, 52], ["cats", "SPECIES", 11, 15], ["Icterus in cats", "PROBLEM", 0, 15], ["a CBC", "TEST", 37, 42], ["serum biochemistry panel", "TEST", 47, 71], ["cats", "OBSERVATION", 11, 15]]], ["Icterus in cats that is not caused by hemolysis usually indicates a hepatic biopsy, because most of these cats have primary hepatic disease.", [["hepatic biopsy", "ANATOMY", 68, 82], ["hepatic", "ANATOMY", 124, 131], ["hemolysis", "DISEASE", 38, 47], ["primary hepatic disease", "DISEASE", 116, 139], ["cats", "ORGANISM", 11, 15], ["hepatic biopsy", "MULTI-TISSUE_STRUCTURE", 68, 82], ["cats", "ORGANISM", 106, 110], ["hepatic", "ORGAN", 124, 131], ["cats", "SPECIES", 11, 15], ["cats", "SPECIES", 106, 110], ["Icterus in cats", "PROBLEM", 0, 15], ["hemolysis", "PROBLEM", 38, 47], ["a hepatic biopsy", "TEST", 66, 82], ["primary hepatic disease", "PROBLEM", 116, 139], ["cats", "OBSERVATION", 11, 15], ["not caused", "UNCERTAINTY", 24, 34], ["hemolysis", "OBSERVATION", 38, 47], ["hepatic", "ANATOMY", 68, 75], ["biopsy", "OBSERVATION", 76, 82], ["hepatic", "ANATOMY", 124, 131], ["disease", "OBSERVATION", 132, 139]]], ["Biopsy is necessary to differentiate causes and institute specific treatment.Microhepatia: Small LiverHepatic function testing is mandatory because these diseases may not significantly change serum ALT, SAP, albumin, BUN, glucose, or bilirubin concentrations.", [["serum", "ANATOMY", 192, 197], ["Microhepatia", "DISEASE", 77, 89], ["glucose", "CHEMICAL", 222, 229], ["bilirubin", "CHEMICAL", 234, 243], ["glucose", "CHEMICAL", 222, 229], ["bilirubin", "CHEMICAL", 234, 243], ["serum", "ORGANISM_SUBSTANCE", 192, 197], ["ALT", "SIMPLE_CHEMICAL", 198, 201], ["SAP", "SIMPLE_CHEMICAL", 203, 206], ["albumin", "GENE_OR_GENE_PRODUCT", 208, 215], ["BUN", "SIMPLE_CHEMICAL", 217, 220], ["glucose", "SIMPLE_CHEMICAL", 222, 229], ["bilirubin", "SIMPLE_CHEMICAL", 234, 243], ["SAP", "PROTEIN", 203, 206], ["albumin", "PROTEIN", 208, 215], ["Biopsy", "TEST", 0, 6], ["specific treatment", "TREATMENT", 58, 76], ["Small LiverHepatic function testing", "TEST", 91, 126], ["these diseases", "PROBLEM", 148, 162], ["serum ALT", "TEST", 192, 201], ["SAP", "TEST", 203, 206], ["albumin", "TEST", 208, 215], ["BUN", "TEST", 217, 220], ["glucose", "TEST", 222, 229], ["bilirubin concentrations", "TEST", 234, 258], ["Small", "OBSERVATION_MODIFIER", 91, 96], ["LiverHepatic function", "OBSERVATION", 97, 118]]], ["Resting blood ammonia concentrations are very specific for hepatic dysfunction, but they are not as sensitive as serum bile acids.", [["blood", "ANATOMY", 8, 13], ["hepatic", "ANATOMY", 59, 66], ["serum", "ANATOMY", 113, 118], ["ammonia", "CHEMICAL", 14, 21], ["hepatic dysfunction", "DISEASE", 59, 78], ["bile acids", "CHEMICAL", 119, 129], ["ammonia", "CHEMICAL", 14, 21], ["bile acids", "CHEMICAL", 119, 129], ["blood", "ORGANISM_SUBSTANCE", 8, 13], ["ammonia", "SIMPLE_CHEMICAL", 14, 21], ["hepatic", "ORGAN", 59, 66], ["serum", "ORGANISM_SUBSTANCE", 113, 118], ["bile acids", "SIMPLE_CHEMICAL", 119, 129], ["Resting blood ammonia concentrations", "TEST", 0, 36], ["hepatic dysfunction", "PROBLEM", 59, 78], ["serum bile acids", "TEST", 113, 129], ["hepatic", "ANATOMY", 59, 66], ["dysfunction", "OBSERVATION", 67, 78]]], ["A patient in an episode of hepatic encephalopathy may have increased or normal resting blood ammonia concentrations.", [["hepatic", "ANATOMY", 27, 34], ["blood", "ANATOMY", 87, 92], ["hepatic encephalopathy", "DISEASE", 27, 49], ["ammonia", "CHEMICAL", 93, 100], ["ammonia", "CHEMICAL", 93, 100], ["patient", "ORGANISM", 2, 9], ["hepatic", "ORGAN", 27, 34], ["blood", "ORGANISM_SUBSTANCE", 87, 92], ["ammonia", "SIMPLE_CHEMICAL", 93, 100], ["patient", "SPECIES", 2, 9], ["hepatic encephalopathy", "PROBLEM", 27, 49], ["normal resting blood ammonia concentrations", "PROBLEM", 72, 115], ["hepatic", "ANATOMY", 27, 34], ["encephalopathy", "OBSERVATION", 35, 49], ["increased", "OBSERVATION_MODIFIER", 59, 68], ["normal", "OBSERVATION", 72, 78]]], ["Ammonia tolerance testing (ATT) and pre-and postprandial serum bile acid concentrations appear to be the most sensitive and specific tests for hepatic dysfunction that causes hepatic encephalopathy.", [["serum", "ANATOMY", 57, 62], ["hepatic", "ANATOMY", 143, 150], ["hepatic", "ANATOMY", 175, 182], ["Ammonia", "CHEMICAL", 0, 7], ["bile acid", "CHEMICAL", 63, 72], ["hepatic dysfunction", "DISEASE", 143, 162], ["hepatic encephalopathy", "DISEASE", 175, 197], ["Ammonia", "CHEMICAL", 0, 7], ["bile acid", "CHEMICAL", 63, 72], ["Ammonia", "SIMPLE_CHEMICAL", 0, 7], ["serum", "ORGANISM_SUBSTANCE", 57, 62], ["bile acid", "SIMPLE_CHEMICAL", 63, 72], ["hepatic", "ORGAN", 143, 150], ["hepatic", "ORGAN", 175, 182], ["Ammonia tolerance testing", "TEST", 0, 25], ["ATT", "TEST", 27, 30], ["pre-and postprandial serum bile acid concentrations", "TEST", 36, 87], ["specific tests", "TEST", 124, 138], ["hepatic dysfunction", "PROBLEM", 143, 162], ["hepatic encephalopathy", "PROBLEM", 175, 197], ["bile", "ANATOMY", 63, 67], ["hepatic", "ANATOMY", 143, 150], ["dysfunction", "OBSERVATION", 151, 162], ["hepatic", "ANATOMY", 175, 182], ["encephalopathy", "OBSERVATION", 183, 197]]], ["A very rare congenital urea cycle enzyme deficiency may cause hepatic encephalopathy and hyperammonemia without affecting enzymes or bile acids, in which case analysis of urea cycle enzymes in hepatic samples is necessary for diagnosis.IcterusIcterus is detected at physical examination or when serum or plasma is inspected at the laboratory.", [["hepatic", "ANATOMY", 62, 69], ["hepatic samples", "ANATOMY", 193, 208], ["serum", "ANATOMY", 295, 300], ["plasma", "ANATOMY", 304, 310], ["urea", "CHEMICAL", 23, 27], ["hepatic encephalopathy", "DISEASE", 62, 84], ["hyperammonemia", "DISEASE", 89, 103], ["bile acids", "CHEMICAL", 133, 143], ["urea", "CHEMICAL", 171, 175], ["urea", "CHEMICAL", 23, 27], ["bile acids", "CHEMICAL", 133, 143], ["urea", "CHEMICAL", 171, 175], ["urea", "SIMPLE_CHEMICAL", 23, 27], ["hepatic", "ORGAN", 62, 69], ["bile acids", "SIMPLE_CHEMICAL", 133, 143], ["urea", "SIMPLE_CHEMICAL", 171, 175], ["hepatic samples", "CANCER", 193, 208], ["serum", "ORGANISM_SUBSTANCE", 295, 300], ["plasma", "ORGANISM_SUBSTANCE", 304, 310], ["enzymes", "PROTEIN", 122, 129], ["urea cycle enzymes", "PROTEIN", 171, 189], ["A very rare congenital urea cycle enzyme deficiency", "PROBLEM", 0, 51], ["hepatic encephalopathy", "PROBLEM", 62, 84], ["hyperammonemia", "PROBLEM", 89, 103], ["affecting enzymes", "PROBLEM", 112, 129], ["bile acids", "TEST", 133, 143], ["urea cycle enzymes", "TEST", 171, 189], ["hepatic samples", "TEST", 193, 208], ["IcterusIcterus", "PROBLEM", 236, 250], ["physical examination", "TEST", 266, 286], ["urea cycle", "OBSERVATION", 23, 33], ["enzyme deficiency", "OBSERVATION", 34, 51], ["may cause", "UNCERTAINTY", 52, 61], ["hepatic", "ANATOMY", 62, 69], ["encephalopathy", "OBSERVATION", 70, 84], ["hyperammonemia", "OBSERVATION", 89, 103], ["hepatic", "ANATOMY", 193, 200]]], ["Hyperbilirubinemia always denotes hepatobiliary or hematopoietic disease (Figure 9 -10).", [["hepatobiliary", "ANATOMY", 34, 47], ["hematopoietic", "ANATOMY", 51, 64], ["Hyperbilirubinemia", "DISEASE", 0, 18], ["hepatobiliary or hematopoietic disease", "DISEASE", 34, 72], ["hepatobiliary", "ORGAN", 34, 47], ["Hyperbilirubinemia", "PROBLEM", 0, 18], ["hepatobiliary or hematopoietic disease", "PROBLEM", 34, 72], ["Figure", "TEST", 74, 80], ["hepatobiliary", "ANATOMY", 34, 47], ["hematopoietic disease", "OBSERVATION", 51, 72]]], ["Hepatic and hematopoietic diseases are not always associated with icterus, and disease in either system may be secondary to other disorders.", [["Hepatic", "ANATOMY", 0, 7], ["hematopoietic", "ANATOMY", 12, 25], ["Hepatic and hematopoietic diseases", "DISEASE", 0, 34], ["icterus", "DISEASE", 66, 73], ["Hepatic", "MULTI-TISSUE_STRUCTURE", 0, 7], ["Hepatic and hematopoietic diseases", "PROBLEM", 0, 34], ["icterus", "PROBLEM", 66, 73], ["disease in either system", "PROBLEM", 79, 103], ["other disorders", "PROBLEM", 124, 139], ["hematopoietic diseases", "OBSERVATION", 12, 34], ["not always associated", "UNCERTAINTY", 39, 60], ["icterus", "OBSERVATION", 66, 73], ["disease", "OBSERVATION", 79, 86]]], ["The presence or absence of icterus is not diagnostic or prognostic.", [["icterus", "DISEASE", 27, 34], ["icterus", "PROBLEM", 27, 34], ["icterus", "OBSERVATION", 27, 34]]], ["Sepsis, pancreatitis, and IBD sometimes cause secondary hepatobiliary dysfunction that may include icterus.TOTAL SERUM BILIRUBINCommon Indications \u2022 Measurement of total serum bilirubin is indicated in cases of icterus (on either physical examination or inspection of nonhemolyzed serum or plasma), bilirubinuria (any amount in a cat or significant amounts in a dog), or suspected hepatic disease that is not apparent on other tests.", [["hepatobiliary", "ANATOMY", 56, 69], ["serum", "ANATOMY", 170, 175], ["serum", "ANATOMY", 281, 286], ["plasma", "ANATOMY", 290, 296], ["hepatic", "ANATOMY", 381, 388], ["Sepsis", "DISEASE", 0, 6], ["pancreatitis", "DISEASE", 8, 20], ["IBD", "DISEASE", 26, 29], ["hepatobiliary dysfunction", "DISEASE", 56, 81], ["icterus", "DISEASE", 99, 106], ["bilirubin", "CHEMICAL", 176, 185], ["icterus", "DISEASE", 211, 218], ["bilirubinuria", "DISEASE", 299, 312], ["hepatic disease", "DISEASE", 381, 396], ["bilirubin", "CHEMICAL", 176, 185], ["hepatobiliary", "ORGAN", 56, 69], ["serum", "ORGANISM_SUBSTANCE", 170, 175], ["bilirubin", "GENE_OR_GENE_PRODUCT", 176, 185], ["serum", "ORGANISM_SUBSTANCE", 281, 286], ["plasma", "ORGANISM_SUBSTANCE", 290, 296], ["dog", "ORGANISM", 362, 365], ["hepatic", "ORGAN", 381, 388], ["Sepsis", "PROBLEM", 0, 6], ["pancreatitis", "PROBLEM", 8, 20], ["IBD", "PROBLEM", 26, 29], ["secondary hepatobiliary dysfunction", "PROBLEM", 46, 81], ["icterus", "PROBLEM", 99, 106], ["TOTAL SERUM BILIRUBINCommon", "TEST", 107, 134], ["Measurement", "TEST", 149, 160], ["total serum bilirubin", "TEST", 164, 185], ["icterus", "PROBLEM", 211, 218], ["physical examination", "TEST", 230, 250], ["inspection", "TEST", 254, 264], ["nonhemolyzed serum", "TEST", 268, 286], ["bilirubinuria", "PROBLEM", 299, 312], ["hepatic disease", "PROBLEM", 381, 396], ["other tests", "TEST", 421, 432], ["pancreatitis", "OBSERVATION", 8, 20], ["IBD", "OBSERVATION", 26, 29], ["hepatobiliary", "ANATOMY", 56, 69], ["dysfunction", "OBSERVATION", 70, 81], ["icterus", "OBSERVATION", 99, 106], ["icterus", "OBSERVATION", 211, 218], ["hepatic", "ANATOMY", 381, 388], ["disease", "OBSERVATION", 389, 396], ["not apparent", "UNCERTAINTY", 405, 417]]], ["The sclera has detectable icterus when the serum bilirubin is greater than 3 to 4 mg/dl, and the plasma is icteric when the serum bilirubin is greater than 1.5 to 2 mg/dl.", [["sclera", "ANATOMY", 4, 10], ["serum", "ANATOMY", 43, 48], ["plasma", "ANATOMY", 97, 103], ["serum", "ANATOMY", 124, 129], ["icterus", "DISEASE", 26, 33], ["bilirubin", "CHEMICAL", 49, 58], ["icteric", "DISEASE", 107, 114], ["bilirubin", "CHEMICAL", 130, 139], ["bilirubin", "CHEMICAL", 49, 58], ["bilirubin", "CHEMICAL", 130, 139], ["sclera", "MULTI-TISSUE_STRUCTURE", 4, 10], ["serum", "ORGANISM_SUBSTANCE", 43, 48], ["bilirubin", "SIMPLE_CHEMICAL", 49, 58], ["plasma", "ORGANISM_SUBSTANCE", 97, 103], ["serum", "ORGANISM_SUBSTANCE", 124, 129], ["bilirubin", "GENE_OR_GENE_PRODUCT", 130, 139], ["detectable icterus", "PROBLEM", 15, 33], ["the serum bilirubin", "TEST", 39, 58], ["the plasma", "TEST", 93, 103], ["icteric", "PROBLEM", 107, 114], ["the serum bilirubin", "TEST", 120, 139], ["sclera", "ANATOMY", 4, 10], ["detectable", "OBSERVATION_MODIFIER", 15, 25], ["icterus", "OBSERVATION", 26, 33], ["icteric", "OBSERVATION", 107, 114]]], ["NOTE: Icterus is absent in many animals (especially dogs) with hepatic disease.", [["hepatic", "ANATOMY", 63, 70], ["hepatic disease", "DISEASE", 63, 78], ["dogs", "ORGANISM", 52, 56], ["hepatic", "ORGAN", 63, 70], ["dogs", "SPECIES", 52, 56], ["Icterus", "PROBLEM", 6, 13], ["hepatic disease", "PROBLEM", 63, 78], ["Icterus", "OBSERVATION", 6, 13], ["absent", "OBSERVATION", 17, 23], ["hepatic", "ANATOMY", 63, 70], ["disease", "OBSERVATION", 71, 78]]], ["Serum bilirubin is not a sensitive test for hepatic disease.TOTAL SERUM BILIRUBINMeasurement of direct (conjugated) and indirect (unconjugated) bilirubin fractions is not useful because hemolytic, hepatic, and biliary tract diseases have unpredictable variation in the amount of each fraction.TOTAL SERUM BILIRUBINAnalysis \u2022 Total bilirubin is measured in serum or heparinized plasma by spectrophotometric and dry reagent methods.", [["Serum", "ANATOMY", 0, 5], ["hepatic", "ANATOMY", 44, 51], ["hepatic", "ANATOMY", 197, 204], ["biliary tract", "ANATOMY", 210, 223], ["serum", "ANATOMY", 356, 361], ["plasma", "ANATOMY", 377, 383], ["bilirubin", "CHEMICAL", 6, 15], ["hepatic disease", "DISEASE", 44, 59], ["bilirubin", "CHEMICAL", 144, 153], ["hemolytic, hepatic, and biliary tract diseases", "DISEASE", 186, 232], ["bilirubin", "CHEMICAL", 331, 340], ["bilirubin", "CHEMICAL", 6, 15], ["bilirubin", "CHEMICAL", 144, 153], ["bilirubin", "CHEMICAL", 331, 340], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["bilirubin", "GENE_OR_GENE_PRODUCT", 6, 15], ["hepatic", "ORGAN", 44, 51], ["unconjugated", "SIMPLE_CHEMICAL", 130, 142], ["bilirubin", "SIMPLE_CHEMICAL", 144, 153], ["hepatic", "MULTI-TISSUE_STRUCTURE", 197, 204], ["biliary tract", "ORGANISM_SUBDIVISION", 210, 223], ["bilirubin", "GENE_OR_GENE_PRODUCT", 331, 340], ["serum", "ORGANISM_SUBSTANCE", 356, 361], ["plasma", "ORGANISM_SUBSTANCE", 377, 383], ["Serum bilirubin", "TEST", 0, 15], ["hepatic disease", "PROBLEM", 44, 59], ["TOTAL SERUM BILIRUBINMeasurement", "TEST", 60, 92], ["direct (conjugated)", "TEST", 96, 115], ["indirect (unconjugated) bilirubin fractions", "TEST", 120, 163], ["hemolytic, hepatic, and biliary tract diseases", "PROBLEM", 186, 232], ["unpredictable variation", "PROBLEM", 238, 261], ["TOTAL SERUM BILIRUBINAnalysis", "TEST", 293, 322], ["Total bilirubin", "TEST", 325, 340], ["serum", "TEST", 356, 361], ["heparinized plasma", "TEST", 365, 383], ["dry reagent methods", "TREATMENT", 410, 429], ["hepatic", "ANATOMY", 44, 51], ["disease", "OBSERVATION", 52, 59], ["hepatic", "ANATOMY", 197, 204], ["biliary tract", "ANATOMY", 210, 223], ["unpredictable", "OBSERVATION_MODIFIER", 238, 251], ["variation", "OBSERVATION_MODIFIER", 252, 261], ["amount", "OBSERVATION_MODIFIER", 269, 275]]], ["The latter require dilutions if the bilirubin is greater than 7.5 mg/dl.", [["bilirubin", "CHEMICAL", 36, 45], ["bilirubin", "CHEMICAL", 36, 45], ["bilirubin", "GENE_OR_GENE_PRODUCT", 36, 45], ["the bilirubin", "TEST", 32, 45]]], ["Bilirubin is stable at 4\u00b0 C for 7 days if not exposed to bright light.", [["Bilirubin", "CHEMICAL", 0, 9], ["Bilirubin", "CHEMICAL", 0, 9], ["Bilirubin", "SIMPLE_CHEMICAL", 0, 9], ["Bilirubin", "TEST", 0, 9], ["stable", "OBSERVATION_MODIFIER", 13, 19]]], ["Measurement of urine bilirubin is discussed in Chapter 7.TOTAL SERUM BILIRUBINNormal Values \u2022 Dogs, less than 1.0 mg/dl; cats, less than 1.0 mg/dl (depends upon the laboratory).", [["urine", "ANATOMY", 15, 20], ["bilirubin", "CHEMICAL", 21, 30], ["bilirubin", "CHEMICAL", 21, 30], ["urine", "ORGANISM_SUBSTANCE", 15, 20], ["bilirubin", "GENE_OR_GENE_PRODUCT", 21, 30], ["cats", "ORGANISM", 121, 125], ["Measurement of urine bilirubin", "TEST", 0, 30], ["TOTAL SERUM BILIRUBINNormal Values", "TEST", 57, 91], ["Dogs", "TEST", 94, 98], ["cats", "TEST", 121, 125], ["urine bilirubin", "OBSERVATION", 15, 30]]], ["Administration of one of these drugs does not automatically explain an increased ALT, however.TOTAL SERUM BILIRUBINCommon causes of nonhemolytic icterus in dogs include pancreatitis obstructing the bile duct, gallbladder mucoceles, cholecystitis, chronic hepatitis, hepatic lymphoma, acute hepatic necrosis, hepatic cirrhosis, and intrahepatic cholestasis.", [["bile duct", "ANATOMY", 198, 207], ["gallbladder mucoceles", "ANATOMY", 209, 230], ["hepatic lymphoma", "ANATOMY", 266, 282], ["hepatic", "ANATOMY", 290, 297], ["hepatic", "ANATOMY", 308, 315], ["intrahepatic cholestasis", "ANATOMY", 331, 355], ["nonhemolytic icterus", "DISEASE", 132, 152], ["pancreatitis", "DISEASE", 169, 181], ["obstructing the bile duct", "DISEASE", 182, 207], ["gallbladder mucoceles", "DISEASE", 209, 230], ["cholecystitis", "DISEASE", 232, 245], ["chronic hepatitis", "DISEASE", 247, 264], ["hepatic lymphoma", "DISEASE", 266, 282], ["acute hepatic necrosis", "DISEASE", 284, 306], ["hepatic cirrhosis", "DISEASE", 308, 325], ["intrahepatic cholestasis", "DISEASE", 331, 355], ["ALT", "SIMPLE_CHEMICAL", 81, 84], ["dogs", "ORGANISM", 156, 160], ["bile duct", "MULTI-TISSUE_STRUCTURE", 198, 207], ["gallbladder mucoceles", "PATHOLOGICAL_FORMATION", 209, 230], ["hepatic lymphoma", "CANCER", 266, 282], ["hepatic", "ORGAN", 290, 297], ["hepatic", "ORGAN", 308, 315], ["ALT", "PROTEIN", 81, 84], ["dogs", "SPECIES", 156, 160], ["these drugs", "TREATMENT", 25, 36], ["an increased ALT", "PROBLEM", 68, 84], ["TOTAL SERUM BILIRUBINCommon", "TEST", 94, 121], ["nonhemolytic icterus in dogs", "PROBLEM", 132, 160], ["pancreatitis obstructing the bile duct", "PROBLEM", 169, 207], ["gallbladder mucoceles", "PROBLEM", 209, 230], ["cholecystitis", "PROBLEM", 232, 245], ["chronic hepatitis", "PROBLEM", 247, 264], ["hepatic lymphoma", "PROBLEM", 266, 282], ["acute hepatic necrosis", "PROBLEM", 284, 306], ["hepatic cirrhosis", "PROBLEM", 308, 325], ["intrahepatic cholestasis", "PROBLEM", 331, 355], ["increased", "OBSERVATION_MODIFIER", 71, 80], ["ALT", "OBSERVATION", 81, 84], ["nonhemolytic", "OBSERVATION_MODIFIER", 132, 144], ["icterus", "OBSERVATION", 145, 152], ["pancreatitis", "OBSERVATION", 169, 181], ["bile duct", "ANATOMY", 198, 207], ["gallbladder", "ANATOMY", 209, 220], ["mucoceles", "OBSERVATION", 221, 230], ["cholecystitis", "OBSERVATION", 232, 245], ["chronic", "OBSERVATION_MODIFIER", 247, 254], ["hepatitis", "OBSERVATION", 255, 264], ["hepatic", "ANATOMY", 266, 273], ["lymphoma", "OBSERVATION", 274, 282], ["acute", "OBSERVATION_MODIFIER", 284, 289], ["hepatic", "ANATOMY", 290, 297], ["necrosis", "OBSERVATION", 298, 306], ["hepatic", "ANATOMY", 308, 315], ["cirrhosis", "OBSERVATION", 316, 325], ["intrahepatic", "ANATOMY", 331, 343], ["cholestasis", "OBSERVATION", 344, 355]]], ["Icterus in dogs is an indication for a CBC and serum biochemistry panel (to include at least ALT, SAP, BUN, cholesterol, and albumin).", [["serum", "ANATOMY", 47, 52], ["cholesterol", "CHEMICAL", 108, 119], ["cholesterol", "CHEMICAL", 108, 119], ["dogs", "ORGANISM", 11, 15], ["serum", "ORGANISM_SUBSTANCE", 47, 52], ["ALT", "SIMPLE_CHEMICAL", 93, 96], ["SAP", "GENE_OR_GENE_PRODUCT", 98, 101], ["BUN", "SIMPLE_CHEMICAL", 103, 106], ["cholesterol", "SIMPLE_CHEMICAL", 108, 119], ["albumin", "GENE_OR_GENE_PRODUCT", 125, 132], ["ALT", "PROTEIN", 93, 96], ["SAP", "PROTEIN", 98, 101], ["BUN", "PROTEIN", 103, 106], ["albumin", "PROTEIN", 125, 132], ["dogs", "SPECIES", 11, 15], ["Icterus in dogs", "PROBLEM", 0, 15], ["a CBC", "TEST", 37, 42], ["serum biochemistry panel", "TEST", 47, 71], ["ALT", "TEST", 93, 96], ["SAP", "TEST", 98, 101], ["BUN", "TEST", 103, 106], ["cholesterol", "TEST", 108, 119], ["albumin", "TEST", 125, 132], ["dogs", "OBSERVATION", 11, 15]]], ["Ultrasonography is indicated to help determine if primary hepatic disease or biliary tract obstruction exists.", [["hepatic", "ANATOMY", 58, 65], ["biliary tract", "ANATOMY", 77, 90], ["primary hepatic disease", "DISEASE", 50, 73], ["biliary tract obstruction", "DISEASE", 77, 102], ["hepatic", "ORGAN", 58, 65], ["biliary tract", "ORGANISM_SUBDIVISION", 77, 90], ["Ultrasonography", "TEST", 0, 15], ["primary hepatic disease", "PROBLEM", 50, 73], ["biliary tract obstruction", "PROBLEM", 77, 102], ["hepatic", "ANATOMY", 58, 65], ["disease", "OBSERVATION", 66, 73], ["biliary tract", "ANATOMY", 77, 90], ["obstruction", "OBSERVATION", 91, 102]]], ["If primary hepatic disease is diagnosed, hepatic biopsy is usually indicated.", [["hepatic", "ANATOMY", 11, 18], ["hepatic biopsy", "ANATOMY", 41, 55], ["primary hepatic disease", "DISEASE", 3, 26], ["hepatic", "ORGAN", 11, 18], ["hepatic biopsy", "MULTI-TISSUE_STRUCTURE", 41, 55], ["primary hepatic disease", "PROBLEM", 3, 26], ["hepatic biopsy", "TEST", 41, 55], ["hepatic", "ANATOMY", 11, 18], ["disease", "OBSERVATION", 19, 26], ["hepatic", "ANATOMY", 41, 48], ["biopsy", "OBSERVATION", 49, 55]]], ["If pancreatitis is present, surgery is not indicated unless a persistent bile duct obstruction necessitates a biliary drainage procedure (e.g., cholecystoduodenostomy or biliary tract stenting-both are very rarely needed) or a pancreatic abscess is symptomatic despite percutaneous drainage.", [["bile duct", "ANATOMY", 73, 82], ["biliary", "ANATOMY", 110, 117], ["biliary tract", "ANATOMY", 170, 183], ["pancreatic abscess", "ANATOMY", 227, 245], ["percutaneous", "ANATOMY", 269, 281], ["pancreatitis", "DISEASE", 3, 15], ["bile duct obstruction", "DISEASE", 73, 94], ["pancreatic abscess", "DISEASE", 227, 245], ["bile duct", "MULTI-TISSUE_STRUCTURE", 73, 82], ["biliary", "PATHOLOGICAL_FORMATION", 110, 117], ["biliary tract", "MULTI-TISSUE_STRUCTURE", 170, 183], ["pancreatic", "ORGAN", 227, 237], ["pancreatitis", "PROBLEM", 3, 15], ["surgery", "TREATMENT", 28, 35], ["a persistent bile duct obstruction", "PROBLEM", 60, 94], ["a biliary drainage procedure", "TREATMENT", 108, 136], ["cholecystoduodenostomy", "TREATMENT", 144, 166], ["biliary tract stenting", "TREATMENT", 170, 192], ["a pancreatic abscess", "PROBLEM", 225, 245], ["symptomatic", "PROBLEM", 249, 260], ["percutaneous drainage", "TREATMENT", 269, 290], ["pancreatitis", "OBSERVATION", 3, 15], ["persistent", "OBSERVATION_MODIFIER", 62, 72], ["bile duct", "ANATOMY", 73, 82], ["obstruction", "OBSERVATION", 83, 94], ["biliary", "ANATOMY", 110, 117], ["drainage", "OBSERVATION", 118, 126], ["biliary tract", "ANATOMY", 170, 183], ["stenting", "OBSERVATION", 184, 192], ["pancreatic", "ANATOMY", 227, 237], ["abscess", "OBSERVATION", 238, 245], ["drainage", "OBSERVATION", 282, 290]]], ["If coexisting extrahepatic disease is found, it should be investigated.ALANINE AMINOTRANSFERASEALT was formerly known as serum glutamic-pyruvic transaminase (SGPT).ALANINE AMINOTRANSFERASECommon Indications \u2022 Systemic disease, including weight loss, hepatomegaly, vomiting, diarrhea, icterus, ascites, depression, and anorexia, is an indication for measurement of ALT; also, ALT is used as a screening procedure for hepatic disease in patients with undiagnosed illness.", [["extrahepatic", "ANATOMY", 14, 26], ["serum", "ANATOMY", 121, 126], ["ascites", "ANATOMY", 293, 300], ["hepatic", "ANATOMY", 416, 423], ["extrahepatic disease", "DISEASE", 14, 34], ["glutamic-pyruvic", "CHEMICAL", 127, 143], ["Systemic disease", "DISEASE", 209, 225], ["weight loss", "DISEASE", 237, 248], ["hepatomegaly", "DISEASE", 250, 262], ["vomiting", "DISEASE", 264, 272], ["diarrhea", "DISEASE", 274, 282], ["icterus", "DISEASE", 284, 291], ["ascites", "DISEASE", 293, 300], ["depression", "DISEASE", 302, 312], ["anorexia", "DISEASE", 318, 326], ["hepatic disease", "DISEASE", 416, 431], ["glutamic-pyruvic", "CHEMICAL", 127, 143], ["extrahepatic", "ORGAN", 14, 26], ["serum", "ORGANISM_SUBSTANCE", 121, 126], ["glutamic-pyruvic transaminase", "GENE_OR_GENE_PRODUCT", 127, 156], ["SGPT", "SIMPLE_CHEMICAL", 158, 162], ["ALT", "SIMPLE_CHEMICAL", 364, 367], ["ALT", "SIMPLE_CHEMICAL", 375, 378], ["hepatic", "ORGAN", 416, 423], ["patients", "ORGANISM", 435, 443], ["serum glutamic-pyruvic transaminase", "PROTEIN", 121, 156], ["SGPT", "PROTEIN", 158, 162], ["patients", "SPECIES", 435, 443], ["coexisting extrahepatic disease", "PROBLEM", 3, 34], ["ALANINE AMINOTRANSFERASEALT", "TEST", 71, 98], ["serum glutamic", "TEST", 121, 135], ["pyruvic transaminase", "TEST", 136, 156], ["SGPT)", "TEST", 158, 163], ["ALANINE AMINOTRANSFERASECommon Indications", "TREATMENT", 164, 206], ["Systemic disease", "PROBLEM", 209, 225], ["weight loss", "PROBLEM", 237, 248], ["hepatomegaly", "PROBLEM", 250, 262], ["vomiting", "PROBLEM", 264, 272], ["diarrhea", "PROBLEM", 274, 282], ["icterus", "PROBLEM", 284, 291], ["ascites", "PROBLEM", 293, 300], ["depression", "PROBLEM", 302, 312], ["anorexia", "PROBLEM", 318, 326], ["ALT", "TEST", 364, 367], ["ALT", "TEST", 375, 378], ["a screening procedure", "TREATMENT", 390, 411], ["hepatic disease", "PROBLEM", 416, 431], ["undiagnosed illness", "PROBLEM", 449, 468], ["extrahepatic", "ANATOMY", 14, 26], ["disease", "OBSERVATION", 27, 34], ["Systemic disease", "OBSERVATION", 209, 225], ["hepatomegaly", "OBSERVATION", 250, 262], ["icterus", "OBSERVATION", 284, 291], ["ascites", "OBSERVATION", 293, 300], ["depression", "OBSERVATION", 302, 312], ["anorexia", "OBSERVATION", 318, 326], ["hepatic", "ANATOMY", 416, 423], ["disease", "OBSERVATION", 424, 431]]], ["Most patients with known chronic hepatitis should undergo periodic ALT determinations to monitor the problem.Advantages \u2022 The serum ALT is specific for the liver.Disadvantages \u2022 The test has lack of sensitivity (i.e., patients with significant hepatic disease such as cirrhosis or hepatic neoplasia may have normal ALT) and cannot distinguish among different hepatic diseases or determine if there is secondary nonhepatic disease involvement.Advantages \u2022 The serum ALT is specific for the liver.Analysis \u2022 ALT is measured in serum (heparinized plasma in selected assays) by spectrophotometric and dry reagent methods.", [["serum", "ANATOMY", 126, 131], ["liver", "ANATOMY", 156, 161], ["hepatic", "ANATOMY", 244, 251], ["hepatic neoplasia", "ANATOMY", 281, 298], ["hepatic", "ANATOMY", 359, 366], ["nonhepatic", "ANATOMY", 411, 421], ["serum", "ANATOMY", 459, 464], ["liver", "ANATOMY", 489, 494], ["serum", "ANATOMY", 525, 530], ["plasma", "ANATOMY", 544, 550], ["chronic hepatitis", "DISEASE", 25, 42], ["hepatic disease", "DISEASE", 244, 259], ["cirrhosis", "DISEASE", 268, 277], ["hepatic neoplasia", "DISEASE", 281, 298], ["hepatic diseases", "DISEASE", 359, 375], ["patients", "ORGANISM", 5, 13], ["serum", "ORGANISM_SUBSTANCE", 126, 131], ["ALT", "SIMPLE_CHEMICAL", 132, 135], ["liver", "ORGAN", 156, 161], ["patients", "ORGANISM", 218, 226], ["hepatic", "ORGAN", 244, 251], ["hepatic neoplasia", "CANCER", 281, 298], ["hepatic", "ORGAN", 359, 366], ["serum", "ORGANISM_SUBSTANCE", 459, 464], ["ALT", "SIMPLE_CHEMICAL", 465, 468], ["liver", "ORGAN", 489, 494], ["ALT", "SIMPLE_CHEMICAL", 506, 509], ["serum", "ORGANISM_SUBSTANCE", 525, 530], ["plasma", "ORGANISM_SUBSTANCE", 544, 550], ["serum ALT", "PROTEIN", 126, 135], ["serum ALT", "PROTEIN", 459, 468], ["ALT", "PROTEIN", 506, 509], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 218, 226], ["known chronic hepatitis", "PROBLEM", 19, 42], ["periodic ALT determinations", "TEST", 58, 85], ["The serum ALT", "TEST", 122, 135], ["The test", "TEST", 178, 186], ["sensitivity", "PROBLEM", 199, 210], ["significant hepatic disease", "PROBLEM", 232, 259], ["cirrhosis", "PROBLEM", 268, 277], ["hepatic neoplasia", "PROBLEM", 281, 298], ["different hepatic diseases", "PROBLEM", 349, 375], ["secondary nonhepatic disease involvement", "PROBLEM", 401, 441], ["The serum ALT", "TEST", 455, 468], ["Analysis", "TEST", 495, 503], ["ALT", "TEST", 506, 509], ["serum", "TEST", 525, 530], ["spectrophotometric", "TEST", 574, 592], ["dry reagent methods", "TREATMENT", 597, 616], ["chronic", "OBSERVATION_MODIFIER", 25, 32], ["hepatitis", "OBSERVATION", 33, 42], ["liver", "ANATOMY", 156, 161], ["hepatic", "ANATOMY", 244, 251], ["disease", "OBSERVATION", 252, 259], ["cirrhosis", "OBSERVATION", 268, 277], ["hepatic", "ANATOMY", 281, 288], ["neoplasia", "OBSERVATION", 289, 298], ["hepatic", "ANATOMY", 359, 366], ["diseases", "OBSERVATION", 367, 375], ["secondary", "OBSERVATION_MODIFIER", 401, 410], ["nonhepatic", "ANATOMY", 411, 421], ["disease", "OBSERVATION", 422, 429], ["liver", "ANATOMY", 489, 494]]], ["ALT is stable in separated serum for approximately 1 (at 22\u00b0 C) to 7 (at 4\u00b0 C) days.Advantages \u2022 The serum ALT is specific for the liver.Normal Values \u2022 Serum enzyme activity may vary markedly among laboratories, depending on the technique and the units used.Advantages \u2022 The serum ALT is specific for the liver.Danger Values \u2022 Despite correlation between ALT and active hepatic damage, no correlation exists between ALT and hepatic function; hence, no danger values exist.Artifacts \u2022 See Chapter 1.Drug Therapy That May Alter Serum ALT \u2022 Any drug causing hepatocellular damage (i.e., drug-induced hepatopathy) may cause increased ALT.", [["serum", "ANATOMY", 27, 32], ["serum", "ANATOMY", 101, 106], ["liver", "ANATOMY", 131, 136], ["serum", "ANATOMY", 276, 281], ["liver", "ANATOMY", 306, 311], ["hepatic", "ANATOMY", 371, 378], ["hepatic", "ANATOMY", 425, 432], ["hepatocellular", "ANATOMY", 556, 570], ["hepatic damage", "DISEASE", 371, 385], ["hepatocellular damage", "DISEASE", 556, 577], ["hepatopathy", "DISEASE", 598, 609], ["ALT", "SIMPLE_CHEMICAL", 0, 3], ["serum", "ORGANISM_SUBSTANCE", 27, 32], ["serum", "ORGANISM_SUBSTANCE", 101, 106], ["ALT", "SIMPLE_CHEMICAL", 107, 110], ["liver", "ORGAN", 131, 136], ["Serum", "ORGANISM_SUBSTANCE", 153, 158], ["serum", "ORGANISM_SUBSTANCE", 276, 281], ["ALT", "SIMPLE_CHEMICAL", 282, 285], ["liver", "ORGAN", 306, 311], ["ALT", "SIMPLE_CHEMICAL", 356, 359], ["hepatic", "ORGAN", 371, 378], ["ALT", "SIMPLE_CHEMICAL", 417, 420], ["hepatic", "ORGAN", 425, 432], ["Serum", "ORGANISM_SUBSTANCE", 527, 532], ["ALT", "SIMPLE_CHEMICAL", 533, 536], ["hepatocellular", "ORGAN", 556, 570], ["ALT", "SIMPLE_CHEMICAL", 631, 634], ["ALT", "PROTEIN", 0, 3], ["serum ALT", "PROTEIN", 101, 110], ["serum ALT", "PROTEIN", 276, 285], ["ALT", "PROTEIN", 631, 634], ["ALT", "TEST", 0, 3], ["separated serum", "TEST", 17, 32], ["The serum ALT", "TEST", 97, 110], ["Serum enzyme activity", "TEST", 153, 174], ["the technique", "TEST", 226, 239], ["The serum ALT", "TEST", 272, 285], ["Danger Values", "TEST", 312, 325], ["ALT", "TEST", 356, 359], ["active hepatic damage", "PROBLEM", 364, 385], ["ALT", "TEST", 417, 420], ["danger values", "PROBLEM", 453, 466], ["Drug Therapy", "TREATMENT", 499, 511], ["Serum ALT", "TEST", 527, 536], ["hepatocellular damage", "PROBLEM", 556, 577], ["drug-induced hepatopathy", "PROBLEM", 585, 609], ["increased ALT", "PROBLEM", 621, 634], ["stable", "OBSERVATION_MODIFIER", 7, 13], ["liver", "ANATOMY", 131, 136], ["liver", "ANATOMY", 306, 311], ["active", "OBSERVATION_MODIFIER", 364, 370], ["hepatic", "ANATOMY", 371, 378], ["damage", "OBSERVATION", 379, 385], ["hepatic", "ANATOMY", 425, 432], ["hepatocellular", "ANATOMY", 556, 570], ["damage", "OBSERVATION", 571, 577], ["hepatopathy", "OBSERVATION", 598, 609], ["increased", "OBSERVATION_MODIFIER", 621, 630], ["ALT", "OBSERVATION_MODIFIER", 631, 634]]], ["The list of all drugs suspected to cause increased ALT is extensive and includes many that are safe in the majority of patients.", [["ALT", "SIMPLE_CHEMICAL", 51, 54], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["all drugs", "TREATMENT", 12, 21], ["increased ALT", "PROBLEM", 41, 54], ["increased", "OBSERVATION_MODIFIER", 41, 50], ["ALT", "OBSERVATION", 51, 54]]], ["A list of selected drugs documented to cause increased ALT in human beings, dogs, and cats is given in Box 9-5.", [["ALT", "SIMPLE_CHEMICAL", 55, 58], ["human", "ORGANISM", 62, 67], ["dogs", "ORGANISM", 76, 80], ["cats", "ORGANISM", 86, 90], ["ALT", "PROTEIN", 55, 58], ["human", "SPECIES", 62, 67], ["dogs", "SPECIES", 76, 80], ["cats", "SPECIES", 86, 90], ["human", "SPECIES", 62, 67], ["selected drugs", "TREATMENT", 10, 24], ["increased ALT in human beings", "PROBLEM", 45, 74]]], ["NOTE: A patient can have an idiosyncratic reaction to almost any drug, causing an increased ALT.Causes of Decreased ALT \u2022 Not significant.Causes of Increased ALT \u2022 Increase in ALT is principally caused by hepatocellular damage from any cause (Box 9-7).", [["hepatocellular", "ANATOMY", 205, 219], ["hepatocellular damage", "DISEASE", 205, 226], ["patient", "ORGANISM", 8, 15], ["ALT", "SIMPLE_CHEMICAL", 92, 95], ["ALT", "GENE_OR_GENE_PRODUCT", 116, 119], ["ALT", "GENE_OR_GENE_PRODUCT", 158, 161], ["ALT", "SIMPLE_CHEMICAL", 176, 179], ["hepatocellular", "CANCER", 205, 219], ["ALT", "PROTEIN", 92, 95], ["ALT", "PROTEIN", 116, 119], ["ALT", "PROTEIN", 158, 161], ["patient", "SPECIES", 8, 15], ["an idiosyncratic reaction", "PROBLEM", 25, 50], ["an increased ALT", "PROBLEM", 79, 95], ["Decreased ALT \u2022", "PROBLEM", 106, 121], ["Increased ALT", "PROBLEM", 148, 161], ["Increase in ALT", "PROBLEM", 164, 179], ["hepatocellular damage", "PROBLEM", 205, 226], ["Box", "TEST", 243, 246], ["increased", "OBSERVATION_MODIFIER", 82, 91], ["ALT", "OBSERVATION", 92, 95], ["Decreased", "OBSERVATION_MODIFIER", 106, 115], ["ALT", "OBSERVATION", 116, 119], ["significant", "OBSERVATION_MODIFIER", 126, 137], ["Increased", "OBSERVATION_MODIFIER", 148, 157], ["ALT", "OBSERVATION_MODIFIER", 158, 161], ["Increase", "OBSERVATION_MODIFIER", 164, 172], ["hepatocellular", "ANATOMY", 205, 219], ["damage", "OBSERVATION", 220, 226]]], ["RBCs and striated muscle cells contain small amounts of ALT, and damage to these may cause relatively minor increases (i.e., less than two to three times normal) in serum ALT, as may exercise.", [["RBCs", "ANATOMY", 0, 4], ["striated muscle cells", "ANATOMY", 9, 30], ["serum", "ANATOMY", 165, 170], ["RBCs", "CELL", 0, 4], ["striated muscle cells", "CELL", 9, 30], ["ALT", "GENE_OR_GENE_PRODUCT", 56, 59], ["serum", "ORGANISM_SUBSTANCE", 165, 170], ["ALT", "SIMPLE_CHEMICAL", 171, 174], ["RBCs", "CELL_TYPE", 0, 4], ["striated muscle cells", "CELL_TYPE", 9, 30], ["ALT", "PROTEIN", 56, 59], ["RBCs", "TEST", 0, 4], ["striated muscle cells", "PROBLEM", 9, 30], ["small amounts of ALT", "PROBLEM", 39, 59], ["damage", "PROBLEM", 65, 71], ["serum ALT", "TEST", 165, 174], ["striated muscle cells", "OBSERVATION", 9, 30], ["small", "OBSERVATION_MODIFIER", 39, 44], ["amounts", "OBSERVATION_MODIFIER", 45, 52], ["ALT", "ANATOMY", 56, 59], ["relatively", "OBSERVATION_MODIFIER", 91, 101], ["minor", "OBSERVATION_MODIFIER", 102, 107], ["increases", "OBSERVATION_MODIFIER", 108, 117]]], ["Dogs with muscular dystrophy may have major increases in ALT, but should also have increases in AST and creatine kinase (CK) values.Causes of Decreased ALT \u2022 Not significant.Hepatocytes contain substantial amounts of ALT in the cytosol, and major increases in serum ALT (i.e., three or more times normal) indicate hepatocellular leakage of the enzyme but do not always signify primary or irreversible hepatic disease.", [["muscular", "ANATOMY", 10, 18], ["Hepatocytes", "ANATOMY", 174, 185], ["cytosol", "ANATOMY", 228, 235], ["serum", "ANATOMY", 260, 265], ["hepatocellular", "ANATOMY", 314, 328], ["hepatic", "ANATOMY", 401, 408], ["muscular dystrophy", "DISEASE", 10, 28], ["creatine", "CHEMICAL", 104, 112], ["hepatic disease", "DISEASE", 401, 416], ["creatine", "CHEMICAL", 104, 112], ["Dogs", "ORGANISM", 0, 4], ["muscular", "ORGAN", 10, 18], ["ALT", "SIMPLE_CHEMICAL", 57, 60], ["AST", "SIMPLE_CHEMICAL", 96, 99], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 104, 119], ["CK", "GENE_OR_GENE_PRODUCT", 121, 123], ["ALT", "GENE_OR_GENE_PRODUCT", 152, 155], ["Hepatocytes", "CELL", 174, 185], ["ALT", "GENE_OR_GENE_PRODUCT", 217, 220], ["cytosol", "CELLULAR_COMPONENT", 228, 235], ["serum", "ORGANISM_SUBSTANCE", 260, 265], ["ALT", "SIMPLE_CHEMICAL", 266, 269], ["hepatocellular", "CANCER", 314, 328], ["hepatic", "ORGAN", 401, 408], ["AST", "PROTEIN", 96, 99], ["creatine kinase", "PROTEIN", 104, 119], ["CK", "PROTEIN", 121, 123], ["ALT", "PROTEIN", 152, 155], ["Hepatocytes", "CELL_TYPE", 174, 185], ["ALT", "PROTEIN", 217, 220], ["serum ALT", "PROTEIN", 260, 269], ["enzyme", "PROTEIN", 344, 350], ["muscular dystrophy", "PROBLEM", 10, 28], ["major increases in ALT", "PROBLEM", 38, 60], ["AST", "TEST", 96, 99], ["creatine kinase", "TEST", 104, 119], ["CK) values", "TEST", 121, 131], ["Decreased ALT \u2022", "PROBLEM", 142, 157], ["Hepatocytes", "TEST", 174, 185], ["ALT in the cytosol", "PROBLEM", 217, 235], ["serum ALT", "TEST", 260, 269], ["hepatocellular leakage of the enzyme", "PROBLEM", 314, 350], ["irreversible hepatic disease", "PROBLEM", 388, 416], ["muscular", "ANATOMY", 10, 18], ["dystrophy", "OBSERVATION", 19, 28], ["major", "OBSERVATION_MODIFIER", 38, 43], ["increases", "OBSERVATION_MODIFIER", 44, 53], ["Decreased", "OBSERVATION_MODIFIER", 142, 151], ["ALT", "OBSERVATION", 152, 155], ["significant", "OBSERVATION_MODIFIER", 162, 173], ["substantial", "OBSERVATION_MODIFIER", 194, 205], ["amounts", "OBSERVATION_MODIFIER", 206, 213], ["ALT", "OBSERVATION_MODIFIER", 217, 220], ["major", "OBSERVATION_MODIFIER", 241, 246], ["increases", "OBSERVATION_MODIFIER", 247, 256], ["serum ALT", "OBSERVATION_MODIFIER", 260, 269], ["hepatocellular", "ANATOMY", 314, 328], ["leakage", "OBSERVATION", 329, 336], ["irreversible", "OBSERVATION_MODIFIER", 388, 400], ["hepatic", "ANATOMY", 401, 408], ["disease", "OBSERVATION", 409, 416]]], ["Hepatic disease may have normal to significantly increased serum ALT activity.", [["Hepatic", "ANATOMY", 0, 7], ["serum", "ANATOMY", 59, 64], ["Hepatic disease", "DISEASE", 0, 15], ["Hepatic", "ORGAN", 0, 7], ["serum", "ORGANISM_SUBSTANCE", 59, 64], ["ALT", "SIMPLE_CHEMICAL", 65, 68], ["ALT", "PROTEIN", 65, 68], ["Hepatic disease", "PROBLEM", 0, 15], ["significantly increased serum ALT activity", "PROBLEM", 35, 77], ["disease", "OBSERVATION", 8, 15], ["significantly", "OBSERVATION_MODIFIER", 35, 48], ["increased", "OBSERVATION_MODIFIER", 49, 58], ["serum", "OBSERVATION_MODIFIER", 59, 64], ["ALT activity", "OBSERVATION", 65, 77]]], ["The magnitude of the increase in ALT does not correlate with the seriousness of the hepatic disease and is not a prognostic indicator unless a specific disease is being considered.", [["hepatic", "ANATOMY", 84, 91], ["hepatic disease", "DISEASE", 84, 99], ["ALT", "SIMPLE_CHEMICAL", 33, 36], ["hepatic", "ORGAN", 84, 91], ["ALT", "PROTEIN", 33, 36], ["the increase in ALT", "PROBLEM", 17, 36], ["the hepatic disease", "PROBLEM", 80, 99], ["a specific disease", "PROBLEM", 141, 159], ["magnitude", "OBSERVATION_MODIFIER", 4, 13], ["increase", "OBSERVATION_MODIFIER", 21, 29], ["hepatic", "ANATOMY", 84, 91], ["disease", "OBSERVATION", 92, 99]]], ["The serum ALT half-life is approximately 1 to 2 days or less, and serum ALT is expected to decrease over 1 to 2 weeks once active hepatic damage ceases.", [["serum", "ANATOMY", 4, 9], ["serum", "ANATOMY", 66, 71], ["hepatic", "ANATOMY", 130, 137], ["hepatic damage", "DISEASE", 130, 144], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["ALT", "SIMPLE_CHEMICAL", 10, 13], ["serum", "ORGANISM_SUBSTANCE", 66, 71], ["ALT", "SIMPLE_CHEMICAL", 72, 75], ["hepatic", "ORGAN", 130, 137], ["The serum ALT", "TEST", 0, 13], ["serum ALT", "TEST", 66, 75], ["active hepatic damage ceases", "PROBLEM", 123, 151], ["hepatic", "ANATOMY", 130, 137], ["damage", "OBSERVATION", 138, 144]]], ["It is thought that ALT remains elevated during hepatic regeneration.Causes of Decreased ALT \u2022 Not significant.After increased serum ALT is identified, many factors must be considered (Figure 9-11 ).", [["hepatic", "ANATOMY", 47, 54], ["serum", "ANATOMY", 126, 131], ["ALT", "SIMPLE_CHEMICAL", 19, 22], ["hepatic", "ORGAN", 47, 54], ["ALT", "GENE_OR_GENE_PRODUCT", 88, 91], ["serum", "ORGANISM_SUBSTANCE", 126, 131], ["ALT", "SIMPLE_CHEMICAL", 132, 135], ["ALT", "PROTEIN", 19, 22], ["ALT", "PROTEIN", 88, 91], ["serum ALT", "PROTEIN", 126, 135], ["ALT", "TEST", 19, 22], ["elevated", "PROBLEM", 31, 39], ["hepatic regeneration", "PROBLEM", 47, 67], ["Decreased ALT \u2022", "PROBLEM", 78, 93], ["increased serum ALT", "TEST", 116, 135], ["Figure", "TEST", 184, 190], ["elevated", "OBSERVATION", 31, 39], ["hepatic", "ANATOMY", 47, 54], ["regeneration", "OBSERVATION", 55, 67], ["Decreased", "OBSERVATION_MODIFIER", 78, 87], ["ALT", "OBSERVATION", 88, 91], ["significant", "OBSERVATION_MODIFIER", 98, 109], ["increased", "OBSERVATION_MODIFIER", 116, 125], ["serum ALT", "OBSERVATION_MODIFIER", 126, 135]]], ["If no other evidence of disease is found, the increased ALT indicates the need for Iatrogenic (see Box 9-5) NOTE: Almost any disease affecting the liver can cause increased ALT levels.", [["liver", "ANATOMY", 147, 152], ["ALT", "SIMPLE_CHEMICAL", 56, 59], ["liver", "ORGAN", 147, 152], ["ALT", "SIMPLE_CHEMICAL", 173, 176], ["ALT", "PROTEIN", 173, 176], ["disease", "PROBLEM", 24, 31], ["the increased ALT", "PROBLEM", 42, 59], ["any disease affecting the liver", "PROBLEM", 121, 152], ["increased ALT levels", "PROBLEM", 163, 183], ["no other evidence of", "UNCERTAINTY", 3, 23], ["disease", "OBSERVATION", 24, 31], ["disease", "OBSERVATION", 125, 132], ["liver", "ANATOMY", 147, 152], ["increased", "OBSERVATION_MODIFIER", 163, 172], ["ALT levels", "OBSERVATION", 173, 183]]], ["The disorders listed are those that may be more likely to cause a significant increase.", [["The disorders", "PROBLEM", 0, 13], ["a significant increase", "PROBLEM", 64, 86], ["may be more likely", "UNCERTAINTY", 36, 54], ["significant", "OBSERVATION_MODIFIER", 66, 77], ["increase", "OBSERVATION", 78, 86]]], ["However, any of these diseases can exist with minor or no increase in ALT values.Causes of Decreased ALT \u2022 Not significant.Disadvantages \u2022 Serum AST is not as specific for the liver as ALT.Causes of Decreased ALT \u2022 Not significant.Analysis \u2022 Measurement of AST is the same as for ALT.Causes of Decreased ALT \u2022 Not significant.Drug Therapy That May Alter AST \u2022 Decreased AST may be caused by metronidazole therapy.", [["Serum", "ANATOMY", 139, 144], ["liver", "ANATOMY", 176, 181], ["metronidazole", "CHEMICAL", 391, 404], ["metronidazole", "CHEMICAL", 391, 404], ["ALT", "SIMPLE_CHEMICAL", 70, 73], ["ALT", "GENE_OR_GENE_PRODUCT", 101, 104], ["Serum", "ORGANISM_SUBSTANCE", 139, 144], ["AST", "SIMPLE_CHEMICAL", 145, 148], ["liver", "ORGAN", 176, 181], ["ALT", "SIMPLE_CHEMICAL", 185, 188], ["ALT", "GENE_OR_GENE_PRODUCT", 209, 212], ["AST", "GENE_OR_GENE_PRODUCT", 257, 260], ["ALT", "SIMPLE_CHEMICAL", 280, 283], ["ALT", "GENE_OR_GENE_PRODUCT", 304, 307], ["AST", "SIMPLE_CHEMICAL", 370, 373], ["metronidazole", "SIMPLE_CHEMICAL", 391, 404], ["ALT", "PROTEIN", 70, 73], ["ALT", "PROTEIN", 101, 104], ["Serum AST", "PROTEIN", 139, 148], ["ALT", "PROTEIN", 209, 212], ["AST", "PROTEIN", 257, 260], ["ALT", "PROTEIN", 280, 283], ["ALT", "PROTEIN", 304, 307], ["AST", "PROTEIN", 354, 357], ["AST", "PROTEIN", 370, 373], ["these diseases", "PROBLEM", 16, 30], ["increase in ALT values", "PROBLEM", 58, 80], ["Decreased ALT \u2022", "PROBLEM", 91, 106], ["Disadvantages", "TEST", 123, 136], ["Serum AST", "TEST", 139, 148], ["ALT", "TEST", 185, 188], ["Decreased ALT \u2022", "PROBLEM", 199, 214], ["Analysis", "TEST", 231, 239], ["Measurement of AST", "TEST", 242, 260], ["ALT", "TEST", 280, 283], ["Decreased ALT \u2022", "PROBLEM", 294, 309], ["Drug Therapy", "TREATMENT", 326, 338], ["Alter AST", "TEST", 348, 357], ["Decreased AST", "PROBLEM", 360, 373], ["metronidazole therapy", "TREATMENT", 391, 412], ["diseases", "OBSERVATION", 22, 30], ["no", "UNCERTAINTY", 55, 57], ["increase", "OBSERVATION_MODIFIER", 58, 66], ["Decreased", "OBSERVATION_MODIFIER", 91, 100], ["ALT", "OBSERVATION", 101, 104], ["significant", "OBSERVATION_MODIFIER", 111, 122], ["liver", "ANATOMY", 176, 181], ["Decreased", "OBSERVATION_MODIFIER", 199, 208], ["ALT", "OBSERVATION", 209, 212], ["significant", "OBSERVATION_MODIFIER", 219, 230], ["Decreased", "OBSERVATION_MODIFIER", 294, 303], ["ALT", "OBSERVATION", 304, 307], ["significant", "OBSERVATION_MODIFIER", 314, 325], ["metronidazole therapy", "OBSERVATION", 391, 412]]], ["Hepatotoxic drugs may cause increased AST (see Box 9-5).Causes of Decreased ALT \u2022 Not significant.Causes of Decreased AST \u2022 None.Causes of Decreased ALT \u2022 Not significant.Causes of Increased AST \u2022 Like ALT, AST is present in significant quantities in hepatocytes.", [["hepatocytes", "ANATOMY", 251, 262], ["AST", "SIMPLE_CHEMICAL", 38, 41], ["ALT", "GENE_OR_GENE_PRODUCT", 76, 79], ["ALT", "GENE_OR_GENE_PRODUCT", 149, 152], ["AST", "SIMPLE_CHEMICAL", 191, 194], ["ALT", "SIMPLE_CHEMICAL", 202, 205], ["AST", "SIMPLE_CHEMICAL", 207, 210], ["hepatocytes", "CELL", 251, 262], ["AST", "PROTEIN", 38, 41], ["ALT", "PROTEIN", 76, 79], ["ALT", "PROTEIN", 149, 152], ["AST", "PROTEIN", 191, 194], ["ALT", "PROTEIN", 202, 205], ["AST", "PROTEIN", 207, 210], ["hepatocytes", "CELL_TYPE", 251, 262], ["Hepatotoxic drugs", "TREATMENT", 0, 17], ["increased AST", "PROBLEM", 28, 41], ["Decreased ALT \u2022", "PROBLEM", 66, 81], ["Decreased AST \u2022", "PROBLEM", 108, 123], ["Decreased ALT \u2022", "PROBLEM", 139, 154], ["Increased AST \u2022", "PROBLEM", 181, 196], ["ALT", "TEST", 202, 205], ["AST", "TEST", 207, 210], ["significant quantities in hepatocytes", "PROBLEM", 225, 262], ["Decreased", "OBSERVATION_MODIFIER", 66, 75], ["ALT", "OBSERVATION", 76, 79], ["significant", "OBSERVATION_MODIFIER", 86, 97], ["Decreased", "OBSERVATION_MODIFIER", 108, 117], ["Decreased", "OBSERVATION_MODIFIER", 139, 148], ["ALT", "OBSERVATION", 149, 152], ["significant", "OBSERVATION_MODIFIER", 159, 170], ["Increased", "OBSERVATION_MODIFIER", 181, 190], ["AST", "OBSERVATION", 191, 194], ["significant", "OBSERVATION_MODIFIER", 225, 236], ["quantities", "OBSERVATION_MODIFIER", 237, 247], ["hepatocytes", "ANATOMY", 251, 262]]], ["Although ALT is present in the cytosol, AST is present in the mitochondria.", [["cytosol", "ANATOMY", 31, 38], ["mitochondria", "ANATOMY", 62, 74], ["ALT", "GENE_OR_GENE_PRODUCT", 9, 12], ["cytosol", "CELLULAR_COMPONENT", 31, 38], ["AST", "SIMPLE_CHEMICAL", 40, 43], ["mitochondria", "CELLULAR_COMPONENT", 62, 74], ["ALT", "PROTEIN", 9, 12], ["AST", "PROTEIN", 40, 43], ["ALT", "TEST", 9, 12], ["AST", "TEST", 40, 43], ["mitochondria", "ANATOMY", 62, 74]]], ["Increased serum ALT reflects cell membrane damage and leakage; significant AST increases tend to reflect more serious hepatocyte damage because the mitochondria are not damaged as readily as is the cell membrane.", [["serum", "ANATOMY", 10, 15], ["cell membrane", "ANATOMY", 29, 42], ["hepatocyte", "ANATOMY", 118, 128], ["mitochondria", "ANATOMY", 148, 160], ["cell membrane", "ANATOMY", 198, 211], ["serum", "ORGANISM_SUBSTANCE", 10, 15], ["ALT", "SIMPLE_CHEMICAL", 16, 19], ["cell membrane", "CELLULAR_COMPONENT", 29, 42], ["AST", "SIMPLE_CHEMICAL", 75, 78], ["hepatocyte", "CELL", 118, 128], ["mitochondria", "CELLULAR_COMPONENT", 148, 160], ["cell membrane", "CELLULAR_COMPONENT", 198, 211], ["serum ALT", "PROTEIN", 10, 19], ["AST", "PROTEIN", 75, 78], ["Increased serum ALT", "PROBLEM", 0, 19], ["cell membrane damage", "PROBLEM", 29, 49], ["leakage", "PROBLEM", 54, 61], ["significant AST increases", "PROBLEM", 63, 88], ["serious hepatocyte damage", "PROBLEM", 110, 135], ["serum ALT", "OBSERVATION_MODIFIER", 10, 19], ["cell membrane damage", "OBSERVATION", 29, 49], ["leakage", "OBSERVATION", 54, 61], ["significant", "OBSERVATION_MODIFIER", 63, 74], ["more serious", "OBSERVATION_MODIFIER", 105, 117], ["hepatocyte", "ANATOMY", 118, 128], ["damage", "OBSERVATION", 129, 135], ["cell membrane", "OBSERVATION", 198, 211]]], ["AST is, however, present in significant quantities in many other tissues, including muscle and RBCs; therefore increased AST is not as specific for hepatic injury as is increased ALT.", [["tissues", "ANATOMY", 65, 72], ["muscle", "ANATOMY", 84, 90], ["RBCs", "ANATOMY", 95, 99], ["hepatic", "ANATOMY", 148, 155], ["hepatic injury", "DISEASE", 148, 162], ["AST", "SIMPLE_CHEMICAL", 0, 3], ["tissues", "TISSUE", 65, 72], ["muscle", "ORGAN", 84, 90], ["RBCs", "CELL", 95, 99], ["AST", "SIMPLE_CHEMICAL", 121, 124], ["hepatic", "ORGAN", 148, 155], ["ALT", "SIMPLE_CHEMICAL", 179, 182], ["AST", "PROTEIN", 0, 3], ["RBCs", "CELL_TYPE", 95, 99], ["AST", "PROTEIN", 121, 124], ["ALT", "PROTEIN", 179, 182], ["AST", "TEST", 0, 3], ["muscle and RBCs", "PROBLEM", 84, 99], ["increased AST", "PROBLEM", 111, 124], ["hepatic injury", "PROBLEM", 148, 162], ["increased ALT", "PROBLEM", 169, 182], ["significant", "OBSERVATION_MODIFIER", 28, 39], ["quantities", "OBSERVATION_MODIFIER", 40, 50], ["muscle", "ANATOMY", 84, 90], ["hepatic", "ANATOMY", 148, 155], ["injury", "OBSERVATION", 156, 162], ["increased", "OBSERVATION_MODIFIER", 169, 178], ["ALT", "OBSERVATION_MODIFIER", 179, 182]]], ["Exercise and intramuscular (IM) injections may increase serum AST.", [["intramuscular", "ANATOMY", 13, 26], ["serum", "ANATOMY", 56, 61], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 13, 26], ["serum", "ORGANISM_SUBSTANCE", 56, 61], ["AST", "SIMPLE_CHEMICAL", 62, 65], ["serum AST", "PROTEIN", 56, 65], ["Exercise and intramuscular (IM) injections", "TREATMENT", 0, 42], ["serum AST", "TEST", 56, 65]]], ["The most common causes of increased AST include hepatic disease, muscle disease (inflammation or necrosis), or hemolysis (spontaneous or artifactual).", [["hepatic", "ANATOMY", 48, 55], ["muscle", "ANATOMY", 65, 71], ["hepatic disease", "DISEASE", 48, 63], ["muscle disease", "DISEASE", 65, 79], ["inflammation", "DISEASE", 81, 93], ["necrosis", "DISEASE", 97, 105], ["hemolysis", "DISEASE", 111, 120], ["AST", "SIMPLE_CHEMICAL", 36, 39], ["hepatic", "ORGAN", 48, 55], ["muscle", "ORGAN", 65, 71], ["increased AST", "PROBLEM", 26, 39], ["hepatic disease", "PROBLEM", 48, 63], ["muscle disease", "PROBLEM", 65, 79], ["inflammation", "PROBLEM", 81, 93], ["necrosis", "PROBLEM", 97, 105], ["hemolysis", "PROBLEM", 111, 120], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["increased", "OBSERVATION_MODIFIER", 26, 35], ["AST", "OBSERVATION", 36, 39], ["hepatic", "ANATOMY", 48, 55], ["disease", "OBSERVATION", 56, 63], ["muscle", "ANATOMY", 65, 71], ["disease", "OBSERVATION", 72, 79], ["inflammation", "OBSERVATION_MODIFIER", 81, 93], ["necrosis", "OBSERVATION", 97, 105], ["hemolysis", "OBSERVATION", 111, 120]]], ["Increased AST is an indication to measure serum ALT to determine whether the increased AST is from the liver (significant increases in both ALT and AST suggest that AST increases are of hepatic origin).", [["serum", "ANATOMY", 42, 47], ["liver", "ANATOMY", 103, 108], ["hepatic", "ANATOMY", 186, 193], ["AST", "SIMPLE_CHEMICAL", 10, 13], ["serum", "ORGANISM_SUBSTANCE", 42, 47], ["ALT", "SIMPLE_CHEMICAL", 48, 51], ["AST", "SIMPLE_CHEMICAL", 87, 90], ["liver", "ORGAN", 103, 108], ["ALT", "SIMPLE_CHEMICAL", 140, 143], ["AST", "SIMPLE_CHEMICAL", 148, 151], ["AST", "SIMPLE_CHEMICAL", 165, 168], ["hepatic", "ORGAN", 186, 193], ["AST", "PROTEIN", 10, 13], ["serum ALT", "PROTEIN", 42, 51], ["AST", "PROTEIN", 87, 90], ["ALT", "PROTEIN", 140, 143], ["AST", "PROTEIN", 148, 151], ["AST", "PROTEIN", 165, 168], ["Increased AST", "PROBLEM", 0, 13], ["serum ALT", "TEST", 42, 51], ["the increased AST", "PROBLEM", 73, 90], ["significant increases", "PROBLEM", 110, 131], ["ALT", "TEST", 140, 143], ["AST", "TEST", 148, 151], ["AST", "TEST", 165, 168], ["increased", "OBSERVATION_MODIFIER", 77, 86], ["AST", "OBSERVATION", 87, 90], ["liver", "ANATOMY", 103, 108], ["significant", "OBSERVATION_MODIFIER", 110, 121], ["increases", "OBSERVATION_MODIFIER", 122, 131], ["hepatic", "ANATOMY", 186, 193], ["origin", "ANATOMY_MODIFIER", 194, 200]]], ["One may also periodic monitoring because it may be the first detectable sign of significant hepatic disease.", [["hepatic", "ANATOMY", 92, 99], ["hepatic disease", "DISEASE", 92, 107], ["hepatic", "ORGAN", 92, 99], ["periodic monitoring", "TEST", 13, 32], ["significant hepatic disease", "PROBLEM", 80, 107], ["significant", "OBSERVATION_MODIFIER", 80, 91], ["hepatic", "ANATOMY", 92, 99], ["disease", "OBSERVATION", 100, 107]]], ["If other abnormalities consistent with hepatic disease are found, the approach is like that in any other patient with hepatic disease.", [["hepatic", "ANATOMY", 39, 46], ["hepatic", "ANATOMY", 118, 125], ["hepatic disease", "DISEASE", 39, 54], ["hepatic disease", "DISEASE", 118, 133], ["hepatic", "ORGAN", 39, 46], ["patient", "ORGANISM", 105, 112], ["hepatic", "ORGAN", 118, 125], ["patient", "SPECIES", 105, 112], ["other abnormalities", "PROBLEM", 3, 22], ["hepatic disease", "PROBLEM", 39, 54], ["hepatic disease", "PROBLEM", 118, 133], ["consistent with", "UNCERTAINTY", 23, 38], ["hepatic", "ANATOMY", 39, 46], ["disease", "OBSERVATION", 47, 54], ["hepatic", "ANATOMY", 118, 125], ["disease", "OBSERVATION", 126, 133]]], ["Common causes of serum ALT more than three times normal include hepatic anoxia, poor hepatic perfusion, spontaneous and surgical trauma (e.g., hit by a car, surgery), chronic hepatitis, cirrhosis, cholangitis and cholangiohepatitis, acute biliary obstruction, hepatic necrosis as the result of any cause, acute pancreatitis, hepatic neoplasia, sepsis, and certain drugs.", [["serum", "ANATOMY", 17, 22], ["hepatic", "ANATOMY", 64, 71], ["hepatic", "ANATOMY", 85, 92], ["biliary", "ANATOMY", 239, 246], ["hepatic", "ANATOMY", 260, 267], ["hepatic neoplasia", "ANATOMY", 325, 342], ["hepatic anoxia", "DISEASE", 64, 78], ["trauma", "DISEASE", 129, 135], ["chronic hepatitis", "DISEASE", 167, 184], ["cirrhosis", "DISEASE", 186, 195], ["cholangitis", "DISEASE", 197, 208], ["cholangiohepatitis", "DISEASE", 213, 231], ["acute biliary obstruction", "DISEASE", 233, 258], ["hepatic necrosis", "DISEASE", 260, 276], ["pancreatitis", "DISEASE", 311, 323], ["hepatic neoplasia", "DISEASE", 325, 342], ["sepsis", "DISEASE", 344, 350], ["serum", "ORGANISM_SUBSTANCE", 17, 22], ["ALT", "SIMPLE_CHEMICAL", 23, 26], ["hepatic", "ORGAN", 64, 71], ["hepatic", "MULTI-TISSUE_STRUCTURE", 85, 92], ["biliary obstruction", "PATHOLOGICAL_FORMATION", 239, 258], ["hepatic", "ORGAN", 260, 267], ["hepatic neoplasia", "CANCER", 325, 342], ["serum ALT", "TEST", 17, 26], ["hepatic anoxia", "PROBLEM", 64, 78], ["poor hepatic perfusion", "PROBLEM", 80, 102], ["spontaneous and surgical trauma", "PROBLEM", 104, 135], ["surgery", "TREATMENT", 157, 164], ["chronic hepatitis", "PROBLEM", 167, 184], ["cirrhosis", "PROBLEM", 186, 195], ["cholangitis", "PROBLEM", 197, 208], ["cholangiohepatitis", "PROBLEM", 213, 231], ["acute biliary obstruction", "PROBLEM", 233, 258], ["hepatic necrosis", "PROBLEM", 260, 276], ["acute pancreatitis", "PROBLEM", 305, 323], ["hepatic neoplasia", "PROBLEM", 325, 342], ["sepsis", "PROBLEM", 344, 350], ["hepatic", "ANATOMY", 64, 71], ["anoxia", "OBSERVATION", 72, 78], ["poor", "OBSERVATION_MODIFIER", 80, 84], ["hepatic", "ANATOMY", 85, 92], ["perfusion", "OBSERVATION_MODIFIER", 93, 102], ["spontaneous", "OBSERVATION_MODIFIER", 104, 115], ["surgical trauma", "OBSERVATION", 120, 135], ["chronic", "OBSERVATION_MODIFIER", 167, 174], ["hepatitis", "OBSERVATION", 175, 184], ["cirrhosis", "OBSERVATION", 186, 195], ["cholangitis", "OBSERVATION", 197, 208], ["acute", "OBSERVATION_MODIFIER", 233, 238], ["biliary", "ANATOMY", 239, 246], ["obstruction", "OBSERVATION", 247, 258], ["hepatic", "ANATOMY", 260, 267], ["necrosis", "OBSERVATION", 268, 276], ["acute", "OBSERVATION_MODIFIER", 305, 310], ["pancreatitis", "OBSERVATION", 311, 323], ["hepatic", "ANATOMY", 325, 332], ["neoplasia", "OBSERVATION", 333, 342], ["sepsis", "OBSERVATION", 344, 350]]], ["Sepsis, especially septicemia and toxemia, may secondarily damage hepatocytes.", [["hepatocytes", "ANATOMY", 66, 77], ["Sepsis", "DISEASE", 0, 6], ["septicemia", "DISEASE", 19, 29], ["toxemia", "DISEASE", 34, 41], ["hepatocytes", "CELL", 66, 77], ["hepatocytes", "CELL_TYPE", 66, 77], ["Sepsis", "PROBLEM", 0, 6], ["septicemia", "PROBLEM", 19, 29], ["toxemia", "PROBLEM", 34, 41], ["secondarily damage hepatocytes", "PROBLEM", 47, 77], ["septicemia", "OBSERVATION", 19, 29], ["toxemia", "OBSERVATION", 34, 41], ["hepatocytes", "ANATOMY", 66, 77]]], ["Abdominal inflammation may do the same.", [["Abdominal", "ANATOMY", 0, 9], ["inflammation", "DISEASE", 10, 22], ["Abdominal inflammation", "PROBLEM", 0, 22], ["inflammation", "OBSERVATION", 10, 22]]], ["The pancreas is close to the liver, and inflammation in the pancreas may cause mechanical damage to the liver.", [["pancreas", "ANATOMY", 4, 12], ["liver", "ANATOMY", 29, 34], ["pancreas", "ANATOMY", 60, 68], ["liver", "ANATOMY", 104, 109], ["inflammation", "DISEASE", 40, 52], ["mechanical damage to the liver", "DISEASE", 79, 109], ["pancreas", "ORGAN", 4, 12], ["liver", "ORGAN", 29, 34], ["pancreas", "ORGAN", 60, 68], ["liver", "ORGAN", 104, 109], ["inflammation in the pancreas", "PROBLEM", 40, 68], ["mechanical damage to the liver", "PROBLEM", 79, 109], ["pancreas", "ANATOMY", 4, 12], ["liver", "ANATOMY", 29, 34], ["inflammation", "OBSERVATION", 40, 52], ["pancreas", "ANATOMY", 60, 68], ["may cause", "UNCERTAINTY", 69, 78], ["mechanical", "OBSERVATION_MODIFIER", 79, 89], ["damage", "OBSERVATION", 90, 96], ["liver", "ANATOMY", 104, 109]]], ["In Doberman pinschers, Bedlington terriers, dalmatians, West Highland white terriers, and Labrador retrievers, a persistently increased serum ALT suggests chronic hepatitis that might be associated with increased hepatic copper concentrations.ASPARTATE AMINOTRANSFERASEAST was formerly known as serum glutamic-oxaloacetic transaminase (SGOT).ASPARTATE AMINOTRANSFERASEOccasional Indications \u2022 Indications for AST are the same as for ALT.", [["serum", "ANATOMY", 136, 141], ["hepatic", "ANATOMY", 213, 220], ["serum", "ANATOMY", 295, 300], ["chronic hepatitis", "DISEASE", 155, 172], ["copper", "CHEMICAL", 221, 227], ["glutamic-oxaloacetic", "CHEMICAL", 301, 321], ["copper", "CHEMICAL", 221, 227], ["glutamic-oxaloacetic", "CHEMICAL", 301, 321], ["serum", "ORGANISM_SUBSTANCE", 136, 141], ["ALT", "SIMPLE_CHEMICAL", 142, 145], ["hepatic", "ORGAN", 213, 220], ["copper", "SIMPLE_CHEMICAL", 221, 227], ["serum", "ORGANISM_SUBSTANCE", 295, 300], ["glutamic-oxaloacetic transaminase", "GENE_OR_GENE_PRODUCT", 301, 334], ["SGOT", "SIMPLE_CHEMICAL", 336, 340], ["AST", "SIMPLE_CHEMICAL", 409, 412], ["ALT", "SIMPLE_CHEMICAL", 433, 436], ["serum ALT", "PROTEIN", 136, 145], ["serum glutamic-oxaloacetic transaminase", "PROTEIN", 295, 334], ["SGOT", "PROTEIN", 336, 340], ["AST", "PROTEIN", 409, 412], ["ALT", "PROTEIN", 433, 436], ["West Highland white terriers", "SPECIES", 56, 84], ["a persistently increased serum ALT", "PROBLEM", 111, 145], ["chronic hepatitis", "PROBLEM", 155, 172], ["increased hepatic copper concentrations", "PROBLEM", 203, 242], ["ASPARTATE AMINOTRANSFERASEAST", "TEST", 243, 272], ["serum glutamic", "TEST", 295, 309], ["oxaloacetic transaminase", "TEST", 310, 334], ["SGOT)", "TEST", 336, 341], ["ASPARTATE AMINOTRANSFERASEOccasional Indications", "TREATMENT", 342, 390], ["AST", "TEST", 409, 412], ["ALT", "TEST", 433, 436], ["persistently", "OBSERVATION_MODIFIER", 113, 125], ["increased", "OBSERVATION_MODIFIER", 126, 135], ["serum ALT", "OBSERVATION_MODIFIER", 136, 145], ["chronic", "OBSERVATION_MODIFIER", 155, 162], ["hepatitis", "OBSERVATION", 163, 172], ["hepatic", "ANATOMY", 213, 220], ["copper concentrations", "OBSERVATION", 221, 242]]], ["Other laboratory tests to evaluate the liver (SAP, albumin, cholesterol, BUN, urinalysis, CBC, and with lipidosis classically have very high SAP with little to no increase in GGT; however, this finding is not consistent enough to allow a diagnosis).", [["liver", "ANATOMY", 39, 44], ["cholesterol", "CHEMICAL", 60, 71], ["cholesterol", "CHEMICAL", 60, 71], ["liver", "ORGAN", 39, 44], ["SAP", "GENE_OR_GENE_PRODUCT", 46, 49], ["albumin", "GENE_OR_GENE_PRODUCT", 51, 58], ["cholesterol", "SIMPLE_CHEMICAL", 60, 71], ["BUN", "SIMPLE_CHEMICAL", 73, 76], ["GGT", "GENE_OR_GENE_PRODUCT", 175, 178], ["SAP", "PROTEIN", 46, 49], ["SAP", "PROTEIN", 141, 144], ["GGT", "PROTEIN", 175, 178], ["Other laboratory tests", "TEST", 0, 22], ["SAP", "TEST", 46, 49], ["albumin", "TEST", 51, 58], ["cholesterol", "TEST", 60, 71], ["BUN", "TEST", 73, 76], ["urinalysis", "TEST", 78, 88], ["CBC", "TEST", 90, 93], ["lipidosis", "PROBLEM", 104, 113], ["very high SAP", "PROBLEM", 131, 144], ["increase in GGT", "PROBLEM", 163, 178], ["liver", "ANATOMY", 39, 44]]], ["Hyperadrenocorticism (spontaneous and iatrogenic) very rarely increases SAP in cats.", [["Hyperadrenocorticism", "DISEASE", 0, 20], ["SAP", "GENE_OR_GENE_PRODUCT", 72, 75], ["cats", "ORGANISM", 79, 83], ["SAP", "PROTEIN", 72, 75], ["cats", "SPECIES", 79, 83], ["Hyperadrenocorticism", "PROBLEM", 0, 20], ["iatrogenic", "PROBLEM", 38, 48], ["increases", "OBSERVATION_MODIFIER", 62, 71], ["SAP", "OBSERVATION_MODIFIER", 72, 75]]], ["Increased SAP in a cat is an indication for serum thyroid hormone determination, urinalysis, blood glucose, and serum ALT measurement, \u00b1 hepatic function testing (e.g., serum bile acids).", [["serum", "ANATOMY", 44, 49], ["blood", "ANATOMY", 93, 98], ["serum", "ANATOMY", 112, 117], ["hepatic", "ANATOMY", 137, 144], ["serum", "ANATOMY", 169, 174], ["glucose", "CHEMICAL", 99, 106], ["bile acids", "CHEMICAL", 175, 185], ["SAP", "GENE_OR_GENE_PRODUCT", 10, 13], ["cat", "ORGANISM", 19, 22], ["serum", "ORGANISM_SUBSTANCE", 44, 49], ["thyroid", "ORGAN", 50, 57], ["blood", "ORGANISM_SUBSTANCE", 93, 98], ["glucose", "SIMPLE_CHEMICAL", 99, 106], ["serum", "ORGANISM_SUBSTANCE", 112, 117], ["ALT", "SIMPLE_CHEMICAL", 118, 121], ["hepatic", "MULTI-TISSUE_STRUCTURE", 137, 144], ["serum", "ORGANISM_SUBSTANCE", 169, 174], ["bile acids", "SIMPLE_CHEMICAL", 175, 185], ["SAP", "PROTEIN", 10, 13], ["Increased SAP", "PROBLEM", 0, 13], ["serum thyroid hormone determination", "TEST", 44, 79], ["urinalysis", "TEST", 81, 91], ["blood glucose", "TEST", 93, 106], ["serum ALT measurement", "TEST", 112, 133], ["hepatic function testing", "TEST", 137, 161], ["serum bile acids", "TEST", 169, 185], ["SAP", "OBSERVATION_MODIFIER", 10, 13], ["hepatic", "ANATOMY", 137, 144]]], ["If hepatic disease is the apparent cause of the increased measure the hematocrit and observe the color of the plasma and serum on a centrifuged blood sample to check for hemolysis.SERUM ALKALINE PHOSPHATASECommon Indications \u2022 Systemic disease, including weight loss, hepatomegaly, vomiting, diarrhea, ascites, icterus, depression, or anorexia, is an indication for measurement of SAP; also, SAP is used as a screen for hepatic disease and hyperadrenocorticism.SERUM ALKALINE PHOSPHATASEAdvantages \u2022 SAP is useful in evaluating the liver for cholestatic disease.SERUM ALKALINE PHOSPHATASEDisadvantages \u2022 Measurement of SAP is affected by corticosteroids (endogenous and exogenous), bone lesions, and osteoblastic activity in young growing dogs.SERUM ALKALINE PHOSPHATASEAnalysis \u2022 SAP is measured in serum or heparinized plasma by spectrophotometric methods.", [["hepatic", "ANATOMY", 3, 10], ["plasma", "ANATOMY", 110, 116], ["serum", "ANATOMY", 121, 126], ["blood sample", "ANATOMY", 144, 156], ["ascites", "ANATOMY", 302, 309], ["hepatic", "ANATOMY", 420, 427], ["liver", "ANATOMY", 532, 537], ["bone lesions", "ANATOMY", 682, 694], ["osteoblastic", "ANATOMY", 700, 712], ["serum", "ANATOMY", 800, 805], ["plasma", "ANATOMY", 821, 827], ["hepatic disease", "DISEASE", 3, 18], ["hemolysis", "DISEASE", 170, 179], ["Systemic disease", "DISEASE", 227, 243], ["weight loss", "DISEASE", 255, 266], ["hepatomegaly", "DISEASE", 268, 280], ["vomiting", "DISEASE", 282, 290], ["diarrhea", "DISEASE", 292, 300], ["ascites", "DISEASE", 302, 309], ["icterus", "DISEASE", 311, 318], ["depression", "DISEASE", 320, 330], ["anorexia", "DISEASE", 335, 343], ["hepatic disease", "DISEASE", 420, 435], ["hyperadrenocorticism", "DISEASE", 440, 460], ["cholestatic disease", "DISEASE", 542, 561], ["corticosteroids", "CHEMICAL", 638, 653], ["hepatic", "ORGAN", 3, 10], ["plasma", "ORGANISM_SUBSTANCE", 110, 116], ["serum", "ORGANISM_SUBSTANCE", 121, 126], ["blood", "ORGANISM_SUBSTANCE", 144, 149], ["SAP", "GENE_OR_GENE_PRODUCT", 381, 384], ["SAP", "GENE_OR_GENE_PRODUCT", 392, 395], ["hepatic", "ORGAN", 420, 427], ["liver", "ORGAN", 532, 537], ["SAP", "GENE_OR_GENE_PRODUCT", 619, 622], ["corticosteroids", "SIMPLE_CHEMICAL", 638, 653], ["bone", "TISSUE", 682, 686], ["osteoblastic", "CELL", 700, 712], ["dogs", "ORGANISM", 739, 743], ["SAP", "GENE_OR_GENE_PRODUCT", 781, 784], ["serum", "ORGANISM_SUBSTANCE", 800, 805], ["plasma", "ORGANISM_SUBSTANCE", 821, 827], ["SAP", "PROTEIN", 381, 384], ["SAP", "PROTEIN", 392, 395], ["SAP", "PROTEIN", 500, 503], ["SAP", "PROTEIN", 619, 622], ["SAP", "PROTEIN", 781, 784], ["dogs", "SPECIES", 739, 743], ["hepatic disease", "PROBLEM", 3, 18], ["the hematocrit", "TEST", 66, 80], ["the color", "TEST", 93, 102], ["the plasma", "TEST", 106, 116], ["a centrifuged blood sample", "TEST", 130, 156], ["hemolysis", "PROBLEM", 170, 179], ["SERUM ALKALINE PHOSPHATASECommon", "TEST", 180, 212], ["Systemic disease", "PROBLEM", 227, 243], ["weight loss", "PROBLEM", 255, 266], ["hepatomegaly", "PROBLEM", 268, 280], ["vomiting", "PROBLEM", 282, 290], ["diarrhea", "PROBLEM", 292, 300], ["ascites", "PROBLEM", 302, 309], ["icterus", "PROBLEM", 311, 318], ["depression", "PROBLEM", 320, 330], ["anorexia", "PROBLEM", 335, 343], ["SAP", "PROBLEM", 381, 384], ["a screen", "TEST", 407, 415], ["hepatic disease", "PROBLEM", 420, 435], ["hyperadrenocorticism", "PROBLEM", 440, 460], ["SERUM ALKALINE PHOSPHATASEAdvantages", "TEST", 461, 497], ["SAP", "TEST", 500, 503], ["cholestatic disease", "PROBLEM", 542, 561], ["SERUM ALKALINE PHOSPHATASEDisadvantages", "TEST", 562, 601], ["SAP", "PROBLEM", 619, 622], ["corticosteroids (endogenous and exogenous)", "PROBLEM", 638, 680], ["bone lesions", "PROBLEM", 682, 694], ["osteoblastic activity", "PROBLEM", 700, 721], ["SERUM ALKALINE PHOSPHATASEAnalysis", "TEST", 744, 778], ["SAP", "TEST", 781, 784], ["serum", "TEST", 800, 805], ["spectrophotometric methods", "TEST", 831, 857], ["hepatic", "ANATOMY", 3, 10], ["disease", "OBSERVATION", 11, 18], ["increased", "OBSERVATION_MODIFIER", 48, 57], ["ALKALINE PHOSPHATASECommon", "OBSERVATION", 186, 212], ["Systemic disease", "OBSERVATION", 227, 243], ["hepatomegaly", "OBSERVATION", 268, 280], ["ascites", "OBSERVATION", 302, 309], ["icterus", "OBSERVATION", 311, 318], ["depression", "OBSERVATION", 320, 330], ["hepatic", "ANATOMY", 420, 427], ["disease", "OBSERVATION", 428, 435], ["hyperadrenocorticism", "OBSERVATION", 440, 460], ["liver", "ANATOMY", 532, 537], ["cholestatic", "OBSERVATION", 542, 553], ["SAP", "OBSERVATION_MODIFIER", 619, 622], ["corticosteroids", "OBSERVATION", 638, 653], ["bone", "ANATOMY", 682, 686], ["lesions", "OBSERVATION", 687, 694], ["osteoblastic activity", "OBSERVATION", 700, 721]]], ["Different techniques (i.e., heat stability, phenylalanine, electrophoresis) have been used to distinguish SAP of bone origin from SAP of hepatic origin.", [["bone", "ANATOMY", 113, 117], ["hepatic", "ANATOMY", 137, 144], ["phenylalanine", "CHEMICAL", 44, 57], ["phenylalanine", "CHEMICAL", 44, 57], ["phenylalanine", "SIMPLE_CHEMICAL", 44, 57], ["SAP", "GENE_OR_GENE_PRODUCT", 106, 109], ["bone", "TISSUE", 113, 117], ["SAP", "GENE_OR_GENE_PRODUCT", 130, 133], ["hepatic", "ORGAN", 137, 144], ["SAP", "PROTEIN", 106, 109], ["SAP", "PROTEIN", 130, 133], ["Different techniques", "TREATMENT", 0, 20], ["phenylalanine, electrophoresis", "TREATMENT", 44, 74], ["bone", "ANATOMY", 113, 117], ["origin", "ANATOMY_MODIFIER", 118, 124], ["SAP", "OBSERVATION_MODIFIER", 130, 133], ["hepatic", "ANATOMY", 137, 144], ["origin", "ANATOMY_MODIFIER", 145, 151]]], ["The diagnostic usefulness of this distinction is doubtful because dogs with various types of hepatic disease often have endogenous steroids released due to the stress of illness.SERUM ALKALINE PHOSPHATASENormal Values \u2022 May vary markedly from laboratory to laboratory.", [["hepatic", "ANATOMY", 93, 100], ["hepatic disease", "DISEASE", 93, 108], ["steroids", "CHEMICAL", 131, 139], ["illness", "DISEASE", 170, 177], ["steroids", "CHEMICAL", 131, 139], ["dogs", "ORGANISM", 66, 70], ["hepatic", "ORGAN", 93, 100], ["dogs", "SPECIES", 66, 70], ["hepatic disease", "PROBLEM", 93, 108], ["endogenous steroids", "TREATMENT", 120, 139], ["the stress of illness", "PROBLEM", 156, 177], ["SERUM ALKALINE PHOSPHATASENormal Values", "TEST", 178, 217], ["hepatic", "ANATOMY", 93, 100], ["disease", "OBSERVATION", 101, 108]]], ["Immature dogs characteristically have SAP (bone origin) activities up to twice those of sexually mature dogs.Danger Values \u2022There is no correlation with hepatic function; therefore no danger values exist.Artifacts \u2022 See Chapter 1.Drug Therapy That May Increase SAP \u2022 Any drug that causes hepatic enzyme induction or cholestasis (see Box 9-6) may increase SAP.", [["bone", "ANATOMY", 43, 47], ["hepatic", "ANATOMY", 153, 160], ["hepatic", "ANATOMY", 288, 295], ["cholestasis", "DISEASE", 316, 327], ["Box 9-6", "CHEMICAL", 333, 340], ["dogs", "ORGANISM", 9, 13], ["bone", "TISSUE", 43, 47], ["dogs", "ORGANISM", 104, 108], ["hepatic", "ORGAN", 153, 160], ["hepatic", "ORGAN", 288, 295], ["SAP", "GENE_OR_GENE_PRODUCT", 355, 358], ["SAP", "PROTEIN", 261, 264], ["hepatic enzyme", "PROTEIN", 288, 302], ["SAP", "PROTEIN", 355, 358], ["dogs", "SPECIES", 9, 13], ["dogs", "SPECIES", 104, 108], ["Immature dogs", "PROBLEM", 0, 13], ["SAP (bone origin", "PROBLEM", 38, 54], ["hepatic function", "TEST", 153, 169], ["danger values", "TEST", 184, 197], ["Drug Therapy", "TREATMENT", 230, 242], ["hepatic enzyme induction", "TREATMENT", 288, 312], ["cholestasis", "PROBLEM", 316, 327], ["increase SAP", "PROBLEM", 346, 358], ["dogs", "OBSERVATION", 9, 13], ["SAP", "OBSERVATION_MODIFIER", 38, 41], ["bone", "ANATOMY", 43, 47], ["no", "UNCERTAINTY", 133, 135], ["hepatic", "ANATOMY", 153, 160], ["hepatic", "ANATOMY", 288, 295], ["cholestasis", "OBSERVATION", 316, 327], ["increase", "OBSERVATION_MODIFIER", 346, 354], ["SAP", "OBSERVATION_MODIFIER", 355, 358]]], ["Glucocorticoids, primidone, and barbiturates typically increase SAP in dogs, but other drugs are less consistent.", [["primidone", "CHEMICAL", 17, 26], ["barbiturates", "CHEMICAL", 32, 44], ["primidone", "CHEMICAL", 17, 26], ["barbiturates", "CHEMICAL", 32, 44], ["primidone", "SIMPLE_CHEMICAL", 17, 26], ["barbiturates", "SIMPLE_CHEMICAL", 32, 44], ["SAP", "GENE_OR_GENE_PRODUCT", 64, 67], ["dogs", "ORGANISM", 71, 75], ["SAP", "PROTEIN", 64, 67], ["dogs", "SPECIES", 71, 75], ["Glucocorticoids", "TREATMENT", 0, 15], ["primidone", "TREATMENT", 17, 26], ["barbiturates", "TREATMENT", 32, 44]]], ["Although glucocorticoids can cause marked SAP increases in dogs, cats are almost never affected.Causes of Decreased SAP \u2022 Not significant.Causes of Increased SAP \u2022 SAP of bone origin is commonly increased (SAP less than three times normal) in dogs less than 6 to 8 months old.", [["bone", "ANATOMY", 171, 175], ["glucocorticoids", "CHEMICAL", 9, 24], ["glucocorticoids", "SIMPLE_CHEMICAL", 9, 24], ["SAP", "GENE_OR_GENE_PRODUCT", 42, 45], ["dogs", "ORGANISM", 59, 63], ["cats", "ORGANISM", 65, 69], ["SAP", "GENE_OR_GENE_PRODUCT", 116, 119], ["SAP", "GENE_OR_GENE_PRODUCT", 158, 161], ["bone", "TISSUE", 171, 175], ["dogs", "ORGANISM", 243, 247], ["SAP", "PROTEIN", 42, 45], ["SAP", "PROTEIN", 116, 119], ["SAP", "PROTEIN", 158, 161], ["SAP", "PROTEIN", 164, 167], ["dogs", "SPECIES", 59, 63], ["cats", "SPECIES", 65, 69], ["dogs", "SPECIES", 243, 247], ["glucocorticoids", "TREATMENT", 9, 24], ["marked SAP increases in dogs", "PROBLEM", 35, 63], ["Decreased SAP", "PROBLEM", 106, 119], ["Increased SAP \u2022 SAP of bone origin", "PROBLEM", 148, 182], ["marked", "OBSERVATION_MODIFIER", 35, 41], ["SAP", "OBSERVATION_MODIFIER", 42, 45], ["increases", "OBSERVATION_MODIFIER", 46, 55], ["Decreased", "OBSERVATION_MODIFIER", 106, 115], ["SAP", "OBSERVATION", 116, 119], ["Not", "UNCERTAINTY", 122, 125], ["significant", "OBSERVATION_MODIFIER", 126, 137], ["Increased", "OBSERVATION_MODIFIER", 148, 157], ["SAP", "OBSERVATION_MODIFIER", 158, 161], ["SAP", "OBSERVATION_MODIFIER", 164, 167], ["bone", "ANATOMY", 171, 175], ["origin", "ANATOMY_MODIFIER", 176, 182], ["commonly", "OBSERVATION_MODIFIER", 186, 194], ["increased", "OBSERVATION_MODIFIER", 195, 204], ["SAP", "OBSERVATION_MODIFIER", 206, 209], ["less", "OBSERVATION_MODIFIER", 210, 214]]], ["Bone disease (e.g., osteosarcoma, osteomyelitis) may increase SAP (usually a minor increase).Causes of Decreased SAP \u2022 Not significant.Increased SAP is interpreted differently in dogs and cats (Box 9-8).", [["Bone", "ANATOMY", 0, 4], ["osteosarcoma", "ANATOMY", 20, 32], ["Bone disease", "DISEASE", 0, 12], ["osteosarcoma", "DISEASE", 20, 32], ["osteomyelitis", "DISEASE", 34, 47], ["Bone", "TISSUE", 0, 4], ["osteosarcoma", "CANCER", 20, 32], ["SAP", "GENE_OR_GENE_PRODUCT", 113, 116], ["SAP", "GENE_OR_GENE_PRODUCT", 145, 148], ["dogs", "ORGANISM", 179, 183], ["cats", "ORGANISM", 188, 192], ["SAP", "PROTEIN", 62, 65], ["SAP", "PROTEIN", 113, 116], ["SAP", "PROTEIN", 145, 148], ["dogs", "SPECIES", 179, 183], ["cats", "SPECIES", 188, 192], ["Bone disease (e.g., osteosarcoma", "PROBLEM", 0, 32], ["osteomyelitis", "PROBLEM", 34, 47], ["increase SAP", "PROBLEM", 53, 65], ["Decreased SAP", "PROBLEM", 103, 116], ["Increased SAP", "PROBLEM", 135, 148], ["disease", "OBSERVATION", 5, 12], ["osteosarcoma", "OBSERVATION", 20, 32], ["osteomyelitis", "OBSERVATION", 34, 47], ["increase", "OBSERVATION_MODIFIER", 53, 61], ["SAP", "OBSERVATION_MODIFIER", 62, 65], ["Decreased", "OBSERVATION_MODIFIER", 103, 112], ["SAP", "OBSERVATION", 113, 116], ["Not", "UNCERTAINTY", 119, 122], ["significant", "OBSERVATION_MODIFIER", 123, 134], ["SAP", "OBSERVATION", 145, 148]]], ["Cats have less hepatocellular SAP, which is readily excreted by their kidneys.", [["hepatocellular", "ANATOMY", 15, 29], ["kidneys", "ANATOMY", 70, 77], ["Cats", "ORGANISM", 0, 4], ["hepatocellular", "ORGAN", 15, 29], ["SAP", "GENE_OR_GENE_PRODUCT", 30, 33], ["kidneys", "ORGAN", 70, 77], ["less hepatocellular SAP", "PROBLEM", 10, 33], ["less", "OBSERVATION_MODIFIER", 10, 14], ["hepatocellular SAP", "OBSERVATION", 15, 33], ["kidneys", "ANATOMY", 70, 77]]], ["Therefore any increase in feline SAP is considered important.", [["feline", "ORGANISM", 26, 32], ["SAP", "GENE_OR_GENE_PRODUCT", 33, 36], ["feline SAP", "PROTEIN", 26, 36], ["feline", "SPECIES", 26, 32], ["any increase in feline SAP", "PROBLEM", 10, 36], ["increase", "OBSERVATION_MODIFIER", 14, 22], ["feline SAP", "OBSERVATION", 26, 36]]], ["Not all cats with hepatic disease have increased SAP.", [["hepatic", "ANATOMY", 18, 25], ["hepatic disease", "DISEASE", 18, 33], ["cats", "ORGANISM", 8, 12], ["hepatic", "ORGAN", 18, 25], ["SAP", "GENE_OR_GENE_PRODUCT", 49, 52], ["SAP", "PROTEIN", 49, 52], ["cats", "SPECIES", 8, 12], ["hepatic disease", "PROBLEM", 18, 33], ["increased SAP", "PROBLEM", 39, 52], ["hepatic", "ANATOMY", 18, 25], ["disease", "OBSERVATION", 26, 33], ["increased", "OBSERVATION_MODIFIER", 39, 48], ["SAP", "OBSERVATION_MODIFIER", 49, 52]]], ["The major causes of increased SAP in cats are hepatic lipidosis, cholangitis and cholangiohepatitis, hyperthyroidism, and diabetes mellitus.", [["hepatic", "ANATOMY", 46, 53], ["hepatic lipidosis", "DISEASE", 46, 63], ["cholangitis", "DISEASE", 65, 76], ["cholangiohepatitis", "DISEASE", 81, 99], ["hyperthyroidism", "DISEASE", 101, 116], ["diabetes mellitus", "DISEASE", 122, 139], ["SAP", "GENE_OR_GENE_PRODUCT", 30, 33], ["cats", "ORGANISM", 37, 41], ["hepatic", "ORGAN", 46, 53], ["SAP", "PROTEIN", 30, 33], ["cats", "SPECIES", 37, 41], ["increased SAP in cats", "PROBLEM", 20, 41], ["hepatic lipidosis", "PROBLEM", 46, 63], ["cholangitis", "PROBLEM", 65, 76], ["cholangiohepatitis", "PROBLEM", 81, 99], ["hyperthyroidism", "PROBLEM", 101, 116], ["diabetes mellitus", "PROBLEM", 122, 139], ["increased", "OBSERVATION_MODIFIER", 20, 29], ["SAP", "OBSERVATION_MODIFIER", 30, 33], ["hepatic", "ANATOMY", 46, 53], ["lipidosis", "OBSERVATION", 54, 63], ["cholangitis", "OBSERVATION", 65, 76], ["hyperthyroidism", "OBSERVATION", 101, 116], ["diabetes mellitus", "OBSERVATION", 122, 139]]], ["SAP increases are generally more specific than GGT in cats with hepatic lipidosis (cats Causes of Decreased GGT \u2022 Not significant.Causes of Decreased SAP \u2022 Not significant.Causes of Increased GGT \u2022 Causes are similar to those of increased SAP and tend to parallel the magnitude of the rise in SAP, but bone lesions are not recognized to increase GGT.", [["hepatic", "ANATOMY", 64, 71], ["bone lesions", "ANATOMY", 302, 314], ["hepatic lipidosis", "DISEASE", 64, 81], ["bone lesions", "DISEASE", 302, 314], ["SAP", "GENE_OR_GENE_PRODUCT", 0, 3], ["GGT", "SIMPLE_CHEMICAL", 47, 50], ["cats", "ORGANISM", 54, 58], ["hepatic", "ORGAN", 64, 71], ["SAP", "GENE_OR_GENE_PRODUCT", 150, 153], ["GGT", "SIMPLE_CHEMICAL", 192, 195], ["SAP", "GENE_OR_GENE_PRODUCT", 239, 242], ["SAP", "GENE_OR_GENE_PRODUCT", 293, 296], ["bone lesions", "PATHOLOGICAL_FORMATION", 302, 314], ["GGT", "SIMPLE_CHEMICAL", 346, 349], ["SAP", "PROTEIN", 0, 3], ["GGT", "PROTEIN", 47, 50], ["SAP", "PROTEIN", 150, 153], ["GGT", "PROTEIN", 192, 195], ["SAP", "PROTEIN", 239, 242], ["SAP", "PROTEIN", 293, 296], ["GGT", "PROTEIN", 346, 349], ["cats", "SPECIES", 54, 58], ["SAP increases", "PROBLEM", 0, 13], ["GGT", "TEST", 47, 50], ["hepatic lipidosis", "PROBLEM", 64, 81], ["Decreased GGT", "PROBLEM", 98, 111], ["Decreased SAP", "PROBLEM", 140, 153], ["Increased GGT", "PROBLEM", 182, 195], ["increased SAP", "PROBLEM", 229, 242], ["the rise in SAP", "PROBLEM", 281, 296], ["bone lesions", "PROBLEM", 302, 314], ["GGT", "TEST", 346, 349], ["increases", "OBSERVATION_MODIFIER", 4, 13], ["hepatic", "ANATOMY", 64, 71], ["lipidosis", "OBSERVATION", 72, 81], ["Decreased GGT", "OBSERVATION", 98, 111], ["significant", "OBSERVATION_MODIFIER", 118, 129], ["Decreased", "OBSERVATION_MODIFIER", 140, 149], ["SAP", "OBSERVATION", 150, 153], ["Not", "UNCERTAINTY", 156, 159], ["significant", "OBSERVATION_MODIFIER", 160, 171], ["Increased", "OBSERVATION_MODIFIER", 182, 191], ["GGT", "OBSERVATION", 192, 195], ["increased", "OBSERVATION_MODIFIER", 229, 238], ["SAP", "OBSERVATION", 239, 242], ["rise", "OBSERVATION_MODIFIER", 285, 289], ["SAP", "OBSERVATION_MODIFIER", 293, 296], ["bone", "ANATOMY", 302, 306], ["lesions", "OBSERVATION", 307, 314]]], ["It is induced by glucocorticoid therapy and certain drugs, as is SAP.", [["glucocorticoid", "SIMPLE_CHEMICAL", 17, 31], ["SAP", "GENE_OR_GENE_PRODUCT", 65, 68], ["SAP", "PROTEIN", 65, 68], ["glucocorticoid therapy", "TREATMENT", 17, 39], ["certain drugs", "TREATMENT", 44, 57], ["glucocorticoid therapy", "OBSERVATION", 17, 39], ["SAP", "OBSERVATION_MODIFIER", 65, 68]]], ["In cats, GGT may increase more than SAP, except in hepatic lipidosis (where classically the SAP is usually quite high, but GGT values show only a mild [or no] increase).", [["hepatic", "ANATOMY", 51, 58], ["cats", "ORGANISM", 3, 7], ["GGT", "SIMPLE_CHEMICAL", 9, 12], ["SAP", "GENE_OR_GENE_PRODUCT", 36, 39], ["hepatic", "ORGAN", 51, 58], ["GGT", "SIMPLE_CHEMICAL", 123, 126], ["GGT", "PROTEIN", 9, 12], ["SAP", "PROTEIN", 36, 39], ["SAP", "PROTEIN", 92, 95], ["GGT", "PROTEIN", 123, 126], ["cats", "SPECIES", 3, 7], ["GGT", "TEST", 9, 12], ["hepatic lipidosis", "PROBLEM", 51, 68], ["the SAP", "TEST", 88, 95], ["GGT values", "TEST", 123, 133], ["a mild [or no] increase)", "PROBLEM", 144, 168], ["increase", "OBSERVATION_MODIFIER", 17, 25], ["hepatic", "ANATOMY", 51, 58], ["lipidosis", "OBSERVATION", 59, 68], ["SAP", "OBSERVATION_MODIFIER", 92, 95], ["mild", "OBSERVATION_MODIFIER", 146, 150]]], ["GGT does not tend to increase after acute hepatic necrosis, as does SAP.", [["hepatic", "ANATOMY", 42, 49], ["acute hepatic necrosis", "DISEASE", 36, 58], ["GGT", "SIMPLE_CHEMICAL", 0, 3], ["hepatic", "ORGAN", 42, 49], ["SAP", "GENE_OR_GENE_PRODUCT", 68, 71], ["GGT", "PROTEIN", 0, 3], ["SAP", "PROTEIN", 68, 71], ["GGT", "TEST", 0, 3], ["acute hepatic necrosis", "PROBLEM", 36, 58], ["acute", "OBSERVATION_MODIFIER", 36, 41], ["hepatic", "ANATOMY", 42, 49], ["necrosis", "OBSERVATION", 50, 58]]], ["Increased GGT should be pursued as for increased SAP (see Figure 9 -12).", [["GGT", "SIMPLE_CHEMICAL", 10, 13], ["GGT", "PROTEIN", 10, 13], ["SAP", "PROTEIN", 49, 52], ["Increased GGT", "PROBLEM", 0, 13], ["increased SAP", "PROBLEM", 39, 52], ["GGT", "OBSERVATION", 10, 13]]], ["Increased GGT may suggest pancreatitis obstructing the bile duct, as for SAP.Causes of Decreased SAP \u2022 Not significant.Causes of Increased Urine GGT \u2022 Increased 24-hour urinary excretion of GGT can be caused by various nephrotoxins (e.g., gentamicin).LACTATE DEHYDROGENASERare Indications \u2022 This test is not recommended.LACTATE DEHYDROGENASEDisadvantages \u2022 Lactate dehydrogenase (LDH) has lack of specificity.LACTATE DEHYDROGENASECauses of Increased LDH \u2022 LDH is found in many body tissues.", [["bile duct", "ANATOMY", 55, 64], ["urinary", "ANATOMY", 169, 176], ["body tissues", "ANATOMY", 477, 489], ["pancreatitis", "DISEASE", 26, 38], ["gentamicin", "CHEMICAL", 239, 249], ["Lactate", "CHEMICAL", 357, 364], ["gentamicin", "CHEMICAL", 239, 249], ["Lactate", "CHEMICAL", 357, 364], ["GGT", "GENE_OR_GENE_PRODUCT", 10, 13], ["bile duct", "MULTI-TISSUE_STRUCTURE", 55, 64], ["SAP", "GENE_OR_GENE_PRODUCT", 73, 76], ["SAP", "GENE_OR_GENE_PRODUCT", 97, 100], ["Urine", "ORGANISM_SUBSTANCE", 139, 144], ["GGT", "SIMPLE_CHEMICAL", 145, 148], ["urinary", "ORGANISM_SUBSTANCE", 169, 176], ["GGT", "SIMPLE_CHEMICAL", 190, 193], ["nephrotoxins", "SIMPLE_CHEMICAL", 219, 231], ["gentamicin", "SIMPLE_CHEMICAL", 239, 249], ["Lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 357, 378], ["LDH", "GENE_OR_GENE_PRODUCT", 380, 383], ["LDH", "GENE_OR_GENE_PRODUCT", 450, 453], ["LDH", "GENE_OR_GENE_PRODUCT", 456, 459], ["body tissues", "TISSUE", 477, 489], ["GGT", "PROTEIN", 10, 13], ["SAP", "PROTEIN", 73, 76], ["SAP", "PROTEIN", 97, 100], ["GGT", "PROTEIN", 190, 193], ["Lactate dehydrogenase", "PROTEIN", 357, 378], ["LDH", "PROTEIN", 380, 383], ["LDH", "PROTEIN", 450, 453], ["LDH", "PROTEIN", 456, 459], ["Increased GGT", "PROBLEM", 0, 13], ["pancreatitis obstructing the bile duct", "PROBLEM", 26, 64], ["SAP", "PROBLEM", 73, 76], ["Decreased SAP", "PROBLEM", 87, 100], ["Increased Urine GGT", "PROBLEM", 129, 148], ["urinary excretion of GGT", "TEST", 169, 193], ["various nephrotoxins", "TREATMENT", 211, 231], ["gentamicin", "TREATMENT", 239, 249], ["LACTATE", "TEST", 251, 258], ["This test", "TEST", 291, 300], ["LACTATE DEHYDROGENASEDisadvantages", "TEST", 320, 354], ["Lactate dehydrogenase", "TEST", 357, 378], ["LDH)", "TEST", 380, 384], ["LACTATE DEHYDROGENASECauses", "TEST", 409, 436], ["Increased LDH \u2022 LDH", "PROBLEM", 440, 459], ["GGT", "OBSERVATION", 10, 13], ["suggest", "UNCERTAINTY", 18, 25], ["pancreatitis", "OBSERVATION", 26, 38], ["bile duct", "ANATOMY", 55, 64], ["Decreased", "OBSERVATION_MODIFIER", 87, 96], ["SAP", "OBSERVATION", 97, 100], ["Not", "UNCERTAINTY", 103, 106], ["significant", "OBSERVATION_MODIFIER", 107, 118], ["Increased", "OBSERVATION_MODIFIER", 129, 138], ["Urine GGT", "OBSERVATION", 139, 148], ["Increased", "OBSERVATION_MODIFIER", 440, 449], ["LDH \u2022 LDH", "OBSERVATION", 450, 459], ["many", "OBSERVATION_MODIFIER", 472, 476], ["body tissues", "ANATOMY_MODIFIER", 477, 489]]], ["Inexplicable increases of small to great magnitude are not uncommon.", [["increases", "OBSERVATION_MODIFIER", 13, 22], ["small", "OBSERVATION_MODIFIER", 26, 31], ["to great magnitude", "OBSERVATION_MODIFIER", 32, 50], ["not", "UNCERTAINTY", 55, 58], ["uncommon", "OBSERVATION_MODIFIER", 59, 67]]], ["Analysis \u2022 SBAs are measured in serum by either a direct enzymatic method that quantifies total serum 3-alphahydroxylated bile acids or an RIA procedure that measures specific bile acids.", [["serum", "ANATOMY", 32, 37], ["serum", "ANATOMY", 96, 101], ["bile", "ANATOMY", 176, 180], ["3-alphahydroxylated bile acids", "CHEMICAL", 102, 132], ["bile acids", "CHEMICAL", 176, 186], ["3-alphahydroxylated bile acids", "CHEMICAL", 102, 132], ["bile acids", "CHEMICAL", 176, 186], ["SBAs", "SIMPLE_CHEMICAL", 11, 15], ["serum", "ORGANISM_SUBSTANCE", 32, 37], ["serum", "ORGANISM_SUBSTANCE", 96, 101], ["3-alphahydroxylated bile acids", "SIMPLE_CHEMICAL", 102, 132], ["bile acids", "SIMPLE_CHEMICAL", 176, 186], ["SBAs", "PROTEIN", 11, 15], ["Analysis", "TEST", 0, 8], ["SBAs", "TEST", 11, 15], ["total serum", "TEST", 90, 101], ["alphahydroxylated bile acids", "TREATMENT", 104, 132], ["an RIA procedure", "TREATMENT", 136, 152]]], ["It is important that a validated assay for dogs and cats be used because some methods are not accurate.", [["dogs", "ORGANISM", 43, 47], ["cats", "ORGANISM", 52, 56], ["dogs", "SPECIES", 43, 47], ["dogs and cats", "TREATMENT", 43, 56]]], ["Values for enzymatic and RIA procedures cannot be compared.SERUM BILE ACIDSSAP, one must determine if hepatic biopsy is indicated (see the discussion under Serum Bile Acids later in this chapter).", [["hepatic biopsy", "ANATOMY", 102, 116], ["Bile Acids", "CHEMICAL", 162, 172], ["hepatic biopsy", "MULTI-TISSUE_STRUCTURE", 102, 116], ["Values", "TEST", 0, 6], ["enzymatic and RIA procedures", "TREATMENT", 11, 39], ["SERUM BILE ACIDSSAP", "TEST", 59, 78], ["hepatic biopsy", "TEST", 102, 116], ["Serum Bile Acids", "TEST", 156, 172], ["BILE", "ANATOMY", 65, 69], ["hepatic", "ANATOMY", 102, 109], ["biopsy", "OBSERVATION", 110, 116]]], ["The major causes of SAP values more than three times normal in dogs are hepatobiliary disease, endogenous steroids (i.e., hyperadrenocorticism or stress), and therapy with glucocorticoids or anticonvulsants.", [["hepatobiliary", "ANATOMY", 72, 85], ["hepatobiliary disease", "DISEASE", 72, 93], ["steroids", "CHEMICAL", 106, 114], ["hyperadrenocorticism", "DISEASE", 122, 142], ["glucocorticoids", "CHEMICAL", 172, 187], ["steroids", "CHEMICAL", 106, 114], ["SAP", "GENE_OR_GENE_PRODUCT", 20, 23], ["dogs", "ORGANISM", 63, 67], ["hepatobiliary", "ORGAN", 72, 85], ["glucocorticoids", "SIMPLE_CHEMICAL", 172, 187], ["SAP", "PROTEIN", 20, 23], ["dogs", "SPECIES", 63, 67], ["SAP values", "TEST", 20, 30], ["hepatobiliary disease", "PROBLEM", 72, 93], ["endogenous steroids", "TREATMENT", 95, 114], ["hyperadrenocorticism", "PROBLEM", 122, 142], ["stress", "PROBLEM", 146, 152], ["therapy", "TREATMENT", 159, 166], ["glucocorticoids", "TREATMENT", 172, 187], ["anticonvulsants", "TREATMENT", 191, 206], ["SAP", "OBSERVATION", 20, 23], ["hepatobiliary", "ANATOMY", 72, 85], ["disease", "OBSERVATION", 86, 93], ["endogenous steroids", "OBSERVATION", 95, 114]]], ["Hepatic disease with increased SAP usually has a cholestatic component; however, this does not imply icterus or gross obstruction of the biliary tract.", [["Hepatic", "ANATOMY", 0, 7], ["biliary tract", "ANATOMY", 137, 150], ["Hepatic disease", "DISEASE", 0, 15], ["cholestatic", "DISEASE", 49, 60], ["icterus", "DISEASE", 101, 108], ["obstruction of the biliary tract", "DISEASE", 118, 150], ["Hepatic", "ORGAN", 0, 7], ["SAP", "GENE_OR_GENE_PRODUCT", 31, 34], ["biliary tract", "ORGAN", 137, 150], ["SAP", "PROTEIN", 31, 34], ["Hepatic disease", "PROBLEM", 0, 15], ["increased SAP", "PROBLEM", 21, 34], ["a cholestatic component", "PROBLEM", 47, 70], ["icterus", "PROBLEM", 101, 108], ["gross obstruction of the biliary tract", "PROBLEM", 112, 150], ["disease", "OBSERVATION", 8, 15], ["increased", "OBSERVATION_MODIFIER", 21, 30], ["SAP", "OBSERVATION_MODIFIER", 31, 34], ["cholestatic", "OBSERVATION_MODIFIER", 49, 60], ["component", "OBSERVATION_MODIFIER", 61, 70], ["icterus", "OBSERVATION", 101, 108], ["gross", "OBSERVATION_MODIFIER", 112, 117], ["obstruction", "OBSERVATION", 118, 129], ["biliary tract", "ANATOMY", 137, 150]]], ["Intrahepatic cholestasis caused by diffuse or focal compression of bile canaliculi may occur in various hepatopathies, even those secondary to septicemia, toxemia, and chronic stress-induced vacuolar (i.e., hydropic change) hepatopathy.", [["bile canaliculi", "ANATOMY", 67, 82], ["hepatopathies", "ANATOMY", 104, 117], ["vacuolar", "ANATOMY", 191, 199], ["Intrahepatic cholestasis", "DISEASE", 0, 24], ["hepatopathies", "DISEASE", 104, 117], ["septicemia", "DISEASE", 143, 153], ["toxemia", "DISEASE", 155, 162], ["hepatopathy", "DISEASE", 224, 235], ["bile canaliculi", "MULTI-TISSUE_STRUCTURE", 67, 82], ["hepatopathies", "CANCER", 104, 117], ["vacuolar", "IMMATERIAL_ANATOMICAL_ENTITY", 191, 199], ["Intrahepatic cholestasis", "PROBLEM", 0, 24], ["diffuse or focal compression of bile canaliculi", "PROBLEM", 35, 82], ["various hepatopathies", "PROBLEM", 96, 117], ["septicemia", "PROBLEM", 143, 153], ["toxemia", "PROBLEM", 155, 162], ["chronic stress-induced vacuolar (i.e., hydropic change) hepatopathy", "PROBLEM", 168, 235], ["cholestasis", "OBSERVATION", 13, 24], ["diffuse", "OBSERVATION_MODIFIER", 35, 42], ["focal", "OBSERVATION_MODIFIER", 46, 51], ["compression", "OBSERVATION", 52, 63], ["bile canaliculi", "ANATOMY", 67, 82], ["various", "OBSERVATION_MODIFIER", 96, 103], ["hepatopathies", "OBSERVATION", 104, 117], ["septicemia", "OBSERVATION", 143, 153], ["toxemia", "OBSERVATION", 155, 162], ["chronic", "OBSERVATION_MODIFIER", 168, 175], ["stress", "OBSERVATION", 176, 182], ["vacuolar", "OBSERVATION_MODIFIER", 191, 199], ["hydropic change", "OBSERVATION", 207, 222], ["hepatopathy", "OBSERVATION", 224, 235]]], ["Acute hepatocellular necrosis can transiently increase SAP.", [["hepatocellular", "ANATOMY", 6, 20], ["Acute hepatocellular necrosis", "DISEASE", 0, 29], ["hepatocellular", "ORGAN", 6, 20], ["SAP", "GENE_OR_GENE_PRODUCT", 55, 58], ["SAP", "PROTEIN", 55, 58], ["Acute hepatocellular necrosis", "PROBLEM", 0, 29], ["hepatocellular", "ANATOMY", 6, 20], ["necrosis", "OBSERVATION", 21, 29], ["increase", "OBSERVATION_MODIFIER", 46, 54], ["SAP", "OBSERVATION_MODIFIER", 55, 58]]], ["Extrahepatic biliary tract obstruction and enzyme induction caused by endogenous or exogenous glucocorticoids or drug administration may increase SAP more than 10 times normal.", [["Extrahepatic biliary tract", "ANATOMY", 0, 26], ["Extrahepatic biliary tract obstruction", "DISEASE", 0, 38], ["glucocorticoids", "CHEMICAL", 94, 109], ["Extrahepatic biliary tract", "PATHOLOGICAL_FORMATION", 0, 26], ["SAP", "GENE_OR_GENE_PRODUCT", 146, 149], ["SAP", "PROTEIN", 146, 149], ["Extrahepatic biliary tract obstruction", "PROBLEM", 0, 38], ["enzyme induction", "TREATMENT", 43, 59], ["exogenous glucocorticoids", "TREATMENT", 84, 109], ["drug administration", "TREATMENT", 113, 132], ["biliary tract", "ANATOMY", 13, 26], ["obstruction", "OBSERVATION", 27, 38], ["enzyme induction", "OBSERVATION", 43, 59], ["endogenous", "OBSERVATION_MODIFIER", 70, 80], ["exogenous glucocorticoids", "OBSERVATION", 84, 109]]], ["As with ALT, the magnitude of the increase in SAP does not correlate with prognosis.SERUM BILE ACIDSIn dogs, it is important first to rule out young age, drug therapy, and hyperadrenocorticism to avoid performing unnecessary diagnostics (Figure 9 -12).", [["hyperadrenocorticism", "DISEASE", 172, 192], ["ALT", "SIMPLE_CHEMICAL", 8, 11], ["SAP", "GENE_OR_GENE_PRODUCT", 46, 49], ["ALT", "PROTEIN", 8, 11], ["SAP", "PROTEIN", 46, 49], ["dogs", "SPECIES", 103, 107], ["ALT", "TEST", 8, 11], ["the increase in SAP", "PROBLEM", 30, 49], ["SERUM BILE ACIDSIn dogs", "PROBLEM", 84, 107], ["drug therapy", "TREATMENT", 154, 166], ["hyperadrenocorticism", "PROBLEM", 172, 192], ["unnecessary diagnostics", "TEST", 213, 236], ["increase", "OBSERVATION_MODIFIER", 34, 42], ["BILE", "ANATOMY", 90, 94]]], ["Hyperadrenocorticism can easily be confused with primary hepatic disease because it typically causes hepatomegaly, pu-pd, increased ALT, and sometimes increased serum bile acids.", [["hepatic", "ANATOMY", 57, 64], ["serum", "ANATOMY", 161, 166], ["Hyperadrenocorticism", "DISEASE", 0, 20], ["primary hepatic disease", "DISEASE", 49, 72], ["hepatomegaly", "DISEASE", 101, 113], ["bile acids", "CHEMICAL", 167, 177], ["bile acids", "CHEMICAL", 167, 177], ["hepatic", "ORGAN", 57, 64], ["ALT", "SIMPLE_CHEMICAL", 132, 135], ["serum", "ORGANISM_SUBSTANCE", 161, 166], ["bile acids", "SIMPLE_CHEMICAL", 167, 177], ["Hyperadrenocorticism", "PROBLEM", 0, 20], ["confused", "PROBLEM", 35, 43], ["primary hepatic disease", "PROBLEM", 49, 72], ["hepatomegaly", "PROBLEM", 101, 113], ["pu-pd", "PROBLEM", 115, 120], ["increased ALT", "PROBLEM", 122, 135], ["sometimes increased serum bile acids", "PROBLEM", 141, 177], ["hepatic", "ANATOMY", 57, 64], ["disease", "OBSERVATION", 65, 72], ["hepatomegaly", "OBSERVATION", 101, 113], ["increased", "OBSERVATION_MODIFIER", 122, 131], ["ALT", "OBSERVATION_MODIFIER", 132, 135], ["bile", "ANATOMY", 167, 171]]], ["If a patient has signs of hepatic failure (i.e., icterus, hepatic encephalopathy, hypoglycemia, weight loss, vomiting, hypoalbuminemia, ascites, microhepatia), one generally assumes that the increased SAP is due to primary hepatic disease.", [["hepatic", "ANATOMY", 26, 33], ["hepatic", "ANATOMY", 58, 65], ["ascites", "ANATOMY", 136, 143], ["microhepatia", "ANATOMY", 145, 157], ["hepatic", "ANATOMY", 223, 230], ["hepatic failure", "DISEASE", 26, 41], ["icterus", "DISEASE", 49, 56], ["hepatic encephalopathy", "DISEASE", 58, 80], ["hypoglycemia", "DISEASE", 82, 94], ["weight loss", "DISEASE", 96, 107], ["vomiting", "DISEASE", 109, 117], ["hypoalbuminemia", "DISEASE", 119, 134], ["ascites", "DISEASE", 136, 143], ["microhepatia", "DISEASE", 145, 157], ["primary hepatic disease", "DISEASE", 215, 238], ["patient", "ORGANISM", 5, 12], ["hepatic", "ORGAN", 26, 33], ["hepatic", "ORGAN", 58, 65], ["SAP", "GENE_OR_GENE_PRODUCT", 201, 204], ["hepatic", "ORGAN", 223, 230], ["SAP", "PROTEIN", 201, 204], ["patient", "SPECIES", 5, 12], ["hepatic failure", "PROBLEM", 26, 41], ["icterus", "PROBLEM", 49, 56], ["hepatic encephalopathy", "PROBLEM", 58, 80], ["hypoglycemia", "PROBLEM", 82, 94], ["weight loss", "PROBLEM", 96, 107], ["vomiting", "PROBLEM", 109, 117], ["hypoalbuminemia", "PROBLEM", 119, 134], ["ascites", "PROBLEM", 136, 143], ["microhepatia", "PROBLEM", 145, 157], ["the increased SAP", "PROBLEM", 187, 204], ["primary hepatic disease", "PROBLEM", 215, 238], ["hepatic", "ANATOMY", 26, 33], ["failure", "OBSERVATION", 34, 41], ["icterus", "OBSERVATION", 49, 56], ["hepatic", "ANATOMY", 58, 65], ["encephalopathy", "OBSERVATION", 66, 80], ["hypoalbuminemia", "OBSERVATION", 119, 134], ["ascites", "OBSERVATION", 136, 143], ["increased", "OBSERVATION_MODIFIER", 191, 200], ["SAP", "OBSERVATION", 201, 204], ["hepatic", "ANATOMY", 223, 230], ["disease", "OBSERVATION", 231, 238]]], ["If it is not obvious that the patient probably has primary hepatic disease and the patient has signs that might be consistent with hyperadrenocorticism (e.g., pu-pd, cutaneous changes, potbelly), then adrenal gland function testing may be appropriate.", [["hepatic", "ANATOMY", 59, 66], ["cutaneous", "ANATOMY", 166, 175], ["adrenal gland", "ANATOMY", 201, 214], ["primary hepatic disease", "DISEASE", 51, 74], ["hyperadrenocorticism", "DISEASE", 131, 151], ["patient", "ORGANISM", 30, 37], ["hepatic", "ORGAN", 59, 66], ["patient", "ORGANISM", 83, 90], ["adrenal gland", "MULTI-TISSUE_STRUCTURE", 201, 214], ["patient", "SPECIES", 30, 37], ["patient", "SPECIES", 83, 90], ["primary hepatic disease", "PROBLEM", 51, 74], ["signs", "PROBLEM", 95, 100], ["hyperadrenocorticism (e.g., pu-pd, cutaneous changes", "PROBLEM", 131, 183], ["adrenal gland function testing", "TEST", 201, 231], ["not obvious", "UNCERTAINTY", 9, 20], ["primary", "OBSERVATION_MODIFIER", 51, 58], ["hepatic", "ANATOMY", 59, 66], ["disease", "OBSERVATION", 67, 74], ["might be consistent with", "UNCERTAINTY", 106, 130], ["hyperadrenocorticism", "OBSERVATION", 131, 151], ["adrenal gland", "ANATOMY", 201, 214]]], ["If the SAP is increased but the ALT and serum bilirubin concentrations are normal, clinically important hepatic disease is unlikely.", [["serum", "ANATOMY", 40, 45], ["hepatic", "ANATOMY", 104, 111], ["bilirubin", "CHEMICAL", 46, 55], ["hepatic disease", "DISEASE", 104, 119], ["bilirubin", "CHEMICAL", 46, 55], ["SAP", "GENE_OR_GENE_PRODUCT", 7, 10], ["ALT", "SIMPLE_CHEMICAL", 32, 35], ["serum", "ORGANISM_SUBSTANCE", 40, 45], ["bilirubin", "SIMPLE_CHEMICAL", 46, 55], ["hepatic", "ORGAN", 104, 111], ["SAP", "PROTEIN", 7, 10], ["ALT", "PROTEIN", 32, 35], ["the SAP", "TEST", 3, 10], ["the ALT and serum bilirubin concentrations", "TEST", 28, 70], ["hepatic disease", "PROBLEM", 104, 119], ["SAP", "OBSERVATION_MODIFIER", 7, 10], ["increased", "OBSERVATION_MODIFIER", 14, 23], ["normal", "OBSERVATION", 75, 81], ["hepatic", "ANATOMY", 104, 111], ["disease", "OBSERVATION", 112, 119]]], ["If the ALT is substantially increased (and especially if it is higher than the SAP), then primary hepatic disease is much more likely.", [["hepatic", "ANATOMY", 98, 105], ["primary hepatic disease", "DISEASE", 90, 113], ["ALT", "SIMPLE_CHEMICAL", 7, 10], ["hepatic", "ORGAN", 98, 105], ["ALT", "PROTEIN", 7, 10], ["the ALT", "TEST", 3, 10], ["primary hepatic disease", "PROBLEM", 90, 113], ["substantially", "OBSERVATION_MODIFIER", 14, 27], ["increased", "OBSERVATION_MODIFIER", 28, 37], ["hepatic", "ANATOMY", 98, 105], ["disease", "OBSERVATION", 106, 113], ["much more likely", "UNCERTAINTY", 117, 133]]], ["If a hepatic biopsy specimen is obtained from a patient with hyperadrenocorticism or other systemic disease that is causing \"stress,\" vacuolar hepatopathy is found.GAMMA-GLUTAMYL TRANSPEPTIDASERare Indications \u2022 GGT is rarely indicated; the indications are similar to those for SAP.", [["hepatic biopsy specimen", "ANATOMY", 5, 28], ["vacuolar", "ANATOMY", 134, 142], ["hyperadrenocorticism", "DISEASE", 61, 81], ["systemic disease", "DISEASE", 91, 107], ["hepatopathy", "DISEASE", 143, 154], ["hepatic biopsy specimen", "CANCER", 5, 28], ["patient", "ORGANISM", 48, 55], ["vacuolar", "CELLULAR_COMPONENT", 134, 142], ["GGT", "SIMPLE_CHEMICAL", 212, 215], ["SAP", "GENE_OR_GENE_PRODUCT", 278, 281], ["GGT", "PROTEIN", 212, 215], ["SAP", "PROTEIN", 278, 281], ["patient", "SPECIES", 48, 55], ["a hepatic biopsy specimen", "TEST", 3, 28], ["hyperadrenocorticism", "PROBLEM", 61, 81], ["other systemic disease", "PROBLEM", 85, 107], ["\"stress", "PROBLEM", 124, 131], ["vacuolar hepatopathy", "PROBLEM", 134, 154], ["GLUTAMYL TRANSPEPTIDASERare Indications", "TREATMENT", 170, 209], ["GGT", "TEST", 212, 215], ["SAP", "PROBLEM", 278, 281], ["hepatic", "ANATOMY", 5, 12], ["biopsy", "OBSERVATION", 13, 19], ["systemic", "OBSERVATION_MODIFIER", 91, 99], ["disease", "OBSERVATION", 100, 107], ["vacuolar hepatopathy", "OBSERVATION", 134, 154]]], ["SAP appears to be more sensitive for hepatobiliary disease in dogs; however, in cats, GGT has slightly greater sensitivity and perhaps greater specificity for hepatic disease (except hepatic lipidosis).", [["hepatobiliary", "ANATOMY", 37, 50], ["hepatic", "ANATOMY", 159, 166], ["hepatic", "ANATOMY", 183, 190], ["hepatobiliary disease", "DISEASE", 37, 58], ["hepatic disease", "DISEASE", 159, 174], ["SAP", "GENE_OR_GENE_PRODUCT", 0, 3], ["hepatobiliary", "ORGAN", 37, 50], ["dogs", "ORGANISM", 62, 66], ["cats", "ORGANISM", 80, 84], ["GGT", "GENE_OR_GENE_PRODUCT", 86, 89], ["hepatic", "ORGAN", 159, 166], ["hepatic", "ORGAN", 183, 190], ["SAP", "PROTEIN", 0, 3], ["GGT", "PROTEIN", 86, 89], ["dogs", "SPECIES", 62, 66], ["cats", "SPECIES", 80, 84], ["SAP", "TEST", 0, 3], ["hepatobiliary disease in dogs", "PROBLEM", 37, 66], ["GGT", "TEST", 86, 89], ["slightly greater sensitivity", "PROBLEM", 94, 122], ["hepatic disease", "PROBLEM", 159, 174], ["hepatic lipidosis", "PROBLEM", 183, 200], ["hepatobiliary", "ANATOMY", 37, 50], ["disease", "OBSERVATION", 51, 58], ["hepatic", "ANATOMY", 159, 166], ["disease", "OBSERVATION", 167, 174], ["hepatic", "ANATOMY", 183, 190], ["lipidosis", "OBSERVATION", 191, 200]]], ["Therefore it is more frequently indicated in cats than in dogs.", [["cats", "ORGANISM", 45, 49], ["dogs", "ORGANISM", 58, 62], ["cats", "SPECIES", 45, 49], ["dogs", "SPECIES", 58, 62]]], ["GGT is less influenced than SAP by secondary hepatic disease conditions or enzyme-inducing drugs.", [["hepatic", "ANATOMY", 45, 52], ["hepatic disease", "DISEASE", 45, 60], ["GGT", "SIMPLE_CHEMICAL", 0, 3], ["SAP", "GENE_OR_GENE_PRODUCT", 28, 31], ["hepatic", "ORGAN", 45, 52], ["GGT", "PROTEIN", 0, 3], ["SAP", "PROTEIN", 28, 31], ["enzyme", "PROTEIN", 75, 81], ["GGT", "TEST", 0, 3], ["secondary hepatic disease conditions", "PROBLEM", 35, 71], ["enzyme-inducing drugs", "TREATMENT", 75, 96], ["less influenced", "OBSERVATION_MODIFIER", 7, 22], ["hepatic", "ANATOMY", 45, 52], ["disease", "OBSERVATION", 53, 60]]], ["The use of SAP and GGT together has a higher predictive value of hepatic disease.GAMMA-GLUTAMYL TRANSPEPTIDASEAnalysis \u2022 GGT is measured in serum, urine, and body fluids by spectrophotometric methods.", [["hepatic", "ANATOMY", 65, 72], ["serum", "ANATOMY", 140, 145], ["urine", "ANATOMY", 147, 152], ["body fluids", "ANATOMY", 158, 169], ["hepatic disease", "DISEASE", 65, 80], ["SAP", "GENE_OR_GENE_PRODUCT", 11, 14], ["GGT", "SIMPLE_CHEMICAL", 19, 22], ["hepatic", "ORGAN", 65, 72], ["GAMMA", "SIMPLE_CHEMICAL", 81, 86], ["GGT", "SIMPLE_CHEMICAL", 121, 124], ["serum", "ORGANISM_SUBSTANCE", 140, 145], ["urine", "ORGANISM_SUBSTANCE", 147, 152], ["body", "ORGANISM_SUBDIVISION", 158, 162], ["fluids", "ORGANISM_SUBSTANCE", 163, 169], ["SAP", "PROTEIN", 11, 14], ["GGT", "PROTEIN", 19, 22], ["GGT", "PROTEIN", 121, 124], ["SAP and GGT", "TEST", 11, 22], ["hepatic disease", "PROBLEM", 65, 80], ["GLUTAMYL TRANSPEPTIDASEAnalysis", "TEST", 87, 118], ["GGT", "TEST", 121, 124], ["serum, urine", "TEST", 140, 152], ["spectrophotometric methods", "TEST", 173, 199], ["hepatic", "ANATOMY", 65, 72], ["disease", "OBSERVATION", 73, 80], ["body", "ANATOMY", 158, 162]]], ["GGT is stable in serum at 4\u00b0 C for at least 3 days and at 20\u00b0 C for up to 1 year.URINARY BILE ACIDSOccasional Indications \u2022 Measurement of urinary bile acids (UBAs) may be indicated when samples for fasting and postprandial SBA determinations are difficult to obtain.Advantages \u2022The client can bring a urine sample into the clinic instead of bringing the patient.", [["serum", "ANATOMY", 17, 22], ["urinary", "ANATOMY", 139, 146], ["samples", "ANATOMY", 187, 194], ["urine sample", "ANATOMY", 302, 314], ["bile acids", "CHEMICAL", 147, 157], ["bile acids", "CHEMICAL", 147, 157], ["GGT", "SIMPLE_CHEMICAL", 0, 3], ["serum", "ORGANISM_SUBSTANCE", 17, 22], ["urinary bile acids", "SIMPLE_CHEMICAL", 139, 157], ["UBAs", "SIMPLE_CHEMICAL", 159, 163], ["urine", "ORGANISM_SUBSTANCE", 302, 307], ["patient", "ORGANISM", 355, 362], ["GGT", "PROTEIN", 0, 3], ["patient", "SPECIES", 355, 362], ["GGT", "TEST", 0, 3], ["urinary bile acids", "TEST", 139, 157], ["fasting", "TEST", 199, 206], ["postprandial SBA determinations", "TEST", 211, 242], ["stable", "OBSERVATION_MODIFIER", 7, 13], ["BILE", "ANATOMY", 89, 93], ["urinary bile", "ANATOMY", 139, 151]]], ["Because the urine bile acids : creatinine ratio represents an average SBA value over time, the urine bile acids : creatinine ratio is probably not substantially affected by transient variation in SBA concentrations and appears to be as or more specific than a random single measurement of SBAs.", [["urine", "ANATOMY", 12, 17], ["urine", "ANATOMY", 95, 100], ["bile acids", "CHEMICAL", 18, 28], ["creatinine", "CHEMICAL", 31, 41], ["bile acids", "CHEMICAL", 101, 111], ["creatinine", "CHEMICAL", 114, 124], ["bile acids", "CHEMICAL", 18, 28], ["creatinine", "CHEMICAL", 31, 41], ["bile acids", "CHEMICAL", 101, 111], ["creatinine", "CHEMICAL", 114, 124], ["urine", "ORGANISM_SUBSTANCE", 12, 17], ["bile acids", "SIMPLE_CHEMICAL", 18, 28], ["creatinine", "SIMPLE_CHEMICAL", 31, 41], ["urine", "ORGANISM_SUBSTANCE", 95, 100], ["bile acids", "SIMPLE_CHEMICAL", 101, 111], ["creatinine", "SIMPLE_CHEMICAL", 114, 124], ["SBA", "SIMPLE_CHEMICAL", 196, 199], ["the urine bile acids", "TEST", 8, 28], ["creatinine ratio", "TEST", 31, 47], ["the urine bile acids", "TEST", 91, 111], ["creatinine ratio", "TEST", 114, 130], ["transient variation in SBA concentrations", "PROBLEM", 173, 214], ["bile", "ANATOMY", 18, 22], ["probably not", "UNCERTAINTY", 134, 146], ["substantially affected", "OBSERVATION_MODIFIER", 147, 169], ["transient", "OBSERVATION_MODIFIER", 173, 182], ["variation", "OBSERVATION_MODIFIER", 183, 192], ["SBA concentrations", "OBSERVATION", 196, 214]]], ["Bilirubin and glucose in the urine are unlikely to interfere with test results.", [["urine", "ANATOMY", 29, 34], ["Bilirubin", "CHEMICAL", 0, 9], ["glucose", "CHEMICAL", 14, 21], ["Bilirubin", "CHEMICAL", 0, 9], ["glucose", "CHEMICAL", 14, 21], ["Bilirubin", "SIMPLE_CHEMICAL", 0, 9], ["glucose", "SIMPLE_CHEMICAL", 14, 21], ["urine", "ORGANISM_SUBSTANCE", 29, 34], ["Bilirubin", "TEST", 0, 9], ["glucose in the urine", "TEST", 14, 34]]], ["Treatment with ursodeoxycholic acid is not known to interfere with test results.Disadvantages \u2022The test may not be as sensitive as SBAs.Disadvantages \u2022Analysis \u2022 UBAs are measured in urine (approximately 5 ml) using enzymatic methodology; the UBA concentration is standardized for urine flow and concentration by measuring concurrent urine creatinine concentration and calculating the ratio (\u00b5mol of urine bile acids/mg of urine creatinine).Disadvantages \u2022Normal Values \u2022 Dog, less than 7.3 \u00b5mol/g; cat, less than 4.4 \u00b5mol/g.", [["urine", "ANATOMY", 183, 188], ["urine", "ANATOMY", 281, 286], ["urine", "ANATOMY", 334, 339], ["urine", "ANATOMY", 400, 405], ["urine", "ANATOMY", 423, 428], ["ursodeoxycholic acid", "CHEMICAL", 15, 35], ["creatinine", "CHEMICAL", 340, 350], ["creatinine", "CHEMICAL", 429, 439], ["ursodeoxycholic acid", "CHEMICAL", 15, 35], ["creatinine", "CHEMICAL", 340, 350], ["bile acids", "CHEMICAL", 406, 416], ["creatinine", "CHEMICAL", 429, 439], ["ursodeoxycholic acid", "SIMPLE_CHEMICAL", 15, 35], ["UBAs", "SIMPLE_CHEMICAL", 162, 166], ["urine", "ORGANISM_SUBSTANCE", 183, 188], ["UBA", "GENE_OR_GENE_PRODUCT", 243, 246], ["urine", "ORGANISM_SUBSTANCE", 281, 286], ["urine", "ORGANISM_SUBSTANCE", 334, 339], ["creatinine", "SIMPLE_CHEMICAL", 340, 350], ["urine", "ORGANISM_SUBSTANCE", 400, 405], ["bile acids", "SIMPLE_CHEMICAL", 406, 416], ["urine", "ORGANISM_SUBSTANCE", 423, 428], ["creatinine", "SIMPLE_CHEMICAL", 429, 439], ["cat", "ORGANISM", 499, 502], ["UBA", "PROTEIN", 243, 246], ["ursodeoxycholic acid", "TREATMENT", 15, 35], ["The test", "TEST", 95, 103], ["UBAs", "TEST", 162, 166], ["enzymatic methodology", "TEST", 216, 237], ["the UBA concentration", "TREATMENT", 239, 260], ["urine flow", "TEST", 281, 291], ["urine creatinine concentration", "TEST", 334, 364], ["calculating the ratio", "TEST", 369, 390], ["urine bile acids", "TEST", 400, 416], ["urine creatinine", "TEST", 423, 439], ["cat", "TEST", 499, 502]]], ["Artifacts \u2022 Hematuria and hemoglobinuria may interfere.", [["Hematuria", "DISEASE", 12, 21], ["hemoglobinuria", "DISEASE", 26, 40], ["Artifacts", "PROBLEM", 0, 9], ["Hematuria", "PROBLEM", 12, 21], ["hemoglobinuria", "PROBLEM", 26, 40], ["Hematuria", "OBSERVATION", 12, 21], ["hemoglobinuria", "OBSERVATION", 26, 40]]], ["Maximum information is obtained by determining a 12-hour fasting preprandial and 2-hour postprandial SBA concentration.", [["SBA", "SIMPLE_CHEMICAL", 101, 104], ["postprandial SBA concentration", "TREATMENT", 88, 118]]], ["Dogs and cats should be fed canned food containing moderate fat content, causing the gallbladder to contract.", [["fat", "ANATOMY", 60, 63], ["gallbladder", "ANATOMY", 85, 96], ["Dogs", "ORGANISM", 0, 4], ["cats", "ORGANISM", 9, 13], ["fat", "TISSUE", 60, 63], ["gallbladder", "ORGAN", 85, 96], ["Dogs", "SPECIES", 0, 4], ["cats", "SPECIES", 9, 13], ["Dogs and cats", "TREATMENT", 0, 13], ["moderate", "OBSERVATION_MODIFIER", 51, 59], ["fat content", "OBSERVATION", 60, 71], ["gallbladder", "ANATOMY", 85, 96]]], ["Preprandial and postprandial SBA concentrations together improve the sensitivity of the test, making it more sensitive than resting blood ammonia concentration.", [["blood", "ANATOMY", 132, 137], ["ammonia", "CHEMICAL", 138, 145], ["ammonia", "CHEMICAL", 138, 145], ["SBA", "SIMPLE_CHEMICAL", 29, 32], ["blood", "ORGANISM_SUBSTANCE", 132, 137], ["ammonia", "SIMPLE_CHEMICAL", 138, 145], ["Preprandial and postprandial SBA concentrations", "TEST", 0, 47], ["the test", "TEST", 84, 92], ["resting blood ammonia concentration", "TEST", 124, 159]]], ["Ceruletide has been administered after taking the fasting sample in an attempt to ensure gallbladder contraction and have more consistent results.", [["gallbladder", "ANATOMY", 89, 100], ["Ceruletide", "CHEMICAL", 0, 10], ["Ceruletide", "CHEMICAL", 0, 10], ["Ceruletide", "SIMPLE_CHEMICAL", 0, 10], ["gallbladder", "ORGAN", 89, 100], ["Ceruletide", "TREATMENT", 0, 10], ["the fasting sample", "TREATMENT", 46, 64], ["gallbladder contraction", "PROBLEM", 89, 112], ["gallbladder", "ANATOMY", 89, 100]]], ["It has not demonstrated increased sensitivity and specificity when looking for PSS, but it might be more sensitive when looking for hepatic disease associated with respiratory tract abnormalities.Disadvantages \u2022Normal Values \u2022 Because of different techniques and assays (\u00b5mol/L or \u00b5g/ml), normal values must be established for each laboratory.Danger Values \u2022 None.Artifacts \u2022 Very increased serum dehydrogenase activities may require modification of the spectrophotometric technique.", [["hepatic", "ANATOMY", 132, 139], ["respiratory tract", "ANATOMY", 164, 181], ["serum", "ANATOMY", 391, 396], ["PSS", "DISEASE", 79, 82], ["hepatic disease", "DISEASE", 132, 147], ["respiratory tract abnormalities", "DISEASE", 164, 195], ["hepatic", "ORGAN", 132, 139], ["respiratory tract", "ORGANISM_SUBDIVISION", 164, 181], ["serum", "ORGANISM_SUBSTANCE", 391, 396], ["dehydrogenase", "GENE_OR_GENE_PRODUCT", 397, 410], ["serum dehydrogenase", "PROTEIN", 391, 410], ["increased sensitivity", "PROBLEM", 24, 45], ["PSS", "PROBLEM", 79, 82], ["hepatic disease", "PROBLEM", 132, 147], ["respiratory tract abnormalities", "PROBLEM", 164, 195], ["assays", "TEST", 263, 269], ["Artifacts", "PROBLEM", 364, 373], ["Very increased serum dehydrogenase activities", "PROBLEM", 376, 421], ["the spectrophotometric technique", "TREATMENT", 450, 482], ["increased", "OBSERVATION_MODIFIER", 24, 33], ["hepatic", "ANATOMY", 132, 139], ["disease", "OBSERVATION", 140, 147], ["respiratory tract", "ANATOMY", 164, 181], ["increased", "OBSERVATION_MODIFIER", 381, 390], ["serum", "OBSERVATION_MODIFIER", 391, 396], ["dehydrogenase activities", "OBSERVATION", 397, 421]]], ["Severe lipemia (i.e., chylomicronemia) and hemolysis may falsely decrease SBA measurements, and hypertriglyceridemia may falsely increase SBA concentrations when spectrophotometric techniques are used, but they do not affect RIA.", [["lipemia", "DISEASE", 7, 14], ["chylomicronemia", "DISEASE", 22, 37], ["hemolysis", "DISEASE", 43, 52], ["hypertriglyceridemia", "DISEASE", 96, 116], ["SBA", "SIMPLE_CHEMICAL", 138, 141], ["Severe lipemia", "PROBLEM", 0, 14], ["chylomicronemia", "PROBLEM", 22, 37], ["hemolysis", "PROBLEM", 43, 52], ["SBA measurements", "TEST", 74, 90], ["hypertriglyceridemia", "PROBLEM", 96, 116], ["SBA concentrations", "PROBLEM", 138, 156], ["spectrophotometric techniques", "TEST", 162, 191], ["lipemia", "OBSERVATION", 7, 14], ["decrease", "OBSERVATION_MODIFIER", 65, 73], ["SBA", "OBSERVATION_MODIFIER", 74, 77]]], ["This test is not useful in icteric patients.Danger Values \u2022 None.Drug Therapy and Other Factors That May Alter SBA Concentration \u2022 Cholestyramine lowers serum concentrations by binding to bile acids in the intestinal lumen, preventing their reabsorption.", [["serum", "ANATOMY", 153, 158], ["intestinal lumen", "ANATOMY", 206, 222], ["icteric", "DISEASE", 27, 34], ["Cholestyramine", "CHEMICAL", 131, 145], ["bile acids", "CHEMICAL", 188, 198], ["Cholestyramine", "CHEMICAL", 131, 145], ["bile acids", "CHEMICAL", 188, 198], ["patients", "ORGANISM", 35, 43], ["SBA", "SIMPLE_CHEMICAL", 111, 114], ["Cholestyramine", "SIMPLE_CHEMICAL", 131, 145], ["serum", "ORGANISM_SUBSTANCE", 153, 158], ["bile acids", "SIMPLE_CHEMICAL", 188, 198], ["intestinal lumen", "MULTI-TISSUE_STRUCTURE", 206, 222], ["patients", "SPECIES", 35, 43], ["This test", "TEST", 0, 9], ["Drug Therapy", "TREATMENT", 65, 77], ["Other Factors", "TREATMENT", 82, 95], ["Alter SBA Concentration", "TREATMENT", 105, 128], ["Cholestyramine lowers serum concentrations", "TREATMENT", 131, 173], ["bile acids", "TEST", 188, 198], ["intestinal lumen", "ANATOMY", 206, 222], ["reabsorption", "OBSERVATION", 241, 253]]], ["Ursodeoxycholic acid (a synthetic bile acid) therapy may increase total SBA concentrations.", [["Ursodeoxycholic acid", "CHEMICAL", 0, 20], ["bile acid", "CHEMICAL", 34, 43], ["Ursodeoxycholic acid", "CHEMICAL", 0, 20], ["bile acid", "CHEMICAL", 34, 43], ["Ursodeoxycholic acid", "SIMPLE_CHEMICAL", 0, 20], ["bile acid", "SIMPLE_CHEMICAL", 34, 43], ["SBA", "SIMPLE_CHEMICAL", 72, 75], ["Ursodeoxycholic acid", "TREATMENT", 0, 20], ["a synthetic bile acid) therapy", "TREATMENT", 22, 52], ["total SBA concentrations", "TREATMENT", 66, 90]]], ["Resection of the ileum (the principal site of bile acid reabsorption), severe ileal disease, or cholecystectomy may also cause SBAs to inaccurately reflect hepatic function.", [["ileum", "ANATOMY", 17, 22], ["site", "ANATOMY", 38, 42], ["bile", "ANATOMY", 46, 50], ["ileal", "ANATOMY", 78, 83], ["hepatic", "ANATOMY", 156, 163], ["bile acid", "CHEMICAL", 46, 55], ["ileal disease", "DISEASE", 78, 91], ["bile acid", "CHEMICAL", 46, 55], ["ileum", "MULTI-TISSUE_STRUCTURE", 17, 22], ["bile acid", "SIMPLE_CHEMICAL", 46, 55], ["ileal", "MULTI-TISSUE_STRUCTURE", 78, 83], ["hepatic", "ORGAN", 156, 163], ["Resection of the ileum", "TREATMENT", 0, 22], ["bile acid reabsorption", "TREATMENT", 46, 68], ["severe ileal disease", "PROBLEM", 71, 91], ["cholecystectomy", "TREATMENT", 96, 111], ["SBAs", "PROBLEM", 127, 131], ["ileum", "ANATOMY", 17, 22], ["bile", "ANATOMY", 46, 50], ["acid reabsorption", "OBSERVATION", 51, 68], ["severe", "OBSERVATION_MODIFIER", 71, 77], ["ileal", "ANATOMY", 78, 83], ["disease", "OBSERVATION", 84, 91], ["cholecystectomy", "OBSERVATION", 96, 111], ["hepatic", "ANATOMY", 156, 163], ["function", "OBSERVATION", 164, 172]]], ["Prolonged anorexia (>1 to 2 days) may cause fasting SBA concentrations to be less than would be found if the patient were eating normally.", [["anorexia", "DISEASE", 10, 18], ["SBA", "SIMPLE_CHEMICAL", 52, 55], ["patient", "ORGANISM", 109, 116], ["patient", "SPECIES", 109, 116], ["Prolonged anorexia", "PROBLEM", 0, 18], ["fasting SBA concentrations", "PROBLEM", 44, 70], ["anorexia", "OBSERVATION", 10, 18]]], ["Intestinal hypomotility may cause the 2-hour postprandial sample to be a less sensitive indicator of hepatic disease because of failure to deliver the bile acids to the ileum in a timely fashion.", [["Intestinal", "ANATOMY", 0, 10], ["hepatic", "ANATOMY", 101, 108], ["bile", "ANATOMY", 151, 155], ["ileum", "ANATOMY", 169, 174], ["hypomotility", "DISEASE", 11, 23], ["hepatic disease", "DISEASE", 101, 116], ["bile acids", "CHEMICAL", 151, 161], ["bile acids", "CHEMICAL", 151, 161], ["Intestinal", "ORGAN", 0, 10], ["hepatic", "ORGAN", 101, 108], ["bile acids", "SIMPLE_CHEMICAL", 151, 161], ["ileum", "MULTI-TISSUE_STRUCTURE", 169, 174], ["Intestinal hypomotility", "PROBLEM", 0, 23], ["hepatic disease", "PROBLEM", 101, 116], ["failure", "PROBLEM", 128, 135], ["hypomotility", "OBSERVATION", 11, 23], ["hepatic", "ANATOMY", 101, 108], ["disease", "OBSERVATION", 109, 116], ["failure", "OBSERVATION", 128, 135], ["bile", "ANATOMY", 151, 155], ["ileum", "ANATOMY", 169, 174]]], ["Hepatic insufficiency does not decrease SBA concentrations.Danger Values \u2022 None.Causes of Decreased SBA Concentration \u2022 Delayed gastric emptying, rapid intestinal transit, malabsorption disorders, and ileal resection may cause subnormal values.", [["Hepatic", "ANATOMY", 0, 7], ["gastric", "ANATOMY", 128, 135], ["intestinal", "ANATOMY", 152, 162], ["ileal", "ANATOMY", 201, 206], ["Hepatic insufficiency", "DISEASE", 0, 21], ["Delayed gastric emptying", "DISEASE", 120, 144], ["malabsorption disorders", "DISEASE", 172, 195], ["Hepatic", "ORGAN", 0, 7], ["SBA", "SIMPLE_CHEMICAL", 40, 43], ["gastric", "ORGAN", 128, 135], ["intestinal", "ORGAN", 152, 162], ["ileal", "ORGAN", 201, 206], ["SBA", "PROTEIN", 40, 43], ["Hepatic insufficiency", "PROBLEM", 0, 21], ["SBA concentrations", "PROBLEM", 40, 58], ["Decreased SBA Concentration", "PROBLEM", 90, 117], ["Delayed gastric emptying", "PROBLEM", 120, 144], ["rapid intestinal transit", "PROBLEM", 146, 170], ["malabsorption disorders", "PROBLEM", 172, 195], ["ileal resection", "TREATMENT", 201, 216], ["subnormal values", "PROBLEM", 227, 243], ["insufficiency", "OBSERVATION", 8, 21], ["decrease", "OBSERVATION_MODIFIER", 31, 39], ["SBA", "OBSERVATION_MODIFIER", 40, 43], ["concentrations", "OBSERVATION_MODIFIER", 44, 58], ["Decreased", "OBSERVATION_MODIFIER", 90, 99], ["SBA Concentration", "OBSERVATION", 100, 117], ["gastric", "ANATOMY", 128, 135], ["emptying", "OBSERVATION", 136, 144], ["rapid", "OBSERVATION_MODIFIER", 146, 151], ["intestinal", "ANATOMY", 152, 162], ["malabsorption disorders", "OBSERVATION", 172, 195], ["ileal", "ANATOMY", 201, 206], ["resection", "OBSERVATION", 207, 216]]], ["With ARE, total measurable moieties may or may not decrease, but it is expected that unconjugated serum bile acid concentrations may increase.Danger Values \u2022 None.Causes of Increased SBA Concentration \u2022 SBA concentrations are increased because of hepatocellular disease, cholestatic disease, hepatic microvascular dysplasia, or PSS.", [["serum", "ANATOMY", 98, 103], ["hepatocellular", "ANATOMY", 247, 261], ["hepatic microvascular", "ANATOMY", 292, 313], ["bile acid", "CHEMICAL", 104, 113], ["hepatocellular disease", "DISEASE", 247, 269], ["cholestatic disease", "DISEASE", 271, 290], ["hepatic microvascular dysplasia", "DISEASE", 292, 323], ["PSS", "DISEASE", 328, 331], ["bile acid", "CHEMICAL", 104, 113], ["serum", "ORGANISM_SUBSTANCE", 98, 103], ["bile acid", "SIMPLE_CHEMICAL", 104, 113], ["SBA", "SIMPLE_CHEMICAL", 183, 186], ["SBA", "SIMPLE_CHEMICAL", 203, 206], ["hepatocellular", "ORGAN", 247, 261], ["hepatic microvascular", "MULTI-TISSUE_STRUCTURE", 292, 313], ["ARE", "DNA", 5, 8], ["total measurable moieties", "TREATMENT", 10, 35], ["unconjugated serum bile acid concentrations", "PROBLEM", 85, 128], ["Increased SBA Concentration", "PROBLEM", 173, 200], ["SBA concentrations", "PROBLEM", 203, 221], ["hepatocellular disease", "PROBLEM", 247, 269], ["cholestatic disease", "PROBLEM", 271, 290], ["hepatic microvascular dysplasia", "PROBLEM", 292, 323], ["PSS", "PROBLEM", 328, 331], ["Increased", "OBSERVATION_MODIFIER", 173, 182], ["SBA Concentration", "OBSERVATION", 183, 200], ["increased", "OBSERVATION_MODIFIER", 226, 235], ["hepatocellular", "ANATOMY", 247, 261], ["disease", "OBSERVATION", 262, 269], ["cholestatic", "OBSERVATION_MODIFIER", 271, 282], ["hepatic", "ANATOMY", 292, 299], ["microvascular", "ANATOMY_MODIFIER", 300, 313], ["dysplasia", "OBSERVATION", 314, 323]]], ["When both fasting and 2-hour postprandial SBA concentrations are determined, the sensitivity of these tests becomes greater than with other hepatic function tests except perhaps the ammonia tolerance test.", [["hepatic", "ANATOMY", 140, 147], ["ammonia", "CHEMICAL", 182, 189], ["ammonia", "CHEMICAL", 182, 189], ["SBA", "SIMPLE_CHEMICAL", 42, 45], ["hepatic", "MULTI-TISSUE_STRUCTURE", 140, 147], ["ammonia", "SIMPLE_CHEMICAL", 182, 189], ["these tests", "TEST", 96, 107], ["other hepatic function tests", "TEST", 134, 162], ["the ammonia tolerance test", "TEST", 178, 204], ["hepatic", "ANATOMY", 140, 147]]], ["Because of the ease of performing and the wide availability of the test, it has replaced other clinical hepatic Drug Therapy That May Alter Ammonia \u2022 Decreased blood ammonia may be the result of intestinal antibacterial drugs, lactulose, Lactobacillus acidophilus cultures, enemas, and diphenhydramine.", [["hepatic", "ANATOMY", 104, 111], ["blood", "ANATOMY", 160, 165], ["intestinal", "ANATOMY", 195, 205], ["Ammonia", "CHEMICAL", 140, 147], ["ammonia", "CHEMICAL", 166, 173], ["lactulose", "CHEMICAL", 227, 236], ["Lactobacillus acidophilus", "CHEMICAL", 238, 263], ["diphenhydramine", "CHEMICAL", 286, 301], ["Ammonia", "CHEMICAL", 140, 147], ["ammonia", "CHEMICAL", 166, 173], ["lactulose", "CHEMICAL", 227, 236], ["diphenhydramine", "CHEMICAL", 286, 301], ["blood", "ORGANISM_SUBSTANCE", 160, 165], ["ammonia", "SIMPLE_CHEMICAL", 166, 173], ["intestinal", "ORGAN", 195, 205], ["lactulose", "SIMPLE_CHEMICAL", 227, 236], ["Lactobacillus acidophilus cultures", "SIMPLE_CHEMICAL", 238, 272], ["enemas", "SIMPLE_CHEMICAL", 274, 280], ["diphenhydramine", "SIMPLE_CHEMICAL", 286, 301], ["Lactobacillus acidophilus", "SPECIES", 238, 263], ["Lactobacillus acidophilus", "SPECIES", 238, 263], ["the test", "TEST", 63, 71], ["clinical hepatic Drug Therapy", "TREATMENT", 95, 124], ["Decreased blood ammonia", "PROBLEM", 150, 173], ["intestinal antibacterial drugs", "TREATMENT", 195, 225], ["lactulose", "TREATMENT", 227, 236], ["Lactobacillus acidophilus cultures", "TREATMENT", 238, 272], ["enemas", "TREATMENT", 274, 280], ["diphenhydramine", "TREATMENT", 286, 301], ["hepatic", "ANATOMY", 104, 111], ["Drug Therapy", "OBSERVATION", 112, 124], ["intestinal", "ANATOMY", 195, 205], ["antibacterial drugs", "OBSERVATION", 206, 225]]], ["Increased blood ammonia may be the result of valproic acid, asparaginase, narcotics, diuretics causing hypokalemia or alkalosis, hyperalimentation, ammonium salts, and high-protein meals (including blood from spontaneous GI bleeding).Danger Values \u2022 None.Causes of Hyperammonemia \u2022 Urea cycle disorders (extremely rare) and hepatic insufficiency (especially congenital or acquired PSS) can cause hyperammonemia.", [["blood", "ANATOMY", 10, 15], ["blood", "ANATOMY", 198, 203], ["GI", "ANATOMY", 221, 223], ["hepatic", "ANATOMY", 324, 331], ["ammonia", "CHEMICAL", 16, 23], ["valproic acid", "CHEMICAL", 45, 58], ["asparaginase", "CHEMICAL", 60, 72], ["narcotics", "CHEMICAL", 74, 83], ["hypokalemia", "DISEASE", 103, 114], ["alkalosis", "DISEASE", 118, 127], ["hyperalimentation", "DISEASE", 129, 146], ["ammonium salts", "CHEMICAL", 148, 162], ["GI bleeding", "DISEASE", 221, 232], ["Hyperammonemia", "DISEASE", 265, 279], ["hepatic insufficiency", "DISEASE", 324, 345], ["congenital or acquired PSS", "DISEASE", 358, 384], ["hyperammonemia", "DISEASE", 396, 410], ["ammonia", "CHEMICAL", 16, 23], ["valproic acid", "CHEMICAL", 45, 58], ["asparaginase", "CHEMICAL", 60, 72], ["ammonium", "CHEMICAL", 148, 156], ["Urea", "CHEMICAL", 282, 286], ["blood", "ORGANISM_SUBSTANCE", 10, 15], ["ammonia", "SIMPLE_CHEMICAL", 16, 23], ["valproic acid", "SIMPLE_CHEMICAL", 45, 58], ["asparaginase", "SIMPLE_CHEMICAL", 60, 72], ["narcotics", "SIMPLE_CHEMICAL", 74, 83], ["diuretics", "SIMPLE_CHEMICAL", 85, 94], ["ammonium salts", "SIMPLE_CHEMICAL", 148, 162], ["blood", "ORGANISM_SUBSTANCE", 198, 203], ["GI", "ORGANISM_SUBDIVISION", 221, 223], ["hepatic", "ORGAN", 324, 331], ["Increased blood ammonia", "PROBLEM", 0, 23], ["valproic acid", "TREATMENT", 45, 58], ["asparaginase", "TREATMENT", 60, 72], ["narcotics", "TREATMENT", 74, 83], ["diuretics", "TREATMENT", 85, 94], ["hypokalemia", "PROBLEM", 103, 114], ["alkalosis", "PROBLEM", 118, 127], ["hyperalimentation", "TREATMENT", 129, 146], ["ammonium salts", "TREATMENT", 148, 162], ["high-protein meals", "TREATMENT", 168, 186], ["spontaneous GI bleeding", "PROBLEM", 209, 232], ["Hyperammonemia", "PROBLEM", 265, 279], ["Urea cycle disorders", "PROBLEM", 282, 302], ["extremely rare)", "PROBLEM", 304, 319], ["hepatic insufficiency", "PROBLEM", 324, 345], ["congenital or acquired PSS", "PROBLEM", 358, 384], ["hyperammonemia", "PROBLEM", 396, 410], ["blood ammonia", "OBSERVATION", 10, 23], ["valproic acid", "OBSERVATION", 45, 58], ["alkalosis", "OBSERVATION", 118, 127], ["GI", "ANATOMY", 221, 223], ["bleeding", "OBSERVATION", 224, 232], ["Hyperammonemia", "OBSERVATION", 265, 279], ["hepatic", "ANATOMY", 324, 331], ["insufficiency", "OBSERVATION", 332, 345], ["hyperammonemia", "OBSERVATION", 396, 410]]], ["Resting blood ammonia concentrations are probably less sensitive than SBAs in detecting hepatic dysfunction, whereas the ATT is possibly as sensitive as preprandial and postprandial SBAs in detecting PSS.", [["blood", "ANATOMY", 8, 13], ["hepatic", "ANATOMY", 88, 95], ["ammonia", "CHEMICAL", 14, 21], ["hepatic dysfunction", "DISEASE", 88, 107], ["PSS", "DISEASE", 200, 203], ["ammonia", "CHEMICAL", 14, 21], ["blood", "ORGANISM_SUBSTANCE", 8, 13], ["ammonia", "SIMPLE_CHEMICAL", 14, 21], ["hepatic", "ORGAN", 88, 95], ["ATT", "SIMPLE_CHEMICAL", 121, 124], ["SBAs", "SIMPLE_CHEMICAL", 182, 186], ["Resting blood ammonia concentrations", "TEST", 0, 36], ["hepatic dysfunction", "PROBLEM", 88, 107], ["the ATT", "TEST", 117, 124], ["postprandial SBAs", "TEST", 169, 186], ["PSS", "PROBLEM", 200, 203], ["ammonia concentrations", "OBSERVATION", 14, 36], ["probably", "UNCERTAINTY", 41, 49], ["less sensitive", "OBSERVATION_MODIFIER", 50, 64], ["hepatic", "ANATOMY", 88, 95], ["dysfunction", "OBSERVATION", 96, 107]]], ["A significantly increased fasting blood ammonia concentration is specific for hepatic insufficiency and renders an ATT unnecessary.", [["blood", "ANATOMY", 34, 39], ["hepatic", "ANATOMY", 78, 85], ["ammonia", "CHEMICAL", 40, 47], ["hepatic insufficiency", "DISEASE", 78, 99], ["ammonia", "CHEMICAL", 40, 47], ["blood", "ORGANISM_SUBSTANCE", 34, 39], ["ammonia", "SIMPLE_CHEMICAL", 40, 47], ["hepatic", "ORGAN", 78, 85], ["A significantly increased fasting blood ammonia concentration", "PROBLEM", 0, 61], ["hepatic insufficiency", "PROBLEM", 78, 99], ["an ATT unnecessary", "TREATMENT", 112, 130], ["significantly", "OBSERVATION_MODIFIER", 2, 15], ["increased", "OBSERVATION_MODIFIER", 16, 25], ["hepatic", "ANATOMY", 78, 85], ["insufficiency", "OBSERVATION", 86, 99]]], ["Clinical signs are not well correlated with blood ammonia concentrations.", [["blood", "ANATOMY", 44, 49], ["ammonia", "CHEMICAL", 50, 57], ["ammonia", "CHEMICAL", 50, 57], ["blood", "ORGANISM_SUBSTANCE", 44, 49], ["ammonia", "SIMPLE_CHEMICAL", 50, 57], ["Clinical signs", "TEST", 0, 14], ["blood ammonia concentrations", "TEST", 44, 72]]], ["An abnormal ATT result or resting blood ammonia concentration in a patient with hepatic disease is generally an indication for imaging (e.g., ultrasound, scintigraphy) \u00b1 hepatic biopsy.", [["blood", "ANATOMY", 34, 39], ["hepatic", "ANATOMY", 80, 87], ["hepatic", "ANATOMY", 170, 177], ["ammonia", "CHEMICAL", 40, 47], ["hepatic disease", "DISEASE", 80, 95], ["ammonia", "CHEMICAL", 40, 47], ["blood", "ORGANISM_SUBSTANCE", 34, 39], ["ammonia", "SIMPLE_CHEMICAL", 40, 47], ["patient", "ORGANISM", 67, 74], ["hepatic", "ORGAN", 80, 87], ["hepatic biopsy", "MULTI-TISSUE_STRUCTURE", 170, 184], ["patient", "SPECIES", 67, 74], ["An abnormal ATT result", "PROBLEM", 0, 22], ["resting blood ammonia concentration", "PROBLEM", 26, 61], ["hepatic disease", "PROBLEM", 80, 95], ["imaging", "TEST", 127, 134], ["ultrasound", "TEST", 142, 152], ["scintigraphy", "TEST", 154, 166], ["hepatic biopsy", "TEST", 170, 184], ["hepatic", "ANATOMY", 80, 87], ["disease", "OBSERVATION", 88, 95], ["hepatic", "ANATOMY", 170, 177], ["biopsy", "OBSERVATION", 178, 184]]], ["Rarely, blood ammonia is increased because of urinary tract obstruction, especially if complicated by infection with urease-producing bacteria.", [["blood", "ANATOMY", 8, 13], ["urinary tract", "ANATOMY", 46, 59], ["ammonia", "CHEMICAL", 14, 21], ["urinary tract obstruction", "DISEASE", 46, 71], ["infection", "DISEASE", 102, 111], ["ammonia", "CHEMICAL", 14, 21], ["blood", "ORGANISM_SUBSTANCE", 8, 13], ["ammonia", "SIMPLE_CHEMICAL", 14, 21], ["urinary tract", "ORGANISM_SUBDIVISION", 46, 59], ["urease", "GENE_OR_GENE_PRODUCT", 117, 123], ["urease", "PROTEIN", 117, 123], ["blood ammonia", "TEST", 8, 21], ["urinary tract obstruction", "PROBLEM", 46, 71], ["infection", "PROBLEM", 102, 111], ["urease-producing bacteria", "PROBLEM", 117, 142], ["urinary tract", "ANATOMY", 46, 59], ["obstruction", "OBSERVATION", 60, 71], ["infection", "OBSERVATION", 102, 111]]], ["Some young dogs (notably Scottish deerhounds in Great Britain) have elevated resting blood ammonia values that spontaneously return to normal as the dog ages.", [["blood", "ANATOMY", 85, 90], ["ammonia", "CHEMICAL", 91, 98], ["ammonia", "CHEMICAL", 91, 98], ["dogs", "ORGANISM", 11, 15], ["blood", "ORGANISM_SUBSTANCE", 85, 90], ["ammonia", "SIMPLE_CHEMICAL", 91, 98], ["dog", "ORGANISM", 149, 152], ["dogs", "SPECIES", 11, 15], ["Some young dogs", "PROBLEM", 0, 15], ["elevated resting blood ammonia values", "PROBLEM", 68, 105], ["normal", "OBSERVATION", 135, 141]]], ["Therefore caution must be used when diagnosing congenital PSS in at least some breeds solely by evaluating the resting blood ammonia concentration.PROTEIN COccasional Indications \u2022 Measurement of protein C may help distinguish dogs with congenital PSS from those with hepatic microvascular dysplasia.", [["blood", "ANATOMY", 119, 124], ["hepatic microvascular dysplasia", "ANATOMY", 268, 299], ["PSS", "DISEASE", 58, 61], ["ammonia", "CHEMICAL", 125, 132], ["congenital PSS", "DISEASE", 237, 251], ["hepatic microvascular dysplasia", "DISEASE", 268, 299], ["ammonia", "CHEMICAL", 125, 132], ["blood", "ORGANISM_SUBSTANCE", 119, 124], ["ammonia", "SIMPLE_CHEMICAL", 125, 132], ["protein C", "GENE_OR_GENE_PRODUCT", 196, 205], ["dogs", "ORGANISM", 227, 231], ["hepatic microvascular dysplasia", "PATHOLOGICAL_FORMATION", 268, 299], ["protein C", "PROTEIN", 196, 205], ["dogs", "SPECIES", 227, 231], ["congenital PSS", "PROBLEM", 47, 61], ["the resting blood ammonia concentration", "TEST", 107, 146], ["protein C", "TREATMENT", 196, 205], ["congenital PSS", "PROBLEM", 237, 251], ["hepatic microvascular dysplasia", "PROBLEM", 268, 299], ["hepatic", "ANATOMY", 268, 275], ["microvascular dysplasia", "OBSERVATION", 276, 299]]], ["Protein C concentrations are low in dogs suffering from aflatoxin poisoning.PROTEIN CAdvantages \u2022 Sensitivity of protein C is less than SBAs for PSS, but the specificity is approximately the same.PROTEIN CDisadvantages \u2022 There is limited availability of the test.", [["aflatoxin poisoning", "DISEASE", 56, 75], ["aflatoxin", "CHEMICAL", 56, 65], ["Protein C", "GENE_OR_GENE_PRODUCT", 0, 9], ["dogs", "ORGANISM", 36, 40], ["aflatoxin", "SIMPLE_CHEMICAL", 56, 65], ["protein C", "GENE_OR_GENE_PRODUCT", 113, 122], ["protein C", "PROTEIN", 113, 122], ["dogs", "SPECIES", 36, 40], ["Protein C concentrations", "PROBLEM", 0, 24], ["aflatoxin poisoning", "PROBLEM", 56, 75], ["PROTEIN CAdvantages", "TEST", 76, 95], ["Sensitivity", "TEST", 98, 109], ["protein C", "TEST", 113, 122], ["PSS", "PROBLEM", 145, 148], ["the specificity", "TEST", 154, 169], ["the test", "TEST", 254, 262], ["concentrations", "OBSERVATION_MODIFIER", 10, 24], ["low", "OBSERVATION_MODIFIER", 29, 32], ["aflatoxin poisoning", "OBSERVATION", 56, 75]]], ["Protein C testing is currently available at Cornell University Diagnostic Laboratory.PROTEIN CAnalysis \u2022 Protein C is measured by chromogenic assay performed on citrated plasma (serum gives falsely high values).", [["plasma", "ANATOMY", 170, 176], ["serum", "ANATOMY", 178, 183], ["Protein C", "GENE_OR_GENE_PRODUCT", 0, 9], ["Protein C", "GENE_OR_GENE_PRODUCT", 105, 114], ["citrated", "ORGANISM_SUBSTANCE", 161, 169], ["plasma", "ORGANISM_SUBSTANCE", 170, 176], ["serum", "ORGANISM_SUBSTANCE", 178, 183], ["Protein C", "PROTEIN", 105, 114], ["citrated plasma", "CELL_TYPE", 161, 176], ["Protein C testing", "TEST", 0, 17], ["PROTEIN CAnalysis", "TEST", 85, 102], ["Protein C", "TEST", 105, 114], ["chromogenic assay", "TEST", 130, 147], ["citrated plasma", "TEST", 161, 176], ["serum", "TEST", 178, 183]]], ["Samples must be shipped refrigerated or frozen.PROTEIN CNormal Values \u2022 75% to 135%.Artifacts \u2022 Hemolysis and lipemia may increase values.Drug Therapy That May Alter Protein C \u2022 Unknown.Artifacts \u2022 Hemolysis and lipemia may increase values.Causes of Low Protein C \u2022 Protein C is decreased by altered hepatic function and coagulation abnormalities.Artifacts \u2022 Hemolysis and lipemia may increase values.Drug Therapy That May Alter UBA Concentrations \u2022 None known.Causes of Low UBAs \u2022 Not significant.Causes of High UBAs \u2022 UBA concentrations are increased by the same factors as for SBA.BLOOD AMMONIA AND AMMONIA TOLERANCE TESTINGFrequent Indications \u2022 Indications for blood ammonia measurement are the same as for SBAs.BLOOD AMMONIA AND AMMONIA TOLERANCE TESTINGAdvantages \u2022 Blood ammonia test has good sensitivity and specificity.BLOOD AMMONIA AND AMMONIA TOLERANCE TESTINGDisadvantages \u2022 There are specific procedural requirements for submitting the samples, and there is a likelihood of vomiting or CNS signs with ATT.BLOOD AMMONIA AND AMMONIA TOLERANCE TESTINGAnalysis \u2022 Ammonia is measured in blood, serum, plasma (heparinized is recommended), CSF, or urine by enzymatic, selective electrode, dry reagent, and resin absorption methods.", [["Samples", "ANATOMY", 0, 7], ["hepatic", "ANATOMY", 300, 307], ["blood", "ANATOMY", 666, 671], ["Blood", "ANATOMY", 773, 778], ["samples", "ANATOMY", 950, 957], ["CNS", "ANATOMY", 1000, 1003], ["blood", "ANATOMY", 1096, 1101], ["serum", "ANATOMY", 1103, 1108], ["plasma", "ANATOMY", 1110, 1116], ["urine", "ANATOMY", 1155, 1160], ["Hemolysis", "DISEASE", 96, 105], ["lipemia", "DISEASE", 110, 117], ["Hemolysis", "DISEASE", 198, 207], ["lipemia", "DISEASE", 212, 219], ["coagulation abnormalities", "DISEASE", 321, 346], ["Hemolysis", "DISEASE", 359, 368], ["lipemia", "DISEASE", 373, 380], ["ammonia", "CHEMICAL", 672, 679], ["ammonia", "CHEMICAL", 779, 786], ["vomiting", "DISEASE", 988, 996], ["Ammonia", "CHEMICAL", 1073, 1080], ["ammonia", "CHEMICAL", 672, 679], ["ammonia", "CHEMICAL", 779, 786], ["Ammonia", "CHEMICAL", 1073, 1080], ["Protein C", "GENE_OR_GENE_PRODUCT", 266, 275], ["hepatic", "MULTI-TISSUE_STRUCTURE", 300, 307], ["UBA", "GENE_OR_GENE_PRODUCT", 520, 523], ["blood", "ORGANISM_SUBSTANCE", 666, 671], ["Blood", "ORGANISM_SUBSTANCE", 773, 778], ["CNS", "ANATOMICAL_SYSTEM", 1000, 1003], ["Ammonia", "SIMPLE_CHEMICAL", 1073, 1080], ["blood", "ORGANISM_SUBSTANCE", 1096, 1101], ["serum", "ORGANISM_SUBSTANCE", 1103, 1108], ["plasma", "ORGANISM_SUBSTANCE", 1110, 1116], ["heparinized", "ORGANISM_SUBSTANCE", 1118, 1129], ["CSF", "ORGANISM_SUBSTANCE", 1147, 1150], ["urine", "ORGANISM_SUBSTANCE", 1155, 1160], ["Low Protein C", "PROTEIN", 250, 263], ["Protein C", "PROTEIN", 266, 275], ["UBA", "PROTEIN", 429, 432], ["UBA", "PROTEIN", 520, 523], ["CSF", "PROTEIN", 1147, 1150], ["Samples", "TEST", 0, 7], ["PROTEIN CNormal Values", "TEST", 47, 69], ["Artifacts", "PROBLEM", 84, 93], ["Hemolysis", "PROBLEM", 96, 105], ["lipemia", "PROBLEM", 110, 117], ["increase values", "PROBLEM", 122, 137], ["Drug Therapy", "TREATMENT", 138, 150], ["Artifacts", "PROBLEM", 186, 195], ["Hemolysis", "PROBLEM", 198, 207], ["lipemia", "PROBLEM", 212, 219], ["increase values", "PROBLEM", 224, 239], ["Low Protein C \u2022 Protein C", "PROBLEM", 250, 275], ["altered hepatic function", "PROBLEM", 292, 316], ["coagulation abnormalities", "PROBLEM", 321, 346], ["Artifacts", "PROBLEM", 347, 356], ["Hemolysis", "PROBLEM", 359, 368], ["lipemia", "PROBLEM", 373, 380], ["increase values", "PROBLEM", 385, 400], ["Drug Therapy", "TREATMENT", 401, 413], ["Low UBAs", "PROBLEM", 471, 479], ["High UBAs \u2022 UBA concentrations", "PROBLEM", 508, 538], ["SBA", "PROBLEM", 580, 583], ["BLOOD AMMONIA", "TEST", 584, 597], ["blood ammonia measurement", "TEST", 666, 691], ["BLOOD AMMONIA", "TEST", 717, 730], ["AMMONIA TOLERANCE", "TEST", 735, 752], ["TESTINGAdvantages", "TEST", 753, 770], ["Blood ammonia test", "TEST", 773, 791], ["BLOOD AMMONIA", "TEST", 829, 842], ["submitting the samples", "TEST", 935, 957], ["vomiting", "PROBLEM", 988, 996], ["CNS signs", "PROBLEM", 1000, 1009], ["ATT", "TREATMENT", 1015, 1018], ["BLOOD AMMONIA", "TEST", 1019, 1032], ["AMMONIA TOLERANCE TESTINGAnalysis", "TEST", 1037, 1070], ["Ammonia", "TEST", 1073, 1080], ["blood", "TEST", 1096, 1101], ["serum", "TEST", 1103, 1108], ["CSF", "TEST", 1147, 1150], ["selective electrode", "TREATMENT", 1175, 1194], ["dry reagent", "TREATMENT", 1196, 1207], ["resin absorption methods", "TREATMENT", 1213, 1237], ["Hemolysis", "OBSERVATION", 96, 105], ["lipemia", "OBSERVATION", 110, 117], ["increase", "OBSERVATION_MODIFIER", 122, 130], ["values", "OBSERVATION_MODIFIER", 131, 137], ["Hemolysis", "OBSERVATION", 198, 207], ["lipemia", "OBSERVATION", 212, 219], ["increase", "OBSERVATION_MODIFIER", 224, 232], ["values", "OBSERVATION_MODIFIER", 233, 239], ["Low Protein", "OBSERVATION_MODIFIER", 250, 261], ["decreased", "OBSERVATION_MODIFIER", 279, 288], ["altered", "OBSERVATION_MODIFIER", 292, 299], ["hepatic", "ANATOMY", 300, 307], ["coagulation abnormalities", "OBSERVATION", 321, 346], ["Hemolysis", "OBSERVATION", 359, 368], ["lipemia", "OBSERVATION", 373, 380], ["increase", "OBSERVATION_MODIFIER", 385, 393], ["values", "OBSERVATION_MODIFIER", 394, 400], ["Low UBAs", "OBSERVATION_MODIFIER", 471, 479], ["Not", "UNCERTAINTY", 482, 485], ["significant", "OBSERVATION_MODIFIER", 486, 497], ["High", "OBSERVATION_MODIFIER", 508, 512], ["increased", "OBSERVATION_MODIFIER", 543, 552], ["AMMONIA TOLERANCE", "OBSERVATION", 602, 619], ["AMMONIA TOLERANCE", "OBSERVATION", 735, 752], ["AMMONIA TOLERANCE", "OBSERVATION", 847, 864], ["AMMONIA TOLERANCE", "OBSERVATION", 1037, 1054]]], ["There does not appear to be any advantage of arterial over venous blood.", [["arterial", "ANATOMY", 45, 53], ["venous blood", "ANATOMY", 59, 71], ["arterial", "MULTI-TISSUE_STRUCTURE", 45, 53], ["venous", "MULTI-TISSUE_STRUCTURE", 59, 65], ["blood", "ORGANISM_SUBSTANCE", 66, 71], ["arterial over venous blood", "PROBLEM", 45, 71], ["not appear to be", "UNCERTAINTY", 11, 27], ["arterial", "ANATOMY_MODIFIER", 45, 53], ["venous", "ANATOMY", 59, 65]]], ["Blood must be drawn into an ice-chilled tube, which is stoppered tightly after filling, immediately put back on ice, and promptly taken to the in-house laboratory.", [["Blood", "ANATOMY", 0, 5], ["tube", "ANATOMY", 40, 44], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["tube", "TISSUE", 40, 44], ["Blood", "TEST", 0, 5], ["an ice-chilled tube", "TREATMENT", 25, 44], ["ice", "TREATMENT", 112, 115], ["tube", "OBSERVATION", 40, 44]]], ["Unless the test is well established at the clinic, a control sample should be taken at the same time using the same technique.", [["the test", "TEST", 7, 15]]], ["The test must be performed within 20 minutes, or the plasma must be frozen at \u221220\u00b0 C, which stabilizes the ammonia concentration for at least 2 days.", [["plasma", "ANATOMY", 53, 59], ["ammonia", "CHEMICAL", 107, 114], ["ammonia", "CHEMICAL", 107, 114], ["plasma", "ORGANISM_SUBSTANCE", 53, 59], ["C", "SIMPLE_CHEMICAL", 83, 84], ["ammonia", "SIMPLE_CHEMICAL", 107, 114], ["The test", "TEST", 0, 8], ["the ammonia concentration", "TREATMENT", 103, 128]]], ["If an ATT is to be performed, samples for ammonia determination should be taken before and 30 or 45 minutes after administration of 100 mg NH 4 Cl/kg of body weight.", [["samples", "ANATOMY", 30, 37], ["body", "ANATOMY", 153, 157], ["ammonia", "CHEMICAL", 42, 49], ["NH 4 Cl", "CHEMICAL", 139, 146], ["ammonia", "CHEMICAL", 42, 49], ["NH", "CHEMICAL", 139, 141], ["Cl", "CHEMICAL", 144, 146], ["ammonia", "SIMPLE_CHEMICAL", 42, 49], ["body", "ORGANISM_SUBDIVISION", 153, 157], ["an ATT", "TEST", 3, 9], ["ammonia determination", "TEST", 42, 63], ["body weight", "TEST", 153, 164]]], ["The NH 4 Cl may be administered orally (20 to 50 ml of a 5% aqueous solution), as a dry powder in gelatin capsules, or rectally (recommended) as a 5% solution.BLOOD AMMONIA AND AMMONIA TOLERANCE TESTINGWarning: Administration of NH 4 Cl to patients with increased resting blood ammonia concentrations may cause encephalopathy.", [["blood", "ANATOMY", 272, 277], ["NH 4 Cl", "CHEMICAL", 4, 11], ["NH 4 Cl", "CHEMICAL", 229, 236], ["ammonia", "CHEMICAL", 278, 285], ["encephalopathy", "DISEASE", 311, 325], ["NH 4 Cl", "CHEMICAL", 4, 11], ["NH 4 Cl", "CHEMICAL", 229, 236], ["ammonia", "CHEMICAL", 278, 285], ["NH 4 Cl", "SIMPLE_CHEMICAL", 4, 11], ["NH 4 Cl", "SIMPLE_CHEMICAL", 229, 236], ["patients", "ORGANISM", 240, 248], ["blood", "ORGANISM_SUBSTANCE", 272, 277], ["ammonia", "SIMPLE_CHEMICAL", 278, 285], ["patients", "SPECIES", 240, 248], ["The NH 4 Cl", "TREATMENT", 0, 11], ["a 5% aqueous solution", "TREATMENT", 55, 76], ["a dry powder in gelatin capsules", "TREATMENT", 82, 114], ["a 5% solution", "TREATMENT", 145, 158], ["BLOOD AMMONIA", "TEST", 159, 172], ["Administration of NH", "TREATMENT", 211, 231], ["increased resting blood ammonia concentrations", "TREATMENT", 254, 300], ["encephalopathy", "PROBLEM", 311, 325], ["AMMONIA TOLERANCE", "OBSERVATION", 177, 194]]], ["The clinician should not perform ATT if the patient is showing obvious encephalopathic signs or is hyperammonemic.", [["encephalopathic", "ANATOMY", 71, 86], ["hyperammonemic", "DISEASE", 99, 113], ["patient", "ORGANISM", 44, 51], ["patient", "SPECIES", 44, 51], ["ATT", "TREATMENT", 33, 36], ["obvious encephalopathic signs", "PROBLEM", 63, 92], ["hyperammonemic", "PROBLEM", 99, 113], ["hyperammonemic", "OBSERVATION", 99, 113]]], ["Lack of obvious encephalopathic signs does not guarantee that blood ammonia levels are normal.", [["encephalopathic", "ANATOMY", 16, 31], ["blood", "ANATOMY", 62, 67], ["ammonia", "CHEMICAL", 68, 75], ["ammonia", "CHEMICAL", 68, 75], ["blood", "ORGANISM_SUBSTANCE", 62, 67], ["ammonia", "SIMPLE_CHEMICAL", 68, 75], ["obvious encephalopathic signs", "PROBLEM", 8, 37], ["blood ammonia levels", "TEST", 62, 82], ["obvious", "OBSERVATION_MODIFIER", 8, 15], ["encephalopathic", "OBSERVATION", 16, 31], ["normal", "OBSERVATION", 87, 93]]], ["The ATT is not recommended in cats.BLOOD AMMONIA AND AMMONIA TOLERANCE TESTINGNormal Values \u2022 Resting blood ammonia: dogs, 45 to 120 \u00b5g/dl; cats, 30 to 100 \u00b5g/dl.", [["blood", "ANATOMY", 102, 107], ["ammonia", "CHEMICAL", 108, 115], ["ammonia", "CHEMICAL", 108, 115], ["ATT", "SIMPLE_CHEMICAL", 4, 7], ["cats", "ORGANISM", 30, 34], ["blood", "ORGANISM_SUBSTANCE", 102, 107], ["ammonia", "SIMPLE_CHEMICAL", 108, 115], ["dogs", "ORGANISM", 117, 121], ["cats", "ORGANISM", 140, 144], ["dogs", "SPECIES", 117, 121], ["cats", "SPECIES", 140, 144], ["The ATT", "TREATMENT", 0, 7], ["BLOOD AMMONIA", "TEST", 35, 48], ["AMMONIA TOLERANCE", "TEST", 53, 70], ["TESTINGNormal", "TEST", 71, 84], ["Values", "TEST", 85, 91], ["Resting blood ammonia", "TEST", 94, 115], ["dogs", "TEST", 117, 121], ["cats", "TEST", 140, 144], ["AMMONIA TOLERANCE", "OBSERVATION", 53, 70]]], ["ATT, ammonia at 30 minutes: dogs, minimal change from normal values.BLOOD AMMONIA AND AMMONIA TOLERANCE TESTINGDanger Values \u2022 Dogs, greater than 1000 \u00b5g/dl (hepatic encephalopathy may be imminent, although poor correlation exists between clinical signs of encephalopathy and blood ammonia concentrations); cats, unknown.BLOOD AMMONIA AND AMMONIA TOLERANCE TESTINGArtifacts \u2022 Blood ammonia concentration may be falsely increased by allowing the blood to stand, and by strenuous exercise (see Chapter 1).BLOOD AMMONIA AND AMMONIA TOLERANCE TESTINGabdominal ultrasound plus thoracic radiographs are appropriate.", [["hepatic", "ANATOMY", 158, 165], ["blood", "ANATOMY", 276, 281], ["Blood", "ANATOMY", 376, 381], ["blood", "ANATOMY", 445, 450], ["thoracic", "ANATOMY", 572, 580], ["ammonia", "CHEMICAL", 5, 12], ["hepatic encephalopathy", "DISEASE", 158, 180], ["encephalopathy", "DISEASE", 257, 271], ["ammonia", "CHEMICAL", 282, 289], ["ammonia", "CHEMICAL", 382, 389], ["ammonia", "CHEMICAL", 5, 12], ["ammonia", "CHEMICAL", 282, 289], ["ammonia", "CHEMICAL", 382, 389], ["ATT", "SIMPLE_CHEMICAL", 0, 3], ["ammonia", "SIMPLE_CHEMICAL", 5, 12], ["hepatic", "ORGAN", 158, 165], ["blood", "ORGANISM_SUBSTANCE", 276, 281], ["ammonia", "SIMPLE_CHEMICAL", 282, 289], ["Blood", "ORGANISM_SUBSTANCE", 376, 381], ["ammonia", "SIMPLE_CHEMICAL", 382, 389], ["blood", "ORGANISM_SUBSTANCE", 445, 450], ["cats", "SPECIES", 307, 311], ["BLOOD AMMONIA", "TEST", 68, 81], ["AMMONIA TOLERANCE", "TEST", 86, 103], ["TESTINGDanger", "TEST", 104, 117], ["Values", "TEST", 118, 124], ["Dogs", "TEST", 127, 131], ["hepatic encephalopathy", "PROBLEM", 158, 180], ["encephalopathy", "PROBLEM", 257, 271], ["blood ammonia concentrations", "PROBLEM", 276, 304], ["BLOOD AMMONIA", "TEST", 321, 334], ["AMMONIA TOLERANCE", "TEST", 339, 356], ["TESTINGArtifacts", "TEST", 357, 373], ["Blood ammonia concentration", "TEST", 376, 403], ["BLOOD AMMONIA", "TEST", 503, 516], ["AMMONIA TOLERANCE", "TEST", 521, 538], ["TESTINGabdominal ultrasound", "TEST", 539, 566], ["thoracic radiographs", "TEST", 572, 592], ["minimal", "OBSERVATION_MODIFIER", 34, 41], ["change", "OBSERVATION", 42, 48], ["AMMONIA TOLERANCE", "OBSERVATION", 86, 103], ["hepatic", "ANATOMY", 158, 165], ["encephalopathy", "OBSERVATION", 166, 180], ["encephalopathy", "OBSERVATION", 257, 271], ["AMMONIA TOLERANCE", "OBSERVATION", 339, 356], ["increased", "OBSERVATION_MODIFIER", 419, 428], ["thoracic", "ANATOMY", 572, 580]]], ["Thoracic radiographs may be very revealing, even if a patient does not have coughing or abnormal lung sounds.", [["lung", "ANATOMY", 97, 101], ["coughing", "DISEASE", 76, 84], ["abnormal lung sounds", "DISEASE", 88, 108], ["patient", "ORGANISM", 54, 61], ["lung", "ORGAN", 97, 101], ["patient", "SPECIES", 54, 61], ["Thoracic radiographs", "TEST", 0, 20], ["coughing", "PROBLEM", 76, 84], ["abnormal lung sounds", "PROBLEM", 88, 108], ["lung", "ANATOMY", 97, 101], ["sounds", "OBSERVATION", 102, 108]]], ["Abdominal ultrasonography is particularly desirable and often more useful than radiographs, assuming the operator is accomplished.", [["Abdominal", "ANATOMY", 0, 9], ["Abdominal ultrasonography", "TEST", 0, 25], ["radiographs", "TEST", 79, 90]]], ["If laboratory or radiographic abnormalities are not present or are unconvincing, one may repeat the tests at 1-to 3-week intervals, depending on the clinical condition of the patient, or immediately proceed to function tests, biopsies, or both.", [["patient", "ORGANISM", 175, 182], ["patient", "SPECIES", 175, 182], ["radiographic abnormalities", "PROBLEM", 17, 43], ["the tests", "TEST", 96, 105], ["function tests", "TEST", 210, 224], ["biopsies", "TEST", 226, 234]]], ["Certain hepatic and adrenal gland diseases may require such function tests.", [["hepatic", "ANATOMY", 8, 15], ["adrenal gland", "ANATOMY", 20, 33], ["hepatic and adrenal gland diseases", "DISEASE", 8, 42], ["hepatic", "MULTI-TISSUE_STRUCTURE", 8, 15], ["adrenal gland", "MULTI-TISSUE_STRUCTURE", 20, 33], ["Certain hepatic and adrenal gland diseases", "PROBLEM", 0, 42], ["such function tests", "TEST", 55, 74], ["hepatic", "ANATOMY", 8, 15], ["adrenal gland", "ANATOMY", 20, 33]]], ["It is noteworthy that severe gastric or intestinal disease may cause anorexia or severe weight loss without vomiting or diarrhea, respectively.BLOOD AMMONIA AND AMMONIA TOLERANCE TESTINGGastroduodenoscopy and ileoscopy plus biopsy are reasonable in patients with severe weight loss of unknown cause.", [["gastric", "ANATOMY", 29, 36], ["intestinal", "ANATOMY", 40, 50], ["gastric or intestinal disease", "DISEASE", 29, 58], ["anorexia", "DISEASE", 69, 77], ["weight loss", "DISEASE", 88, 99], ["vomiting", "DISEASE", 108, 116], ["diarrhea", "DISEASE", 120, 128], ["weight loss", "DISEASE", 270, 281], ["gastric", "ORGAN", 29, 36], ["intestinal", "ORGAN", 40, 50], ["patients", "ORGANISM", 249, 257], ["patients", "SPECIES", 249, 257], ["severe gastric or intestinal disease", "PROBLEM", 22, 58], ["anorexia", "PROBLEM", 69, 77], ["severe weight loss", "PROBLEM", 81, 99], ["vomiting", "PROBLEM", 108, 116], ["diarrhea", "PROBLEM", 120, 128], ["BLOOD AMMONIA", "TEST", 143, 156], ["AMMONIA TOLERANCE TESTINGGastroduodenoscopy", "TEST", 161, 204], ["ileoscopy", "TEST", 209, 218], ["biopsy", "TEST", 224, 230], ["severe weight loss", "PROBLEM", 263, 281], ["severe", "OBSERVATION_MODIFIER", 22, 28], ["gastric", "ANATOMY", 29, 36], ["intestinal", "ANATOMY", 40, 50], ["disease", "OBSERVATION", 51, 58], ["severe", "OBSERVATION_MODIFIER", 81, 87], ["weight loss", "OBSERVATION", 88, 99], ["AMMONIA TOLERANCE", "OBSERVATION", 161, 178], ["severe", "OBSERVATION_MODIFIER", 263, 269], ["weight loss", "OBSERVATION", 270, 281]]], ["Some cases with gastric neoplasia may present only for anorexia and weight loss.", [["gastric neoplasia", "ANATOMY", 16, 33], ["gastric neoplasia", "DISEASE", 16, 33], ["anorexia", "DISEASE", 55, 63], ["weight loss", "DISEASE", 68, 79], ["gastric neoplasia", "CANCER", 16, 33], ["gastric neoplasia", "PROBLEM", 16, 33], ["anorexia", "PROBLEM", 55, 63], ["weight loss", "PROBLEM", 68, 79], ["gastric", "ANATOMY", 16, 23], ["neoplasia", "OBSERVATION", 24, 33]]], ["Clinicians without access to endoscopic equipment may consider exploratory laparotomy.", [["endoscopic equipment", "TREATMENT", 29, 49], ["exploratory laparotomy", "TEST", 63, 85], ["laparotomy", "OBSERVATION", 75, 85]]], ["If surgery is performed, gastric, duodenal, jejunal, ileal, mesenteric lymph node, and hepatic biopsies are usually appropriate, regardless of a normal gross appearance of the organs.", [["gastric", "ANATOMY", 25, 32], ["duodenal", "ANATOMY", 34, 42], ["jejunal", "ANATOMY", 44, 51], ["ileal", "ANATOMY", 53, 58], ["mesenteric lymph node", "ANATOMY", 60, 81], ["hepatic biopsies", "ANATOMY", 87, 103], ["organs", "ANATOMY", 176, 182], ["gastric", "MULTI-TISSUE_STRUCTURE", 25, 32], ["duodenal", "MULTI-TISSUE_STRUCTURE", 34, 42], ["jejunal", "MULTI-TISSUE_STRUCTURE", 44, 51], ["ileal", "MULTI-TISSUE_STRUCTURE", 53, 58], ["mesenteric lymph node", "MULTI-TISSUE_STRUCTURE", 60, 81], ["hepatic biopsies", "MULTI-TISSUE_STRUCTURE", 87, 103], ["organs", "ORGAN", 176, 182], ["surgery", "TREATMENT", 3, 10], ["gastric, duodenal, jejunal, ileal, mesenteric lymph node", "PROBLEM", 25, 81], ["hepatic biopsies", "TEST", 87, 103], ["gastric", "ANATOMY", 25, 32], ["duodenal", "ANATOMY", 34, 42], ["jejunal", "ANATOMY", 44, 51], ["ileal", "ANATOMY", 53, 58], ["mesenteric", "ANATOMY", 60, 70], ["lymph node", "OBSERVATION", 71, 81], ["hepatic", "ANATOMY", 87, 94], ["biopsies", "OBSERVATION", 95, 103], ["normal", "OBSERVATION", 145, 151], ["gross", "OBSERVATION_MODIFIER", 152, 157], ["organs", "ANATOMY", 176, 182]]], ["In cats, the pancreas should also be biopsied.BLOOD AMMONIA AND AMMONIA TOLERANCE TESTINGCancer cachexia can be particularly difficult to diagnose.", [["pancreas", "ANATOMY", 13, 21], ["cachexia", "DISEASE", 96, 104], ["cats", "ORGANISM", 3, 7], ["pancreas", "ORGAN", 13, 21], ["cats", "SPECIES", 3, 7], ["BLOOD AMMONIA", "TEST", 46, 59], ["AMMONIA TOLERANCE TESTINGCancer cachexia", "PROBLEM", 64, 104], ["pancreas", "ANATOMY", 13, 21], ["should also be", "UNCERTAINTY", 22, 36], ["biopsied", "OBSERVATION", 37, 45], ["AMMONIA TOLERANCE", "OBSERVATION", 64, 81]]], ["It is a poorly defined, multifaceted syndrome that Protein C less than 70% is suggestive of PSS as opposed to microvascular dysplasia.BLOOD AMMONIA AND AMMONIA TOLERANCE TESTINGCauses of High Protein C \u2022 Protein C greater than 70% is suggestive of microvascular dysplasia as opposed to PSS.", [["microvascular dysplasia", "ANATOMY", 110, 133], ["microvascular dysplasia", "ANATOMY", 248, 271], ["PSS", "DISEASE", 92, 95], ["microvascular dysplasia", "DISEASE", 110, 133], ["microvascular dysplasia", "DISEASE", 248, 271], ["PSS", "DISEASE", 286, 289], ["Protein C", "GENE_OR_GENE_PRODUCT", 51, 60], ["microvascular dysplasia", "PATHOLOGICAL_FORMATION", 110, 133], ["High Protein C \u2022 Protein C", "GENE_OR_GENE_PRODUCT", 187, 213], ["microvascular dysplasia", "PATHOLOGICAL_FORMATION", 248, 271], ["High Protein C", "PROTEIN", 187, 201], ["Protein C", "PROTEIN", 204, 213], ["a poorly defined, multifaceted syndrome", "PROBLEM", 6, 45], ["Protein C", "TEST", 51, 60], ["PSS", "PROBLEM", 92, 95], ["microvascular dysplasia", "PROBLEM", 110, 133], ["BLOOD AMMONIA", "TEST", 134, 147], ["AMMONIA TOLERANCE", "TEST", 152, 169], ["TESTINGCauses", "TEST", 170, 183], ["High Protein C", "TEST", 187, 201], ["Protein C", "TEST", 204, 213], ["microvascular dysplasia", "PROBLEM", 248, 271], ["poorly defined", "OBSERVATION_MODIFIER", 8, 22], ["multifaceted", "OBSERVATION_MODIFIER", 24, 36], ["syndrome", "OBSERVATION", 37, 45], ["suggestive of", "UNCERTAINTY", 78, 91], ["PSS", "OBSERVATION", 92, 95], ["microvascular", "ANATOMY", 110, 123], ["dysplasia", "OBSERVATION", 124, 133], ["AMMONIA TOLERANCE", "OBSERVATION", 152, 169], ["suggestive of", "UNCERTAINTY", 234, 247], ["microvascular", "ANATOMY", 248, 261], ["dysplasia", "OBSERVATION", 262, 271]]], ["A protein C value that increased to 70% or greater after corrective surgery for PSS suggests that portal blood is being directed through the liver and not through the shunt.HEPATIC MINERAL ANALYSISOccasional Indications \u2022 Hepatic mineral analysis may be used to distinguish between patients in which copper is the cause of the hepatic disease versus those in which it is the effect of the hepatic disease.HEPATIC MINERAL ANALYSISAdvantages \u2022 Hepatic mineral analysis is more specific and definitive than special stains for copper.HEPATIC MINERAL ANALYSISDisadvantages \u2022 Hepatic mineral analysis requires 50 mg of liver tissue for analysis.HEPATIC MINERAL ANALYSISAnalysis \u2022 Measurement of hepatic minerals is done by atomic absorption spectroscopy or atomic emission spectroscopy.HEPATIC MINERAL ANALYSISNormal Values \u2022 Less than 400 \u00b5g/g dry weight of liver.HEPATIC MINERAL ANALYSISArtifacts \u2022 Measurement of hepatic minerals may be affected by an inadequate tissue sample or a contaminated sample.HEPATIC MINERAL ANALYSISDrug Therapy That May Alter Mineral Analysis \u2022 Unknown.HEPATIC MINERAL ANALYSISInterpretation \u2022 Secondary hepatic copper retention from cholestasis may range from 400 to 1000 \u00b5g/g.", [["portal blood", "ANATOMY", 98, 110], ["liver", "ANATOMY", 141, 146], ["Hepatic", "ANATOMY", 222, 229], ["hepatic", "ANATOMY", 327, 334], ["hepatic", "ANATOMY", 389, 396], ["Hepatic", "ANATOMY", 442, 449], ["Hepatic", "ANATOMY", 570, 577], ["liver tissue", "ANATOMY", 613, 625], ["hepatic", "ANATOMY", 689, 696], ["liver", "ANATOMY", 853, 858], ["hepatic", "ANATOMY", 910, 917], ["tissue sample", "ANATOMY", 960, 973], ["sample", "ANATOMY", 992, 998], ["hepatic", "ANATOMY", 1129, 1136], ["PSS", "DISEASE", 80, 83], ["copper", "CHEMICAL", 300, 306], ["hepatic disease", "DISEASE", 327, 342], ["hepatic disease", "DISEASE", 389, 404], ["copper", "CHEMICAL", 523, 529], ["copper", "CHEMICAL", 1137, 1143], ["cholestasis", "DISEASE", 1159, 1170], ["copper", "CHEMICAL", 300, 306], ["copper", "CHEMICAL", 523, 529], ["copper", "CHEMICAL", 1137, 1143], ["protein C", "GENE_OR_GENE_PRODUCT", 2, 11], ["portal", "MULTI-TISSUE_STRUCTURE", 98, 104], ["blood", "ORGANISM_SUBSTANCE", 105, 110], ["liver", "ORGAN", 141, 146], ["patients", "ORGANISM", 282, 290], ["copper", "SIMPLE_CHEMICAL", 300, 306], ["hepatic", "ORGAN", 327, 334], ["hepatic", "ORGAN", 389, 396], ["copper", "SIMPLE_CHEMICAL", 523, 529], ["liver tissue", "TISSUE", 613, 625], ["hepatic", "ORGAN", 689, 696], ["liver", "ORGAN", 853, 858], ["hepatic", "ORGAN", 910, 917], ["tissue", "TISSUE", 960, 966], ["hepatic", "ORGAN", 1129, 1136], ["copper", "SIMPLE_CHEMICAL", 1137, 1143], ["protein C", "PROTEIN", 2, 11], ["patients", "SPECIES", 282, 290], ["A protein C value", "TEST", 0, 17], ["corrective surgery", "TREATMENT", 57, 75], ["PSS", "PROBLEM", 80, 83], ["portal blood", "PROBLEM", 98, 110], ["the shunt", "TREATMENT", 163, 172], ["Hepatic mineral analysis", "TEST", 222, 246], ["the hepatic disease", "PROBLEM", 323, 342], ["the hepatic disease", "PROBLEM", 385, 404], ["HEPATIC MINERAL ANALYSISAdvantages", "TEST", 405, 439], ["Hepatic mineral analysis", "TEST", 442, 466], ["special stains", "TEST", 504, 518], ["HEPATIC MINERAL ANALYSISDisadvantages", "TREATMENT", 530, 567], ["Hepatic mineral analysis", "TEST", 570, 594], ["analysis", "TEST", 630, 638], ["HEPATIC MINERAL ANALYSISAnalysis", "TEST", 639, 671], ["atomic absorption spectroscopy", "TEST", 717, 747], ["atomic emission spectroscopy", "TEST", 751, 779], ["HEPATIC MINERAL ANALYSISNormal Values", "TEST", 780, 817], ["HEPATIC MINERAL ANALYSISArtifacts", "TEST", 859, 892], ["a contaminated sample", "TEST", 977, 998], ["HEPATIC MINERAL ANALYSISDrug Therapy", "TREATMENT", 999, 1035], ["Alter Mineral Analysis", "TEST", 1045, 1067], ["HEPATIC MINERAL ANALYSISInterpretation", "TREATMENT", 1078, 1116], ["Secondary hepatic copper retention", "PROBLEM", 1119, 1153], ["cholestasis", "PROBLEM", 1159, 1170], ["increased", "OBSERVATION_MODIFIER", 23, 32], ["portal blood", "ANATOMY", 98, 110], ["liver", "ANATOMY", 141, 146], ["shunt", "OBSERVATION", 167, 172], ["MINERAL ANALYSISOccasional", "OBSERVATION", 181, 207], ["Hepatic", "ANATOMY", 222, 229], ["hepatic", "ANATOMY", 327, 334], ["disease", "OBSERVATION", 335, 342], ["hepatic", "ANATOMY", 389, 396], ["disease", "OBSERVATION", 397, 404], ["MINERAL ANALYSISAdvantages", "OBSERVATION", 413, 439], ["Hepatic", "ANATOMY", 442, 449], ["MINERAL ANALYSISDisadvantages", "OBSERVATION", 538, 567], ["Hepatic", "ANATOMY", 570, 577], ["liver", "ANATOMY", 613, 618], ["MINERAL ANALYSISAnalysis", "OBSERVATION", 647, 671], ["hepatic", "ANATOMY", 689, 696], ["MINERAL ANALYSISNormal", "OBSERVATION", 788, 810], ["liver", "ANATOMY", 853, 858], ["MINERAL ANALYSISArtifacts", "OBSERVATION", 867, 892], ["hepatic", "ANATOMY", 910, 917], ["inadequate", "OBSERVATION", 949, 959], ["MINERAL ANALYSISDrug", "OBSERVATION", 1007, 1027], ["MINERAL ANALYSISInterpretation", "OBSERVATION", 1086, 1116], ["hepatic", "ANATOMY", 1129, 1136], ["copper retention", "OBSERVATION", 1137, 1153], ["cholestasis", "OBSERVATION", 1159, 1170]]], ["Hereditary copper-associated hepatopathies can range from 750 \u00b5g/g and higher (often in the several thousands).WEIGHT LOSS OR ANOREXIA OF UNKNOWN CAUSEWeight loss has many causes (Box 9-9).", [["Hereditary copper-associated hepatopathies", "DISEASE", 0, 42], ["CAUSEWeight loss", "DISEASE", 146, 162], ["Hereditary copper-associated hepatopathies", "PROBLEM", 0, 42], ["WEIGHT LOSS", "PROBLEM", 111, 122], ["ANOREXIA", "PROBLEM", 126, 134], ["UNKNOWN CAUSEWeight loss", "PROBLEM", 138, 162], ["hepatopathies", "OBSERVATION", 29, 42], ["ANOREXIA", "OBSERVATION", 126, 134], ["CAUSEWeight loss", "OBSERVATION", 146, 162]]], ["Concurrent problems with fewer potential causes (e.g., regurgitation, vomiting, diarrhea, icterus) should be considered first.", [["vomiting", "DISEASE", 70, 78], ["diarrhea", "DISEASE", 80, 88], ["icterus", "DISEASE", 90, 97], ["regurgitation", "PROBLEM", 55, 68], ["vomiting", "PROBLEM", 70, 78], ["diarrhea", "PROBLEM", 80, 88], ["icterus", "PROBLEM", 90, 97], ["regurgitation", "OBSERVATION", 55, 68], ["icterus", "OBSERVATION", 90, 97]]], ["If a patient had a reasonable appetite when weight loss began, major differential diagnoses are small intestinal disease, maldigestion, hepatic disease, increased use of calories (e.g., hyperthyroidism, lactation), increased loss of calories (e.g., diabetes mellitus) or caloric-deficient diet.", [["intestinal", "ANATOMY", 102, 112], ["hepatic", "ANATOMY", 136, 143], ["weight loss", "DISEASE", 44, 55], ["intestinal disease", "DISEASE", 102, 120], ["maldigestion", "DISEASE", 122, 134], ["hepatic disease", "DISEASE", 136, 151], ["hyperthyroidism", "DISEASE", 186, 201], ["loss of calories", "DISEASE", 225, 241], ["diabetes mellitus", "DISEASE", 249, 266], ["patient", "ORGANISM", 5, 12], ["intestinal", "ORGAN", 102, 112], ["hepatic", "ORGAN", 136, 143], ["patient", "SPECIES", 5, 12], ["weight loss", "PROBLEM", 44, 55], ["small intestinal disease", "PROBLEM", 96, 120], ["maldigestion", "PROBLEM", 122, 134], ["hepatic disease", "PROBLEM", 136, 151], ["calories", "TREATMENT", 170, 178], ["hyperthyroidism", "PROBLEM", 186, 201], ["increased loss of calories", "PROBLEM", 215, 241], ["diabetes mellitus", "PROBLEM", 249, 266], ["caloric-deficient diet", "TREATMENT", 271, 293], ["small", "OBSERVATION_MODIFIER", 96, 101], ["intestinal", "ANATOMY", 102, 112], ["disease", "OBSERVATION", 113, 120], ["hepatic", "ANATOMY", 136, 143], ["disease", "OBSERVATION", 144, 151], ["increased", "OBSERVATION_MODIFIER", 153, 162]]], ["If no other identifiable problems (other than weight loss or anorexia) can be pursued, a systematic search is indicated (Figure 9 -13).", [["weight loss", "DISEASE", 46, 57], ["anorexia", "DISEASE", 61, 69], ["other identifiable problems", "PROBLEM", 6, 33], ["weight loss", "PROBLEM", 46, 57], ["anorexia", "PROBLEM", 61, 69], ["a systematic search", "TEST", 87, 106], ["no other", "UNCERTAINTY", 3, 11]]], ["One should first preclude as many causes as possible with the history and physical examination (i.e., lack of food, calorie-deficient food, inability to eat, regurgitation, vomiting and diarrhea).", [["regurgitation", "DISEASE", 158, 171], ["vomiting", "DISEASE", 173, 181], ["diarrhea", "DISEASE", 186, 194], ["physical examination", "TEST", 74, 94], ["inability to eat", "PROBLEM", 140, 156], ["regurgitation", "PROBLEM", 158, 171], ["vomiting", "PROBLEM", 173, 181], ["diarrhea", "PROBLEM", 186, 194]]], ["Next, extensive clinicopathologic screening is indicated.", [["extensive clinicopathologic screening", "TEST", 6, 43]]], ["Imaging is considered an extension of the physical examination, and (e.g., spinal problems) and patients predisposed to nonsurgical diseases (e.g., pancreatitis) must be identified early.WEIGHT LOSS OR ANOREXIA OF UNKNOWN CAUSEIn patients with severe, progressive, acute abdomen (severe unrelenting pain or shock or stupor in a deteriorating patient), surgery is often indicated as soon as fluid, electrolyte, and acid-base status are acceptable for anesthesia.", [["spinal", "ANATOMY", 75, 81], ["abdomen", "ANATOMY", 271, 278], ["pancreatitis", "DISEASE", 148, 160], ["pain", "DISEASE", 299, 303], ["shock", "DISEASE", 307, 312], ["stupor", "DISEASE", 316, 322], ["patients", "ORGANISM", 96, 104], ["patients", "ORGANISM", 230, 238], ["abdomen", "ORGANISM_SUBDIVISION", 271, 278], ["patient", "ORGANISM", 342, 349], ["patients", "SPECIES", 96, 104], ["patients", "SPECIES", 230, 238], ["patient", "SPECIES", 342, 349], ["Imaging", "TEST", 0, 7], ["the physical examination", "TEST", 38, 62], ["nonsurgical diseases", "PROBLEM", 120, 140], ["pancreatitis", "PROBLEM", 148, 160], ["WEIGHT LOSS", "PROBLEM", 187, 198], ["ANOREXIA", "PROBLEM", 202, 210], ["severe, progressive, acute abdomen", "PROBLEM", 244, 278], ["severe unrelenting pain", "PROBLEM", 280, 303], ["shock", "PROBLEM", 307, 312], ["stupor", "PROBLEM", 316, 322], ["surgery", "TREATMENT", 352, 359], ["fluid, electrolyte", "TEST", 390, 408], ["acid-base status", "TEST", 414, 430], ["anesthesia", "TREATMENT", 450, 460], ["spinal", "ANATOMY", 75, 81], ["pancreatitis", "OBSERVATION", 148, 160], ["ANOREXIA", "OBSERVATION", 202, 210], ["severe", "OBSERVATION_MODIFIER", 244, 250], ["progressive", "OBSERVATION_MODIFIER", 252, 263], ["acute", "OBSERVATION_MODIFIER", 265, 270], ["abdomen", "ANATOMY", 271, 278], ["severe", "OBSERVATION_MODIFIER", 280, 286], ["unrelenting", "OBSERVATION_MODIFIER", 287, 298]]], ["Imaging is critically important, but extensive laboratory testing is unlikely to identify the more common causes of acute abdomen (e.g., intestinal obstruction, gastric dilation and volvulus, peritonitis, organ ischemia, tumor, sepsis, or bleeding) and usually only delays surgical resolution of disease.", [["abdomen", "ANATOMY", 122, 129], ["intestinal", "ANATOMY", 137, 147], ["gastric", "ANATOMY", 161, 168], ["organ", "ANATOMY", 205, 210], ["tumor", "ANATOMY", 221, 226], ["intestinal obstruction", "DISEASE", 137, 159], ["gastric dilation", "DISEASE", 161, 177], ["volvulus", "DISEASE", 182, 190], ["peritonitis", "DISEASE", 192, 203], ["organ ischemia", "DISEASE", 205, 219], ["tumor", "DISEASE", 221, 226], ["sepsis", "DISEASE", 228, 234], ["bleeding", "DISEASE", 239, 247], ["abdomen", "ORGANISM_SUBDIVISION", 122, 129], ["intestinal", "ORGAN", 137, 147], ["gastric", "ORGAN", 161, 168], ["organ", "ORGAN", 205, 210], ["tumor", "CANCER", 221, 226], ["Imaging", "TEST", 0, 7], ["extensive laboratory testing", "TEST", 37, 65], ["acute abdomen", "PROBLEM", 116, 129], ["intestinal obstruction", "PROBLEM", 137, 159], ["gastric dilation", "PROBLEM", 161, 177], ["volvulus", "PROBLEM", 182, 190], ["peritonitis", "PROBLEM", 192, 203], ["organ ischemia", "PROBLEM", 205, 219], ["tumor", "PROBLEM", 221, 226], ["sepsis", "PROBLEM", 228, 234], ["bleeding", "PROBLEM", 239, 247], ["disease", "PROBLEM", 296, 303], ["acute", "OBSERVATION_MODIFIER", 116, 121], ["abdomen", "ANATOMY", 122, 129], ["intestinal", "ANATOMY", 137, 147], ["obstruction", "OBSERVATION", 148, 159], ["gastric", "ANATOMY", 161, 168], ["dilation", "OBSERVATION", 169, 177], ["volvulus", "OBSERVATION", 182, 190], ["peritonitis", "OBSERVATION", 192, 203], ["organ", "ANATOMY", 205, 210], ["ischemia", "OBSERVATION", 211, 219], ["tumor", "OBSERVATION", 221, 226], ["sepsis", "OBSERVATION", 228, 234], ["bleeding", "OBSERVATION", 239, 247], ["delays", "OBSERVATION_MODIFIER", 266, 272], ["surgical", "OBSERVATION_MODIFIER", 273, 281], ["resolution", "OBSERVATION_MODIFIER", 282, 292], ["disease", "OBSERVATION", 296, 303]]], ["Abdominal exploration offers a good chance for definitive diagnosis plus resolution of the disease process. may involve loss of taste, malabsorption, increased metabolism with energy wasting, and other mechanisms.", [["Abdominal", "ANATOMY", 0, 9], ["malabsorption", "DISEASE", 135, 148], ["wasting", "DISEASE", 183, 190], ["Abdominal exploration", "TEST", 0, 21], ["the disease process", "PROBLEM", 87, 106], ["loss of taste", "PROBLEM", 120, 133], ["malabsorption", "PROBLEM", 135, 148], ["increased metabolism", "PROBLEM", 150, 170], ["energy wasting", "PROBLEM", 176, 190], ["disease", "OBSERVATION", 91, 98], ["increased", "OBSERVATION_MODIFIER", 150, 159], ["metabolism", "OBSERVATION_MODIFIER", 160, 170]]], ["Almost any tumor can cause cancer cachexia, and no consistent laboratory findings exist.", [["tumor", "ANATOMY", 11, 16], ["cancer", "ANATOMY", 27, 33], ["tumor", "DISEASE", 11, 16], ["cancer cachexia", "DISEASE", 27, 42], ["tumor", "CANCER", 11, 16], ["cancer cachexia", "CANCER", 27, 42], ["any tumor", "PROBLEM", 7, 16], ["cancer cachexia", "PROBLEM", 27, 42], ["tumor", "OBSERVATION", 11, 16], ["cancer", "OBSERVATION", 27, 33]]], ["The causative cancer may be large or small, focal or diffuse; lymphomas and carcinomas are probably the most common causes.WEIGHT LOSS OR ANOREXIA OF UNKNOWN CAUSEAnorexia of unknown cause is similar to weight loss in being difficult to evaluate if no other identifiable abnormalities are seen.", [["cancer", "ANATOMY", 14, 20], ["lymphomas", "ANATOMY", 62, 71], ["carcinomas", "ANATOMY", 76, 86], ["cancer", "DISEASE", 14, 20], ["lymphomas", "DISEASE", 62, 71], ["carcinomas", "DISEASE", 76, 86], ["weight loss", "DISEASE", 203, 214], ["cancer", "CANCER", 14, 20], ["lymphomas", "CANCER", 62, 71], ["carcinomas", "CANCER", 76, 86], ["The causative cancer", "PROBLEM", 0, 20], ["large or small, focal or diffuse; lymphomas", "PROBLEM", 28, 71], ["carcinomas", "PROBLEM", 76, 86], ["WEIGHT LOSS", "PROBLEM", 123, 134], ["ANOREXIA", "PROBLEM", 138, 146], ["UNKNOWN CAUSEAnorexia", "PROBLEM", 150, 171], ["weight loss", "PROBLEM", 203, 214], ["other identifiable abnormalities", "PROBLEM", 252, 284], ["causative", "OBSERVATION_MODIFIER", 4, 13], ["cancer", "OBSERVATION", 14, 20], ["may be", "UNCERTAINTY", 21, 27], ["large", "OBSERVATION_MODIFIER", 28, 33], ["small", "OBSERVATION_MODIFIER", 37, 42], ["focal", "OBSERVATION_MODIFIER", 44, 49], ["diffuse", "OBSERVATION_MODIFIER", 53, 60], ["lymphomas", "OBSERVATION", 62, 71], ["carcinomas", "OBSERVATION", 76, 86], ["probably the", "UNCERTAINTY", 91, 103], ["most common", "OBSERVATION_MODIFIER", 104, 115], ["ANOREXIA", "OBSERVATION", 138, 146], ["abnormalities", "OBSERVATION", 271, 284]]], ["The diagnostic approach is similar to that for chronic weight loss (see Figure 9 -13; Box 9-10).", [["weight loss", "DISEASE", 55, 66], ["chronic weight loss", "PROBLEM", 47, 66]]], ["Anorexia can be divided into three categories: (1) inability to eat (due to oral, pharyngeal, or esophageal disease), (2) primary anorexia (rare) associated with a primary CNS disorder, and (3) secondary anorexia (the most common), which is caused by systemic or metabolic disease.WEIGHT LOSS OR ANOREXIA OF UNKNOWN CAUSEIf necessary, one may elect a therapeutic trial to treat for a suspected problem in a patient in whom a diagnosis cannot be made.", [["oral", "ANATOMY", 76, 80], ["pharyngeal", "ANATOMY", 82, 92], ["esophageal", "ANATOMY", 97, 107], ["CNS", "ANATOMY", 172, 175], ["Anorexia", "DISEASE", 0, 8], ["oral, pharyngeal, or esophageal disease", "DISEASE", 76, 115], ["primary anorexia", "DISEASE", 122, 138], ["primary CNS disorder", "DISEASE", 164, 184], ["anorexia", "DISEASE", 204, 212], ["systemic or metabolic disease", "DISEASE", 251, 280], ["oral", "ORGANISM_SUBDIVISION", 76, 80], ["pharyngeal", "ORGAN", 82, 92], ["esophageal", "ORGAN", 97, 107], ["patient", "ORGANISM", 407, 414], ["patient", "SPECIES", 407, 414], ["Anorexia", "PROBLEM", 0, 8], ["inability to eat", "PROBLEM", 51, 67], ["oral, pharyngeal, or esophageal disease)", "PROBLEM", 76, 116], ["primary anorexia", "PROBLEM", 122, 138], ["a primary CNS disorder", "PROBLEM", 162, 184], ["secondary anorexia", "PROBLEM", 194, 212], ["systemic or metabolic disease", "PROBLEM", 251, 280], ["WEIGHT LOSS", "PROBLEM", 281, 292], ["ANOREXIA", "PROBLEM", 296, 304], ["a therapeutic trial", "TREATMENT", 349, 368], ["pharyngeal", "ANATOMY", 82, 92], ["esophageal", "ANATOMY", 97, 107], ["disease", "OBSERVATION", 108, 115], ["anorexia", "OBSERVATION", 204, 212], ["systemic", "OBSERVATION_MODIFIER", 251, 259], ["metabolic disease", "OBSERVATION", 263, 280]]], ["It is vital that one design such therapy so that it is safe and extremely likely to succeed if the presumptive disease is present.", [["such therapy", "TREATMENT", 28, 40], ["the presumptive disease", "PROBLEM", 95, 118], ["disease", "OBSERVATION", 111, 118]]], ["Then, if the trial fails, one may rule out that disease and go on to treat for something else.", [["disease", "PROBLEM", 48, 55], ["disease", "OBSERVATION", 48, 55]]], ["To do this, the clinician must be sure that the dose and duration of the treatment are sufficient.", [["the treatment", "TREATMENT", 69, 82]]]], "PMC7442196": [["An event is serious (based on the ICH definition) when the patient outcome is:", [["ICH", "DISEASE", 34, 37], ["patient", "ORGANISM", 59, 66], ["patient", "SPECIES", 59, 66], ["the ICH definition", "TEST", 30, 48], ["serious", "OBSERVATION_MODIFIER", 12, 19]]]], "PMC3773900": [], "PMC7091713": [], "PMC7195078": [["Declaration of competing interestWe declare that there is no conflict of interest.", [["no", "UNCERTAINTY", 58, 60]]]], "PMC7365853": [["IntroductionNovel coronavirus disease 2019 (COVID-19) is a global pandemic caused by the pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1).", [["coronavirus disease", "DISEASE", 18, 37], ["COVID-19", "CHEMICAL", 44, 52], ["acute respiratory syndrome coronavirus", "DISEASE", 105, 143], ["COVID-19", "ORGANISM", 44, 52], ["SARS-CoV-2", "ORGANISM", 147, 157], ["Novel coronavirus disease 2019 (COVID-19", "SPECIES", 12, 52], ["severe acute respiratory syndrome coronavirus", "SPECIES", 98, 143], ["SARS-CoV-2", "SPECIES", 147, 157], ["Novel coronavirus disease", "PROBLEM", 12, 37], ["COVID", "TEST", 44, 49], ["a global pandemic", "PROBLEM", 57, 74], ["the pathogen severe acute respiratory syndrome coronavirus", "PROBLEM", 85, 143], ["coronavirus disease", "OBSERVATION", 18, 37], ["global", "OBSERVATION_MODIFIER", 59, 65], ["pandemic", "OBSERVATION", 66, 74], ["pathogen", "OBSERVATION_MODIFIER", 89, 97], ["severe", "OBSERVATION_MODIFIER", 98, 104], ["acute", "OBSERVATION_MODIFIER", 105, 110], ["respiratory syndrome", "OBSERVATION", 111, 131]]], ["SARS-CoV-2 causes a respiratory illness that primarily manifests in symptomatic individuals as fever, cough, and myalgias.", [["respiratory", "ANATOMY", 20, 31], ["SARS", "DISEASE", 0, 4], ["respiratory illness", "DISEASE", 20, 39], ["fever", "DISEASE", 95, 100], ["cough", "DISEASE", 102, 107], ["myalgias", "DISEASE", 113, 121], ["SARS-CoV-2", "ORGANISM", 0, 10], ["SARS-CoV", "SPECIES", 0, 8], ["a respiratory illness", "PROBLEM", 18, 39], ["symptomatic individuals", "PROBLEM", 68, 91], ["fever", "PROBLEM", 95, 100], ["cough", "PROBLEM", 102, 107], ["myalgias", "PROBLEM", 113, 121], ["respiratory", "ANATOMY", 20, 31], ["illness", "OBSERVATION", 32, 39]]], ["More severe infection leads to pneumonia, acute respiratory distress syndrome (ARDS) or a large systemic inflammatory cytokine response (2), resulting in multi-organ damage.IntroductionThe full spectrum of neurological manifestations of COVID-19 not fully elucidated.", [["respiratory", "ANATOMY", 48, 59], ["multi-organ", "ANATOMY", 154, 165], ["neurological", "ANATOMY", 206, 218], ["infection", "DISEASE", 12, 21], ["pneumonia", "DISEASE", 31, 40], ["acute respiratory distress syndrome", "DISEASE", 42, 77], ["ARDS", "DISEASE", 79, 83], ["multi-organ damage", "DISEASE", 154, 172], ["COVID", "DISEASE", 237, 242], ["COVID-19", "CHEMICAL", 237, 245], ["multi-organ", "ORGAN", 154, 165], ["cytokine", "PROTEIN", 118, 126], ["More severe infection", "PROBLEM", 0, 21], ["pneumonia", "PROBLEM", 31, 40], ["acute respiratory distress syndrome", "PROBLEM", 42, 77], ["ARDS", "PROBLEM", 79, 83], ["a large systemic inflammatory cytokine response", "PROBLEM", 88, 135], ["multi-organ damage", "PROBLEM", 154, 172], ["COVID", "TEST", 237, 242], ["severe", "OBSERVATION_MODIFIER", 5, 11], ["infection", "OBSERVATION", 12, 21], ["pneumonia", "OBSERVATION", 31, 40], ["acute", "OBSERVATION_MODIFIER", 42, 47], ["respiratory distress syndrome", "OBSERVATION", 48, 77], ["ARDS", "OBSERVATION", 79, 83], ["large", "OBSERVATION_MODIFIER", 90, 95], ["systemic", "OBSERVATION_MODIFIER", 96, 104], ["inflammatory", "OBSERVATION_MODIFIER", 105, 117], ["multi-organ", "ANATOMY", 154, 165], ["damage", "OBSERVATION", 166, 172]]], ["Other coronavirus strains are associated with seizures, encephalitis, and demyelinating syndromes (3).", [["seizures", "DISEASE", 46, 54], ["encephalitis", "DISEASE", 56, 68], ["demyelinating syndromes", "DISEASE", 74, 97], ["coronavirus", "ORGANISM", 6, 17], ["Other coronavirus strains", "PROBLEM", 0, 25], ["seizures", "PROBLEM", 46, 54], ["encephalitis", "PROBLEM", 56, 68], ["demyelinating syndromes", "PROBLEM", 74, 97], ["coronavirus strains", "OBSERVATION", 6, 25], ["encephalitis", "OBSERVATION", 56, 68], ["demyelinating syndromes", "OBSERVATION", 74, 97]]], ["Proposed mechanisms of disease for these strains include entry into the central nervous system through breakdown of the blood brain barrier and invasion through peripheral nerves (3).", [["central nervous system", "ANATOMY", 72, 94], ["blood brain barrier", "ANATOMY", 120, 139], ["peripheral nerves", "ANATOMY", 161, 178], ["central nervous system", "ANATOMICAL_SYSTEM", 72, 94], ["blood brain barrier", "TISSUE", 120, 139], ["peripheral nerves", "MULTI-TISSUE_STRUCTURE", 161, 178], ["disease", "PROBLEM", 23, 30], ["these strains", "PROBLEM", 35, 48], ["the blood brain barrier", "TREATMENT", 116, 139], ["disease", "OBSERVATION", 23, 30], ["central", "ANATOMY_MODIFIER", 72, 79], ["nervous system", "ANATOMY", 80, 94], ["blood brain", "ANATOMY", 120, 131], ["invasion", "OBSERVATION", 144, 152], ["peripheral", "ANATOMY_MODIFIER", 161, 171], ["nerves", "ANATOMY", 172, 178]]], ["For SARS-CoV-2 in particular, limited knowledge exists regarding its effect on the nervous system and impact on pre-existing neurological disorders.", [["nervous system", "ANATOMY", 83, 97], ["neurological", "ANATOMY", 125, 137], ["neurological disorders", "DISEASE", 125, 147], ["nervous system", "ANATOMICAL_SYSTEM", 83, 97], ["SARS-CoV", "SPECIES", 4, 12], ["SARS", "PROBLEM", 4, 8], ["pre-existing neurological disorders", "PROBLEM", 112, 147], ["neurological disorders", "OBSERVATION", 125, 147]]], ["Case series have primarily reported symptoms of hyposmia, hypogeusia, dizziness, encephalopathy, and delirium (4, 5).", [["hyposmia", "DISEASE", 48, 56], ["hypogeusia", "DISEASE", 58, 68], ["dizziness", "DISEASE", 70, 79], ["encephalopathy", "DISEASE", 81, 95], ["delirium", "DISEASE", 101, 109], ["symptoms", "PROBLEM", 36, 44], ["hyposmia", "PROBLEM", 48, 56], ["hypogeusia", "PROBLEM", 58, 68], ["dizziness", "PROBLEM", 70, 79], ["encephalopathy", "PROBLEM", 81, 95], ["delirium", "PROBLEM", 101, 109], ["hyposmia", "OBSERVATION", 48, 56], ["encephalopathy", "OBSERVATION", 81, 95], ["delirium", "OBSERVATION", 101, 109]]], ["Only one case of new-onset seizure has been reported (4).", [["seizure", "DISEASE", 27, 34], ["new-onset seizure", "PROBLEM", 17, 34], ["new", "OBSERVATION_MODIFIER", 17, 20], ["seizure", "OBSERVATION", 27, 34]]], ["A few studies have noted an increase incidence in stroke with COVID-19 infection (4, 6\u20138). including in young adults (9).IntroductionWith the rapid spread of SARS-CoV-2, neurologists will increasingly be consulted to guide care for patients with existing neurological conditions and new neurological symptoms due to COVID-19.", [["neurological", "ANATOMY", 255, 267], ["neurological", "ANATOMY", 287, 299], ["stroke", "DISEASE", 50, 56], ["COVID-19", "CHEMICAL", 62, 70], ["infection", "DISEASE", 71, 80], ["SARS", "DISEASE", 158, 162], ["neurological symptoms", "DISEASE", 287, 308], ["patients", "ORGANISM", 232, 240], ["patients", "SPECIES", 232, 240], ["SARS-CoV", "SPECIES", 158, 166], ["A few studies", "TEST", 0, 13], ["stroke", "PROBLEM", 50, 56], ["COVID", "TEST", 62, 67], ["infection", "PROBLEM", 71, 80], ["existing neurological conditions", "PROBLEM", 246, 278], ["new neurological symptoms", "PROBLEM", 283, 308], ["COVID", "TEST", 316, 321], ["increase", "OBSERVATION_MODIFIER", 28, 36], ["incidence", "OBSERVATION_MODIFIER", 37, 46], ["stroke", "OBSERVATION", 50, 56], ["infection", "OBSERVATION", 71, 80], ["rapid", "OBSERVATION_MODIFIER", 142, 147], ["spread", "OBSERVATION_MODIFIER", 148, 154]]], ["We conducted a single-center retrospective review of our first experiences with COVID-19 infection in inpatients with or without pre-existing neurological disorders.", [["neurological", "ANATOMY", 142, 154], ["COVID-19", "CHEMICAL", 80, 88], ["infection", "DISEASE", 89, 98], ["neurological disorders", "DISEASE", 142, 164], ["inpatients", "ORGANISM", 102, 112], ["COVID-19 infection", "PROBLEM", 80, 98], ["pre-existing neurological disorders", "PROBLEM", 129, 164], ["infection", "OBSERVATION", 89, 98]]], ["We document 33 patients who had neurological symptoms while hospitalized with COVID-19 infection and summarize the associated laboratory and ancillary data performed.", [["neurological", "ANATOMY", 32, 44], ["neurological symptoms", "DISEASE", 32, 53], ["infection", "DISEASE", 87, 96], ["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["neurological symptoms", "PROBLEM", 32, 53], ["COVID-19 infection", "PROBLEM", 78, 96], ["ancillary data", "TEST", 141, 155], ["infection", "OBSERVATION", 87, 96]]], ["We discuss unique cases that raise questions about the nuances of management in a neurological population.Patients ::: MethodsAdult inpatients diagnosed with COVID-19 infection by nasopharyngeal swab reverse transcription polymerase chain reaction (RT-PCR) and required neurological evaluation by consultation or admission for primary neurological care were included in this single-center retrospective case-series study at Columbia University Irving Medical Center (CUIMC)-New York Presbyterian Hospital.", [["neurological", "ANATOMY", 82, 94], ["neurological", "ANATOMY", 270, 282], ["neurological", "ANATOMY", 335, 347], ["infection", "DISEASE", 167, 176], ["Patients", "ORGANISM", 106, 114], ["inpatients", "ORGANISM", 132, 142], ["Patients", "SPECIES", 106, 114], ["management", "TREATMENT", 66, 76], ["a neurological population", "PROBLEM", 80, 105], ["COVID-19 infection", "PROBLEM", 158, 176], ["nasopharyngeal swab reverse transcription polymerase chain reaction", "PROBLEM", 180, 247], ["RT-PCR", "TEST", 249, 255], ["neurological evaluation", "TEST", 270, 293], ["infection", "OBSERVATION", 167, 176], ["nasopharyngeal", "ANATOMY", 180, 194]]], ["Clinical information was gathered by patient chart review, including demographics, medical history, clinical presentation, clinical course, radiographic imaging, laboratory values, hospital duration, therapeutic agents, and outcome.", [["patient", "ORGANISM", 37, 44], ["patient", "SPECIES", 37, 44], ["radiographic imaging", "TEST", 140, 160], ["laboratory values", "TEST", 162, 179], ["therapeutic agents", "TREATMENT", 200, 218]]], ["Pulmonary disease includes pre-existing obstructive lung disease, restrictive lung disease, and/or chronic tobacco use.", [["Pulmonary", "ANATOMY", 0, 9], ["lung", "ANATOMY", 52, 56], ["lung", "ANATOMY", 78, 82], ["Pulmonary disease", "DISEASE", 0, 17], ["obstructive lung disease", "DISEASE", 40, 64], ["restrictive lung disease", "DISEASE", 66, 90], ["Pulmonary", "ORGAN", 0, 9], ["lung", "ORGAN", 52, 56], ["lung", "ORGAN", 78, 82], ["tobacco", "ORGANISM", 107, 114], ["tobacco", "SPECIES", 107, 114], ["Pulmonary disease", "PROBLEM", 0, 17], ["pre-existing obstructive lung disease", "PROBLEM", 27, 64], ["restrictive lung disease", "PROBLEM", 66, 90], ["disease", "OBSERVATION", 10, 17], ["obstructive", "OBSERVATION_MODIFIER", 40, 51], ["lung", "ANATOMY", 52, 56], ["disease", "OBSERVATION", 57, 64], ["restrictive", "OBSERVATION_MODIFIER", 66, 77], ["lung", "ANATOMY", 78, 82], ["disease", "OBSERVATION", 83, 90], ["chronic", "OBSERVATION_MODIFIER", 99, 106], ["tobacco use", "OBSERVATION", 107, 118]]], ["Cardiovascular disease includes hyperlipidemia or hypercholesterolemia, hypertension, coronary artery disease (CAD), peripheral arterial disease, diabetes mellitus, and morbid obesity.", [["Cardiovascular", "ANATOMY", 0, 14], ["coronary artery", "ANATOMY", 86, 101], ["peripheral arterial", "ANATOMY", 117, 136], ["Cardiovascular disease", "DISEASE", 0, 22], ["hyperlipidemia", "DISEASE", 32, 46], ["hypercholesterolemia", "DISEASE", 50, 70], ["hypertension", "DISEASE", 72, 84], ["coronary artery disease", "DISEASE", 86, 109], ["CAD", "DISEASE", 111, 114], ["peripheral arterial disease", "DISEASE", 117, 144], ["diabetes mellitus", "DISEASE", 146, 163], ["morbid obesity", "DISEASE", 169, 183], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 86, 101], ["peripheral arterial", "MULTI-TISSUE_STRUCTURE", 117, 136], ["Cardiovascular disease", "PROBLEM", 0, 22], ["hyperlipidemia", "PROBLEM", 32, 46], ["hypercholesterolemia", "PROBLEM", 50, 70], ["hypertension", "PROBLEM", 72, 84], ["coronary artery disease", "PROBLEM", 86, 109], ["CAD", "PROBLEM", 111, 114], ["peripheral arterial disease", "PROBLEM", 117, 144], ["diabetes mellitus", "PROBLEM", 146, 163], ["morbid obesity", "PROBLEM", 169, 183], ["disease", "OBSERVATION", 15, 22], ["hyperlipidemia", "OBSERVATION", 32, 46], ["hypercholesterolemia", "OBSERVATION", 50, 70], ["hypertension", "OBSERVATION", 72, 84], ["coronary artery", "ANATOMY", 86, 101], ["disease", "OBSERVATION", 102, 109], ["peripheral", "ANATOMY_MODIFIER", 117, 127], ["arterial", "ANATOMY", 128, 136], ["disease", "OBSERVATION", 137, 144], ["diabetes mellitus", "OBSERVATION", 146, 163], ["morbid", "OBSERVATION_MODIFIER", 169, 175], ["obesity", "OBSERVATION", 176, 183]]], ["Renal disease is defined as pre-existing chronic kidney disease or end-stage renal disease requiring dialysis.", [["Renal", "ANATOMY", 0, 5], ["kidney", "ANATOMY", 49, 55], ["renal", "ANATOMY", 77, 82], ["Renal disease", "DISEASE", 0, 13], ["chronic kidney disease", "DISEASE", 41, 63], ["end-stage renal disease", "DISEASE", 67, 90], ["Renal", "ORGAN", 0, 5], ["kidney", "ORGAN", 49, 55], ["renal", "ORGAN", 77, 82], ["Renal disease", "PROBLEM", 0, 13], ["pre-existing chronic kidney disease", "PROBLEM", 28, 63], ["end-stage renal disease", "PROBLEM", 67, 90], ["dialysis", "TREATMENT", 101, 109], ["disease", "OBSERVATION", 6, 13], ["chronic", "OBSERVATION_MODIFIER", 41, 48], ["kidney", "ANATOMY", 49, 55], ["disease", "OBSERVATION", 56, 63], ["end", "OBSERVATION_MODIFIER", 67, 70], ["-stage", "OBSERVATION_MODIFIER", 70, 76], ["renal", "ANATOMY", 77, 82], ["disease", "OBSERVATION", 83, 90], ["dialysis", "OBSERVATION", 101, 109]]], ["Immune suppression is defined as autoimmune disorder on immunosuppressive therapy, immunodeficiency from HIV/AIDS, or history of cancer on chemotherapy.", [["cancer", "ANATOMY", 129, 135], ["Immune suppression", "DISEASE", 0, 18], ["autoimmune disorder", "DISEASE", 33, 52], ["immunodeficiency", "DISEASE", 83, 99], ["HIV/AIDS", "DISEASE", 105, 113], ["cancer", "DISEASE", 129, 135], ["cancer", "CANCER", 129, 135], ["HIV", "SPECIES", 105, 108], ["HIV", "SPECIES", 105, 108], ["Immune suppression", "PROBLEM", 0, 18], ["autoimmune disorder", "PROBLEM", 33, 52], ["immunosuppressive therapy", "TREATMENT", 56, 81], ["immunodeficiency", "PROBLEM", 83, 99], ["HIV", "PROBLEM", 105, 108], ["AIDS", "PROBLEM", 109, 113], ["cancer", "PROBLEM", 129, 135], ["chemotherapy", "TREATMENT", 139, 151], ["cancer", "OBSERVATION", 129, 135]]], ["Encephalopathy is defined as depressed consciousness, fluctuations in consciousness, or impaired consciousness leading to language comprehension deficits excluding aphasia.Standard Protocol Approvals and Patient Consents ::: MethodsThis study was approved by the Institutional Review Board (IRB) of CUIMC.", [["Encephalopathy", "DISEASE", 0, 14], ["depressed consciousness", "DISEASE", 29, 52], ["impaired consciousness", "DISEASE", 88, 110], ["language comprehension deficits", "DISEASE", 122, 153], ["aphasia", "DISEASE", 164, 171], ["Encephalopathy", "PROBLEM", 0, 14], ["depressed consciousness", "PROBLEM", 29, 52], ["fluctuations in consciousness", "PROBLEM", 54, 83], ["impaired consciousness", "PROBLEM", 88, 110], ["language comprehension deficits", "PROBLEM", 122, 153], ["aphasia", "PROBLEM", 164, 171], ["Methods", "TREATMENT", 225, 232], ["This study", "TEST", 232, 242]]], ["Informed consent was not required by our institutional IRB for the remainder of the participants.Statistical Analysis ::: MethodsStatistical associations were calculated using mean, median, range, and standard deviation.", [["participants", "SPECIES", 84, 96], ["mean", "TEST", 176, 180]]], ["All statistical analyses were carried out using SAS (version 9.4, trademarks of SAS Institute Inc., Cary, NC, USA).Patients ::: ResultsThirty-three patients were included in this study of which 1 was near adult age (17 years).", [["Patients", "ORGANISM", 115, 123], ["patients", "ORGANISM", 148, 156], ["Patients", "SPECIES", 115, 123], ["patients", "SPECIES", 148, 156], ["All statistical analyses", "TEST", 0, 24], ["SAS (version", "TEST", 48, 60], ["this study", "TEST", 174, 184]]], ["The mean age of patients was 56.1 (\u00b117.1) years (Table 1).", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24]]], ["Twenty-two patients (66.7%) had a known neurological condition, including epilepsy (n = 6), ischemic stroke (n = 5), dementia (n = 5), developmental delay (n = 4), myasthenia gravis (n = 2), and multiple sclerosis or other central autoimmune disease (n = 2).", [["neurological", "ANATOMY", 40, 52], ["neurological condition", "DISEASE", 40, 62], ["epilepsy", "DISEASE", 74, 82], ["ischemic stroke", "DISEASE", 92, 107], ["dementia", "DISEASE", 117, 125], ["developmental delay", "DISEASE", 135, 154], ["myasthenia gravis", "DISEASE", 164, 181], ["multiple sclerosis", "DISEASE", 195, 213], ["autoimmune disease", "DISEASE", 231, 249], ["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["a known neurological condition", "PROBLEM", 32, 62], ["epilepsy", "PROBLEM", 74, 82], ["ischemic stroke", "PROBLEM", 92, 107], ["dementia", "PROBLEM", 117, 125], ["developmental delay (n = 4)", "PROBLEM", 135, 162], ["myasthenia gravis (n", "PROBLEM", 164, 184], ["multiple sclerosis", "PROBLEM", 195, 213], ["other central autoimmune disease", "PROBLEM", 217, 249], ["neurological condition", "OBSERVATION", 40, 62], ["epilepsy", "OBSERVATION", 74, 82], ["ischemic", "OBSERVATION_MODIFIER", 92, 100], ["stroke", "OBSERVATION", 101, 107], ["dementia", "OBSERVATION", 117, 125], ["myasthenia gravis", "OBSERVATION", 164, 181], ["multiple", "OBSERVATION_MODIFIER", 195, 203], ["sclerosis", "OBSERVATION", 204, 213], ["central", "ANATOMY_MODIFIER", 223, 230], ["autoimmune disease", "OBSERVATION", 231, 249]]], ["Seventeen (51.5%) had cardiovascular comorbidities, 5 (15.2%) pulmonary disease, and 7 (21.2%) renal disease (Table 1).", [["cardiovascular", "ANATOMY", 22, 36], ["pulmonary", "ANATOMY", 62, 71], ["renal", "ANATOMY", 95, 100], ["cardiovascular comorbidities", "DISEASE", 22, 50], ["pulmonary disease", "DISEASE", 62, 79], ["renal disease", "DISEASE", 95, 108], ["pulmonary", "ORGAN", 62, 71], ["renal", "ORGAN", 95, 100], ["cardiovascular comorbidities", "PROBLEM", 22, 50], ["pulmonary disease", "PROBLEM", 62, 79], ["7 (21.2%) renal disease", "PROBLEM", 85, 108], ["pulmonary", "ANATOMY", 62, 71], ["disease", "OBSERVATION", 72, 79], ["renal", "ANATOMY", 95, 100], ["disease", "OBSERVATION", 101, 108]]], ["Ten (30.3%) were immunocompromised due to transplant (n = 2), cancer with or without chemotherapy (n = 7), and autoimmune disorder on immunosuppression (n = 1) (Table 1).", [["cancer", "ANATOMY", 62, 68], ["cancer", "DISEASE", 62, 68], ["autoimmune disorder", "DISEASE", 111, 130], ["immunosuppression", "DISEASE", 134, 151], ["cancer", "CANCER", 62, 68], ["immunocompromised", "PROBLEM", 17, 34], ["transplant", "TREATMENT", 42, 52], ["cancer", "PROBLEM", 62, 68], ["chemotherapy", "TREATMENT", 85, 97], ["autoimmune disorder", "PROBLEM", 111, 130], ["immunosuppression", "TREATMENT", 134, 151], ["cancer", "OBSERVATION", 62, 68], ["autoimmune disorder", "OBSERVATION", 111, 130]]], ["These cases represented 3.9% of inpatients who had tested positive for SARS-CoV-2 during the 2-week time course.Clinical Presentation ::: ResultsThe most frequent reason for neurology consultation was encephalopathy (n = 12, 36.4%).", [["SARS", "DISEASE", 71, 75], ["encephalopathy", "DISEASE", 201, 215], ["inpatients", "ORGANISM", 32, 42], ["SARS-CoV", "SPECIES", 71, 79], ["SARS", "PROBLEM", 71, 75], ["CoV", "TEST", 76, 79], ["neurology consultation", "TEST", 174, 196], ["encephalopathy", "PROBLEM", 201, 215]]], ["Encephalopathy was attributed to toxic/metabolic derangements, systemic infection, or concern for cytokine storm.", [["Encephalopathy", "DISEASE", 0, 14], ["systemic infection", "DISEASE", 63, 81], ["cytokine", "PROTEIN", 98, 106], ["Encephalopathy", "PROBLEM", 0, 14], ["toxic/metabolic derangements", "PROBLEM", 33, 61], ["systemic infection", "PROBLEM", 63, 81], ["cytokine storm", "PROBLEM", 98, 112], ["attributed to", "UNCERTAINTY", 19, 32], ["toxic", "OBSERVATION_MODIFIER", 33, 38], ["metabolic derangements", "OBSERVATION", 39, 61], ["systemic", "OBSERVATION_MODIFIER", 63, 71], ["infection", "OBSERVATION", 72, 81], ["concern for", "UNCERTAINTY", 86, 97], ["cytokine storm", "OBSERVATION", 98, 112]]], ["Continuous EEG (cEEG) was obtained for 7 (21.2%) patients to rule out seizure as cause of the encephalopathy.", [["seizure", "DISEASE", 70, 77], ["encephalopathy", "DISEASE", 94, 108], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["Continuous EEG", "TEST", 0, 14], ["cEEG", "TEST", 16, 20], ["seizure", "PROBLEM", 70, 77], ["the encephalopathy", "PROBLEM", 90, 108], ["encephalopathy", "OBSERVATION", 94, 108]]], ["Continuous EEG monitoring showed triphasic waveforms in one patient with hepatic encephalopathy (case 18) and one patient with acute renal failure due to septic shock (case 16).Clinical Presentation ::: ResultsThe second most frequent reason for neurology consultation was seizure (n = 9, 27.2%), of which 6 (66.7%) patients had first seizure of life (Table 2).", [["hepatic", "ANATOMY", 73, 80], ["renal", "ANATOMY", 133, 138], ["hepatic encephalopathy", "DISEASE", 73, 95], ["acute renal failure", "DISEASE", 127, 146], ["septic shock", "DISEASE", 154, 166], ["seizure", "DISEASE", 273, 280], ["seizure", "DISEASE", 335, 342], ["patient", "ORGANISM", 60, 67], ["hepatic", "ORGAN", 73, 80], ["patient", "ORGANISM", 114, 121], ["renal", "ORGAN", 133, 138], ["patients", "ORGANISM", 316, 324], ["patient", "SPECIES", 60, 67], ["patient", "SPECIES", 114, 121], ["patients", "SPECIES", 316, 324], ["Continuous EEG monitoring", "TEST", 0, 25], ["triphasic waveforms", "TEST", 33, 52], ["hepatic encephalopathy", "PROBLEM", 73, 95], ["acute renal failure", "PROBLEM", 127, 146], ["septic shock", "PROBLEM", 154, 166], ["neurology consultation", "TEST", 246, 268], ["seizure", "PROBLEM", 273, 280], ["waveforms", "OBSERVATION_MODIFIER", 43, 52], ["hepatic", "ANATOMY", 73, 80], ["encephalopathy", "OBSERVATION", 81, 95], ["acute", "OBSERVATION_MODIFIER", 127, 132], ["renal", "ANATOMY", 133, 138], ["failure", "OBSERVATION", 139, 146], ["septic shock", "OBSERVATION", 154, 166]]], ["Three patients with first seizure of life had cEEG monitoring which showed frontotemporal seizures, parasagittal seizures, and marked attenuation (cases 12, 13, and 21, respectively).", [["parasagittal", "ANATOMY", 100, 112], ["seizure", "DISEASE", 26, 33], ["frontotemporal seizures", "DISEASE", 75, 98], ["seizures", "DISEASE", 113, 121], ["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["first seizure of life", "PROBLEM", 20, 41], ["cEEG monitoring", "TEST", 46, 61], ["frontotemporal seizures", "PROBLEM", 75, 98], ["parasagittal seizures", "PROBLEM", 100, 121], ["marked attenuation (cases", "PROBLEM", 127, 152], ["frontotemporal", "OBSERVATION_MODIFIER", 75, 89], ["seizures", "OBSERVATION", 90, 98], ["parasagittal", "OBSERVATION_MODIFIER", 100, 112], ["seizures", "OBSERVATION", 113, 121], ["marked", "OBSERVATION_MODIFIER", 127, 133], ["attenuation", "OBSERVATION_MODIFIER", 134, 145]]], ["Only one patient with first seizure of life had a history of neurological disease, which was possible anoxic brain injury from ventricular fibrillation arrest (case 21).", [["neurological", "ANATOMY", 61, 73], ["brain", "ANATOMY", 109, 114], ["ventricular", "ANATOMY", 127, 138], ["seizure", "DISEASE", 28, 35], ["neurological disease", "DISEASE", 61, 81], ["brain injury", "DISEASE", 109, 121], ["ventricular fibrillation", "DISEASE", 127, 151], ["arrest", "DISEASE", 152, 158], ["patient", "ORGANISM", 9, 16], ["brain", "ORGAN", 109, 114], ["patient", "SPECIES", 9, 16], ["neurological disease", "PROBLEM", 61, 81], ["anoxic brain injury", "PROBLEM", 102, 121], ["ventricular fibrillation arrest", "PROBLEM", 127, 158], ["neurological disease", "OBSERVATION", 61, 81], ["possible", "UNCERTAINTY", 93, 101], ["anoxic brain injury", "OBSERVATION", 102, 121], ["ventricular", "ANATOMY", 127, 138], ["fibrillation", "OBSERVATION", 139, 151]]], ["Five (83.3%) patients with first seizure of life had inflammatory marker data.", [["seizure", "DISEASE", 33, 40], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["first seizure of life", "PROBLEM", 27, 48], ["inflammatory marker data", "PROBLEM", 53, 77]]], ["All had elevated C-RP >100 milligram per liter (mg/L), four (80%) ferritin >1,000 nanogram per milliliter (ng/mL), and four (80%) IL-6 >30 picogram per mL (pg/mL) (Figure 1).", [["ferritin", "GENE_OR_GENE_PRODUCT", 66, 74], ["IL-6", "GENE_OR_GENE_PRODUCT", 130, 134], ["ferritin", "PROTEIN", 66, 74], ["IL", "PROTEIN", 130, 132], ["elevated C-RP", "PROBLEM", 8, 21], ["ferritin", "TEST", 66, 74]]], ["Two patients with focal seizures had no evidence of structural lesion on CT head.", [["lesion", "ANATOMY", 63, 69], ["head", "ANATOMY", 76, 80], ["seizures", "DISEASE", 24, 32], ["patients", "ORGANISM", 4, 12], ["head", "ORGANISM_SUBDIVISION", 76, 80], ["patients", "SPECIES", 4, 12], ["focal seizures", "PROBLEM", 18, 32], ["structural lesion", "PROBLEM", 52, 69], ["CT head", "TEST", 73, 80], ["focal", "OBSERVATION_MODIFIER", 18, 23], ["seizures", "OBSERVATION", 24, 32], ["no evidence of", "UNCERTAINTY", 37, 51], ["structural", "OBSERVATION_MODIFIER", 52, 62], ["lesion", "OBSERVATION", 63, 69], ["head", "ANATOMY", 76, 80]]], ["MRI brain with and without contrast was normal for the pediatric first seizure of life patient (case 1).", [["brain", "ANATOMY", 4, 9], ["seizure", "DISEASE", 71, 78], ["brain", "ORGAN", 4, 9], ["patient", "ORGANISM", 87, 94], ["patient", "SPECIES", 87, 94], ["MRI brain", "TEST", 0, 9]]], ["All patients with first seizure of life were treated with levetiracetam except for the pediatric patient who was discharged home on no antiepileptic medications.Clinical Presentation ::: ResultsFive (15.2%) patients presented with acute cerebrovascular insults due to ischemia (n = 3; ages 45, 57, and 67 years), intracerebral hemorrhage (ICH)/intraventricular hemorrhage (IVH)/subarachnoid hemorrhage (SAH) (n = 1), and subdural hematoma (SDH) (n = 1) (Table 2).", [["antiepileptic", "ANATOMY", 135, 148], ["cerebrovascular", "ANATOMY", 237, 252], ["intracerebral", "ANATOMY", 313, 326], ["intraventricular", "ANATOMY", 344, 360], ["subarachnoid", "ANATOMY", 378, 390], ["subdural", "ANATOMY", 421, 429], ["seizure", "DISEASE", 24, 31], ["levetiracetam", "CHEMICAL", 58, 71], ["cerebrovascular insults", "DISEASE", 237, 260], ["ischemia", "DISEASE", 268, 276], ["intracerebral hemorrhage", "DISEASE", 313, 337], ["ICH", "DISEASE", 339, 342], ["intraventricular hemorrhage", "DISEASE", 344, 371], ["IVH", "DISEASE", 373, 376], ["subarachnoid hemorrhage", "DISEASE", 378, 401], ["SAH", "DISEASE", 403, 406], ["subdural hematoma", "DISEASE", 421, 438], ["SDH", "DISEASE", 440, 443], ["levetiracetam", "CHEMICAL", 58, 71], ["patients", "ORGANISM", 4, 12], ["levetiracetam", "SIMPLE_CHEMICAL", 58, 71], ["patient", "ORGANISM", 97, 104], ["patients", "ORGANISM", 207, 215], ["subdural hematoma", "PATHOLOGICAL_FORMATION", 421, 438], ["patients", "SPECIES", 4, 12], ["patient", "SPECIES", 97, 104], ["patients", "SPECIES", 207, 215], ["levetiracetam", "TREATMENT", 58, 71], ["antiepileptic medications", "TREATMENT", 135, 160], ["acute cerebrovascular insults", "PROBLEM", 231, 260], ["ischemia", "PROBLEM", 268, 276], ["intracerebral hemorrhage (ICH)/intraventricular hemorrhage", "PROBLEM", 313, 371], ["IVH)/subarachnoid hemorrhage", "PROBLEM", 373, 401], ["SAH) (n = 1), and subdural hematoma (SDH)", "PROBLEM", 403, 444], ["acute", "OBSERVATION_MODIFIER", 231, 236], ["cerebrovascular insults", "OBSERVATION", 237, 260], ["ischemia", "OBSERVATION", 268, 276], ["intracerebral", "ANATOMY", 313, 326], ["hemorrhage", "OBSERVATION", 327, 337], ["ICH", "OBSERVATION", 339, 342], ["intraventricular", "ANATOMY", 344, 360], ["hemorrhage", "OBSERVATION", 361, 371], ["IVH", "OBSERVATION", 373, 376], ["subarachnoid", "ANATOMY", 378, 390], ["hemorrhage", "OBSERVATION", 391, 401], ["SAH", "OBSERVATION", 403, 406], ["subdural", "ANATOMY", 421, 429], ["hematoma", "OBSERVATION", 430, 438]]], ["All patients with ischemic strokes had cardiovascular risk factors (cases 8, 15, and 22).", [["cardiovascular", "ANATOMY", 39, 53], ["ischemic strokes", "DISEASE", 18, 34], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["ischemic strokes", "PROBLEM", 18, 34], ["cardiovascular risk factors", "PROBLEM", 39, 66], ["ischemic", "OBSERVATION_MODIFIER", 18, 26], ["strokes", "OBSERVATION", 27, 34]]], ["One patient had sickle cell trait (case 8).Clinical Presentation ::: ResultsRecrudescence of a prior neurological condition occurred in 4 (12.1%) patients.", [["sickle cell", "ANATOMY", 16, 27], ["neurological", "ANATOMY", 101, 113], ["sickle cell trait", "DISEASE", 16, 33], ["neurological condition", "DISEASE", 101, 123], ["patient", "ORGANISM", 4, 11], ["sickle cell", "CELL", 16, 27], ["patients", "ORGANISM", 146, 154], ["patient", "SPECIES", 4, 11], ["patients", "SPECIES", 146, 154], ["sickle cell trait", "PROBLEM", 16, 33], ["a prior neurological condition", "PROBLEM", 93, 123], ["sickle cell trait", "OBSERVATION", 16, 33]]], ["Recrudescence was diagnosed if a patient had a prior neurological deficit that worsened in the setting of infection but improved back to baseline after symptomatic treatment of underlying infection.Laboratory and Radiographic Data ::: ResultsOf the inflammatory marker levels obtained, ferritin was elevated in 75% (n = 21/28) of patients, IL-6 in 57% (n = 12/21), d-dimer in 65% (n = 15/23), and C-RP in 90% (n = 26/29) (Figure 2).Laboratory and Radiographic Data ::: ResultsBrain imaging was obtained for 20 (60%) patients, including 3 (7.6%) patients who underwent MRI.", [["neurological", "ANATOMY", 53, 65], ["Brain", "ANATOMY", 476, 481], ["Recrudescence", "DISEASE", 0, 13], ["neurological deficit", "DISEASE", 53, 73], ["infection", "DISEASE", 106, 115], ["infection", "DISEASE", 188, 197], ["patient", "ORGANISM", 33, 40], ["ferritin", "GENE_OR_GENE_PRODUCT", 286, 294], ["patients", "ORGANISM", 330, 338], ["IL-6", "GENE_OR_GENE_PRODUCT", 340, 344], ["d-dimer", "SIMPLE_CHEMICAL", 365, 372], ["patients", "ORGANISM", 516, 524], ["patients", "ORGANISM", 545, 553], ["ferritin", "PROTEIN", 286, 294], ["patient", "SPECIES", 33, 40], ["patients", "SPECIES", 330, 338], ["patients", "SPECIES", 516, 524], ["patients", "SPECIES", 545, 553], ["a prior neurological deficit", "PROBLEM", 45, 73], ["infection", "PROBLEM", 106, 115], ["symptomatic treatment", "TREATMENT", 152, 173], ["underlying infection", "PROBLEM", 177, 197], ["the inflammatory marker levels", "TEST", 245, 275], ["ferritin", "TEST", 286, 294], ["elevated", "PROBLEM", 299, 307], ["IL", "TEST", 340, 342], ["d-dimer", "TEST", 365, 372], ["C", "TEST", 397, 398], ["RP", "TEST", 399, 401], ["Brain imaging", "TEST", 476, 489], ["MRI", "TEST", 568, 571], ["worsened", "OBSERVATION_MODIFIER", 79, 87], ["infection", "OBSERVATION", 106, 115], ["infection", "OBSERVATION", 188, 197], ["inflammatory", "OBSERVATION_MODIFIER", 249, 261]]], ["Relevant findings included acute SDH, ICH/IVH/SAH, acute ischemic strokes (n = 2), and meningioma with vasogenic edema (n = 1).", [["meningioma", "ANATOMY", 87, 97], ["vasogenic edema", "ANATOMY", 103, 118], ["ICH", "DISEASE", 38, 41], ["IVH", "DISEASE", 42, 45], ["SAH", "DISEASE", 46, 49], ["acute ischemic strokes", "DISEASE", 51, 73], ["meningioma", "DISEASE", 87, 97], ["vasogenic edema", "DISEASE", 103, 118], ["meningioma", "CANCER", 87, 97], ["vasogenic edema", "PATHOLOGICAL_FORMATION", 103, 118], ["acute SDH", "PROBLEM", 27, 36], ["ICH", "PROBLEM", 38, 41], ["IVH", "PROBLEM", 42, 45], ["SAH", "PROBLEM", 46, 49], ["acute ischemic strokes", "PROBLEM", 51, 73], ["meningioma", "PROBLEM", 87, 97], ["vasogenic edema", "PROBLEM", 103, 118], ["acute", "OBSERVATION_MODIFIER", 27, 32], ["SDH", "OBSERVATION", 33, 36], ["ICH", "OBSERVATION", 38, 41], ["IVH", "OBSERVATION", 42, 45], ["SAH", "OBSERVATION", 46, 49], ["acute", "OBSERVATION_MODIFIER", 51, 56], ["ischemic", "OBSERVATION_MODIFIER", 57, 65], ["strokes", "OBSERVATION", 66, 73], ["meningioma", "OBSERVATION", 87, 97], ["vasogenic", "OBSERVATION_MODIFIER", 103, 112], ["edema", "OBSERVATION", 113, 118]]], ["The remainder showed chronic changes or were unremarkable.", [["chronic changes", "PROBLEM", 21, 36], ["chronic", "OBSERVATION_MODIFIER", 21, 28], ["unremarkable", "OBSERVATION", 45, 57]]], ["Of note, one patient who had several months of hyposmia and facial numbness presented with worsening of the symptoms.", [["facial", "ANATOMY", 60, 66], ["hyposmia", "DISEASE", 47, 55], ["facial numbness", "DISEASE", 60, 75], ["patient", "ORGANISM", 13, 20], ["patient", "SPECIES", 13, 20], ["hyposmia", "PROBLEM", 47, 55], ["facial numbness", "PROBLEM", 60, 75], ["the symptoms", "PROBLEM", 104, 116], ["hyposmia", "OBSERVATION", 47, 55], ["facial", "ANATOMY", 60, 66], ["numbness", "OBSERVATION", 67, 75], ["worsening", "OBSERVATION_MODIFIER", 91, 100]]], ["MRI brain with and without contrast was unremarkable with no abnormal contrast enhancement (case 14).Laboratory and Radiographic Data ::: ResultsIn an attempt to reduce exposure and preserve personal protective equipment (PPE), CSF testing was only pursued if there was another indication.", [["brain", "ANATOMY", 4, 9], ["brain", "ORGAN", 4, 9], ["MRI brain", "TEST", 0, 9], ["abnormal contrast enhancement", "PROBLEM", 61, 90], ["CSF testing", "TEST", 228, 239], ["unremarkable", "OBSERVATION", 40, 52], ["no", "UNCERTAINTY", 58, 60], ["abnormal", "OBSERVATION_MODIFIER", 61, 69], ["contrast enhancement", "OBSERVATION_MODIFIER", 70, 90]]], ["As a result, CSF was only obtained in one case highlighted below for autoimmune encephalitis.Patient Outcomes ::: ResultsTwenty-one (63.6%) patients were discharged from the hospital and 12 (36.4%) died.", [["autoimmune encephalitis", "DISEASE", 69, 92], ["CSF", "GENE_OR_GENE_PRODUCT", 13, 16], ["patients", "ORGANISM", 140, 148], ["CSF", "PROTEIN", 13, 16], ["Patient", "SPECIES", 93, 100], ["patients", "SPECIES", 140, 148], ["CSF", "TEST", 13, 16], ["autoimmune encephalitis", "PROBLEM", 69, 92], ["ResultsTwenty", "TEST", 114, 127], ["autoimmune encephalitis", "OBSERVATION", 69, 92]]], ["One 70-year-old male known epilepsy and intellectual disability from childhood meningitis presented with breakthrough seizures and died due to presumed cytokine storm and multiorgan failure.", [["multiorgan", "ANATOMY", 171, 181], ["epilepsy", "DISEASE", 27, 35], ["intellectual disability", "DISEASE", 40, 63], ["meningitis", "DISEASE", 79, 89], ["seizures", "DISEASE", 118, 126], ["multiorgan failure", "DISEASE", 171, 189], ["cytokine", "PROTEIN", 152, 160], ["epilepsy", "PROBLEM", 27, 35], ["intellectual disability", "PROBLEM", 40, 63], ["childhood meningitis", "PROBLEM", 69, 89], ["breakthrough seizures", "PROBLEM", 105, 126], ["cytokine storm", "PROBLEM", 152, 166], ["multiorgan failure", "PROBLEM", 171, 189], ["epilepsy", "OBSERVATION", 27, 35], ["meningitis", "OBSERVATION", 79, 89], ["cytokine storm", "OBSERVATION", 152, 166], ["multiorgan failure", "OBSERVATION", 171, 189]]], ["One patient with relapsing-remitting multiple sclerosis on natalizumab who presented with worsening bilateral leg weakness died due to severe ARDS and shock.Case 29 ::: ResultsA 74-year-old woman with a history of remote breast and pancreatic cancers, recent varicella zoster virus (VZV) radiculitis, and possible antibody negative autoimmune encephalitis was transferred to our institution for worsening mental status manifested as stupor and global aphasia.", [["leg", "ANATOMY", 110, 113], ["breast", "ANATOMY", 221, 227], ["pancreatic cancers", "ANATOMY", 232, 250], ["multiple sclerosis", "DISEASE", 37, 55], ["natalizumab", "CHEMICAL", 59, 70], ["leg weakness", "DISEASE", 110, 122], ["ARDS", "DISEASE", 142, 146], ["shock", "DISEASE", 151, 156], ["breast and pancreatic cancers", "DISEASE", 221, 250], ["varicella zoster virus (VZV) radiculitis", "DISEASE", 259, 299], ["autoimmune encephalitis", "DISEASE", 332, 355], ["stupor", "DISEASE", 433, 439], ["aphasia", "DISEASE", 451, 458], ["patient", "ORGANISM", 4, 11], ["leg", "ORGANISM_SUBDIVISION", 110, 113], ["woman", "ORGANISM", 190, 195], ["breast", "CANCER", 221, 227], ["pancreatic cancers", "CANCER", 232, 250], ["varicella zoster virus", "ORGANISM", 259, 281], ["VZV", "ORGANISM", 283, 286], ["patient", "SPECIES", 4, 11], ["woman", "SPECIES", 190, 195], ["varicella zoster virus", "SPECIES", 259, 281], ["varicella zoster virus", "SPECIES", 259, 281], ["VZV", "SPECIES", 283, 286], ["relapsing-remitting multiple sclerosis", "PROBLEM", 17, 55], ["natalizumab", "TREATMENT", 59, 70], ["worsening bilateral leg weakness", "PROBLEM", 90, 122], ["severe ARDS", "PROBLEM", 135, 146], ["shock", "PROBLEM", 151, 156], ["remote breast and pancreatic cancers", "PROBLEM", 214, 250], ["recent varicella zoster virus", "PROBLEM", 252, 281], ["VZV) radiculitis", "PROBLEM", 283, 299], ["antibody negative autoimmune encephalitis", "PROBLEM", 314, 355], ["worsening mental status", "PROBLEM", 395, 418], ["stupor", "PROBLEM", 433, 439], ["global aphasia", "PROBLEM", 444, 458], ["relapsing", "OBSERVATION_MODIFIER", 17, 26], ["remitting", "OBSERVATION_MODIFIER", 27, 36], ["multiple", "OBSERVATION_MODIFIER", 37, 45], ["sclerosis", "OBSERVATION", 46, 55], ["worsening", "OBSERVATION_MODIFIER", 90, 99], ["bilateral", "ANATOMY_MODIFIER", 100, 109], ["leg", "ANATOMY", 110, 113], ["weakness", "OBSERVATION", 114, 122], ["severe", "OBSERVATION_MODIFIER", 135, 141], ["ARDS", "OBSERVATION", 142, 146], ["shock", "OBSERVATION", 151, 156], ["breast", "ANATOMY", 221, 227], ["pancreatic", "ANATOMY", 232, 242], ["cancers", "OBSERVATION", 243, 250], ["varicella zoster virus", "OBSERVATION", 259, 281], ["radiculitis", "OBSERVATION", 288, 299], ["possible", "UNCERTAINTY", 305, 313], ["antibody negative", "OBSERVATION", 314, 331], ["autoimmune encephalitis", "OBSERVATION", 332, 355], ["global", "OBSERVATION_MODIFIER", 444, 450], ["aphasia", "OBSERVATION", 451, 458]]], ["CSF studies were notable for a white blood cell count 12 per microliter (\u03bcL) (99% lymphocytes), red blood cell count 32/\u03bcL, glucose 59 mg per decaliter (mg/dL), protein 38 mg/dL, negative meningitis/encephalitis panel (BioFire Diagnostics, Salt Lake City, UT) that includes VZV, and negative paraneoplastic panel (Mayo Clinic Laboratories).", [["white blood cell", "ANATOMY", 31, 47], ["lymphocytes", "ANATOMY", 82, 93], ["red blood cell", "ANATOMY", 96, 110], ["glucose", "CHEMICAL", 124, 131], ["meningitis", "DISEASE", 188, 198], ["encephalitis", "DISEASE", 199, 211], ["paraneoplastic", "DISEASE", 292, 306], ["glucose", "CHEMICAL", 124, 131], ["CSF", "GENE_OR_GENE_PRODUCT", 0, 3], ["blood cell", "CELL", 37, 47], ["lymphocytes", "CELL", 82, 93], ["red blood cell", "CELL", 96, 110], ["glucose", "SIMPLE_CHEMICAL", 124, 131], ["VZV", "ORGANISM", 274, 277], ["lymphocytes", "CELL_TYPE", 82, 93], ["VZV", "SPECIES", 274, 277], ["CSF studies", "TEST", 0, 11], ["a white blood cell count", "TEST", 29, 53], ["microliter", "TEST", 61, 71], ["lymphocytes", "TEST", 82, 93], ["red blood cell count", "TEST", 96, 116], ["\u03bcL", "TEST", 120, 122], ["glucose", "TEST", 124, 131], ["decaliter", "TEST", 142, 151], ["protein", "TEST", 161, 168], ["meningitis", "PROBLEM", 188, 198], ["encephalitis panel", "TEST", 199, 217], ["VZV", "PROBLEM", 274, 277], ["meningitis", "OBSERVATION", 188, 198]]], ["MRI brain with and without contrast demonstrated stable periventricular and subcortical white matter T2 hyperintensities.", [["brain", "ANATOMY", 4, 9], ["periventricular", "ANATOMY", 56, 71], ["subcortical white matter", "ANATOMY", 76, 100], ["brain", "ORGAN", 4, 9], ["MRI brain", "TEST", 0, 9], ["stable periventricular and subcortical white matter T2 hyperintensities", "PROBLEM", 49, 120], ["stable", "OBSERVATION_MODIFIER", 49, 55], ["periventricular", "ANATOMY_MODIFIER", 56, 71], ["subcortical", "ANATOMY_MODIFIER", 76, 87], ["white matter", "ANATOMY", 88, 100], ["T2 hyperintensities", "OBSERVATION", 101, 120]]], ["Continuous EEG was negative for seizures.", [["seizures", "DISEASE", 32, 40], ["Continuous EEG", "TEST", 0, 14], ["seizures", "PROBLEM", 32, 40]]], ["She was treated with high dose IV steroids for 3 days and IV immunoglobulin (IVIG) for 5 days resulting in improvement of her mental status.", [["steroids", "CHEMICAL", 34, 42], ["steroids", "CHEMICAL", 34, 42], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 61, 75], ["IVIG", "SIMPLE_CHEMICAL", 77, 81], ["IV immunoglobulin", "PROTEIN", 58, 75], ["high dose IV steroids", "TREATMENT", 21, 42], ["IV immunoglobulin (IVIG)", "TREATMENT", 58, 82]]], ["However, 5 days after completing IVIG, she developed an increasing oxygen requirement, lethargy, and worsening aphasia.", [["oxygen", "CHEMICAL", 67, 73], ["lethargy", "DISEASE", 87, 95], ["aphasia", "DISEASE", 111, 118], ["oxygen", "CHEMICAL", 67, 73], ["oxygen", "SIMPLE_CHEMICAL", 67, 73], ["IVIG", "TREATMENT", 33, 37], ["an increasing oxygen requirement", "PROBLEM", 53, 85], ["lethargy", "PROBLEM", 87, 95], ["worsening aphasia", "PROBLEM", 101, 118], ["increasing", "OBSERVATION_MODIFIER", 56, 66], ["oxygen requirement", "OBSERVATION", 67, 85], ["worsening", "OBSERVATION_MODIFIER", 101, 110], ["aphasia", "OBSERVATION", 111, 118]]], ["Chest X-ray revealed multifocal pneumonia, and nasopharyngeal swab was positive for SARS-CoV-2 on hospital day 17.", [["nasopharyngeal swab", "ANATOMY", 47, 66], ["pneumonia", "DISEASE", 32, 41], ["SARS", "DISEASE", 84, 88], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 47, 66], ["SARS-CoV", "SPECIES", 84, 92], ["Chest X-ray", "TEST", 0, 11], ["multifocal pneumonia", "PROBLEM", 21, 41], ["nasopharyngeal swab", "TEST", 47, 66], ["SARS", "PROBLEM", 84, 88], ["CoV", "TEST", 89, 92], ["multifocal", "OBSERVATION_MODIFIER", 21, 31], ["pneumonia", "OBSERVATION", 32, 41], ["nasopharyngeal", "ANATOMY", 47, 61]]], ["Initial laboratory work-up was notable for new lymphopenia and elevated inflammatory markers.", [["lymphopenia", "DISEASE", 47, 58], ["inflammatory markers", "PROTEIN", 72, 92], ["Initial laboratory work", "TEST", 0, 23], ["new lymphopenia", "PROBLEM", 43, 58], ["elevated inflammatory markers", "PROBLEM", 63, 92], ["new", "OBSERVATION_MODIFIER", 43, 46], ["lymphopenia", "OBSERVATION", 47, 58], ["elevated", "OBSERVATION_MODIFIER", 63, 71], ["inflammatory markers", "OBSERVATION", 72, 92]]], ["Her mental status decline was attributed to COVID-19 infection and recrudescence of her autoimmune encephalitis, so repeat LP was deferred.", [["infection", "DISEASE", 53, 62], ["autoimmune encephalitis", "DISEASE", 88, 111], ["Her mental status decline", "PROBLEM", 0, 25], ["COVID-19 infection", "PROBLEM", 44, 62], ["her autoimmune encephalitis", "PROBLEM", 84, 111], ["repeat LP", "TEST", 116, 125], ["infection", "OBSERVATION", 53, 62], ["autoimmune encephalitis", "OBSERVATION", 88, 111]]], ["Azithromycin and hydroxychloroquine were started for SARS-Cov-2-directed experimental therapy.", [["Azithromycin", "CHEMICAL", 0, 12], ["hydroxychloroquine", "CHEMICAL", 17, 35], ["SARS", "DISEASE", 53, 57], ["Azithromycin", "CHEMICAL", 0, 12], ["hydroxychloroquine", "CHEMICAL", 17, 35], ["Azithromycin", "SIMPLE_CHEMICAL", 0, 12], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 17, 35], ["Azithromycin", "TREATMENT", 0, 12], ["hydroxychloroquine", "TREATMENT", 17, 35], ["SARS", "PROBLEM", 53, 57], ["Cov-2", "TREATMENT", 58, 63], ["experimental therapy", "TREATMENT", 73, 93]]], ["One day after initiation, she had significant improvement in her mental status and oxygenation.", [["significant", "OBSERVATION_MODIFIER", 34, 45], ["improvement", "OBSERVATION_MODIFIER", 46, 57]]], ["Nine days after symptom-onset, she returned to her neurological baseline.Case 15 ::: ResultsA 57-year-old man with history of hypertension, type 2 diabetes mellitus, and CAD was admitted with chest pain and found to have a myocardial infarction for which he underwent a 3-vessel coronary artery bypass grafting (CABG).", [["neurological", "ANATOMY", 51, 63], ["chest", "ANATOMY", 192, 197], ["myocardial", "ANATOMY", 223, 233], ["3-vessel coronary artery", "ANATOMY", 270, 294], ["hypertension", "DISEASE", 126, 138], ["type 2 diabetes mellitus", "DISEASE", 140, 164], ["CAD", "DISEASE", 170, 173], ["chest pain", "DISEASE", 192, 202], ["myocardial infarction", "DISEASE", 223, 244], ["man", "ORGANISM", 106, 109], ["chest", "ORGANISM_SUBDIVISION", 192, 197], ["myocardial", "MULTI-TISSUE_STRUCTURE", 223, 233], ["vessel coronary artery", "MULTI-TISSUE_STRUCTURE", 272, 294], ["man", "SPECIES", 106, 109], ["symptom", "PROBLEM", 16, 23], ["hypertension", "PROBLEM", 126, 138], ["type 2 diabetes mellitus", "PROBLEM", 140, 164], ["CAD", "PROBLEM", 170, 173], ["chest pain", "PROBLEM", 192, 202], ["a myocardial infarction", "PROBLEM", 221, 244], ["a 3-vessel coronary artery bypass grafting", "TREATMENT", 268, 310], ["CABG", "TREATMENT", 312, 316], ["hypertension", "OBSERVATION", 126, 138], ["diabetes mellitus", "OBSERVATION", 147, 164], ["chest", "ANATOMY", 192, 197], ["myocardial", "ANATOMY", 223, 233], ["infarction", "OBSERVATION", 234, 244], ["vessel", "ANATOMY", 272, 278], ["coronary artery", "ANATOMY", 279, 294], ["bypass", "OBSERVATION", 295, 301], ["CABG", "OBSERVATION", 312, 316]]], ["On post-operative day one (hospital day 6), a stroke code was called for acute onset right-sided weakness and obtundation.", [["stroke", "DISEASE", 46, 52], ["acute onset right-sided weakness", "PROBLEM", 73, 105], ["obtundation", "PROBLEM", 110, 121], ["right", "ANATOMY_MODIFIER", 85, 90], ["sided", "ANATOMY_MODIFIER", 91, 96], ["weakness", "OBSERVATION", 97, 105], ["obtundation", "OBSERVATION", 110, 121]]], ["Following CT head, he was given tissue plasminogen activator (tPA).", [["head", "ANATOMY", 13, 17], ["tissue", "ANATOMY", 32, 38], ["head", "ORGAN", 13, 17], ["tissue plasminogen activator", "GENE_OR_GENE_PRODUCT", 32, 60], ["tissue plasminogen activator", "PROTEIN", 32, 60], ["CT head", "TEST", 10, 17], ["tissue plasminogen activator", "TREATMENT", 32, 60], ["head", "ANATOMY", 13, 17]]], ["CT angiogram demonstrated vertebrobasilar occlusion.", [["vertebrobasilar", "ANATOMY", 26, 41], ["vertebrobasilar occlusion", "DISEASE", 26, 51], ["vertebrobasilar", "MULTI-TISSUE_STRUCTURE", 26, 41], ["CT angiogram", "TEST", 0, 12], ["vertebrobasilar occlusion", "PROBLEM", 26, 51], ["vertebrobasilar", "ANATOMY", 26, 41], ["occlusion", "OBSERVATION", 42, 51]]], ["He underwent successful thrombectomy of the basilar artery.", [["basilar artery", "ANATOMY", 44, 58], ["basilar artery", "MULTI-TISSUE_STRUCTURE", 44, 58], ["successful thrombectomy of the basilar artery", "TREATMENT", 13, 58], ["successful", "OBSERVATION_MODIFIER", 13, 23], ["thrombectomy", "OBSERVATION", 24, 36], ["basilar artery", "ANATOMY", 44, 58]]], ["Angiogram at time of the thrombectomy demonstrated interval development of a new right internal carotid artery occlusion, which was also successfully treated.", [["right internal carotid artery", "ANATOMY", 81, 110], ["right internal carotid artery occlusion", "DISEASE", 81, 120], ["carotid artery", "MULTI-TISSUE_STRUCTURE", 96, 110], ["Angiogram", "TEST", 0, 9], ["the thrombectomy", "TREATMENT", 21, 37], ["a new right internal carotid artery occlusion", "PROBLEM", 75, 120], ["thrombectomy", "OBSERVATION", 25, 37], ["new", "OBSERVATION_MODIFIER", 77, 80], ["right", "ANATOMY_MODIFIER", 81, 86], ["internal carotid artery", "ANATOMY", 87, 110], ["occlusion", "OBSERVATION", 111, 120]]], ["Follow-up CT head revealed a complete left posterior cerebral artery stroke with other smaller posterior circulation strokes with petechial hemorrhage in the right basal ganglia.", [["head", "ANATOMY", 13, 17], ["left posterior cerebral artery", "ANATOMY", 38, 68], ["petechial", "ANATOMY", 130, 139], ["right basal ganglia", "ANATOMY", 158, 177], ["cerebral artery stroke", "DISEASE", 53, 75], ["strokes", "DISEASE", 117, 124], ["hemorrhage", "DISEASE", 140, 150], ["head", "ORGAN", 13, 17], ["cerebral artery", "MULTI-TISSUE_STRUCTURE", 53, 68], ["basal ganglia", "MULTI-TISSUE_STRUCTURE", 164, 177], ["Follow-up CT head", "TEST", 0, 17], ["a complete left posterior cerebral artery stroke", "PROBLEM", 27, 75], ["other smaller posterior circulation strokes", "PROBLEM", 81, 124], ["petechial hemorrhage in the right basal ganglia", "PROBLEM", 130, 177], ["head", "ANATOMY", 13, 17], ["left", "ANATOMY_MODIFIER", 38, 42], ["posterior cerebral artery", "ANATOMY", 43, 68], ["stroke", "OBSERVATION", 69, 75], ["smaller", "OBSERVATION_MODIFIER", 87, 94], ["posterior", "ANATOMY_MODIFIER", 95, 104], ["circulation", "ANATOMY", 105, 116], ["strokes", "OBSERVATION", 117, 124], ["petechial", "OBSERVATION_MODIFIER", 130, 139], ["hemorrhage", "OBSERVATION", 140, 150], ["right", "ANATOMY_MODIFIER", 158, 163], ["basal", "ANATOMY_MODIFIER", 164, 169], ["ganglia", "ANATOMY", 170, 177]]], ["Within 12 h of tPA administration, he developed thrombosis of the right brachial artery.", [["right brachial artery", "ANATOMY", 66, 87], ["thrombosis", "DISEASE", 48, 58], ["tPA", "GENE_OR_GENE_PRODUCT", 15, 18], ["right brachial artery", "MULTI-TISSUE_STRUCTURE", 66, 87], ["tPA", "PROTEIN", 15, 18], ["tPA administration", "TREATMENT", 15, 33], ["thrombosis of the right brachial artery", "PROBLEM", 48, 87], ["thrombosis", "OBSERVATION", 48, 58], ["right", "ANATOMY_MODIFIER", 66, 71], ["brachial artery", "ANATOMY", 72, 87]]], ["He remained intubated.", [["intubated", "TREATMENT", 12, 21], ["intubated", "OBSERVATION", 12, 21]]], ["On hospital day 7, CT chest revealed bilateral consolidation concerning for pneumonia.", [["pneumonia", "DISEASE", 76, 85], ["CT chest", "TEST", 19, 27], ["bilateral consolidation", "PROBLEM", 37, 60], ["pneumonia", "PROBLEM", 76, 85], ["chest", "ANATOMY", 22, 27], ["bilateral", "ANATOMY_MODIFIER", 37, 46], ["consolidation", "OBSERVATION", 47, 60], ["concerning for", "UNCERTAINTY", 61, 75], ["pneumonia", "OBSERVATION", 76, 85]]], ["He developed ARDS and tested positive for SARS-CoV-2 on hospital day 11.", [["ARDS", "DISEASE", 13, 17], ["SARS", "DISEASE", 42, 46], ["SARS-CoV", "SPECIES", 42, 50], ["ARDS", "PROBLEM", 13, 17], ["SARS", "PROBLEM", 42, 46], ["CoV", "TEST", 47, 50], ["ARDS", "OBSERVATION", 13, 17]]], ["He sustained multi-organ failure due to mixed cardiogenic and septic shock and died on hospital day 25.DiscussionThe most common reasons for neurological evaluation in the setting of COVID-19 infection at our institution were encephalopathy, seizure, and stroke.", [["multi-organ", "ANATOMY", 13, 24], ["neurological", "ANATOMY", 141, 153], ["multi-organ failure", "DISEASE", 13, 32], ["cardiogenic", "DISEASE", 46, 57], ["septic shock", "DISEASE", 62, 74], ["COVID-19", "CHEMICAL", 183, 191], ["infection", "DISEASE", 192, 201], ["encephalopathy", "DISEASE", 226, 240], ["seizure", "DISEASE", 242, 249], ["stroke", "DISEASE", 255, 261], ["multi-organ failure", "PROBLEM", 13, 32], ["mixed cardiogenic", "PROBLEM", 40, 57], ["septic shock", "PROBLEM", 62, 74], ["neurological evaluation", "TEST", 141, 164], ["COVID-19 infection", "PROBLEM", 183, 201], ["encephalopathy", "PROBLEM", 226, 240], ["seizure", "PROBLEM", 242, 249], ["stroke", "PROBLEM", 255, 261], ["multi-organ", "ANATOMY", 13, 24], ["failure", "OBSERVATION", 25, 32], ["mixed", "OBSERVATION_MODIFIER", 40, 45], ["cardiogenic", "OBSERVATION", 46, 57], ["septic shock", "OBSERVATION", 62, 74], ["infection", "OBSERVATION", 192, 201], ["encephalopathy", "OBSERVATION", 226, 240], ["stroke", "OBSERVATION", 255, 261]]], ["Most of the patients in our case series developed neurological symptoms several days after COVID-19 symptom-onset and demonstrated elevated inflammatory markers.", [["neurological", "ANATOMY", 50, 62], ["neurological symptoms", "DISEASE", 50, 71], ["patients", "ORGANISM", 12, 20], ["inflammatory markers", "PROTEIN", 140, 160], ["patients", "SPECIES", 12, 20], ["neurological symptoms", "PROBLEM", 50, 71], ["COVID", "TEST", 91, 96], ["elevated inflammatory markers", "PROBLEM", 131, 160], ["elevated", "OBSERVATION_MODIFIER", 131, 139], ["inflammatory markers", "OBSERVATION", 140, 160]]], ["It is shown that patients with moderate to severe disease requiring hospitalization are more likely to develop a secondary, delayed hyperinflammatory state with elevated cytokine levels (2, 10).", [["patients", "ORGANISM", 17, 25], ["cytokine", "PROTEIN", 170, 178], ["patients", "SPECIES", 17, 25], ["moderate to severe disease", "PROBLEM", 31, 57], ["a secondary, delayed hyperinflammatory state", "PROBLEM", 111, 155], ["elevated cytokine levels", "PROBLEM", 161, 185], ["moderate", "OBSERVATION_MODIFIER", 31, 39], ["severe", "OBSERVATION_MODIFIER", 43, 49], ["disease", "OBSERVATION", 50, 57], ["secondary", "OBSERVATION_MODIFIER", 113, 122], ["delayed", "OBSERVATION_MODIFIER", 124, 131], ["hyperinflammatory state", "OBSERVATION", 132, 155], ["elevated", "OBSERVATION_MODIFIER", 161, 169], ["cytokine levels", "OBSERVATION", 170, 185]]], ["However, we are not able to comment on how these levels compare to COVID-19 patients without neurologic symptoms in our inpatient population, COVID-19 patients in the outpatient setting, nor to healthy controls.", [["neurologic", "ANATOMY", 93, 103], ["neurologic symptoms", "DISEASE", 93, 112], ["patients", "ORGANISM", 76, 84], ["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 76, 84], ["patients", "SPECIES", 151, 159], ["these levels", "TEST", 43, 55], ["COVID", "TEST", 67, 72], ["neurologic symptoms", "PROBLEM", 93, 112], ["COVID", "TEST", 142, 147]]], ["This will be important to evaluate in future studies.DiscussionSevere SARS-CoV-2 infection can lead to impaired consciousness (4).", [["infection", "DISEASE", 81, 90], ["impaired consciousness", "DISEASE", 103, 125], ["CoV-2", "ORGANISM", 75, 80], ["future studies", "TEST", 38, 52], ["SARS", "PROBLEM", 70, 74], ["CoV-2 infection", "PROBLEM", 75, 90], ["impaired consciousness", "PROBLEM", 103, 125]]], ["Many factors can attribute to toxic-metabolic encephalopathy in patient with COVID-19, including hypoxia, organ dysfunction, and metabolic abnormalities (11).", [["organ", "ANATOMY", 106, 111], ["encephalopathy", "DISEASE", 46, 60], ["COVID-19", "CHEMICAL", 77, 85], ["hypoxia", "DISEASE", 97, 104], ["organ dysfunction", "DISEASE", 106, 123], ["metabolic abnormalities", "DISEASE", 129, 152], ["patient", "ORGANISM", 64, 71], ["organ", "ORGAN", 106, 111], ["patient", "SPECIES", 64, 71], ["toxic-metabolic encephalopathy", "PROBLEM", 30, 60], ["COVID", "TEST", 77, 82], ["hypoxia", "PROBLEM", 97, 104], ["organ dysfunction", "PROBLEM", 106, 123], ["metabolic abnormalities", "PROBLEM", 129, 152], ["toxic", "OBSERVATION_MODIFIER", 30, 35], ["metabolic encephalopathy", "OBSERVATION", 36, 60], ["hypoxia", "OBSERVATION", 97, 104], ["organ", "ANATOMY", 106, 111], ["dysfunction", "OBSERVATION", 112, 123], ["metabolic abnormalities", "OBSERVATION", 129, 152]]], ["Many patients who require intubation and critical care also require prolonged sedation, immobilization, hospitalization, and social isolation, which also may contribute to toxic-metabolic encephalopathy (11).", [["toxic-metabolic encephalopathy", "DISEASE", 172, 202], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["intubation", "TREATMENT", 26, 36], ["critical care", "TREATMENT", 41, 54], ["prolonged sedation", "TREATMENT", 68, 86], ["immobilization", "TREATMENT", 88, 102], ["hospitalization", "TREATMENT", 104, 119], ["social isolation", "TREATMENT", 125, 141], ["toxic-metabolic encephalopathy", "PROBLEM", 172, 202], ["toxic", "OBSERVATION_MODIFIER", 172, 177], ["metabolic encephalopathy", "OBSERVATION", 178, 202]]], ["A postmortem brain examination has demonstrated brain edema and neuronal degeneration (12); however, these findings can be seen with hypoxia and metabolic abnormalities (13).", [["brain", "ANATOMY", 13, 18], ["brain edema", "ANATOMY", 48, 59], ["neuronal", "ANATOMY", 64, 72], ["brain edema", "DISEASE", 48, 59], ["neuronal degeneration", "DISEASE", 64, 85], ["hypoxia", "DISEASE", 133, 140], ["metabolic abnormalities", "DISEASE", 145, 168], ["brain", "ORGAN", 13, 18], ["brain edema", "PATHOLOGICAL_FORMATION", 48, 59], ["neuronal", "CELL", 64, 72], ["A postmortem brain examination", "TEST", 0, 30], ["brain edema", "PROBLEM", 48, 59], ["neuronal degeneration", "PROBLEM", 64, 85], ["hypoxia", "PROBLEM", 133, 140], ["metabolic abnormalities", "PROBLEM", 145, 168], ["brain", "ANATOMY", 48, 53], ["edema", "OBSERVATION", 54, 59], ["neuronal degeneration", "OBSERVATION", 64, 85], ["can be seen with", "UNCERTAINTY", 116, 132], ["hypoxia", "OBSERVATION", 133, 140], ["metabolic abnormalities", "OBSERVATION", 145, 168]]], ["Direct invasion of SARS-CoV-2 has not been demonstrated.", [["SARS", "DISEASE", 19, 23], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 19, 29], ["SARS-CoV", "SPECIES", 19, 27], ["Direct invasion of SARS", "PROBLEM", 0, 23], ["invasion", "OBSERVATION", 7, 15], ["SARS", "OBSERVATION", 19, 23]]], ["The ability of our study to sample CSF in the initial stages of the pandemic at our institution were limited.DiscussionAcute symptomatic seizures can occur in the setting of systemic illness and sepsis (14), proposing a systemic inflammatory response leading to a decreased seizure threshold.", [["seizures", "DISEASE", 137, 145], ["systemic illness", "DISEASE", 174, 190], ["sepsis", "DISEASE", 195, 201], ["seizure", "DISEASE", 274, 281], ["CSF", "GENE_OR_GENE_PRODUCT", 35, 38], ["our study", "TEST", 15, 24], ["sample CSF", "TEST", 28, 38], ["the pandemic", "PROBLEM", 64, 76], ["DiscussionAcute symptomatic seizures", "PROBLEM", 109, 145], ["systemic illness", "PROBLEM", 174, 190], ["sepsis", "PROBLEM", 195, 201], ["a systemic inflammatory response", "PROBLEM", 218, 250], ["a decreased seizure threshold", "PROBLEM", 262, 291], ["symptomatic", "OBSERVATION_MODIFIER", 125, 136], ["seizures", "OBSERVATION", 137, 145], ["systemic", "OBSERVATION_MODIFIER", 174, 182], ["illness", "OBSERVATION", 183, 190], ["sepsis", "OBSERVATION", 195, 201], ["systemic", "OBSERVATION_MODIFIER", 220, 228], ["inflammatory", "OBSERVATION", 229, 241], ["decreased", "OBSERVATION_MODIFIER", 264, 273], ["seizure", "OBSERVATION", 274, 281]]], ["The six patients who presented with first-time seizure of life had high inflammatory markers known to be elevated in COVID-19 infection, which suggests that these seizures could be categorized as provoked seizures in the setting of robust systemic inflammatory response.", [["seizure", "DISEASE", 47, 54], ["infection", "DISEASE", 126, 135], ["seizures", "DISEASE", 163, 171], ["seizures", "DISEASE", 205, 213], ["patients", "ORGANISM", 8, 16], ["inflammatory markers", "PROTEIN", 72, 92], ["patients", "SPECIES", 8, 16], ["COVID-19", "SPECIES", 117, 125], ["high inflammatory markers", "PROBLEM", 67, 92], ["elevated in COVID-19 infection", "PROBLEM", 105, 135], ["these seizures", "PROBLEM", 157, 171], ["seizures", "PROBLEM", 205, 213], ["robust systemic inflammatory response", "PROBLEM", 232, 269], ["elevated", "OBSERVATION_MODIFIER", 105, 113], ["infection", "OBSERVATION", 126, 135], ["robust", "OBSERVATION_MODIFIER", 232, 238], ["systemic", "OBSERVATION_MODIFIER", 239, 247], ["inflammatory", "OBSERVATION", 248, 260]]], ["Other coronavirus infections have been associated with seizures (15).", [["coronavirus infections", "DISEASE", 6, 28], ["seizures", "DISEASE", 55, 63], ["coronavirus", "ORGANISM", 6, 17], ["Other coronavirus infections", "PROBLEM", 0, 28], ["seizures", "PROBLEM", 55, 63], ["coronavirus", "OBSERVATION_MODIFIER", 6, 17], ["infections", "OBSERVATION", 18, 28]]], ["CSF was not obtained in our cases, so we could not exclude direct neuroinvasion or encephalitis as the cause of seizures.DiscussionInfection is a known trigger for stroke, potentially contributing up to one-third of ischemic strokes (16).", [["neuroinvasion", "DISEASE", 66, 79], ["encephalitis", "DISEASE", 83, 95], ["seizures", "DISEASE", 112, 120], ["DiscussionInfection", "DISEASE", 121, 140], ["stroke", "DISEASE", 164, 170], ["ischemic strokes", "DISEASE", 216, 232], ["CSF", "GENE_OR_GENE_PRODUCT", 0, 3], ["CSF", "PROTEIN", 0, 3], ["CSF", "TEST", 0, 3], ["direct neuroinvasion", "PROBLEM", 59, 79], ["encephalitis", "PROBLEM", 83, 95], ["seizures", "PROBLEM", 112, 120], ["stroke", "PROBLEM", 164, 170], ["ischemic strokes", "PROBLEM", 216, 232], ["neuroinvasion", "OBSERVATION", 66, 79], ["encephalitis", "OBSERVATION", 83, 95], ["ischemic", "OBSERVATION_MODIFIER", 216, 224], ["strokes", "OBSERVATION", 225, 232]]], ["Respiratory infections in particular have been associated with acute cerebrovascular events, most notably with influenza-like viral illnesses (17, 18).", [["Respiratory", "ANATOMY", 0, 11], ["cerebrovascular", "ANATOMY", 69, 84], ["Respiratory infections", "DISEASE", 0, 22], ["acute cerebrovascular events", "DISEASE", 63, 91], ["influenza-like viral illnesses", "DISEASE", 111, 141], ["cerebrovascular", "ANATOMICAL_SYSTEM", 69, 84], ["Respiratory infections", "PROBLEM", 0, 22], ["acute cerebrovascular events", "PROBLEM", 63, 91], ["influenza", "PROBLEM", 111, 120], ["viral illnesses", "PROBLEM", 126, 141], ["infections", "OBSERVATION", 12, 22], ["associated with", "UNCERTAINTY", 47, 62], ["acute", "OBSERVATION_MODIFIER", 63, 68], ["cerebrovascular", "OBSERVATION", 69, 84], ["influenza", "OBSERVATION", 111, 120], ["viral illnesses", "OBSERVATION", 126, 141]]], ["Stroke is emerging as a potential complication of infection with SARS-CoV-2.", [["Stroke", "DISEASE", 0, 6], ["infection", "DISEASE", 50, 59], ["SARS", "DISEASE", 65, 69], ["SARS-CoV-2", "ORGANISM", 65, 75], ["SARS-CoV", "SPECIES", 65, 73], ["Stroke", "PROBLEM", 0, 6], ["infection", "PROBLEM", 50, 59], ["SARS", "PROBLEM", 65, 69], ["infection", "OBSERVATION", 50, 59]]], ["The incidence and relative risk of stroke from COVID-19 infection remains unknown.", [["stroke", "DISEASE", 35, 41], ["COVID-19", "CHEMICAL", 47, 55], ["infection", "DISEASE", 56, 65], ["stroke", "PROBLEM", 35, 41], ["COVID", "TEST", 47, 52], ["19 infection", "PROBLEM", 53, 65], ["stroke", "OBSERVATION", 35, 41], ["infection", "OBSERVATION", 56, 65]]], ["Retrospective studies in different countries have reported an incidence of 2.5\u20135.7% for acute stroke (4, 6, 7).", [["stroke", "DISEASE", 94, 100], ["Retrospective studies", "TEST", 0, 21], ["acute stroke", "PROBLEM", 88, 100], ["acute", "OBSERVATION_MODIFIER", 88, 93], ["stroke", "OBSERVATION", 94, 100]]], ["Case series in the United States have also demonstrated acute stroke occurring in young adults (9) and in patients with only mild respiratory symptoms from COVID-19 (8).", [["respiratory", "ANATOMY", 130, 141], ["acute stroke", "DISEASE", 56, 68], ["COVID-19", "CHEMICAL", 156, 164], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["acute stroke", "PROBLEM", 56, 68], ["only mild respiratory symptoms", "PROBLEM", 120, 150], ["COVID", "TEST", 156, 161], ["acute", "OBSERVATION_MODIFIER", 56, 61], ["stroke", "OBSERVATION", 62, 68], ["mild", "OBSERVATION_MODIFIER", 125, 129], ["respiratory symptoms", "OBSERVATION", 130, 150]]], ["These studies did not have comparative controls.DiscussionThe mechanisms whereby COVID-19 may increase stroke risk include the following: Hypercoagulability (as demonstrated in part by elevated D-dimer) may contribute.", [["COVID-19", "CHEMICAL", 81, 89], ["stroke", "DISEASE", 103, 109], ["Hypercoagulability", "DISEASE", 138, 156], ["COVID-19", "CHEMICAL", 81, 89], ["COVID-19", "GENE_OR_GENE_PRODUCT", 81, 89], ["D-dimer", "GENE_OR_GENE_PRODUCT", 194, 201], ["COVID-19", "DNA", 81, 89], ["D-dimer", "PROTEIN", 194, 201], ["These studies", "TEST", 0, 13], ["COVID", "TEST", 81, 86], ["increase stroke risk", "PROBLEM", 94, 114], ["Hypercoagulability", "PROBLEM", 138, 156], ["elevated D-dimer", "PROBLEM", 185, 201], ["Hypercoagulability", "OBSERVATION", 138, 156]]], ["Systemic inflammation and a cascade of pro-inflammatory cytokines (as demonstrated in part by elevated IL-6) may be a mediator between infection and hypercoagulability and may also destabilize atheromatous plaque (4, 19, 20).", [["atheromatous plaque", "ANATOMY", 193, 212], ["inflammation", "DISEASE", 9, 21], ["infection", "DISEASE", 135, 144], ["hypercoagulability", "DISEASE", 149, 167], ["atheromatous plaque", "DISEASE", 193, 212], ["IL-6", "GENE_OR_GENE_PRODUCT", 103, 107], ["atheromatous plaque", "PATHOLOGICAL_FORMATION", 193, 212], ["pro-inflammatory cytokines", "PROTEIN", 39, 65], ["IL-6", "PROTEIN", 103, 107], ["Systemic inflammation", "PROBLEM", 0, 21], ["pro-inflammatory cytokines", "PROBLEM", 39, 65], ["elevated IL", "PROBLEM", 94, 105], ["a mediator between infection", "PROBLEM", 116, 144], ["hypercoagulability", "PROBLEM", 149, 167], ["atheromatous plaque", "PROBLEM", 193, 212], ["inflammation", "OBSERVATION", 9, 21], ["pro-inflammatory cytokines", "OBSERVATION", 39, 65], ["infection", "OBSERVATION", 135, 144], ["hypercoagulability", "OBSERVATION", 149, 167], ["atheromatous", "OBSERVATION_MODIFIER", 193, 205], ["plaque", "OBSERVATION", 206, 212]]], ["Coronavirus-related cardiac injury may lead to embolic strokes (21).", [["cardiac", "ANATOMY", 20, 27], ["Coronavirus", "CHEMICAL", 0, 11], ["cardiac injury", "DISEASE", 20, 34], ["embolic strokes", "DISEASE", 47, 62], ["cardiac", "ORGAN", 20, 27], ["Coronavirus", "PROBLEM", 0, 11], ["cardiac injury", "PROBLEM", 20, 34], ["embolic strokes", "PROBLEM", 47, 62], ["cardiac", "ANATOMY", 20, 27], ["injury", "OBSERVATION", 28, 34], ["embolic", "OBSERVATION_MODIFIER", 47, 54], ["strokes", "OBSERVATION", 55, 62]]], ["Direct viral invasion of the vascular wall via binding at and depletion of the angiotensin-converting enzyme 2 (ACE2) receptor may generate endothelial dysfunction, vasoconstriction, and stroke (22).DiscussionAs in prior literature reviewing neurological manifestations of COVID-19 infection, our case series included instances of both ischemic stroke and intracranial hemorrhage, although our patients also had other cardiovascular risk factors for stroke.", [["vascular wall", "ANATOMY", 29, 42], ["endothelial", "ANATOMY", 140, 151], ["neurological", "ANATOMY", 242, 254], ["intracranial", "ANATOMY", 356, 368], ["cardiovascular", "ANATOMY", 418, 432], ["angiotensin", "CHEMICAL", 79, 90], ["endothelial dysfunction", "DISEASE", 140, 163], ["stroke", "DISEASE", 187, 193], ["infection", "DISEASE", 282, 291], ["ischemic stroke", "DISEASE", 336, 351], ["intracranial hemorrhage", "DISEASE", 356, 379], ["stroke", "DISEASE", 450, 456], ["vascular wall", "MULTI-TISSUE_STRUCTURE", 29, 42], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 79, 110], ["ACE2", "GENE_OR_GENE_PRODUCT", 112, 116], ["endothelial", "CELL", 140, 151], ["patients", "ORGANISM", 394, 402], ["angiotensin-converting enzyme 2 (ACE2) receptor", "PROTEIN", 79, 126], ["patients", "SPECIES", 394, 402], ["Direct viral invasion of the vascular wall", "PROBLEM", 0, 42], ["the angiotensin-converting enzyme 2 (ACE2) receptor", "TREATMENT", 75, 126], ["endothelial dysfunction", "PROBLEM", 140, 163], ["vasoconstriction", "PROBLEM", 165, 181], ["stroke", "PROBLEM", 187, 193], ["COVID-19 infection", "PROBLEM", 273, 291], ["both ischemic stroke", "PROBLEM", 331, 351], ["intracranial hemorrhage", "PROBLEM", 356, 379], ["other cardiovascular risk factors", "PROBLEM", 412, 445], ["stroke", "PROBLEM", 450, 456], ["viral", "OBSERVATION_MODIFIER", 7, 12], ["invasion", "OBSERVATION", 13, 21], ["vascular wall", "ANATOMY", 29, 42], ["endothelial dysfunction", "OBSERVATION", 140, 163], ["vasoconstriction", "OBSERVATION_MODIFIER", 165, 181], ["stroke", "OBSERVATION", 187, 193], ["infection", "OBSERVATION", 282, 291], ["both", "OBSERVATION_MODIFIER", 331, 335], ["ischemic", "OBSERVATION_MODIFIER", 336, 344], ["stroke", "OBSERVATION", 345, 351], ["intracranial", "ANATOMY", 356, 368], ["hemorrhage", "OBSERVATION", 369, 379], ["stroke", "OBSERVATION", 450, 456]]], ["Due to our limited sample, we cannot comment on SARS-CoV-2 increasing the risk of acute stroke.DiscussionThis study had several limitations.", [["stroke", "DISEASE", 88, 94], ["SARS-CoV", "SPECIES", 48, 56], ["SARS", "TEST", 48, 52], ["CoV", "TEST", 53, 56], ["acute stroke", "PROBLEM", 82, 94], ["This study", "TEST", 105, 115], ["acute", "OBSERVATION_MODIFIER", 82, 87], ["stroke", "OBSERVATION", 88, 94]]], ["First, it was a retrospective study including patients at a single urban academic medical center.", [["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["a retrospective study", "TEST", 14, 35]]], ["While the goal of this study was to provide an account of our early experiences with the neurological manifestations of COVID-19 infection, these factors limit the generalizability of our data.", [["neurological", "ANATOMY", 89, 101], ["COVID", "DISEASE", 120, 125], ["infection", "DISEASE", 129, 138], ["this study", "TEST", 18, 28], ["COVID-19 infection", "PROBLEM", 120, 138], ["these factors", "PROBLEM", 140, 153], ["our data", "TEST", 184, 192], ["infection", "OBSERVATION", 129, 138]]], ["This study included only cases for which neurology was consulted or involved in primary care of the patients, so these cases do not represent all neurological manifestations of COVID-19 infection.", [["neurological", "ANATOMY", 146, 158], ["COVID-19", "CHEMICAL", 177, 185], ["infection", "DISEASE", 186, 195], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["This study", "TEST", 0, 10], ["all neurological manifestations", "PROBLEM", 142, 173], ["COVID-19 infection", "PROBLEM", 177, 195], ["infection", "OBSERVATION", 186, 195]]], ["Although in some cases diagnostic tests may have better elucidated mechanisms of neurologic symptoms in our patients, these were not uniformly performed due to either patient illness severity, PPE scarcity, or healthcare exposure.", [["neurologic", "ANATOMY", 81, 91], ["illness", "DISEASE", 175, 182], ["patients", "ORGANISM", 108, 116], ["patient", "ORGANISM", 167, 174], ["patients", "SPECIES", 108, 116], ["patient", "SPECIES", 167, 174], ["diagnostic tests", "TEST", 23, 39], ["neurologic symptoms", "PROBLEM", 81, 100], ["patient illness severity", "PROBLEM", 167, 191], ["PPE scarcity", "PROBLEM", 193, 205]]], ["This was particularly true for lumbar punctures given the risk of prolonged exposure during the procedure.", [["lumbar", "ANATOMY", 31, 37], ["lumbar punctures", "MULTI-TISSUE_STRUCTURE", 31, 47], ["lumbar punctures", "TREATMENT", 31, 47], ["the procedure", "TREATMENT", 92, 105], ["lumbar", "ANATOMY", 31, 37]]], ["We therefore were unable to rule out alternative neurological infections as a cause of seizure, including in the three immunocompromised patients.", [["neurological", "ANATOMY", 49, 61], ["neurological infections", "DISEASE", 49, 72], ["seizure", "DISEASE", 87, 94], ["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 137, 145], ["alternative neurological infections", "PROBLEM", 37, 72], ["seizure", "PROBLEM", 87, 94], ["infections", "OBSERVATION", 62, 72]]], ["Lastly, since this is a short-term study period, long-term outcomes are not known.DiscussionHere we present the most common neurological problems during the first two weeks of the SARS-CoV-2 outbreak at our institution.", [["neurological", "ANATOMY", 124, 136], ["SARS", "DISEASE", 180, 184], ["long-term outcomes", "PROBLEM", 49, 67], ["the SARS", "PROBLEM", 176, 184], ["long-term", "OBSERVATION_MODIFIER", 49, 58]]], ["COVID-19 infection did not change the overall management of neurological problems.", [["neurological", "ANATOMY", 60, 72], ["infection", "DISEASE", 9, 18], ["neurological problems", "DISEASE", 60, 81], ["COVID", "TEST", 0, 5], ["infection", "PROBLEM", 9, 18], ["neurological problems", "PROBLEM", 60, 81], ["infection", "OBSERVATION", 9, 18]]], ["All deaths were directly related to severe sepsis, ARDS, or cytokine storm causing refractory shock.", [["deaths", "DISEASE", 4, 10], ["sepsis", "DISEASE", 43, 49], ["ARDS", "DISEASE", 51, 55], ["shock", "DISEASE", 94, 99], ["cytokine", "PROTEIN", 60, 68], ["All deaths", "PROBLEM", 0, 10], ["severe sepsis", "PROBLEM", 36, 49], ["ARDS", "PROBLEM", 51, 55], ["cytokine storm", "PROBLEM", 60, 74], ["refractory shock", "PROBLEM", 83, 99], ["severe", "OBSERVATION_MODIFIER", 36, 42], ["sepsis", "OBSERVATION", 43, 49], ["ARDS", "OBSERVATION", 51, 55], ["refractory", "OBSERVATION_MODIFIER", 83, 93], ["shock", "OBSERVATION", 94, 99]]], ["Future studies will investigate if SARS-CoV-2 has direct neurological toxicity requiring alternative management strategies.Data Availability StatementThe raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.Ethics StatementThe studies involving human participants were reviewed and approved by Columbia University Irving Medical Center Institutional Review Board.", [["neurological", "ANATOMY", 57, 69], ["neurological toxicity", "DISEASE", 57, 78], ["SARS-CoV-2", "ORGANISM", 35, 45], ["human", "ORGANISM", 309, 314], ["human", "SPECIES", 309, 314], ["participants", "SPECIES", 315, 327], ["SARS-CoV", "SPECIES", 35, 43], ["human", "SPECIES", 309, 314], ["Future studies", "TEST", 0, 14], ["SARS", "PROBLEM", 35, 39], ["CoV", "TEST", 40, 43], ["direct neurological toxicity", "PROBLEM", 50, 78], ["alternative management strategies", "TREATMENT", 89, 122]]], ["Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin.", [["participants", "SPECIES", 74, 86], ["this study", "TEST", 43, 53]]], ["Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.Author ContributionsSR, SE, HR, AM, and SS have full access to all of the data and takes full responsibility for the data presented, accuracy of the data analysis and interpretation, the conduct of the research design, and drafting of the manuscript for intellectual content.", [["the data analysis", "TEST", 298, 315], ["intellectual content", "PROBLEM", 407, 427]]], ["TW and AB has full access to all of the data and contributed to the conduct of the research design and statistical analysis.", [["the data", "TEST", 36, 44], ["statistical analysis", "TEST", 103, 123]]], ["JD has full access to all of the data and takes full responsibility for the data presented and accuracy of the data analysis and interpretation.", [["the data analysis", "TEST", 107, 124]]], ["JB has full access to all of the data and takes full responsibility for the data presented, accuracy of the data analysis, interpretation, and revising the manuscript for intellectual content.", [["the data analysis", "TEST", 104, 121], ["intellectual content", "PROBLEM", 171, 191]]], ["JW and KT were responsible for conduct of the research design, analysis and interpretation of the data, and revising the manuscript for intellectual content.", [["the data", "TEST", 94, 102], ["intellectual content", "PROBLEM", 136, 156]]]], "98e63352a0759cb5c2c7dfb2859a1d30da390fbf": [["INTRODUCTIONCoronavirus disease 2019 (COVID-19) is a novel infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).", [["INTRODUCTIONCoronavirus disease", "DISEASE", 0, 31], ["COVID-19", "CHEMICAL", 38, 46], ["infectious disease", "DISEASE", 59, 77], ["acute respiratory syndrome coronavirus", "DISEASE", 95, 133], ["SARS-CoV-2", "ORGANISM", 137, 147], ["INTRODUCTIONCoronavirus disease 2019 (COVID-19", "SPECIES", 0, 46], ["severe acute respiratory syndrome coronavirus", "SPECIES", 88, 133], ["SARS-CoV-2", "SPECIES", 137, 147], ["INTRODUCTIONCoronavirus disease", "PROBLEM", 0, 31], ["COVID", "TEST", 38, 43], ["a novel infectious disease", "PROBLEM", 51, 77], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 88, 133], ["CoV", "TEST", 142, 145], ["infectious", "OBSERVATION", 59, 69], ["severe", "OBSERVATION_MODIFIER", 88, 94], ["acute", "OBSERVATION_MODIFIER", 95, 100], ["respiratory syndrome", "OBSERVATION", 101, 121]]], ["The outbreak initially occurred in Wuhan, China, in late 2019, and is spreading globally (1) .", [["outbreak", "OBSERVATION_MODIFIER", 4, 12]]], ["Society, in general, is required to adapt to the changes induced by the COVID-19 crisis.INTRODUCTIONEpilepsy is a neurological chronic disorder characterized by a spontaneous recurrence of unprovoked seizures.", [["neurological", "ANATOMY", 114, 126], ["neurological chronic disorder", "DISEASE", 114, 143], ["seizures", "DISEASE", 200, 208], ["a neurological chronic disorder", "PROBLEM", 112, 143], ["unprovoked seizures", "PROBLEM", 189, 208], ["neurological chronic", "OBSERVATION_MODIFIER", 114, 134], ["unprovoked", "OBSERVATION_MODIFIER", 189, 199], ["seizures", "OBSERVATION", 200, 208]]], ["In the field of neurology, as well as other departments, telemedicine is recommended as an alternative option for outpatient practice during the COVID-19 crisis to avoid the risk of exposure to SARS-CoV2 (2) .", [["SARS", "DISEASE", 194, 198], ["the COVID", "TEST", 141, 150]]], ["Telemedicine was already in use before the COVID-19 crisis for some patients who had difficulty accessing medical facilities.", [["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["Telemedicine", "TREATMENT", 0, 12]]], ["However, the COVID-19 crisis has made telemedicine an option that should be actively considered in most patients, not just some patients who have difficulty accessing medical facilities.", [["patients", "ORGANISM", 104, 112], ["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 104, 112], ["patients", "SPECIES", 128, 136], ["the COVID", "TEST", 9, 18]]], ["In the field of epilepsy, the importance of telemedicine is emphasized during this crisis; however, no consensus about decision making is available (2) .INTRODUCTIONThe present study article emphasizes the decision-making process by clinicians for patients with epilepsy via telemedicine during the COVID-19 crisis.", [["epilepsy", "DISEASE", 16, 24], ["epilepsy", "DISEASE", 262, 270], ["patients", "ORGANISM", 248, 256], ["patients", "SPECIES", 248, 256], ["epilepsy", "PROBLEM", 16, 24], ["epilepsy", "PROBLEM", 262, 270], ["the COVID", "TEST", 295, 304], ["epilepsy", "OBSERVATION", 16, 24]]], ["Considering the decision-making factors, a decision-making tree has been proposed (Figure 1 ).Strength and Weakness of TelemedicineTelemedicine consultation between clinicians and patients with epilepsy has certain advantages.", [["epilepsy", "DISEASE", 194, 202], ["patients", "ORGANISM", 180, 188], ["patients", "SPECIES", 180, 188], ["Weakness", "PROBLEM", 107, 115], ["epilepsy", "PROBLEM", 194, 202], ["Weakness", "OBSERVATION", 107, 115]]], ["First, the patients can save time, consultation fees, and travel expenses required to visit their doctors (3) .", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19]]], ["Second, Patients living in areas with poor medical resources can have access to professional doctors of the required fields (3).", [["Patients", "ORGANISM", 8, 16], ["Patients", "SPECIES", 8, 16]]], ["Third, patients can avoid public exposure, which is highly recommended during COVID-19 crisis (2).Strength and Weakness of TelemedicineIn contrast, telemedicine has certain limitations compared to physical consultation.", [["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15], ["Weakness of TelemedicineIn contrast", "PROBLEM", 111, 146], ["physical consultation", "TEST", 197, 218]]], ["It is difficult to examine the patients online, the effectiveness is limited, and remains unauthenticated (4).", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39]]], ["In general, patients cannot undergo clinical tests associated with epilepsy such as blood test, cerebrospinal-fluid test, neuroimaging, and electroencephalogram, thereby indicating that patients requiring such examination have to physically visit the testing centers despite the exposure risk to SARS-CoV-2.Decision Making by Clinicians for Patients With Epilepsy via Telemedicine During COVID-19 CrisisBased on the above-mentioned advantages and limitations of telemedicine, physicians should recommend both outpatient consultation at clinic and telemedicine appropriately.", [["blood", "ANATOMY", 84, 89], ["cerebrospinal", "ANATOMY", 96, 109], ["epilepsy", "DISEASE", 67, 75], ["SARS", "DISEASE", 296, 300], ["Epilepsy", "DISEASE", 355, 363], ["patients", "ORGANISM", 12, 20], ["blood", "ORGANISM_SUBSTANCE", 84, 89], ["cerebrospinal", "ORGANISM_SUBSTANCE", 96, 109], ["patients", "ORGANISM", 186, 194], ["CoV-2", "ORGANISM", 301, 306], ["Patients", "ORGANISM", 341, 349], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 186, 194], ["Patients", "SPECIES", 341, 349], ["SARS-CoV", "SPECIES", 296, 304], ["clinical tests", "TEST", 36, 50], ["epilepsy", "PROBLEM", 67, 75], ["blood test", "TEST", 84, 94], ["cerebrospinal-fluid test", "TEST", 96, 120], ["neuroimaging", "TEST", 122, 134], ["electroencephalogram", "TEST", 140, 160], ["such examination", "TEST", 205, 221], ["CoV", "TEST", 301, 304], ["Epilepsy", "PROBLEM", 355, 363], ["COVID", "TEST", 388, 393], ["cerebrospinal", "ANATOMY", 96, 109]]], ["During telemedicine consultation, the doctors should decide whether the patients require a visit to the clinics.Access to the System of TelemedicineTo continue telemedicine, the feasibility and accessibility for patients remain one of the most important factors.", [["patients", "ORGANISM", 72, 80], ["patients", "ORGANISM", 212, 220], ["patients", "SPECIES", 72, 80], ["patients", "SPECIES", 212, 220], ["telemedicine", "TREATMENT", 160, 172]]], ["Some factors disturb the patients to continue the telemedicine (2).", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["Some factors", "PROBLEM", 0, 12]]], ["People who are blind or hard of hearing may be more inconvenienced by telemedicine.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["blind", "PROBLEM", 15, 20], ["hard of hearing", "PROBLEM", 24, 39]]], ["Some patients are unable to use a video-call system for a variety of reasons, such as difficulty accessing the internet, location, or financial situation.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13]]], ["Patients in such situations should be encouraged to visit the clinics.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["It is more important to provide continued medical care.New PatientsIn the cases of new patients, we would collect general information, including clinical history, family history, seizure semiology, medical history, and birth and developmental history.", [["seizure", "DISEASE", 179, 186], ["Patients", "ORGANISM", 59, 67], ["patients", "ORGANISM", 87, 95], ["Patients", "SPECIES", 59, 67], ["patients", "SPECIES", 87, 95], ["continued medical care", "TREATMENT", 32, 54], ["seizure semiology", "PROBLEM", 179, 196], ["new", "OBSERVATION_MODIFIER", 83, 86]]], ["If additional testing is needed, including blood test, tap test, electroencephalogram, or neuroimaging, an appointment can be made for the patient to come into the clinic.", [["blood", "ANATOMY", 43, 48], ["blood", "ORGANISM_SUBSTANCE", 43, 48], ["patient", "ORGANISM", 139, 146], ["patient", "SPECIES", 139, 146], ["additional testing", "TEST", 3, 21], ["blood test", "TEST", 43, 53], ["tap test", "TEST", 55, 63], ["electroencephalogram", "TEST", 65, 85], ["neuroimaging", "TEST", 90, 102]]], ["In cases where more examinations are not needed, we can continue with telemedicine.The Presence of New Seizure TypeThe occurrence of seizure types would indicate acute symptomatic seizure due to onset of new diseases including COVID-19 (5) .", [["Seizure", "DISEASE", 103, 110], ["seizure", "DISEASE", 133, 140], ["seizure", "DISEASE", 180, 187], ["COVID-19", "CHEMICAL", 227, 235], ["more examinations", "TEST", 15, 32], ["telemedicine", "TREATMENT", 70, 82], ["New Seizure Type", "PROBLEM", 99, 115], ["seizure types", "PROBLEM", 133, 146], ["acute symptomatic seizure", "PROBLEM", 162, 187], ["new diseases", "PROBLEM", 204, 216], ["COVID", "TEST", 227, 232], ["New", "OBSERVATION_MODIFIER", 99, 102], ["Seizure Type", "OBSERVATION", 103, 115], ["seizure", "OBSERVATION", 133, 140], ["acute", "OBSERVATION_MODIFIER", 162, 167], ["symptomatic", "OBSERVATION_MODIFIER", 168, 179], ["seizure", "OBSERVATION", 180, 187], ["new", "OBSERVATION_MODIFIER", 204, 207], ["diseases", "OBSERVATION", 208, 216]]], ["Even for patients with epilepsy as a neurological chronic disorder, the new types of seizures should be distinguished from the original seizures and must be examined in detail.", [["epilepsy", "DISEASE", 23, 31], ["neurological chronic disorder", "DISEASE", 37, 66], ["seizures", "DISEASE", 85, 93], ["seizures", "DISEASE", 136, 144], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["epilepsy", "PROBLEM", 23, 31], ["a neurological chronic disorder", "PROBLEM", 35, 66], ["seizures", "PROBLEM", 85, 93], ["the original seizures", "PROBLEM", 123, 144], ["chronic", "OBSERVATION_MODIFIER", 50, 57], ["disorder", "OBSERVATION", 58, 66], ["seizures", "OBSERVATION", 136, 144]]], ["The diseases which cause seizures include cerebrovascular disease, head trauma, central nervous system infection, auto immune encephalitis, and intoxication (6) .", [["cerebrovascular", "ANATOMY", 42, 57], ["head", "ANATOMY", 67, 71], ["central nervous system", "ANATOMY", 80, 102], ["seizures", "DISEASE", 25, 33], ["cerebrovascular disease", "DISEASE", 42, 65], ["head trauma", "DISEASE", 67, 78], ["central nervous system infection", "DISEASE", 80, 112], ["auto immune encephalitis", "DISEASE", 114, 138], ["head", "ORGANISM_SUBDIVISION", 67, 71], ["central nervous system", "ANATOMICAL_SYSTEM", 80, 102], ["The diseases", "PROBLEM", 0, 12], ["seizures", "PROBLEM", 25, 33], ["cerebrovascular disease", "PROBLEM", 42, 65], ["head trauma", "PROBLEM", 67, 78], ["central nervous system infection", "PROBLEM", 80, 112], ["auto immune encephalitis", "PROBLEM", 114, 138], ["intoxication", "PROBLEM", 144, 156], ["diseases", "OBSERVATION", 4, 12], ["cerebrovascular disease", "OBSERVATION", 42, 65], ["head", "ANATOMY", 67, 71], ["trauma", "OBSERVATION", 72, 78], ["central", "ANATOMY_MODIFIER", 80, 87], ["nervous system", "ANATOMY", 88, 102], ["infection", "OBSERVATION", 103, 112], ["auto immune encephalitis", "OBSERVATION", 114, 138]]], ["We should also remember that psychogenic non-epileptic seizures are a disorder that is often difficult to differentiate from epilepsy (7) .", [["psychogenic non-epileptic seizures", "DISEASE", 29, 63], ["epilepsy", "DISEASE", 125, 133], ["psychogenic non-epileptic seizures", "PROBLEM", 29, 63], ["a disorder", "PROBLEM", 68, 78], ["epilepsy", "PROBLEM", 125, 133]]], ["Therefore, epileptologists should confirm the presence of seizure types, differing from the original seizures.Seizure FrequencyWhile consulting outpatients with epilepsy, an essential factor is the change in seizure frequency.", [["seizure", "DISEASE", 58, 65], ["seizures", "DISEASE", 101, 109], ["Seizure", "DISEASE", 110, 117], ["epilepsy", "DISEASE", 161, 169], ["seizure", "DISEASE", 208, 215], ["outpatients", "ORGANISM", 144, 155], ["outpatients", "SPECIES", 144, 155], ["seizure types", "PROBLEM", 58, 71], ["the original seizures", "PROBLEM", 88, 109], ["Seizure", "PROBLEM", 110, 117], ["epilepsy", "PROBLEM", 161, 169], ["the change in seizure frequency", "PROBLEM", 194, 225]]], ["Several factors affect the seizure control (8) .", [["seizure", "DISEASE", 27, 34], ["the seizure control", "TREATMENT", 23, 42]]], ["If the seizure frequency increases, clinicians should consider all factors responsible for the loss of seizure control.Seizure FrequencyIn the cases of increasing seizures, clinicians have to confirm several factors associated with seizure occurrence.", [["seizure", "DISEASE", 7, 14], ["seizure", "DISEASE", 103, 110], ["Seizure", "DISEASE", 119, 126], ["seizures", "DISEASE", 163, 171], ["seizure", "DISEASE", 232, 239], ["the seizure frequency", "PROBLEM", 3, 24], ["the loss of seizure control", "PROBLEM", 91, 118], ["Seizure", "PROBLEM", 119, 126], ["increasing seizures", "PROBLEM", 152, 171], ["seizure occurrence", "PROBLEM", 232, 250]]], ["Changing lifestyle, such as change of sleep duration, decreased medication compliance, and stressful/anxious situations can affect the seizure control.", [["seizure", "DISEASE", 135, 142], ["decreased medication compliance", "TREATMENT", 54, 85], ["stressful/anxious situations", "PROBLEM", 91, 119], ["the seizure control", "TREATMENT", 131, 150]]], ["Alcohol consumption is a known trigger for seizures in patients with epilepsy.", [["Alcohol", "CHEMICAL", 0, 7], ["seizures", "DISEASE", 43, 51], ["epilepsy", "DISEASE", 69, 77], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["seizures", "PROBLEM", 43, 51], ["epilepsy", "PROBLEM", 69, 77], ["epilepsy", "OBSERVATION", 69, 77]]], ["It is widely known that people under stressful situation tend to consume alcohol more frequently (9) .", [["alcohol", "CHEMICAL", 73, 80], ["alcohol", "CHEMICAL", 73, 80], ["people", "ORGANISM", 24, 30], ["alcohol", "SIMPLE_CHEMICAL", 73, 80], ["people", "SPECIES", 24, 30]]], ["Moreover, it is widely known that anxiety and mental stress can increase seizures (10) .", [["anxiety", "DISEASE", 34, 41], ["seizures", "DISEASE", 73, 81], ["anxiety", "PROBLEM", 34, 41], ["mental stress", "PROBLEM", 46, 59], ["seizures", "PROBLEM", 73, 81]]], ["To control seizure, medication compliance is essential.", [["seizure", "DISEASE", 11, 18], ["seizure", "PROBLEM", 11, 18], ["medication compliance", "TREATMENT", 20, 41]]], ["During the COVID-19 crisis, lifestyle changes are bound to occur, which may decrease the medication compliance (11) .", [["the COVID", "TEST", 7, 16], ["crisis", "PROBLEM", 20, 26], ["lifestyle changes", "PROBLEM", 28, 45]]], ["Considering prevention or supportive therapy of COVID-19, patients with epilepsy might be exposed to various supplements or newly started medications.", [["epilepsy", "DISEASE", 72, 80], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["supportive therapy", "TREATMENT", 26, 44], ["COVID", "TREATMENT", 48, 53], ["epilepsy", "PROBLEM", 72, 80], ["various supplements", "TREATMENT", 101, 120], ["newly started medications", "TREATMENT", 124, 149]]], ["As reported, some antiviral therapy used for COVID-19 may interact with the antiepileptic drugs (AEDs) (12).", [["COVID-19", "CHEMICAL", 45, 53], ["COVID-19", "CHEMICAL", 45, 53], ["COVID-19", "SIMPLE_CHEMICAL", 45, 53], ["antiepileptic drugs", "SIMPLE_CHEMICAL", 76, 95], ["some antiviral therapy", "TREATMENT", 13, 35], ["COVID", "TEST", 45, 50], ["the antiepileptic drugs", "TREATMENT", 72, 95], ["antiviral therapy", "OBSERVATION", 18, 35]]], ["According to The Italian League Against Epilepsy (https://www.lice. it/pdf/Antiepileptic_drugs_interactions_in_COVID-19.pdf), some AEDs (gabapentin, levetiracetam, lorazepam, pregabalin, clonazepam, ethosuximide, et al.) have relatively few interactions with antiviral medications and are easy to combine with them.", [["Epilepsy", "DISEASE", 40, 48], ["gabapentin", "CHEMICAL", 137, 147], ["levetiracetam", "CHEMICAL", 149, 162], ["lorazepam", "CHEMICAL", 164, 173], ["pregabalin", "CHEMICAL", 175, 185], ["clonazepam", "CHEMICAL", 187, 197], ["ethosuximide", "CHEMICAL", 199, 211], ["gabapentin", "CHEMICAL", 137, 147], ["levetiracetam", "CHEMICAL", 149, 162], ["lorazepam", "CHEMICAL", 164, 173], ["pregabalin", "CHEMICAL", 175, 185], ["clonazepam", "CHEMICAL", 187, 197], ["ethosuximide", "CHEMICAL", 199, 211], ["AEDs", "SIMPLE_CHEMICAL", 131, 135], ["gabapentin", "SIMPLE_CHEMICAL", 137, 147], ["levetiracetam", "SIMPLE_CHEMICAL", 149, 162], ["lorazepam", "SIMPLE_CHEMICAL", 164, 173], ["pregabalin", "SIMPLE_CHEMICAL", 175, 185], ["clonazepam", "SIMPLE_CHEMICAL", 187, 197], ["ethosuximide", "SIMPLE_CHEMICAL", 199, 211], ["Epilepsy", "PROBLEM", 40, 48], ["it/pdf", "TREATMENT", 68, 74], ["Antiepileptic_drugs_interactions_in_COVID", "TEST", 75, 116], ["some AEDs", "TREATMENT", 126, 135], ["gabapentin", "TREATMENT", 137, 147], ["levetiracetam", "TREATMENT", 149, 162], ["lorazepam", "TREATMENT", 164, 173], ["pregabalin", "TREATMENT", 175, 185], ["clonazepam", "TREATMENT", 187, 197], ["ethosuximide", "TREATMENT", 199, 211], ["antiviral medications", "TREATMENT", 259, 280]]], ["O the other hand, some AEDs (carbamazepine, phenytoin, phenobarbital, et al.) have strong interaction with antiviral drugs.", [["carbamazepine", "CHEMICAL", 29, 42], ["phenytoin", "CHEMICAL", 44, 53], ["phenobarbital", "CHEMICAL", 55, 68], ["carbamazepine", "CHEMICAL", 29, 42], ["phenytoin", "CHEMICAL", 44, 53], ["phenobarbital", "CHEMICAL", 55, 68], ["carbamazepine", "SIMPLE_CHEMICAL", 29, 42], ["phenytoin", "SIMPLE_CHEMICAL", 44, 53], ["phenobarbital", "SIMPLE_CHEMICAL", 55, 68], ["some AEDs", "TREATMENT", 18, 27], ["carbamazepine", "TREATMENT", 29, 42], ["phenytoin", "TREATMENT", 44, 53], ["phenobarbital", "TREATMENT", 55, 68], ["antiviral drugs", "TREATMENT", 107, 122]]], ["In addition, some combinations can induce fatal arrhythmias in patients.", [["arrhythmias", "DISEASE", 48, 59], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["fatal arrhythmias", "PROBLEM", 42, 59], ["fatal", "OBSERVATION_MODIFIER", 42, 47], ["arrhythmias", "OBSERVATION", 48, 59]]], ["Therefore, clinicians should consider the effects of interaction between such medications and AEDs.Seizure FrequencyWe should first confirm such factors, including medication adherence, lifestyle, shortage of sleep, stressful situations, alcohol intake, and supplemental or new medications.", [["Seizure", "DISEASE", 99, 106], ["alcohol", "CHEMICAL", 238, 245], ["alcohol", "CHEMICAL", 238, 245], ["alcohol", "SIMPLE_CHEMICAL", 238, 245], ["such medications", "TREATMENT", 73, 89], ["AEDs", "TREATMENT", 94, 98], ["Seizure FrequencyWe", "PROBLEM", 99, 118], ["medication adherence", "TREATMENT", 164, 184], ["new medications", "TREATMENT", 274, 289]]], ["If there is no change in terms of these factors, we would consider about adjustment of AEDs.", [["AEDs", "TREATMENT", 87, 91], ["no", "UNCERTAINTY", 12, 14], ["change", "OBSERVATION_MODIFIER", 15, 21]]], ["If the increase in seizures disturbs the patients' daily activities, physician could encourage making appointment for physical consultation, whatever the causes of exacerbation might be.Patients' General StateAny person could be infected by SARS-CoV-2.", [["seizures", "DISEASE", 19, 27], ["SARS", "DISEASE", 241, 245], ["patients", "ORGANISM", 41, 49], ["Patients", "ORGANISM", 186, 194], ["SARS-CoV-2", "ORGANISM", 241, 251], ["patients", "SPECIES", 41, 49], ["Patients", "SPECIES", 186, 194], ["person", "SPECIES", 213, 219], ["SARS-CoV", "SPECIES", 241, 249], ["seizures", "PROBLEM", 19, 27], ["physical consultation", "TEST", 118, 139], ["exacerbation", "PROBLEM", 164, 176], ["increase", "OBSERVATION_MODIFIER", 7, 15], ["infected", "OBSERVATION", 229, 237]]], ["Therefore, clinicians should ask the patients with epilepsy whether they have any symptoms of COVID-19.", [["epilepsy", "DISEASE", 51, 59], ["COVID", "DISEASE", 94, 99], ["COVID-19", "CHEMICAL", 94, 102], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["epilepsy", "PROBLEM", 51, 59], ["any symptoms", "PROBLEM", 78, 90], ["COVID", "TEST", 94, 99]]], ["Similar to the general population, patients with epilepsy who have comorbidities, such as smoking, obesity, diabetes, heart disease, lung disease, and cancer, are at a higher risk of developing COVID-19 (13) .", [["heart", "ANATOMY", 118, 123], ["lung", "ANATOMY", 133, 137], ["cancer", "ANATOMY", 151, 157], ["epilepsy", "DISEASE", 49, 57], ["obesity", "DISEASE", 99, 106], ["diabetes", "DISEASE", 108, 116], ["heart disease", "DISEASE", 118, 131], ["lung disease", "DISEASE", 133, 145], ["cancer", "DISEASE", 151, 157], ["COVID", "DISEASE", 194, 199], ["COVID-19", "CHEMICAL", 194, 202], ["patients", "ORGANISM", 35, 43], ["heart", "ORGAN", 118, 123], ["lung", "ORGAN", 133, 137], ["cancer", "CANCER", 151, 157], ["patients", "SPECIES", 35, 43], ["epilepsy", "PROBLEM", 49, 57], ["comorbidities", "PROBLEM", 67, 80], ["obesity", "PROBLEM", 99, 106], ["diabetes", "PROBLEM", 108, 116], ["heart disease", "PROBLEM", 118, 131], ["lung disease", "PROBLEM", 133, 145], ["cancer", "PROBLEM", 151, 157], ["COVID", "TEST", 194, 199], ["obesity", "OBSERVATION", 99, 106], ["diabetes", "OBSERVATION", 108, 116], ["heart", "ANATOMY", 118, 123], ["disease", "OBSERVATION", 124, 131], ["lung", "ANATOMY", 133, 137], ["disease", "OBSERVATION", 138, 145], ["cancer", "OBSERVATION", 151, 157]]], ["Among the COVID-19 symptoms, fever should be appropriately monitored as it could decrease the threshold of seizures (14).", [["fever", "DISEASE", 29, 34], ["seizures", "DISEASE", 107, 115], ["the COVID", "TEST", 6, 15], ["symptoms", "PROBLEM", 19, 27], ["fever", "PROBLEM", 29, 34], ["seizures", "PROBLEM", 107, 115]]], ["If required, the clinicians should consider prescription of antifebrile medications.", [["antifebrile medications", "TREATMENT", 60, 83]]], ["In particular, for patients with Dravet syndrome, the management of fever is critical (15) .", [["Dravet syndrome", "DISEASE", 33, 48], ["fever", "DISEASE", 68, 73], ["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["Dravet syndrome", "PROBLEM", 33, 48], ["fever", "PROBLEM", 68, 73]]], ["Moreover, it is reasonable to use paracetamol if patients with Dravet syndrome have a fever (16) .", [["paracetamol", "CHEMICAL", 34, 45], ["Dravet syndrome", "DISEASE", 63, 78], ["fever", "DISEASE", 86, 91], ["paracetamol", "CHEMICAL", 34, 45], ["paracetamol", "SIMPLE_CHEMICAL", 34, 45], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["paracetamol", "TREATMENT", 34, 45], ["Dravet syndrome", "PROBLEM", 63, 78], ["a fever", "PROBLEM", 84, 91]]], ["In addition to patients with Dravet syndrome, those with epilepsy can also be prescribed antifebrile medications, such as paracetamol.Side-Effect of AEDsIf the patients with increased seizure lack the aforementioned factors (medication adherence, lifestyle, shortage of sleep, stressful situations, alcohol intake, supplemental or new medication, and patients' general state) or when improvement in such factors does not decrease the seizure frequency, clinicians may consider adjusting the AEDs.Side-Effect of AEDsWhile adjusting AEDs on telemedicine, the side-effect of AEDs should be considered.", [["Dravet syndrome", "DISEASE", 29, 44], ["epilepsy", "DISEASE", 57, 65], ["paracetamol", "CHEMICAL", 122, 133], ["seizure", "DISEASE", 184, 191], ["alcohol", "CHEMICAL", 299, 306], ["seizure", "DISEASE", 434, 441], ["paracetamol", "CHEMICAL", 122, 133], ["alcohol", "CHEMICAL", 299, 306], ["patients", "ORGANISM", 15, 23], ["paracetamol", "SIMPLE_CHEMICAL", 122, 133], ["patients", "ORGANISM", 160, 168], ["alcohol", "SIMPLE_CHEMICAL", 299, 306], ["patients", "ORGANISM", 351, 359], ["patients", "SPECIES", 15, 23], ["patients", "SPECIES", 160, 168], ["patients", "SPECIES", 351, 359], ["Dravet syndrome", "PROBLEM", 29, 44], ["epilepsy", "PROBLEM", 57, 65], ["antifebrile medications", "TREATMENT", 89, 112], ["paracetamol", "TREATMENT", 122, 133], ["increased seizure", "PROBLEM", 174, 191], ["medication adherence", "TREATMENT", 225, 245], ["new medication", "TREATMENT", 331, 345], ["the seizure frequency", "PROBLEM", 430, 451], ["the AEDs", "TREATMENT", 487, 495], ["AEDs", "TREATMENT", 511, 515], ["AEDs", "TREATMENT", 531, 535], ["telemedicine", "TREATMENT", 539, 551], ["AEDs", "TREATMENT", 572, 576]]], ["Telemedicine allows us to weigh the side-effects of the treatment (17) .", [["the treatment", "TREATMENT", 52, 65]]], ["In case of critical sideeffects, clinicians may consider physical consultation.", [["physical consultation", "TEST", 57, 78]]], ["We may consider continuing the AEDs if the side-effects are mild and acceptable to both clinician and patients.", [["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["continuing the AEDs", "TREATMENT", 16, 35], ["mild", "OBSERVATION_MODIFIER", 60, 64]]], ["We need to consider discontinuing or changing the therapeutic drug on telemedicine if the side effects are not critical, and are unacceptable to either the physician or the patient.", [["patient", "ORGANISM", 173, 180], ["patient", "SPECIES", 173, 180], ["telemedicine", "TREATMENT", 70, 82]]], ["If the sideeffects do not improve despite decreasing or stopping the AEDs, the patient should be encouraged to physically visit the clinician for further evaluation.Other Treatments for EpilepsySome patients with epilepsy resort to the diet-therapy to control seizures.", [["epilepsy", "DISEASE", 213, 221], ["seizures", "DISEASE", 260, 268], ["patient", "ORGANISM", 79, 86], ["patients", "ORGANISM", 199, 207], ["patient", "SPECIES", 79, 86], ["patients", "SPECIES", 199, 207], ["the AEDs", "TREATMENT", 65, 73], ["further evaluation", "TEST", 146, 164], ["EpilepsySome", "TREATMENT", 186, 198], ["epilepsy", "PROBLEM", 213, 221], ["therapy", "TREATMENT", 241, 248], ["seizures", "PROBLEM", 260, 268]]], ["Diet-therapy would be vulnerable under the effect of COVID-19 crisis owing to the difficulty of obtaining the required foods for diet-therapy (18).", [["therapy", "TREATMENT", 5, 12], ["COVID-19 crisis", "TREATMENT", 53, 68], ["diet-therapy", "TREATMENT", 129, 141]]], ["Therefore, the clinicians should confirm the compliance to diet-therapy on telemedicine.", [["therapy", "TREATMENT", 64, 71], ["telemedicine", "TREATMENT", 75, 87]]], ["Few patients with diet-therapy would need online-dietary-counseling by dieticians.Other Treatments for EpilepsyPatients with epilepsy who underwent surgeries, such as vagus nerve stimulation, deep brain stimulation, or responsive neurostimulation, require the adjustment of parameter for stimulation.", [["vagus nerve", "ANATOMY", 167, 178], ["brain", "ANATOMY", 197, 202], ["epilepsy", "DISEASE", 125, 133], ["patients", "ORGANISM", 4, 12], ["vagus nerve", "MULTI-TISSUE_STRUCTURE", 167, 178], ["brain", "ORGAN", 197, 202], ["patients", "SPECIES", 4, 12], ["diet-therapy", "TREATMENT", 18, 30], ["EpilepsyPatients", "PROBLEM", 103, 119], ["epilepsy", "PROBLEM", 125, 133], ["surgeries", "TREATMENT", 148, 157], ["vagus nerve stimulation", "TREATMENT", 167, 190], ["deep brain stimulation", "TREATMENT", 192, 214], ["responsive neurostimulation", "TREATMENT", 219, 246], ["the adjustment of parameter", "TREATMENT", 256, 283], ["stimulation", "TREATMENT", 288, 299], ["epilepsy", "OBSERVATION", 125, 133], ["vagus nerve", "ANATOMY", 167, 178], ["deep", "ANATOMY_MODIFIER", 192, 196], ["brain", "ANATOMY", 197, 202]]], ["In the present scenario, clinicians have no alternative options to manage and control such procedure on telemedicine.", [["alternative options", "TREATMENT", 44, 63], ["such procedure", "TREATMENT", 86, 100], ["telemedicine", "TREATMENT", 104, 116]]], ["In particular, patients who are not very long post-operatively or who need to have parameters set may need an actual visit even in a COVID-19 situation.Other Treatments for EpilepsySome patients take medications, such as everolimus or corticosteroid, which affect the immune system.", [["immune system", "ANATOMY", 268, 281], ["everolimus", "CHEMICAL", 221, 231], ["everolimus", "CHEMICAL", 221, 231], ["patients", "ORGANISM", 15, 23], ["patients", "ORGANISM", 186, 194], ["everolimus", "SIMPLE_CHEMICAL", 221, 231], ["corticosteroid", "SIMPLE_CHEMICAL", 235, 249], ["patients", "SPECIES", 15, 23], ["patients", "SPECIES", 186, 194], ["EpilepsySome patients take medications", "TREATMENT", 173, 211], ["everolimus", "TREATMENT", 221, 231], ["corticosteroid", "TREATMENT", 235, 249]]], ["Under normal conditions, such medications are normally prescribed to control seizures (12).", [["seizures", "DISEASE", 77, 85], ["such medications", "TREATMENT", 25, 41], ["seizures", "PROBLEM", 77, 85], ["normal conditions", "OBSERVATION", 6, 23]]], ["However, these medications may need to be discontinued for a short period for patients with exposure to SARS-CoV-2 or diagnosed as COVID-19 positive (19) .Other Treatments for EpilepsyVigabatrin is an AED often used for patients with tuberous sclerosis complex.", [["SARS", "DISEASE", 104, 108], ["Epilepsy", "DISEASE", 176, 184], ["Vigabatrin", "CHEMICAL", 184, 194], ["tuberous sclerosis complex", "DISEASE", 234, 260], ["patients", "ORGANISM", 78, 86], ["SARS-CoV-2", "ORGANISM", 104, 114], ["patients", "ORGANISM", 220, 228], ["tuberous sclerosis complex", "GENE_OR_GENE_PRODUCT", 234, 260], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 220, 228], ["SARS-CoV", "SPECIES", 104, 112], ["these medications", "TREATMENT", 9, 26], ["SARS", "TEST", 104, 108], ["CoV", "TEST", 109, 112], ["COVID", "TEST", 131, 136], ["Other Treatments", "TREATMENT", 155, 171], ["Epilepsy", "PROBLEM", 176, 184], ["Vigabatrin", "TREATMENT", 184, 194], ["an AED", "TREATMENT", 198, 204], ["tuberous sclerosis complex", "PROBLEM", 234, 260], ["sclerosis", "OBSERVATION", 243, 252]]], ["Clinicians can continue prescribing this medication on telemedicine if approved by the opthalmologists, as it is known to cause visual field defect (20) .Other Treatments for EpilepsySome patients with infantile spasm might have undergone adrenocorticotropic hormone (ACTH) therapy for epilepsy (21) .", [["visual field defect", "DISEASE", 128, 147], ["EpilepsySome", "DISEASE", 175, 187], ["infantile spasm", "DISEASE", 202, 217], ["epilepsy", "DISEASE", 286, 294], ["patients", "ORGANISM", 188, 196], ["adrenocorticotropic hormone", "GENE_OR_GENE_PRODUCT", 239, 266], ["ACTH", "SIMPLE_CHEMICAL", 268, 272], ["patients", "SPECIES", 188, 196], ["this medication", "TREATMENT", 36, 51], ["visual field defect", "PROBLEM", 128, 147], ["EpilepsySome", "TREATMENT", 175, 187], ["infantile spasm", "PROBLEM", 202, 217], ["adrenocorticotropic hormone (ACTH) therapy", "TREATMENT", 239, 281], ["epilepsy", "PROBLEM", 286, 294]]], ["This therapy is generally provided on admission; however, during the COVID-19 crisis, physicians could consider using oral steroid as an alternative option for ACTH therapy on telemedicine to reduce the risk of virus exposure (21, 22) .CONCLUSIONThe present study summarizes and suggests the management of patients with epilepsy on telemedicine during the COVID-19 crisis.", [["oral", "ANATOMY", 118, 122], ["steroid", "CHEMICAL", 123, 130], ["epilepsy", "DISEASE", 320, 328], ["steroid", "CHEMICAL", 123, 130], ["oral", "ORGANISM_SUBDIVISION", 118, 122], ["ACTH", "SIMPLE_CHEMICAL", 160, 164], ["patients", "ORGANISM", 306, 314], ["patients", "SPECIES", 306, 314], ["This therapy", "TREATMENT", 0, 12], ["oral steroid", "TREATMENT", 118, 130], ["an alternative option", "TREATMENT", 134, 155], ["ACTH therapy", "TREATMENT", 160, 172], ["telemedicine", "TREATMENT", 176, 188], ["virus exposure", "PROBLEM", 211, 225], ["The present study", "TEST", 246, 263], ["epilepsy", "PROBLEM", 320, 328], ["telemedicine", "TREATMENT", 332, 344], ["the COVID", "TEST", 352, 361], ["epilepsy", "OBSERVATION", 320, 328]]], ["Epileptologists are required to manage their outpatients using telemedicine due to COVID-19 pandemic.", [["COVID", "TEST", 83, 88], ["pandemic", "PROBLEM", 92, 100]]], ["Decisionmaking tree prescribed in this article would be helpful for the epileptologists to manage their patients on telemedicine.", [["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112]]], ["In COVID-19 situations, patients are exposed to various aspects of psychological stress.", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["psychological stress", "PROBLEM", 67, 87]]], ["Therefore, in addition to decisionmaking, understanding and listening to the patient's stress in the telemedicine is important during the COVID-19 crisis.", [["patient", "ORGANISM", 77, 84], ["patient", "SPECIES", 77, 84]]], ["It is also important to establish a medical system that allows for the continuation of telemedicine in the long term, even after the COVID-19 crisis.", [["telemedicine", "TREATMENT", 87, 99], ["the COVID", "TEST", 129, 138]]], ["Research will also be needed to evaluate the effectiveness and safety of telemedicine in the COVID-19 crisis.", [["telemedicine", "TREATMENT", 73, 85]]]]}